<SEC-DOCUMENT>0001171843-26-001337.txt : 20260305
<SEC-HEADER>0001171843-26-001337.hdr.sgml : 20260305
<ACCEPTANCE-DATETIME>20260305073053
ACCESSION NUMBER:		0001171843-26-001337
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		99
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260305
DATE AS OF CHANGE:		20260305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Compass Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001738021
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39696
		FILM NUMBER:		26724201

	BUSINESS ADDRESS:	
		STREET 1:		80 GUEST STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02135
		BUSINESS PHONE:		617-500-8099

	MAIL ADDRESS:	
		STREET 1:		80 GUEST STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02135

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Olivia Ventures, Inc.
		DATE OF NAME CHANGE:	20180419
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cmpx20251231_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:cmpx="http://www.compasstherapeutics.com/20251231" xmlns:rr="http://xbrl.sec.gov/rr/2023" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21"><head>
	<title>cmpx20251231_10k.htm</title>


	<!-- Generated by ThunderDome Portal - 3/4/2026 2:02:30 PM -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentFiscalPeriodFocus" id="ixv-13059">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentFiscalYearFocus" id="ixv-13060">2025</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:CurrentFiscalYearEndDate" id="ixv-13061">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:AmendmentFlag" id="ixv-13062">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityCentralIndexKey" id="ixv-13063">0001738021</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="ecd:NonRule10b51ArrTrmntdFlag" id="c1177" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="ecd:Rule10b51ArrAdoptedFlag" id="c1176" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="ecd:Rule10b51ArrTrmntdFlag" id="c1175" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="ecd:NonRule10b51ArrAdoptedFlag" id="c1174" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonFraction id="c1115" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:NumberOfOperatingSegments" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c1000" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c999" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c998" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c997" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c945" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c944" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c891" contextRef="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-AdimabAgreementMember" unitRef="USD" name="cmpx:MilestonePaymentsPaid" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020StockOptionAndIncentivePlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c686" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020StockOptionAndIncentivePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c685" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonFraction id="c312" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c311" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c305" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:NumberOfOperatingSegments" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:SecurityExchangeName" id="c19" format="ixt-sec:exchnameen">NASDAQ</ix:nonNumeric></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="cmpx-20251231.xsd" xlink:type="simple"/></ix:references>
<ix:resources>
<xbrli:context id="d_2025-01-01_2025-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2024-01-01_2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-GeneralMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:GeneralMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-GeneralMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:GeneralMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-PersonnelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:PersonnelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-PersonnelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:PersonnelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-CTX10726Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:CTX10726Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-CTX10726Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:CTX10726Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-CTX8371Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:CTX8371Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-CTX8371Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:CTX8371Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-CTX471Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:CTX471Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-CTX471Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:CTX471Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-TovecimigMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:TovecimigMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-TovecimigMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:TovecimigMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2025-12-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-01_2025-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-09-30_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_LeaseContractualTermAxis-FacilityLeaseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cmpx:FacilityLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_LeaseContractualTermAxis-FacilityLeaseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cmpx:FacilityLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-27_GuaranteeObligationsByNatureAxis-FinancialStandbyLetterOfCreditMember_LeaseContractualTermAxis-FacilityLeaseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialStandbyLetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cmpx:FacilityLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-27</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2025-12-31_LeaseContractualTermAxis-FacilityLeaseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cmpx:FacilityLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-07-27_2024-09-27_LeaseContractualTermAxis-FacilityLeaseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cmpx:FacilityLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-27</xbrli:startDate><xbrli:endDate>2024-09-27</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="SquareFoot"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-09-27_LeaseContractualTermAxis-FacilityLeaseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cmpx:FacilityLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-27</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_TypeOfArrangementAxis-AdimabAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cmpx:AdimabAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-AdimabAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cmpx:AdimabAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-11-30_ProductOrServiceAxis-OphthalmologyMember_TypeOfArrangementAxis-ABLBioAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmpx:OphthalmologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cmpx:ABLBioAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-11-30_ProductOrServiceAxis-OncologyMember_TypeOfArrangementAxis-ABLBioAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmpx:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cmpx:ABLBioAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-11-30_TypeOfArrangementAxis-ABLBioAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cmpx:ABLBioAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-11-01_2018-11-30_TypeOfArrangementAxis-ABLBioAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cmpx:ABLBioAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="i_2025-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantsInConnectionWithUnderwritingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmpx:PreFundedWarrantsInConnectionWithUnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020StockOptionAndIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmpx:The2020StockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2026-01-01_PlanNameAxis-The2020StockOptionAndIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmpx:The2020StockOptionAndIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2026-01-01_2026-01-01_PlanNameAxis-The2020StockOptionAndIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmpx:The2020StockOptionAndIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_PlanNameAxis-The2020StockOptionAndIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmpx:The2020StockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_PlanNameAxis-The2020StockOptionAndIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmpx:The2020StockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-03-31_SubsidiarySaleOfStockAxis-AtTheMarketMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmpx:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_SubsidiarySaleOfStockAxis-AtTheMarketMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmpx:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-08-12_2025-08-12_SubsidiarySaleOfStockAxis-UnderwritingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmpx:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-12</xbrli:startDate><xbrli:endDate>2025-08-12</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-08-12_2025-08-12_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-12</xbrli:startDate><xbrli:endDate>2025-08-12</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-08-12_ClassOfWarrantOrRightAxis-PreFundedWarrantsInConnectionWithUnderwritingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmpx:PreFundedWarrantsInConnectionWithUnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-12</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-08-12_SubsidiarySaleOfStockAxis-UnderwritingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmpx:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-12</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-08-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-08-12</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareAndSoftwareDevelopmentCostsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-07-01_2025-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2026-02-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-02-27</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsAndOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001738021</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmpx:RestrictedStockUnitsAndOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources>
</ix:header></div>
<div>&#160;</div>

<div>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; text-align: center; margin: 0pt;"><b>UNITED STATES </b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; font-variant: normal; text-align: center; margin: 0pt;"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549 </b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">____________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt;"><b>FORM <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentType" id="c3">10-K</ix:nonNumeric></b></p>

<p style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">____________________________</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(Mark One) </b></p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentAnnualReport" id="c4" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p>
			</td>
			<td style="vertical-align:top;width:49.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>For the fiscal year ended <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentPeriodEndDate" id="c5" format="ixt:date-monthname-day-year-en">December 31, 2025</ix:nonNumeric></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>OR </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentTransitionReport" id="c6" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p>
			</td>
			<td style="vertical-align:top;width:49.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM&#160; &#160; &#160; &#160; &#160; &#160;TO </b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Commission File Number <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityFileNumber" id="c7">000-55939</ix:nonNumeric></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityRegistrantName" id="c8">Compass Therapeutics, Inc.</ix:nonNumeric></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Exact name of Registrant as specified in its Charter) </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:25.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityIncorporationStateCountryCode" id="c9" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></b></p>
			</td>
			<td style="vertical-align:bottom;width:25.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityTaxIdentificationNumber" id="c10">82-4876496</ix:nonNumeric></b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:25.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(State or other jurisdiction of</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>incorporation or organization)</b></p>
			</td>
			<td style="vertical-align:bottom;width:25.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(I.R.S. Employer</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Identification No.)</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:25.9%;">&#160;</td>
			<td style="vertical-align:bottom;width:25.9%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:25.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityAddressAddressLine1" id="c11">80 Guest Street, Suite 601</ix:nonNumeric></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityAddressCityOrTown" id="c12">Boston</ix:nonNumeric>, <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityAddressStateOrProvince" id="c13" format="ixt-sec:stateprovnameen">Massachusetts</ix:nonNumeric></b></p>
			</td>
			<td style="vertical-align:bottom;width:25.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityAddressPostalZipCode" id="c14">02135</ix:nonNumeric></b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:25.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Address of principal executive offices)</b></p>
			</td>
			<td style="vertical-align:bottom;width:25.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Zip Code)</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Registrant</b>&#8217;<b>s telephone number, including area code: (<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:CityAreaCode" id="c15">617</ix:nonNumeric>) <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:LocalPhoneNumber" id="c16">500-8099</ix:nonNumeric> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:20.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title of each class</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:10.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Symbol(s)</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:20.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange on which registered</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:20.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:Security12bTitle" id="c17">Common Stock, $0.0001 par value per share</ix:nonNumeric></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:10.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:TradingSymbol" id="c18">CMPX</ix:nonNumeric></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:20.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:c19">Nasdaq</span> Capital Market</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities registered pursuant to Section 12(g) of the Act: <b>None </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES &#9744; <span style="text-transform:uppercase;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityWellKnownSeasonedIssuer" id="c20">No</ix:nonNumeric></span>&#160;&#9746;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES &#9744; <span style="text-transform:uppercase;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityVoluntaryFilers" id="c21">No</ix:nonNumeric></span>&#160;&#9746;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <span style="text-transform:uppercase;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityCurrentReportingStatus" id="c22">Yes</ix:nonNumeric></span>&#160;&#9746; NO &#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). <span style="text-transform:uppercase;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityInteractiveDataCurrent" id="c23">Yes</ix:nonNumeric></span>&#160;&#9746; NO &#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 162px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Large accelerated filer</p>
			</td>
			<td style="vertical-align: top; width: 473px;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="vertical-align: top; width: 175px;">&#160;</td>
			<td style="vertical-align: top; width: 463px;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 162px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityFilerCategory" id="c24" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p>
			</td>
			<td style="vertical-align: top; width: 473px;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9746;</p>
			</td>
			<td style="vertical-align: top; width: 175px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Smaller reporting company</p>
			</td>
			<td style="vertical-align: top; width: 463px;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntitySmallBusiness" id="c25" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 162px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accelerated filer</p>
			</td>
			<td style="vertical-align: top; width: 473px;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="vertical-align: top; width: 175px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company</p>
			</td>
			<td style="vertical-align: top; width: 463px;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityEmergingGrowthCompany" id="c26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:IcfrAuditorAttestationFlag" id="c27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentFinStmtErrorCorrectionFlag" id="c28" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityShellCompany" id="c29" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> NO &#9746;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The aggregate market value of the registrant's voting and non-voting common stock held by non-affiliates as of the last business day of its most recently completed second fiscal quarter (June 30, 2025), traded on the Nasdaq Capital Market in the United States under the symbol CMPX was approximately $<ix:nonFraction id="c30" contextRef="i_2025-06-30" unitRef="USD" name="dei:EntityPublicFloat" scale="6" format="ixt:num-dot-decimal" decimals="-6">277</ix:nonFraction> million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The number of shares of Registrant&#8217;s Common Stock outstanding as of February 27, 2026 was <ix:nonFraction id="c31" contextRef="i_2026-02-27" unitRef="Share" name="dei:EntityCommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">180,087,915</ix:nonFraction>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">DOCUMENTS INCORPORATED BY REFERENCE</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2025 Annual Meeting of Stockholders within 120 days of the end of the registrant&#8217;s fiscal year ended December 31, 2025. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Auditor Firm Id:&#160;&#160;<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:AuditorFirmId" id="c32">596</ix:nonNumeric></p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Auditor Name: <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:AuditorName" id="c33">CohnReznick LLP</ix:nonNumeric></p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Auditor Location:&#160;&#160;<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:AuditorLocation" id="c34">Melville, NY U.S.A.</ix:nonNumeric></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p>
</div>

<div>&#160;</div>

<div>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Table of Contents</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:middle;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Page</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#pt1" style="-sec-extract:exhibit;"><b><span style="text-decoration: underline; ">PART I</span></b></a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 7pt;"><a href="#itm1" style="-sec-extract:exhibit;">Item 1.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm1" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Business</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm1">5</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 7pt;"><a href="#itm1a" style="-sec-extract:exhibit;">Item 1A.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm1a" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Risk Factors</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm1a">38</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 7pt;"><a href="#itm1b" style="-sec-extract:exhibit;">Item 1B.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm1b" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Unresolved Staff Comments</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm1b">89</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 7pt;"><a href="#itm1c" style="-sec-extract:exhibit;">Item 1C.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm1c" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Cybersecurity</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm1c">89</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 7pt;"><a href="#itm2" style="-sec-extract:exhibit;">Item 2.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm2" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Properties</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm2">90</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 7pt;"><a href="#itm3" style="-sec-extract:exhibit;">Item 3.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm3" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Legal Proceedings</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm3">90</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 7pt;"><a href="#itm4" style="-sec-extract:exhibit;">Item 4.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm4" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Mine Safety Disclosures</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm4">90</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#part2" style="-sec-extract:exhibit;"><b><span style="text-decoration: underline; ">PART II</span></b></a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 7pt;"><a href="#itm5" style="-sec-extract:exhibit;">Item 5.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm5" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Market for Registrant</span><span style="text-decoration: underline; ">&#8217;</span><span style="text-decoration: underline; ">s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm5">91</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 7pt;"><a href="#itm6" style="-sec-extract:exhibit;">Item 6.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm6" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">[Reserved]</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm6">91</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 7pt;"><a href="#itm7" style="-sec-extract:exhibit;">Item 7.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm7" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Management</span><span style="text-decoration: underline; ">&#8217;</span><span style="text-decoration: underline; ">s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm7">92</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 7pt;"><a href="#itm7a" style="-sec-extract:exhibit;">Item 7A.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm7a" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Quantitative and Qualitative Disclosures About Market Risk</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm7a">102</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><a href="#itm8" style="-sec-extract:exhibit;">Item 8.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm8" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Financial Statements and Supplementary Data</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm8">103</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><a href="#itm9" style="-sec-extract:exhibit;">Item 9.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm9" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm9">125</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><a href="#itm9a" style="-sec-extract:exhibit;">Item 9A.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm9a" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Controls and Procedures</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm9a">125</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><a href="#itm9b" style="-sec-extract:exhibit;">Item 9B.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm9b" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Other Information</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm9b">126</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><a href="#itm9c" style="-sec-extract:exhibit;">Item 9C.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm9c" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm9c">126</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#part3" style="-sec-extract:exhibit;"><b><span style="text-decoration: underline; ">PART III</span></b></a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><a href="#itm10" style="-sec-extract:exhibit;">Item 10.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm10" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Directors, Executive Officers and Corporate Governance</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm10">127</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><a href="#itm11" style="-sec-extract:exhibit;">Item 11.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm11" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Executive Compensation</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm11">127</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><a href="#itm12" style="-sec-extract:exhibit;">Item 12.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm12" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm12">127</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><a href="#itm13" style="-sec-extract:exhibit;">Item 13.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm13" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certain Relationships and Related Transactions, and Director Independence</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm13">128</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><a href="#itm14" style="-sec-extract:exhibit;">Item 14.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm14" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Principal Accountant Fees and Services</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm14">128</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#part4" style="-sec-extract:exhibit;"><b><span style="text-decoration: underline; ">PART IV</span></b></a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">&#160;</td>
			<td style="vertical-align:bottom;width:3.7%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><a href="#itm15" style="-sec-extract:exhibit;">Item 15.</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm15" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Exhibits and Financial Statement Schedules</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm15">129</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><a href="#itm16" style="-sec-extract:exhibit;">Item 16</a></p>
			</td>
			<td style="vertical-align:top;width:43.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#itm16" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form 10-K Summary</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#itm16">131</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">&#160;</td>
			<td style="vertical-align:top;width:43.8%;">&#160;</td>
			<td style="vertical-align:bottom;width:3.7%;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">i</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p>
</div>

<div>&#160;</div>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>RISK FACTOR SUMMARY</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:28pt;"><i>Unless otherwise stated or the context otherwise indicates, references to the </i>&#8220;<i>Company</i>&#8221;<i>, </i>&#8220;<i>we</i>&#8221;<i>, </i>&#8220;<i>our</i>&#8221;<i>, </i>&#8220;<i>us</i>&#8221;<i> or similar terms refer to Compass Therapeutics, Inc. (formerly named Olivia Ventures, Inc.) together with its wholly-owned subsidiaries, including Compass Therapeutics LLC, Trigr Therapeutics, Inc.</i> , Compass Acquisition Company, LLC,<i> and Compass Therapeutics Securities Corporation, which we refer to as Compass Therapeutics.</i> <i>Our business is subject to numerous risks and uncertainties, including those described in Item 1A </i>&#8220;<i>Risk Factors</i>&#8221;<i>. These risk factors include, but are not limited to the following: </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have a limited operating history and no products approved for commercial sale. We have a history of significant losses, expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have never generated revenue from product sales and may never be profitable.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We will require substantial additional financing to pursue our business objectives, which may not be available on acceptable terms, or at all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development, commercialization efforts or other operations.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Clinical development involves a lengthy and expensive process with uncertain outcomes. We may incur additional costs and experience delays in developing and commercializing or be unable to develop or commercialize our current and future product candidates.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Positive results from preclinical studies and early-stage clinical trials may not be predictive of future results. Initial positive results in any of our clinical trials may not be indicative of results obtained when the trial is completed or in later stage trials.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The regulatory approval processes of the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be materially harmed.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Even if a current or future product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The successful commercialization of our product candidates will depend in part on the extent to which third-party payors, including governmental authorities and private health insurers, provide coverage and adequate reimbursement levels, as well as implement pricing policies favorable for our product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates may be adversely affected.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Others may claim an ownership interest in our intellectual property and our product candidates, which could expose us to litigation and have a significant adverse effect on our prospects.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We depend on our information technology systems, and any failure of these systems could harm our business. Security breaches, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</p>
			</td>
		</tr>

</tbody></table>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:25pt;"><b>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">This Annual Report on Form 10-K ("Form 10-K") contains forward-looking statements. All statements other than statements of historical facts contained in this report, including statements regarding our future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that are in some cases beyond our control and may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. Forward-looking statements contained in this report include, but are not limited to, statements about:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the timing and focus of our future clinical trials, and the reporting of data from those trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the expected potential benefits of strategic collaborations with third parties and our ability to attract collaborators with development;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">regulatory and commercialization expertise;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that will enroll in our clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the size of the market opportunity for our product candidates in each of the diseases we are targeting;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to expand our product candidates into additional indications and patient populations;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the success of competing therapies that are or may become available;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the beneficial characteristics, safety, efficacy, and therapeutic effects of our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the timing or likelihood of regulatory filings and approvals, including our expectation to seek special designations, such as orphan drug or breakthrough therapy designation, for our product candidates for various diseases;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to obtain and maintain regulatory approval of our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our plans relating to the further development and manufacturing of our product candidates, including additional indications that we may pursue;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">existing regulations and regulatory developments in the United States and other jurisdictions;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and the outcome of our ongoing arbitration proceedings;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the need to hire additional personnel and our ability to attract and retain such personnel;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our financial performance; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the sufficiency of our existing cash, cash equivalents and marketable securities to fund our future operating expenses and capital expenditure requirements.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:23pt;">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations, and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this report and are subject to a number of risks, uncertainties, and assumptions described in the section titled &#8220;Risk Factors&#8221; and elsewhere in this report. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. All forward-looking statements are made as of the date of this report and we do not undertake any obligation to update our forward-looking statements, except as required by applicable law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:23pt;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:23pt;">Investors and others should note that we may announce material business and financial information to our investors using our investor relations website (https://investors.compasstherapeutics.com), Securities and Exchange Commission ("SEC"), filings, webcasts, press releases, and conference calls. We use these mediums, including our website, to communicate with our members and public about our company, our products, and other issues. It is possible that the information that we make available may be deemed to be material information. We therefore encourage investors and others interested in our company to review the information that we make available on our website.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART I<a id="pt1" href="#"></a></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 1. Business.<a id="itm1" href="#"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Overview </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We are a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Our scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Our pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. We plan to advance our product candidates through clinical development and commercialization as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our pipeline consists of four clinical product candidates. Our lead product candidate, tovecimig (formerly known as CTX-009), is a bispecific antibody targeting Delta-like ligand 4 (&#8220;DLL4&#8221;), a ligand of Notch-1, and vascular endothelial growth factor A (&#8220;VEGF-A&#8221;). Simultaneous blockade of the VEGF-A and the Notch pathways is known to turn productive angiogenesis into non-productive angiogenesis, which leads to tumor shrinkage and apoptosis. Our second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137 or 4-1BB, a co-stimulatory receptor which is mostly expressed on activated, but not on resting, T-cells and NK cells. Our third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (&#8220;PD-1&#8221;), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets. Our fourth program, CTX-10726, is a bispecific antibody targeting PD-1 and VEFG-A.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">Tovecimig (CTX-009), our bispecific antibody targeting DLL4 and VEGF-A, is currently being evaluated in a randomized Phase 2/3 trial in the United States in combination with paclitaxel in patients with biliary tract cancer (&#8220;BTC&#8221;) who received one prior treatment regimen. The trial met its primary endpoint with an overall response rate (&#8220;ORR&#8221;) of 17.1% for tovecimig in combination with paclitaxel, including one complete response, compared to a 5.3% ORR for paclitaxel alone. This difference was statistically significant with p=0.031. In the Phase 2/3 trial, the prespecified event threshold of 80% overall survival (OS) events was reached in Q1 2026; therefore, the analyses of progression-free survival (PFS) and OS are expected to be reported in April 2026.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Further, an ongoing Investigator Sponsored Trial (&#8220;IST&#8221;) is evaluating tovecimig in the front-line setting for patients with BTC, combining tovecimig with the standard first-line regimen of gemcitabine, cisplatin, and durvalumab.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We estimate that there are approximately 26,500 patients newly diagnosed with BTC in the United States each year and over 200,000 patients worldwide. Patients with BTC have a poor prognosis despite first-line treatment with chemotherapy and immunotherapy, and there is no generally accepted standard of care in later lines of treatment, except for therapies addressing targeted mutations, which is estimated to be approximately 15% to 20% of the patient population.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Beyond BTC, we intend to expand the development of tovecimig to additional solid tumor indications with significant unmet need and a mechanistic rationale for using an angiogenic inhibitor, such as colorectal cancer (&#8220;CRC&#8221;), ovarian cancer, gastric cancer, renal cell carcinoma, and hepatocellular carcinoma. In CRC, we presented data in January 2026 showing tovecimig demonstrated a 5% overall response rate (&#8220;ORR&#8221;) as a monotherapy in our Phase 2 study of patients with advanced, metastatic CRC treated in the third- and fourth-line settings. Following the generation of positive clinical data in later lines of therapy, we plan to study tovecimig in earlier settings in all indications where the data support it.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">CTX-471, our CD137 (or 4-1BB) agonistic antibody, targets a key node of the immune system with the goal of becoming a next generation immune-oncology treatment for patients across a variety of cancers who do not have a sustained response to current therapies. During its early clinical development, CTX-471 demonstrated monotherapy activity in the post-PD-1/PD-L1 patient population across three solid tumor indications: melanoma, small cell lung cancer (&#8220;SCLC&#8221;) and mesothelioma. The Phase 1 program, which included one complete response, also identified a potential biomarker of activity for CTX-471, neural cell adhesion molecule (NCAM or CD56). We expect to initiate a Phase 2 basket study of CTX-471 in patients with NCAM+ tumors in mid-2026.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">CTX-8371, our bispecific antibody targeting PD-1 and PD-L1, is currently in a first-in-human Phase 1 clinical trial. In the dose escalation portion of the trial, CTX-8371 demonstrated deep responses in patients with three different tumor types; non-small cell lung cancer (&#8220;NSCLC&#8221;), triple-negative breast cancer (&#8220;TNBC&#8221;) and Hodgkin lymphoma (&#8220;HL&#8221;), with no dose limiting toxicities observed. We have initiated cohort expansions in patients with NSCLC and TNBC and expect a further expansion cohort in patients with HL to begin shortly. CTX-8371 emerged from an unbiased screen for synergy conducted with our StitchMabs<sup style="vertical-align:top;line-height:120%;">TM</sup> platform. We subsequently tested CTX-8371 in several in vitro and in vivo models where it demonstrated enhanced activation of immune responses when compared with commercially available checkpoint blockers, which target either PD-1 or PD-L1, but not both. We believe that CTX-8371 has the potential to become a next generation checkpoint inhibitor with improved activity across various solid tumors relative to approved checkpoint blockers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Finally, CTX-10726, our bispecific antibody targeting PD-1 and VEGF-A, is a fully human IgG1 with silenced Fc-&#947; receptor binding that was discovered and developed in-house. In early 2026, we received FDA clearance for the IND for CTX-10726 and initiated a Phase 1 dose escalation study. We expect to accelerate the development of CTX-10726 by leveraging our experience developing and manufacturing bispecific structures containing the VEGF-A and PD-1 components.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Our Strategy </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Our pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Our strategy to achieve this goal includes advancing our product candidates through clinical development and commercialization. This may include combining our product candidates with other drugs or with each other through various indications and lines of therapy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We may also seek strategic partnerships for select product candidates. Our research and discovery platform is designed to generate a broad pipeline of product candidates with high potential for clinical application. We intend to assess on a case-by-case basis the opportunities for accelerating the preclinical development, clinical development and commercialization of these candidates in a capital-efficient manner, including selectively pursuing strategic partnerships with leading biopharmaceutical companies with domain-specific clinical development and commercial expertise to maximize the value of our pipeline.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Pipeline </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The figure below details our pipeline of product candidates.</p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div style="text-align: center;"><img alt="table1.jpg" src="table1.jpg"/></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Product Candidates</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We currently have four product candidates in the clinical stage of development: tovecimig, CTX-471, CTX-8371, and CTX-10726. In addition, we are developing multiple additional product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Tovecimig (DLL4 X VEGF-A bispecific antibody) </span></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Tovecimig (formerly known as CTX-009) is an investigational bispecific antibody that is designed to simultaneously block the DLL4 and VEGF-A signaling pathways, which are critical to angiogenesis and tumor vascularization. Preclinical and early clinical data of tovecimig as a monotherapy and in combination with chemotherapy suggest that blockade of both pathways provides robust anti-tumor activity across several solid tumor indications, including cholangiocarcinoma, colorectal cancer, gastric cancer, pancreatic cancer, and NSCLC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Tovecimig is undergoing clinical development in patients with advanced solid tumors in the United States. We are currently conducting a randomized Phase 2/3 trial of tovecimig in combination with paclitaxel in patients with advanced BTC. Previously, tovecimig underwent a Phase 1 dose escalation and dose expansion monotherapy trial in patients with solid tumors, a Phase 1b trial in combination with chemotherapy, and a Phase 2 trial in combination with chemotherapy in patients with advanced biliary tract cancer, all of which were completed in South Korea. In addition, an investigator sponsored trial of tovecimig in the first-line setting in combination with gemcitabine/cisplatin and durvalumab in patients with BTC was initiated in the first quarter of 2025, led by investigators at The University of Texas MD Anderson Cancer Center.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We have licensed exclusive global rights to tovecimig, outside of South Korea, from ABL Bio, Inc. (&#8220;ABL Bio&#8221;), a South Korea-based clinical-stage company focused on developing antibody therapeutics. South Korean rights are held by Handok Pharmaceuticals, Inc. (&#8220;Handok&#8221;) and China rights were out-licensed to Elpiscience Biopharmaceuticals Co., Limited (&#8220;Elpiscience&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Phase 1b and 2 Trials of Tovecimig with Paclitaxel in Patients with BTC - South Korea</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In the Phase 1b study, there were four patients enrolled with cholangiocarcinoma. Two of these four patients had deep, durable, and confirmed responses. Both of these patients received tovecimig in combination with paclitaxel. Based on this observation, a Phase 2 trial of tovecimig in combination with paclitaxel was completed by Handok and Compass in patients with BTC, with data reported in the first quarter of 2023. The trial enrolled patients with unresectable advanced, metastatic, or relapsed BTC who had received one or two prior systemic therapies.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">This Phase 2 trial utilized a Simon Two-Stage adaptive design where the criteria to advance to the second stage of the trial was three PRs observed in 21 evaluable patients. In the preliminary analysis of 24 patients participating in the study, tovecimig with paclitaxel demonstrated a 37.5% ORR based on 9 patients with PRs that were confirmed by RECIST 1.1. The results of Part 1 of the Phase 2 trial were presented at the 2023 ASCO GI meeting in January 2023.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Based on the efficacy data and following discussions with the FDA, while the trial had met the criteria to advance to Part 2, FDA recommended and we agreed to forego the second stage of the study and advance tovecimig directly to a randomized Phase 2/3 study in patients with BTC treated in the second-line setting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;"><b><i>Safety Data Summary</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Tovecimig safety data has been analyzed and was observed to be generally well-tolerated. Of the 24 patients enrolled in the trial, all patients had at least one treatment emergent adverse event (&#8220;TEAE&#8221;). Grade 3 or greater TEAEs were reported in 95.8% of patients regardless of the relationship to tovecimig or paclitaxel, including decreased neutrophil count (83.3%), hypertension (16.7%), anemia (20.8%), and decreased platelet count (12.5%). Grade 3 or greater adverse events that were designated to be of special interest (&#8220;AESIs&#8221;) by the trial investigators were hemoptysis or hemorrhage (12.5%) and GI or tumor perforation (8.3%), with 0% for pulmonary hypertension, wound healing complication and cardiac failure.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The table below depicts a summary of the TEAEs in 24 patients for the study.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 28pt; margin-right: auto;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b>Total</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b>Total</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b>Grade 3</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b>Grade 3</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Treatment Emergent Adverse Events observed in &gt; 1 patient</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b>(n) </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b>(%)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b>(n) </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b>(%) </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Neutrophil count decreased</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">92</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">83</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Hypertension</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Platelet count decreased</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Anaemia</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Ascites</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Decreased appetite</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Neutropenia</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Liver abscess</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Hepatic infection</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cholangitis</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Embolism</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;"><b><i>Activity Data Summary</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The first stage of the trial enrolled 24 patients and 22 of those patients were considered evaluable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Nine PRs confirmed by RECIST 1.1 were observed leading to an ORR of 37.5%, and 22 of the 24 patients evaluated have had stable disease or better with a decline in tumor burden leading to a Disease Control Rate (DCR) of 92%. PRs were observed in all four tumor sub-types types (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">After a median follow up of approximately 12 months, the median progression free survival (&#8220;PFS&#8221;) was 9.4 months, median duration of response (&#8220;DOR&#8221;) was 6.9 months and median overall survival (&#8220;OS&#8221;) was 12.5 months.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">For reference, one regimen that has been studied in patients with advanced BTC is the three-drug combination FOLFOX. FOLFOX demonstrated an ORR of 4.9%, a median PFS of 4.0 months, and a median OS of 6.2 months in a randomized study against best supportive care.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The waterfall plot below depicts the best response for the 22 patients evaluable in the trial.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:25pt;"><b>Phase 2 Data</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:25pt;"><b>tovecimig + paclitaxel in BTC</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:25pt;"><b>Best Response by Patient</b></p>

<div style="text-align: center;"><img alt="graph1.jpg" src="graph1.jpg"/></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Phase 2/3 Trial of Tovecimig with Paclitaxel in BTC </b>&#8211;<b> United States </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Following conversations with the FDA, we submitted a protocol for a randomized Phase 2/3 trial for tovecimig in combination with paclitaxel in adult patients with unresectable, advanced, metastatic or recurrent biliary tract cancers who have received one prior systemic chemotherapy regimen. The trial is designed to assess the safety and efficacy of the combination of tovecimig and paclitaxel versus paclitaxel alone. A schema of the trial design is provided below:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<div style="text-align: center;"><img alt="graph2.jpg" src="graph2.jpg"/></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The trial was fully enrolled in August 2024 with 168 patients randomized in a 2:1 ratio to receive tovecimig plus paclitaxel (n=111) or paclitaxel alone (n=57). The primary endpoint of the trial was ORR and the secondary endpoints include PFS, OS, and DOR. Patients who were randomized to receive paclitaxel and progressed on their regimen could cross over to the tovecimig plus paclitaxel arm after progression on paclitaxel if they still met the enrollment criteria for the study. To adjust for this treatment crossover, OS will be evaluated using the rank preserving structural failure time (&#8220;RPSFT&#8221;) method, as well as on an intent-to-treat basis. A detailed description of the trial can be found on www.clinicaltrials.gov (Identifier NCT 05506943).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In April 2025, we announced that the trial met its primary endpoint of ORR with a response rate of 17.1% for tovecimig in combination with paclitaxel, including one complete response, compared to 5.3% ORR for paclitaxel alone, with a p-value of 0.031.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<div style="text-align: center;"><img alt="table2.jpg" src="table2.jpg"/></div>

<div style="text-align: center;">&#160;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The waterfall plot below depicts the best overall response for patients evaluated in the trial.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<div style="text-align: center;"><img alt="graph3.jpg" src="graph3.jpg"/></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">We expect to report additional top-line data from this study in April 2026, including progression-free survival and overall survival.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Phase 2 Trial of Tovecimig in CRC </b>&#8211;<b> United States</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In January 2026, we presented data at ASCO GI from tovecimig&#8217;s Phase 2 monotherapy study in patients with advanced, metastatic CRC treated in the third- and fourth-line settings. Tovecimig demonstrated monotherapy activity, with an overall response rate of 5% (2 out of 40 patients), in heavily pre-treated patients, all of whom had previously been treated with bevacizumab (~51% had been treated with two or more prior rounds of bevacizumab). Tovecimig also demonstrated a DCR of 68% (27 out of 40), median PFS of 3.9 months and median OS of 10.2 months. Although DLL4 expression on colorectal tumors is a negative prognostic factor, the data indicate that patients with DLL4-positive tumors did better with tovecimig therapy than patients with DLL4-negative tumors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Tovecimig&#8217;s safety profile was generally consistent with prior studies with hypertension as the most common treatment-emergent adverse event, all of which occurred in patients with a prior history of hypertension.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Additional Development Plans for Tovecimig</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:23pt;">We are preparing for a Phase 2 basket study of tovecimig in a broader set of patients with DLL4+ cancers, potentially including gastric, ovarian, renal, hepatocellular, and colorectal cancers. We expect to initiate the study mid-2026 following a comprehensive analysis of the complete data set from the COMPANION-002 BTC trial.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In addition, we are developing a plan to study the combination of tovecimig with our novel bispecific checkpoint inhibitor, CTX-8371, and with other checkpoint inhibitors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">CTX-471 (CD137 or 4-1BB agonist antibody) </span></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">CTX-471, our monoclonal antibody product candidate, is a fully human, IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. Binding of CTX-471 to CD137 has been observed to lead to ligand-stimulated activation of T-cells and NK cells. In treated mice, dosing with CTX-471 led to extensive reprogramming of the tumor microenvironment, including increased recruitment of immune cells, reversal of exhausted cytotoxic CD8+ T-cells, reductions in immunosuppressive regulatory T-cells and reductions in immunosuppressive tumor-associated macrophages. Long after the completion of the treatment with CTX-471, a period equal to eight half-lives of the antibody, treated mice exhibited immune memory that prevented reestablishment of the same tumor.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The CD137 antigenic site recognized by CTX-471 does not block the binding of CD137 ligand and is differentiated from the site recognized by CD137 antibodies from competitors. We designed the antibody using different backbones and chose to use a human IgG4 backbone for CTX-471 to enable engagement of Fc receptors Fc&#611;RI and Fc&#611;RIIb to facilitate CD137 cross-linking while avoiding binding to Fc&#611;RIIIa and depletion of immune effector cells.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Immune cell depletion experiments showed that the activity of CTX-471 required the presence of CD4+ T-cells, CD8+ T-cells, and NK cells, indicating a coordinated involvement of both innate and adaptive immune cells. Encouragingly, treatment of tumors in mice with CTX-471 led to a marked reprogramming of the immune component of the tumor microenvironment. We also observed that tumors treated with CTX-471 had an approximate two-fold reduction in the number of immunosuppressive tumor-associated macrophages.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Phase 1 Clinical Trial of CTX-471 </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In July 2019, we initiated a Phase 1 trial evaluating the safety and tolerability of CTX-471 as a monotherapy in patients with solid tumors who were previously treated with PD-1 or PD-L1 immune checkpoint inhibitors and subsequently relapsed or progressed after a period of stable disease. The design of this trial included a Phase 1a dose escalation stage followed by a Phase 1b dose expansion stage.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In the Phase 1a dose escalation, CTX-471 was observed to be generally well-tolerated in the Phase 1a stage of the trial. The dose-limiting toxicity was thrombocytopenia. Based on these results, 0.6 mg/kg was determined to be the maximum tolerated dose.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"><b><i>Phase 1b </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In a Phase 1b monotherapy study, we evaluated CTX-471 in patients with solid tumors that had progressed after at least three months on an approved PD-1 or PD-L1 inhibitor. 60 patients with 17 different cancers were enrolled in the trial. Initial results reported from the study included five clinical responses, including a durable PR in a patient with SCLC that converted to a complete response (as confirmed by PET scan) and four additional PRs (three confirmed by RECIST 1.1 and one unconfirmed) in patients with melanoma (3 out of 11 patients) and mesothelioma (1 out of 4 patients). The ORR in the subset of patients with advanced melanoma was 27% (3 of 11). There have been nine SAEs related to CTX-471 in the dose expansion stage of the trial. All nine events resolved. Data were presented at the American Society of Clinical Oncology (&#8220;ASCO&#8221;) Annual Meeting in June 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The responses observed are described below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Three PRs were observed in patients with metastatic melanoma among 11 patients with melanoma in the study. Two of the PRs were confirmed and one was unconfirmed by RECIST 1.1.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A PR was observed in a patient with mesothelioma and confirmed by RECIST 1.1.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The CR was observed in a patient with advanced SCLC who was previously treated with the carboplatin/etoposide and atezolizumab (a PD-L1 blocker) regimen in the first line followed by a treatment with nivolumab (a PD-1 blocker) in the second line. After progression on prior regimens this patient joined the trial and had a PR at week 17 which was confirmed at week 25. This patient was dosed with CTX-471 for more than three years with a durable PR, and in Q4 2023, following tumor regression observed by CT-Scan, the patient was tested by PET scan and a CR was determined. Below is a series of CT scan images from this patient of the largest mass (RUL Lung) which was ~4 cm at baseline.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div style="text-align: center;"><img alt="scan1.jpg" src="scan1.jpg"/></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"><b><i>Biomarker discovery</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In November 2024, we presented novel biomarker data associated with CTX-471 at the 39th Society for Immunotherapy of Cancer (&#8220;SITC&#8221;) Annual Meeting demonstrating a correlation between the levels of neural cell adhesion molecule (&#8220;NCAM&#8221; or CD56) in baseline tumor cell biopsies and disease control in patients treated with CTX-471. To measure pharmacodynamic effects, comparisons were made between pre- and post-CTX-471 treatment. To survey response biomarkers, values from baseline samples obtained from patients with tumors showing complete or partial responses as well as stable disease were compared with tumors showing progressive disease. We hypothesize that NCAM facilitates responses to CTX-471 by enriching for activated NK cells expressing the CTX-471 target, CD137. The dataset shows these effects to be specific for NCAM expressing lymphocytes such as NK cells and is not observed in other lymphocyte subsets such as CD8 T cells. These findings are novel in a clinical setting and support potential use of NCAM as a selection marker.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Additional</b> <b>Development Plans for CTX-471</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Based on the results of the monotherapy and combination arms of the Phase 1 trial, we plan to initiate a Phase 2 study of CTX-471 using NCAM as a biomarker in mid-2026.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">CTX-8371 (PD-1 x PDL-1 Bispecific Antibody)</span></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">CTX-8371 is a bispecific antibody that binds to both PD-1 and PD-L1, the targets of well-known and widely used checkpoint inhibitor antibodies. Preclinical studies demonstrate that CTX-8371 has the ability to outperform PD-1 inhibitors, PD-L1 inhibitors, and combinations of the two to activate T-cells in <i>in vitro</i> assays. In mouse xenografts, treatment with CTX-8371 led to significantly greater tumor growth control and longer survival than treatment with a PD-1 inhibitor alone, a PD-L1 inhibitor alone or the combination of PD-1 and PD-L1 inhibitors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><img alt="cell1.jpg" src="cell1.jpg"/></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CTX-8371 is a PD-1 x PD-L1 bispecific antibody </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Overview of PD-1 and PD-L1 Checkpoint Inhibitors </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">PD-L1 is a surface protein that is overexpressed by over 35% of certain types of cancer, such as melanoma, hepatocellular carcinoma, CRC, and NSCLC. Binding of PD-L1 to its receptor, PD-1, on immune T-cells leads to suppression of cytotoxic CD8+ T-cells preventing immune attack of the tumor. Multiple inhibitors of PD-1 and PD-L1 have been approved as therapies for a broad range of tumors including melanoma, NSCLC, SCLC, head and neck squamous cell cancer, renal cell carcinoma, bladder cancer, gastric cancer, cervical cancer and other cancers with microsatellite instability or mismatch repair deficiency. While PD-1/PD-L1 checkpoint therapies have resulted in remarkable clinical efficacy across multiple cancer types, their efficacy, even in tumors with high immunogenicity, is limited to approximately 20% of patients. Nevertheless, aggregate sales for checkpoint therapies is currently estimated to be approximately $50 billion. There is no approved therapy that combines inhibition of both PD-1 and PD-L1 in the same molecule.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Discovery and Preclinical Activity for CTX-8371 </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The desire to improve the efficacy of PD-1/PD-L1 inhibitors has sparked multiple attempts to create bispecific antibodies in which one antigen binding site targets PD-1 or PD-L1 and the other targets immuno-oncology receptors such as CTLA-4, LAG-3 or CD137. In contrast to those bispecific efforts described by others that have focused on a single pair of antigen-binding domains at a time, we applied our StitchMabs<sup style="vertical-align:top;line-height:120%;">TM</sup> technology in combination with our broad portfolio of selective antibodies to of immune targets across the innate and adaptive immune system to broadly screen for pairs of bispecific antigen-binding domains with the highest potential to generate antitumor activity.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We designed our combinatorial screen such that one antigen-binding domain was directed against PD-1, and the other selected from our library of candidate antibodies. We screened these bispecific constructs in T-cell activation assays in the presence of PD-L1 expressing cells. Our unbiased screening led us to an antibody that pairs a PD-1 binding domain and a PD-L1 binding domain. This novel bispecific antibody contributed to T-cell activation that outperformed the activation observed in response to treatment with only PD-1 antibodies. We designated CTX-8371 as the bispecific antibody we constructed using our common light chain antibodies having a PD-1 and PD-L1 antigen binding domain.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<div style="text-align: center;"><img alt="table3.jpg" src="table3.jpg"/></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>A PD-1 x PD-L1 bispecific antibody outperformed single PD-1 antibodies in a T-cell activation assay </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The observation that the combination of a PD-1 and PD-L1 antibody into a bispecific antibody would be hundreds to thousands fold more potent in a T-cell activation assay than a PD-1 antibody alone was unexpected. A simple model would suggest that inhibiting either PD-1 or PD-L1 should have approximately equal effects in this assay and there would be no advantage to inhibiting both. Further investigation into the mechanism of CTX-8371 found that it led to T-cell activation through four synergistic mechanisms:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Dual checkpoint blocker</b>: preventing PD-L1 to PD-1 binding, thus relieving the immunosuppressive PD-1 signal;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Cell engager</b>: bridging the connection between the PD-L1 expressing tumor cell and the PD-1 expressing T-cell, potentially facilitating T-cell engagement and enhancement of effector function;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Downregulation of PD-1</b>: triggering the cleavage of the extracellular domain of PD-1 receptors from the surface of T-cells resulting in the conversion of PD-1 positive T-cells into PD-1 negative; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Indirect CD28 agonist:</b>&#160;increasing the pool of free CD80 on tumor cells making it available to bind and activate the CD28 T-cell co-stimulatory receptor, thereby, sending a positive signal to the T-cell, which enhances its activation.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<div style="text-align: center;"><img alt="graph4.jpg" src="graph4.jpg"/></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Differentiated mechanism of action of CTX-8371 drives enhanced T-cell activation </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Phase 1 and Development Plans for CTX-8371</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In the first quarter of 2024 we initiated a first-in-human Phase 1 study of CTX-8371 in patients with metastatic or locally advanced malignancies. This Phase 1 trial is a multiple ascending, dose escalation with five doses: 0.1, 0.3, 1.0, 3.0 and 10 mg/kg. The study includes patients who progressed while receiving an approved PD-1 or PD-L1 inhibitor. Other eligibility criteria include patients with metastatic or locally advanced melanoma, non-small cell lung cancer (&#8220;NSCLC&#8221;), head and neck cancer (&#8220;HNCC&#8221;), Hodgkin&#8217;s Lymphoma (&#8220;HL&#8221;) and triple negative breast cancer (&#8220;TNBC&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In the Phase 1 dose-escalation study, CTX-8371 demonstrated 3 confirmed responses out of 15 patients, including patients with both solid tumor and hematologic malignancies: NSCLC, TNBC and HL. The patient with NSCLC achieved complete resolution of all measurable target tumor lesions, and the patient with TNBC achieved over 90% reduction in target tumor lesions. No dose limiting toxicities were observed at any dose level.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">CT scans from the responding patient with NSCLC are below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div style="text-align: center;"><img alt="scan2.jpg" src="scan2.jpg"/></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">CT scans from the responding patient with TNBC are below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div style="text-align: center;"><img alt="scan3.jpg" src="scan3.jpg"/></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Cohort expansions for CTX-8371 are now enrolling patients with TNBC (n=28) and NSCLC (n=28) with an expansion cohort in patients with HL (n=12) expected to begin shortly, all in the post-checkpoint inhibitor setting. Half of the patients with each tumor type will be dosed at 3.0 mg/kg and half will be dosed at 10.0 mg/kg. Initial data from these cohort expansions, as well as available data from the Phase 1 dose-escalation portion of the study, are expected to be presented at a major medical conference in the first half of 2026.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">CTX-10726 (PD-1 x VEGF-A Bispecific Antibody)</span></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">CTX-10726 is a novel, tetravalent PD-1 x VEGF-A bispecific antibody that we discovered, engineered and developed at Compass. CTX-10726 is designed to synergistically deliver VEGF-A blockade and checkpoint inhibition, which is potentially applicable to multiple solid tumor indications.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">CTX-10726 utilizes a fully human IgG1 with silenced Fc-&#947; receptor binding and demonstrates a highly stable structure with high affinity target binding. Based on preclinical studies, CTX-10726 exhibits several-fold more potent PD-1 blockade compared with publicly available data reported for other drugs in the class, and we believe this may be a key differentiator from comparable bispecifics.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The development of CTX-10726 was informed and accelerated by our experience with two of our clinical-stage assets: tovecimig, which contains a VEGF-A targeted component, and CTX-8371, which contains a PD-1 targeted component.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin: 0pt;">&#160;</p>

<div style="text-align: center;"><img alt="cell2.jpg" src="cell2.jpg"/></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CTX-10726 is a PD-1 x VEGF-A bispecific antibody </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In the first quarter 2026, we received FDA clearance for the IND for CTX-10726 and the Phase 1 study will be open for enrollment in Q1 2026. This Phase 1 multiple ascending dose-escalation study of CTX-10726 will include four doses (0.3, 1.0, 3.0, and 10.0 mg/kg) in a 3+3 format. The multi-center study will enroll patients with locally advanced, unresectable or metastatic malignancies, including renal cell carcinoma, gastroesophageal cancer, hepatocellular carcinoma, and endometrial cancer, in whom standard of care therapies have failed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Discovery and Preclinical Activity for CTX-10726 </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">CTX-10726 showed high-affinity binding to both human and cynomolgus monkey VEGF-A and PD-1. CTX-10726 effectively blocked VEGF-A/VEGFR2 and PD-1/PD-L1 interactions in a dose dependent manner and showed reduced engagement with Fc&#947; receptors, limiting off-target immune activation. Functionally, it significantly enhanced IFN-&#947; production in MLRs and tumor cell killing by activated PBMCs. In vivo, CTX-10726 outperformed benchmark biosimilar anti-VEGF or PD-1 antibodies in controlling tumor growth across multiple xenograft and syngeneic models.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The dual blockade of PD-1 and VEGF-A by CTX-10726 produced superior anti-tumor activity compared to anti-VEGF-A treatment or ivonescimab (****, P &lt;0.0001, Two-way ANOVA), demonstrating enhanced in vivo potency in the following model:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Human NSCLC (HCC827) Xenografts</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Treated with human PBMCs and indicated antibodies</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Testing both PD-1 and VEGF-A targeting</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div style="text-align: center;"><img alt="graph5.jpg" src="graph5.jpg"/></div>

<div style="text-align: center;">&#160;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>License Agreements </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"><b><i>Tovecimig (DLL4 X VEGF-A bispecific antibody)</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our wholly owned subsidiary Trigr Therapeutics, Inc. (&#8220;TRIGR&#8221;) and ABL Bio, a South Korean biotechnology company, entered into an exclusive global (excluding South Korea) license agreement (the &#8220;TRIGR License Agreement&#8221;) which granted TRIGR a license to ABL001 (renamed CTX-009 and subsequently tovecimig). Under the terms of the agreement, ABL Bio and TRIGR would jointly develop tovecimig, with ABL Bio responsible for development of tovecimig throughout the end of Phase 1 clinical trials and TRIGR responsible for the development of tovecimig from Phase 2 and onward.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">ABL Bio received a $5 million upfront payment and a $6 million milestone payment. In addition, ABL Bio is eligible to receive up to $96 million of development and regulatory milestone payments, up to $303 million of commercial milestone payments and tiered single-digit royalties on net sales of tovecimig in oncology. ABL Bio is also eligible to receive up to $75 million in development and regulatory milestone payments and up to $110 million in commercial milestone payments and tiered, single-digit royalties on net sales of tovecimig in ophthalmology. The financial terms of the agreement were amended in May 2021 but remain substantially similar to the terms in the TRIGR License Agreement. As a result of the TRIGR acquisition, we have assumed all the rights and obligations of the TRIGR License Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"><b><i>CTX-471 (CD137 agonist antibody)</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We entered into an amended and restated collaboration agreement with Adimab, LLC ("Adimab"), dated February 11, 2015. This agreement relates to our license from Adimab for certain antibodies for development and commercialization as biopharmaceutical products, including our acquired product candidate, CTX-471. We were granted an exclusive option to license and potentially acquire antibodies under the agreement, which we exercised with respect to CTX-471. We are required to make payments upon achievement of development milestones that, as of December 31, 2025, amounted to $3.5 million, of which we have already made $1.5 million in milestone payments, and we have additional potential payments due in the amount of $2.0 million. In addition, we are required to pay royalties at rates ranging in the single digits as a percentage of future net sales within a specified term from the first commercial sale.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Intellectual Property </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Overview </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We strive to protect the proprietary technology, inventions, and know-how to enhance improvements that are important to the development of our business, including seeking, maintaining, and defending patent rights. We also rely on trade secrets and know-how relating to our proprietary technology platform, on continuing technological innovation and on in-licensing opportunities to develop, strengthen and maintain the strength of our position in the field of antibody therapeutics that may be important for the development of our business. We additionally may rely on regulatory protection afforded through data exclusivity, market exclusivity and patent term extensions where available.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our success depends in part on our ability to: obtain and maintain patent and other protections for commercially important technology, inventions and know-how related to our business; defend and enforce our patents; preserve the confidentiality of our trade secrets; and operate without infringing the valid enforceable patents and intellectual property rights of third parties.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our ability to stop third parties from making, using, selling, offering to sell, or importing our products depends in large part on the extent to which we have rights under valid and enforceable licenses, patents, or trade secrets that cover these activities. In some cases, these rights may need to be enforced by third-party licensors. With respect to company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be useful in protecting our commercial products and methods of manufacturing the same. For more information, please see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We seek to protect our proprietary position by, among other things, filing patent applications in the United States and internationally in certain jurisdictions where it is available. For example, we file U.S. and selected foreign patent applications related to our proprietary technology, inventions, and improvements that are important to the development of our business. We also intend to seek patent protection, or rely upon trade secret rights, to protect other technologies that may be used to discover and validate targets and that may be used to identify and develop novel products or improvements thereof. We seek protection, in part, through confidentiality and proprietary information agreements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional application which matures into a granted patent. A U.S. patent also may be accorded a patent term adjustment ("PTA"), under certain circumstances to compensate for delays in obtaining the patent caused by the U.S. Patent and Trademark Office. In some instances, such a PTA may result in a U.S. patent term extending beyond 20 years from the earliest date of filing a non-provisional patent application. In addition, in the U.S., the term of a U.S. patent that covers an FDA approved drug may also be eligible for patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the original expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We plan to seek patent term extensions to any of our issued patents in any jurisdiction where these are available; however, there is no guarantee that the applicable authorities, including the FDA in the U.S., will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Patent Protection </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">For all patent applications, we determine strategy for claim scope on a case-by-case basis, taking into account advice of counsel and our business model and needs. We file patents containing claims for protection of all useful applications of our proprietary technologies and any products, as well as all new applications and/or uses we discover for existing technologies and products, based on our assessment of their strategic value. We continuously reassess the number and type of patent applications, as well as pending and issued patent claims to ensure that maximum coverage and value are obtained for our processes and compositions, given existing patent office rules and regulations. Further, claims may be modified during patent prosecution to meet our intellectual property and business needs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our patent estate includes patent applications with claims relating to our product candidates, methods of use and manufacturing processes, and claims for potential future products and developments. As of January 31, 2026, we have nearly 100 issued patents and patent applications pending in the United States and foreign jurisdictions relating to tovecimig, CTX-471, CTX-8371, CTX-10726, and other discovery and research programs. We have 7 patents issued in the United States and 23 issued patents in Taiwan, China, Eurasia, Japan, Korea, Malaysia, Singapore and New Zealand related to our CTX-471 program, and 3 patents issued in the United States, and 8 issued patents in China, Japan, Malaysia, Mexico, and Taiwan, related to our CTX-8371 program. We also have access to patents issued in Australia, Europe and the United States related to our antibody and display programs, as well as 27 patents issued in Australia, Canada, China, Europe, Japan, Korea, Russia and 2 in United States related to our tovecimig program.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">More specifically, we have licensed 2 patent families with 2 issued patents in U.S. and 27 issued patents in foreign jurisdictions, related to our DLL4/VEGF antibody program including, but not limited to, our tovecimig therapeutic candidate. Patents in these patent families are generally expected to start to expire in 2033, subject to possible extension.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We own 4 pending patent families with 10 issued U.S. patents and issued patents in Taiwan, China, Eurasia, Israel, Japan, Korea, Malaysia, Mexico, Singapore, and New Zealand, 3 U.S. patent applications, and 35 patent applications in foreign jurisdictions, related to our CD137 agonist antibody therapeutic platform including, but not limited to, our CTX-471 therapeutic candidate. Patents that grant from these patent families are generally expected to start to expire in 2038, subject to possible patent term extension.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We own 1 pending patent family with 3 issued U.S. patents, issued patents in China, Japan, Malaysia, Mexico, and Taiwan, 1 U.S. patent application, and 21 patent applications in foreign jurisdictions, related to our PD-1/PD-L1 bispecific antibody therapeutic platform including, but not limited to, our CTX-8371 therapeutic candidate. Patents that grant from these patent families are generally expected to start to expire in 2039, subject to possible patent term extension.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We own, or have an ownership interest in, 2 pending patent families with 1 issued patent in the U.S., 1 U.S. pending patent application and 2 patent applications in foreign jurisdictions, related to our CD277 discovery and research programs. Patents that grant from these patent families are generally expected to start to expire in 2039, subject to possible patent term extension.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We own 1 pending patent family with 1 issued U.S. patent and 1 patent application in foreign jurisdictions related to our antibody and display programs including, but not limited to, common light chains. Patents that grant from this patent family are generally expected to start to expire in 2039, subject to possible patent term extension.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Trademark Protection </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We have filed for and obtained trademark protection in multiple jurisdictions for the COMPASS THERAPEUTICS word mark and logo for goods and services. We have filed for and obtained trademark protection on the StitchMabs<sup style="vertical-align:top;line-height:120%;">TM</sup> word mark in the United States for services.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Trade Secret Protection </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Finally, we may rely, in some circumstances, on trade secrets to protect our technology. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. For further information, please see &#8220;<i>Risk Factors</i>&#8212;<i>Risks Related to Our Intellectual Property</i>.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Competition </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The biotechnology and pharmaceutical industries, and the immuno-oncology subsector, are characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property. We believe that our programs, including tovecimig, CTX-471, CTX-8371, CTX-10726, and our platform technologies, including our StitchMabs<sup style="vertical-align:top;line-height:120%;">TM</sup> platform and our programs, technology, knowledge, experience and scientific resources provide us with competitive advantages, but we also face competition from pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others. Our competitors include larger and better funded biopharmaceutical, biotechnology and therapeutics companies, including companies focused on cancer immunotherapies, such as AbbVie, Amgen, Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly, Genentech, Inc., GlaxoSmithKline PLC, Johnson &amp; Johnson, Merck &amp; Co., Inc., Merck KGaA, Novartis AG, Pfizer Inc., Roche Holding Ltd and Sanofi S.A. Moreover, we may also compete with smaller or earlier-stage companies, universities and other research institutions that have developed, are developing or may be developing current and future cancer therapeutics.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Product candidates that we successfully develop will compete with a range of therapies that are currently approved and any new therapies that may become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products. Currently marketed oncology drugs and therapeutics range from traditional cancer therapies, including chemotherapy, to antibody-drug conjugates, such as Genentech Inc.&#8217;s Kadcyla, to immune checkpoint inhibitors targeting CTLA-4, such as BMS&#8217;s Yervoy, to PD-1/PD-L1, such as BMS&#8217;s Opdivo, Merck &amp; Co.&#8217;s Keytruda and Genentech&#8217;s Tecentriq, to T cell-engager immunotherapies, such as Amgen&#8217;s Blincyto and VEGF targets, such as Genentech Inc.&#8217;s Avastin. In addition to these marketed therapies, numerous compounds are in clinical development for the potential treatment of cancer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">20</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Biliary tract cancers are aggressive gastrointestinal cancers that have a very poor prognosis. First line treatment of locally advanced or metastatic BTC includes the chemotherapy combination of gemcitabine and cisplatin, often with the addition of the PD-L1 inhibitor Imfinzi&#174; (durvalumab) or PD-1 inhibitor Keytruda (pemrolizumab). In September of 2022, AstraZeneca received FDA approval of durvalumab in combination with gemcitabine/cisplatin for the first line treatment of BTC. In addition, Merck received FDA approval of pembrolizumab&#160;in combination with gemcitabine/cisplatin for the first line treatment of BTC in October of 2023. The only FDA approved therapies for second line treatment of BTC are targeted therapies that address specific tumor mutations or solid tumors that are microsatellite instability high. For example, in November 2024, Jazz Pharmaceuticals received FDA approval of Ziihera (zanidatamab-hrii) for previously treated, unresectable, or metastatic human epidermal growth factor receptor (&#8220;HER2&#8221;) positive (IHC 3+) biliary tract cancer, which may be beneficial to the small subset of patients in whom HER2 is amplified overexpressed. We believe that the combination of all targeted therapies are appropriately 10-15% of patients with BTC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Colorectal cancer is the second most common cause of cancer deaths in the United States and constitutes approximately 10% of all annually diagnosed cancer and cancer related deaths globally. Treatment of metastatic disease in the first line typically includes either the VEGF inhibitor Avastin&#174; (bevacizumab) or an EGFR inhibitor such as Erbitux&#174; (cetuximab), combined with chemotherapy. Treatment in the second line includes re-treatment with either a VEGR or EGFR inhibitor and a different chemotherapy regimen that is either oxaliplatin or irinotecan based. Approved therapies for advanced patients with metastatic disease are limited, with approved agents such as Lonsurf&#174; (trifluridine and tipiracil) and Stivarga&#174; (regorafenib) offering only 1-2% response rates and improvement in survival of 1-2 months.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">If we are successful in advancing one or more of our product candidates toward registrational trials and filing a BLA or BLAs, and if we are successful at obtaining approvals from the FDA or any other regulatory agency to market one or more of our product candidates, then the availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. Our competitors, who may be successful at obtaining marketing approval from the FDA or other regulatory approval for their products prior to us obtaining marketing approval for our product candidates, could result in our competitors launching their products sooner and establishing a strong market position before we are even able to enter the market.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Sales and Marketing </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We hold worldwide rights to all of our product candidates (with the exception of limited countries for tovecimig), which provide us the optionality to grow our internal pipeline independently or partner selected rights to our product candidates in different geographies throughout the world. Subject to receiving marketing approval, we intend to maximize the value of our product candidates by either independently planning to pursue the commercialization of our products in one or more major geographies by building an internal sales and marketing organization, or by seeking collaborations with third parties with commercialization infrastructure.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Manufacturing </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We do not currently own or operate manufacturing facilities for the production of clinical quantities of our product candidates. We have relied on, and intend to continue to rely on, qualified third-party contract manufacturers to produce our product candidates, including clinical supplies to support our clinical trials. At the appropriate time in the product development process, we will determine whether to establish manufacturing facilities or continue to rely on third parties to manufacture clinical quantities of any products that we may successfully develop. We expect that commercial quantities of any compound and materials for our product candidates, if approved, will be manufactured in facilities and by processes that comply with FDA and other regulations, which may differ from our current clinical supply manufacturers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Government Regulation </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Government authorities in the United States, including federal, state, and local authorities, and in other countries, extensively regulate, among other things, the manufacturing, research and clinical development, marketing, labeling and packaging, storage, distribution, post-approval monitoring and reporting, advertising and promotion, and export and import of biological products, such as those we are developing. In addition, some government authorities regulate the pricing of such products. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and financial resources.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Review and Approval for Licensing Biologics in the United States </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In the United States, the FDA regulates biological products under the Federal Food, Drug, and Cosmetic Act ("FDCA"), and the Public Health Service Act ("PHSA"), and their implementing regulations. FDA approval is required before any biological product can be marketed in the United States. Biological products are also subject to other federal, state, and local statutes and regulations. If we fail to comply with applicable FDA or other requirements at any time during the product development process, clinical testing, the approval process or after approval, we may become subject to administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, untitled or warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution. Any FDA enforcement action could have a material adverse effect on us.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The process required by the FDA before product candidates may be marketed in the United States generally involves the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">completion of extensive nonclinical laboratory tests and nonclinical animal studies, all performed in accordance with the Good Laboratory Practices ("GLP"), regulations;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">submission to the FDA of an IND, which must become effective before human clinical trials may begin and must be updated annually;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">approval by an independent institutional review board ("IRB"), or ethics committee representing each clinical site before each clinical trial may be initiated;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practices ("GCPs"), to establish the safety and efficacy of the product candidate for each proposed indication;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">preparation of and submission to the FDA of a BLA, after completion of all pivotal clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">review of the product application by an FDA advisory committee, where appropriate and if applicable;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review; satisfactory completion of an FDA pre-approval inspection of the manufacturing facilities where the proposed product is produced to assess compliance with current Good Manufacturing Practices ("cGMP");</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">satisfactory completion of any FDA audits of the clinical trial sites to assure compliance with GCPs, and the integrity of clinical data in support of the BLA; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">FDA review and approval of a BLA for a biological product candidate that is safe, pure, and potent prior to any commercial marketing or sale of the product in the United States.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The nonclinical and clinical testing and approval process requires substantial time, effort, and financial resources, and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, if at all.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Before testing any drug or biologic in humans, a product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluations of product chemistry, formulation, and stability, as well as in vitro and animal studies to assess safety and in some cases to establish the rationale for therapeutic use. The conduct of preclinical studies is subject to federal and state regulation and requirements, including GLP requirements for safety/toxicology studies. The results of the preclinical studies, together with manufacturing information and analytical data, must be submitted to the FDA as part of an IND.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">22</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">An IND is a request for authorization from the FDA to administer an investigational biological product to humans in clinical trials. The central focus of an IND submission is on the general investigational plan, the protocol(s) for human trials and the safety of trial participants. The IND also includes results of animal and in vitro studies assessing the toxicology, PK, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. An IND will automatically become effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to the proposed clinical trials. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before clinical trials can begin. Accordingly, submission of an IND may or may not result in the FDA allowing clinical trials to commence. The FDA may impose a clinical hold at any time during clinical trials and may impose a partial clinical hold that would limit trials, for example, to certain doses or for a certain length of time.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Clinical Trials </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the efficacy criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. Additionally, approval must also be obtained from each clinical trial site&#8217;s IRB, before the trials may be initiated and the IRB must monitor the trial until completed. There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The clinical investigation of a biological product is generally divided into three or four phases. Although the phases are usually conducted sequentially, they may overlap or be combined.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;"><i>Phase 1</i>. The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These trials are designed to evaluate the safety, dosage tolerance, metabolism and pharmacologic actions of the investigational product in humans, the side effects associated with increasing doses, and if possible, to gain early evidence on effectiveness.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;"><i>Phase 2</i>. The investigational product is administered to a limited patient population to evaluate dosage tolerance and optimal dosage, identify possible adverse side effects and safety risks, and preliminarily evaluate efficacy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;"><i>Phase 3</i>. The investigational product is administered to an expanded patient population, generally at geographically dispersed clinical trial sites to generate enough data to statistically evaluate safety, purity and potency, to evaluate the overall benefit-risk profile of the investigational product, and to provide an adequate basis for physician labeling.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;"><i>Phase 4</i>. In some cases, the FDA may condition approval of a BLA for a product candidate on the sponsor&#8217;s agreement to conduct additional clinical trials after approval. In other cases, a sponsor may voluntarily conduct additional clinical trials after approval to gain more information about the biological product. Such post-approval trials are typically referred to as Phase 4 clinical trials.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In March 2022, the FDA released a final guidance titled &#8220;Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics,&#8221; which outlines how drug developers can utilize an adaptive trial design commonly referred to as a seamless trial design in early stages of oncology drug development (i.e., the first-in-human clinical trial) to compress the traditional three phases of trials into one continuous trial called an expansion cohort trial. Information to support the design of individual expansion cohorts is included in IND applications and assessed by FDA. Expansion cohort trials can potentially bring efficiency to drug development and reduce development costs and time.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">23</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Sponsors must also report to the FDA, within certain timeframes, serious and unexpected adverse reactions, any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator&#8217;s brochure, or any findings from other studies or animal or in vitro testing that suggest a significant risk in humans exposed to the product candidate. The FDA, the IRB, or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data and safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the trial. We may also suspend or terminate a clinical trial based on evolving business objectives or competitive climate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">A sponsor of an investigational biological product for a serious disease or condition is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for individual patient access to such investigational biological product. This requirement applies on the earlier of the first initiation of a Phase 2 or Phase 3 trial of the investigational biological product or, as applicable, 15 days after the biological product receives a designation as a breakthrough therapy or fast track product.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Concurrent with clinical trials, sponsors usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate and finalize a process for manufacturing the drug product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and manufacturers must develop, among other things, methods for testing the identity, strength, quality, and purity of the final drug product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Sponsors of applicable clinical trials of FDA-regulated products are required to register and disclose certain clinical trial information within specific timeframes for publication on www.clinicaltrials.gov. Sponsors also must disclose certain results of these clinical trials, although disclosure of results may be delayed until after the new product or new indication has been approved by the FDA. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs, as well as clinical trial design. Failure to timely register a covered clinical study or to submit study results as provided for in the law can give rise to public notifications of noncompliance, civil monetary penalties, and also prevent the non-compliant party from receiving future grant funds from the federal government.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Submission of a BLA to the FDA </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, detailed investigational product information is submitted to the FDA in the form of a BLA requesting approval to market the product for one or more indications. Under federal law, the submission of most BLAs is subject to an application user fee. For fiscal year 2025, the user fee for an application requiring clinical data is $4,310,002, and the sponsor of an approved BLA is also subject to an annual program fee of $403,889 for each approved biological product on the market. These fees are typically increased annually. Applications for orphan drug products are exempted from the BLA application fee and may be exempted from program fees, unless the application includes an indication for other than a rare disease or condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">A BLA must include all relevant data available from pertinent nonclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including trials initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the investigational product to the satisfaction of the FDA.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">24</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The FDA conducts a preliminary review of all BLAs within the first 60 days after submission before accepting them for filing to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an application for filing. Once a BLA has been submitted, the FDA&#8217;s goal for novel biological products generally is to review the application within ten months after it accepts the application for filing, or, if the application relates to an unmet medical need in a serious or life-threatening indication, six months after the FDA accepts the application for filing. The review process is often significantly extended by the FDA&#8217;s requests for additional information or clarification.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Before approving a BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The FDA is required to refer an application for a novel biological product to an advisory committee or explain why such referral was not made. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>The FDA</i>&#8217;<i>s Decision on a BLA </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">After the FDA evaluates the BLA and conducts relevant inspections, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the biological product with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete Response Letter will identify the deficiencies that prevent the FDA from approving the application and may require additional clinical data or an additional Phase 3 clinical trial(s), or other significant, expensive and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. Even if such additional information is submitted, the FDA may ultimately decide that the BLA does not satisfy the criteria for approval and issue a denial.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The FDA could also approve the BLA with a Risk Evaluation and Mitigation Strategy ("REMS"), program to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling, development of adequate controls and specifications, or a commitment to conduct one or more post-market studies or clinical trials. Such post-market testing may include Phase 4 clinical trials and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">New government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Expedited Review and Accelerated Approval Programs </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">A sponsor may seek approval of its product candidate under programs designed to accelerate FDA&#8217;s review and approval of BLAs. For example, fast track designation may be granted to a biological product intended for treatment of a serious or life-threatening disease or condition that has potential to address unmet medical needs. The key benefits of fast track designation are more frequent interactions with the FDA during development and testing, the eligibility for priority review, and rolling review, which is submission of portions of an application before the complete marketing application is submitted.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">25</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Additionally, the FDA may grant a product candidate priority review designation, which sets the target date for FDA action on the marketing application for a novel product at six months after the FDA accepts the application for filing. Priority review is granted where the proposed product is intended to treat a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. If criteria are not met for priority review, the application is subject to the standard FDA review period of ten months after FDA accepts the application for filing. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Under the accelerated approval program, the FDA may approve a BLA for a product that is intended to treat a serious or life-threatening disease or condition upon the determination that the product generally provides meaningful therapeutic benefit to patients over available treatments and demonstrates an effect on either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Accelerated approval is usually contingent on a sponsor&#8217;s agreement to conduct post-approval confirmatory trials or complete ongoing trials in a diligent manner to verify the product&#8217;s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022 (&#8220;FDORA&#8221;), the FDA is now permitted to require, as appropriate, that post-approval confirmatory trials be underway prior to approval or within a specific time period after accelerated approval is granted and the FDA has increased authority for expedited procedures to withdraw approval of a product or an indication approved under accelerated approval if, for example, the confirmatory trial is not conducted with due diligence or fails to verify the predicted clinical benefit of the product. Additionally, the FDA generally requires, unless otherwise informed by the agency, that all advertising and promotional materials intended for dissemination or publication within 120 days of marketing approval be submitted to the agency for preapproval and pre-use review.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In addition, a sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the biological product is intended, alone or in combination with one or more other drugs or biological products, to treat a serious or life- threatening disease or condition and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The benefits of breakthrough therapy designation include the same benefits as a fast-track designation, in addition to intensive guidance from FDA to ensure an efficient development program.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Finally, with respect to oncology products, the FDA may review applications under Real-Time Oncology Review (&#8220;RTOR&#8221;) established by the FDA&#8217;s Oncology Center of Excellence. RTOR allows an applicant to pre-submit components of the application to allow the FDA to review clinical data before the complete filing is submitted in order to create more efficient review process to ensure that safe and effective treatments are available to patients as early as possible, while maintaining and improving review quality. Drugs considered for review under RTOR must, among other things, be likely to demonstrate substantial improvements on a clinically relevant endpoint(s) over available therapy and must have easily interpreted endpoints. In addition, no aspect of the application should be likely to require a longer review time (for example, a Risk Evaluation and Mitigation Strategy). To determine eligibility for RTOR, the FDA requires top-line efficacy and safety results from an applicant.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Post-Approval Requirements </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Biological products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. Biological product manufacturers are subject to periodic unannounced inspections by the FDA and state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide to use. Manufacturers and manufacturers&#8217; facilities are also required to comply with applicable product tracking and tracing requirements and notify the FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the United States. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">26</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We rely, and expect to continue to rely, on third parties for the production of clinical quantities of our product candidates and expect to rely in the future on third parties for the production of commercial quantities. Future FDA and state inspections may identify compliance issues at our facilities or at the facilities of our contract manufacturers that may disrupt production, or distribution, or may require substantial resources to correct. In addition, discovery of previously unknown problems with a product or the failure to comply with applicable requirements may result in restrictions on a product, manufacturer or holder of an approved BLA, including withdrawal or recall of the product from the market or other voluntary, FDA-initiated or judicial action that could delay or prohibit further marketing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The FDA may suspend or revoke product license approvals if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. FDA has authority to require post-market studies, in certain circumstances, on reduced effectiveness of a biological product and FDA may require labeling changes related to new reduced effectiveness information. Other potential consequences of a failure to maintain regulatory compliance include, among other things:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">fines, untitled or warning letters or holds on post-approval clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">refusal of the FDA to approve pending BLAs or supplements to approved BLAs;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">product seizure or detention, or refusal to permit the import or export of products; or</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">injunctions or the imposition of civil or criminal penalties.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Biological products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Pediatric Trials and Exclusivity </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">A sponsor who is planning to submit a marketing application for a biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must submit an initial Pediatric Study Plan ("PSP"), within sixty days of an end of Phase 2 meeting or as may be agreed between the sponsor and FDA. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. Generally, development program candidates designated as orphan drugs are exempt from the above requirements. FDA and the sponsor must reach agreement on the PSP. A sponsor can submit amendments to an agreed upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from nonclinical studies, early phase clinical trials, and/or other clinical development programs. Additionally, for molecularly targeted cancer drugs, beginning after February 3, 2029, the FDA may require testing of certain novel single ingredient or combination regimens to yield clinically meaningful pediatric study data that is gathered using appropriate formulations for each age group for which the study is required, including dosing, safety, and preliminary efficacy to inform potential pediatric labeling.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">27</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Pediatric exclusivity is another type of non-patent exclusivity in the United States and, if granted for a biologic, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity for all formulations, dosage forms, and indications of the biologic, including the five-year and three-year non-patent and orphan exclusivity. This six-month exclusivity may be granted if a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data, provided that at the time pediatric exclusivity is granted there is not less than nine months of term remaining. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of FDA-requested pediatric trials are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity covering the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot accept or approve another application relying on the BLA sponsor&#8217;s data.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Patent Term Restoration </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Depending upon the timing, duration, and specifics of the FDA approval of the use of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA, plus the time between the submission date and the approval of that application. Only one patent applicable to an approved product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent and within 60 days of the product&#8217;s approval. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for one of our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Biosimilars and Exclusivity </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The Patient Protection and Affordable Care Act ("Affordable Care Act"), signed into law on March 23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 ("BPCIA"), which created an abbreviated approval pathway for biological products shown to be similar to, or interchangeable with, an FDA-licensed reference biological product. This amendment to the Public Health Service Act (&#8220;PHSA&#8221;) attempts to minimize duplicative testing. Biosimilarity, which requires that there be no clinically meaningful differences between the proposed biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical trial or trials. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of its product. In addition, the BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. The first biologic submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product is eligible for a period of exclusivity against other biologics submitted under the abbreviated approval pathway during which time the FDA may not determine that another product is interchangeable with the same reference product for any condition of use. The FDA may approve multiple &#8220;first&#8221; interchangeable products so long as they are all approved on the same first day of marketing. This exclusivity period, which may be shared amongst multiple first interchangeable products, lasts for the lesser of (i) one year after the first commercial marketing, (ii) 18 months after approval if there is no legal challenge, (iii) 18 months after the resolution in the applicant&#8217;s favor of a lawsuit challenging the biologic&#8217;s patents if an application has been submitted, or (iv) 42 months after the application has been approved if a lawsuit is ongoing within the 42-month period. Products deemed &#8220;interchangeable&#8221; by the FDA may be readily substituted by pharmacies and such substitution is which are governed by state pharmacy law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">28</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>European Union/Rest of World Government Regulation </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. The cost of establishing a regulatory compliance system for numerous varying jurisdictions can be very significant. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union and in other jurisdictions, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. The requirements and process governing the conduct of clinical trials vary from country to country. In all cases, the clinical trials are conducted in accordance with GCP, the applicable regulatory requirements, and the ethical principles that have their origin in the Declaration of Helsinki. To obtain regulatory approval of a medicinal product under European Union regulatory systems, we must submit a marketing authorization application. The content of the BLA filed in the United States is similar to that required in the European Union, with the exception of, among other things, country-specific document requirements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">For other countries outside of the European Union, such as countries in Eastern Europe, Latin America or Asia, the requirements governing product licensing, pricing, and reimbursement vary from country to country.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Countries that are part of the European Union, as well as countries outside of the European Union, have their own governing bodies, requirements, and processes with respect to the approval of biological products. If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Clinical Trial Approval in the European Union</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In April 2014, the European Union adopted the Clinical Trials Regulation (EU) No 536/2014, which replaced the Clinical Trials Directive 2001/20/EC on January 31, 2022. The Clinical Trials Regulation is directly applicable in all European Union Member States meaning no national implementing legislation in each European Union Member State is required. The Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the European Union. Under the new coordinated procedure for the approval of clinical trials, the sponsor of a clinical trial is required to submit a single application for approval of a clinical trial to a reporting European Union Member State centralized portal known as the Clinical Trials Information System. The submission procedure is the same irrespective of whether the clinical trial is to be conducted in a single European Union Member State or in more than one European Union Member State.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">29</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Marketing Authorization Procedures in the European Union </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Medicines can be authorized in the European Union by using either the centralized authorization procedure or a national authorization procedure.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"><i>Centralized procedure</i>. The European Medicines Agency ("EMA"), implemented the centralized procedure for the approval of human medicines to facilitate marketing authorizations that are valid throughout the European Economic Area ("EEA"), which is comprised of the Member States of the European Union plus Norway, Iceland, and Lichtenstein. This procedure results in a single marketing authorization issued by the EMA that is valid across the EEA. The centralized procedure is compulsory for human medicines that: are derived from biotechnology processes, such as genetic engineering; contain a new active substance indicated for the treatment of certain diseases, such as HIV, AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases and other immune dysfunctions; are advanced therapy medicines (gene-therapy, somatic cell-therapy or tissue-engineered medicines); and are officially designated orphan medicines.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">For medicines that do not fall within these categories, an applicant has the option of submitting an application for a centralized marketing, as long as the medicine concerned is a significant therapeutic, scientific or technical innovation, or if its authorization would be in the interest of public health in the European Union.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Under the centralized procedure, the EMA&#8217;s Committee for Medicinal Products for Human Use ("CHMP") is responsible for conducting the initial assessment of a product and for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure in the European Union, the maximum timeframe for the evaluation of a marketing authorization application is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP). Clock stops may extend the timeframe of evaluation of a marketing authorization application considerably beyond 210 days. Where the CHMP gives a positive opinion, it provides the opinion together with supporting documentation to the European Commission, who makes the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#8217;s recommendation. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. In this circumstance, the EMA ensures that the opinion of the CHMP is given within 150 days, excluding clock stops, but it is possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"><i>National authorization procedures</i>. There are also two other possible routes to authorize medicinal products in several European Union countries, which are available for medicinal products that fall outside the scope of the centralized procedure:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"><i>Decentralized procedure</i>. Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one European Union Member State of medicinal products that have not yet been authorized in any European Union Member State and that do not fall within the mandatory scope of the centralized procedure.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"><i>Mutual recognition procedure</i>. In the mutual recognition procedure, a medicine is first authorized in one European Union Member State, in accordance with the national procedures of that Member State. Following this, further marketing authorizations can be sought from other European Union Member States in a procedure whereby the Member State concerned agree to recognize the validity of the original, national marketing authorization.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Companies applying for a marketing authorization in the Europea Union must also agree upon a pediatric investigation plan (&#8220;PIP&#8221;) with the EMA&#8217;s Pediatric Committee and must conduct pediatric clinical trials in accordance with that PIP unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">30</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Data and Market Exclusivity in the European Union </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In the European Union, innovative medicinal products approved on the basis of a complete and independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing the innovator&#8217;s pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the European Union, during a period of eight years from the date on which the reference product was first authorized in the European Union. During an additional two-year period of market exclusivity, a generic or biosimilar marketing authorization application can be submitted and authorized, and the innovator&#8217;s data may be referenced, but no generic or biosimilar medicinal product can be placed on the European Union market until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. There is no guarantee that a product will be considered by the EMA to be an innovative medicinal product, and products may not qualify for data exclusivity. Even if a product is considered to be an innovative medicinal product so that the innovator gains the prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company obtained a marketing authorization based on a marketing authorization application with a complete and independent data package of pharmaceutical tests, preclinical tests and clinical trials.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">All of the aforementioned European Union rules are generally applicable in the EEA.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Reform of the Regulatory Framework in the European Union</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The European Commission introduced legislative proposals in April 2023 that, if implemented, will replace the current regulatory framework in the European Union for all medicines (including those for rare diseases and for children). The European Commission has provided the legislative proposals to the European Parliament and the European Council for their review and approval and, in April 2024, the European Parliament proposed amendments to the legislative proposals. Once the European Commission&#8217;s legislative proposals are approved (with or without amendment), they will be adopted into EU law. In October 2023, the European Parliament published draft reports proposing amendments to the legislative proposals, which will be debated by the European Parliament. Once the European Commission&#8217;s legislative proposals are approved (with or without amendment), they will be adopted into European Union law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Pharmaceutical Coverage, Pricing and Reimbursement </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we may receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement for our products from third-party payors, such as government healthcare programs (e.g., Medicare, Medicaid), managed care providers, private health insurers, health maintenance organizations, and other organizations. These third-party payors decide which medications they will pay for and will establish reimbursement levels. The availability of coverage and extent of reimbursement by governmental and other third-party payors is essential for most patients to be able to afford treatments such as antibody-based therapies.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services ("CMS"), an agency within the U.S. Department of Health and Human Services ("HHS"). CMS decides whether and to what extent our products will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. Factors payors consider in determining reimbursement are based on whether the product is:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a covered benefit under its health plan;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">safe, effective and medically necessary;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">appropriate for the specific patient;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">31</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">cost-effective; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">neither experimental nor investigational.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors, including government healthcare programs (e.g., Medicare, Medicaid), managed care providers, private health insurers, health maintenance organizations, and other organizations. Moreover, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">No uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the reimbursement rate that the payor will pay for the product. One payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. Third-party payors may also limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Further, third-party payors are increasingly challenging the price and examining the medical necessity and cost- effectiveness of medical products and services, in addition to their safety and efficacy. In order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or comparable regulatory approvals. Additionally, we may also need to provide discounts to purchasers, private health plans or government healthcare programs. Our product candidates may nonetheless not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union Member States can restrict the range of medicinal products for which their national health insurance systems provide reimbursement and they can control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A European Union Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Approaches between European Union Member States are diverging. For example, in France, effective market access will be supported by agreements with hospitals and products may be reimbursed by the Social Security Fund. The price of medicines is negotiated with the Economic Committee for Health Products ("CEPS"). There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Current and future healthcare reform legislation </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In the United States and in some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively, the Affordable Care Act ("ACA"), among other things, subjects biological products to potential competition by lower-cost biosimilars, expands the types of entities eligible for the 340B drug discount program, increases rebates for drugs sold to Medicaid programs owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and created a mandatory discount program for certain Medicare Part D beneficiaries in which manufacturers must agree 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">32</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In addition, other legislative and regulatory changes have been proposed and adopted in the United States since the ACA was enacted:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On August 2, 2011, the U.S. Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year, which will remain in effect through 2031.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On January 2, 2013, the U.S. American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On April 13, 2017, CMS published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On&#8239;May 23, 2019, CMS published a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminated the statutory Medicaid drug rebate cap, set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. Recently, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. Such scrutiny has resulted in several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare and reform government program reimbursement methodologies for drug products. For example, at the federal level, President Trump reversed some of President Biden&#8217;s executive orders including rescinding Executive Order 14087 titled &#8220;Lowering Prescription Drug Costs for Americans." President Trump may issue new executive orders designed to impact drug pricing. A number of these and other proposed measures may require authorization through additional legislation to become effective. Congress and the Trump administration have indicated that they will continue to seek new legislative measures to control drug costs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In August 2022, the IRA was signed into law. The IRA includes several provisions that will impact our business to varying degrees, including provisions that create a $2,000 out-of-pocket cap for Medicare Part D beneficiaries, impose new manufacturer financial liability on all drugs in Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, require companies to pay rebates to Medicare for drug prices that increase faster than inflation, and delay the rebate rule that would require pass through of pharmacy benefit manager rebates to beneficiaries. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which the only approved indication is for that disease or condition.&#8239; Under the One Big Beautiful Bill Act of 2025, this restriction was eliminated; and effective for the 2028 initial price applicability year, all orphan drugs, regardless of the number of orphan drug designations or indications, are exempt from the Medicare drug price negotiation program. The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA&#8217;s Medicare drug price negotiation program. The effect of IRA on our business and the healthcare industry in general is not yet known.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">33</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">On April 15, 2025, the Trump administration published Executive Order 14273, &#8220;Lowering Drug Prices by Once Again Putting Americans First,&#8221; which generally directs the federal government to take measures to reduce drug prices, including eliminating the so-called &#8220;pill penalty&#8221; under the IRA that creates a distinction between small molecule and large molecule products for purposes of determining when a drug may be eligible for drug price negotiation. On May 12, 2025, the Trump administration published Executive Order 14297, &#8220;Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients&#8221; which generally, among other things, directs the federal government to establish and communicate most-favored-nation (&#8220;MFN&#8221;) price targets to pharmaceutical manufacturers to bring prices for American patients in line with comparably developed nations. Further, the Executive Order directs the federal government to support regulatory paths to allow direct-to-patient sales for companies that meet these targets. It also states that the Administration will take additional aggressive action (for example, examining whether marketing approvals should be modified or rescinded or opening the door for individual drug importation waivers) should manufacturers fail to offer American consumers the MFN lowest price. It also directs the Secretary of Commerce and the U.S. Trade Representative to &#8220;take all necessary and appropriate action to ensure foreign countries are not engaged in any act, policy, or practice that may be unreasonable or discriminatory or that may impair United States national security . . . including by suppressing the price of pharmaceutical products below fair market value in foreign countries.&#8221; Notably, a similar &#8220;Most Favored Nation&#8221; pricing rule enacted under the first Trump administration was subject to an injunction resulting from judicial challenges to the rule, which was formally rescinded by the former Biden Administration in August 2021.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">On December 19, 2025, CMS released two proposed rules that would incorporate MFN pricing principles into federal reimbursement for prescription drugs. The first proposal, the Global Benchmark for Efficient Drug Pricing Model (&#8220;GLOBE&#8221;) for Medicare Part B, would require manufacturers of specified single source drugs and sole source biologics to pay incremental rebates based on international benchmark prices, with participation triggered for products meeting CMS&#8217;s spending and eligibility criteria. The second proposal, the Guarding U.S. Medicare Against Rising Drug Costs (&#8220;GUARD&#8221;) model for Medicare Part D, would similarly mandate manufacturer rebates for qualifying sole source drugs where the Medicare net price exceeds an MFN benchmark derived from international reference pricing methodologies. As proposed, GLOBE would begin a five year performance period on October 1, 2026 and GUARD would begin its performance period in 2027. These proposals will likely be subject to legal challenges that could delay their implementation or modify their impact on manufacturer pricing and revenue. Additionally, in November 2025, CMS introduced the GENErating cost Reductions fOr U.S. Medicaid (&#8220;GENEROUS&#8221;) Model, a voluntary MFN framework for manufacturers participating in the Medicaid Drug Rebate Program. Although it is voluntary, the GENEROUS Model could also impact the drug pricing landscape for manufacturers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Certain states are also pursuing cost containment efforts through Prescription Drug Affordability Boards (&#8220;PDABs&#8221;) and similar entities. While many PDABs have been granted authority to promote drug price transparency and reporting, some states have granted PDABs more expansive authority, including to set Upper Payment Limits (&#8220;UPLs&#8221;) on select, high price drugs. The adoption and implementation of UPLs may put downward pressure on drug prices and impact our company&#8217;s future revenues.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Other Healthcare Laws and Compliance Requirements </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Healthcare providers, physicians, and third-party payors will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our business operations and any current or future arrangements with third-party payors, healthcare providers and physicians may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we develop, market, sell and distribute any drugs for which we obtain marketing approval. In the United States, these laws include, among others:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">34</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration (including any kickback, bribe, or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or for the purchase, lease, order or recommendation of, or arranging for, an item, good, facility or service for which payment may be made under a federal healthcare program such as Medicare and Medicaid. The term remuneration has been interpreted broadly to include anything of value. The federal Anti-Kickback Statute has been interpreted to apply to arrangements between manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. A person or entity need not have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. Violations are subject to significant civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act ("FCA");</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">federal civil and criminal false claims laws, including the FCA, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other third-party payors, that are false, fictitious or fraudulent; knowingly making, using, or causing to be made or used, a false statement or record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221;&#160;the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221;&#160;to bring qui tam actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. When an entity is determined to have violated the FCA, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), which created additional criminal and civil liability for knowingly and willfully executing, or attempting to execute, a scheme, to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the federal Physician Payment Sunshine Act, created under the ACA and its implementing regulations, which requires drug, device, medical supply, and biologics manufacturers to disclose payments under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to HHS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other licensed healthcare practitioners and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">HIPAA, as amended by the Health Information Technology and Clinical Health Act of 2009 ("HITECH"), and its implementing regulations, which imposes, among other things, certain requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to &#8220;business associates,&#8221;&#160;those independent contractors or agents of covered entities that create, receive, maintain, transmit or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">35</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">analogous state and foreign law equivalents of each of the above U.S. federal laws, such as anti- kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers or patients; state and local marketing and/or transparency laws applicable to manufacturers that may be broader in scope than the federal requirements; state laws that require the reporting of information related to drug pricing; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information; state and local laws that require the licensure of sales representatives; state laws that require biopharmaceutical companies to comply with the biopharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state and local laws that require the registration of pharmaceutical sales representatives; data privacy and security laws and regulations in foreign jurisdictions that may be more stringent than those in the United States (such as the European Union, which adopted the General Data Protection Regulation, which became effective in May 2018); and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to administrative, civil, and criminal penalties, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, imprisonment, damages, fines, disgorgement, reputational harm, the curtailment or restructuring of our operations, and additional oversight and reporting obligations if we become subject to a corporate integrity agreement or similar settlement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to similar actions, penalties and sanctions. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from its business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We are also subject to the U.S. Foreign Corrupt Practices Act ("FCPA"), which prohibits improper payments or offers of payments to foreign governments and their officials for the purpose of obtaining or retaining business and requires companies to maintain accurate books and records and a system of internal accounting controls. Safeguards we implement to discourage improper payments or offers of payments by our employees, consultants, and others may be ineffective, and violations of the FCPA and similar laws may result in severe criminal or civil sanctions, or other liabilities or proceedings against us, any of which would likely harm our reputation, business, financial condition and result of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">36</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Employees and Human Capital</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">As of December 31, 2025, we had 39 employees, 25 of which were primarily engaged in research and development and clinical activities. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase shareholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">As a company operating in a competitive industry, much of our success is rooted in the diversity of our teams and our commitment to inclusion. We value diversity at all levels and continue to focus on extending our diversity and inclusion initiatives across our entire workforce, from working with managers to develop strategies for building diverse teams to promoting the advancement of leaders from different backgrounds.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Corporate Information </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We were incorporated in the State of Delaware on March 20, 2018. On June 17, 2020, a wholly-owned subsidiary of ours merged with and into Compass Therapeutics, a private limited liability company formed in 2014. Following the Merger, Compass Therapeutics was the surviving entity and became our wholly-owned subsidiary, and all of the outstanding common and preferred membership interests of Compass Therapeutics were converted into shares of our common stock. On June 17, 2020, we changed our name to Compass Therapeutics, Inc. As a result of the Merger, we acquired the business of Compass Therapeutics and we will continue the existing business operations of Compass Therapeutics as a public reporting company under the name Compass Therapeutics, Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our principal executive offices are located at 80 Guest Street, Suite 601, Boston, Massachusetts 02135, and our telephone number is (617) 500-8099.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our website is www.compasstherapeutics.com. Our Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to such reports are filed with the SEC. We are subject to the informational requirements of the Exchange Act and file or furnish reports, proxy statements, and other information with the SEC. Such reports and other information filed by us with the SEC will be available free of charge on our website. The SEC maintains a website that contains proxy and other information that issuers file electronically with the SEC at <span style="text-decoration: underline; ">www.sec.gov</span>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The contents of the websites referred to above are not incorporated into this filing. Further, our references to the URLs for these websites are intended to be inactive textual references only.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">37</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 1A. Risk Factors.<a id="itm1a" href="#"></a></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below together with all of the other information in this Annual Report on Form 10-K ("Form 10-K"), including our financial statements and the related notes and the information described in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and in our other filings with the SEC. If any of the events described below actually occurs, our business, results of operations, financial conditions, cash flows or prospects could be harmed. If that were to happen, you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Risks Related to Our Financial Position and Need for Additional Capital</span></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have a limited operating history and no products approved for commercial sale. We have a history of significant losses, expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability</i></b>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We are a clinical-stage biopharmaceutical company with a limited operating history. Since our founding in 2014, we have incurred significant net losses with an accumulated deficit of $431 million as of December 31, 2025. We have funded our operations to date primarily with proceeds from private placements of preferred and common equity, an underwritten public offering and a PIPE offering, as well as sales under our at-the-market offering program. Since commencing operations, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, identifying business development opportunities, raising capital, securing intellectual property rights related to our product candidates, conducting discovery, and research and development activities, including clinical development, for our product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We expect that it will be several years, if ever, before we have a commercialized product. We expect to continue to incur significant expenses and operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially if, and as, we:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">continue to advance the preclinical and clinical development of our existing product candidates and our research programs;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">leverage our research and development capabilities, including our proprietary StitchMabs<sup style="vertical-align:top;line-height:120%;">TM</sup>&#160;technology, to advance additional product candidates into preclinical and clinical development;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">hire additional clinical, quality control, regulatory, scientific and administrative personnel;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">expand our operational, financial and management systems and increase personnel, including to support our clinical development and our operations as a public company;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">maintain, expand and protect our intellectual property portfolio;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">establish a marketing, sales, distribution and medical affairs infrastructure to commercialize any products for which we may obtain marketing approval and commercialize, whether on our own or jointly with a partner;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">acquire or in-license other technologies or engage in strategic partnerships; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">incur additional legal, accounting or other expenses in operating our business, including the additional costs associated with operating as a public company.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">38</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">To become and remain profitable, we must develop and eventually commercialize products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials, obtaining marketing approval for product candidates, manufacturing, marketing and selling products and satisfying any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have never generated revenue from product sales and may never be profitable.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with our collaboration partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our product candidates. We do not anticipate generating revenue from product sales for the next several years, if ever. Our ability to generate future revenue from product sales depends heavily on our, or our existing or future collaborators&#8217;, success in:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">completing preclinical studies and clinical trials of our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">seeking and obtaining marketing approvals for any product candidates that we or our collaborators develop;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">identifying and developing new product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">launching and commercializing product candidates for which we obtain marketing approval by establishing a marketing, sales, distribution and medical affairs infrastructure or, alternatively, collaborating with a commercialization partner;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">achieving coverage and adequate reimbursement by hospitals and third-party payors, including governmental authorities, such as Medicare and Medicaid, private insurers and managed care organizations, for product candidates, if approved, that we or our collaborators develop;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">obtaining market acceptance of product candidates, if approved, that we develop as viable treatment options;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">addressing any competing technological and market developments;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our obligations under such arrangements;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">defending against third-party interference or infringement claims, if any; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">attracting, hiring and retaining qualified personnel.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We anticipate incurring significant costs associated with commercializing any product candidate that is approved for commercial sale. Our expenses could increase beyond expectations if we are required by the FDA or other regulatory agencies to perform clinical trials or studies in addition to those that we currently anticipate, or if there are any delays in establishing appropriate manufacturing arrangements for or in completing our clinical trials for the development of any of our product candidates. Even if we are able to generate revenue from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">39</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We will require substantial additional financing to pursue our business objectives, which may not be available on acceptable terms, or at all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development, commercialization efforts or other operations.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to continue the preclinical and clinical development of our current and future programs. If we receive marketing approval for any product candidates, we will require significant additional amounts of cash in order to launch and commercialize such product candidates. In addition, other unanticipated costs may arise. Because the designs and outcomes of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development of and commercialize any product candidate we develop. Additionally, any delays due to changes in federal, state, or local laws and regulations or clinical site policies could impact our programs and increase our expenditures.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our future capital requirements depend on many factors, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the scope, progress, timing, results and costs of researching and developing our product candidates, and of conducting preclinical studies and clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the timing of, and the costs involved in, obtaining marketing approval for any of our current or future product candidates we develop, if clinical trials are successful;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the costs of manufacturing our current and any future product candidates for preclinical studies and clinical trials and in preparation for marketing approval and commercialization;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the costs of commercialization activities, including marketing, sales and distribution costs, for our products and any future product candidates we develop, whether alone or with a collaborator, if any of these product candidates are approved for sale;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to establish and maintain strategic collaborations, licensing or other arrangements on favorable terms, if at all;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of any such litigation;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our current collaboration and license agreements remaining in effect and our achievement of milestones and the timing and amount of milestone payments we are required to make, or that we may be eligible to receive, under those agreements;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the timing, receipt and amount of sales of, on our future products, if any; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the emergence of competing therapies and other adverse developments in the oncology and immunology market.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Until we can generate sufficient product revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity and debt financings, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements. As of December 31, 2025, we had $209 million in cash, cash equivalents and marketable securities. Based on our research and development plans, we expect that these cash resources will enable us to fund our operating expenses and capital expenditure requirements into 2028. This estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we expect. Changes may occur beyond our control that would cause us to consume our available capital before that time, including changes in, and progress of, our development activities, acquisitions of additional product candidates and changes in regulation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">40</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">If we raise additional capital through marketing, sales and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, future revenue streams or research programs, technologies or grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. Further, to the extent that we raise additional capital through additional sales of common stock or securities convertible or exchangeable into common stock, investors&#8217; ownership interest will be diluted. If we raise additional capital through debt financing, we would be subject to fixed payment obligations and may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to obtain additional financing on favorable terms when needed, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials, or other research and development activities or one or more of our development programs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Recent volatility in capital markets and lower market prices for our securities may affect our ability to access new capital through sales of shares of our common stock or issuance of indebtedness, which may harm our liquidity and limit our ability to grow our business, pursue acquisitions, or improve our operating infrastructure.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our operations consume substantial amounts of cash, and we intend to continue to make significant investments to support our business growth, respond to business challenges or opportunities, develop our product candidates, retain or expand our current levels of personnel, enhance our operating infrastructure, and potentially acquire complementary businesses and technologies. Our future capital requirements may be significantly different from our current estimates and will depend on many factors, including the need to:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">finance unanticipated working capital requirements;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">develop our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">pursue acquisitions or other strategic relationships; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">respond to competitive pressures.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Accordingly, we may need to pursue equity or debt financings to meet our capital needs. With uncertainty in the capital markets and other factors, such financing may not be available on terms favorable to us or at all. If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our common stock. Any debt financing secured by us in the future could involve additional restrictive covenants relating to our capital-raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. If we are unable to obtain adequate financing or financing on terms satisfactory to us, we could face significant limitations on our ability to invest in our operations and otherwise suffer harm to our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Risks Related to the Discovery and Development of Our Product Candidates</span></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our business is dependent on our ability to advance our current and future product candidates through clinical trials, obtain marketing approval and ultimately commercialize them.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We are early in our development efforts. Our ability to generate product revenues, which we do not expect will occur for several years, if ever, will depend heavily on the successful development and eventual commercialization of our current products or future product candidates we develop, which may never occur. Our current product candidates and any future product candidates we develop will require additional preclinical or clinical development, management of clinical, preclinical and manufacturing activities, marketing approval in the United States and other jurisdictions, demonstration of effectiveness to pricing and reimbursement authorities, sufficient cGMP manufacturing supply for both preclinical and clinical development and commercial production, building of a commercial organization and substantial investment and significant marketing efforts before we generate any revenues from product sales.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">41</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The clinical and commercial success of our current and future product candidates will depend on several factors, including the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">timely and successful completion of preclinical studies and our clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our plans to successfully submit new INDs with the FDA for our current and future product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to complete preclinical studies for current or future product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">successful enrollment in, and completion of clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">successful data from our clinical program that supports an acceptable risk-benefit profile of our product candidates in the intended patient populations;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to establish agreements with third-party manufacturers on a timely and cost-efficient manner;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">whether we are required by the FDA or comparable foreign regulatory authorities to conduct additional clinical trials or other studies beyond those planned or anticipated to support approval of our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">acceptance of our proposed indications and the primary endpoint assessments evaluated in the clinical trials of our product candidates by the FDA and comparable foreign regulatory authorities;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">receipt and maintenance of timely marketing approvals from applicable regulatory authorities;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">successfully launching commercial sales of our product candidates, if approved;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates, if approved;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">entry into collaborations to further the development of our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">acceptance of the benefits and uses of our product candidates, if approved, by patients, the medical community and third-party payors;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">maintaining a continued acceptable safety, tolerability and efficacy profile of the product candidates following approval;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our compliance with any post-approval requirements imposed on our products, such as post-marketing studies, REMS or additional requirements that might limit the promotion, advertising, distribution or sales of our products or make the products cost prohibitive;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">competing effectively with other therapies;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">42</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to identify bispecifics; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">enforcing and defending intellectual property rights and claims.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">These factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our current or future product candidates, and could otherwise materially harm our business. Successful completion of preclinical studies and clinical trials does not mean that any other current or future product candidates we develop will receive regulatory approval. Even if regulatory approvals are obtained, we could experience significant delays or an inability to successfully commercialize our current and any future product candidates we develop, which would materially harm our business. If we are not able to generate sufficient revenue through the sale of any current or future product candidate, we may not be able to continue our business operations or achieve profitability.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Clinical development involves a lengthy and expensive process with uncertain outcomes. We may incur additional costs and experience delays in developing and commercializing or be unable to develop or commercialize our current and future product candidates.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">To obtain the requisite regulatory approvals to commercialize any of our product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe, pure and potent in humans. Clinical testing is expensive and can take many years to complete, and its outcome is highly uncertain. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful. We may experience delays in completing our clinical trials or preclinical studies and initiating or completing additional clinical trials. We cannot be certain the ongoing and planned preclinical studies or clinical trials for our current or any other future product candidates will begin on time, not require redesign, enroll an adequate number of subjects on time or be completed on schedule, if at all. We may also experience numerous unforeseen events during our clinical trials that could delay or prevent our ability to receive marketing approval or commercialize the product candidates we develop, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">results from preclinical studies or clinical trials may not be predictive of results from later clinical trials of any product candidate;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the FDA or other regulatory authorities, Institutional Review Boards ("IRBs"), or independent ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the FDA or other regulatory authorities may require us to submit additional data such as long-term toxicology studies, or impose other requirements on us, before permitting us to initiate a clinical trial;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract research organizations ("CROs"), as the terms of these agreements can be subject to extensive negotiation and vary significantly among different CROs and trial sites;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">clinical trials of any product candidate may fail to show safety, purity or potency, or may produce negative or inconclusive results, which may cause us to decide, or regulators to require us, to conduct additional nonclinical studies or clinical trials or which may cause us to decide to abandon product candidate development programs;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the number of patients required for clinical trials may be larger than we anticipate, or we may have difficulty in recruiting and enrolling patients to participate in clinical trials, including as a result of the size and nature of the patient population, the proximity of patients to clinical trial sites, eligibility criteria for the clinical trial, the nature of the clinical trial protocol, the availability of approved effective treatments for the relevant disease and competition from other clinical trial programs for similar indications and clinical trial subjects;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">43</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or may fail to return for post-treatment follow-up at a higher rate than we anticipate;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our CROs and other third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we may elect to, or regulators, IRBs or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that participants are being exposed to unacceptable health risks;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">any of our product candidates could cause undesirable side effects that could result in significant negative consequences, including the inability to enter clinical development or receive regulatory approval;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the cost of preclinical or nonclinical testing and studies and clinical trials of any product candidates may be greater than we anticipate;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we may face hurdles in addressing subject safety concerns that arise during the course of a trial, causing us or our investigators, regulators, IRBs or ethics committees to suspend or terminate trials, or reports may arise from nonclinical or clinical testing of other cancer therapies that raise safety or efficacy concerns about our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the supply, quality or timeliness of delivery of materials for product candidates we develop or other materials necessary to conduct clinical trials may be insufficient or inadequate; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we may need to change the manufacturing site and potentially the contract development manufacturing organizations ("CDMO") for our product candidates from those that are able to produce clinical supply for our Phase 1 clinical trials to those with the capacity and ability to perform commercial manufacturing and/or the production of clinical material for our later stage clinical trials.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We could encounter delays if a clinical trial is suspended or terminated by us, or by the IRBs of the institutions in which such trials are being conducted, ethics committees or the Data and Safety Monitoring Board ("DSMB"), for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing approval of our product candidates. The FDA or other regulatory authorities may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials. Further, the FDA or other regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials. For example, we are conducting and may in the future conduct additional &#8220;open-label&#8221; clinical trials. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. Moreover, patients selected for early clinical trials often include the most severe sufferers and their symptoms may have been bound to improve notwithstanding the new treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">44</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or a regulatory authority concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of the marketing application we submit. Any such delay or rejection could prevent or delay us from commercializing our current or future product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">If we experience delays in the completion, or termination, of any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down the development and approval process for our product candidates and jeopardize our ability to commence product sales and generate revenues. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize our product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Any such events would impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates or result in the development of our product candidates stopping early.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The risk of failure for product candidates still in the discovery or preclinical stage is high. In addition, any one or more of our product candidates that have not yet entered the clinic may never advance into clinical development. In order to obtain FDA approval to market a new biologic we must demonstrate proof of safety, purity and potency, including efficacy, in humans. To meet these requirements, we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our planned clinical trials in humans. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of our current or future product candidates. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time of such testing may vary substantially according to the type, complexity and novelty of the program, and often can be several years or more per program. Delays associated with programs for which we are conducting preclinical testing and studies may cause us to incur additional operating expenses. The commencement and rate of completion of preclinical studies and clinical trials for a product candidate may be delayed by many factors, including but not limited to:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">45</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">an inability to generate sufficient preclinical or other <i>in vivo</i>&#160;or <i>in vitro</i>&#160;data to support the initiation of clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">delays in reaching a consensus with regulatory agencies on trial design; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the FDA or foreign regulatory authorities not permitting the reliance on preclinical or other data from published scientific literature.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Positive results from preclinical studies and early-stage clinical trials may not be predictive of future results. Initial positive results in any of our clinical trials may not be indicative of results obtained when the trial is completed or in later stage trials.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The results of preclinical studies may not be predictive of the results of clinical trials. Preclinical studies and early-stage clinical trials are primarily designed to test safety, to study PK and pharmacodynamics and to understand the side effects of product candidates at various doses and schedules, and the results of any early-stage clinical trials may not be predictive of the results of later-stage, large-scale efficacy clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. There can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development of any of our product candidates. There is a high failure rate for drugs and biological products proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies, and any such setbacks in our clinical development could have a material adverse effect on our business and operating results.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, the results of our preclinical studies may not be predictive of the results of outcomes in human clinical trials. For example, our current or future product candidates may demonstrate different chemical, biological and pharmacological properties in patients than they do in laboratory studies or may interact with human biological systems in unforeseen or harmful ways. Product candidates in later stages of clinical trials may fail to show desired pharmacological properties or produce the necessary safety and efficacy results despite having progressed through preclinical studies and initial clinical trials. Even if we are able to initiate and complete clinical trials, the results may not be sufficient to obtain regulatory approval for our product candidates. In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations and prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Interim and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit, validation and verification procedures that could result in material changes in the final data.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">From time to time, we may publish interim data, including interim top-line results or preliminary results from our clinical trials. Interim data and results from our clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line results also remain subject to audit, validation and verification procedures that may result in the final data being materially different from the interim and preliminary data we previously published. As a result, interim and preliminary data may not be predictive of final results and should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">46</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our bispecific and monoclonal antibody product candidates are a new potential class of therapeutics, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval, if at all.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our bispecific and monoclonal antibody technology is relatively new. As such it is difficult to accurately predict the developmental challenges we may incur for our product candidates as they proceed through product discovery or identification, preclinical studies and clinical trials. In addition, because we have not yet completed clinical trials that we have sponsored, we have not yet been able to meaningfully assess safety of those candidates in humans, and there may be short-term or long-term effects from treatment with any product candidates that we develop that we cannot predict at this time. Also, animal models may not exist for some of the diseases we choose to pursue in our programs. Furthermore, agonist antibodies have demonstrated substantial toxicity in humans and there is no assurance that our product candidates will not have the same adverse side effects. As a result of these factors, it is more difficult for us to predict the time and cost of product candidate development, and we cannot predict whether the application of our antibody therapeutics and our bispecifics, or any similar or competitive technologies, will result in the identification, development, and regulatory approval of any products. There can be no assurance that any development problems we experience in the future related to our agonist antibodies or any of our research programs will not cause significant delays or unanticipated costs, or that such development problems can be solved. Any of these factors may prevent us from completing our preclinical studies or any clinical trials that we may initiate or commercializing any product candidates we may develop on a timely or profitable basis, if at all.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The clinical trial requirements of the FDA, the EMA and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the product candidate. No products based on agonist antibodies have been approved to date by regulators. As a result, the regulatory approval process for product candidates such as ours is uncertain and may be more expensive and take longer than the approval process for product candidates based on other, better known or more extensively studied technologies. It is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in either the United States or the European Union or other regions of the world or how long it will take to commercialize our product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product candidate to market could decrease our ability to generate sufficient product revenue, and our business, financial condition, results of operations and prospects may be harmed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our current or future product candidates may cause undesirable side effects or have other properties when used alone or in combination with other approved products or investigational new drugs that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are safe, pure and potent for use in each target indication, and failures can occur at any stage of testing. As with most biological products, use of our current or future product candidates could be associated with side effects or adverse events which can vary in severity from minor reactions to death and in frequency from infrequent to prevalent. There have been serious adverse side effects reported in response to antibody therapeutics and bispecifics in oncology.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Immuno-oncology drugs have been observed to cause side effects, generally related to over activation of the immune system. These include colitis, diabetes, pituitary inflammation, thyroiditis, myocarditis, liver inflammation, thrombocytopenia, among others. Our immuno-oncology product candidates may have similar or additional side effects. Treatment-related side effects may emerge at a later time in our trials. In addition to any potential side effects caused by the product or product candidate, the administration process or related procedures also can cause adverse side effects. If unacceptable adverse events occur, our clinical trials or any future marketing authorization could be suspended or terminated. There can be no assurance that any of our current or future product candidates will not demonstrate unacceptable toxicities in later testing that may render it unsafe or intolerable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">47</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">If unacceptable side effects arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which our trials are conducted or the DSMB could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our clinical trials or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Although our current and future product candidates have undergone and will undergo safety testing to the extent possible and, where applicable, under such conditions discussed with regulatory authorities, not all adverse effects of drugs can be predicted or anticipated. Antibody therapeutics and bispecifics and their method of action of harnessing the body&#8217;s immune system are powerful and could lead to serious side effects that we only discover in clinical trials or during commercial marketing. Unforeseen side effects could arise either during clinical development or after our product candidates have been approved by regulatory authorities and the approved product has been marketed, resulting in the exposure of additional patients. So far, we have not demonstrated that our current product candidates are safe in humans, and we cannot predict if ongoing or future clinical trials will do so. If any of our current or future product candidates fail to demonstrate safety and efficacy in clinical trials or do not gain marketing approval, we will not be able to generate revenue and our business will be harmed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In addition, we intend to pursue our product candidates in combination with other therapies and may develop future product candidates in combination with other therapies, which exposes us to additional risks relating to undesirable side effects or other properties. For example, the other therapies may lead to toxicities that are improperly attributed to our product candidates or the combination of our product candidates with other therapies may result in toxicities that the product candidate or other therapy does not produce when used alone. The other therapies we are using in combination may be removed from the market, or we may not be able to secure adequate quantities of such materials for which we have no guaranteed supply contract, and thus be unavailable for testing or commercial use with any of our approved products. The other therapies we may use in combination with our product candidates may also be supplanted in the market by newer, safer or more efficacious products or combinations of products.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Even if we successfully advance our product candidates through clinical trials, such trials will likely only include a limited number of subjects and limited duration of exposure to our product candidates. As a result, we cannot be assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of patients are exposed to the product candidate. Further, any clinical trial may not be sufficient to determine the effect and safety consequences of taking our product candidates over a multi-year period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">If any of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">regulatory authorities may withdraw their approval of the product;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we may be required to recall a product or change the way such product is administered to patients;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221;&#160;warning or a contraindication;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">48</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we may be required to implement a REMS or create a medication guide outlining the risks of such side effects for distribution to patients;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we could be sued and held liable for harm caused to patients;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the product may become less competitive; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our reputation may suffer.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues, which would materially harm our business. In addition, if one or more of our product candidates or our antibody therapeutic development approach generally prove to be unsafe, our entire technology platform and pipeline could be affected, which would also materially harm our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>As an organization, we have limited experience designing and implementing clinical trials and we have never conducted pivotal clinical trials. Failure to adequately design a trial, or incorrect assumptions about the design of the trial, could adversely affect the ability to initiate the trial, enroll patients, complete the trial, or obtain regulatory approval on the basis of the trial results, as well as lead to increased or unexpected costs and in delayed timelines.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The design and implementation of clinical trials is a complex process. We have limited experience designing and implementing clinical trials, and we may not successfully or cost-effectively design and implement clinical trials that achieve our desired clinical endpoints efficiently, or at all. A clinical trial that is not well designed may delay or even prevent initiation of the trial, can lead to increased difficulty in enrolling patients, may make it more difficult to obtain regulatory approval for the product candidate on the basis of the trial results, or, even if a product candidate is approved, could make it more difficult to commercialize the product successfully or obtain reimbursement from third-party payors. Additionally, a trial that is not well-designed could be inefficient or more expensive than it otherwise would have been, or we may incorrectly estimate the costs to implement the clinical trial, which could lead to a shortfall in funding. We also expect to continue to rely on third parties to conduct our clinical trials. See &#8220;&#8212;<i>Risks Related to Reliance on Third Parties</i>&#8212;<i>We rely or will rely on third parties to help conduct our ongoing and planned preclinical studies and clinical trials for our current product candidates and any future product candidates we develop. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize for our current product candidates or future product candidates we develop and our business could be materially harmed</i>.&#8221; Consequently, we may be unable to successfully and efficiently execute and complete clinical trials that are required for BLA submission and FDA approval of our current or future product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we or our collaborators encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise be adversely affected.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The successful and timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to enroll a sufficient number of patients who remain in the trial until the trial&#8217;s conclusion, including any follow-up period. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the patient eligibility criteria defined in the protocol;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the nature and size of the patient population required for analysis of the trial&#8217;s primary endpoints and the process for identifying patients;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the number and location of participating clinical sites or patients;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the design of the trial;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">49</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">clinicians&#8217;&#160;and patients&#8217;&#160;perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the availability of competing commercially available therapies and other competing drug candidates&#8217;&#160;clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to obtain and maintain patient informed consents for participation in our clinical trials; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may be late-stage cancer patients, will not survive the full terms of the clinical trials.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our current and potential future product candidates. This competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such sites. Moreover, because our current and potential future product candidates may represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy, rather than enroll patients in our ongoing or any future clinical trial.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Delays of difficulties in patient enrollment may result in increased costs or may affect the timing, outcome or completion of clinical trials, which would adversely affect our ability to advance the development of the product candidates we develop.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Because the number of subjects in our clinical trials are small, the results from these trials, once completed, may be less reliable than results achieved in larger clinical trials.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">A trial design that is considered appropriate includes a sufficiently large sample size with appropriate statistical power, as well as proper control of bias, to allow a meaningful interpretation of the results. The preliminary results of trials with smaller sample sizes and heterogeneous patient populations, can be disproportionately influenced by the impact the treatment had on a few individuals, which limits the ability to generalize the results across a broader community, thus making the trial results less reliable than trials with a larger number of subjects and with more homogeneous patient populations. As a result, there may be less certainty that our product candidates would achieve a statistically significant effect in any future clinical trials. If we conduct any future clinical trials, we may not achieve a statistically significant result or the same level of statistical significance seen, if any, in our clinical trials.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have chosen to prioritize certain product candidates for development as described in this Annual Report on Form 10-K. We may expend our limited resources on product candidates or indications that do not yield a successful product and fail to capitalize on other candidates or indications for which there may be a greater likelihood of success or may be more profitable</i></b>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Because we have limited resources, we have strategically determined to prioritize development of certain product candidates as described in this Annual Report on Form 10-K, rather than other product candidates. This decision is based, in part, on the significant resources required for developing and manufacturing antibody therapeutics and bispecifics. As a result, we may be foregoing other potentially more profitable antibody therapies or drugs with a greater likelihood of success. Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate or collaborate with third parties with respect to certain programs may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our current or future product candidates or misread trends in the oncology, autoimmunology or biopharmaceutical industry, our business, financial condition and results of operations could be materially adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain development and commercialization rights.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">50</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our clinical trials may be conducted in overseas jurisdictions, which may subject us to delays and expenses.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We may conduct certain clinical trials in overseas jurisdictions. Regulators in the United States, such as the FDA, or in other foreign jurisdictions, may not support our trial design and protocol, which would delay our clinical development plans and increase our expenses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In addition, there are risks inherent in conducting clinical trials in overseas jurisdictions, which may subject us to delays and expenses, such as:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">regulatory and administrative requirements of the jurisdiction where the trial is conducted that could burden or limit our ability to conduct clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">differing and conflicting regulatory requirements;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">foreign exchange fluctuations; manufacturing, customs, shipment, and storage requirements;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">cultural differences in medical practice and clinical research; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the risk that the patient populations in such trials are not considered representative as compared to the patient population in the target markets where approval is being sought.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Risks Related to Regulatory Approval of Our Product Candidates</span></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be materially harmed.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate. Neither we nor any future collaborator is permitted to market any biological product in the United States until we or the future collaborator receives regulatory approval of a biologics license application ("BLA"), from the FDA. It is possible that none of our current or future product candidates will ever obtain regulatory approval from the FDA or comparable foreign regulatory authorities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">51</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our current and future product candidates could fail to receive regulatory approval for many reasons, including the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate has an acceptable risk-benefit profile in the proposed indication;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that the facility in which a product candidate is manufactured meets standards designed to assure that the product candidate continues to be safe, pure, and potent;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from clinical trials or preclinical studies;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA to the FDA or regulatory submissions to comparable regulatory authorities to obtain regulatory approval in such jurisdiction; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the FDA or comparable foreign regulatory authorities may find deficiencies with or fail to approve our manufacturing processes or facility or the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">This lengthy approval process as well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval to market any product candidate we develop, which would significantly harm our business, results of operations and prospects. The FDA and other comparable foreign authorities have substantial discretion in the approval process and in determining when or whether regulatory approval will be granted for any product candidate that we develop. Even if we believe the data collected from future clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA or any other regulatory authority.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In addition, even if we were to obtain approval, the FDA may approve any of our product candidates for fewer or more limited indications, or a more limited patient population, than we request, may grant approval contingent on the performance of costly clinical trials or other post-marketing requirements, or may approve a product candidate with a label that does not include the labeling claims we believe are necessary or desirable for the successful commercialization of such product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In addition, the FDA or comparable foreign regulatory authorities may change their policies, promulgate additional regulations, revise existing regulations or take other actions that may prevent or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may be unable to obtain FDA approval of our product candidates under applicable regulatory requirements. The denial or delay of any such approval would prevent or delay commercialization of our product candidates and adversely impact our potential to generate revenue, our business and our results of operations.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">52</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">To gain approval to market our product candidates in the United States, we must provide the FDA with clinical data that adequately demonstrate the safety, purity and potency, including efficacy, of the product candidate for the proposed indication or indications in a BLA submission. Product development is a long, expensive and uncertain process, and delay or failure can occur at any stage of any of our clinical development programs. A number of companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in clinical trials, even after promising results in earlier preclinical studies or clinical trials. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and the results of clinical trials by other parties may not be indicative of the results in trials we may conduct.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We have not previously submitted a BLA or any other marketing application to the FDA or similar filings to comparable foreign regulatory authorities. A BLA or other similar regulatory filing requesting approval to market a product candidate must include extensive preclinical and clinical data and supporting information to establish that the product candidate is safe, pure and potent for each desired indication. The BLA or other similar regulatory filing must also include significant information regarding the chemistry, manufacturing and controls for the product.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The research, testing, manufacturing, labeling, approval, marketing, sale and distribution of biological products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, and such regulations differ from country to country. We are not permitted to market our product candidates in the United States or in any foreign countries until they receive the requisite approval from the applicable regulatory authorities of such jurisdictions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of our product candidates for many reasons, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our inability to demonstrate to the satisfaction of the FDA or a comparable foreign regulatory authority that our product candidates are safe and effective for the requested indication;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the FDA or a comparable foreign regulatory authority&#8217;s disagreement with our trial protocol or the interpretation of data from preclinical studies or clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our inability to demonstrate that the clinical and other benefits of our product candidates outweigh any safety or other perceived risks;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the FDA or a comparable foreign regulatory authority&#8217;s requirement for additional preclinical studies or clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the FDA or a comparable foreign regulatory authority&#8217;s non-approval of the formulation, labeling, or specifications of our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the FDA or a comparable regulatory authority&#8217;s failure to approve our manufacturing processes and facilities or the manufacturing processes and facilities of third-party manufacturers upon which we rely; or</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">potential for approval policies or regulations of the FDA or a comparable foreign regulatory authority to significantly change in a manner rendering our clinical data insufficient for approval.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Even if we eventually complete clinical testing and receive approval from the FDA or comparable foreign regulatory authorities for any of our product candidates, the FDA or comparable foreign regulatory authorities may grant approval contingent on the performance of costly additional clinical trials which may be required after approval. The FDA or comparable foreign regulatory authorities also may approve any of our product candidates for a more limited indication or a narrower patient population than we originally requested, and the FDA or comparable foreign regulatory authorities may not approve any of our product candidates with the labeling that we believe is necessary or desirable for the successful commercialization of any such product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">53</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Of the large number of biopharmaceutical products in development, only a small percentage successfully complete the FDA or other regulatory bodies&#8217; approval processes and are commercialized. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of our product candidates and would materially harm our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which could negatively impact our business.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for biological products or modifications to approved biological products to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 43 days beginning on October 1, 2025, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. Currently, federal agencies in the United States are operating under a continuing resolution that is set to expire on September 30, 2026. Without appropriation of additional funding to federal agencies, our business operations related to our product development activities for the U.S. market could be impacted.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may be required to suspend, repeat or terminate our clinical trials if they are not conducted in accordance with regulatory requirements, the results are negative or inconclusive or the trials are not well designed.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Clinical trials must be conducted in accordance with the FDA&#8217;s current good clinical practices requirements ("cGCP"), or analogous requirements of applicable foreign regulatory authorities. Clinical trials are subject to oversight by the FDA, other foreign governmental agencies and IRBs or ethical committees at the trial sites where the clinical trials are conducted. In addition, clinical trials must be conducted with product candidates manufactured in accordance with applicable cGMP. Clinical trials may be suspended by the FDA, other foreign regulatory authorities, us, or by an IRB or ethics committee with respect to a particular clinical trial site, for various reasons, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">deficiencies in the conduct of the clinical trials, including failure to conduct the clinical trial in accordance with regulatory requirements or trial protocols;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">deficiencies in the clinical trial operations or trial sites;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">unforeseen adverse side effects or the emergence of undue risks to trial subjects;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">deficiencies in the trial design necessary to demonstrate efficacy;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the product candidate may not appear to offer benefits over current therapies; or</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the quality or stability of the product candidate may fall below acceptable standards.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">54</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We intend to develop our product candidates in part in combination with other therapies and may develop our future product candidates in combination with other therapies, which exposes us to additional regulatory risks.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We intend to develop our product candidates in part in combination with other therapies and may develop our current and future product candidates in combination with one or more currently approved cancer therapies. These combinations have not been previously tested in the clinic and may, among other things, fail to demonstrate synergistic activity, may fail to achieve superior outcomes relative to the use of single agents or other combination therapies, or may fail to demonstrate sufficient safety or efficacy traits in clinical trials to enable us to complete those clinical trials or obtain marketing approval for the combination therapy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In addition, we did not develop or obtain regulatory approval for, and we do not manufacture or sell, any of these approved therapeutics. Therefore, even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risk that the FDA or comparable foreign regulatory authorities could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. This could result in our own products being removed from the market or being less successful commercially. Combination therapies are commonly used for the treatment of cancer diseases, and we would be subject to similar risks if we develop any of our product candidates for use in combination with other drugs or for indications other than cancer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We may also evaluate our current or any future product candidate in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA or comparable foreign regulatory authorities. We will not be able to market and sell any product candidate we develop in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">If the FDA or comparable foreign regulatory authorities do not approve these other biological products or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the biological products we choose to evaluate in combination with any product candidate we develop, we may be unable to obtain approval of or market any such product candidate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Even if we receive marketing approval of a product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. If we fail to comply or experience unanticipated problems with our products, we may be subject to administrative and judicial enforcement, including monetary penalties, for non-compliance and our approved products, if any, could be deemed misbranded or adulterated and prohibited from continued distribution.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Any marketing approvals that we receive for any current or future product candidate may be subject to limitations on the approved indicated uses for which the product may be marketed or the conditions of approval, or contain requirements for potentially costly post-market testing and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require implementation of a REMS as a condition of approval of any product candidate, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves a product candidate, the manufacturing processes, labeling, packaging, distribution, tracking and tracing, adverse event and deviation reporting, storage, advertising, promotion, import and export and record keeping for the product candidate will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP and cGCP, for any clinical trials that we may conduct post-approval. Additionally, we will be required to build and validate interoperable electronic tracing systems to implement with future trading partners for any product candidates we may commercialize. Later discovery of previously unknown problems with any approved candidate, including adverse events of unanticipated severity or frequency, or with our or our third-party manufacturers&#8217; manufacturing processes or facilities, or failure to comply with regulatory requirements, may result in, among other things:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">55</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">suspension of, or imposition of restrictions on, the marketing or manufacturing of the product, withdrawal of the product from the market, or product recalls;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Warning Letters or Untitled Letters, or holds on clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">refusal by the FDA to approve pending applications or supplements to approved applications we file, or suspension or revocation of approved biologics licenses;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">product seizure or detention, monetary penalties, refusal to permit the import or export of the product, or placement on Import Alert; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">permanent injunctions and consent decrees including the imposition of civil or criminal penalties.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Given the nature of biological products manufacturing, there is a risk of contamination. Any contamination could materially adversely affect our ability to produce product candidates on schedule and could, therefore, harm our results of operations and cause reputational damage. Some of the raw materials and other components required in our manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product or product candidates could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could materially and adversely affect our development and commercialization timelines and our business, financial condition, results of operations and prospects and could adversely affect our ability to meet our supply obligations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Moreover, the FDA strictly regulates the promotional claims that may be made about drug and biological products. In particular, an approved product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling, or off-label uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. The FDA has issued guidance on the factors that it will consider in determining whether a firm&#8217;s product communication is consistent with the FDA-required labeling for that product, and those factors contain complexity and potential for overlap and misinterpretation. A company that is found to have improperly promoted off-label uses of their products may be subject to significant civil, criminal and administrative penalties. In the current administration, the FDA has increased its enforcement scrutiny over prescription drug advertising, particularly direct-to-consumer product promotion and advertising.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The FDA and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay marketing approval of a product. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In addition, if we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">56</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Accelerated approval by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive regulatory approval. </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We may seek accelerated approval of our current or future product candidates using the FDA&#8217;s accelerated approval pathway. A product may be eligible for accelerated approval if it treats a serious or life-threatening condition. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (&#8220;IMM&#8221;), that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA generally requires that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing confirmatory clinical trials. These confirmatory trials must be completed with due diligence. FDA must specify the conditions for any post-approval trials by the date of accelerated approval and the agency has flexibility in setting forth such conditions, which may include enrollment targets, clinical trial protocol and milestones &#8211; including the target date of trial completion. The FDA may also require, as appropriate, that certain confirmatory trials be underway prior to accelerated approval or within a specified time from the date of approval. Accelerated approval sponsors must submit progress reports every six months on required post-approval trials. FDORA also gives the FDA increased authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited basis if the sponsor fails to conduct such studies in a timely manner, send the necessary updates to the FDA, or if such post-approval studies fail to verify the drug&#8217;s predicted clinical benefit. Under the FDORA, the FDA is empowered to take action, such as issuing fines, against companies that fail to conduct with due diligence any post-marketing confirmatory trial or submit timely reports to the agency on their progress. In addition, the FDA currently requires, unless otherwise informed by the agency, as a condition for accelerated approval pre-approval of promotional materials for products being considered for accelerated approval, unless otherwise informed by the FDA, which could adversely impact the timing of the commercial launch of the product. Even if we do receive accelerated approval, we may not experience a faster development, regulatory review or approval process, and receiving accelerated approval does not assure that the product&#8217;s accelerated approval will eventually be converted to a traditional approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Risks Related to the Commercialization of Our Product Candidates </span></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Even if a current or future product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">If any current or future product candidate we develop receives marketing approval, whether as a single agent or in combination with other therapies, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, and others in the medical community. For example, current approved antibody therapeutics, and other cancer treatments like chemotherapy and radiation therapy, are well established in the medical community, and doctors may continue to rely on these therapies. Our approach to targeting different components of the tumor microenvironment is novel and unproven. In addition, adverse events in clinical trials testing our product candidates or in clinical trials of others developing similar product candidates and the resulting publicity, as well as any other adverse events in the field of immuno-oncology that may occur in the future, could result in a decrease in demand for our current or future product candidates. Furthermore, to date, only a few bispecific products have received marketing approval and only a few have advanced to late-stage clinical development. Future adverse events in immuno-oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our products. Similarly, the use of agonist antibodies for the treatment of autoimmune diseases is novel and there can be no assurance that our product candidates for the treatment of autoimmune diseases, if approved, would gain sufficient market acceptance by physicians, patients, third-party payors, and others in the medical community.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">If our current and any future product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our current and any future product candidates, if approved for commercial sale, will depend on a number of factors, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">57</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">efficacy and potential advantages compared to alternative treatments, including those that are not yet approved;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the ability to offer our products, if approved, for sale at competitive prices;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">convenience and ease of administration compared to alternative treatments;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the strength of marketing, sales and distribution support;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the ability to obtain sufficient third-party coverage and adequate reimbursement, including with respect to the use of the approved product as a combination therapy; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the prevalence and severity of any side effects.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The market opportunities for any current or future product candidate we develop, if approved, may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed, and may be small.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Any revenue we are able to generate in the future from product sales will be dependent, in part, upon the size of the market in the United States and any other jurisdiction for which we gain regulatory approval and have commercial rights. If the markets or patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, even if approved.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Cancer therapies are sometimes characterized as first-line, second-line or third-line, and the FDA often approves new therapies initially only for third-line use. When cancer is detected early enough, first-line therapy, usually chemotherapy, hormone therapy, surgery, radiation therapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. The number of patients who receive second- and third-line treatment is significantly smaller than the number of patients who receive first-line treatment, and the prognosis of patients who receive second- or third-line treatment is often poorer than that of patients who receive first-line treatment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We may initially seek approval for any other product candidates we develop as second- or third-line therapies. If we do so, for those products that prove to be sufficiently beneficial, if any, we would expect potentially to seek approval as a first-line therapy, but there is no guarantee that any product candidate we develop, even if approved, would be approved for first-line therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The number of patients who have the types of cancer or autoimmune diseases we are targeting may turn out to be lower than expected. Additionally, the potentially addressable patient population for our current or future product candidates may be limited, if and when approved. Even if we obtain significant market share for any product candidate, if and when approved, if the potential target populations are small, we may never achieve profitability without obtaining marketing approval for additional indications, including to be used as first- or second-line therapy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Obtaining and maintaining marketing approval of our current and future product candidates in one jurisdiction does not mean that we will be successful in obtaining and maintaining marketing approval of our current and future product candidates in other jurisdictions.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">58</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Obtaining and maintaining marketing approval of our current and future product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain marketing approval in any other jurisdiction, while a failure or delay in obtaining marketing approval in one jurisdiction may have a negative effect on the marketing approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign marketing approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we are unable to establish marketing, sales and distribution capabilities for any product candidate that may receive regulatory approval, we may not be successful in commercializing those product candidates if and when they are approved.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We do not have sales or marketing infrastructure. To achieve commercial success for any product candidate for which we may obtain marketing approval, we will need to establish a sales and marketing organization. In the future, we expect to build a focused sales and marketing infrastructure to market some of our product candidates in the United States, if and when they are approved. There are risks involved with establishing our own marketing, sales and distribution capabilities. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Factors that may inhibit our efforts to market our products on our own include:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the inability of sales personnel to obtain access to physicians in order to educate physicians about our product candidates, once approved;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">If we are unable to establish our own marketing, sales and distribution capabilities and are forced to enter into arrangements with, and rely on, third parties to perform these services, our revenue and our profitability, if any, are likely to be lower than if we had developed such capabilities ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute our product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish marketing, sales and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">59</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Risks Related to Healthcare, Insurance and Legal Matters</span></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of our product candidates.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human trials and may face greater risk if we commercialize any products that we develop. Product liability claims may be brought against us by subjects enrolled in our trials, patients, healthcare providers or others using, administering or selling our products. If we cannot successfully defend ourselves against such claims, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">decreased demand for any product candidate we may develop;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">withdrawal of trial participants;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">termination of clinical trial sites or entire trial programs;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">injury to our reputation and significant negative media attention;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">initiation of investigations by regulators;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">significant time and costs to defend the related litigation;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">substantial monetary awards to trial subjects or patients;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">diversion of management and scientific resources from our business operations; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the inability to commercialize any product candidates that we may develop.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">While we currently hold trial liability insurance coverage consistent with industry standards, the amount of coverage may not adequately cover all liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. We intend to expand our insurance coverage for products to include the sale of commercial products if we obtain marketing approval for our product candidates, but we may be unable to obtain commercially reasonable product liability insurance. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business and financial condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The successful commercialization of our product candidates will depend in part on the extent to which third-party payors, including governmental authorities and private health insurers, provide coverage and adequate reimbursement levels, as well as implement pricing policies favorable for our product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. The availability of coverage and adequacy of reimbursement by third-party payors, including government healthcare programs (e.g., Medicare, Medicaid), managed care providers, private health insurers, health maintenance organizations, and other organizations is essential for most patients to be able to afford medical services and pharmaceutical products such as our product candidates. Third-party payors decide which medications they will pay for and establish reimbursement levels. The availability of coverage and extent of reimbursement by governmental and other third-party payors is essential for most patients to be able to afford treatments such as antibody-based therapies. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services ("CMS"), an agency within the U.S. Department of Health and Human Services ("HHS"). CMS decides whether and to what extent our products will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. See the section entitled, &#8220;Business &#8212; Government Regulation &#8212; Pharmaceutical Coverage, Pricing and Reimbursement&#8221;.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">60</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our ability to successfully commercialize our product candidates, whether as a single agent or combination therapy, will depend in part on the extent to which coverage and adequate reimbursement for our products and related treatments will be available from third-party payors. If coverage and adequate reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">A decision by a third-party payor not to cover or not to separately reimburse for our products or procedures using our products could reduce physician utilization of our products once approved. Assuming there is coverage for our product candidates, or procedures using our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, will be available for our current or future product candidates, or for any procedures using such product candidates, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future. Further, if we or our collaborators develop companion diagnostic tests for use with our product candidates, we, or our collaborators, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our product candidates, once approved.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Further, increasing efforts by third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. In order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or comparable regulatory approvals. Additionally, we may also need to provide discounts to purchasers, private health plans or government healthcare programs. Our product candidates may nonetheless not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition. We expect to experience pricing pressures from third-party payors in connection with the potential sale of any of our product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Enacted healthcare legislation, changes in healthcare law and implementation of regulations, as well as changes in healthcare policy, may increase the difficulty and cost for us to commercialize our product candidates, may impact our business in ways that we cannot currently predict, could affect the prices we may set, and could have a material adverse effect on our business and financial condition.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In the United States and in some foreign jurisdictions, there have been and likely will continue to be a number of legislative and regulatory changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. For example, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, was passed, which substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. See the section titled, &#8220;Business &#8212; Government Regulation &#8212; Current and future healthcare reform legislation&#8221;.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">61</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Moreover, increasing efforts by governmental and other third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions on coverage or access could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates that we successfully commercialize or put pressure on our product pricing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the extent to which state and federal governments cover particular healthcare products and services and could limit the amounts that the federal and state governments will pay for healthcare products and services. For example, recent CMS proposals, including the GLOBE, GUARD, and GENEROUS, could materially impact the Company&#8217;s revenue. This could result in reduced demand for any product candidate or complementary or companion diagnostics we develop or could result in additional pricing pressures.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the demand for our product candidates, if we obtain regulatory approval;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;our ability to set a price that we believe is fair for our approved products;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;our ability to generate revenue and achieve or maintain profitability;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the level of taxes that we are required to pay; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the availability of capital.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our relationships with customers, third-party payors and others may be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare providers, third-party payors, customers, and others may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, which may constrain the business or financial arrangements and relationships through which we research, as well as sell, market and distribute any products for which we obtain marketing approval. See the section titled, &#8220;Business &#8212; Government Regulation &#8212; Other Healthcare Laws and Compliance Requirements&#8221;.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">62</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to significant sanctions, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, reputational harm, exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Further, if the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to similar penalties. In addition, the approval and commercialization of any product candidate we develop outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. All of these could harm our ability to operate our business and our financial results.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Risks Related to Manufacturing of Our Product Candidates</span></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The loss of our third-party manufacturing partners or our, or our partners</i></b>&#8217;<b><i>, failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We have contracted with qualified third-party CDMOs, to manufacture our product candidates for preclinical and clinical trials. If approved, commercial supply of any product candidates may also be manufactured at one or more CDMOs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The facilities used by our CDMOs to manufacture our product candidates are subject to various regulatory requirements and may be subject to the inspection of the FDA or other regulatory authorities. We do not control the manufacturing process at our CDMOs and are completely dependent on them for compliance with current regulatory requirements. If we or our CDMO cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable regulatory authorities in foreign jurisdictions, we may not be able to rely on their manufacturing facilities for the manufacture of elements of our product candidates. In addition, we have limited control over the ability of our CDMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds our facilities or those of our CDMOs inadequate for the manufacture of our product candidates or if such facilities are subject to enforcement action in the future or are otherwise inadequate, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Additionally, our CDMOs may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments or on account of global pandemics or similar events. If our CDMOs were to encounter any of these difficulties, our ability to provide our product candidate to patients in clinical trials, or to provide product for the treatment of patients once approved, would be jeopardized.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">63</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. In addition, we will likely need to change our CDMO for manufacturing any of our product candidates to one that can support commercial-scale manufacturing. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing, FDA notification or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and generate revenue.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We are subject to multiple manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The process of manufacturing antibody therapeutics and bispecifics, including our product candidates, is complex, time-consuming, highly regulated and subject to several risks, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">product loss during the manufacturing process, including loss caused by contamination, equipment failure or improper installation or operation of equipment, or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or in the manufacturing facilities in which our products are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we will likely need to change our CDMO for manufacturing our product candidates to one that can support large-scale manufacturing for later stage clinical trials as well as commercial supply needs;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the manufacturing facilities in which our products are made could be adversely affected by equipment failures, labor and raw material shortages, natural disasters, power failures and numerous other factors; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">any adverse developments affecting manufacturing operations for our products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We may also make changes to our manufacturing processes at various points during development, for a number of reasons, such as controlling costs, achieving scale, decreasing processing time, increasing manufacturing success rate or other reasons. Such changes carry the risk that they will not achieve their intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of our ongoing or future clinical trials. In some circumstances, changes in the manufacturing process may require us to perform ex vivo comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials. For instance, changes in our process during the course of clinical development may require us to show the comparability of the product used in earlier clinical phases or at earlier portions of a trial to the product used in later clinical phases or later portions of the trial.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">64</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Risks Related to Intellectual Property</span></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates may be adversely affected.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our success depends, in large part, on our and in a few cases, our licensors&#8217; ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates and platform. We and our licensors have sought, and intend to seek, to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates and technology that are important to our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our technology or product candidates or that effectively prevent others from commercializing competitive technologies and product candidates. In particular, during prosecution of any patent application, the issuance of any patents based on the application may depend upon our ability to generate additional preclinical or clinical data that support the patentability of our proposed claims. We may not be able to generate sufficient additional data on a timely basis, or at all. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We may not be aware of all third-party intellectual property rights potentially relating to our product candidates. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, only upon issuance or not at all. Therefore, we cannot be certain that we, or a licensor, were the first to make the inventions claimed in any owned or any licensed patents or pending patent applications, respectively, or which entity was the first to file for patent protection until such patent application publishes or issues as a patent. Databases for patents and publications, and methods for searching them, are inherently limited, so it is not practical to review and know the full scope of all issued and pending patent applications. As a result, the issuance, scope, validity, enforceability, and commercial value of our and our licensed patent rights are uncertain. Furthermore, if third parties have filed such patent applications, we may challenge their ownership, for example in a derivation proceeding before the U.S. Patent and Trademark Office ("USPTO"), to determine who has the right to the claimed subject matter in the applications. Similarly, if our patent applications are challenged in a derivation proceeding, the USPTO may hold that a third-party is entitled to certain patent ownership rights instead of us. We may then be forced to seek a license from the third party that may not be available on commercially favorable terms, or at all.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The patent prosecution process is expensive, time consuming and complex, and we may not have and may not in the future be able to file, prosecute, maintain, enforce, defend or license all necessary or desirable patent applications in some or all relevant jurisdictions at a reasonable cost or in a timely manner. For example, in some cases, the work of certain academic researchers in the field has entered the public domain, which may compromise our ability to obtain patent protection for certain inventions related to or building upon such prior work. Consequently, we may not be able to obtain any such patents to prevent others from using our technology for, and developing and marketing competing products to treat, these indications. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. In some cases, we may be able to obtain patent protection, but such protections may expire before we commercialize the product protected by those rights, leaving us no meaningful protection for our products. In other cases, where our intellectual property is being managed by a third-party collaborator, licensee or partner, that third party may fail to act diligently in prosecuting, maintaining, defending or enforcing our patents. Such conduct may result in the failure to maintain or obtain protections, loss of rights, loss of patent term or, in cases where a third party has acted negligently or inequitably, patents being found unenforceable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">65</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Even if the patent applications we license or own do issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In spite of a legal presumption of validity, the issuance of a patent is not conclusive as to its inventorship, ownership, scope, validity, or enforceability which may be challenged in the courts and patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology, resulting in termination of our access to such intellectual property or increase our financial or other obligations to our licensors.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology or affect financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our licensed patents and/or applications and any patent rights we own or may own in the future. We rely, in part, on our third party payment services or our licensing partners to pay these fees due to the USPTO and to non-U.S. patent agencies. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction and may compromise the strength of other intellectual property in our portfolio. In such an event, potential competitors might be able to enter the market and this circumstance could have a material adverse effect on our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">On February 1, 2019 the government of Venezuela, in response to certain U.S. sanctions, began to require that foreign entities pay all official fees, including patent fees (either for pending matters or new petitions), in PETRO, a &#8220;cryptocurrency&#8221; created by the Nicol&#225;s Maduro administration in February 2018 as a way to collect U.S. dollars while avoiding American financial sanctions issued under an Executive Order of then-President Trump on March 19, 2018. The Executive Order banned transactions involving &#8220;any digital currency, digital coin, or digital token, that was issued by, for, or on behalf of the Government of Venezuela on or after January 9, 2018.&#8221; The prohibition is applicable to any U.S. entity unless exempted by license. We do not hold such a license and therefore may not be able to secure patents in Venezuela. A presidential decree dated January 14, 2020 formally established the PETRO as a mandatory means of payment. In response, the Venezuelan Patent Office established an alternative payment method allowing the receipt of deposits with the value of corresponding Official fees in U.S. Dollars and Euros in cash at a non-sanctioned governmental bank. While this has been an adequate course of action to proceed in compliance, there is no guarantee it will remain so.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">66</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may not be able to protect our intellectual property rights throughout the world.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Filing, prosecuting and enforcing patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States are and could remain less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may be less likely to be able to prevent third parties from infringing our patents in all countries outside the United States, or from selling or importing products that infringe our patents in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Many companies have encountered significant problems protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products or methods of treatment, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. For example, with &#8220;Brexit&#8221;, there is uncertainty associated with obtaining, defending, and enforcing intellectual property rights in the United Kingdom. International treaties and regulations promulgated as a result of this transition could impede or eliminate our ability to obtain or maintain meaningful intellectual property rights in the United Kingdom. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired and our business, financial condition, results of operations and prospects may be adversely affected.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Patents have a limited lifespan. In most countries, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest national filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new product candidates, it is possible that patents protecting our product candidates might expire before or shortly after we commercialize those candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">67</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we do not obtain patent term extension and data exclusivity for our product candidates, our business may be materially harmed.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Depending upon the timing, duration and specifics of any FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 ("the Hatch-Waxman Act"). The Hatch-Waxman Act permits a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval or more than five years beyond the patent&#8217;s natural expiration date, only one patent may be extended per FDA-approved product, and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. Further, certain of our licenses currently or in the future may not provide us with the right to control decisions the licensor or its other licensees on Orange Book listings or patent term extension decisions under the Hatch-Waxman Act. Thus, if one of our important licensed patents is eligible for a patent term extension under the Hatch-Waxman Act, and it covers a product of another licensee in addition to our own product candidate, we may not be able to obtain that extension if the other licensee seeks and obtains that extension first. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The Biologics Price Competition and Innovation Act of 2009 provides up to 12 years of market exclusivity for a reference biological product. We may not be able to obtain such exclusivity for our products. Moreover, the applicable time-period or the scope of patent protection afforded during any such extension could be less than we request. If we are unable to obtain patent term extension or the scope of term of any such extension is less than we request, the period during which we will have the right to exclusively market our product may be shortened and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be materially reduced.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act, enacted in September 2011 ("the America Invents Act"), the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The America Invents Act also includes several significant changes that affect the way patent applications are prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity or ownership of a patent by USPTO administered post-grant proceedings, including post-grant review, <i>inter partes</i> review and derivation proceedings. The America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We may be subject to such third-party pre-issuance submission of prior art to the USPTO or become involved in other contested proceedings such as opposition, derivation, reexamination, <i>inter partes</i> review, or post-grant review proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">68</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In addition, the patent positions of companies in the development and commercialization of biological products and pharmaceuticals are particularly uncertain. Recent rulings from the U.S. Court of Appeals for the Federal Circuit and the U.S. Supreme Court have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Competitors may infringe our patents or the patents of our licensors, or we may be required to defend against claims of infringement. Countering infringement or unauthorized use claims or defending against claims of infringement can be expensive and time-consuming. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future marketing, sales or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In addition, many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own, develop or license.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court. We may not be able to protect our trade secrets in court.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">If we or one of our licensing partners initiate legal proceedings against a third party to enforce any patent that is issued covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or non-enablement. In addition, patent validity challenges may, under certain circumstances, be based upon non-statutory obviousness-type double patenting, which, if successful, could result in a finding that the claims are invalid for obviousness-type double patenting or the loss of patent term, including a patent term adjustment granted by the USPTO, if a terminal disclaimer is filed to obviate a finding of obviousness-type double patenting. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, <i>inter partes</i> review and equivalent proceedings in foreign jurisdictions. Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art of which the patent examiner and we or our licensing partners were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we could lose part, and perhaps all, of the patent protection on one or more of our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">69</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect, and some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business and financial condition.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our commercial success depends upon our ability and the ability of any collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current manufacturing methods, product candidates or future methods or products, resulting in either an injunction prohibiting our manufacture or sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates and technology, including post grant review and <i>inter partes</i> review before the USPTO. The risks of being involved in such litigation and proceedings may also increase as our product candidates approach commercialization and as we gain greater visibility as a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could materially and adversely affect our ability to commercialize any of our product candidates or technologies covered by the asserted third-party patents.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">If we are found to infringe a third party&#8217;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidates and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidates. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing and commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">70</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Others may claim an ownership interest in our intellectual property and our product candidates, which could expose us to litigation and have a significant adverse effect on our prospects.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">While we are presently unaware of any claims or assertions by third parties with respect to our patents or other intellectual property, we cannot guarantee that a third party will not assert a claim or an interest in any of such patents or intellectual property. For example, a third party may claim an ownership interest in one or more of our, or our licensors&#8217;, patents or other proprietary or intellectual property rights. A third party could bring legal actions against us to seek monetary damages or enjoin clinical testing, manufacturing or marketing of the affected product candidate or product. If we become involved in any litigation, it could consume a substantial portion of our resources and cause a significant diversion of effort by our technical and management personnel. If any such action is successful, in addition to any potential liability for damages, we could be required to obtain a license to continue to manufacture or market the affected product candidate or product, in which case we could be required to pay substantial royalties or grant cross-licenses to patents. We cannot, however, assure you that any such license would be available on acceptable terms, if at all. Ultimately, we could be prevented from commercializing a product, or forced to cease some aspect of our business operations as a result of claims of patent infringement or violation of other intellectual property rights. Further, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of witnesses and the identity of any adverse party. This is especially true in intellectual property cases, which may turn on the testimony of experts as to technical facts upon which experts may reasonably disagree. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely affected.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Trade secrets and know-how can be difficult to protect. To maintain the confidentiality of trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators and others upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#8217;s relationship with us be kept confidential and not disclosed to third parties. Our agreements with employees and our personnel policies also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes, and individuals with whom we have these agreements may not comply with their terms. Thus, despite such agreement, there can be no assurance that such inventions will not be assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. To the extent that an individual who is not obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property from that individual, or a third party or from that individual&#8217;s assignee. Such assignment or license may not be available on commercially reasonable terms or at all. We also seek to preserve the integrity and confidentiality of our trade secrets by other means, including maintaining physical security of our premises and physical and electronic security of our information technology systems. However, these security measures may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Adequate remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets would impair our competitive position and may materially harm our business, financial condition and results of operations. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent discovery. For example, a public presentation in the scientific or popular press on the properties of our product candidates could motivate a third party, despite any perceived difficulty, to assemble a team of scientists having backgrounds similar to those of our employees to attempt to independently reverse engineer or otherwise duplicate our antibody technologies to replicate our success.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">71</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Many of our directors, employees, consultants, and advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals, or we, have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates, are rightfully owned by their former or current employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In addition, while it is our policy to require our employees, consultants, advisors and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Any registered trademarks or trade names may be challenged, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Collaborations with third parties, including academic collaborations, may limit our ability to obtain, maintain, enforce or defend intellectual property necessary to conduct our business.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We may sometimes collaborate with non-profit and academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to develop our program.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">72</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In some circumstances, particularly in-licenses with academic institutions, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain, enforce or defend the patents, covering technology that we license from third parties. Therefore, we cannot be certain that these patents and applications will be prosecuted, maintained and enforced in a manner consistent with the best interests of our business. If our licensors fail to maintain such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated and our right to develop and commercialize any of our products that are the subject of such licensed rights could be adversely affected. In certain circumstances, we have or may license technology from third parties on a non-exclusive basis. In such instances, other licensees may have the right to enforce our licensed patents in their respective fields, without our oversight or control. Those other licensees may choose to enforce our licensed patents in a way that harms our interest, for example, by advocating for claim interpretations or agreeing on invalidity positions that conflict with our positions or our interest. In addition to the foregoing, the risks associated with patent rights that we license from third parties will also apply to patent rights we own or may own in the future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Intellectual property rights do not necessarily address all potential threats.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">others may be able to make products that are similar to our product candidates but that are not covered by the claims of the patents that we own or license or may own in the future;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we, or any partners or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or may own in the future;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we, or any partners or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">it is possible that our pending licensed patent applications or those that we may own in the future will not lead to issued patents;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we may not develop additional proprietary technologies that are patentable;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the patents of others may have an adverse effect on our business; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">we may choose not to file a patent for certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">73</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Risks Related to Information Technology and Data Privacy</span></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We depend on our information technology systems, and any failure of these systems could harm our business. Cybersecurity incidents, data breaches, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We collect and maintain information in digital form that is necessary to conduct our business, and we are dependent on our information technology systems and those of third parties to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information, and data to comply with cGMP and data integrity requirements. It is critical that we do so in a secure manner to maintain data security and data integrity of such information. We have established physical, electronic and organizational measures to safeguard and secure our systems to prevent a data compromise. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. Our internal information technology systems and infrastructure, and those of our current and any future collaborators, contractors and consultants and other third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions, phishing, persons inside our organization or persons with access to systems inside our organization.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We, like other organizations in our industry, may experience cybersecurity incidents. The risk of cybersecurity incidents, data breaches or disruption or data loss, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information or other intellectual property. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. Moreover, if a computer security breach affects our systems or results in the unauthorized release of personally identifiable information, our reputation could be materially damaged. In addition, such a breach may require notification to impacted stakeholders (including affected individuals, regulators and investors pursuant to various federal and state privacy and security laws, if applicable, including the Health Insurance Portability and Accountability Act of 1996, as amended ("HIPAA"), and its implementing rules and regulations, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. We would also be exposed to a risk of loss or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition. Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our privacy and data security obligations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We are or may become subject to other U.S. federal and state laws governing the privacy and security of health information, many of which differ from each other in significant ways and may not be preempted by HIPAA. For example, the California Consumer Privacy Act (CCPA) created individual privacy rights for California residents, including requiring covered businesses to provide notice regarding how personal information is collected and how individuals can limit the sharing of their personal information. The California Privacy Rights Act (CPRA) amended the CCPA and requires specific disclosures and safeguarding requirements around sensitive personal information. The CPRA also establishes a state agency vested with the authority to enforce the CCPA. The CCPA also applies to personal information collected about employees, applicants and retirees, as well as that which is collected in a business-to-business capacity. While there is currently an exception in the CCPA for protected health information that is subject to HIPAA, the CCPA may nevertheless impact our data use and sharing practices and require significant investment in our effort to comply with its obligations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">74</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">More than a dozen other U.S. states have enacted legislation similar to the CCPA, but contain key differences in their scope, application, and enforcement. Clear enforcement guidelines, as well as associated penalties for noncompliance, are likely to be unpredictable for the foreseeable future. Moreover, certain states have advanced privacy laws focused on protecting consumer health information, such as Washington&#8217;s My Health My Data Act, which contains a private right of action and my increase the risk of litigation. and this remains a rapidly changing legislative and regulatory environment. Any actual or perceived noncompliance with privacy and data protection laws by us or our partners may damage to our reputation, lead to loss of existing or future business, require us to change our data practices and increase our expenses related to litigation and compliance ongoing compliance, any of which could adversely affect our business, results of operations and financial condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In December 2024, the U.S. Department of Justice issued regulations implementing Executive Order (&#8220;EO&#8221;) 14117, &#8220;Preventing Access to Americans&#8217; Bulk Sensitive Personal Data and United Stated Government-Related Data by Countries of Concern,&#8221; which became effective in April 2025. These regulations prohibit transactions involving access to bulk sensitive data by countries of concern, such as China (including Hong Kong). In the life sciences sector, the regulations prohibit investment agreements, employment agreements, vendor agreements, and other transactions involving human genomic data and biospecimens, except where necessary for specified exempt activities. Tracking and complying with these regulations may require significant time and expense.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Our use of new and evolving technologies, such as artificial intelligence, may present risks and challenges that can impact our business, including by posing cybersecurity and other risks to our confidential and/or proprietary information, including personal information, and as a result we may be exposed to reputational harm and liability. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We may use and integrate artificial intelligence into our business processes. Use of this rapidly evolving technology will require the application of significant resources to design, develop, test, and maintain such systems to help ensure that artificial intelligence is implemented in accordance with applicable law and in a socially responsible manner. If we enable or use solutions that draw controversy due to perceived or actual negative societal impact, we may experience brand or reputational harm, competitive harm, or legal liability.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">A growing number of legislators and regulators are adopting laws and regulations and have focused enforcement efforts on the adoption of artificial intelligence, and use of such technologies in compliance with ethical standards and societal expectations. These developments may increase our compliance burden and costs in connection with use of artificial intelligence and lead to legal liability if we fail to meet evolving legal standards or if use of such technologies results in harms or other causes of action we did not predict. For example, the EU&#8217;s Artificial Intelligence Act (&#8220;AI Act&#8221;) entered into force on August 1, 2024, with most provisions becoming effective on August 2, 2026. This legislation imposes significant obligations on providers and deployers of artificial intelligence systems and encourages providers and deployers of artificial intelligence systems to account for EU ethical principles in their development and use of these systems. The scope of requirements depends on legal and risk determinations that rely on novel legal provisions that have not yet been interpreted by courts or regulators, and non-compliance can lead to significant fines.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Likewise, in the U.S., several states, including Colorado and California, passed laws that will take effect in 2026, to regulate various uses of artificial intelligence, including to make consequential decisions. In addition, various federal regulators have issued guidance and focused enforcement efforts on the use of AI in regulated sectors. Additionally, the FDA, for example, issued draft guidance on the use of AI in regulatory decision-making for drug and biological products that centers on the context of use while establishing a credibility assessment framework for establishing and evaluating AI model outputs intended to support regulatory decision-making. If we develop or use AI systems governed by these laws or regulations, including as informed by regulatory guidance, we will need to meet higher standards of data quality, transparency, monitoring, and human oversight, and we would need to adhere to specific and potentially burdensome and costly ethical, accountability, and administrative requirements, with the potential for significant enforcement or litigation in the event of any perceived non-compliance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">75</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our vendors may in turn incorporate artificial intelligence tools into their offerings, and the providers of these artificial intelligence tools may not meet existing or rapidly evolving regulatory or industry standards, including with respect to privacy and data security. Further, global threat actors are using increasingly sophisticated methods, including artificial intelligence, to engage in the theft and misuse of confidential information and proprietary information. Any of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and adversely impact our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>European data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In the event we decide to conduct clinical trials in the EEA or the UK or enroll subjects residing in the EEA or the UK in our future clinical trials, we may be subject to additional privacy restrictions. The collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the EEA, including personal health data, is subject to the EU General Data Protection Regulation (&#8220;EU GDPR&#8221;). EU GDPR has been incorporated into U.K. domestic law by virtue of section 3 of the European Union (Withdrawal) Act 2018 and amended by the Data Protection, Privacy and Electronic Communications (Amendments etc.) (EU Exit) Regulations 2019 (&#8220;U.K. GDPR&#8221;, together with the EU GDPR referred to as &#8220;GDPR&#8221;). The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to the processing of sensitive data (such as health data), obtaining consent of the individuals to whom the personal data relates or ensuring another legal basis or condition applies to the processing of personal data, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, where required providing notification of data breaches, requiring data protection impact assessments for high risk processing and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA or the U.K. (see below), including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million (&#163;17.5 million) or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The GDPR may increase our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. The U.K. plans to reform the country&#8217;s data protection legal framework in its Data Use and Access Bill, which was introduced into the U.K. legislative process on October 23, 2024 and, if passed, will introduce significant changes. This may lead to additional compliance costs and could increase our overall risk exposure as we may no longer be able to take a unified approach across the EU and the U.K.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The GDPR includes restrictions on cross-border data transfers. Adequate safeguards must be implemented to enable the transfer of personal data outside of the EEA or the U.K., in particular to the U.S., in compliance with European and U.K. data protection laws. On June 4, 2021, the European Commission (&#8220;EC&#8221;) issued new forms of standard contractual clauses for data transfers from controllers or processors in the EEA (or otherwise subject to the EU GDPR) to controllers or processors established outside the EEA (and not subject to the EU GDPR). The U.K. is not subject to the EC&#8217;s new standard contractual clauses but has published its own version of standard clauses, referred to as &#8220;International Data Transfer Agreement&#8221; which entered into force on 21 March 2022 and enables transfers originating from the U.K. The U.K. Government has confirmed that transfers from the U.K. to the EEA may currently continue to flow freely. Transfers made pursuant to these new mechanisms need to be assessed on a case-by-case basis to ensure the law in the recipient country provides &#8220;essentially equivalent&#8221; protections to safeguard the transferred personal data as the EU, and businesses are required to adopt supplementary measures if such standard is not met. Further, the EU has adopted its adequacy decision for the EU-U.S. Data Privacy Framework ("Framework"), which entered into force on July 11, 2023. This Framework provides that the protection of personal data transferred from the EU to companies which are certified to the Framework in the United States is comparable to that offered in the EU. This provides a further avenue to ensuring transfers to the United States are carried out in line with GDPR. There has been an extension to the Framework to cover U.K. transfers to the United States. The Framework could be challenged like its predecessor frameworks. We will be required to implement these new safeguards when conducting restricted data transfers under the GDPR and doing so will require significant effort and cost.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">76</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The use of new and evolving technologies, such as artificial intelligence, in our business may result in spending material resources and presents risks and challenges that can impact our business including by posing security and other risks to our confidential and/or proprietary information, including personal information, and as a result we may be exposed to reputational harm and liability.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Risks Related to Our Work with Third Parties</span></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We rely or will rely on third parties to help conduct our ongoing and planned preclinical studies and clinical trials for our current product candidates and any future product candidates we develop. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize our current product candidates and any current or future product candidates we develop and our business could be materially harmed.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We currently do not have the ability to independently conduct preclinical studies that comply with the regulatory requirements known as current good laboratory practice ("GLP") requirements. We also do not currently have the ability to independently conduct any clinical trials. The FDA and regulatory authorities in other jurisdictions require us to comply with regulations and standards, including cGCP, or requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct GLP-compliant preclinical studies and cGCP-compliant clinical trials on our product candidates properly and on time. While we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their actual performance. The third parties with whom we contract for execution of our GLP-compliant preclinical studies and our cGCP-compliant clinical trials play a significant role in the conduct of these studies and trials and the subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability to control the amount or timing of resources that they devote to our current or future product candidates. Although we rely on these third parties to conduct our GLP-compliant preclinical studies and cGCP-compliant clinical trials, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. Further, under certain circumstances, these third parties may unilaterally terminate their agreements with us. If the third parties conducting our preclinical studies or our clinical trials do not adequately perform their contractual duties or obligations, experience significant business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GLP and cGCP, or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly or impossible, and our preclinical studies or clinical trials may need to be extended, delayed, terminated or repeated. As a result, we may not be able to obtain regulatory approval in a timely fashion, or at all, for the applicable product candidate, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">77</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may depend on other third-party collaborators for the discovery, development and commercialization of certain of our current and future product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In the future, we may form or seek other strategic alliances, joint ventures or collaborations, or enter into licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to product candidates we develop. Such potential future collaborations involving our product candidates may pose various risks to us, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">collaborators may not properly enforce, maintain or defend our intellectual property rights or may use our proprietary information in a way that gives rise to actual or threatened litigation or that could jeopardize or invalidate our intellectual property or proprietary information, exposing us to potential litigation or other intellectual property proceedings;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">disputes may arise between a collaborator and us that cause the delay or termination of the research, development or commercialization of the product candidate, or that result in costly litigation or arbitration that diverts management attention and resources;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such products;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">if a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">collaboration agreements may restrict our right to independently pursue new product candidates.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">If we enter into collaboration agreements and strategic partnerships or license our intellectual property, products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or net income that justifies such transaction. Any of the factors set forth above, among others, could delay the development and commercialization of our product candidates, which would harm our business prospects, financial condition and results of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may seek to establish collaborations, and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The advancement of our product candidates and development programs and the potential commercialization of our current and future product candidates will require substantial additional cash to fund expenses. For some of our current or future product candidates, we may decide to collaborate with pharmaceutical and biotechnology companies with respect to development and potential commercialization. Any of these relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">78</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Whether we reach a definitive agreement for other collaborations will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the progress of our clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Further, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for future product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. Such exclusivity could limit our ability to enter into strategic collaborations with future collaborators. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any marketing or sales activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Risks Related to Our Business</span></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The biotechnology industry is intensely competitive and subject to rapid and significant technological change. Our current or future product candidates may face competition from major pharmaceutical companies, specialty pharmaceutical companies, universities and other research institutions and from products and therapies that currently exist or are being developed, some of which products and therapies we may not currently know about. Many of our competitors have significantly greater financial, manufacturing, marketing, product development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining marketing approvals, recruiting patients and manufacturing pharmaceutical products, and they may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or FDA or other regulatory approval or discovering, developing and commercializing products in our field before we do, which could result in our competitors establishing a strong market position before we are able to enter the market.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">79</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our competitors may obtain FDA or other regulatory approval of their product candidates more rapidly than we may or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates or platform technologies. Our competitors may also develop drugs or discovery platforms that are more effective, more convenient, more widely used or less costly than our product candidates or, in the case of drugs, have a better safety profile than our product candidates. These competitors may also be more successful than us in manufacturing and marketing their products, and have significantly greater financial resources and expertise in research and development.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. Currently marketed oncology drugs and therapeutics range from traditional cancer therapies, including chemotherapy, to antibody-drug conjugates, such as Genentech&#8217;s Kadcyla, to immune checkpoint inhibitors targeting CTLA-4, such as BMS&#8217; Yervoy, and PD-1/PD-L1, such as BMS&#8217; Opdivo, Merck &amp; Co.&#8217;s Keytruda and Genentech&#8217;s Tecentriq, to T cell-engager antibody therapeutics, such as Amgen&#8217;s Blincyto. In addition, numerous compounds are in clinical development for cancer treatment. Many of these companies are well-capitalized and have significant clinical experience.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Smaller and other early-stage companies may also prove to be significant competitors. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our current and future product candidates. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our product candidates obsolete, less competitive or not economical.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop. Our competitors may also obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates or platform technologies. Even if our product candidates achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness. If we do not compete successfully, we may not generate or derive sufficient revenue from any product candidate for which we obtain marketing approval and may not become or remain profitable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">As our development plans and strategies develop, and as we continue operating as a public company, we expect to need additional managerial, operational, marketing, sales, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">identifying, recruiting, integrating, maintaining and motivating additional employees;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">managing our internal development efforts effectively, including the clinical and FDA review process for our current product candidates and any other current or future product candidates we develop, while complying with our contractual obligations to contractors and other third parties; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">improving our operational, financial and management controls, reporting systems and procedures.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">80</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our future financial performance and our ability to advance development of and, if approved, commercialize our current product candidates and any current or future product candidates we develop will depend, in part, on our ability to effectively manage any future growth, and our management may have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of any current or future product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our current product candidates and any current or future product candidates we develop and, accordingly, may not achieve our research, development and commercialization goals.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have broad discretion in the use of our cash resources and may not use them effectively.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We currently intend to use our cash resources for clinical development of our product candidates, the advancement of our preclinical and discovery programs in development, and for working capital and other general corporate purposes. Although we currently intend to use our cash resources in such a manner, we will have broad discretion in their application. Our failure to apply these funds effectively could affect our ability to continue to develop and commercialize our product candidates. Pending their use, we may invest our cash resources in a manner that does not produce income or loses value.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We are highly dependent on members of our executive team. The loss of the services of any of them may adversely impact the achievement of our objectives. Any of our executive officers could leave our employment at any time, as all of our employees are &#8220;at-will&#8221; employees. The loss of the services of these officers could impede the achievement of our research, development and commercialization objectives.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Historically, we have experienced significant turnover in our research and development workforce and have operated with a limited team of scientific and technical personnel. We have had difficulty attracting and retaining qualified personnel for certain positions in our research and development groups and we may not be able to attract and retain such personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for skilled individuals. Recruiting and retaining qualified employees for our business, including scientific and technical personnel, will also be critical to our success. In addition, failure to succeed in preclinical studies, clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified scientific and technical personnel. The inability to recruit, or the loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse effect on our business, financial condition, results of operations and growth prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">81</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Pursuant to Section 404 of the Sarbanes-Oxley Act, our management is required to annually report upon the effectiveness of our internal control over financial reporting. When we reach an accelerated filer threshold, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. As we grow, we expect to hire additional personnel and may utilize external temporary resources to implement, document and modify policies and procedures to maintain effective internal controls. However, it is possible that we may identify significant deficiencies and/or material weaknesses in our internal controls. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Although we have determined that our internal control over financial reporting was effective as of December 31, 2025, we cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begin its Section 404 audits, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Our business, results of operations and future growth prospects could be or continue to be affected by global pandemics, such as the COVID-19 pandemic, or the future outbreak of other highly infectious or contagious diseases.</i></b></p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our business could be adversely affected by health epidemics in regions where we have concentrations of clinical trial sites or other business activities and could cause significant disruption in the operations of third-parties on which we rely. We cannot precisely determine or quantify the impact the future outbreak of any highly infectious our contagious diseases, such as the COVID-19 pandemic, will have on our business operations in the future, which will depend on a variety of factors and future developments, which are highly uncertain and cannot be predicted with confidence, including the ultimate geographic spread of the disease, the duration, scope and severity of the pandemic, the duration and extent of travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and the pandemic.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Under current law, unused federal net operating losses generated for tax years beginning after December 31, 2017 are not subject to expiration and may be carried forward indefinitely. For taxable years beginning after December 31, 2020, the deductibility of such federal net operating losses is limited to 80% of our taxable income in any future taxable year. In addition, in general, under Sections 382 and 383 of the Code, a corporation that undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership by certain stockholders over a three-year period, is subject to limitations on its ability to utilize its pre-change net operating losses and research and development tax credit carryforwards to offset future taxable income. We may have experienced such ownership changes in the past and may experience such ownership changes in the future (which may be outside our control). As a result, if, and to the extent that, we earn net taxable income, our ability to use our pre-change net operating losses and research and development tax credit carryforwards to offset such taxable income may be subject to limitations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">82</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Risks Related to Our Common Stock</span></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our principal stockholders and management own a significant percentage of our stock and will be able to exercise significant influence over matters subject to stockholder approval.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">As of December 31, 2025, our executive officers, directors and principal stockholders, together with their respective affiliates, beneficially owned approximately 18% of our common stock. Accordingly, these stockholders will be able to exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of our board of directors and approval of significant corporate transactions. This concentration of ownership could have the effect of entrenching our management and/or the board of directors, delaying or preventing a change in our control or otherwise discouraging a potential acquirer from attempting to obtain control of us, which in turn could have a material and adverse effect on the fair market value of our common stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Future issuances of common or preferred stock to fund our operations may substantially dilute your investment and reduce your equity interest in our company.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We may need to raise capital in the future through issuances of common or preferred stock to fund the development of our drug candidates or for other purposes. At its sole discretion, our board of directors may issue additional securities without seeking stockholder approval. Any future issuances of common or preferred stock to fund our operations may substantially dilute your investment and reduce your equity interest in our company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Provisions in our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws that we have adopted in connection with the reverse contain provisions that may have the effect of discouraging, delaying or preventing a change in control of us or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Some of these provisions include:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a requirement that special meetings of stockholders be called only by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">83</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporate Law ("DGCL"), which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These antitakeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Any provision of our amended and restated certificate of incorporation, our amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our amended and restated bylaws designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders</i></b>&#8217;<b><i> ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our amended and restated bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers and employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our bylaws (in each case, as they may be amended form time to time) or (iv) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein; provided, however, that this exclusive forum provision will not apply to any causes of action arising under the Securities Act of 1933, as amended ("the Securities Act" or "the Exchange Act"). Our bylaws further provide that, unless we consent in writing to an alternative forum, the United States District Court for the District of Massachusetts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. We have chosen the United States District Court for the District of Massachusetts as the exclusive forum for such Securities Act causes of action because our principal executive offices are located in Boston, Massachusetts. In addition, our amended and restated bylaws will provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions. We recognize that the forum selection clause in our bylaws may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or the Commonwealth of Massachusetts, as applicable. Additionally, the forum selection clause in our bylaws may limit our stockholders&#8217; ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. The Court of Chancery of the State of Delaware or the United States District Court for the District of Massachusetts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">84</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">You should not rely on an investment in our common stock to provide dividend income. We do not anticipate that we will pay any cash dividends to holders of our common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our operations. In addition, any future debt financing arrangement we enter into may contain, terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any return on their investment. As a result, investors seeking cash dividends should not purchase our common stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">General Risk Factors</span></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations, or, collectively, Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our business is heavily regulated and therefore involves significant interaction with public officials. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our non-U.S. activities to increase in time. Additionally, in many other countries, the healthcare providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the U.S. Foreign Corrupt Practices Act of 1977, as amended ("FCPA"). We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. In particular, our operations will be subject to FCPA, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government-owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof. Recently, the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents, suppliers, manufacturers, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of facilities, including those of our suppliers and manufacturers, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs and prohibitions on the conduct of our business. Any such violations could also result in prohibitions on our ability to offer our products in one or more countries as well as difficulties in manufacturing or continuing to develop our products, and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees and our business, prospects, operating results and financial condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">85</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We will continue to incur increased costs as a result of being a public company and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">As a public company, we will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. We will be subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC, annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act ("the Dodd-Frank Act"), was enacted. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have an adverse effect on our business. The increased costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to accept reduced coverage or incur substantially higher costs to maintain sufficient coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. Moreover, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">86</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We are a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to smaller reporting companies will make our common stock less attractive to investors.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We are a smaller reporting company, meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue is less than $100 million during the most recently completed fiscal year. We will continue to be a &#8220;smaller reporting company&#8221; until (i) the market value of our stock held by non-affiliates is more than $700 million or (ii) our annual revenue is more than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is more than $250 million as of the prior June 30. Being a small reporting company allows us to take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not smaller reporting companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended ("the Sarbanes-Oxley Act"), we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and we have reduced disclosure obligations regarding executive compensation. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The designation of our common stock as </i></b>&#8220;<b><i>penny stock</i></b>&#8221;<b><i> would limit the liquidity of our common stock.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our common stock may be deemed a &#8220;penny stock&#8221; (as that term is defined under Rule 3a51-1 of the Exchange Act) in any market that may develop in the future. Generally, a &#8220;penny stock&#8221; is a common stock that is not listed on a securities exchange and trades for less than $5.00 a share. Prices often are not available to buyers and sellers and the market may be very limited. Penny stock in start-up companies is among the riskiest equity investments. Broker-dealers who sell penny stock must provide purchasers with a standardized risk-disclosure document prepared by the SEC. The document provides information about penny stock and the nature and level of risks involved in investing in the penny stock market. A broker must also provide purchasers with bid and offer quotations and information regarding broker and salesperson compensation and make a written determination that the penny stock is a suitable investment for the purchaser and obtain the purchaser&#8217;s written agreement to the purchase. Many brokers choose not to participate in penny stock transactions. If our common stock is deemed &#8220;penny stock&#8221;, because of penny stock rules, there may be less trading activity in any market that develops for our common stock in the future and stockholders are likely to have difficulty selling their shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>FINRA sales practice requirements may limit a stockholder</i></b>&#8217;<b><i>s ability to buy and sell our common stock.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) has adopted rules requiring that, in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative or low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer&#8217;s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA has indicated its belief that there is a high probability that speculative or low-priced securities will not be suitable for at least some customers. If these FINRA requirements are applicable to us or our securities, they may make it more difficult for broker-dealers to recommend that at least some of their customers buy our common stock, which may limit the ability of our stockholders to buy and sell our common stock and could have an adverse effect on the market for and price of our common stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">87</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The market price of our common stock may be highly volatile, and may be influenced by numerous factors, some of which are beyond our control.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">If a market for our common stock develops, its market price could fluctuate substantially due to a variety of factors, including market perception of our ability to meet our growth projections and expectations, quarterly operating results of other companies in the same industry, trading volume in our common stock, changes in general conditions in the economy and the financial markets or other developments affecting our business and the business of others in our industry. In addition, the stock market itself is subject to extreme price and volume fluctuations. This volatility has had a significant effect on the market price of securities issued by many companies for reasons related and unrelated to their operating performance and could have the same effect on our common stock. The market price of shares of our common stock could be subject to wide fluctuations in response to many risk factors listed in this section, and others beyond our control, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">results of clinical trials of our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the timing of the release of results of our clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">results of clinical trials of our competitors&#8217;&#160;products;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">safety issues with respect to our products or our competitors&#8217;&#160;products;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">regulatory actions with respect to our products or our competitors&#8217;&#160;products;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">actual or anticipated fluctuations in our financial condition and operating results;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">publication of research reports by securities analysts about us or our competitors or our industry;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our failure or the failure of our competitors to meet analysts&#8217;&#160;projections or guidance that we or our competitors may give to the market;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">additions and departures of key personnel;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the passage of legislation or other regulatory developments affecting us or our industry;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">sales of our common stock by us, our insiders or our other stockholders;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">speculation in the press or investment community;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">announcement or expectation of additional financing efforts;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">changes in accounting principles;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">terrorist acts, acts of war or periods of widespread civil unrest;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">natural disasters and other calamities;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">changes in market conditions for biopharmaceutical stocks; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">88</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">changes in general market and economic conditions.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In addition, the volatility of pharmaceutical, biotechnology and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. As we operate in a single industry, we are especially vulnerable to these factors to the extent that they affect our industry or our products, or to a lesser extent our markets. In the past, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management&#8217;s attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Changes in tax law could adversely affect our business and financial condition.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application), including with respect to net operating losses and research and development tax credits could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 1B. Unresolved Staff Comments.<a id="itm1b" href="#"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Not applicable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 1C. Cybersecurity.<a id="itm1c" href="#"></a> </b></p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="c38" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="c41" format="ixt:fixed-true"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="c42">We recognize the importance of safeguarding the security of our computer systems, software, networks, and other technology assets. We have implemented and maintain a security risk management program that is designed to preserve the confidentiality, integrity, and continued availability of information under our ownership or care with the aim to continually improve security features in order to keep pace with the evolving cyber threat landscape.</ix:nonNumeric></ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="c43" format="ixt:fixed-true">We face a number of cybersecurity risks in connection with our business and recognize the growing threat within the general marketplace and our industry. Although such risks have not materially affected us, including our business strategy, results of operations or financial condition, to date, we and our vendors have, from time to time, experienced threats to and breaches of our data and systems. For more information about the cybersecurity risks we face, see the section titled &#8220;Risk Factors &#8212; Risks Related to Information Technology and Data Privacy&#8221;.</ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Risk Management and Strategy</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="c44" format="ixt:fixed-true"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="c45" format="ixt:fixed-true">We have implemented internal controls including regular risk assessments designed to address financial, operational and information technology (including cybersecurity) risks and controls across our organization. These assessments are overseen by our Head of IT and Chief Accounting Officer. We implement cybersecurity controls and procedures designed to address cyber risks and threats, supported by third-party technologies and security advisors and providers. We also provide cybersecurity awareness training to our employees during the onboarding process and periodically thereafter. In addition, we engage external third-party information security consultants to periodically conduct information security testing and assessments, and to evaluate our overarching information security program and specific incident response procedures. We also maintain a Cyber Incident Response Plan, which is overseen by our Head of IT and is designed to coordinate our response to information security incidents. Finally, we hold and maintain third-party insurance coverage for cybersecurity risks commensurate with industry standards for a company of our size and stage.</ix:nonNumeric></ix:nonNumeric></p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">89</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="c46" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Cybersecurity Oversight </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="c49"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="c50"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="c51"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="c52">The Head of IT is responsible for implementing and maintaining the information security program. The Head of IT role is currently held by an individual who has more than 20 years of professional IT management experience and maintains a Global Information Assurance Certification. The Head of IT reports to our Chief Accounting Officer, who together are responsible for coordinating information security risk assessments and overseeing periodic testing of our cybersecurity controls. Our Chief Accounting Officer meets with the audit committee of our board of directors periodically for the audit committee to provide guidance on the prioritization of the risk remediation and ongoing implementation of cybersecurity improvements across our organization. We also engage an external auditing firm with information security expertise to conduct regular auditing, testing, and review of our information technology risks, processes, and operations.</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Management also generally provides quarterly updates to the audit committee on <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="c53" format="ixt:fixed-true">cybersecurity</ix:nonNumeric> and other information technology risks. We have <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="c54" format="ixt:fixed-true">implemented a process for the Head of IT</ix:nonNumeric> and the Chief Accounting Officer to receive incident reports and report quarterly (and, if applicable, in the event of a cybersecurity incident), to our internal disclosure committee and the audit committee, as appropriate. Management presents to the entire board of directors on an annual basis, including any key findings identified in our cybersecurity assessments.</p>
</ix:nonNumeric>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 2. Properties.<a id="itm2" href="#"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our corporate headquarters is located at 80 Guest Street, Boston, Massachusetts, and consists of 29,836 square feet of office space and laboratory space pursuant to a lease agreement that expires in May 2031. We believe that these facilities are adequate for our current needs and that suitable additional or substitute space will be available in the future if needed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 3. Legal Proceedings.<a id="itm3" href="#"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">From time to time, we may become involved in litigation or other legal proceedings as part of our ordinary course of business. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 4. Mine Safety Disclosures.<a id="itm4" href="#"></a></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Not applicable.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">90</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART II<a id="part2" href="#"></a></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 5. Market for Registrant</b>&#8217;<b>s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.<a id="itm5" href="#"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Market Information and Holders of Record</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">On November 2, 2021, shares of our common stock were approved for trading on the Nasdaq Capital Market under the symbol &#8220;CMPX&#8221;.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">As of February 20, 2026, there were approximately 90 stockholders of record of our common stock. The actual number of stockholders is greater than this number and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Dividends</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We currently intend to retain future earnings, if any, to maintain and expand our operations. We have never declared or paid cash dividends on our common stock and we do not intend to pay any cash dividends on our common stock for the foreseeable future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Securities Authorized for Issuance under Equity Compensation Plans</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our 2020 Stock Option and Incentive Plan (the &#8220;2020 Plan&#8221;) is the only equity incentive plan approved and adopted by our stockholders and provides for the issuance of shares of our common stock to our officers and other employees, directors and consultants. In addition, in December 2025 our board of directors adopted the Compass Therapeutics, Inc. 2025 Inducement Plan (the &#8220;Inducement Plan&#8221;) to enable us to grant equity awards to induce highly-qualified prospective employees to accept employment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The following table presents information as of December 31, 2025 with respect to compensation plans or arrangements under which shares of our common stock may be issued:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: auto; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Plan category</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of securities to be issued upon exercise of outstanding stock options, warrants and rights (000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-average exercise price of outstanding stock options, warrants and rights</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of securities remaining available for issuance under equity compensation plans (000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity compensation plans approved by security holders</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,380</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><sup style="vertical-align:top;line-height:120%;">(1)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.13</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><sup style="vertical-align:top;line-height:120%;">(1)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,265</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity compensation plans not approved by security holders</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,380</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.13</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,265</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:15pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Includes 1.0 million shares of common stock issuable (subject to vesting) with respect to restricted stock units granted pursuant to the 2020 Plan; 250 thousand at a grant date fair market value of $3.93 per share, 300 thousand at a grant date fair market value of $1.65 per share and 478 thousand at a grant date fair market value of $1.93 per share. This value is not included in the weighted average exercise price.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:15pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In December 2025, we adopted the Compass Therapeutics, Inc. 2025 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). There were no issues from this plan as of December 31, 2025. On January 1, 2026, a total of two million options were granted as part of the Inducement Plan to two new officers.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:15pt;">On January 1, 2026, an additional 7.1 million shares became available for issuance for a total of 12.4 million shares available for future issuance under equity compensation plans approved by security holders. For further description of the equity compensation plans, see Note 9 to the consolidated financial statements included in this Annual Report on Form 10-K.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 6. [Reserved].<a id="itm6" href="#"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">91</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 7. Management</b>&#8217;<b>s Discussion and Analysis of Financial Condition and Results of Operations.<a id="itm7" href="#"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;"><i>Unless otherwise stated or the context otherwise indicates, references to the </i>&#8220;<i>Company</i>&#8221;<i>, </i>&#8220;<i>we</i>&#8221;<i>, </i>&#8220;<i>our</i>&#8221;<i>, </i>&#8220;<i>us</i>&#8221;<i> or similar terms refer to Compass Therapeutics, Inc. together with its wholly-owned subsidiaries, which we refer to as Compass Therapeutics.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"><i>You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included in this Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties as described under the heading </i>&#8220;<i>Special Note Regarding Forward-Looking Statements</i>&#8221;<i> elsewhere in this Form 10-K. You should review the disclosure under the heading </i>&#8220;<i>Risk Factors</i>&#8221;<i> in this Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Overview </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We are a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Our scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Our pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. We plan to advance our product candidates through clinical development and commercialization as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"><b><i>Financial Overview</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Since our inception, we have devoted substantially all of our efforts to organizing and staffing our Company, business planning, raising capital, research and development activities, building our intellectual property portfolio and providing general and administrative support for these operations. We have funded our operations primarily with proceeds from the sale of equity securities of $568 million through December 31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We have incurred significant operating losses since inception. We have not generated any revenue since our inception and do not expect to generate any revenue from the sale of products in the near future, if at all. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of our therapies and any future product candidates. Our net losses were $66 million and $49 million for the years ended December 31, 2025 and 2024, respectively, and as of December 31, 2025, we had an accumulated deficit of $431 million. We expect to continue to incur significant expenses for at least the next several years as we advance through clinical development, develop additional product candidates and seek regulatory approval of any product candidates that complete clinical development. In addition, if we obtain marketing approval for any product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. We may also incur expenses in connection with the in-licensing or acquisition of additional product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through equity and debt financings, or other capital sources, which may include collaborations with other companies or other strategic transactions. As of December 31, 2025, we had $209 million in cash, cash equivalents and marketable securities. Based on our research and development plans, we expect that these cash resources will enable us to fund our operating expenses and capital expenditures requirements into 2028. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, reduce or eliminate the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">92</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><b><i>Listing on the Nasdaq Capital Market</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">On November 2, 2021, shares of our common stock were approved for trading on the Nasdaq Capital Market under the symbol &#8220;CMPX&#8221;.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><b><i>Private Investment in Public Entity (</i></b>&#8220;<b><i>PIPE</i></b>&#8221;<b><i>) Offering</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">On November 2, 2023, we entered into a securities purchase agreement ("the "Securities Purchase Agreement") with certain accredited investors (the "Investors") pursuant to which we agreed to sell and issue to the Investors in a PIPE financing an aggregate of 25,000,000 shares of our common stock at a purchase price of $3.21 per share. The 25,000,000 shares were issued on November 4, 2023. The gross proceeds to us from the PIPE are $80.3 million (before deducting placement agent fees and other expenses in connection with the offering).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In connection with the PIPE offering, we paid $4.5 million to the underwriters and for other legal and accounting costs, for net proceeds of $75.8 million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The PIPE offering was made pursuant to our registration statement on Form S-3 (File No. 333-268652), filed with the SEC on December 2, 2023, and declared effective by the SEC on January 20, 2024, including a prospectus thereto that was filed with the SEC on January 24, 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The PIPE offering was exempt from registration under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated by the SEC thereunder. The common stock in the PIPE offering was sold to &#8220;accredited investors&#8221;, as defined in Regulation D.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><b><i>At-The-Market (</i></b>&#8220;<b><i>ATM</i></b>&#8221;<b><i>) Offering</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In 2025, there were no issuances of common stock through our Open Market Sale Agreement<sup style="vertical-align:top;line-height:120%;">SM</sup> with Jefferies LLC (&#8220;Jefferies ATM Agreement&#8221;). In December 2025, we entered into a Sales Agreement for our ATM offering with Leerink Partners LLC and Cantor Fitzgerald &amp; Co and the prior Jefferies ATM Agreement was terminated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In the first quarter of 2024, we sold, through our Jefferies ATM Agreement, 9,790,577 shares of common stock at an average price of $1.85 for total proceeds of $18.1 million and net proceeds of $17.6 million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><b><i>Underwritten Offering</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">On August 12, 2025, we entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Jefferies LLC, Piper Sandler &amp; Co., and Guggenheim Securities, LLC, as representatives (the &#8220;Representatives&#8221;) of the underwriters named therein (the &#8220;Underwriters&#8221;), pursuant to which the Company agreed to issue and sell an aggregate of (a) 33,290,000 shares (the &#8220;Firm Shares&#8221;) of its common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), at a price to the public of $3.00 per share, and (b) pre-funded warrants to purchase up to 6,710,000 shares of the Company&#8217;s Common Stock (the &#8220;Pre-Funded Warrants&#8221;), at a price to the public of $2.9999 per warrant with an exercise price of $0.0001 per share (the &#8220;Offering&#8221;). Pursuant to the Underwriting Agreement, the Company granted the underwriters a 30-day option, which the underwriters exercised, to purchase up to an additional 6,000,000 shares of its Common Stock (the &#8220;Optional Shares&#8221;, and together with the Firm Shares, the &#8220;Shares&#8221;) at the public offering price, less underwriting discounts and commissions. The Company received aggregate net proceeds of $129.3 million, after deducting underwriting discounts and commissions of $8.3 million and other offering costs of $0.4 million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">93</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The 2025 Pre-Funded Warrants were determined to be equity classified. Accordingly, proceeds from the offering were allocated to common stock, the 2025 Pre-Funded Warrants on a relative fair value basis and were recorded in stockholders&#8217; equity. As of December 31, 2025, all of the 2025 Pre-Funded Warrants remain outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><b><i>Inflation Reduction Act of 2022</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) was enacted on August 16, 2022. The IRA includes provisions imposing a 1% excise tax on share repurchases that occur after December 31, 2022 and introduces a 15% corporate alternative minimum tax on adjusted financial statement income. To date, the IRA has not had a material impact on our consolidated financial statements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Components of Results of Operations </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><b><i>Research and development </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Research and development expenses consist primarily of costs incurred in connection with the development of our clinical product candidates, tovecimig, CTX-471, CTX-8371 and CTX-10726, as well as unrelated preclinical and discovery program expenses. We expense research and development costs as incurred. These expenses include:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">development milestone payments due in connection with our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">employee-related expenses, including salaries, related benefits and equity-based compensation expense, for employees engaged in research and development functions;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Contract Research Organizations (&#8220;CROs&#8221;) that are primarily engaged to support the clinical development of our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Contract Development Manufacturing Organizations (&#8220;CDMOs&#8221;) that are primarily engaged to provide drug substance and drug product for our clinical trials, research and development programs, as well as investigative sites and consultants that conduct our clinical trials, nonclinical studies and other scientific development services;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">cost of acquiring and manufacturing nonclinical and clinical trial materials, including manufacturing registration and validation batches;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">costs related to compliance with quality and regulatory requirements; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">payments made under third-party licensing agreements.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will increase substantially in connection with our planned clinical development activities in the future. At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the clinical development of any future product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">94</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our clinical development costs may vary significantly based on factors such as:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">per patient trial costs;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the number of trials required for approval;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the number of sites included in the trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the location where the trials are conducted;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the length of time required to enroll eligible patients;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the number of patients that participate in the trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the number of doses that patients receive;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the drop-out or discontinuation rates of patients;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">potential additional safety monitoring requested by regulatory agencies;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the duration of patient participation in the trials and follow-up;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the cost and timing of manufacturing our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the phase of development of our product candidates; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the efficacy and safety profile of our product candidates.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The successful development and commercialization of product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with product development and commercialization, including the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the timing and progress of nonclinical and clinical development activities;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the number and scope of nonclinical and clinical programs we decide to pursue;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">raising necessary additional funds;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the progress of the development efforts of parties with whom we may enter into collaboration arrangements;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to maintain our current development program and to establish new ones;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to establish new licensing or collaboration arrangements;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the successful initiation and completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the receipt and related terms of regulatory approvals from applicable regulatory authorities;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the availability of drug substance and drug product for use in production of our product candidate;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">establishing and maintaining agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidates are approved;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">95</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to obtain and maintain patents, trade secret protection and regulatory exclusivity, both in the United States and internationally;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to protect our rights in our intellectual property portfolio;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the commercialization of our product candidate, if and when approved;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">obtaining and maintaining third-party insurance coverage and adequate reimbursement;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the acceptance of our product candidate, if approved, by patients, the medical community and third-party payors;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">competition with other products; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a continued acceptable safety profile of our therapies following approval.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">A change in the outcome of any of these variables with respect to the development of our product candidates could significantly change the costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any of our product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><b><i>General and administrative expenses </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, corporate and business development, and administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax and administrative consulting services; insurance costs; administrative travel expenses; marketing expenses and other operating costs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our business operations. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs, as well as investor and public relations expenses associated with being a public company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><b><i>Other income</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In 2025 and 2024, the only component of other income was interest income from cash deposits and marketable securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><b><i>Income taxes</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We are organized as a Delaware corporation and treated as a c-corporation for federal and state income taxes. Our wholly-owned subsidiaries are included in the consolidated corporate tax return. Prior to the Merger in 2020, we were established as a Delaware limited liability company, and the business that was acquired in the Merger was treated as a partnership for income tax reporting purposes; therefore, federal and state income taxes were the responsibility of its individual members. As such, no federal or state income taxes related to the limited liability company were recorded in our consolidated financial statements. All such taxes have been recorded in our financial statements. As of December 31, 2025 we recorded a deferred tax asset of $79.2&#160;million primarily related to a net operating loss carryforward, section 174 capitalization, research and development tax credit carryforward, and capitalized licensing fees. The asset has a corresponding fully deferred tax valuation allowance. Pursuant to Section 382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an ownership change (generally defined as a greater than 50% change (by value) in the ownership of its equity over a three-year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income may be limited. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our stock ownership, some of which are outside our control. See Note 14 to our consolidated financial statements appearing in this Form 10-K.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">96</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Results of Operations </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><b><i>Comparison of the Years Ended December 31, 2025 and 2024 </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The following table summarizes the results of operations for the years ended December 31, 2025 and 2024:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 28pt; margin-right: auto;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Change</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Licensing revenue</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">850</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(850</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">55,969</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">42,342</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,627</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,870</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,133</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,737</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total operating expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">72,839</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">57,475</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,364</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Loss from operations</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(72,839</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(56,625</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(15,364</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,350</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,250</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(900</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(66,489</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(49,375</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(16,264</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><i>Licensing revenue </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">There was no licensing revenue for the year ended December 31, 2025. Licensing revenue was $850 thousand for the year ended December 31, 2024. The licensing revenue consisted of a $1 million milestone payment from Elpiscience for completing a Phase 1 trial in China. This license revenue is reported net of a 15% sublicense royalty due to ABL Bio (see Note 11 of the consolidated financial statements appearing in this Form 10-K for further information on this sublicense agreement).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><i>Research and development expenses </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">Research and development expenses increased by $13.6 million from $42.3 million in 2024 to $56.0 million in 2025. This increase was primarily attributable to an increase of $14.2 million of manufacturing expenses related to tovecimig and CTX-10726.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We track supplies, outsourced development, personnel costs and other research and development costs of specific programs. Facility and equipment costs are not allocated to programs. Research and development expenses are summarized by program in the table below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 28pt; margin-right: auto;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31, </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Change</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">tovecimig</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,259</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">27,938</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,679</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CTX-471</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,248</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,863</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,385</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CTX-8371</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,781</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,473</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,308</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CTX-10726</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,216</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,216</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other research and development expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,465</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,068</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,397</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total research and development expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">55,969</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">42,342</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,627</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><i>General and administrative expenses </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">General and administrative expenses increased by $1.7 million from $15.1 million in 2024 to $16.9 million in 2025. The increase was primarily attributable to commercialization expenses of approximately $0.7 million and $0.5 million of advisory fees. We anticipate that our general and administrative expenses will increase in the future as we expand our commercial operations and to support our growing research and development efforts.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">97</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><i>Other income</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Other income consists only of interest income which decreased by $0.9 million from $7.3 million in 2024 to $6.4 million in 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><i>Income tax expense </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We did not have income tax expense in 2025 or 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liquidity and Capital Resources </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Since our inception, we have not generated any revenue from any product sales or any other sources, and we have incurred significant operating losses. We have not yet commercialized any products and we do not expect to generate revenue from sales of products for several years, if at all. We have funded our operations primarily with proceeds from multiple equity financings. As of December 31, 2025, we had cash, cash equivalents and marketable securities of $209 million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">On July 9, 2021, we filed an S-3 registration statement which became effective July 20, 2021. Included in this registration statement was a shelf registration allowing us to sell securities up to $300 million. The Follow-On Public Offering was made pursuant to this registration statement. In addition, the S-3 registration statement included a sales agreement with B. Riley Securities, Inc., pursuant to which we could offer and sell shares of our common stock having an aggregate of up to $75 million. We terminated the sales agreement with B. Riley effective July 29, 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">On August 1, 2022, we entered into an Open Market Sale Agreement<sup style="vertical-align:top;line-height:120%;">SM</sup> with Jefferies LLC, pursuant to which we may offer and sell, from time to time at our sole discretion, shares of our common stock, which has since been terminated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">On December 2, 2022, we filed an S-3 registration statement which was declared effective by the SEC on January 20, 2023, for the shares issued through the PIPE offering.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">On August 30, 2024, we filed an S-3 registration statement which was declared effective by the SEC on September 6, 2024. This registration statement includes (i) a base prospectus that covers the offering, issuance and sale by us of up to $300 million of our common stock, preferred stock, debt securities, warrants and/or units and (ii) a sale agreement prospectus supplement that covers the offer and sale, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $55 million pursuant to our Open Market Sale Agreement<sup style="vertical-align:top;line-height:120%;">SM</sup> with Jefferies LLC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">On December 30, 2025, we filed an S-3 registration statement which was declared effective by the SEC on January 7, 2026. This registration statement includes (i) a base prospectus that covers the offering, issuance and sale by us of up to $400 million of our common stock, preferred stock, debt securities, warrants and/or units and (ii) a sale agreement prospectus supplement that covers the offer and sale, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $100 million pursuant to our Sales Agreement with Leerink Partners LLC and Cantor Fitzgerald &amp; Co. The prior Open Market Sale Agreement<sup style="vertical-align:top;line-height:120%;">SM</sup> with Jefferies LLC was terminated as part of this filing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><b><i>Funding Requirements </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our primary use of cash is to fund operating expenses, primarily research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable, accrued expenses and prepaid expenses. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">98</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the scope, timing, progress and results of discovery, preclinical development, laboratory testing and clinical trials for our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the costs of manufacturing our product candidates for clinical trials and in preparation for marketing approval and commercialization;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the extent to which we enter into collaborations or other arrangements with additional third parties in order to further develop our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the costs and fees associated with the discovery, acquisition or in-license of additional product candidates or technologies;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to establish additional collaborations on favorable terms, if at all;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the costs required to scale up our clinical, regulatory and manufacturing capabilities;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the costs of future commercialization activities, if any, including establishing sales, marketing, manufacturing and distribution capabilities, for any of our product candidates for which we receive marketing approval; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We will need additional funds to meet operational needs and capital requirements for clinical trials, other research and development expenditures, and business development activities. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><b><i>Cash Flows </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The following table shows a summary of our cash flows for the periods indicated:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 28pt; margin-right: auto;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year ended December 31, </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash used in operating activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(49,143</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(44,855</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash (used in) provided by investing activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(93,306</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,772</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash provided by financing activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">129,609</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,338</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net (decrease) increase in cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(12,840</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">19,255</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><b><i>Operating Activities </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">During the year ended December 31, 2025, we used $49.1 million of cash in operating activities, resulting from our net loss of $66.5 million and the change in operating assets and liabilities of $9.2 million and non-cash charges of $8.2 million. Our non-cash charges primarily consisted of stock-based compensation expense of $8.4 million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">During the year ended December 31, 2024, we used $44.9 million of cash in operating activities, resulting from our net loss of $49.4 million and the change in operating assets and liabilities of $4.1 million, offset by non-cash charges of $8.7 million. Our non-cash charges primarily consisted of stock-based compensation expense of $8.6 million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">99</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><b><i>Investing Activities </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">During the year ended December 31, 2025, cash used in investing activities was $93.3 million, which was primarily attributed to the net purchases of marketable securities of $93.3 million. During the year ended December 31, 2024, cash provided by investing activities was $46.8 million, which was primarily attributed to the net proceeds from the sale of marketable securities of $46.8 million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><b><i>Financing Activities </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">During the year ended December 31, 2025, cash provided by financing activities was $129.6 million. This was primarily from the issuance of stock through an underwritten stock offering for net proceeds of $129.4 million. During the year ended December 31, 2024, cash provided by financing activities was $17.3 million. This was primarily from the issuance of stock pursuant to our ATM program for net proceeds of $17.6 million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><b><i>Future Funding Requirements </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance our product candidates into their next clinical trial phases. The timing and amount of our operating expenditures will depend largely on:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the initiation, progress, timing, costs and results of clinical trials for our current product candidates or any future product candidates we may develop;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the initiation, progress, timing, costs and results of nonclinical studies for our product candidates or any future product candidates we may develop;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to maintain our relationships with key collaborators;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA and comparable foreign regulatory authorities, including the potential for such authorities to require that we perform more nonclinical studies or clinical trials than those that we currently expect or change their requirements on studies or trials that had previously been agreed to;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the cost to establish, maintain, expand, enforce and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing any patents or other intellectual property rights;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the effect of competing technological and market developments;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the costs of continuing to grow our business, including hiring key personnel and maintain or acquiring operating space;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">market acceptance of any approved product candidates, including product pricing, as well as product coverage and the adequacy of reimbursement by third-party payors;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the cost of acquiring, licensing or investing in additional businesses, products, product candidates and technologies;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the cost and timing of selecting, auditing and potentially validating a manufacturing site for commercial-scale manufacturing;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">100</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval and that we determine to commercialize; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:25pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our need to implement additional internal systems and infrastructure, including financial and reporting systems.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We believe that our existing cash, cash equivalents and marketable securities as of December 31, 2025 will enable us to fund our operating expenses and capital expenditure requirements into 2028. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. We expect that we will require additional funding to complete the clinical development of our product candidates, commercialize our product candidates, if we receive regulatory approval, and pursue in-licenses or acquisitions of other product candidates. If we receive regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize our product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity and debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our shareholders&#8217; ownership interests may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, reduce or eliminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Contractual Obligations and Commitments </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The following table summarizes our contractual obligations as of December 31, 2025 and the effects that such obligations are expected to have on our liquidity and cash flows in future periods:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<table cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 28pt; margin-right: auto;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 49%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Payments due by Period (000's)<sup style="vertical-align:top;line-height:120%;">(2)</sup></b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Less than<br/>
			1 year </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>1 to 3<br/>
			years </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>3 to 5<br/>
			years </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>More than<br/>
			5 years </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease commitments<sup style="vertical-align:top;line-height:120%;">(1)</sup></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,623</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,525</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,453</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,650</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">995</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:0pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Reflects payments due for our leases of office and laboratory space in Boston, Massachusetts under an operating lease agreement that expires in May 2031.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:0pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This table does not include (i) any milestone payments that are not deemed probable under license agreements as the timing and likelihood of such payments are not known with certainty, (ii) any royalty payments to third parties as the amounts, timing and likelihood of such payments are not known, and (iii) contracts that are entered into in the ordinary course of business which are cancelable.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Critical Accounting Estimates </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenue and expenses during the reporting period. We base our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">101</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">While our significant accounting policies are described in more detail in Note 3 to our consolidated financial statements appearing in this Form 10-K, we believe that the following accounting policies are the most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><b><i>Research and Development Expenses </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Research and development expenses consist primarily of costs incurred in connection with the development of our product candidates. We expense research and development costs as incurred.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">At the end of each reporting period, we compare payments made to third-party service providers to the estimated progress toward completion of the applicable research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that we estimate has been made as a result of the service provided, we may record net prepaid or accrued expenses relating to these costs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 13pt;"><b><i>Stock Awards and Unit-Based Compensation </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The following table summarizes stock awards and unit-based compensation expense:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;">&#160;</p>

<table cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 28pt; margin-right: auto;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended<br/>
			December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,346</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,971</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,022</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,589</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,368</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,560</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">See Notes 3 and 9 to our consolidated financial statements appearing in this Form 10-K for additional stock compensation information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recently Issued and Adopted Accounting Pronouncements </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 3 to our consolidated financial statements appearing in this Annual Report.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 7A. Quantitative and Qualitative Disclosures About Market Risk.<a id="itm7a" href="#"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation ("FDIC") insurance coverage limit of $250,000 per depositor, per FDIC-insured bank, per ownership category. We have reviewed the consolidated financial statements of this institution and believe it has sufficient assets and liquidity to conduct its operations in the ordinary course of business with little or no credit risk to us. Financial instruments that potentially subject us to concentrations of credit risk principally consist of cash equivalents and marketable securities including corporate bonds, commercial paper certificates of deposit, U.S. government treasuries and asset backed securities, all of which are subject to interest rate risk. We limit our credit risk by investing in highly-rated securities. Changes in the general level of interest rates can affect the fair value of our investment portfolio. If interest rates in the general economy were to change, our holdings could change as a result.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">102</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 8. Financial Statements and Supplementary Data.<a id="itm8" href="#"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>COMPASS THERAPEUTICS, INC. AND SUBSIDIARIES</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:49.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Page(s)</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:49.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#reportofindependt" style="-sec-extract:exhibit;"><b><span style="text-decoration: underline; ">Report of Independent Registered Public Accounting Firm</span></b><b>&#160;</b></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#reportofindependt">104</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:49.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Consolidated Financial Statements</b></p>
			</td>
			<td style="vertical-align:bottom;width:4.3%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:49.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#BS" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Consolidated Balance Sheets</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#BS">105</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:49.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#loss" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Consolidated Statements of Operations and Comprehensive Loss</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#loss">106</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:49.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#equity" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Consolidated Statements of Changes in Stockholders</span><span style="text-decoration: underline; ">&#8217;</span><span style="text-decoration: underline; ">&#160;Equity</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#equity">107</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:49.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#cashfloww" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Consolidated Statements of Cash Flows</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#cashfloww">108</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:49.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#notes" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Notes to Consolidated Financial Statements</span></a></p>
			</td>
			<td style="vertical-align:bottom;width:4.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#notes">109</a></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">103</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<div>&#160;</div>

<div>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Report of Independent Registered Public Accounting Firm<a id="reportofindependt" href="#"></a></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To the Board of Directors and Stockholders</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Compass Therapeutics, Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Opinion on the Financial Statements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We have audited the accompanying consolidated balance sheets of Compass Therapeutics, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2025 and 2024, and the related consolidated statements of operations and comprehensive loss, changes in stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025 in conformity with accounting principles generally accepted in the United States of America.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Basis for Opinion</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
&#160;

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control over financial reporting. Accordingly, we express no such opinion.</p>
&#160;

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Critical Audit Matters </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) related to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. We have determined that there are no critical audit matters.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ CohnReznick LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have served as the Company&#8217;s auditor since March 2020.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Melville, New York</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 5, 2026</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">104</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p>
</div>

<div>&#160;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Compass Therapeutics, Inc. and Subsidiaries<a id="BS" href="#"></a></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Consolidated Balance Sheets</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(In thousands, except par value per share data)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current assets:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">30,643</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c64" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">43,483</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c65" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:MarketableSecuritiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">178,263</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c66" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:MarketableSecuritiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">83,239</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid expenses and other current assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c67" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">913</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c68" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,029</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total current assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c69" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">209,819</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c70" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">132,751</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Property and equipment, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c71" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">102</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c72" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">353</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease, right-of-use ("ROU") asset</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,099</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c74" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,731</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Restricted cash</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c75" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:RestrictedCash" scale="3" format="ixt:num-dot-decimal" decimals="-3">568</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c76" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:RestrictedCash" scale="3" format="ixt:num-dot-decimal" decimals="-3">568</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c77" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-3">219,588</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c78" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-3">140,403</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Liabilities and Stockholders' Equity</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current liabilities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts payable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,585</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,249</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,383</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,287</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease obligations, current portion</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c84" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-6">1,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c85" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">338</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total current liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c86" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">13,968</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c87" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,874</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease obligations, net of current portion</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c88" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,829</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c89" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,296</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c90" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">22,797</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c91" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:num-dot-decimal" decimals="-4">15,170</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commitments and Contingencies (Note 12)</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<ix:nonFraction id="c92" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<ix:nonFraction id="c93" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stockholders' equity:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Common stock, $<ix:nonFraction id="c95" contextRef="i_2025-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF"><ix:nonFraction id="c96" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction id="c97" contextRef="i_2025-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="3" format="ixt:num-dot-decimal" decimals="-8"><ix:nonFraction id="c98" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="3" format="ixt:num-dot-decimal" decimals="-8">300,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction id="c99" contextRef="i_2025-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3"><ix:nonFraction id="c100" contextRef="i_2025-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="3" format="ixt:num-dot-decimal" decimals="-3">178,324</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2025; <ix:nonFraction id="c101" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-4"><ix:nonFraction id="c102" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="3" format="ixt:num-dot-decimal" decimals="-4">137,820</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2024</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c103" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">18</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">14</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Additional paid-in-capital</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c105" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" format="ixt:num-dot-decimal" decimals="-3">627,665</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c106" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" format="ixt:num-dot-decimal" decimals="-3">489,692</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accumulated other comprehensive income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-4">280</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c108" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-4">210</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accumulated deficit</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c109" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">431,172</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c110" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">364,683</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total stockholders' equity</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c111" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">196,791</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c112" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">125,233</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total liabilities and stockholders' equity</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c113" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">219,588</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c114" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">140,403</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">105</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div>&#160;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Compass Therapeutics, Inc. and Subsidiaries<a id="loss" href="#"></a></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Consolidated Statements of Operations and Comprehensive Loss</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(In thousands, except per share data)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Licensing revenue</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c118" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c119" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-4">850</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c121" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">55,969</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c122" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">42,342</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c123" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">16,870</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c124" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">15,133</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total operating expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">72,839</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c126" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">57,475</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Loss from operations</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c127" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">72,839</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c128" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">56,625</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Interest Income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c129" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">6,350</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c130" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">7,250</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c131" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">66,489</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c132" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">49,375</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share - basic and diluted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c133" contextRef="d_2025-01-01_2025-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.42</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c134" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.36</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Basic and diluted weighted average shares outstanding</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c135" contextRef="d_2025-01-01_2025-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">157,695</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c136" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">137,384</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other comprehensive loss:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c138" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">66,489</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c139" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">49,375</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Unrealized gain on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c140" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-4">70</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c141" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">173</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Comprehensive loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c142" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">66,419</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c143" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">49,202</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">106</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div>&#160;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Compass Therapeutics, Inc. and Subsidiaries<a id="equity" href="#"></a></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Consolidated Statements of Changes in Stockholders</b>&#8217;<b> Equity </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(In thousands)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Common Stock</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Additional<br/>
			Paid-in</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated Other<br/>
			Comprehensive</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total<br/>
			Stockholders'</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Capital</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Income</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Deficit</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Equity</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance at December 31, 2023</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c147" contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">127,668</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c148" contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">13</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c149" contextRef="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">463,796</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c150" contextRef="i_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">37</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c151" contextRef="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">315,308</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c152" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">148,538</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock issued in ATM offering, net of costs of $<ix:nonFraction id="c153" contextRef="d_2024-01-01_2024-03-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.5</ix:nonFraction>million</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c154" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-4">9,790</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c155" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c156" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">17,568</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c157" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c158" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c159" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">17,569</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based awards, net of tax remittance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c160" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">362</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c161" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c162" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">232</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c163" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c164" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c165" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">232</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c167" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c168" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:num-dot-decimal" decimals="-4">8,560</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c169" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c170" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c171" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:num-dot-decimal" decimals="-4">8,560</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unrealized gain on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c173" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c174" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c175" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">173</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c176" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c177" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">173</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c179" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c180" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c181" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c182" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">49,375</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c183" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">49,375</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance at December 31, 2024</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c184" contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-4">137,820</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c185" contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">14</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c186" contextRef="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">489,692</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c187" contextRef="i_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-4">210</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c188" contextRef="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">364,683</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c189" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">125,233</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock and warrants issued, net of costs of $<ix:nonFraction id="c190" contextRef="d_2025-07-01_2025-09-30" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">8.6</ix:nonFraction> million</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c191" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-4">39,290</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c192" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">4</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c193" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">129,357</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c194" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c195" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c196" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">129,361</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock issued upon exercise of options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c197" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">545</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c198" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c199" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,275</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c200" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c201" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c202" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,275</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based awards, net of tax remittance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c203" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">669</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c204" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c205" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,027</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c206" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c207" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c208" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,027</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c210" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c211" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,368</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c212" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c213" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c214" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,368</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unrealized gain on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c216" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c217" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c218" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-4">70</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c219" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c220" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-4">70</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c222" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c223" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c224" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c225" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">66,489</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c226" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">66,489</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance at December 31, 2025</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c227" contextRef="i_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">178,324</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c228" contextRef="i_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">18</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c229" contextRef="i_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">627,665</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c230" contextRef="i_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-4">280</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c231" contextRef="i_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">431,172</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c232" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">196,791</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">107</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div>&#160;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Compass Therapeutics, Inc. and Subsidiaries<a id="cashfloww" href="#"></a></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Consolidated Statements of Cash Flows</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(In thousands)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash flows from operating activities:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c237" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">66,489</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c238" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">49,375</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Depreciation and amortization</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-left: 9pt;"><ix:nonFraction id="c240" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:DepreciationAndAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">276</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c241" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:DepreciationAndAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">589</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c242" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,368</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c243" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-4">8,560</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Amortization of premium and discount on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c244" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="cmpx:MarketableSecuritiesAmortizationOfPremiumAndDiscount" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,673</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c245" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="cmpx:MarketableSecuritiesAmortizationOfPremiumAndDiscount" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,651</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">ROU asset amortization</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c246" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,196</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c247" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,164</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Changes in operating assets and liabilities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid expenses and other current assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c249" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">5,116</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c250" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,857</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts payable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c251" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">664</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c252" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,841</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c253" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,096</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c254" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,773</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease liability</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c255" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">369</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c256" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,217</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net cash used in operating activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c257" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">49,143</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c258" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">44,855</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash flows from investing activities:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Purchases of marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c260" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">194,557</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c261" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">88,158</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Proceeds from sale or maturities of marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c262" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">101,276</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c263" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">134,974</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Purchases of property and equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c264" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">25</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c265" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">44</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net cash (used in) provided by in investing activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c266" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">93,306</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c267" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,772</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash flows from financing activities:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Proceeds from issuance of common stock</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c269" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:num-dot-decimal" decimals="-3">137,999</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c270" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:num-dot-decimal" decimals="-3">18,113</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issuance costs from issuance of common stock</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c271" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,638</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c272" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">543</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Proceeds from exercise of stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c273" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,275</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c274" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Taxes paid related to net shares settlement of RSUs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c275" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,027</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c276" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">232</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net cash provided by financing activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c277" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">129,609</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c278" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">17,338</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net change in cash, cash equivalents and restricted cash</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c279" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">12,840</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c280" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3">19,255</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash, cash equivalents and restricted cash&#160;at beginning of year</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c281" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">44,051</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c282" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">24,228</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash,&#160;cash equivalents and restricted cash&#160;at end of year</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c283" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">31,211</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c284" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">44,051</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Reconciliation of cash, cash equivalents and restricted cash to the&#160;Consolidated Balance Sheets</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c286" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">30,643</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c287" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">43,483</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Restricted cash</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c288" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" format="ixt:num-dot-decimal" decimals="-3">568</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c289" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" format="ixt:num-dot-decimal" decimals="-3">568</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total cash, cash equivalents and restricted cash</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c290" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" format="ixt:num-dot-decimal" decimals="-3">31,211</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c291" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" format="ixt:num-dot-decimal" decimals="-3">44,051</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Supplemental disclosure of cash flow information</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unrealized gain on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c293" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" format="ixt:num-dot-decimal" decimals="-4">70</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c294" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3">173</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">108</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>Compass Therapeutics, Inc. and Subsidiaries<a id="notes" href="#"></a></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Notes to Consolidated Financial Statements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="c295" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>1.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Formation and Business of the Company</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Compass Therapeutics, Inc. (&#8220;Compass&#8221; or the &#8220;Company&#8221;) is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Our scientific focus is on the relationship between angiogenesis and the immune system. Our pipeline includes novel product candidates that leverage our understanding of the tumor microenvironment, including both angiogenesis-targeted agents and immune-oncology focused agents. These product candidates are designed to optimize critical components required for an effective anti-tumor response to cancer. These include modulation of the microvasculature via angiogenesis-targeted agents; induction of a potent immune response via activators on effector cells in the tumor microenvironment; and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. We plan to advance our product candidates through clinical development as both standalone therapies and in combination with our proprietary drug candidates as long as their continued development is supported by clinical and nonclinical data. References to Compass or the Company herein include Compass Therapeutics, Inc. and its wholly owned subsidiaries.</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company is subject to risks and uncertainties common to companies in the biotechnology and pharmaceutical industries. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants.</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="c298" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>2.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Liquidity, Uncertainties and Going Concern </b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Since its inception, the Company has funded its operations primarily with proceeds from the sale of its equity securities. The Company has incurred recurring losses since its inception and had an accumulated deficit of $<ix:nonFraction id="c301" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" format="ixt:num-dot-decimal" decimals="-6" sign="-">431</ix:nonFraction> million on December 31, 2025. The Company expects to continue to generate operating losses for the foreseeable future. The Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into 2028. The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company is subject to risks common to early stage companies in the biotechnology industry including, but not limited to: having a limited operating history and no products approved for commercial sale; having a history of significant losses; its need to obtain additional financing; dependence on its ability to advance its current and future product candidates through clinical trials, marketing approval and commercialization; the lengthy and expensive nature and uncertain outcomes of the clinical development process; the lengthy, time consuming and unpredictable nature of the regulatory approval process; the results of preclinical studies and early stage clinical trials that may not be predictive of future results; dependence on its key personnel; risks related to patent protection and the Company&#8217;s pending patent applications; dependence on third party collaborators for the discovery, development and commercialization of current and future product candidates; and significant competition from other biotechnology and pharmaceutical companies. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">109</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p></ix:exclude>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c302" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>3.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Summary of Significant Accounting Policies</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="c772607327200208" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Basis of Presentation</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The accompanying consolidated financial statements are presented in U.S. dollars and have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and as amended by Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ConsolidationPolicyTextBlock" id="c1157138965408101" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Principles of Consolidation</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The accompanying consolidated financial statements include the accounts of Compass Therapeutics, Inc., and its wholly-owned subsidiaries, including Compass Therapeutics LLC, Compass Therapeutics Advisors Inc., Trigr Therapeutics, Inc., Compass Acquisition Company, LLC, and Compass Therapeutics Securities Corporation. All intercompany accounts and transactions have been eliminated in consolidation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:UseOfEstimates" id="c751342916814027" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Use of Estimates</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the accrual of research and development expenses, useful lives of equipment, interest rate and term operating lease ROU and liability, the percentage of completion of contractual arrangements, future cash expenditures for liquidity estimates, the valuation of common stock and estimates associated with stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates. Changes in estimates are recorded prospectively in the period that they become known.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="c829312459439601" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Segment Information </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has <span style="-sec-ix-hidden:c305">one</span> operating segment. The Company&#8217;s chief operating decision-maker, its chief executive officer, manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources. All the Company&#8217;s long-lived assets are held in the United States.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c1437120533271784" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Cash and Cash Equivalents</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company considers all highly liquid investments that are readily convertible into cash with original maturities of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held in money market funds or commercial paper. Cash equivalents are stated at cost, which approximates market value. Cash and cash equivalents were $<ix:nonFraction id="c306" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" format="ixt:num-dot-decimal" decimals="-5">30.6</ix:nonFraction> million and $<ix:nonFraction id="c307" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" format="ixt:num-dot-decimal" decimals="-5">43.5</ix:nonFraction> million on December 31, 2025 and 2024, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
</ix:nonNumeric>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">110</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:MarketableSecuritiesPolicy" id="c1538126537632555" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Marketable Securities</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">All of the Company&#8217;s investment securities are debt securities and bank instruments. The Company carries these investments at fair value. Unrealized gains and losses, if any, are reported as a separate component of stockholders&#8217; equity. The cost of investment securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income. Realized gains and losses, if any, are also included in interest income. The cost of securities sold is based on the specific identification method.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ConcentrationRiskCreditRisk" id="c1054360942950580" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Concentrations of Credit Risk</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash equivalents and marketable securities. The Company invests its excess cash primarily in money market funds, U.S. treasury notes, and high quality, marketable debt instruments of corporations in accordance with the Company&#8217;s investment policy. The Company&#8217;s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. The Company has not experienced any realized losses related to its cash equivalents and marketable securities.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="c404024024206495" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Property and Equipment</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are recorded using the straight-line method over the estimated useful lives of the related assets as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cmpx:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" id="c337" escape="true">
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%; margin-left: 28pt; margin-right: auto;">

		<tbody><tr class="finHeading" style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 30.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Asset Classification</b></p>
			</td>
			<td style="vertical-align: bottom; width: 39.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b>Estimated Useful Life</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 30.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment</p>
			</td>
			<td style="vertical-align: bottom; width: 39.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><ix:nonNumeric contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c340" format="ixt-sec:duryear">5</ix:nonNumeric> years</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 30.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and fixtures</p>
			</td>
			<td style="vertical-align: bottom; width: 39.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><ix:nonNumeric contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c341" format="ixt-sec:duryear">7</ix:nonNumeric> years</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 30.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Software</p>
			</td>
			<td style="vertical-align: bottom; width: 39.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><ix:nonNumeric contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareAndSoftwareDevelopmentCostsMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c342" format="ixt-sec:duryear">5</ix:nonNumeric> years</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 30.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p>
			</td>
			<td style="vertical-align: bottom; width: 39.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">Lesser of estimated useful life or lease term</p>
			</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheet and any resulting gains or losses are included in the consolidated statement of operations and comprehensive loss in the period of disposal. Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="c636160645746866" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Impairment of Long-Lived Assets</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Long-lived assets consist of property, equipment and right-of-use (&#8220;ROU&#8221;) assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in the consolidated statements of operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did <span style="-sec-ix-hidden:c311"><span style="-sec-ix-hidden:c312">not</span></span> record any impairment losses on long-lived assets during the years ended December 31, 2025 and 2024.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">111</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="c450096947591934" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Fair Value Measurements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:29pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level 1 &#8211;&#160;Quoted prices in active markets for identical assets or liabilities.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:29pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level 2 &#8211;&#160;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets and liabilities, or other inputs that are observable or can be corroborated by observable market data.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:29pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level 3 &#8211;&#160;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected are reported in earnings.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c806276026833883" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Research and Development Costs</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Costs associated with internal research and development and external research and development services, including drug development and preclinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation and amortization, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials and other costs. The Company recognizes external research and development costs based on an evaluation of the progress of specific tasks using information provided to the Company by its service providers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">112</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Costs associated with licenses of technology acquired as part of collaborative arrangements are expensed as incurred and are generally included in research and development expense in the consolidated statements of operations if it is determined the license has no alternative future use.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cmpx:AccruedResearchAndDevelopmentExpensesPolicyTextBlock" id="c202012018494545" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Accrued Research and Development Expenses</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company has entered into various research and development and other agreements with commercial firms, researchers, universities and others for provisions of goods and services. These agreements are generally cancelable, and the related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made to determine the accrued balances at the end of any reporting period. Actual results could differ materially from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cmpx:PatentsCostsPolicyTextBlock" id="c1476105353443896" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Patent Costs</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expense in the consolidated statements of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c1405223953845236" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Stock-Based Compensation</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company recognizes the grant&#8209;date fair value of stock&#8209;based awards issued to employees and nonemployee board members as compensation expense on a straight&#8209;line basis over the service period of the award. The Company uses the Black&#8209;Scholes option pricing model to determine the grant&#8209;date fair value of stock options and adjusts expense for forfeitures in the periods they occur.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The fair value of each equity award was determined by the Company on the date of grant and by using the methods and assumptions discussed below. Certain of these inputs are subjective and generally require judgment to determine.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><i>Stock price: </i>The stock price used to value equity awards is based on the closing price of the Company&#8217;s common stock as reported on the date of the grant. For equity awards issued after June 2020 until the Company started trading on a public market in the second quarter of 2021, the valuation of the Company&#8217;s common stock was $<ix:nonFraction id="c313" contextRef="i_2021-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.00</ix:nonFraction> per share, which was the share price paid by outside investors in the Company&#8217;s Private Placement in June 2020.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><i>Expected term</i>: The expected term of the equity award represents the weighted average period the award is expected to be outstanding. The Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average time to vesting and the contractual life of the award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><i>Expected volatility</i> &#8211; The expected volatility is calculated based on the historical volatility of our common stock over the expected term of the option.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><i>Risk-free interest rate</i> &#8211; The risk-free rate assumption is based on U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#8217;s equity award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><i>Expected dividend </i>&#8211; The Company has not paid and does not intend to pay dividends.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">113</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c232136627471447" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Net Loss per Share </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, stock options, restricted stock units, unvested restricted stock awards and common stock warrants that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The following potentially dilutive securities outstanding as of December 31, 2025 and 2024 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsAndOptionsMember" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="c343" escape="true">
<table cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: auto; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c346" contextRef="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,028</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c347" contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,766</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c348" contextRef="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">16,352</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c349" contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">14,062</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c350" contextRef="d_2025-01-01_2025-12-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-4">17,380</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c351" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">17,828</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" id="c8860181257756" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:29pt;"><b>Income Taxes</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the deferred tax benefits will not be realized.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company files income tax returns in the U.S. Federal jurisdiction and in various states. The Company has tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c393391838793906" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>New Accounting Pronouncements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">In November 2024, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2024-03<i>, Income Statement </i>&#8211;<i> Reporting Comprehensive Income </i>&#8211;<i> Expense Disaggregation Disclosures</i>, which amends existing income statement disclosure guidance, primarily requiring more detailed disclosure for expenses. The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The amendments can be applied on either a prospective or retroactive basis. We are currently evaluating the ASU to determine its impact on our disclosures.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Recently Adopted Accounting Pronouncements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">In December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09). The amendments in ASU 2023-09 are intended to enhance the transparency and decision usefulness of income tax disclosures through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 for public entities, with early adoption permitted. The Company applied the amendments prospectively for the year ended December 31, 2025, and the impact of the adoption of the amendments in this update was not material to the Company&#8217;s consolidated financial position and results of operations for the year ended December 31, 2025, since the amendments require only enhancement of existing income tax disclosures in the footnotes to the Company&#8217;s consolidated financial statements. See Note 14 for additional disclosures.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">114</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:FairValueDisclosuresTextBlock" id="c352" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>4.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Fair Value Measurements</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The following tables present information about the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="c2FD2CAF0-77CA-45A2-BCBB-F4BA8F129984" escape="true" continuedAt="AEDE4588-CB91-4F1E-84F1-C51739BCAF55">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>Fair Value Measurements as of December 31, 2025 (000's):</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Quoted Prices</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>in Active</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Other</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Markets for</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Observable</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unobservable</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Identical Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Inputs</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Inputs</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 1)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 2)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 3)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c414" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c415" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">86,636</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c416" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c417" contextRef="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">86,636</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Certificates of deposit</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c418" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c419" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-4">14,960</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c420" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c421" contextRef="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-4">14,960</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c422" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">68,977</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c423" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c424" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c425" contextRef="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">68,977</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. government treasuries</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c426" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,664</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c427" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c428" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c429" contextRef="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,664</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Asset-backed securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c430" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c431" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,026</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c432" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c433" contextRef="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,026</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds (cash equivalents)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c434" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,383</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c435" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c436" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c437" contextRef="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,383</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c438" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:num-dot-decimal" decimals="-3">79,024</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c439" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:num-dot-decimal" decimals="-3">107,622</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c440" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c441" contextRef="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:num-dot-decimal" decimals="-3">186,646</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:continuation id="AEDE4588-CB91-4F1E-84F1-C51739BCAF55">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Measurements as of December 31, 2024 (000's):</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Quoted Prices</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>in Active</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Other</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Markets for</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Observable</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unobservable</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Identical Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Inputs</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Inputs</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 1)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 2)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 3)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c445" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c446" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">44,963</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c447" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c448" contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">44,963</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Certificates of deposit</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c449" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c450" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">15,269</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c451" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c452" contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">15,269</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c453" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,084</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c454" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c455" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c456" contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,084</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. government treasuries</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c457" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,399</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c458" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c459" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c460" contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,399</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Asset-backed securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c461" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c462" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,524</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c463" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c464" contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,524</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds (cash equivalents)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c465" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:num-dot-decimal" decimals="-4">23,880</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c466" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c467" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c468" contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:num-dot-decimal" decimals="-4">23,880</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c469" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:num-dot-decimal" decimals="-3">40,363</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c470" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:num-dot-decimal" decimals="-3">66,756</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c471" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c472" contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:num-dot-decimal" decimals="-3">107,119</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
		</tr>

</tbody></table>
</ix:continuation>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="c473" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>5.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Marketable Securities</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The objectives of the Company&#8217;s investment policy are to ensure the safety and preservation of invested funds, as well as to maintain liquidity sufficient to meet cash flow requirements. The Company invests its excess cash in securities issued by financial institutions, commercial companies, and government agencies that management believes to be of high credit quality in order to limit the amount of its credit exposure. The Company has not realized any net losses from its investments.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">115</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Unrealized gains and losses on investments that are available for sale are recognized in accumulated comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are included in other income in the consolidated statements of operations and comprehensive loss and are determined using the specific identification method with transactions recorded on a trade date basis. The Company classifies marketable securities that are available for use in current operations as current assets on the consolidated balance sheet.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The following tables summarize marketable securities held at December 31, 2025 and 2024 (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:MarketableSecuritiesTextBlock" id="c3AC0D799-3BD4-48BE-9E24-0B78E3EE9AAC" escape="true" continuedAt="c41C8CDA4-4A9A-47D5-A8A5-7D9DF807BC19">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Measurements as of December 31, 2025 Using:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amortized Cost</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized gains</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized Losses</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c533" contextRef="i_2025-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:num-dot-decimal" decimals="-3">86,417</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c534" contextRef="i_2025-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">223</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c535" contextRef="i_2025-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">4</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c536" contextRef="i_2025-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">86,636</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Certificates of deposit</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c537" contextRef="i_2025-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:num-dot-decimal" decimals="-4">14,950</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c538" contextRef="i_2025-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:num-dot-decimal" decimals="-4">10</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c539" contextRef="i_2025-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c540" contextRef="i_2025-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-4">14,960</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c541" contextRef="i_2025-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:num-dot-decimal" decimals="-3">68,943</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c542" contextRef="i_2025-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">34</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c543" contextRef="i_2025-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c544" contextRef="i_2025-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">68,977</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Asset-backed securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c545" contextRef="i_2025-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:num-dot-decimal" decimals="-4">6,010</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c546" contextRef="i_2025-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">16</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c547" contextRef="i_2025-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c548" contextRef="i_2025-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,026</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. government treasuries</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c549" contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,663</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c550" contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c551" contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c552" contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,664</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c553" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:num-dot-decimal" decimals="-3">177,983</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c554" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">284</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c555" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">4</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c556" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">178,263</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:continuation id="c41C8CDA4-4A9A-47D5-A8A5-7D9DF807BC19">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Measurements as of December 31, 2024 Using:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amortized Cost</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized gains</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized Losses</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c560" contextRef="i_2024-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:num-dot-decimal" decimals="-3">44,794</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c561" contextRef="i_2024-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">175</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c562" contextRef="i_2024-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">6</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c563" contextRef="i_2024-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">44,963</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Certificates of deposit</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c564" contextRef="i_2024-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:num-dot-decimal" decimals="-3">15,262</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c565" contextRef="i_2024-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">8</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c566" contextRef="i_2024-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c567" contextRef="i_2024-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">15,269</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c568" contextRef="i_2024-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,081</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c569" contextRef="i_2024-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">5</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c570" contextRef="i_2024-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">2</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c571" contextRef="i_2024-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,084</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Asset-backed securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c572" contextRef="i_2024-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,484</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c573" contextRef="i_2024-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:num-dot-decimal" decimals="-4">40</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c574" contextRef="i_2024-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c575" contextRef="i_2024-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,524</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. government treasuries</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c576" contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,408</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c577" contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">2</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c578" contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">11</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c579" contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,399</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c580" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:num-dot-decimal" decimals="-3">83,029</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c581" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:num-dot-decimal" decimals="-4">230</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c582" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:num-dot-decimal" decimals="-4">20</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c583" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">83,239</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:continuation>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="c584" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Maturing in one year or less</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c587" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">126,119</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c588" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">56,386</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Maturing after one year through two years</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c589" contextRef="i_2025-12-31" unitRef="USD" name="cmpx:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" scale="3" format="ixt:num-dot-decimal" decimals="-3">52,144</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c590" contextRef="i_2024-12-31" unitRef="USD" name="cmpx:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" scale="3" format="ixt:num-dot-decimal" decimals="-3">26,853</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c591" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">178,263</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c592" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">83,239</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">116</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p></ix:exclude>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="c593" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>6.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Property and Equipment</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Property and equipment consist of the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="c612" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c615" contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,741</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c616" contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,716</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and fixtures</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c617" contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">22</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c618" contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">22</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c619" contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,612</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c620" contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,612</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Software</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c621" contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">364</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c622" contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">364</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total property and equipment&#8211;at cost</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c623" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,739</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c624" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,714</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Accumulated depreciation and amortization</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c625" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,637</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c626" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,361</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Property and equipment, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c627" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">102</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c628" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">353</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Total depreciation and amortization expense for years ended December 31, 2025 and 2024, was $<ix:nonFraction id="c610" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction> million and $<ix:nonFraction id="c611" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.6</ix:nonFraction> million, respectively.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="c629" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>7.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Accrued Expenses</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Accrued expenses consist of the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="c642" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Project expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c645" contextRef="i_2025-12-31" unitRef="USD" name="cmpx:AccruedProjectExpensesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,217</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c646" contextRef="i_2024-12-31" unitRef="USD" name="cmpx:AccruedProjectExpensesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,873</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Compensation and benefits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c647" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,682</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c648" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,793</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c649" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">484</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c650" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">621</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total accrued expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c651" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,383</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c652" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,287</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Project expenses in 2025 were primarily made up of $<ix:nonFraction id="c640" contextRef="i_2025-12-31" unitRef="USD" name="cmpx:AccruedManufacturingExpenses" scale="6" format="ixt:num-dot-decimal" decimals="-5">7.9</ix:nonFraction> million of accrued manufacturing expenses related to tovecimig and CTX-10726.&#160;Project expenses in 2024 were primarily made up of $<ix:nonFraction id="c641" contextRef="i_2024-12-31" unitRef="USD" name="cmpx:AccruedManufacturingExpenses" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.6</ix:nonFraction> million of accrued manufacturing expenses related to minimum contractual obligations.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c653" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>8.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Stockholders</b>&#8217;<b>&#160;Equity</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">On August 12, 2025, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Jefferies LLC, Piper Sandler &amp; Co., and Guggenheim Securities, LLC, as representatives (the &#8220;Representatives&#8221;) of the underwriters named therein (the &#8220;Underwriters&#8221;), pursuant to which the Company agreed to issue and sell an aggregate of (a) <ix:nonFraction id="c656" contextRef="d_2025-08-12_2025-08-12_SubsidiarySaleOfStockAxis-UnderwritingAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">33,290,000</ix:nonFraction> shares (the &#8220;Firm Shares&#8221;) of its common stock, par value $<ix:nonFraction id="c657" contextRef="i_2025-08-12" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), at a price to the public of $<ix:nonFraction id="c658" contextRef="i_2025-08-12_SubsidiarySaleOfStockAxis-UnderwritingAgreementMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.00</ix:nonFraction> per share, and (b) pre-funded warrants to purchase up to <ix:nonFraction id="c659" contextRef="i_2025-08-12_ClassOfWarrantOrRightAxis-PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,710,000</ix:nonFraction> shares of the Company&#8217;s Common Stock (the &#8220;Pre-Funded Warrants&#8221;), at a price to the public of $<ix:nonFraction id="c660" contextRef="i_2025-08-12_ClassOfWarrantOrRightAxis-PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" unitRef="USDPerShare" name="cmpx:ClassOfWarrantOrRightPurchasePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.9999</ix:nonFraction> per warrant with an exercise price of $<ix:nonFraction id="c661" contextRef="i_2025-08-12_ClassOfWarrantOrRightAxis-PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0001</ix:nonFraction> per share (the &#8220;Offering&#8221;). Pursuant to the Underwriting Agreement, the Company granted the underwriters a 30-day option, which the underwriters exercised, to purchase up to an additional <ix:nonFraction id="c662" contextRef="d_2025-08-12_2025-08-12_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" unitRef="Share" name="cmpx:StockIssuableDuringPeriodShares" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,000,000</ix:nonFraction> shares of its Common Stock (the &#8220;Optional Shares&#8221;, and together with the Firm Shares, the &#8220;Shares&#8221;) at the public offering price, less underwriting discounts and commissions. The Company received aggregate net proceeds of $<ix:nonFraction id="c663" contextRef="d_2025-08-12_2025-08-12_SubsidiarySaleOfStockAxis-UnderwritingAgreementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:num-dot-decimal" decimals="-5">129.3</ix:nonFraction> million, after deducting underwriting discounts and commissions of $<ix:nonFraction id="c664" contextRef="d_2025-08-12_2025-08-12_SubsidiarySaleOfStockAxis-UnderwritingAgreementMember" unitRef="USD" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" scale="6" format="ixt:num-dot-decimal" decimals="-5">8.3</ix:nonFraction> million and other offering costs of $<ix:nonFraction id="c665" contextRef="d_2025-08-12_2025-08-12_SubsidiarySaleOfStockAxis-UnderwritingAgreementMember" unitRef="USD" name="us-gaap:NoninterestExpenseOfferingCost" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction> million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The 2025 Pre-Funded Warrants were determined to be equity classified. Accordingly, proceeds from the offering were allocated to common stock, the 2025 Pre-Funded Warrants on a relative fair value basis and were recorded in stockholders&#8217; equity. As of December 31, 2025, all of the 2025 Pre-Funded Warrants remain outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">117</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">In the first quarter of 2024, the Company sold through its Jefferies ATM Agreement, <ix:nonFraction id="c666" contextRef="d_2024-01-01_2024-03-31_SubsidiarySaleOfStockAxis-AtTheMarketMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">9,790,577</ix:nonFraction> shares of common stock at an average price of $<ix:nonFraction id="c667" contextRef="i_2024-03-31_SubsidiarySaleOfStockAxis-AtTheMarketMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.85</ix:nonFraction> for total proceeds of $<ix:nonFraction id="c668" contextRef="d_2024-01-01_2024-03-31_SubsidiarySaleOfStockAxis-AtTheMarketMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:num-dot-decimal" decimals="-5">18.1</ix:nonFraction> million and net proceeds of $<ix:nonFraction id="c669" contextRef="d_2024-01-01_2024-03-31_SubsidiarySaleOfStockAxis-AtTheMarketMember" unitRef="USD" name="cmpx:ProceedsFromIssuanceOfCommonStockNet" scale="6" format="ixt:num-dot-decimal" decimals="-5">17.6</ix:nonFraction> million.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="c670" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>9.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Stock-Based Compensation</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Stock-based compensation expense for the years ended December 31, 2025 and 2024 was classified in the consolidated statements of operations as follows:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="c768" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended<br/>
			December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c771" contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,346</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c772" contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,971</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c773" contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,022</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c774" contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,589</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c775" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,368</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c776" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">8,560</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>2020 Stock Option and Incentive Plan</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">In June 2020, the Company&#8217;s board of directors adopted the 2020 Plan and reserved <ix:nonFraction id="c679" contextRef="i_2020-06-30_PlanNameAxis-The2020StockOptionAndIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.9</ix:nonFraction> million shares of common stock for issuance under this plan. The 2020 Plan provides that the number of shares reserved and available for issuance under the 2020 Plan will automatically increase each January 1, beginning on January 1, 2021, by the lesser of 4% of the outstanding number of shares of our common stock on the immediately preceding December 31 or such number of shares as determined by the plan administrator no later than the immediately preceding December 31. As of December 31, 2025, <ix:nonFraction id="c681" contextRef="i_2025-12-31_PlanNameAxis-The2020StockOptionAndIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" format="ixt:num-dot-decimal" decimals="-5">5.3</ix:nonFraction> million shares remain available for future grant. On January 1, 2026, an additional <ix:nonFraction id="c682" contextRef="d_2026-01-01_2026-01-01_PlanNameAxis-The2020StockOptionAndIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="6" format="ixt:num-dot-decimal" decimals="-5">7.1</ix:nonFraction> million shares became available for issuance based on 4% of the outstanding shares of common stock, for a total of <ix:nonFraction id="c684" contextRef="i_2026-01-01_PlanNameAxis-The2020StockOptionAndIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" format="ixt:num-dot-decimal" decimals="-5">12.4</ix:nonFraction> million shares available for issuance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The 2020 Plan authorizes the board of directors or a committee of the board to grant incentive stock options, nonqualified stock options, restricted stock awards and restricted stock units ("RSUs") to eligible officers, employees, consultants and directors of the Company. Options generally vest over a period of <span style="-sec-ix-hidden:c685">four</span> years and have a contractual life of <span style="-sec-ix-hidden:c686">ten</span> years from the date of grant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><i>Stock Options:</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The following table summarizes the stock option activity for the 2020 Plan:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c777" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options (000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average<br/>
			Exercise Price<br/>
			Price Per Share</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average<br/>
			Remaining Contractual<br/>
			Life (in years)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate Intrinsic Value (000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c780" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,876</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c781" contextRef="i_2023-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.81</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c782" format="ixt-sec:duryear">8.05</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c783" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">11</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c784" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,193</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c785" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.58</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" id="c786" format="ixt-sec:duryear">7.10</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c787" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c788" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c789" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited/cancelled</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c792" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" format="ixt:num-dot-decimal" decimals="-3">7</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c793" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.04</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c795" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2024</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c796" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" format="ixt:num-dot-decimal" decimals="-3">14,062</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c797" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.83</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c798" format="ixt-sec:duryear">6.23</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c799" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">579</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c800" contextRef="d_2025-01-01_2025-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,777</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c801" contextRef="d_2025-01-01_2025-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.63</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" id="c802" format="ixt-sec:duryear">8.76</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c803" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" scale="3" format="ixt:num-dot-decimal" decimals="-3">2</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c804" contextRef="d_2025-01-01_2025-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">545</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c805" contextRef="d_2025-01-01_2025-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.34</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c807" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,214</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited/cancelled</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c808" contextRef="d_2025-01-01_2025-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,942</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c809" contextRef="d_2025-01-01_2025-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.40</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c811" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,341</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c812" contextRef="i_2025-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" format="ixt:num-dot-decimal" decimals="-3">16,352</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c813" contextRef="i_2025-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.13</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c814" format="ixt-sec:duryear">6.69</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c815" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">36,614</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested at December 31, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c816" contextRef="i_2025-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,513</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c817" contextRef="i_2025-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.38</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="c818" format="ixt-sec:duryear">5.24</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c819" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">18,932</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">For the year ended December 31, 2025, the weighted average grant date fair value for options granted was $<ix:nonFraction id="c727" contextRef="d_2025-01-01_2025-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.69</ix:nonFraction>. The aggregate intrinsic value for options vested and outstanding as of December 31, 2025 and 2024 was $<ix:nonFraction id="c728" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" format="ixt:num-dot-decimal" decimals="-5">36.6</ix:nonFraction> million and $<ix:nonFraction id="c729" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">579</ix:nonFraction> thousand, respectively. As of December 31, 2025, the unrecognized compensation cost related to outstanding options was $<ix:nonFraction id="c730" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" format="ixt:num-dot-decimal" decimals="-5">13.7</ix:nonFraction> million, expected to be recognized over a weighted average period of approximately <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c731" format="ixt-sec:duryear">1.4</ix:nonNumeric> years.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">118</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The weighted average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and directors during the years ended December 31, 2025 and 2024 were as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="c820" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected term (in years)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c823" format="ixt-sec:duryear">6.0</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c824" format="ixt-sec:duryear">6.0</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c825" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.26</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c826" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">3.92</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c827" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">86</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c828" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">81</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><i>RSUs:</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The following table summarizes the RSU activity for the 2020 Plan:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="c829" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares<br/>
			(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted<br/>
			Average Price<br/>
			Per Share</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted<br/>
			Average Fair Value (000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested, December 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c832" contextRef="i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" format="ixt:num-dot-decimal" decimals="-5">1,500</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c833" contextRef="i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.83</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c834" contextRef="i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,745</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c835" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,791</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c836" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.89</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c837" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USD" name="cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,275</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c838" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" format="ixt:num-dot-decimal" decimals="-3">525</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c839" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.87</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c840" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,032</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited or canceled</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c841" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c842" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c843" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USD" name="cmpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested, December 31, 2024</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c844" contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,766</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c845" contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.41</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c846" contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,076</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c847" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c848" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c849" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USD" name="cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c850" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,073</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c851" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.59</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c852" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,779</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited or canceled</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c853" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,665</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c854" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.34</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c855" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USD" name="cmpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,896</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested, December 31, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c856" contextRef="i_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,028</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c857" contextRef="i_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.33</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c858" contextRef="i_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,395</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants. The weighted average fair value is the weighted average share price times the number of shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">As of December 31, 2025, remaining unrecognized compensation cost related to RSUs to be recognized in future periods totaled $<ix:nonFraction id="c765" contextRef="i_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.6</ix:nonFraction> million, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c766" format="ixt-sec:duryear">1.2</ix:nonNumeric> years. As of December 31, 2025, the total unrecognized compensation cost from all plans to be recognized in future periods totaled approximately $<ix:nonFraction id="c767" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:num-dot-decimal" decimals="-5">15.3</ix:nonFraction> million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>2025 Inducement Plan</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">In December 2025, the Company&#8217;s board of directors adopted the Compass Therapeutics, Inc. 2025 Inducement Plan (the &#8220;Inducement Plan&#8221;). The purpose of the Inducement Plan is to enable the Company to grant equity awards to induce highly-qualified prospective officers and employees to accept employment and provide them with a proprietary interest in the Company. The Company intends that the Inducement Plan be reserved for persons to whom the Company may issue securities without stockholder approval as an inducement pursuant to Rule 5635(c)(4) of the Marketplace Rules of The NASDAQ Stock Market LLC. The maximum number of shares of Stock reserved and available for issuance under the Inducement Plan is four million shares. As of December 31, 2025, no equity had been granted or outstanding with the Inducement Plan. On January 1, 2026, a total of two million options were granted as part of the Inducement Plan to two new officers as a material inducement for those officers to join the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">119</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p></ix:exclude>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:EarningsPerShareTextBlock" id="c859" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>10.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Basic and Diluted Net Loss Per Share</span></b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Basic net loss per share has been computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock plus potentially dilutive securities outstanding during the period. Potential shares of common stock exercisable for little or no consideration are included in both basic and diluted weighted-average number of shares of common stock outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 29pt; text-indent: -2pt;">&#160;During the year ended December 31, 2025, basic and diluted weighted-average number of shares outstanding were <ix:nonFraction id="c862" contextRef="d_2025-01-01_2025-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" format="ixt:num-dot-decimal" decimals="-5">157.7</ix:nonFraction> million and included pre-funded warrants to purchase <ix:nonFraction id="c863" contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,710,000</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction id="c864" contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0001</ix:nonFraction> per share. During the year ended December 31, 2024, basic and diluted weighted-average number of shares outstanding were <ix:nonFraction id="c865" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" format="ixt:num-dot-decimal" decimals="-5"><ix:nonFraction id="c866" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" format="ixt:num-dot-decimal" decimals="-5">137.4</ix:nonFraction></ix:nonFraction> million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 29pt; text-indent: -2pt;">&#160;The computation of diluted net loss per share for the year ended December 31, 2025 excluded <ix:nonFraction id="c867" contextRef="d_2025-01-01_2025-12-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">17.4</ix:nonFraction> million shares subject to outstanding stock options and restricted stock units because their inclusion would have had an anti-dilutive effect on diluted net loss per share. The computation of diluted net loss per share for the year ended December 31, 2024 excluded <ix:nonFraction id="c869" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">17.8</ix:nonFraction> million shares, subject to outstanding stock options and restricted stock because their inclusion would have had an anti-dilutive effect on diluted net loss per share. The following potentially dilutive securities (in common stock equivalents) have been excluded from the computation of diluted weighted-average shares outstanding for the years ended December 31, 2025 and 2024, as they would be antidilutive:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="c875" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c878" contextRef="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">16,352,430</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c879" contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">14,061,604</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c880" contextRef="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,028,125</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c881" contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,765,625</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="c882" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>11.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>License, Research and Collaboration Agreements</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Collaboration Agreements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b><i>ABL Bio Corporation ("ABL Bio") Agreements</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">In November 2018, the Company and ABL Bio, a South Korean biotechnology company, entered into an exclusive global (excluding South Korea) license agreement which granted the Company a license to tovecimig (ABL001), ABL Bio&#8217;s bispecific antibody targeting DLL4 and VEGF-A. Under the terms of the agreement, the two companies would jointly develop tovecimig, with ABL Bio responsible for development of tovecimig throughout the end of Phase 1 clinical trials and the Company responsible for the development of tovecimig from Phase 2 and onward. ABL Bio received a $<ix:nonFraction id="c885" contextRef="d_2018-11-01_2018-11-30_TypeOfArrangementAxis-ABLBioAgreementMember" unitRef="USD" name="cmpx:UpfrontPayment" scale="6" format="ixt:num-dot-decimal" decimals="-6">5</ix:nonFraction> million upfront payment and $<ix:nonFraction id="c886" contextRef="d_2018-11-01_2018-11-30_TypeOfArrangementAxis-ABLBioAgreementMember" unitRef="USD" name="cmpx:DevelopmentMilestonePayment" scale="6" format="ixt:num-dot-decimal" decimals="-6">6</ix:nonFraction> million development milestone payment. In addition, ABL Bio is eligible to receive up to $<ix:nonFraction id="c887" contextRef="i_2018-11-30_TypeOfArrangementAxis-ABLBioAgreementMember" unitRef="USD" name="cmpx:MaximumDevelopmentAndRegulatoryMilestonePayments" scale="6" format="ixt:num-dot-decimal" decimals="-6">96</ix:nonFraction> million of development and regulatory milestone payments, and up to $<ix:nonFraction id="c888" contextRef="i_2018-11-30_ProductOrServiceAxis-OncologyMember_TypeOfArrangementAxis-ABLBioAgreementMember" unitRef="USD" name="cmpx:MaximumCommercialMilestonePaymentsAndRoyalties" scale="6" format="ixt:num-dot-decimal" decimals="-6">303</ix:nonFraction> million of commercial milestone payments and tiered single-digit royalties on net sales of tovecimig in oncology. ABL Bio is also eligible to receive up to $<ix:nonFraction id="c889" contextRef="i_2018-11-30_ProductOrServiceAxis-OphthalmologyMember_TypeOfArrangementAxis-ABLBioAgreementMember" unitRef="USD" name="cmpx:MaximumDevelopmentAndRegulatoryMilestonePayments" scale="6" format="ixt:num-dot-decimal" decimals="-6">75</ix:nonFraction> million in development and regulatory milestones and up to $<ix:nonFraction id="c890" contextRef="i_2018-11-30_ProductOrServiceAxis-OphthalmologyMember_TypeOfArrangementAxis-ABLBioAgreementMember" unitRef="USD" name="cmpx:MaximumCommercialMilestonePaymentsAndRoyalties" scale="6" format="ixt:num-dot-decimal" decimals="-7">110</ix:nonFraction> million in commercial milestone payments and tiered, single-digit royalties on net sales of tovecimig in ophthalmology.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">120</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">In May 2021, TRIGR and ABL Bio terminated license agreements to several preclinical assets. As a result of the return of these assets to ABL Bio and termination of the license agreements, the Company is eligible to receive royalty payments if ABL Bio develops or licenses two bispecific antibodies that were previously licensed to TRIGR.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b><i>Adimab Agreement</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company entered into a collaboration agreement with Adimab, LLC on October 16, 2014. The agreement includes provisions for payment of royalties at rates ranging in the single digits as a percentage of future net sales within a specified term from the first commercial sale for certain antibodies, including our product candidate, CTX-471. There were <span style="-sec-ix-hidden:c891">no</span> milestone payments made during 2025. As of December 31, 2025, future potential milestone payments in connection with this agreement amounted to $<ix:nonFraction id="c892" contextRef="i_2025-12-31_TypeOfArrangementAxis-AdimabAgreementMember" unitRef="USD" name="cmpx:MilestonePaymentObligation" scale="6" format="ixt:num-dot-decimal" decimals="-6">2.0</ix:nonFraction> million.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="c893" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>12.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Commitments and Contingencies </b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Leases</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company accounts for operating leases on a straight-line basis over the lease term, with recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments. For leases with a term of 12 months or less, we recognize lease expense on a straight-line basis over the lease term.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company has evaluated its leases under ASC 842, <i>Leases</i>, and determined that it has one lease that is classified as an operating lease. The classification of this lease is consistent with the Company&#8217;s determination under the previous accounting standard.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">When available, the Company will use the rate implicit in the lease to discount lease payments to present value; however, the Company&#8217;s current lease does not provide an implicit rate. Therefore, the Company used its incremental borrowing rate of <ix:nonFraction id="c896" contextRef="i_2025-12-31_LeaseContractualTermAxis-FacilityLeaseMember" unitRef="Pure" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">6.25</ix:nonFraction>% to discount the lease payments based on the date of the lease commencement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company has one operating lease for its corporate office and laboratory facility (&#8220;Facility&#8221;) that was signed in December 2020. The Company moved into the Facility in January 2021. The Facility lease has an initial term of four years and five months, beginning on January 1, 2021.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The terms of the Facility lease were modified effective September 27, 2024 through the execution of a new lease. The modified terms extended the non-cancelable lease term through May 2031. The modified terms also included the right to use an additional <ix:nonFraction id="c897" contextRef="i_2024-09-27_LeaseContractualTermAxis-FacilityLeaseMember" unitRef="SquareFoot" name="us-gaap:AreaOfRealEstateProperty" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,724</ix:nonFraction> square feet that commenced in May 2025. The classification and incremental borrowing rate for the lease did not change as a result of this lease modification. Right-of-use assets obtained in exchange for new operating lease liabilities due to the lease modification were $<ix:nonFraction id="c898" contextRef="d_2024-07-27_2024-09-27_LeaseContractualTermAxis-FacilityLeaseMember" unitRef="USD" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" format="ixt:num-dot-decimal" decimals="-5">9.9</ix:nonFraction> million for a total right-of-use assets as of December 31, 2025 of $<ix:nonFraction id="c899" contextRef="i_2025-12-31_LeaseContractualTermAxis-FacilityLeaseMember" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" format="ixt:num-dot-decimal" decimals="-5">9.1</ix:nonFraction> million. The remaining lease term of the Facility lease is <ix:nonNumeric contextRef="i_2025-12-31_LeaseContractualTermAxis-FacilityLeaseMember" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="c900" format="ixt-sec:duryear">5.4</ix:nonNumeric> years as of December 31, 2025. The Company has $<ix:nonFraction id="c901" contextRef="i_2024-09-27_GuaranteeObligationsByNatureAxis-FinancialStandbyLetterOfCreditMember_LeaseContractualTermAxis-FacilityLeaseMember" unitRef="USD" name="us-gaap:RestrictedCash" scale="3" format="ixt:num-dot-decimal" decimals="-3">568</ix:nonFraction> thousand of restricted cash associated with an irrevocable letter of credit required by the landlord to enter into this lease.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Lease costs related to the Facility were $<ix:nonFraction id="c902" contextRef="d_2025-01-01_2025-12-31_LeaseContractualTermAxis-FacilityLeaseMember" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.3</ix:nonFraction> million and $<ix:nonFraction id="c903" contextRef="d_2024-01-01_2024-12-31_LeaseContractualTermAxis-FacilityLeaseMember" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.1</ix:nonFraction> million for the years ending December 31, 2025 and 2024, respectively. Cash paid for this lease was $<ix:nonFraction id="c904" contextRef="d_2025-01-01_2025-12-31_LeaseContractualTermAxis-FacilityLeaseMember" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.8</ix:nonFraction> million and $<ix:nonFraction id="c905" contextRef="d_2024-01-01_2024-12-31_LeaseContractualTermAxis-FacilityLeaseMember" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.4</ix:nonFraction> million for the years ended December 31, 2025 and 2024, respectively.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">121</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The table below presents the undiscounted cash flows for the lease term. The undiscounted cash flows are reconciled to the operating lease liabilities recorded on the consolidated balance sheets:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="c922" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(000's)</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 84%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Years ending December 31,</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c925" contextRef="i_2025-09-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,525</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c926" contextRef="i_2025-09-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,204</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c927" contextRef="i_2025-09-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,249</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2029</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c928" contextRef="i_2025-09-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,294</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2030</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c929" contextRef="i_2025-09-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,356</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c930" contextRef="i_2025-09-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" format="ixt:num-dot-decimal" decimals="-3">995</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total minimum lease payments</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c931" contextRef="i_2025-09-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,623</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: amount of lease payments representing interest</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c932" contextRef="i_2025-09-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,794</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Present value of future minimum lease payments</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c933" contextRef="i_2025-09-30" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,829</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: operating lease obligations, current portion</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c934" contextRef="i_2025-09-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-6">1,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease obligations, long-term portion</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c935" contextRef="i_2025-09-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,829</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Defined Contribution Plan </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company has a 401(k) defined contribution plan (the &#8220;401(k) Plan&#8221;) for substantially all its employees. Eligible employees may make pre-tax or post-tax (Roth) contributions to the 401(k) Plan up to statutory limits. Since January 1, 2020, the Company has been matching employee contributions to the plan up to <ix:nonFraction id="c917" contextRef="d_2025-01-01_2025-09-30_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" format="ixt:num-dot-decimal" decimals="2">4</ix:nonFraction>% of salary. On July 1, 2023, the Company increased the employee matching contribution from <ix:nonFraction id="c918" contextRef="d_2023-07-01_2025-12-31_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" format="ixt:num-dot-decimal" decimals="2">4</ix:nonFraction>% to <ix:nonFraction id="c919" contextRef="d_2023-07-01_2025-12-31_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" format="ixt:num-dot-decimal" decimals="2">6</ix:nonFraction>%. The Company made matching contributions of $<ix:nonFraction id="c920" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction> million and $<ix:nonFraction id="c921" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction> million for the years ended December 31, 2025 and 2024, respectively.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock" id="c936" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>13.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Other income</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Other income consisted of interest income from investments on marketable securities of $<ix:nonFraction id="c939" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="6" format="ixt:num-dot-decimal" decimals="-5">6.4</ix:nonFraction> million and $<ix:nonFraction id="c940" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="6" format="ixt:num-dot-decimal" decimals="-5">7.3</ix:nonFraction> million for the years ended December 31, 2025 and 2024, respectively.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c941" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>14.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Income Taxes </b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company had <span style="-sec-ix-hidden:c944"><span style="-sec-ix-hidden:c945">no</span></span> income tax for the years ended December 31, 2025 and 2024.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">&#8208;The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="c1030" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal statutory rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1033" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">13,963</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1034" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1035" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">10,368</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1036" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Adjustment resulting from the tax effect of:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">State and local income tax, net of federal (national) income tax effect</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1038" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">4,416</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1039" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:num-dot-decimal" decimals="3">6.6</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1040" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3,454</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1041" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:num-dot-decimal" decimals="2">7.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Foreign Tax Effects</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1042" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1043" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1044" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1045" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Effect of changes in tax laws or rates enacted in the current period</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1046" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1047" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1048" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1049" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Effect of cross-border tax laws</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1050" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1051" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1052" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1053" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Tax Credits</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Research and development tax credits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1055" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,045</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1056" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">3.1</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1057" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,864</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1058" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">5.8</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Changes in valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1059" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">19,744</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-<ix:nonFraction id="c1060" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">29.8</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1061" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">15,778</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-<ix:nonFraction id="c1062" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:num-dot-decimal" decimals="2" sign="-">32.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Nontaxable or nondeductible items</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock compensation &amp; other nondeductible expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1064" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">680</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-<ix:nonFraction id="c1065" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">0.9</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1066" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">532</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-<ix:nonFraction id="c1067" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">1.1</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Changes in unrecognized tax benefits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1068" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="cmpx:EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1069" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="cmpx:EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1070" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="cmpx:EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1071" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="cmpx:EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1072" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1073" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1074" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" format="ixt:num-dot-decimal" decimals="-3">376</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-<ix:nonFraction id="c1075" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">0.7</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Effective income tax rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c1076" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c1077" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c1078" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c1079" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">122</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">In 2025, state and local income taxes in Massachusetts comprise the state and local income taxes category. The company had no federal or state income tax payments or refunds for the years ended December 31, 2025 and December 31, 2024. The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. In determining the need for a valuation allowance, management reviews both positive and negative evidence, including current and historical results of operations, future income projections and the overall prospects of our business. Based upon management&#8217;s assessment of all available evidence, the Company believes that it is more-likely-than-not that the deferred tax assets will not be realizable, and therefore, a valuation allowance has been established. The valuation allowance for deferred tax assets was approximately $<ix:nonFraction id="c993" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" format="ixt:num-dot-decimal" decimals="-5">79.2</ix:nonFraction>&#160;million and $<ix:nonFraction id="c994" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" format="ixt:num-dot-decimal" decimals="-5">59.5</ix:nonFraction> million as of December 31, 2025 and 2024, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">As of December 31, 2025, the Company has U.S. federal and state net operating loss carryforwards (&#8220;NOLs&#8221;) of $<ix:nonFraction id="c995" contextRef="i_2025-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:num-dot-decimal" decimals="-5">200.4</ix:nonFraction>&#160;million and $<ix:nonFraction id="c996" contextRef="i_2024-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:num-dot-decimal" decimals="-5">206.7</ix:nonFraction>&#160;million, respectively. As of December 31, 2025, the Company has federal and state research and development credit carryforwards (&#8220;R&amp;D credits&#8221;) of $9.3 million and $2.5 million, respectively. For income tax purposes, federal NOLs will not expire since they were generated after 2017 and federal R&amp;D credits will begin expiring in 2039. For income tax purposes, state NOLs and state R&amp;D credits will begin to expire in 2040 and 2031, respectively.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service (the &#8220;IRS&#8221;) and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50% as defined under Sections 382 and 383 in the Internal Revenue Code, which could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the Company&#8217;s value immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) amended IRC Section 174 to require capitalization of all research and developmental (R&amp;D) costs incurred in tax years beginning after December 31, 2021. These costs are required to be amortized with a half-year convention over five years if the R&amp;D activities are performed in the U.S., or over 15 years if the activities were performed outside the U.S. The One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) enacted in 2025 allows for current deductibility of domestic R&amp;D costs and immediate deduction for previously capitalized costs for certain taxpayers retroactive to 2024. The Company elected to take the deduction in 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">As of December 31, 2025 and 2024, the Company had <span style="-sec-ix-hidden:c997"><span style="-sec-ix-hidden:c998">no</span></span> uncertain tax positions, and as such, <span style="-sec-ix-hidden:c999"><span style="-sec-ix-hidden:c1000">no</span></span> related interest or penalties have been recorded in the statements of operations and comprehensive loss. The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense. All tax years of the Company from inception are open to examination by federal tax and state tax authorities. To the extent utilized in future years&#8217; tax returns, net operating loss carryforwards at December 31, 2025 will remain subject to examination until the respective tax year is closed. The Company has not been informed by any tax authorities for any jurisdiction that any of its tax years is under examination as of December 31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">123</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="c1080" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred tax assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal net operating loss carryforwards</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1083" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="3" format="ixt:num-dot-decimal" decimals="-3">42,075</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1084" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="3" format="ixt:num-dot-decimal" decimals="-3">16,775</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State net operating loss carryforwards</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1085" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="3" format="ixt:num-dot-decimal" decimals="-3">13,063</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1086" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,063</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development credits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1087" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,297</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1088" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,252</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Section 174 Capitalization</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1089" contextRef="i_2025-12-31" unitRef="USD" name="cmpx:DeferredTaxAssetsSection174Capitalization" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,015</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1090" contextRef="i_2024-12-31" unitRef="USD" name="cmpx:DeferredTaxAssetsSection174Capitalization" scale="3" format="ixt:num-dot-decimal" decimals="-3">22,724</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1091" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,001</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1092" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,922</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1093" contextRef="i_2025-12-31" unitRef="USD" name="cmpx:DeferredTaxAssetsLeaseLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,685</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1094" contextRef="i_2024-12-31" unitRef="USD" name="cmpx:DeferredTaxAssetsLeaseLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,812</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Capitalized licensing fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1095" contextRef="i_2025-12-31" unitRef="USD" name="cmpx:DeferredTaxAssetsCapitalizedLicensingFees" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,266</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1096" contextRef="i_2024-12-31" unitRef="USD" name="cmpx:DeferredTaxAssetsCapitalizedLicensingFees" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,375</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1097" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOther" scale="3" format="ixt:num-dot-decimal" decimals="-3">406</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1098" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOther" scale="3" format="ixt:num-dot-decimal" decimals="-3">494</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Subtotal</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1099" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">81,808</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1100" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">61,417</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c1101" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">79,245</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c1102" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">59,521</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets, net of valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1103" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,563</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1104" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,896</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred tax liabilities</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Right-of-use assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1106" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,486</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1107" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,839</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c1108" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" format="ixt:num-dot-decimal" decimals="-3">77</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c1109" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" format="ixt:num-dot-decimal" decimals="-3">57</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c1110" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c1111" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:SegmentReportingDisclosureTextBlock" id="c1112" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>15.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Segment Information </b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Segment reporting is prepared on the same basis that our chief executive officer, who is our CODM, manages the business, makes operating decisions and assesses performance. The Company operates in <span style="-sec-ix-hidden:c1115">one</span> segment. The Company&#8217;s business is research and development of drug candidates. Costs, including supplies, outsourced development, and other research and development costs are tracked by major program. While internal personnel costs are tracked by program for overall program spending, it is not broken out for management review. Facility and equipment costs are not allocated to programs. Research and development expenses are summarized by program in the table below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="c1142" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Licensing revenue</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c1145" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c1146" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:num-dot-decimal" decimals="-4">850</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Personnel</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1147" contextRef="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-PersonnelMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,935</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1148" contextRef="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-PersonnelMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,918</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1149" contextRef="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-GeneralMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,616</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1150" contextRef="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-GeneralMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,965</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Tovecimig</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1151" contextRef="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-TovecimigMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">23,680</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1152" contextRef="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-TovecimigMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">23,177</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CTX-471</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1153" contextRef="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-CTX471Member" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,183</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1154" contextRef="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-CTX471Member" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,879</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CTX-8371</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1155" contextRef="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-CTX8371Member" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,355</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1156" contextRef="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-CTX8371Member" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,403</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CTX-10726</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1157" contextRef="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-CTX10726Member" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-5">8,200</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1158" contextRef="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-CTX10726Member" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1159" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">55,969</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1160" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">42,342</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Personnel</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1161" contextRef="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-PersonnelMember" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,236</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1162" contextRef="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-PersonnelMember" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,472</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1163" contextRef="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-GeneralMember" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,634</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1164" contextRef="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-GeneralMember" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,661</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1165" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">16,870</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1166" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">15,133</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Other income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1167" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">6,350</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1168" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">7,250</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c1169" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">66,489</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c1170" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">49,375</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">124</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p></ix:exclude>
</ix:nonNumeric>

<div>&#160;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.<a id="itm9" href="#"></a></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Not applicable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 9A. Controls and Procedures.<a id="itm9a" href="#"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Management</i></b>&#8217;<b><i>s Evaluation of our Disclosure Controls and Procedures</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Under the supervision of and with the participation of our management, including our principal executive officer, our principal financial officer and our principal accounting officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of December 31, 2025, the end of the period covered by this Form 10-K. The term &#8220;disclosure controls and procedures,&#8221; as set forth in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms promulgated by the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Based on this evaluation, the principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Management</i></b>&#8217;<b><i>s Report on Internal Control over Financial Reporting</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements in accordance with GAAP. Internal control over financial reporting includes maintaining records that in reasonable detail accurately and fairly reflect our transactions; providing reasonable assurance that transactions are recorded as necessary for preparation of our consolidated financial statements; providing reasonable assurance that receipts and expenditures of company assets are made in accordance with management authorization; and providing reasonable assurance that unauthorized acquisition, use or disposition of company assets that could have a material effect on our consolidated financial statements would be prevented or detected on a timely basis. Because of its inherent limitations, internal control over financial reporting is not intended to provide absolute assurance that a misstatement of our consolidated financial statements would be prevented or detected.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">125</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We are required, under Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting beginning with this Form 10-K. This assessment includes disclosure of any material weaknesses identified by our management in our internal control over financial reporting. The SEC defines a material weakness as a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual or interim consolidated financial statements will not be detected or prevented on a timely basis. Management conducted an evaluation of the effectiveness, as of December 31, 2025, of our internal control over financial reporting based on the framework in <i>Internal Control</i>&#8212;<i>Integrated Framework</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013). Based on this evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">As a smaller reporting company, we are exempt from the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002. As a result, our independent registered public accounting firm has not audited or issued an attestation report with respect to the effectiveness of our internal control over financial reporting as of December 31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Changes in Internal Control over Financial Reporting</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">During the quarter ended December 31, 2025, there have been no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15(d)-15(f) promulgated under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="ecd:MtrlTermsOfTrdArrTextBlock" id="c1171" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 9B. Other Information.<a id="itm9b" href="#"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Rule 10b5-1 Trading Plans</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">During the three months ended December 31, 2025, <span style="-sec-ix-hidden:c1174"><span style="-sec-ix-hidden:c1175"><span style="-sec-ix-hidden:c1176"><span style="-sec-ix-hidden:c1177">none</span></span></span></span> of our directors or officers adopted, materially modified, or terminated any contract, instruction, or written plan for the purchase or sale our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any non-Rule 10b5-1 trading arrangement.</p>
</ix:nonNumeric>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.<a id="itm9c" href="#"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Not applicable.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">126</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:25pt;"><b>PART III<a id="part3" href="#"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<div>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 10. Directors, Executive Officers and Corporate Governance.<a id="itm10" href="#"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The information required by this Item 10 will be included in our Definitive Proxy Statement to be filed with the Securities and Exchange Commission ("SEC"), with respect to our 2026 Annual Meeting of Stockholders and is <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="c1181" format="ixt:fixed-true">incorporated herein by reference</ix:nonNumeric>.</p>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="ecd:AwardTmgHowMnpiCnsdrdTextBlock" id="c1182" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 11. Executive Compensation.<a id="itm11" href="#"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The information required by this Item 11 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2026 Annual Meeting of Stockholders and is <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="ecd:AwardTmgMnpiCnsdrdFlag" id="c1185" format="ixt:fixed-true">incorporated herein by reference</ix:nonNumeric>.</p>
</ix:nonNumeric>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.<a id="itm12" href="#"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Except to the extent provided below, the information required by this Item 12 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2026 Annual Meeting of Stockholders and is incorporated herein by reference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"><b>2025 Inducement Plan</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In December 2025, our board of directors adopted the Inducement Plan. The Inducement Plan provides for the grant of non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, unrestricted stock awards, and dividend equivalent rights with respect to an aggregate of 4,000,000 shares of common stock (subject to adjustment as provided in the Inducement Plan). Awards under the Inducement Plan may only be granted to new employees who were not previously employed by us or our affiliates in accordance with the requirements of Nasdaq Stock Market Rule 5635(c)(4).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The Inducement Plan provides that in the event of a merger, consolidation, reorganization, substantial asset sale, stock sale or similar event affecting the Company in which the owners of the Company&#8217;s outstanding voting power prior to such event do not own at least a majority of the voting power of the successor or surviving entity (in each case, a &#8220;Sale Event&#8221;), to the extent that awards are not assumed, continued or substituted by the successor entity, the Inducement Plan and all outstanding awards will terminate. In such case, except as may otherwise be provided in the relevant award certificate, all options and stock appreciation rights granted thereunder with time-based vesting conditions or restrictions that are not vested and/or exercisable immediately prior to the effective time of the Sale Event shall become fully vested and exercisable as of the effective time of the Sale Event, all other outstanding awards granted thereunder with time-based vesting, conditions, or restrictions shall become fully vested and exercisable or nonforfeitable as of the effective time of the Sale Event, and all outstanding awards granted thereunder with conditions and restrictions relating to the attainment of performance goals may become vested and exercisable or nonforfeitable in connection with a Sale Event in the Administrator&#8217;s discretion or to the extent specified in the relevant award certificate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">If the Inducement Plan and outstanding awards terminate, each holder of an outstanding stock option or stock appreciation right may receive a payment, in cash or in kind, from the Company equal to the excess of the consideration payable per share in the Sale Event over the applicable exercise price, multiplied by the number of shares of Common Stock then exercisable under the stock option or stock appreciation right (to the extent then exercisable at prices not exceeding such consideration payable per share) or be permitted to exercise their stock option or stock appreciation right (to the extent exercisable) for a period of time prior to the termination of the Inducement Plan, as determined by the Administrator. Stock options or stock appreciation rights with exercise prices equal to or greater than the consideration payable per share in the Sale Event may be cancelled for no consideration. The Company shall also have the option to make or provide for payment, in cash or in kind, to grantee holding other awards in an amount equal to the sale price multiplied by the number of vested shares of Common Stock underlying such awards.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">127</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 13. Certain Relationships and Related Transactions, and Director Independence.<a id="itm13" href="#"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The information required by this Item 13 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2026 Annual Meeting of Stockholders and is incorporated herein by reference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 14. Principal Accountant Fees and Services.<a id="itm14" href="#"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The information required by this Item 14 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2026 Annual Meeting of Stockholders and is incorporated herein by reference.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">128</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART IV<a id="part4" href="#"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 15. Exhibits and Financial Statement Schedules.<a id="itm15" href="#"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:0pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">See Index to the Consolidated Financial Statements in Part II, Item 8 of this Annual Report on Form 10-K.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:0pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the accompanying notes.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:0pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(3)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Exhibits</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278-8k_compasstherap.htm" style="-sec-extract:exhibit;">2.1</a></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278-8k_compasstherap.htm" style="-sec-extract:exhibit;">Agreement and Plan of Merger, dated June 17, 2020, by and among the Olivia Ventures, Inc., Compass Acquisition LLC, Compass Therapeutics LLC, BBV International Compass Inc., Biomatics&#8212;Compass, Inc., CHI II Blocker LLC, OrbiMed Private Investments V&#8212;KA (Blocker), Inc., Eight Roads Investments, Biomatics Capital Partners, L.P., Cowen Healthcare Investments II LP, CHI EF II LP, and OrbiMed Private Investments V&#8212;KA (Feeder), LP (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed with the SEC on June 23, 2020)</a></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex3-1_compass.htm" style="-sec-extract:exhibit;">3.1</a></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex3-1_compass.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Merger relating to the merger of Compass Acquisition LLC with and into Compass Therapeutics LLC, filed with the Secretary of State of the State of Delaware on June 17, 2020 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on June 23, 2020)</span></a></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex3-2_compass.htm" style="-sec-extract:exhibit;">3.2</a></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex3-2_compass.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed with the SEC on June 23, 2020)</span></a></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/0001738021/000121390020015594/ea123278ex3-3_compass.htm" style="-sec-extract:exhibit;">3.3</a></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/0001738021/000121390020015594/ea123278ex3-3_compass.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.3 to the Current Report on Form 8-K filed with the SEC on June 23, 2020)</span></a></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000156459021027411/cmpx-ex101_19.htm" style="-sec-extract:exhibit;">3.4</a></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000156459021027411/cmpx-ex101_19.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Agreement and Plan of Merger and Reorganization by and among Compass Therapeutics, Inc. Compass Intermediate Acquisition Company, Inc., Compass Acquisition Company, LLC, Trigr Therapeutics, Inc. and Peng Ventures, LLC, as Stockholder Representative (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K filed with the SEC on May 13, 2021)</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000119312520271775/d67515dex41.htm" style="-sec-extract:exhibit;">4.1</a></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000119312520271775/d67515dex41.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Specimen Certificate for Common Stock (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1 filed with the SEC on October 19, 2020)</span></a></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000156459021011110/cmpx-ex42_124.htm" style="-sec-extract:exhibit;">4.2</a></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000156459021011110/cmpx-ex42_124.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Description of Registered Securities (incorporated by reference to Exhibit 4.2 to the Annual Report on Form 10-K filed with the SEC on March 5, 2021)</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000119312525179958/d153873dex41.htm" style="-sec-extract:exhibit;">4.3</a></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000119312525179958/d153873dex41.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on August 13, 2025).</span></a></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex10-1_compass.htm" style="-sec-extract:exhibit;">10.1#</a></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex10-1_compass.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">2020 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on June 23, 2020)</span></a></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex10-2_compass.htm" style="-sec-extract:exhibit;">10.2#</a></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex10-2_compass.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">2020 Senior Executive Cash Incentive Bonus Plan (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on June 23, 2020)</span></a></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex10-4_compass.htm" style="-sec-extract:exhibit;">10.3#</a></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex10-4_compass.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Indemnification Agreement (directors) (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed with the SEC on June 23, 2020)</span></a></p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">129</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex10-5_compass.htm" style="-sec-extract:exhibit;">10.4#</a></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex10-5_compass.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Indemnification Agreement (executive officers) (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed with the SEC on June 23, 2020</span>)</a></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex10-6_compass.htm" style="-sec-extract:exhibit;">10.5#</a></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex10-6_compass.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Pre-Merger Indemnification Agreement (directors and executive officers) (incorporated by reference to Exhibit 10.6 to the Current Report on Form 8-K filed with the SEC on June 23, 2020)</span></a></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex10-7_compass.htm" style="-sec-extract:exhibit;">10.6</a></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex10-7_compass.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Registration Rights Agreement, dated June 19, 2020, by and among Compass Therapeutics, Inc. and the parties thereto (incorporated by reference to Exhibit 10.7 to the Current Report on Form 8-K filed with the SEC on June 23, 2020)</span></a></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex10-8_compass.htm" style="-sec-extract:exhibit;">10.7</a></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex10-8_compass.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Subscription Agreement, dated June 19, 2020, by and between Compass Therapeutics, Inc. and the investors party thereto (incorporated by reference to Exhibit 10.8 to the Current Report on Form 8-K filed with the SEC on June 23, 2020)</span></a></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex10-9_compass.htm" style="-sec-extract:exhibit;">10.8&#8224;</a></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex10-9_compass.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amended and Restated Collaboration Agreement, dated February 11, 2015, by and between Adimab LLC and Kairos Biologics Foundation LLC (incorporated by reference to Exhibit 10.9 to the Current Report on Form 8-K filed with the SEC on June 23, 2020)</span></a></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000156459021011110/cmpx-ex1016_91.htm" style="-sec-extract:exhibit;">10.9</a></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000156459021011110/cmpx-ex1016_91.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Sublease Agreement, effective as of December 1, 2020, by and between Roche Diagnostic Operations, Inc. and Compass Therapeutics, Inc. (incorporated by reference to Exhibit 10.16 to the Annual Report on Form 10-K filed with the SEC on March 5, 2021)</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000117184324006248/ex_741309.htm" style="-sec-extract:exhibit;">10.10</a></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000117184324006248/ex_741309.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Lease Agreement, effective as of September 27, 2024, by and between ICE BOX, LLC and Compass Therapeutics, Inc. (incorporated by reference to Exhibit 10.13 to the Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024)</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000117184324001516/ex_639454.htm" style="-sec-extract:exhibit;">10.11#</a></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000117184324001516/ex_639454.htm" style="-sec-extract:exhibit;">Employment Agreement between Compass Therapeutics, Inc. and Thomas J. Schuetz, M.D., Ph.D., dated January 8, <span style="text-decoration: underline; ">2024 (incorporated by reference to Exhibit 10.10 to the Annual Report on Form 10-K filed with the SEC on March 21, 2024)</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000117184324006847/exh_101.htm" style="-sec-extract:exhibit;">10.12#</a></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000117184324006847/exh_101.htm" style="-sec-extract:exhibit;">Employment Agreement between Compass Therapeutics, Inc. and Barry Shin, dated December 9, <span style="text-decoration: underline; ">2024 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on December 10, 2024)</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000117184324003129/exh_101.htm" style="-sec-extract:exhibit;">10.13</a></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000117184324003129/exh_101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Separation Agreement, dated May 28, 2024, by and between Compass Therapeutics, Inc. and Vered Bisker-Leib, PhD (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on May 28, 2024)</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000117184324003129/exh_102.htm" style="-sec-extract:exhibit;">10.14</a></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000117184324003129/exh_102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Consulting Agreement, dated May 28, 2024, by and between Compass Therapeutics, Inc. and Vered Bisker-Leib, PhD (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on May 28, 2024)</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000095017021001486/cmpx-20210630ex10_1.htm" style="-sec-extract:exhibit;">10.15</a></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000095017021001486/cmpx-20210630ex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Research and Development Collaboration and License Agreement, dated November 30, 2018, between Trigr Therapeutics, Inc. and ABL Bio Inc. (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed with the SEC on August 16, 2021)</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_923540.htm" style="-sec-extract:exhibit;">10.16*</a></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_923540.htm" style="-sec-extract:exhibit;">Compass Therapeutics, Inc. 2025 Inducement Plan</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_923541.htm" style="-sec-extract:exhibit;">10.17*</a></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_923541.htm" style="-sec-extract:exhibit;">Employment Agreement between Compass Therapeutics, Inc. and Arjun Prasad, dated January 1, 2026</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_923542.htm" style="-sec-extract:exhibit;">10.18*</a></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_923542.htm" style="-sec-extract:exhibit;">Employment Agreement between Compass Therapeutics, Inc. and Cynthia Sirard, dated January 1, 2026</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000117184325001106/ex_779117.htm" style="-sec-extract:exhibit;">19.1</a></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000117184325001106/ex_779117.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Insider Trading Compliance Policy&#160;(incorporated by reference to Exhibit 19.1 to the Annual Report on Form 10-K filed with the SEC on February 27, 2025)</span></a></p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">130</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex21-1_compass.htm" style="-sec-extract:exhibit;">21.1</a></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000121390020015594/ea123278ex21-1_compass.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Current Report on Form 8-K filed with the SEC on June 23, 2020)</span></a></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_923473.htm" style="-sec-extract:exhibit;">23.1*</a></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_923473.htm" style="-sec-extract:exhibit;">Consent of CohnReznick LLP, <span style="text-decoration: underline; ">independent registered public accounting firm</span></a></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#poa" style="-sec-extract:exhibit;">24.1*</a></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#poa" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Power of Attorney (included on signature page)</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:48.1%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_923474.htm" style="-sec-extract:exhibit;">31.1*</a></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:top;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_923474.htm" style="-sec-extract:exhibit;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_923475.htm" style="-sec-extract:exhibit;">31.2*</a></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:top;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_923475.htm" style="-sec-extract:exhibit;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_923476.htm" style="-sec-extract:exhibit;">32.1**</a></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:top;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_923476.htm" style="-sec-extract:exhibit;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:48.1%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_923477.htm" style="-sec-extract:exhibit;">32.2**</a></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:top;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_923477.htm" style="-sec-extract:exhibit;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:48.1%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000117184324001516/ex_641411.htm" style="-sec-extract:exhibit;">97.1</a></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1738021/000117184324001516/ex_641411.htm" style="-sec-extract:exhibit;">Registrant&#8217;s Compensation Clawback Policy (incorporated by reference to Exhibit 97.1 to the Annual Report on Form 10-K filed with the SEC on March 21, 2024)</a></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.INS</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Instance Document</p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.SCH</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.CAL</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.DEF</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Definition</p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.LAB</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:53.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.PRE</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Presentation Linkbase Document</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:48.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"># Indicates a management contract or any compensatory plan, contract or arrangement.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">* Filed herewith.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">** The certification furnished in Exhibit 32.1 hereto is deemed to accompany this Annual Report on Form 10-K and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8224; Portions of this exhibit have been omitted in accordance with the rules of the SEC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 16. Form 10-K Summary<a id="itm16" href="#"></a></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">None.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">131</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES<a id="sig" href="#"></a></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized<b>.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:24.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td colspan="2" style="vertical-align:bottom;width:27%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Compass Therapeutics, Inc.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:24.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:24.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:24.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: March 5, 2026</p>
			</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:top;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:24.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Thomas Schuetz</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:24.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:middle;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="vertical-align:bottom;width:24.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Thomas Schuetz</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:24.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="vertical-align:bottom;width:24.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Chief Executive Officer</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:25pt;"><b>POWER OF ATTORNEY AND SIGNATURES<a id="poa" href="#"></a></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Each person whose individual signature appears below hereby authorizes and appoints Thomas J. Schuetz, Barry Shin and Carl L. Gordon, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:27.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>&#160;</b></p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Thomas J. Schuetz</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chief Executive Officer and Vice Chair of the Board (Principal Executive Officer)</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 5, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Thomas J. Schuetz</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Barry Shin</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chief Financial Officer (Principal Financial Officer)</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 5, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Barry Shin</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:13.4%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.2%;">&#160;</td>
			<td style="vertical-align:bottom;width:27.9%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Neil Lerner</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chief Accounting Officer (Principal Accounting Officer)</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 5, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Neil Lerner</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:13.4%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.2%;">&#160;</td>
			<td style="vertical-align:bottom;width:27.9%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Carl L. Gordon</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chair of the Board</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 5, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Carl L. Gordon</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Phil Ferneau</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 5, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Phil Ferneau</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Mary Ann Gray</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 5, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Mary Ann Gray</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Ellen Chiniara</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 5, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Ellen Chiniara</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ James Boylan</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 5, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>James Boylan</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Richard Lindahl</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 5, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Richard Lindahl</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:13.4%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.2%;">&#160;</td>
			<td style="vertical-align:bottom;width:27.9%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:13.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:27.9%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">132</div>

<div>&#160;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>2
<FILENAME>ex_923540.htm
<DESCRIPTION>EXHIBIT 10.16
<TEXT>
<html><head>
	<title>ex_923540.htm</title>
	<!-- Generated by ThunderDome Portal - 2/22/2026 4:42:10 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.16</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>COMPASS THERAPEUTICS, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>2025 INDUCEMENT PLAN</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">SECTION 1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>GENERAL PURPOSE OF THE PLAN; DEFINITIONS</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The name of the plan is the Compass Therapeutics, Inc. 2025 Inducement Plan (the &#8220;Plan&#8221;). The purpose of the Plan is to enable Compass Therapeutics, Inc. (the &#8220;Company&#8221;) and its Affiliates to grant equity awards to induce highly-qualified prospective officers and employees who are Eligible Employees to accept employment and to provide them with a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company&#8217;s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company&#8217;s behalf and strengthening their desire to remain with the Company. The Company intends that the Plan be reserved for persons to whom the Company may issue securities without stockholder approval as an inducement pursuant to Rule 5635(c)(4) of the Marketplace Rules of The NASDAQ Stock Market LLC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following terms shall be defined as set forth below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Act</i>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Administrator</i>&#8221; means either the Board or the compensation committee of the Board or a similar committee performing the functions of the compensation committee and which is comprised of not less than two Non&#8209;Employee Directors who are independent.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Affiliate</i>&#8221; means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule 405 of the Act. The Board will have the authority to determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Award</i>&#8221; or &#8220;<i>Awards,</i>&#8221; except where referring to a particular category of grant under the Plan, shall include Stock Options, Stock Appreciation Rights, Restricted Stock Units, Restricted Stock Awards, Unrestricted Stock Awards, and Dividend Equivalent Rights.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Award Certificate</i>&#8221; means a written or electronic document setting forth the terms and provisions applicable to an Award granted under the Plan. Each Award Certificate is subject to the terms and conditions of the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Board</i>&#8221; means the Board of Directors of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Code</i>&#8221; means the Internal Revenue Code of 1986, as amended, and any successor Code, and related rules, regulations and interpretations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Consultant</i>&#8221; means a consultant or adviser who provides <i>bona fide</i> services to the Company or an Affiliate as an independent contractor and who qualifies as a consultant or advisor under Instruction A.1.(a)(1) of Form S-8 under the Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#8220;<i>Dividend Equivalent Right</i>&#8221; means an Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other award to which it relates) if such shares had been issued to and held by the grantee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Eligible Employee</i>&#8221;<i> </i>means any individual to whom the Company may issue securities without stockholder approval in accordance with the NASDAQ Inducement Exception.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Effective Date</i>&#8221; means the date on which the Plan becomes effective as set forth in Section&nbsp;19.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Exchange Act</i>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Fair Market Value</i>&#8221; of the Stock on any given date means the fair market value of the Stock determined in good faith by the Administrator; provided, however, that if the Stock is listed on the NASDAQ, NASDAQ Global Market, The New York Stock Exchange or another national securities exchange or traded on any established market, the determination shall be made by reference to market quotations. If there are no market quotations for such date, the determination shall be made by reference to the last date preceding such date for which there are market quotations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Non-Employee Director</i>&#8221; means a member of the Board who is not also an employee of the Company or any Subsidiary.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;NASDAQ Inducement Exception</i>&#8221;&nbsp;means Rule&nbsp;5635(c)(4)&nbsp;of the Marketplace Rules&nbsp;of the NASDAQ Stock Market LLC, or any successor rule, and related guidance thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Option</i>&#8221; or &#8220;<i>Stock Option</i>&#8221; means any option to purchase shares of Stock granted pursuant to Section&nbsp;5.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#8220;<i>Restricted Shares</i>&#8221; means the shares of Stock underlying a Restricted Stock Award that remain subject to a risk of forfeiture or the Company&#8217;s right of repurchase.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Restricted Stock Award</i>&#8221; means an Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Restricted Stock Units</i>&#8221; means an Award of stock units subject to such restrictions and conditions as the Administrator may determine at the time of grant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Sale Event</i>&#8221; shall mean (i) the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (ii) a merger, reorganization or consolidation pursuant to which the holders of the Company&#8217;s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction, (iii) the sale of all of the Stock of the Company to an unrelated person, entity or group thereof acting in concert, or (iv) any other transaction in which the owners of the Company&#8217;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company.</p>

<div contenteditable="false" data-applyto="p" data-auto-pgnum="start" data-displaynum="2" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="2" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Sale Price</i>&#8221; means the value as determined by the Administrator of the consideration payable, or otherwise to be received by stockholders, per share of Stock pursuant to a Sale Event.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Section 409A</i>&#8221; means Section 409A of the Code and the regulations and other guidance promulgated thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Service Relationship</i>&#8221;<i> </i>means any relationship as an employee, director or Consultant of the Company or any Affiliate (e.g., a Service Relationship shall be deemed to continue without interruption in the event an individual&#8217;s status changes from full-time employee to part-time employee or Consultant).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Stock</i>&#8221; means the Common Stock, par value $0.0001 per share, of the Company, subject to adjustments pursuant to Section&nbsp;3.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Stock Appreciation Right</i>&#8221; means an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Certificate) having a value equal to the excess of the Fair Market Value of the Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Subsidiary</i>&#8221; means any corporation or other entity (other than the Company) in which the Company has at least a 50 percent interest, either directly or indirectly.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>&#8220;Unrestricted Stock Award</i>&#8221; means an Award of shares of Stock free of any restrictions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">SECTION 2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Administration of Plan</u>. The Plan shall be administered by the Administrator.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Powers of Administrator</u>. The Administrator shall have the power and authority to grant Awards consistent with the terms of the Plan, including the power and authority:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;to select the individuals to whom Awards may from time to time be granted; provided, such individuals are Eligible Employees;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;to determine the time or times of grant, and the extent, if any, of Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Restricted Stock Units, Unrestricted Stock Awards, and Dividend Equivalent Rights, or any combination of the foregoing, granted to any one or more grantees;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;to determine the number of shares of Stock to be covered by any Award;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;to determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan, of any Award, which terms and conditions may differ among individual Awards and grantees, and to approve the forms of Award Certificates;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;to accelerate at any time the exercisability or vesting of all or any portion of any Award;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;subject to the provisions of Section&nbsp;5(c), to extend at any time the period in which Stock Options may be exercised; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;at any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for its own acts and proceedings as it shall deem advisable; to interpret the terms and provisions of the Plan and any Award (including related written instruments); to make all determinations it deems advisable for the administration of the Plan; to decide all disputes arising in connection with the Plan; and to otherwise supervise the administration of the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">All decisions and interpretations of the Administrator shall be binding on all persons, including the Company and Plan grantees.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Delegation of Authority to Grant Awards</u>. Subject to applicable law and the NASDAQ Inducement Exception, the Administrator, in its discretion, may delegate to a committee consisting of one or more officers of the Company including the Chief Executive Officer of the Company all or part of the Administrator&#8217;s authority and duties with respect to the granting of Awards to individuals who are (i) not subject to the reporting and other provisions of Section&nbsp;16 of the Exchange Act and (ii) not members of the delegated committee. Any such delegation by the Administrator shall include a limitation as to the amount of Stock underlying Awards that may be granted during the period of the delegation and shall contain guidelines as to the determination of the exercise price and the vesting criteria. The Administrator may revoke or amend the terms of a delegation at any time but such action shall not invalidate any prior actions of the Administrator&#8217;s delegate or delegates that were consistent with the terms of the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Award Certificate</u>. Awards under the Plan shall be evidenced by Award Certificates that set forth the terms, conditions and limitations for each Award which may include, without limitation, the term of an Award and the provisions applicable in the event employment or service terminates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnification</u>. Neither the Board nor the Administrator, nor any member of either or any delegate thereof, shall be liable for any act, omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Administrator (and any delegate thereof) shall be entitled in all cases to indemnification and reimbursement by the Company in respect of any claim, loss, damage or expense (including, without limitation, reasonable attorneys&#8217; fees) arising or resulting therefrom to the fullest extent permitted by law and/or under the Company&#8217;s articles or bylaws or any directors&#8217; and officers&#8217; liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between such individual and the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Foreign Award Recipients</u>. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in other countries in which the Company and its Subsidiaries operate or have employees eligible for Awards, the Administrator, in its sole discretion, shall have the power and authority to: (i) determine which Subsidiaries shall be covered by the Plan; (ii) determine which Eligible Employees outside the United States are eligible to participate in the Plan; (iii) modify the terms and conditions of any Award granted to individuals outside the United States to comply with applicable foreign laws; (iv) subject to the NASDAQ Inducement Exception, establish subplans and modify exercise procedures and other terms and procedures, to the extent the Administrator determines such actions to be necessary or advisable (and such subplans and/or modifications shall be attached to this Plan as appendices); provided, however, that no such subplans and/or modifications shall increase the share limitation contained in Section 3(a) hereof; and (v) take any action, before or after<b> </b>an Award is made, that the Administrator determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals. Notwithstanding the foregoing, the Administrator may not take any actions hereunder, and no Awards shall be granted, that would violate the Exchange Act, the NASDAQ Inducement Exception or any other applicable United States securities law, the Code, or any other applicable United States governing statute or law .</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">SECTION 3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Stock Issuable</u>. The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 4,000,000 shares (the &#8220;Initial Limit&#8221;), subject to adjustment as provided in this Section 3. For purposes of this limitation, the shares of Stock underlying any awards under the Plan that are forfeited, canceled, held back upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) shall be added back to the shares of Stock available for issuance under the Plan. The shares available for issuance under the Plan may be authorized but unissued shares of Stock or shares of Stock reacquired by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Changes in Stock</u>. Subject to Section&nbsp;3(c) hereof, if, as a result of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change in the Company&#8217;s capital stock, the outstanding shares of Stock are increased or decreased or are exchanged for a different number or kind of shares or other securities of the Company, or additional shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such shares of Stock or other securities, or, if, as a result of any merger or consolidation, sale of all or substantially all of the assets of the Company, the outstanding shares of Stock are converted into or exchanged for securities of the Company or any successor entity (or a parent or subsidiary thereof), the Administrator shall make an appropriate or proportionate adjustment in (i) the maximum number of shares reserved for issuance under the Plan, (ii) the number and kind of shares or other securities subject to any then outstanding Awards under the Plan, (iii) the repurchase price, if any, per share subject to each outstanding Restricted Stock Award, and (iv)&nbsp;the exercise price for each share subject to any then outstanding Stock Options and Stock Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by the number of shares subject to Stock Options and Stock Appreciation Rights) as to which such Stock Options and Stock Appreciation Rights remain exercisable. The Administrator shall also make equitable or proportionate adjustments in the number of shares subject to outstanding Awards and the exercise price and the terms of outstanding Awards to take into consideration cash dividends paid other than in the ordinary course or any other extraordinary corporate event. The adjustment by the Administrator shall be final, binding and conclusive. No fractional shares of Stock shall be issued under the Plan resulting from any such adjustment, but the Administrator in its discretion may make a cash payment in lieu of fractional shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Mergers and Other Transactions</u>. In the case of and subject to the consummation of a Sale Event, the parties thereto may cause the assumption or continuation of Awards theretofore granted by the successor entity, or the substitution of such Awards with new Awards of the successor entity or parent thereof, with appropriate adjustment as to the number and kind of shares and, if appropriate, the per share exercise prices, as such parties shall agree. To the extent the parties to such Sale Event do not provide for the assumption, continuation or substitution of Awards, upon the effective time of the Sale Event, the Plan and all outstanding Awards granted hereunder shall terminate. In such case, except as may be otherwise provided in the relevant Award Certificate, all Options and Stock Appreciation Rights with time-based vesting conditions or restrictions that are not vested and/or exercisable immediately prior to the effective time of the Sale Event shall become fully vested and exercisable as of the effective time of the Sale Event, all other Awards with time-based vesting, conditions or restrictions shall become fully vested and nonforfeitable as of the effective time of the Sale Event, and all Awards with conditions and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in connection with a Sale Event in the Administrator&#8217;s discretion or to the extent specified in the relevant Award Certificate. In the event of such termination, (i) the Company shall have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding Options and Stock Appreciation Rights, in exchange for the cancellation thereof, in an amount equal to the difference between (A) the Sale Price multiplied by the number of shares of Stock subject to outstanding Options and Stock Appreciation Rights (to the extent then exercisable at prices not in excess of the Sale Price) and (B) the aggregate exercise price of all such outstanding Options and Stock Appreciation Rights (provided that, in the case of an Option or Stock Appreciation Right with an exercise price equal to or greater than the Sale Price, such Option or Stock Appreciation Right shall be cancelled for no consideration); or (ii) each grantee shall be permitted, within a specified period of time prior to the consummation of the Sale Event as determined by the Administrator, to exercise all outstanding Options and Stock Appreciation Rights (to the extent then exercisable) held by such grantee. The Company shall also have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding other Awards in an amount equal to the Sale Price multiplied by the number of vested shares of Stock under such Awards.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">SECTION 4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>ELIGIBILITY</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Grantees under the Plan will be such Eligible Employees as are selected from time to time by the Administrator in its sole discretion.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">SECTION 5.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>STOCK OPTIONS</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Stock Options granted pursuant to this Section&nbsp;5 shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Administrator shall deem desirable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Award of Stock Options</u>. The Administrator may grant Stock Options under the Plan. All Stock Options granted under the Plan shall be non-qualified stock options and are not intended to qualify as &#8220;incentive stock options&#8221; as defined in Section 422 of the Code.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise Price</u>. The exercise price per share for the Stock covered by a Stock Option granted pursuant to this Section&nbsp;5 shall be determined by the Administrator at the time of grant but shall not be less than 100 percent of the Fair Market Value on the date of grant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Option Term</u>. The term of each Stock Option shall be fixed by the Administrator, but no Stock Option shall be exercisable more than ten years after the date the Stock Option is granted.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercisability; Rights of a Stockholder</u>. Stock Options shall become exercisable at such time or times, whether or not in installments, as shall be determined by the Administrator at or after the grant date. The Administrator may at any time accelerate the exercisability of all or any portion of any Stock Option. An optionee shall have the rights of a stockholder only as to shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Method of Exercise</u>. Stock Options may be exercised in whole or in part, by giving written or electronic notice of exercise to the Company, specifying the number of shares to be purchased. Payment of the purchase price may be made by one or more of the following methods except to the extent otherwise provided in the Award Certificate:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;In cash, by certified or bank check or other instrument acceptable to the Administrator;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Through the delivery (or attestation to the ownership following such procedures as the Company may prescribe) of shares of Stock that are not then subject to restrictions under any Company plan. Such surrendered shares shall be valued at Fair Market Value on the exercise date;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;By the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price; provided that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Company shall prescribe as a condition of such payment procedure; or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;By a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Payment instruments will be received subject to collection. The transfer to the optionee on the records of the Company or of the transfer agent of the shares of Stock to be purchased pursuant to the exercise of a Stock Option will be contingent upon receipt from the optionee (or a purchaser acting in his stead in accordance with the provisions of the Stock Option) by the Company of the full purchase price for such shares and the fulfillment of any other requirements contained in the Award Certificate or applicable provisions of laws (including the satisfaction of any withholding taxes that the Company is obligated to withhold with respect to the optionee). In the event an optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the optionee upon the exercise of the Stock Option shall be net of the number of attested shares. In the event that the Company establishes, for itself or using the services of a third party, an automated system for the exercise of Stock Options, such as a system using an internet website or interactive voice response, then the paperless exercise of Stock Options may be permitted through the use of such an automated system.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">SECTION 6.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>STOCK APPRECIATION RIGHTS</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Award of Stock Appreciation Rights</u>. The Administrator may grant Stock Appreciation Rights under the Plan. A Stock Appreciation Right is an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Certificate) having a value equal to the excess of the Fair Market Value of a share of Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise Price of Stock Appreciation Rights</u>. The exercise price of a Stock Appreciation Right shall not be less than 100 percent of the Fair Market Value of the Stock on the date of grant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Grant and Exercise of Stock Appreciation Rights</u>. Stock Appreciation Rights may be granted by the Administrator independently of any Stock Option granted pursuant to Section&nbsp;5 of the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Terms and Conditions of Stock Appreciation Rights</u>. Stock Appreciation Rights shall be subject to such terms and conditions as shall be determined on the date of grant by the Administrator. The term of a Stock Appreciation Right may not exceed ten years. The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">SECTION 7.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>RESTRICTED STOCK AWARDS</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Nature of Restricted Stock Awards</u>. The Administrator may grant Restricted Stock Awards under the Plan. A Restricted Stock Award is any Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant. Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of pre-established performance goals and objectives.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Rights as a Stockholder</u>. Upon the grant of the Restricted Stock Award and payment of any applicable purchase price, a grantee shall have the rights of a stockholder with respect to the voting of the Restricted Shares and receipt of dividends; provided that if the lapse of restrictions with respect to the Restricted Stock Award is tied to the attainment of performance goals, any dividends paid by the Company during the performance period shall accrue and shall not be paid to the grantee until and to the extent the performance goals are met with respect to the Restricted Stock Award. Unless the Administrator shall otherwise determine, (i) uncertificated Restricted Shares shall be accompanied by a notation on the records of the Company or the transfer agent to the effect that they are subject to forfeiture until such Restricted Shares are vested as provided in Section 7(d) below, and (ii) certificated Restricted Shares shall remain in the possession of the Company until such Restricted Shares are vested as provided in Section&nbsp;7(d) below, and the grantee shall be required, as a condition of the grant, to deliver to the Company such instruments of transfer as the Administrator may prescribe.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Restrictions</u>. Restricted Shares may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as specifically provided herein or in the Restricted Stock Award Certificate. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 16 below, in writing after the Award is issued, if a grantee&#8217;s employment (or other Service Relationship) with the Company and its Subsidiaries terminates for any reason, any Restricted Shares that have not vested at the time of termination shall automatically and without any requirement of notice to such grantee from or other action by or on behalf of, the Company be deemed to have been reacquired by the Company at its original purchase price (if any) from such grantee or such grantee&#8217;s legal representative simultaneously with such termination of employment (or other Service Relationship), and thereafter shall cease to represent any ownership of the Company by the grantee or rights of the grantee as a stockholder. Following such deemed reacquisition of Restricted Shares that are represented by physical certificates, a grantee shall surrender such certificates to the Company upon request without consideration.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Vesting of Restricted Shares</u>. The Administrator at the time of grant shall specify the date or dates and/or the attainment of pre-established performance goals, objectives and other conditions on which the non-transferability of the Restricted Shares and the Company&#8217;s right of repurchase or forfeiture shall lapse. Subsequent to such date or dates and/or the attainment of such pre-established performance goals, objectives and other conditions, the shares on which all restrictions have lapsed shall no longer be Restricted Shares and shall be deemed &#8220;vested.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">SECTION 8.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>RESTRICTED STOCK UNITS</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Nature of Restricted Stock Units</u>. The Administrator may grant Restricted Stock Units under the Plan. A Restricted Stock Unit is an Award of stock units that may be settled in shares of Stock (or cash, to the extent explicitly provided for in the Award Certificate) upon the satisfaction of such restrictions and conditions at the time of grant. Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of pre-established performance goals and objectives. The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees. Except in the case of Restricted Stock Units with a deferred settlement date that complies with Section 409A, at the end of the vesting period, the Restricted Stock Units, to the extent vested, shall be settled in the form of shares of Stock. Restricted Stock Units with deferred settlement dates are subject to Section 409A and shall contain such additional terms and conditions as the Administrator shall determine in its sole discretion in order to comply with the requirements of Section 409A.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>[Reserved].</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Rights as a Stockholder</u>. A grantee shall have the rights as a stockholder only as to shares of Stock acquired by the grantee upon settlement of Restricted Stock Units; provided, however, that the grantee may be credited with Dividend Equivalent Rights with respect to the stock units underlying his Restricted Stock Units, subject to the provisions of Section 11 and such terms and conditions as the Administrator may determine.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination</u>. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section&nbsp;16 below, in writing after the Award is issued, a grantee&#8217;s right in all Restricted Stock Units that have not vested shall automatically terminate upon the grantee&#8217;s termination of employment (or cessation of Service Relationship) with the Company and its Subsidiaries for any reason.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">SECTION 9.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>UNRESTRICTED STOCK AWARDS</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><u>Grant or Sale of Unrestricted Stock</u>. The Administrator may grant (or sell at par value or such higher purchase price determined by the Administrator) an Unrestricted Stock Award under the Plan. An Unrestricted Stock Award is an Award pursuant to which the grantee may receive shares of Stock free of any restrictions under the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">SECTION 10.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>[RESERVED]</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">SECTION 11.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>DIVIDEND EQUIVALENT RIGHTS</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Dividend Equivalent Rights</u>. The Administrator may grant Dividend Equivalent Rights under the Plan. A Dividend Equivalent Right is an Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other Award to which it relates) if such shares had been issued to the grantee. A Dividend Equivalent Right may be granted hereunder to any grantee as a component of an award of Restricted Stock Units or as a freestanding award. The terms and conditions of Dividend Equivalent Rights shall be specified in the Award Certificate. Dividend equivalents credited to the holder of a Dividend Equivalent Right may be paid currently or may be deemed to be reinvested in additional shares of Stock, which may thereafter accrue additional equivalents. Any such reinvestment shall be at Fair Market Value on the date of reinvestment or such other price as may then apply under a dividend reinvestment plan sponsored by the Company, if any. Dividend Equivalent Rights may be settled in cash or shares of Stock or a combination thereof, in a single installment or installments. A Dividend Equivalent Right granted as a component of an Award of Restricted Stock Units shall provide that such Dividend Equivalent Right shall be settled only upon settlement or payment of, or lapse of restrictions on, such other Award, and that such Dividend Equivalent Right shall expire or be forfeited or annulled under the same conditions as such other Award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination</u>. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section&nbsp;16 below, in writing after the Award is issued, a grantee&#8217;s rights in all Dividend Equivalent Rights shall automatically terminate upon the grantee&#8217;s termination of employment (or cessation of Service Relationship) with the Company and its Subsidiaries for any reason.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">SECTION 12.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>TRANSFERABILITY OF AWARDS</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transferability</u>. Except as provided in Section&nbsp;12(b) below, during a grantee&#8217;s lifetime, his or her Awards shall be exercisable only by the grantee, or by the grantee&#8217;s legal representative or guardian in the event of the grantee&#8217;s incapacity. No Awards shall be sold, assigned, transferred or otherwise encumbered or disposed of by a grantee other than by will or by the laws of descent and distribution or pursuant to a domestic relations order. No Awards shall be subject, in whole or in part, to attachment, execution, or levy of any kind, and any purported transfer in violation hereof shall be null and void.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Administrator Action</u>. Notwithstanding Section&nbsp;12(a), the Administrator, in its discretion, may provide either in the Award Certificate regarding a given Award or by subsequent written approval that the grantee (who is an employee) may transfer his or her Stock Options to his or her immediate family members, to trusts for the benefit of such family members, or to partnerships in which such family members are the only partners, provided that the transferee agrees in writing with the Company to be bound by all of the terms and conditions of this Plan and the applicable Award. In no event may an Award be transferred by a grantee for value.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Family Member</u>. For purposes of Section&nbsp;12(b), &#8220;family member&#8221; shall mean a grantee&#8217;s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the grantee&#8217;s household (other than a tenant of the grantee), a trust in which these persons (or the grantee) have more than 50 percent of the beneficial interest, a foundation in which these persons (or the grantee) control the management of assets, and any other entity in which these persons (or the grantee) own more than 50 percent of the voting interests.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Designation of Beneficiary</u>. To the extent permitted by the Company, each grantee to whom an Award has been made under the Plan may designate a beneficiary or beneficiaries to exercise any Award or receive any payment under any Award payable on or after the grantee&#8217;s death. Any such designation shall be on a form provided for that purpose by the Administrator and shall not be effective until received by the Administrator. If no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee&#8217;s estate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">SECTION 13.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>TAX WITHHOLDING</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Payment by Grantee</u>. Each grantee shall, no later than the date as of which the value of an Award or of any Stock or other amounts received thereunder first becomes includable in the gross income of the grantee for Federal income tax purposes, pay to the Company, or make arrangements satisfactory to the Administrator regarding payment of, any Federal, state, or local taxes of any kind required by law to be withheld by the Company with respect to such income. The Company and its Subsidiaries shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the grantee. The Company&#8217;s obligation to deliver evidence of book entry (or stock certificates) to any grantee is subject to and conditioned on tax withholding obligations being satisfied by the grantee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Payment in Stock</u>. The Administrator may require the Company&#8217;s tax withholding obligation to be satisfied, in whole or in part, by the Company withholding from shares of Stock to be issued pursuant to any Award a number of shares with an aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the withholding amount due; provided, however, that the amount withheld does not exceed the maximum statutory tax rate or such lesser amount as is necessary to avoid liability accounting treatment. For purposes of share withholding, the Fair Market Value of withheld shares shall be determined in the same manner as the value of Stock includible in income of the grantees. The Administrator may also require the Company&#8217;s tax withholding obligation to be satisfied, in whole or in part, by an arrangement whereby a certain number of shares of Stock issued pursuant to any Award are immediately sold and proceeds from such sale are remitted to the Company in an amount that would satisfy the withholding amount due.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">SECTION 14.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>SECTION 409A AWARDS</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Awards are intended to be exempt from Section 409A to the greatest extent possible and to otherwise comply with Section 409A. The Plan and all Awards shall be interpreted in accordance with such intent. To the extent that any Award is determined to constitute &#8220;nonqualified deferred compensation&#8221; within the meaning of Section 409A (a &#8220;409A Award&#8221;), the Award shall be subject to such additional rules and requirements as specified by the Administrator from time to time in order to comply with Section 409A. In this regard, if any amount under a 409A Award is payable upon a &#8220;separation from service&#8221; (within the meaning of Section 409A) to a grantee who is then considered a &#8220;specified employee&#8221; (within the meaning of Section 409A), then no such payment shall be made prior to the date that is the earlier of (i) six months and one day after the grantee&#8217;s separation from service, or (ii) the grantee&#8217;s death, but only to the extent such delay is necessary to prevent such payment from being subject to interest, penalties and/or additional tax imposed pursuant to Section 409A. Further, the settlement of any 409A Award may not be accelerated except to the extent permitted by Section 409A.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">SECTION 15.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>TERMINATION OF SERVICE RELATIONSHIP, TRANSFER, LEAVE OF ABSENCE, ETC.</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination of Service Relationship</u>. If the grantee&#8217;s Service Relationship is with an Affiliate and such Affiliate ceases to be an Affiliate, the grantee shall be deemed to have terminated his or her Service Relationship for purposes of the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of the Plan, the following events shall not be deemed a termination of a Service Relationship:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;a transfer to the employment of the Company from an Affiliate or from the Company to an Affiliate, or from one Affiliate to another; or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the employee&#8217;s right to re-employment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise so provides in writing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">SECTION 16.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>AMENDMENTS AND TERMINATION</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Board may, at any time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Award for the purpose of satisfying changes in law or for any other lawful purpose, but no such action shall materially and adversely affect rights under any outstanding Award without the holder&#8217;s consent. Except as provided in Section 3(b) or 3(c), without prior stockholder approval, in no event may the Administrator exercise its discretion to reduce the exercise price of outstanding Options or Stock Appreciation Rights or effect repricing through cancellation and re-grants or cancellation of Options or Stock Appreciation Rights in exchange for other Awards. . Nothing in this Section&nbsp;16 shall limit the Administrator&#8217;s authority to take any action permitted pursuant to Section&nbsp;3(b) or 3(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">SECTION 17.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>STATUS OF PLAN</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">With respect to the portion of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by a grantee, a grantee shall have no rights greater than those of a general creditor of the Company unless the Administrator shall otherwise expressly determine in connection with any Award or Awards. In its sole discretion, the Administrator may authorize the creation of trusts or other arrangements to meet the Company&#8217;s obligations to deliver Stock or make payments with respect to Awards hereunder, provided that the existence of such trusts or other arrangements is consistent with the foregoing sentence.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">SECTION 18.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>GENERAL PROVISIONS</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Distribution</u>. The Administrator may require each person acquiring Stock pursuant to an Award to represent to and agree with the Company in writing that such person is acquiring the shares without a view to distribution thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Issuance of Stock</u>. To the extent certificated, stock certificates to grantees under this Plan shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the grantee, at the grantee&#8217;s last known address on file with the Company. Uncertificated Stock shall be deemed delivered for all purposes when the Company or a Stock transfer agent of the Company shall have given to the grantee by electronic mail (with proof of receipt) or by United States mail, addressed to the grantee, at the grantee&#8217;s last known address on file with the Company, notice of issuance and recorded the issuance in its records (which may include electronic &#8220;book entry&#8221; records). Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any evidence of book entry or certificates evidencing shares of Stock pursuant to the exercise or settlement of any Award, unless and until the Administrator has determined, with advice of counsel (to the extent the Administrator deems such advice necessary or advisable), that the issuance and delivery is in compliance with all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any exchange on which the shares of Stock are listed, quoted or traded. Any Stock issued pursuant to the Plan shall be subject to any stop-transfer orders and other restrictions as the Administrator deems necessary or advisable to comply with federal, state or foreign jurisdiction, securities or other laws, rules and quotation system on which the Stock is listed, quoted or traded. The Administrator may place legends on any Stock certificate or notations on any book entry to reference restrictions applicable to the Stock. In addition to the terms and conditions provided herein, the Administrator may require that an individual make such reasonable covenants, agreements, and representations as the Administrator, in its discretion, deems necessary or advisable in order to comply with any such laws, regulations, or requirements. The Administrator shall have the right to require any individual to comply with any timing or other restrictions with respect to the settlement or exercise of any Award, including a window-period limitation, as may be imposed in the discretion of the Administrator.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Stockholder Rights</u>. Until Stock is deemed delivered in accordance with Section 18(b), no right to vote or receive dividends or any other rights of a stockholder will exist with respect to shares of Stock to be issued in connection with an Award, notwithstanding the exercise of a Stock Option or any other action by the grantee with respect to an Award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Other Compensation Arrangements; No Employment Rights</u>. Nothing contained in this Plan shall prevent the Board from adopting other or additional compensation arrangements, including trusts, and such arrangements may be either generally applicable or applicable only in specific cases. The adoption of this Plan and the grant of Awards do not confer upon any employee any right to continued employment with the Company or any Subsidiary.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Trading Policy Restrictions</u>. Option exercises and other Awards under the Plan shall be subject to the Company&#8217;s insider trading policies and procedures, as in effect from time to time.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Clawback Policy</u>. Awards under the Plan shall be subject to the Company&#8217;s clawback policy, as in effect from time to time.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">SECTION 19.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>EFFECTIVE DATE OF PLAN</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This Plan shall become effective immediately upon approval by the Board.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 81pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">SECTION 20.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><u>GOVERNING LAW</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This Plan and all Awards and actions taken thereunder shall be governed by, and construed in accordance with, the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, applied without regard to conflict of law principles.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">14</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DATE APPROVED BY BOARD OF DIRECTORS: December 18, 2025</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">15</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>3
<FILENAME>ex_923541.htm
<DESCRIPTION>EXHIBIT 10.17
<TEXT>
<html><head>
	<title>ex_923541.htm</title>
	<!-- Generated by ThunderDome Portal - 2/22/2026 4:52:17 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.17</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>COMPASS THERAPEUTICS, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>EMPLOYMENT AGREEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This Employment Agreement (&#8220;Agreement&#8221;), dated as of January 1, 2026, is made between Compass Therapeutics, Inc., a Delaware corporation (including all wholly owned subsidiaries of Compass Therapeutics, Inc., the &#8220;Company&#8221;), and Arjun Prasad (the &#8220;Executive&#8221;). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation any offer letter, employment agreement or severance agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and conditions contained herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">NOW, THEREFORE,<i> </i>in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;<u>Employment</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Term</u>. The Company shall employ the Executive and the Executive shall be employed by the Company pursuant to this Agreement until such employment is terminated in accordance with the provisions hereof (the &#8220;Term&#8221;). The Executive&#8217;s employment with the Company will be &#8220;at will,&#8221; meaning that the Executive&#8217;s employment may be terminated by the Company or the Executive at any time and for any reason subject to the terms of this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Position and Duties</u>. The Executive shall serve as the Chief Commercial Officer of the Company, reporting to the Chief Executive Officer (&#8220;CEO&#8221;), and shall have such powers and duties as may from time to time be prescribed by the CEO or other duly authorized executive. The Executive shall devote the Executive&#8217;s full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Board of Directors of the Company (the &#8220;Board&#8221;), or engage in religious, charitable or other community activities as long as such services and activities are disclosed to the Board and do not interfere with the Executive&#8217;s performance of the Executive&#8217;s<b> </b>duties to the Company. To the extent applicable, the Executive shall be deemed to have resigned from all officer and board member positions that the Executive holds with the Company or any officer and board member positions of its respective subsidiaries and affiliates upon the termination of the Executive&#8217;s employment for any reason. The Executive shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;<u>Compensation and Related Matters</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Base Salary</u>. The Executive&#8217;s initial base salary shall be paid at the rate of $475,000 per year. The Executive&#8217;s base salary shall be subject to periodic review by<b> </b>the Board or the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;). The base salary in effect at any given time is referred to herein as &#8220;Base Salary.&#8221; The Base Salary shall be payable in a manner that is consistent with the Company&#8217;s usual payroll practices for executive officers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Incentive Compensation</u>. The Executive shall be eligible to receive cash incentive compensation as determined by the Board or the Compensation Committee from time to time. The Executive&#8217;s target annual incentive compensation shall be 45% of the Executive&#8217;s Base Salary. The target annual incentive compensation in effect at any given time is referred to herein as &#8220;Target Bonus.&#8221; The actual amount of the Executive&#8217;s annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee (to the extent it has the authority to do so), subject to the terms of any applicable incentive compensation plan that may be in effect from time to time. Except as provided in Sections 5 and 6 with respect to severance benefits, to earn incentive compensation, the Executive must be employed by the Company on the day such incentive compensation is paid.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Sign-On Incentives</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Bonus</u>. The Executive shall be entitled to receive a sign-on bonus of $50,000 (&#8220;Sign-On Bonus&#8221;), which shall be paid in the second pay period following the Executive&#8217;s first date of employment with the Company (&#8220;Start Date&#8221;) and is subject to all applicable taxes and withholdings. To earn the Sign-On Bonus, Executive must be employed by Company on the day the bonus is to be paid. If Executive resigns from the Company or is terminated for cause under Section 3(c) of this Agreement within six (6) months of the Start Date, Executive agrees to and shall repay the Sign-On Bonus to Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<u>Stock Options</u>. Subject to the approval of the Compensation Committee in its discretion, as soon as reasonably practicable following the Start Date, Company will grant to Executive stock options (the &#8220;Option&#8221;) for the purchase of an aggregate of 1,000,000 shares of common stock of the Company at a price per share equal to the closing sale price of the common stock on the NASDAQ Market on the date of grant. The Option shall be granted pursuant to and in accordance with the Company&#8217;s 2025 Inducement Plan (&#8220;2025 Plan&#8221;) or otherwise structured as an inducement award, and shall be subject to all terms, vesting schedules and other provisions set forth in a separate option agreement. The Option will have a term of ten (10) years, except as otherwise set forth in the stock option agreement, and be subject to a vesting schedule of four (4)&nbsp;years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining shares vesting equally each month over the following thirty-six (36) months. The&nbsp;Option will be, to the maximum extent permissible under applicable law, deemed an inducement award under NASDAQ Listing Rule 5635(c)(4).&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Expenses</u>. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its executive officers.</p>

<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="2" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="2" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Other Benefits</u>. The Executive shall be eligible to participate in or receive benefits under the Company&#8217;s employee benefit plans in effect from time to time, subject to the terms of such plans.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Paid Time Off</u>. The Executive shall be entitled to take paid time off in accordance with the Company&#8217;s applicable paid time off policy for executives, as may be in effect from time to time.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Equity</u>. The equity awards held by or awarded to the Executive, including those specified herein, shall be governed by the terms and conditions of the Company&#8217;s applicable equity incentive plan(s) and the applicable award agreement(s) governing the terms of such equity awards held by the Executive (collectively, the &#8220;Equity Documents&#8221;); provided, however, and notwithstanding anything to the contrary in the Equity Documents, Section 6(a)(ii) of this Agreement shall apply in the event of a termination by the Company without Cause or by the Executive for Good Reason in either event within the Change in Control Period (as such terms are defined below).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination</u>. The Executive&#8217;s employment hereunder may be terminated without any breach of this Agreement under the following circumstances:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Death</u>. The Executive&#8217;s employment hereunder shall terminate upon death.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Disability</u>. The Company may terminate the Executive&#8217;s employment if the Executive is disabled and unable to perform or expected to be unable to perform the essential functions of the Executive&#8217;s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive&#8217;s then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executive&#8217;s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company&#8217;s determination of such issue shall be binding on the Executive. Nothing in this Section 3(b) shall be construed to waive the Executive&#8217;s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. &#167;2601 <i>et seq</i>. and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 <i>et seq.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination by Company for Cause</u>. The Company may terminate the Executive&#8217;s employment hereunder for Cause. For purposes of this Agreement, &#8220;<u>Cause</u>&#8221; shall mean any of the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:108pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;conduct by the Executive constituting a material act of misconduct in connection with the performance of the Executive&#8217;s duties, including, without limitation, (A) willful failure or refusal to perform material responsibilities that have been requested by the CEO; (B) dishonesty to the CEO with respect to any material matter; or (C) misappropriation of funds or property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and <i>de minimis</i> use of Company property for personal purposes;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:108pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the commission by the Executive of acts satisfying the elements of (A)&nbsp;any felony or (B)&nbsp;a misdemeanor involving moral turpitude, deceit, dishonesty or fraud;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:108pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;any misconduct by the Executive, regardless of whether or not in the course of the Executive&#8217;s employment, that would reasonably be expected to result in material injury or reputational harm to the Company or any of its subsidiaries or affiliates if the Executive were to continue to be employed in the same position;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:108pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;continued non-performance by the Executive of the Executive&#8217;s duties hereunder (other than by reason of the Executive&#8217;s physical or mental illness, incapacity or disability) which has continued for more than 30 days following written notice of such non-performance from the CEO;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:108pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;a breach by the Executive of any of the provisions contained in Section 8 of this Agreement or the Restrictive Covenants Agreement (as defined below);</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:108pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;a material violation by the Executive of any of the Company&#8217;s written employment policies; or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:108pt;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;the Executive&#8217;s failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination by the Company without Cause</u>. The Company may terminate the Executive&#8217;s employment hereunder at any time without Cause. Any termination by the Company of the Executive&#8217;s employment under this Agreement which does not constitute a termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under Section 3(a) or (b) shall be deemed a termination without Cause.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination by the Executive</u>. The Executive may terminate employment hereunder at any time for any reason, including but not limited to, Good Reason. For purposes of this Agreement, &#8220;<u>Good Reason</u>&#8221; shall mean that the Executive has completed all steps of the Good Reason Process (hereinafter defined) following the occurrence of any of the following events without the Executive&#8217;s consent (each, a &#8220;<u>Good Reason Condition</u>&#8221;):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;a material diminution in the Executive&#8217;s responsibilities, authority or duties;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;a material diminution in the Executive&#8217;s Base Salary except for across-the-board salary reductions similarly affecting all or substantially all senior management employees of the Company;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;a material change in the geographic location at which the Executive provides services to the Company, such that there is an increase of at least thirty (30) miles of driving distance to such location from the Executive&#8217;s principal residence as of such change; or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;a material breach of this Agreement by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The &#8220;<u>Good Reason Process</u>&#8221; consists of the following steps:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;the Executive reasonably determines in good faith that a Good Reason Condition has occurred;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the Executive notifies the Company in writing of the first occurrence of the Good Reason Condition within 60 days of the first occurrence of such condition;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the Executive cooperates in good faith with the Company&#8217;s efforts, for a period of not less than 30 days following such notice (the &#8220;<u>Cure Period</u>&#8221;), to remedy the Good Reason Condition;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;notwithstanding such efforts, the Good Reason Condition continues to exist; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;the Executive terminates employment within 60 days after the end of the Cure Period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If the Company cures the Good Reason Condition during the Cure Period, Good Reason shall be deemed not to have occurred.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If the Executive&#8217;s employment with the Company is terminated for any reason, the Company shall pay or provide to the Executive (or to the Executive&#8217;s<b> </b>authorized representative or estate) (i) any Base Salary earned through the Date of Termination; (ii) unpaid expense reimbursements (subject to, and in accordance with, Section 2(c) of this Agreement); and (iii) any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the &#8220;Accrued Obligations&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice and Date of Termination</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice of Termination</u>. Except for termination as specified in Section 3(a), any termination of the Executive&#8217;s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a &#8220;Notice of Termination&#8221; shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Date of Termination</u>. &#8220;Date of Termination&#8221; shall mean: (i) if the Executive&#8217;s employment is terminated by death, the date of death; (ii) if the Executive&#8217;s employment is terminated on account of disability under Section 3(b) or by the Company for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if the Executive&#8217;s employment is terminated by the Company without Cause under Section 3(d), the date on which a Notice of Termination is given or the date otherwise specified by the Company in the Notice of Termination; (iv) if the Executive&#8217;s employment is terminated by the Executive under Section 3(e) other than for Good Reason, fourteen (14) days after the date on which a Notice of Termination is given, and (v) if the Executive&#8217;s employment is terminated by the Executive under Section 3(e) for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;<u>Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason Outside the Change in Control Period</u>. Outside of the Change in Control Period (as defined below): If the Executive&#8217;s employment is terminated by the Company without Cause as provided in Section 3(d) or the Executive terminates employment for Good Reason as provided in Section 3(e), then, in addition to the<b> </b>Accrued Obligations, and subject to (i) the Executive signing a separation agreement and release in a form and manner satisfactory to the Company, which shall include, without limitation, a general release of claims against the Company and all related persons and entities, a reaffirmation of all of the Executive&#8217;s Continuing Obligations (as defined below<b>)</b>, and, and shall provide that if the Executive breaches any of the Continuing Obligations, all payments of the Severance Amount shall immediately cease (the &#8220;Separation Agreement and Release&#8221;), and (ii) the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven (7) business day revocation period:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay the Executive an amount equal to nine (9) months of Base Salary continuation (the &#8220;Severance Amount&#8221;); provided in the event the Executive is entitled to any payments pursuant to the Restrictive Covenants Agreement, the Severance Amount received in any calendar year will be reduced by the amount the Executive is paid in the same such calendar year pursuant to the Restrictive Covenants Agreement (the &#8220;Restrictive Covenants Agreement Setoff&#8221;);</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;subject to the Executive&#8217;s copayment of premium amounts at the applicable active employees&#8217; rate and the Executive&#8217;s proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;<u>COBRA</u>&#8221;), the Company shall pay to the group health plan provider, the COBRA provider or the Executive a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A) the end of the period during which the Severance Amount is paid; (B) the Executive&#8217;s eligibility for group medical plan benefits under any other employer&#8217;s group medical plan; or (C) the cessation of the Executive&#8217;s continuation rights under COBRA; provided, however, if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments shall be subject to tax-related deductions and withholdings and paid on the Company&#8217;s regular payroll dates; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;if the Date of Termination is in the first quarter of the calendar year, the Company shall pay the Executive any earned but as of yet unpaid annual bonus (as determined by the Board) from the prior calendar year&#8217;s performance, which portion the Company shall pay on or around the same time the Company pays other bonuses for that year&#8217;s performance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The amounts payable under Section 5, to the extent taxable, shall be paid out in substantially equal installments as salary continuation in accordance with the Company&#8217;s payroll practice, commencing within 60<b> </b>days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Severance Amount, to the extent it qualifies as &#8220;non-qualified deferred compensation&#8221; within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">6.&nbsp;&nbsp;&nbsp;&nbsp;<u>Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason within the Change in Control Period</u>. During the Change in Control Period (as defined below): The provisions of this Section 6 shall apply in lieu of, and expressly supersede, the provisions of Section 5 if (i) the Executive&#8217;s employment is terminated either (a) by the Company without Cause as provided in Section 3(d), or (b) by the Executive for Good Reason as provided in Section 3, <i><u>and</u></i> (ii) the Date of Termination is within 12 months after the occurrence of the first event constituting a Change in Control (such period, the &#8220;Change in Control Period&#8221;). These provisions shall terminate and be of no further force or effect after a Change in Control Period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;If the Executive&#8217;s employment is terminated by the Company without Cause as provided in Section 3(d) or the Executive terminates employment for Good Reason as provided in Section 3(e) and in each case the Date of Termination occurs during the Change in Control Period, then, in addition to the Accrued Obligations, and subject to the signing of the Separation Agreement and Release by the Executive and the Separation Agreement and Release becoming fully effective, all within the time frame set forth in the Separation Agreement and Release but in no event more than 60 days after the Date of Termination:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay the Executive a lump sum in cash in an amount equal to<b> </b>(A) twelve (12) months of the Executive&#8217;s Base Salary and Target Bonus plus (B) the Executive&#8217;s Target Bonus for the year of the Date of Termination prorated for the amount of time employed in that year prior to the Date of Termination plus (C) if the if the Date of Termination is in the first quarter of the calendar year, the Company shall pay the Executive any earned but as of yet unpaid annual bonus (as determined by the Board) from the prior calendar year&#8217;s performance ((A), (B), and (C) together, the &#8220;Change in Control Payment&#8221;); provided the Change in Control Payment shall be reduced by the amount of the Restrictive Covenants Agreement Setoff, if applicable; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;notwithstanding anything to the contrary in any applicable option agreement or other stock-based award agreement, all time-based stock options and other stock-based awards subject to time-based vesting held by the Executive (the &#8220;Time-Based Equity Awards&#8221;) shall immediately accelerate and become fully exercisable or nonforfeitable as of the later of (i) the Date of Termination or (ii) the effective date of the Separation Agreement and Release (the &#8220;Accelerated Vesting Date,&#8221; and such acceleration, the &#8220;Acceleration&#8221;); <i>provided</i> that any termination or forfeiture of the unvested portion of such Time-Based Equity Awards that would otherwise occur on the Date of Termination in the absence of this Agreement will be delayed until the effective date of the Separation Agreement and Release and will only occur if the vesting pursuant to this subsection does not occur due to the absence of the Separation Agreement and Release becoming fully effective within the time period set forth therein. Notwithstanding the foregoing, no additional vesting of the Time-Based Equity Awards shall occur during the period between the Executive&#8217;s Date of Termination and the Accelerated Vesting Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;subject to the Executive&#8217;s copayment of premium amounts at the applicable active employees&#8217; rate and the Executive&#8217;s proper election to receive benefits under COBRA, the Company shall pay to the group health plan provider, the COBRA provider or the Executive a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A) the 12-month anniversary of the Date of Termination; (B) the Executive&#8217;s eligibility for group medical plan benefits under any other employer&#8217;s group medical plan; or (C) the cessation of the Executive&#8217;s continuation rights under COBRA; provided, however, if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments shall be subject to tax-related deductions and withholdings and paid on the Company&#8217;s regular payroll dates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The amounts payable under this Section 6(a), to the extent taxable, shall be paid or commence to be paid within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payments to the extent they qualify as &#8220;non-qualified deferred compensation&#8221; within the meaning of Section 409A of the Code, shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Additional Limitation</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Code, and the applicable regulations thereunder (the &#8220;Aggregate Payments&#8221;), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. &#167;1.280G-1, Q&amp;A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. &#167;1.280G-1, Q&amp;A-24(b) or (c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Section 6(b), the &#8220;After Tax Amount&#8221; means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive&#8217;s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section 6(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the &#8220;Accounting Firm&#8221;), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Executive.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>. For purposes of this Section 6, the following terms shall have the following meanings:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#8220;Change in Control&#8221; shall mean any of the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;any &#8220;person,&#8221; as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Act&#8221;) (other than the Company, any of its subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of the Company or any of its subsidiaries), together with all &#8220;affiliates&#8221; and &#8220;associates&#8221; (as such terms are defined in Rule 12b-2 under the Act) of such person, shall become the &#8220;beneficial owner&#8221; (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the Company representing fifty (50) percent or more of the combined voting power of the Company&#8217;s then outstanding securities having the right to vote in an election of the Board (&#8220;Voting Securities&#8221;) (in such case other than as a result of an acquisition of securities directly from the Company); or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the date a majority of the members of the Board is replaced during any 12-month period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment or election; or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the consummation of (A) any consolidation or merger of the Company where the stockholders of the Company, immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, shares representing in the aggregate more than fifty (50) percent of the voting shares of the Company issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or (B) any sale or other transfer (in one transaction or a series of transactions contemplated or arranged by any party as a single plan) of all or substantially all of the assets of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Notwithstanding the foregoing, a &#8220;Change in Control&#8221; shall not be deemed to have occurred for purposes of the foregoing clause (i) solely as the result of an acquisition of securities by the Company which, by reducing the number of shares of Voting Securities outstanding, increases the proportionate number of Voting Securities beneficially owned by any person to fifty (50) percent or more of the combined voting power of all of the then outstanding Voting Securities; provided, however, that if any person referred to in this sentence shall thereafter become the beneficial owner of any additional shares of Voting Securities (other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from the Company) and immediately thereafter beneficially owns fifty (50) percent or more of the combined voting power of all of the then outstanding Voting Securities, then a &#8220;Change in Control&#8221; shall be deemed to have occurred for purposes of the foregoing clause (i).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">7.&nbsp;&nbsp;&nbsp;&nbsp;<u>Section 409A</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive&#8217;s separation from service within the meaning of Section 409A of the Code, the Company determines that the Executive is a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement or otherwise on account of the Executive&#8217;s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executive&#8217;s separation from service, or (B) the Executive&#8217;s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;To the extent that any payment or benefit described in this Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive&#8217;s termination of employment, then such payments or benefits shall be payable only upon the Executive&#8217;s &#8220;separation from service.&#8221; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A&#8209;1(h).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement or the Restrictive Covenants Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A&#8209;2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">8.&nbsp;&nbsp;&nbsp;&nbsp;<u>Continuing Obligations</u>.<u> </u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Restrictive Covenants Agreement</u>. The terms of the Invention, Non-Competition and Non-Disclosure Agreement, dated January 1, 2025 (the &#8220;Restrictive Covenants Agreement&#8221;), between the Company and the Executive, attached hereto as <u>Exhibit A</u>, continue to be in full force and effect. For purposes of this Agreement, the obligations in this Section 8 and those that arise in the Restrictive Covenants Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#8220;Continuing Obligations.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Third-Party Agreements and Rights</u>. The Executive hereby confirms that the Executive is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Executive&#8217;s use or disclosure of information, other than confidentiality restrictions (if any), or the Executive&#8217;s engagement in any business. The Executive represents to the Company that the Executive&#8217;s execution of this Agreement, the Executive&#8217;s employment with the Company and the performance of the Executive&#8217;s proposed duties for the Company will not violate any obligations the Executive may have to any such previous employer or other party. In the Executive&#8217;s work for the Company, the Executive will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Litigation and Regulatory Cooperation</u>. During and after the Executive&#8217;s employment, the Executive shall cooperate fully with the Company in (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed by the Company, and (ii) the investigation, whether internal or external, of any matters about which the Company believes the Executive may have knowledge or information. The Executive&#8217;s full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after the Executive&#8217;s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable out&#8209;of&#8209;pocket expenses incurred in connection with the Executive&#8217;s performance of obligations pursuant to this Section 8(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Relief</u>. The Executive agrees that it would be difficult to measure any damages caused to the Company which might result from any breach by the Executive of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, the Executive agrees that if the Executive breaches, or proposes to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Protected Disclosures and Other Protected Action</u>. Nothing in this Agreement shall be interpreted or applied to prohibit the Executive from making any good faith report to any governmental agency or other governmental entity (a &#8220;Government Agency&#8221;) concerning any act or omission that the Executive reasonably believes constitutes a possible violation of federal or state law or making other disclosures that are protected under the anti-retaliation or whistleblower provisions of applicable federal or state law or regulation. In addition, nothing contained in this Agreement limits the Executive&#8217;s ability to communicate with any Government Agency or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including the Executive&#8217;s ability to provide documents or other information, without notice to the Company. In addition, for the avoidance of doubt, pursuant to the federal Defend Trade Secrets Act of 2016, the Executive shall not be held criminally or civilly liable under any federal or state trade secret law or under this Agreement or the Restrictive Covenants Agreement for the disclosure of a trade secret that (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">9.&nbsp;&nbsp;&nbsp;&nbsp;<u>Consent to Jurisdiction</u>. The parties hereby consent to the jurisdiction of the state and federal courts of the Commonwealth of Massachusetts. Accordingly, with respect to any such court action, the Executive (a) submits to the exclusive personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">10.&nbsp;&nbsp;&nbsp;&nbsp;<u>Waiver of Jury Trial</u>. Each of the Executive and the Company irrevocably and unconditionally WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE EXECUTIVE&#8217;S EMPLOYMENT BY THE COMPANY OR ANY AFFILIATE OF THE COMPANY, INCLUDING WITHOUT LIMITATION THE EXECUTIVE&#8217;S OR THE COMPANY&#8217;S PERFORMANCE UNDER, OR THE ENFORCEMENT OF, THIS AGREEMENT.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">11.&nbsp;&nbsp;&nbsp;&nbsp;<u>Integration</u>. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter, provided that the Restrictive Covenants Agreement and the Equity Documents remain in full force and effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">12.&nbsp;&nbsp;&nbsp;&nbsp;<u>Withholding; Tax Effect</u>. All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the Executive for any adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">13.&nbsp;&nbsp;&nbsp;&nbsp;<u>Assignment</u>. Neither the Executive nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement (including the Restrictive Covenants Agreement) without the Executive&#8217;s consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further that if the Executive remains employed or becomes employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then the Executive shall not be entitled to any payments, benefits or vesting pursuant to Section 5 or pursuant to Section 6 of this Agreement. This Agreement shall inure to the benefit of and be binding upon the Executive and the Company, and each of the Executive&#8217;s and the Company&#8217;s respective successors, executors, administrators, heirs and permitted assigns.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">14.&nbsp;&nbsp;&nbsp;&nbsp;<u>Enforceability</u>. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">15.&nbsp;&nbsp;&nbsp;&nbsp;<u>Survival</u>. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the Executive&#8217;s employment to the extent necessary to effectuate the terms contained herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">16.&nbsp;&nbsp;&nbsp;&nbsp;<u>Waiver</u>. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">17.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">18.&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendment</u>. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">19.&nbsp;&nbsp;&nbsp;&nbsp;<u>Effect on Other Plans and Agreements</u>. An election by the Executive to resign for Good Reason under the provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions of any of the Company's benefit plans, programs or policies. Nothing in this Agreement shall be construed to limit the rights of the Executive under the Company&#8217;s benefit plans, programs or policies except as otherwise provided in Section 8 hereof, and except that the Executive shall have no rights to any severance benefits under any Company severance pay plan, offer letter or otherwise. Except for the Restrictive Covenants Agreement, in the event that the Executive is party to an agreement with the Company providing for payments or benefits under such plan or agreement and under this Agreement, the terms of this Agreement shall govern and the Executive may receive payment under this Agreement only and not both. Further, Section 5 and Section 6 of this Agreement are mutually exclusive and in no event shall the Executive be entitled to payments or benefits pursuant to both Section 5 and Section 6 of this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">20.&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law</u>. This is a Massachusetts contract and shall be construed under and be governed in all respects by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles thereof. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the First Circuit.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">21.&nbsp;&nbsp;&nbsp;&nbsp;<u>Counterparts</u>. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: middle; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>COMPASS THERAPEUTICS, INC.</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: middle; width: 5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: middle; width: 5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="vertical-align: bottom; width: 45%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 5%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="vertical-align: middle; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Thomas Schuetz</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: middle; width: 5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="vertical-align: middle; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Executive Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 5%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 5%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 5%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="vertical-align: middle; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>EXECUTIVE</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: middle; width: 5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: middle; width: 5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: middle; width: 5%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="vertical-align: middle; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Arjun Prasad</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 234pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: center;"><b><u>Exhibit A</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Restrictive Covenants Agreement</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(i.e., Invention, Non-Competition and Non-Disclosure Agreement)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>4
<FILENAME>ex_923542.htm
<DESCRIPTION>EXHIBIT 10.18
<TEXT>
<html><head>
	<title>ex_923542.htm</title>
	<!-- Generated by ThunderDome Portal - 2/22/2026 4:58:55 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.18</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>COMPASS THERAPEUTICS, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>EMPLOYMENT AGREEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This Employment Agreement (&#8220;Agreement&#8221;), dated as of January 1, 2026, is made between Compass Therapeutics, Inc., a Delaware corporation (including all wholly owned subsidiaries of Compass Therapeutics, Inc., the &#8220;Company&#8221;), and Cynthia Sirard (the &#8220;Executive&#8221;). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation any offer letter, employment agreement or severance agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and conditions contained herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">NOW, THEREFORE,<i> </i>in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;<u>Employment</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Term</u>. The Company shall employ the Executive and the Executive shall be employed by the Company pursuant to this Agreement until such employment is terminated in accordance with the provisions hereof (the &#8220;Term&#8221;). The Executive&#8217;s employment with the Company will be &#8220;at will,&#8221; meaning that the Executive&#8217;s employment may be terminated by the Company or the Executive at any time and for any reason subject to the terms of this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Position and Duties</u>. The Executive shall serve as the Chief Medical Officer of the Company, reporting to the Chief Executive Officer (&#8220;CEO&#8221;), and shall have such powers and duties as may from time to time be prescribed by the CEO or other duly authorized executive. The Executive shall devote the Executive&#8217;s full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Board of Directors of the Company (the &#8220;Board&#8221;), or engage in religious, charitable or other community activities as long as such services and activities are disclosed to the Board and do not interfere with the Executive&#8217;s performance of the Executive&#8217;s<b> </b>duties to the Company. To the extent applicable, the Executive shall be deemed to have resigned from all officer and board member positions that the Executive holds with the Company or any officer and board member positions of its respective subsidiaries and affiliates upon the termination of the Executive&#8217;s employment for any reason. The Executive shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;<u>Compensation and Related Matters</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Base Salary</u>. The Executive&#8217;s initial base salary shall be paid at the rate of $525,000 per year. The Executive&#8217;s base salary shall be subject to periodic review by<b> </b>the Board or the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;). The base salary in effect at any given time is referred to herein as &#8220;Base Salary.&#8221; The Base Salary shall be payable in a manner that is consistent with the Company&#8217;s usual payroll practices for executive officers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Incentive Compensation</u>. The Executive shall be eligible to receive cash incentive compensation as determined by the Board or the Compensation Committee from time to time. The Executive&#8217;s target annual incentive compensation shall be 45% of the Executive&#8217;s Base Salary. The target annual incentive compensation in effect at any given time is referred to herein as &#8220;Target Bonus.&#8221; The actual amount of the Executive&#8217;s annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee (to the extent it has the authority to do so), subject to the terms of any applicable incentive compensation plan that may be in effect from time to time. Except as provided in Sections 5 and 6 with respect to severance benefits, to earn incentive compensation, the Executive must be employed by the Company on the day such incentive compensation is paid.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Sign-On Stock Options</u>. Subject to the approval of the Compensation Committee in its discretion, as soon as reasonably practicable following the Start Date, Company will grant to Executive stock options (the &#8220;Option&#8221;) for the purchase of an aggregate of 1,000,000 shares of common stock of the Company at a price per share equal to the closing sale price of the common stock on the NASDAQ Market on the date of grant. The Option shall be granted pursuant to and in accordance with the Company&#8217;s 2025 Inducement Plan (&#8220;2025 Plan&#8221;) or otherwise structured as an inducement award, and shall be subject to all terms, vesting schedules and other provisions set forth in a separate option agreement. The Option will have a term of ten (10) years, except as otherwise set forth in the stock option agreement, and be subject to a vesting schedule of four (4)&nbsp;years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining shares vesting equally each month over the following thirty-six (36) months. The&nbsp;Option will be, to the maximum extent permissible under applicable law, deemed an inducement award under NASDAQ Listing Rule 5635(c)(4).&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Expenses</u>. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its executive officers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Other Benefits</u>. The Executive shall be eligible to participate in or receive benefits under the Company&#8217;s employee benefit plans in effect from time to time, subject to the terms of such plans.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Paid Time Off</u>. The Executive shall be entitled to take paid time off in accordance with the Company&#8217;s applicable paid time off policy for executives, as may be in effect from time to time.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Equity</u>. The equity awards held by or awarded to the Executive, including those specified herein, shall be governed by the terms and conditions of the Company&#8217;s applicable equity incentive plan(s) and the applicable award agreement(s) governing the terms of such equity awards held by the Executive (collectively, the &#8220;Equity Documents&#8221;); provided, however, and notwithstanding anything to the contrary in the Equity Documents, Section 6(a)(ii) of this Agreement shall apply in the event of a termination by the Company without Cause or by the Executive for Good Reason in either event within the Change in Control Period (as such terms are defined below).</p>

<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="2" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="2" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination</u>. The Executive&#8217;s employment hereunder may be terminated without any breach of this Agreement under the following circumstances:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Death</u>. The Executive&#8217;s employment hereunder shall terminate upon death.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Disability</u>. The Company may terminate the Executive&#8217;s employment if the Executive is disabled and unable to perform or expected to be unable to perform the essential functions of the Executive&#8217;s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive&#8217;s then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executive&#8217;s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company&#8217;s determination of such issue shall be binding on the Executive. Nothing in this Section 3(b) shall be construed to waive the Executive&#8217;s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. &#167;2601 <i>et seq</i>. and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 <i>et seq.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination by Company for Cause</u>. The Company may terminate the Executive&#8217;s employment hereunder for Cause. For purposes of this Agreement, &#8220;<u>Cause</u>&#8221; shall mean any of the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:108pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;conduct by the Executive constituting a material act of misconduct in connection with the performance of the Executive&#8217;s duties, including, without limitation, (A) willful failure or refusal to perform material responsibilities that have been requested by the CEO; (B) dishonesty to the CEO with respect to any material matter; or (C) misappropriation of funds or property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and <i>de minimis</i> use of Company property for personal purposes;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:108pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the commission by the Executive of acts satisfying the elements of (A)&nbsp;any felony or (B)&nbsp;a misdemeanor involving moral turpitude, deceit, dishonesty or fraud;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:108pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;any misconduct by the Executive, regardless of whether or not in the course of the Executive&#8217;s employment, that would reasonably be expected to result in material injury or reputational harm to the Company or any of its subsidiaries or affiliates if the Executive were to continue to be employed in the same position;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:108pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;continued non-performance by the Executive of the Executive&#8217;s duties hereunder (other than by reason of the Executive&#8217;s physical or mental illness, incapacity or disability) which has continued for more than 30 days following written notice of such non-performance from the CEO;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:108pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;a breach by the Executive of any of the provisions contained in Section 8 of this Agreement or the Restrictive Covenants Agreement (as defined below);</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:108pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;a material violation by the Executive of any of the Company&#8217;s written employment policies; or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:108pt;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;the Executive&#8217;s failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination by the Company without Cause</u>. The Company may terminate the Executive&#8217;s employment hereunder at any time without Cause. Any termination by the Company of the Executive&#8217;s employment under this Agreement which does not constitute a termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under Section 3(a) or (b) shall be deemed a termination without Cause.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination by the Executive</u>. The Executive may terminate employment hereunder at any time for any reason, including but not limited to, Good Reason. For purposes of this Agreement, &#8220;<u>Good Reason</u>&#8221; shall mean that the Executive has completed all steps of the Good Reason Process (hereinafter defined) following the occurrence of any of the following events without the Executive&#8217;s consent (each, a &#8220;<u>Good Reason Condition</u>&#8221;):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;a material diminution in the Executive&#8217;s responsibilities, authority or duties;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;a material diminution in the Executive&#8217;s Base Salary except for across-the-board salary reductions similarly affecting all or substantially all senior management employees of the Company;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;a material change in the geographic location at which the Executive provides services to the Company, such that there is an increase of at least thirty (30) miles of driving distance to such location from the Executive&#8217;s principal residence as of such change; or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;a material breach of this Agreement by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The &#8220;<u>Good Reason Process</u>&#8221; consists of the following steps:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;the Executive reasonably determines in good faith that a Good Reason Condition has occurred;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the Executive notifies the Company in writing of the first occurrence of the Good Reason Condition within 60 days of the first occurrence of such condition;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the Executive cooperates in good faith with the Company&#8217;s efforts, for a period of not less than 30 days following such notice (the &#8220;<u>Cure Period</u>&#8221;), to remedy the Good Reason Condition;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;notwithstanding such efforts, the Good Reason Condition continues to exist; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;the Executive terminates employment within 60 days after the end of the Cure Period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If the Company cures the Good Reason Condition during the Cure Period, Good Reason shall be deemed not to have occurred.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If the Executive&#8217;s employment with the Company is terminated for any reason, the Company shall pay or provide to the Executive (or to the Executive&#8217;s<b> </b>authorized representative or estate) (i) any Base Salary earned through the Date of Termination; (ii) unpaid expense reimbursements (subject to, and in accordance with, Section 2(c) of this Agreement); and (iii) any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the &#8220;Accrued Obligations&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice and Date of Termination</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice of Termination</u>. Except for termination as specified in Section 3(a), any termination of the Executive&#8217;s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a &#8220;Notice of Termination&#8221; shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Date of Termination</u>. &#8220;Date of Termination&#8221; shall mean: (i) if the Executive&#8217;s employment is terminated by death, the date of death; (ii) if the Executive&#8217;s employment is terminated on account of disability under Section 3(b) or by the Company for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if the Executive&#8217;s employment is terminated by the Company without Cause under Section 3(d), the date on which a Notice of Termination is given or the date otherwise specified by the Company in the Notice of Termination; (iv) if the Executive&#8217;s employment is terminated by the Executive under Section 3(e) other than for Good Reason, fourteen (14) days after the date on which a Notice of Termination is given, and (v) if the Executive&#8217;s employment is terminated by the Executive under Section 3(e) for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;<u>Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason Outside the Change in Control Period</u>. Outside of the Change in Control Period (as defined below): If the Executive&#8217;s employment is terminated by the Company without Cause as provided in Section 3(d) or the Executive terminates employment for Good Reason as provided in Section 3(e), then, in addition to the<b> </b>Accrued Obligations, and subject to (i) the Executive signing a separation agreement and release in a form and manner satisfactory to the Company, which shall include, without limitation, a general release of claims against the Company and all related persons and entities, a reaffirmation of all of the Executive&#8217;s Continuing Obligations (as defined below<b>)</b>, and, and shall provide that if the Executive breaches any of the Continuing Obligations, all payments of the Severance Amount shall immediately cease (the &#8220;Separation Agreement and Release&#8221;), and (ii) the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven (7) business day revocation period:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay the Executive an amount equal to nine (9) months of Base Salary continuation (the &#8220;Severance Amount&#8221;); provided in the event the Executive is entitled to any payments pursuant to the Restrictive Covenants Agreement, the Severance Amount received in any calendar year will be reduced by the amount the Executive is paid in the same such calendar year pursuant to the Restrictive Covenants Agreement (the &#8220;Restrictive Covenants Agreement Setoff&#8221;);</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;subject to the Executive&#8217;s copayment of premium amounts at the applicable active employees&#8217; rate and the Executive&#8217;s proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;<u>COBRA</u>&#8221;), the Company shall pay to the group health plan provider, the COBRA provider or the Executive a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A) the end of the period during which the Severance Amount is paid; (B) the Executive&#8217;s eligibility for group medical plan benefits under any other employer&#8217;s group medical plan; or (C) the cessation of the Executive&#8217;s continuation rights under COBRA; provided, however, if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments shall be subject to tax-related deductions and withholdings and paid on the Company&#8217;s regular payroll dates; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;if the Date of Termination is in the first quarter of the calendar year, the Company shall pay the Executive any earned but as of yet unpaid annual bonus (as determined by the Board) from the prior calendar year&#8217;s performance, which portion the Company shall pay on or around the same time the Company pays other bonuses for that year&#8217;s performance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The amounts payable under Section 5, to the extent taxable, shall be paid out in substantially equal installments as salary continuation in accordance with the Company&#8217;s payroll practice, commencing within 60<b> </b>days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Severance Amount, to the extent it qualifies as &#8220;non-qualified deferred compensation&#8221; within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">6.&nbsp;&nbsp;&nbsp;&nbsp;<u>Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason within the Change in Control Period</u>. During the Change in Control Period (as defined below): The provisions of this Section 6 shall apply in lieu of, and expressly supersede, the provisions of Section 5 if (i) the Executive&#8217;s employment is terminated either (a) by the Company without Cause as provided in Section 3(d), or (b) by the Executive for Good Reason as provided in Section 3, <i><u>and</u></i> (ii) the Date of Termination is within 12 months after the occurrence of the first event constituting a Change in Control (such period, the &#8220;Change in Control Period&#8221;). These provisions shall terminate and be of no further force or effect after a Change in Control Period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;If the Executive&#8217;s employment is terminated by the Company without Cause as provided in Section 3(d) or the Executive terminates employment for Good Reason as provided in Section 3(e) and in each case the Date of Termination occurs during the Change in Control Period, then, in addition to the Accrued Obligations, and subject to the signing of the Separation Agreement and Release by the Executive and the Separation Agreement and Release becoming fully effective, all within the time frame set forth in the Separation Agreement and Release but in no event more than 60 days after the Date of Termination:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay the Executive a lump sum in cash in an amount equal to<b> </b>(A) twelve (12) months of the Executive&#8217;s Base Salary and Target Bonus plus (B) the Executive&#8217;s Target Bonus for the year of the Date of Termination prorated for the amount of time employed in that year prior to the Date of Termination plus (C) if the if the Date of Termination is in the first quarter of the calendar year, the Company shall pay the Executive any earned but as of yet unpaid annual bonus (as determined by the Board) from the prior calendar year&#8217;s performance ((A), (B), and (C) together, the &#8220;Change in Control Payment&#8221;); provided the Change in Control Payment shall be reduced by the amount of the Restrictive Covenants Agreement Setoff, if applicable; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;notwithstanding anything to the contrary in any applicable option agreement or other stock-based award agreement, all time-based stock options and other stock-based awards subject to time-based vesting held by the Executive (the &#8220;Time-Based Equity Awards&#8221;) shall immediately accelerate and become fully exercisable or nonforfeitable as of the later of (i) the Date of Termination or (ii) the effective date of the Separation Agreement and Release (the &#8220;Accelerated Vesting Date,&#8221; and such acceleration, the &#8220;Acceleration&#8221;); <i>provided</i> that any termination or forfeiture of the unvested portion of such Time-Based Equity Awards that would otherwise occur on the Date of Termination in the absence of this Agreement will be delayed until the effective date of the Separation Agreement and Release and will only occur if the vesting pursuant to this subsection does not occur due to the absence of the Separation Agreement and Release becoming fully effective within the time period set forth therein. Notwithstanding the foregoing, no additional vesting of the Time-Based Equity Awards shall occur during the period between the Executive&#8217;s Date of Termination and the Accelerated Vesting Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;subject to the Executive&#8217;s copayment of premium amounts at the applicable active employees&#8217; rate and the Executive&#8217;s proper election to receive benefits under COBRA, the Company shall pay to the group health plan provider, the COBRA provider or the Executive a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A) the 12-month anniversary of the Date of Termination; (B) the Executive&#8217;s eligibility for group medical plan benefits under any other employer&#8217;s group medical plan; or (C) the cessation of the Executive&#8217;s continuation rights under COBRA; provided, however, if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments shall be subject to tax-related deductions and withholdings and paid on the Company&#8217;s regular payroll dates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The amounts payable under this Section 6(a), to the extent taxable, shall be paid or commence to be paid within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payments to the extent they qualify as &#8220;non-qualified deferred compensation&#8221; within the meaning of Section 409A of the Code, shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Additional Limitation</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Code, and the applicable regulations thereunder (the &#8220;Aggregate Payments&#8221;), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. &#167;1.280G-1, Q&amp;A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. &#167;1.280G-1, Q&amp;A-24(b) or (c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Section 6(b), the &#8220;After Tax Amount&#8221; means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive&#8217;s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section 6(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the &#8220;Accounting Firm&#8221;), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Executive.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>. For purposes of this Section 6, the following terms shall have the following meanings:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#8220;Change in Control&#8221; shall mean any of the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;any &#8220;person,&#8221; as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Act&#8221;) (other than the Company, any of its subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of the Company or any of its subsidiaries), together with all &#8220;affiliates&#8221; and &#8220;associates&#8221; (as such terms are defined in Rule 12b-2 under the Act) of such person, shall become the &#8220;beneficial owner&#8221; (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the Company representing fifty (50) percent or more of the combined voting power of the Company&#8217;s then outstanding securities having the right to vote in an election of the Board (&#8220;Voting Securities&#8221;) (in such case other than as a result of an acquisition of securities directly from the Company); or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the date a majority of the members of the Board is replaced during any 12-month period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment or election; or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:72pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the consummation of (A) any consolidation or merger of the Company where the stockholders of the Company, immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, shares representing in the aggregate more than fifty (50) percent of the voting shares of the Company issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or (B) any sale or other transfer (in one transaction or a series of transactions contemplated or arranged by any party as a single plan) of all or substantially all of the assets of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Notwithstanding the foregoing, a &#8220;Change in Control&#8221; shall not be deemed to have occurred for purposes of the foregoing clause (i) solely as the result of an acquisition of securities by the Company which, by reducing the number of shares of Voting Securities outstanding, increases the proportionate number of Voting Securities beneficially owned by any person to fifty (50) percent or more of the combined voting power of all of the then outstanding Voting Securities; provided, however, that if any person referred to in this sentence shall thereafter become the beneficial owner of any additional shares of Voting Securities (other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from the Company) and immediately thereafter beneficially owns fifty (50) percent or more of the combined voting power of all of the then outstanding Voting Securities, then a &#8220;Change in Control&#8221; shall be deemed to have occurred for purposes of the foregoing clause (i).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">7.&nbsp;&nbsp;&nbsp;&nbsp;<u>Section 409A</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive&#8217;s separation from service within the meaning of Section 409A of the Code, the Company determines that the Executive is a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement or otherwise on account of the Executive&#8217;s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executive&#8217;s separation from service, or (B) the Executive&#8217;s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;To the extent that any payment or benefit described in this Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive&#8217;s termination of employment, then such payments or benefits shall be payable only upon the Executive&#8217;s &#8220;separation from service.&#8221; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A&#8209;1(h).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement or the Restrictive Covenants Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A&#8209;2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">8.&nbsp;&nbsp;&nbsp;&nbsp;<u>Continuing Obligations</u>.<u> </u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Restrictive Covenants Agreement</u>. The terms of the Invention, Non-Competition and Non-Disclosure Agreement, dated January 1, 2025 (the &#8220;Restrictive Covenants Agreement&#8221;), between the Company and the Executive, attached hereto as <u>Exhibit A</u>, continue to be in full force and effect. For purposes of this Agreement, the obligations in this Section 8 and those that arise in the Restrictive Covenants Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#8220;Continuing Obligations.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Third-Party Agreements and Rights</u>. The Executive hereby confirms that the Executive is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Executive&#8217;s use or disclosure of information, other than confidentiality restrictions (if any), or the Executive&#8217;s engagement in any business. The Executive represents to the Company that the Executive&#8217;s execution of this Agreement, the Executive&#8217;s employment with the Company and the performance of the Executive&#8217;s proposed duties for the Company will not violate any obligations the Executive may have to any such previous employer or other party. In the Executive&#8217;s work for the Company, the Executive will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Litigation and Regulatory Cooperation</u>. During and after the Executive&#8217;s employment, the Executive shall cooperate fully with the Company in (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed by the Company, and (ii) the investigation, whether internal or external, of any matters about which the Company believes the Executive may have knowledge or information. The Executive&#8217;s full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after the Executive&#8217;s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable out&#8209;of&#8209;pocket expenses incurred in connection with the Executive&#8217;s performance of obligations pursuant to this Section 8(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Relief</u>. The Executive agrees that it would be difficult to measure any damages caused to the Company which might result from any breach by the Executive of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, the Executive agrees that if the Executive breaches, or proposes to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Protected Disclosures and Other Protected Action</u>. Nothing in this Agreement shall be interpreted or applied to prohibit the Executive from making any good faith report to any governmental agency or other governmental entity (a &#8220;Government Agency&#8221;) concerning any act or omission that the Executive reasonably believes constitutes a possible violation of federal or state law or making other disclosures that are protected under the anti-retaliation or whistleblower provisions of applicable federal or state law or regulation. In addition, nothing contained in this Agreement limits the Executive&#8217;s ability to communicate with any Government Agency or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including the Executive&#8217;s ability to provide documents or other information, without notice to the Company. In addition, for the avoidance of doubt, pursuant to the federal Defend Trade Secrets Act of 2016, the Executive shall not be held criminally or civilly liable under any federal or state trade secret law or under this Agreement or the Restrictive Covenants Agreement for the disclosure of a trade secret that (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">9.&nbsp;&nbsp;&nbsp;&nbsp;<u>Consent to Jurisdiction</u>. The parties hereby consent to the jurisdiction of the state and federal courts of the Commonwealth of Massachusetts. Accordingly, with respect to any such court action, the Executive (a) submits to the exclusive personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">10.&nbsp;&nbsp;&nbsp;&nbsp;<u>Waiver of Jury Trial</u>. Each of the Executive and the Company irrevocably and unconditionally WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE EXECUTIVE&#8217;S EMPLOYMENT BY THE COMPANY OR ANY AFFILIATE OF THE COMPANY, INCLUDING WITHOUT LIMITATION THE EXECUTIVE&#8217;S OR THE COMPANY&#8217;S PERFORMANCE UNDER, OR THE ENFORCEMENT OF, THIS AGREEMENT.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">11.&nbsp;&nbsp;&nbsp;&nbsp;<u>Integration</u>. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter, provided that the Restrictive Covenants Agreement and the Equity Documents remain in full force and effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">12.&nbsp;&nbsp;&nbsp;&nbsp;<u>Withholding; Tax Effect</u>. All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the Executive for any adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">13.&nbsp;&nbsp;&nbsp;&nbsp;<u>Assignment</u>. Neither the Executive nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement (including the Restrictive Covenants Agreement) without the Executive&#8217;s consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further that if the Executive remains employed or becomes employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then the Executive shall not be entitled to any payments, benefits or vesting pursuant to Section 5 or pursuant to Section 6 of this Agreement. This Agreement shall inure to the benefit of and be binding upon the Executive and the Company, and each of the Executive&#8217;s and the Company&#8217;s respective successors, executors, administrators, heirs and permitted assigns.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">14.&nbsp;&nbsp;&nbsp;&nbsp;<u>Enforceability</u>. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">15.&nbsp;&nbsp;&nbsp;&nbsp;<u>Survival</u>. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the Executive&#8217;s employment to the extent necessary to effectuate the terms contained herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">16.&nbsp;&nbsp;&nbsp;&nbsp;<u>Waiver</u>. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">17.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">18.&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendment</u>. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">19.&nbsp;&nbsp;&nbsp;&nbsp;<u>Effect on Other Plans and Agreements</u>. An election by the Executive to resign for Good Reason under the provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions of any of the Company's benefit plans, programs or policies. Nothing in this Agreement shall be construed to limit the rights of the Executive under the Company&#8217;s benefit plans, programs or policies except as otherwise provided in Section 8 hereof, and except that the Executive shall have no rights to any severance benefits under any Company severance pay plan, offer letter or otherwise. Except for the Restrictive Covenants Agreement, in the event that the Executive is party to an agreement with the Company providing for payments or benefits under such plan or agreement and under this Agreement, the terms of this Agreement shall govern and the Executive may receive payment under this Agreement only and not both. Further, Section 5 and Section 6 of this Agreement are mutually exclusive and in no event shall the Executive be entitled to payments or benefits pursuant to both Section 5 and Section 6 of this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">20.&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law</u>. This is a Massachusetts contract and shall be construed under and be governed in all respects by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles thereof. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the First Circuit.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">21.&nbsp;&nbsp;&nbsp;&nbsp;<u>Counterparts</u>. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="vertical-align: middle; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>COMPASS THERAPEUTICS, INC.</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: middle; width: 5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: middle; width: 5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="vertical-align: middle; width: 45%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 5%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="vertical-align: middle; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Thomas Schuetz</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: middle; width: 5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="vertical-align: middle; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Executive Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 5%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 5%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 5%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="vertical-align: middle; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>EXECUTIVE</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: middle; width: 5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: middle; width: 5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: middle; width: 5%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="vertical-align: middle; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cynthia Sirard</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 234pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 234pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><u>Exhibit A</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Restrictive Covenants Agreement</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(i.e., Invention, Non-Competition and Non-Disclosure Agreement)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ex_923473.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 23.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><u>Consent of Independent Registered Public Accounting Firm</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We consent to the incorporation by reference in the following Registration Statements:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Registration Statements (Form S-3 File Nos. 333-268652, 333-281891 and 333-292491) of Compass Therapeutics, Inc., and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(2)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Registration Statements (Form S-8 No. 333-252103 and 333-286148) of Compass Therapeutics, Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">of our report dated March 5, 2026, with respect to the consolidated financial statements of Compass Therapeutics, Inc. and subsidiaries included in this Annual Report (Form 10-K) of Compass Therapeutics, Inc. for the year ended December 31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">/s/ CohnReznick LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Melville, New York</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">March 5, 2026</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ex_923474.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 31.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">I, Thomas Schuetz, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">I have reviewed this Annual Report on Form 10-K of Compass Therapeutics, Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">c.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">d.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Date: March 5, 2026</p>
			</td>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">/s/ Thomas Schuetz</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Thomas Schuetz</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Principal Executive Officer</b></p>
			</td>
		</tr>

</table>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ex_923475.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 31.2</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">I, Barry Shin, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">I have reviewed this Annual Report on Form 10-K of Compass Therapeutics, Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">c.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">d.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Date:&nbsp;March 5, 2026</p>
			</td>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">/s/ Barry Shin</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Barry Shin</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Principal Financial Officer</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ex_923476.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 32.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:25pt;">In connection with the Annual Report of Compass Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:50pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:50pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Date:&nbsp;&nbsp;March 5, 2026</p>
			</td>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">/s/ Thomas Schuetz</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Thomas Schuetz</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Principal Executive Officer</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>ex_923477.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 32.2</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:25pt;">In connection with the Annual Report of Compass Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:50pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:50pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Date:&nbsp;&nbsp;March 5, 2026</p>
			</td>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">/s/ Barry Shin</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Barry Shin</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Principal Financial Officer</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>cmpx-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:02PM UTC 2026-03-04--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:cmpx="http://www.compasstherapeutics.com/20251231" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.compasstherapeutics.com/20251231">
  <xsd:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2025" schemaLocation="https://xbrl.sec.gov/exch/2025/exch-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2025" schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/cyd-af-sub/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmpx-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmpx-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmpx-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cmpx-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-parentheticals" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-stockholders-equity" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-stockholders-equity-parentheticals" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-cash-flows" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-formation-and-business-of-the-company" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-1-formation-and-business-of-the-company">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995550 - Disclosure - Note 1 - Formation and Business of the Company</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-liquidity-uncertainties-and-going-concern" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995551 - Disclosure - Note 2 - Liquidity, Uncertainties and Going Concern</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995552 - Disclosure - Note 3 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-fair-value-measurements" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995553 - Disclosure - Note 4 - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-marketable-securities" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995554 - Disclosure - Note 5 - Marketable Securities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-property-and-equipment" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995555 - Disclosure - Note 6 - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-accrued-expenses" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995556 - Disclosure - Note 7 - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockholders-equity" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995557 - Disclosure - Note 8 - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockbased-compensation" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995558 - Disclosure - Note 9 - Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-basic-and-diluted-net-loss-per-share" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995559 - Disclosure - Note 10 - Basic and Diluted Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-license-research-and-collaboration-agreements" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995560 - Disclosure - Note 11 - License, Research and Collaboration Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-commitments-and-contingencies" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995561 - Disclosure - Note 12 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-other-income" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995562 - Disclosure - Note 13 - Other Income</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-income-taxe" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995563 - Disclosure - Note 14 - Income Taxe</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-segment-information-" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995564 - Disclosure - Note 15 - Segment Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995565 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-tables" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995566 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-fair-value-measurements-tables" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995567 - Disclosure - Note 4 - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-marketable-securities-tables" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995568 - Disclosure - Note 5 - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-property-and-equipment-tables" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995569 - Disclosure - Note 6 - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-accrued-expenses-tables" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995570 - Disclosure - Note 7 - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockbased-compensation-tables" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995571 - Disclosure - Note 9 - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-basic-and-diluted-net-loss-per-share-tables" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995572 - Disclosure - Note 10 - Basic and Diluted Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-commitments-and-contingencies-tables" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995573 - Disclosure - Note 12 - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-income-taxe-tables" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995574 - Disclosure - Note 14 - Income Taxe (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-segment-information-tables" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995575 - Disclosure - Note 15 - Segment Information (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-liquidity-uncertainties-and-going-concern-details-textual" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995576 - Disclosure - Note 2 - Liquidity, Uncertainties and Going Concern (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-details-textual" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995577 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995578 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Schedule of Estimated Lives (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995579 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995580 - Disclosure - Note 4 - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-marketable-securities-marketable-securities-details" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995581 - Disclosure - Note 5 - Marketable Securities - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-marketable-securities-maturity-details" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-maturity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995582 - Disclosure - Note 5 - Marketable Securities - Maturity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-property-and-equipment-details-textual" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995583 - Disclosure - Note 6 - Property and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995584 - Disclosure - Note 6 - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-accrued-expenses-details-textual" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995585 - Disclosure - Note 7 - Accrued Expenses (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995586 - Disclosure - Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockholders-equity-details-textual" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995587 - Disclosure - Note 8 - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockbased-compensation-details-textual" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995588 - Disclosure - Note 9 - Stock-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995589 - Disclosure - Note 9 - Stock-based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995590 - Disclosure - Note 9 - Stock-based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockbased-compensation-weighted-average-assumptions-details" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-weighted-average-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995591 - Disclosure - Note 9 - Stock-based Compensation - Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockbased-compensation-summary-of-rsu-activity-details" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995592 - Disclosure - Note 9 - Stock-based Compensation - Summary of RSU Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-basic-and-diluted-net-loss-per-share-details-textual" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995593 - Disclosure - Note 10 - Basic and Diluted Net Loss Per Share (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995594 - Disclosure - Note 10 - Basic and Diluted Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-license-research-and-collaboration-agreements-details-textual" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995595 - Disclosure - Note 11 - License, Research and Collaboration Agreements (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-commitments-and-contingencies-details-textual" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995596 - Disclosure - Note 12 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995597 - Disclosure - Note 12 - Commitments and Contingencies - Undiscounted Cash Flows Reconciled to Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-other-income-details-textual" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995598 - Disclosure - Note 13 - Other Income (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-income-taxe-details-textual" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995599 - Disclosure - Note 14 - Income Taxe (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995600 - Disclosure - Note 14 - Income Taxes - Schedule of Effective Tax Rate of Provision for Income Taxes differs from Federal Statutory Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995601 - Disclosure - Note 14 - Income Taxes - Significant Components of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-segment-information-details-textual" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995602 - Disclosure - Note 15 - Segment Information (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-segment-information-schedule-of-segment-reporting-information-details" roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995603 - Disclosure - Note 15 - Segment Information - Schedule of Segment Reporting Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="cmpx_ABLBioAgreementMember" name="ABLBioAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="cmpx_AccruedManufacturingExpenses" name="AccruedManufacturingExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="cmpx_AccruedProjectExpensesCurrent" name="AccruedProjectExpensesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="cmpx_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" name="AccruedResearchAndDevelopmentExpensesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_AdimabAgreementMember" name="AdimabAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_AtTheMarketMember" name="AtTheMarketMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_CTX10726Member" name="CTX10726Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_CTX471Member" name="CTX471Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_CTX8371Member" name="CTX8371Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="cmpx_ClassOfWarrantOrRightPurchasePrice" name="ClassOfWarrantOrRightPurchasePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="cmpx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" name="DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="cmpx_DeferredTaxAssetsCapitalizedLicensingFees" name="DeferredTaxAssetsCapitalizedLicensingFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="cmpx_DeferredTaxAssetsLeaseLiabilities" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="cmpx_DeferredTaxAssetsSection174Capitalization" name="DeferredTaxAssetsSection174Capitalization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="cmpx_DevelopmentMilestonePayment" name="DevelopmentMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" name="EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" name="EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_FacilityLeaseMember" name="FacilityLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_GeneralMember" name="GeneralMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount" name="MarketableSecuritiesAmortizationOfPremiumAndDiscount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="cmpx_MaximumCommercialMilestonePaymentsAndRoyalties" name="MaximumCommercialMilestonePaymentsAndRoyalties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="cmpx_MaximumDevelopmentAndRegulatoryMilestonePayments" name="MaximumDevelopmentAndRegulatoryMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="cmpx_MilestonePaymentObligation" name="MilestonePaymentObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="cmpx_MilestonePaymentsPaid" name="MilestonePaymentsPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_OncologyMember" name="OncologyMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_OphthalmologyMember" name="OphthalmologyMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="cmpx_PatentsCostsPolicyTextBlock" name="PatentsCostsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_PersonnelMember" name="PersonnelMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_PolicyTable" name="PolicyTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" name="PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="cmpx_ProceedsFromIssuanceOfCommonStockNet" name="ProceedsFromIssuanceOfCommonStockNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="cmpx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" name="PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_RestrictedStockUnitsAndOptionsMember" name="RestrictedStockUnitsAndOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="cmpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="cmpx_StockIssuableDuringPeriodShares" name="StockIssuableDuringPeriodShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_The2020StockOptionAndIncentivePlanMember" name="The2020StockOptionAndIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_TovecimigMember" name="TovecimigMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_UnderwritingAgreementMember" name="UnderwritingAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="cmpx_UpfrontPayment" name="UpfrontPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-insider-trading-policy-" name="statement-statement-insider-trading-policy-" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" name="statement-statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-10-basic-and-diluted-net-loss-per-share-tables" name="statement-statement-note-10-basic-and-diluted-net-loss-per-share-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-12-commitments-and-contingencies-tables" name="statement-statement-note-12-commitments-and-contingencies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details" name="statement-statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-14-income-taxe-tables" name="statement-statement-note-14-income-taxe-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details" name="statement-statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details" name="statement-statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-15-segment-information-schedule-of-segment-reporting-information-details" name="statement-statement-note-15-segment-information-schedule-of-segment-reporting-information-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-15-segment-information-tables" name="statement-statement-note-15-segment-information-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" name="statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details" name="statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-tables" name="statement-statement-note-3-summary-of-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details" name="statement-statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-detailsB89F0306-65CC-44A9-A230-083F5EC03FE9" name="statement-statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-detailsB89F0306-65CC-44A9-A230-083F5EC03FE9" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-4-fair-value-measurements-tables" name="statement-statement-note-4-fair-value-measurements-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-5-marketable-securities-marketable-securities-details" name="statement-statement-note-5-marketable-securities-marketable-securities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-5-marketable-securities-marketable-securities-detailsA417C50A-BB80-4EE1-AF99-1150A3090D20" name="statement-statement-note-5-marketable-securities-marketable-securities-detailsA417C50A-BB80-4EE1-AF99-1150A3090D20" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-5-marketable-securities-maturity-details" name="statement-statement-note-5-marketable-securities-maturity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-5-marketable-securities-tables" name="statement-statement-note-5-marketable-securities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" name="statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details" name="statement-statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-6-property-and-equipment-tables" name="statement-statement-note-6-property-and-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-7-accrued-expenses-tables" name="statement-statement-note-7-accrued-expenses-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" name="statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-9-stockbased-compensation-summary-of-rsu-activity-details" name="statement-statement-note-9-stockbased-compensation-summary-of-rsu-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" name="statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-9-stockbased-compensation-tables" name="statement-statement-note-9-stockbased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-note-9-stockbased-compensation-weighted-average-assumptions-details" name="statement-statement-note-9-stockbased-compensation-weighted-average-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="cmpx_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>cmpx-20251231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:02PM UTC 2026-03-04--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-1-formation-and-business-of-the-company" xlink:href="cmpx-20251231.xsd#statement-note-1-formation-and-business-of-the-company" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-1-formation-and-business-of-the-company" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfProductInformationTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information" xlink:href="cmpx-20251231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="37" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-" xlink:href="cmpx-20251231.xsd#statement-condensed-consolidated-balance-sheets-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCash" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals" xlink:href="cmpx-20251231.xsd#statement-condensed-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="cmpx-20251231.xsd#statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity" xlink:href="cmpx-20251231.xsd#statement-condensed-consolidated-statements-of-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity-parentheticals" xlink:href="cmpx-20251231.xsd#statement-condensed-consolidated-statements-of-stockholders-equity-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows" xlink:href="cmpx-20251231.xsd#statement-condensed-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount" xlink:label="cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern" xlink:href="cmpx-20251231.xsd#statement-note-2-liquidity-uncertainties-and-going-concern" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies" xlink:href="cmpx-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements" xlink:href="cmpx-20251231.xsd#statement-note-4-fair-value-measurements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities" xlink:href="cmpx-20251231.xsd#statement-note-5-marketable-securities" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment" xlink:href="cmpx-20251231.xsd#statement-note-6-property-and-equipment" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses" xlink:href="cmpx-20251231.xsd#statement-note-7-accrued-expenses" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplierFinanceProgramTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity" xlink:href="cmpx-20251231.xsd#statement-note-8-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_AtTheMarketMember" xlink:label="cmpx_AtTheMarketMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:label="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_UnderwritingAgreementMember" xlink:label="cmpx_UnderwritingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cmpx_UnderwritingAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cmpx_AtTheMarketMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation" xlink:href="cmpx-20251231.xsd#statement-note-9-stockbased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_The2020StockOptionAndIncentivePlanMember" xlink:label="cmpx_The2020StockOptionAndIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cmpx_The2020StockOptionAndIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share" xlink:href="cmpx-20251231.xsd#statement-note-10-basic-and-diluted-net-loss-per-share" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:label="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements" xlink:href="cmpx-20251231.xsd#statement-note-11-license-research-and-collaboration-agreements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_ABLBioAgreementMember" xlink:label="cmpx_ABLBioAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_AdimabAgreementMember" xlink:label="cmpx_AdimabAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_OncologyMember" xlink:label="cmpx_OncologyMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_OphthalmologyMember" xlink:label="cmpx_OphthalmologyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cmpx_ABLBioAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cmpx_OncologyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cmpx_OphthalmologyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cmpx_AdimabAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies" xlink:href="cmpx-20251231.xsd#statement-note-12-commitments-and-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_FacilityLeaseMember" xlink:label="cmpx_FacilityLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialStandbyLetterOfCreditMember" xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsNatureDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="cmpx_FacilityLeaseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GuaranteeObligationsNatureDomain" xlink:to="us-gaap_FinancialStandbyLetterOfCreditMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsNatureDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingenciesTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income" xlink:href="cmpx-20251231.xsd#statement-note-13-other-income" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe" xlink:href="cmpx-20251231.xsd#statement-note-14-income-taxe" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-" xlink:href="cmpx-20251231.xsd#statement-note-15-segment-information-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_CTX10726Member" xlink:label="cmpx_CTX10726Member" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_CTX471Member" xlink:label="cmpx_CTX471Member" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_CTX8371Member" xlink:label="cmpx_CTX8371Member" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_GeneralMember" xlink:label="cmpx_GeneralMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PersonnelMember" xlink:label="cmpx_PersonnelMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_TovecimigMember" xlink:label="cmpx_TovecimigMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="cmpx_PersonnelMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="cmpx_GeneralMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="cmpx_TovecimigMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="cmpx_CTX471Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="cmpx_CTX8371Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="cmpx_CTX10726Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies" xlink:href="cmpx-20251231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:label="cmpx_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PatentsCostsPolicyTextBlock" xlink:label="cmpx_PatentsCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PolicyTable" xlink:label="cmpx_PolicyTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cmpx_PolicyTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_PolicyTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cmpx_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cmpx_PatentsCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables" xlink:href="cmpx-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="cmpx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_RestrictedStockUnitsAndOptionsMember" xlink:label="cmpx_RestrictedStockUnitsAndOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cmpx_RestrictedStockUnitsAndOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="cmpx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-tables" xlink:href="cmpx-20251231.xsd#statement-note-4-fair-value-measurements-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-tables" xlink:href="cmpx-20251231.xsd#statement-note-5-marketable-securities-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-tables" xlink:href="cmpx-20251231.xsd#statement-note-6-property-and-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-tables" xlink:href="cmpx-20251231.xsd#statement-note-7-accrued-expenses-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplierFinanceProgramTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-tables" xlink:href="cmpx-20251231.xsd#statement-note-9-stockbased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-tables" xlink:href="cmpx-20251231.xsd#statement-note-10-basic-and-diluted-net-loss-per-share-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-tables" xlink:href="cmpx-20251231.xsd#statement-note-12-commitments-and-contingencies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingenciesTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-tables" xlink:href="cmpx-20251231.xsd#statement-note-14-income-taxe-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-tables" xlink:href="cmpx-20251231.xsd#statement-note-15-segment-information-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-2-liquidity-uncertainties-and-going-concern-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details" xlink:href="cmpx-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:href="cmpx-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details" xlink:href="cmpx-20251231.xsd#statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details" xlink:href="cmpx-20251231.xsd#statement-note-5-marketable-securities-marketable-securities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-maturity-details" xlink:href="cmpx-20251231.xsd#statement-note-5-marketable-securities-maturity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-maturity-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:label="cmpx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-6-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details" xlink:href="cmpx-20251231.xsd#statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-7-accrued-expenses-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-details-textual" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_AccruedManufacturingExpenses" xlink:label="cmpx_AccruedManufacturingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplierFinanceProgramTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_AccruedManufacturingExpenses" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:href="cmpx-20251231.xsd#statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_AccruedProjectExpensesCurrent" xlink:label="cmpx_AccruedProjectExpensesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplierFinanceProgramTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_AccruedProjectExpensesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-8-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_AtTheMarketMember" xlink:label="cmpx_AtTheMarketMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_ClassOfWarrantOrRightPurchasePrice" xlink:label="cmpx_ClassOfWarrantOrRightPurchasePrice" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:label="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_ProceedsFromIssuanceOfCommonStockNet" xlink:label="cmpx_ProceedsFromIssuanceOfCommonStockNet" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_StockIssuableDuringPeriodShares" xlink:label="cmpx_StockIssuableDuringPeriodShares" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_UnderwritingAgreementMember" xlink:label="cmpx_UnderwritingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="us-gaap_NoninterestExpenseOfferingCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cmpx_UnderwritingAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cmpx_AtTheMarketMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_ClassOfWarrantOrRightPurchasePrice" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_StockIssuableDuringPeriodShares" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoninterestExpenseOfferingCost" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_ProceedsFromIssuanceOfCommonStockNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-9-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_The2020StockOptionAndIncentivePlanMember" xlink:label="cmpx_The2020StockOptionAndIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cmpx_The2020StockOptionAndIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:href="cmpx-20251231.xsd#statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:href="cmpx-20251231.xsd#statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:label="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue" xlink:label="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-weighted-average-assumptions-details" xlink:href="cmpx-20251231.xsd#statement-note-9-stockbased-compensation-weighted-average-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-weighted-average-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details" xlink:href="cmpx-20251231.xsd#statement-note-9-stockbased-compensation-summary-of-rsu-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:label="cmpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:label="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-10-basic-and-diluted-net-loss-per-share-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:label="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" xlink:href="cmpx-20251231.xsd#statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-11-license-research-and-collaboration-agreements-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_ABLBioAgreementMember" xlink:label="cmpx_ABLBioAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_AdimabAgreementMember" xlink:label="cmpx_AdimabAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_DevelopmentMilestonePayment" xlink:label="cmpx_DevelopmentMilestonePayment" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_MaximumCommercialMilestonePaymentsAndRoyalties" xlink:label="cmpx_MaximumCommercialMilestonePaymentsAndRoyalties" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_MaximumDevelopmentAndRegulatoryMilestonePayments" xlink:label="cmpx_MaximumDevelopmentAndRegulatoryMilestonePayments" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_MilestonePaymentObligation" xlink:label="cmpx_MilestonePaymentObligation" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_MilestonePaymentsPaid" xlink:label="cmpx_MilestonePaymentsPaid" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_OncologyMember" xlink:label="cmpx_OncologyMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_OphthalmologyMember" xlink:label="cmpx_OphthalmologyMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_UpfrontPayment" xlink:label="cmpx_UpfrontPayment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cmpx_ABLBioAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cmpx_OncologyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cmpx_OphthalmologyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cmpx_AdimabAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_UpfrontPayment" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_DevelopmentMilestonePayment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_MaximumDevelopmentAndRegulatoryMilestonePayments" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_MaximumCommercialMilestonePaymentsAndRoyalties" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_MilestonePaymentsPaid" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_MilestonePaymentObligation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-12-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_FacilityLeaseMember" xlink:label="cmpx_FacilityLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialStandbyLetterOfCreditMember" xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsNatureDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="cmpx_FacilityLeaseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GuaranteeObligationsNatureDomain" xlink:to="us-gaap_FinancialStandbyLetterOfCreditMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsNatureDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingenciesTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCash" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details" xlink:href="cmpx-20251231.xsd#statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-13-other-income-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-14-income-taxe-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details" xlink:href="cmpx-20251231.xsd#statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" xlink:label="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" xlink:label="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details" xlink:href="cmpx-20251231.xsd#statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_DeferredTaxAssetsCapitalizedLicensingFees" xlink:label="cmpx_DeferredTaxAssetsCapitalizedLicensingFees" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_DeferredTaxAssetsLeaseLiabilities" xlink:label="cmpx_DeferredTaxAssetsLeaseLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_DeferredTaxAssetsSection174Capitalization" xlink:label="cmpx_DeferredTaxAssetsSection174Capitalization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_DeferredTaxAssetsSection174Capitalization" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_DeferredTaxAssetsCapitalizedLicensingFees" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-15-segment-information-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details" xlink:href="cmpx-20251231.xsd#statement-note-15-segment-information-schedule-of-segment-reporting-information-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_CTX10726Member" xlink:label="cmpx_CTX10726Member" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_CTX471Member" xlink:label="cmpx_CTX471Member" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_CTX8371Member" xlink:label="cmpx_CTX8371Member" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_GeneralMember" xlink:label="cmpx_GeneralMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PersonnelMember" xlink:label="cmpx_PersonnelMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_TovecimigMember" xlink:label="cmpx_TovecimigMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="cmpx_PersonnelMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="cmpx_GeneralMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="cmpx_TovecimigMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="cmpx_CTX471Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="cmpx_CTX8371Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="cmpx_CTX10726Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>cmpx-20251231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:02PM UTC 2026-03-04--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_DocumentAndEntityInformation" xlink:label="cmpx_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="cmpx_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_DocumentAndEntityInformation" xlink:to="cmpx_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NoteToFinancialStatementDetailsTextual" xlink:label="cmpx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="cmpx_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_NoteToFinancialStatementDetailsTextual" xlink:to="cmpx_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal statutory rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-significant-accounting-policies-policies" xlink:label="cmpx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-significant-accounting-policies-policies" xlink:to="cmpx_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-free rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:label="cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:to="cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-4-fair-value-measurements-tables" xlink:label="cmpx_statement-statement-note-4-fair-value-measurements-tables" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-4-fair-value-measurements-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Fair Value Measurements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-4-fair-value-measurements-tables" xlink:to="cmpx_statement-statement-note-4-fair-value-measurements-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-5-marketable-securities-tables" xlink:label="cmpx_statement-statement-note-5-marketable-securities-tables" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-5-marketable-securities-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Marketable Securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-5-marketable-securities-tables" xlink:to="cmpx_statement-statement-note-5-marketable-securities-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-6-property-and-equipment-tables" xlink:label="cmpx_statement-statement-note-6-property-and-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-6-property-and-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Property and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-6-property-and-equipment-tables" xlink:to="cmpx_statement-statement-note-6-property-and-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-7-accrued-expenses-tables" xlink:label="cmpx_statement-statement-note-7-accrued-expenses-tables" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-7-accrued-expenses-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Accrued Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-7-accrued-expenses-tables" xlink:to="cmpx_statement-statement-note-7-accrued-expenses-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-9-stockbased-compensation-tables" xlink:label="cmpx_statement-statement-note-9-stockbased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-9-stockbased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Stock-based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-9-stockbased-compensation-tables" xlink:to="cmpx_statement-statement-note-9-stockbased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-10-basic-and-diluted-net-loss-per-share-tables" xlink:label="cmpx_statement-statement-note-10-basic-and-diluted-net-loss-per-share-tables" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-10-basic-and-diluted-net-loss-per-share-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Basic and Diluted Net Loss Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-10-basic-and-diluted-net-loss-per-share-tables" xlink:to="cmpx_statement-statement-note-10-basic-and-diluted-net-loss-per-share-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-12-commitments-and-contingencies-tables" xlink:label="cmpx_statement-statement-note-12-commitments-and-contingencies-tables" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-12-commitments-and-contingencies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Commitments and Contingencies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-12-commitments-and-contingencies-tables" xlink:to="cmpx_statement-statement-note-12-commitments-and-contingencies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized gain on marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-14-income-taxe-tables" xlink:label="cmpx_statement-statement-note-14-income-taxe-tables" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-14-income-taxe-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Income Taxe</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-14-income-taxe-tables" xlink:to="cmpx_statement-statement-note-14-income-taxe-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-15-segment-information-tables" xlink:label="cmpx_statement-statement-note-15-segment-information-tables" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-15-segment-information-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 15 - Segment Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-15-segment-information-tables" xlink:to="cmpx_statement-statement-note-15-segment-information-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details" xlink:label="cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Summary of Significant Accounting Policies - Schedule of Estimated Lives (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details" xlink:to="cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:label="cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:to="cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details" xlink:label="cmpx_statement-statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details" xlink:to="cmpx_statement-statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-5-marketable-securities-marketable-securities-details" xlink:label="cmpx_statement-statement-note-5-marketable-securities-marketable-securities-details" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-5-marketable-securities-marketable-securities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Marketable Securities - Marketable Securities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-5-marketable-securities-marketable-securities-details" xlink:to="cmpx_statement-statement-note-5-marketable-securities-marketable-securities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetBackedSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetBackedSecuritiesMember" xlink:to="us-gaap_AssetBackedSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected term (in years) (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unvested, weighted average fair value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-5-marketable-securities-maturity-details" xlink:label="cmpx_statement-statement-note-5-marketable-securities-maturity-details" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-5-marketable-securities-maturity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Marketable Securities - Maturity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-5-marketable-securities-maturity-details" xlink:to="cmpx_statement-statement-note-5-marketable-securities-maturity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details" xlink:label="cmpx_statement-statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Property and Equipment - Schedule of Property and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details" xlink:to="cmpx_statement-statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:label="cmpx_statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:to="cmpx_statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested, weighted average fair value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:label="cmpx_statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Stock-based Compensation - Stock-based Compensation Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:to="cmpx_statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:label="cmpx_statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Stock-based Compensation - Summary of Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:to="cmpx_statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-9-stockbased-compensation-weighted-average-assumptions-details" xlink:label="cmpx_statement-statement-note-9-stockbased-compensation-weighted-average-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-9-stockbased-compensation-weighted-average-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Stock-based Compensation - Weighted Average Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-9-stockbased-compensation-weighted-average-assumptions-details" xlink:to="cmpx_statement-statement-note-9-stockbased-compensation-weighted-average-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-9-stockbased-compensation-summary-of-rsu-activity-details" xlink:label="cmpx_statement-statement-note-9-stockbased-compensation-summary-of-rsu-activity-details" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-9-stockbased-compensation-summary-of-rsu-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Stock-based Compensation - Summary of RSU Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-9-stockbased-compensation-summary-of-rsu-activity-details" xlink:to="cmpx_statement-statement-note-9-stockbased-compensation-summary-of-rsu-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" xlink:label="cmpx_statement-statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Basic and Diluted Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" xlink:to="cmpx_statement-statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details" xlink:label="cmpx_statement-statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Commitments and Contingencies - Undiscounted Cash Flows Reconciled to Operating Lease Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details" xlink:to="cmpx_statement-statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details" xlink:label="cmpx_statement-statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Income Taxes - Schedule of Effective Tax Rate of Provision for Income Taxes differs from Federal Statutory Rate (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details" xlink:to="cmpx_statement-statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details" xlink:label="cmpx_statement-statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Income Taxes - Significant Components of Deferred Tax Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details" xlink:to="cmpx_statement-statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-15-segment-information-schedule-of-segment-reporting-information-details" xlink:label="cmpx_statement-statement-note-15-segment-information-schedule-of-segment-reporting-information-details" xlink:type="locator"/>
    <link:label xlink:label="cmpx_statement-statement-note-15-segment-information-schedule-of-segment-reporting-information-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 15 - Segment Information - Schedule of Segment Reporting Information (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_statement-statement-note-15-segment-information-schedule-of-segment-reporting-information-details" xlink:to="cmpx_statement-statement-note-15-segment-information-schedule-of-segment-reporting-information-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, weighted average price per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NotesToFinancialStatements" xlink:label="cmpx_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="cmpx_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_NotesToFinancialStatements" xlink:to="cmpx_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sale or maturities of marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested, weighted average price per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NotesToFinancialStatementsAbstract" xlink:label="cmpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="cmpx_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_NotesToFinancialStatementsAbstract" xlink:to="cmpx_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited or canceled, weighted average price per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_USTreasurySecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested, weighted average price per share (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested, December 31, 2024 (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited or canceled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested, balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested, December 31, 2024 (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CorporateDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested at December 31, 2025 (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GuaranteeObligationsByNatureAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GuaranteeObligationsNatureDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Nature [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsNatureDomain" xlink:to="us-gaap_GuaranteeObligationsNatureDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested at December 31, 2025 (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested at December 31, 2025 (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested at December 31, 2025</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average remaining contractual term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, aggregate intrinsic value</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireMarketableSecurities</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at December 31, 2024 (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited/cancelled (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinancialInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, options (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at December 31, 2024 (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherAccruedLiabilitiesCurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount" xlink:label="cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount" xlink:type="locator"/>
    <link:label xlink:label="cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount</link:label>
    <link:label xlink:label="cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of premium and discount on marketable securities</link:label>
    <link:label xlink:label="cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents amortization of premium and discount for marketable securities .</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount" xlink:to="cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of cross-border tax laws</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RestrictedCashAndCashEquivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of cross-border tax laws</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialStandbyLetterOfCreditMember" xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Standby Letter of Credit [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialStandbyLetterOfCreditMember" xlink:to="us-gaap_FinancialStandbyLetterOfCreditMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LossContingenciesTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total property and equipment&#8211;at cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleSecuritiesDebtSecurities</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_MarketableSecuritiesUnrealizedGainLoss</link:label>
    <link:label xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccruedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanCostRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanCostRecognized</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanCostRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label xlink:label="us-gaap_RestrictedCash-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_CityAreaCode</link:label>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseCost</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConsolidationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentPeriodEndDate</link:label>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</link:label>
    <link:label xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityFileNumber</link:label>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityEmergingGrowthCompany</link:label>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentType</link:label>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntitySmallBusiness</link:label>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityShellCompany</link:label>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:label="cmpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:type="locator"/>
    <link:label xlink:label="cmpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cmpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited</link:label>
    <link:label xlink:label="cmpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited, weighted average fair value</link:label>
    <link:label xlink:label="cmpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intrinsic value of forfeited award under share-based payment arrangement. Excludes share and unit options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:to="cmpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AreaOfRealEstateProperty</link:label>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfExpenseAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_NatureOfExpenseAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityPublicFloat</link:label>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityFilerCategory</link:label>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityCurrentReportingStatus</link:label>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityVoluntaryFilers</link:label>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityWellKnownSeasonedIssuer</link:label>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="ecd_AwardTmgDiscLineItems" xlink:type="locator"/>
    <link:label xlink:label="ecd_AwardTmgDiscLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgDiscLineItems" xlink:to="ecd_AwardTmgDiscLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_UnderwritingAgreementMember" xlink:label="cmpx_UnderwritingAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="cmpx_UnderwritingAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwriting Agreement [Member]</link:label>
    <link:label xlink:label="cmpx_UnderwritingAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the underwriting agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_UnderwritingAgreementMember" xlink:to="cmpx_UnderwritingAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</link:label>
    <link:label xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:label="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants in Connection with Underwriting Agreement [Member]</link:label>
    <link:label xlink:label="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents pre-funded warrants in connection with underwriting agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:to="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="locator"/>
    <link:label xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_AwardTmgMnpiCnsdrdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_AwardTmgMnpiCnsdrdFlag</link:label>
    <link:label xlink:label="ecd_AwardTmgMnpiCnsdrdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityTaxIdentificationNumber</link:label>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" xlink:type="locator"/>
    <link:label xlink:label="ecd_InsiderTradingPoliciesProcLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityRegistrantName</link:label>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:label xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityAddressAddressLine1</link:label>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityAddressCityOrTown</link:label>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityAddressPostalZipCode</link:label>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityAddressStateOrProvince</link:label>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:label xlink:label="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MarketableSecuritiesTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_ClassOfWarrantOrRightPurchasePrice" xlink:label="cmpx_ClassOfWarrantOrRightPurchasePrice" xlink:type="locator"/>
    <link:label xlink:label="cmpx_ClassOfWarrantOrRightPurchasePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cmpx_ClassOfWarrantOrRightPurchasePrice</link:label>
    <link:label xlink:label="cmpx_ClassOfWarrantOrRightPurchasePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant Or Right, Purchase Price (in dollars per share)</link:label>
    <link:label xlink:label="cmpx_ClassOfWarrantOrRightPurchasePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The purchase price of the warrant or right.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_ClassOfWarrantOrRightPurchasePrice" xlink:to="cmpx_ClassOfWarrantOrRightPurchasePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_StockIssuableDuringPeriodShares" xlink:label="cmpx_StockIssuableDuringPeriodShares" xlink:type="locator"/>
    <link:label xlink:label="cmpx_StockIssuableDuringPeriodShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cmpx_StockIssuableDuringPeriodShares</link:label>
    <link:label xlink:label="cmpx_StockIssuableDuringPeriodShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issuable During Period, Shares (in shares)</link:label>
    <link:label xlink:label="cmpx_StockIssuableDuringPeriodShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares issuable during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_StockIssuableDuringPeriodShares" xlink:to="cmpx_StockIssuableDuringPeriodShares-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityCommonStockSharesOutstanding</link:label>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" xlink:type="locator"/>
    <link:label xlink:label="ecd_TradingArrByIndTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MarketableSecuritiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_TradingSymbol</link:label>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfProductInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operation, Product Information, Concentration of Risk [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_LocalPhoneNumber</link:label>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued upon exercise of options (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised, options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued upon exercise of options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based awards, net of tax remittance (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based awards, net of tax remittance</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited/cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued in ATM offering, net of costs of $0.5 million (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued in ATM offering, net of costs of $0.5 million</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ResearchAndDevelopmentExpense</link:label>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MoneyMarketFundsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash to the Consolidated Balance Sheets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="cmpx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="cmpx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives [Table Text Block]</link:label>
    <link:label xlink:label="cmpx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of estimated useful lives of property, plant and equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="cmpx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease obligations, long-term portion</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease obligations, long-term portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseLiability</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of future minimum lease payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease obligations, current portion</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: operating lease obligations, current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease, right-of-use ("ROU") asset</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: amount of lease payments representing interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PolicyTable" xlink:label="cmpx_PolicyTable" xlink:type="locator"/>
    <link:label xlink:label="cmpx_PolicyTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cmpx_PolicyTable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_PolicyTable" xlink:to="cmpx_PolicyTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Depreciation</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Money market funds (cash equivalents)</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsFairValueDisclosure</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value: 300,000 shares authorized; 178,324 shares issued and outstanding at December 31, 2025; 137,820 shares issued and outstanding at December 31, 2024</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PatentsCostsPolicyTextBlock" xlink:label="cmpx_PatentsCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="cmpx_PatentsCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents Costs [Policy Text Block]</link:label>
    <link:label xlink:label="cmpx_PatentsCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the patents cost policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_PatentsCostsPolicyTextBlock" xlink:to="cmpx_PatentsCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_AccruedProjectExpensesCurrent" xlink:label="cmpx_AccruedProjectExpensesCurrent" xlink:type="locator"/>
    <link:label xlink:label="cmpx_AccruedProjectExpensesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project expenses</link:label>
    <link:label xlink:label="cmpx_AccruedProjectExpensesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of accrued project expenses classified as current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_AccruedProjectExpensesCurrent" xlink:to="cmpx_AccruedProjectExpensesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_AccruedManufacturingExpenses" xlink:label="cmpx_AccruedManufacturingExpenses" xlink:type="locator"/>
    <link:label xlink:label="cmpx_AccruedManufacturingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cmpx_AccruedManufacturingExpenses</link:label>
    <link:label xlink:label="cmpx_AccruedManufacturingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Manufacturing Expenses</link:label>
    <link:label xlink:label="cmpx_AccruedManufacturingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of accrued manufacturing expenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_AccruedManufacturingExpenses" xlink:to="cmpx_AccruedManufacturingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:label="cmpx_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="cmpx_AccruedResearchAndDevelopmentExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research and Development Expenses [Policy Text Block]</link:label>
    <link:label xlink:label="cmpx_AccruedResearchAndDevelopmentExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued research and development expenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:to="cmpx_AccruedResearchAndDevelopmentExpensesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CertificatesOfDepositMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseDiscountRate</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_ProceedsFromIssuanceOfCommonStockNet" xlink:label="cmpx_ProceedsFromIssuanceOfCommonStockNet" xlink:type="locator"/>
    <link:label xlink:label="cmpx_ProceedsFromIssuanceOfCommonStockNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cmpx_ProceedsFromIssuanceOfCommonStockNet</link:label>
    <link:label xlink:label="cmpx_ProceedsFromIssuanceOfCommonStockNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock, Net</link:label>
    <link:label xlink:label="cmpx_ProceedsFromIssuanceOfCommonStockNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash inflow from the issuance of common stock, net of issuance costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_ProceedsFromIssuanceOfCommonStockNet" xlink:to="cmpx_ProceedsFromIssuanceOfCommonStockNet-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_MilestonePaymentObligation" xlink:label="cmpx_MilestonePaymentObligation" xlink:type="locator"/>
    <link:label xlink:label="cmpx_MilestonePaymentObligation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cmpx_MilestonePaymentObligation</link:label>
    <link:label xlink:label="cmpx_MilestonePaymentObligation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Obligation</link:label>
    <link:label xlink:label="cmpx_MilestonePaymentObligation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of obligation for milestone payments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_MilestonePaymentObligation" xlink:to="cmpx_MilestonePaymentObligation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasePayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasePayments</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasePayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeLeaseDescriptionTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue" xlink:label="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited/cancelled</link:label>
    <link:label xlink:label="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The aggregate intrinsic value of options forfeited or cancelled under share-based compensation arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue" xlink:to="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:label="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:type="locator"/>
    <link:label xlink:label="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, aggregate intrinsic value</link:label>
    <link:label xlink:label="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intrinsic value of granted award under share-based payment arrangement. Excludes share and unit options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:to="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net of valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:label="cmpx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:type="locator"/>
    <link:label xlink:label="cmpx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturing after one year through two years</link:label>
    <link:label xlink:label="cmpx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:to="cmpx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_DeferredTaxAssetsSection174Capitalization" xlink:label="cmpx_DeferredTaxAssetsSection174Capitalization" xlink:type="locator"/>
    <link:label xlink:label="cmpx_DeferredTaxAssetsSection174Capitalization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cmpx_DeferredTaxAssetsSection174Capitalization</link:label>
    <link:label xlink:label="cmpx_DeferredTaxAssetsSection174Capitalization-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Section 174 Capitalization</link:label>
    <link:label xlink:label="cmpx_DeferredTaxAssetsSection174Capitalization-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from section 174 capitalization..</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_DeferredTaxAssetsSection174Capitalization" xlink:to="cmpx_DeferredTaxAssetsSection174Capitalization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsLiabilitiesNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_DeferredTaxAssetsLeaseLiabilities" xlink:label="cmpx_DeferredTaxAssetsLeaseLiabilities" xlink:type="locator"/>
    <link:label xlink:label="cmpx_DeferredTaxAssetsLeaseLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cmpx_DeferredTaxAssetsLeaseLiabilities</link:label>
    <link:label xlink:label="cmpx_DeferredTaxAssetsLeaseLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label xlink:label="cmpx_DeferredTaxAssetsLeaseLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_DeferredTaxAssetsLeaseLiabilities" xlink:to="cmpx_DeferredTaxAssetsLeaseLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_DeferredTaxAssetsCapitalizedLicensingFees" xlink:label="cmpx_DeferredTaxAssetsCapitalizedLicensingFees" xlink:type="locator"/>
    <link:label xlink:label="cmpx_DeferredTaxAssetsCapitalizedLicensingFees-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cmpx_DeferredTaxAssetsCapitalizedLicensingFees</link:label>
    <link:label xlink:label="cmpx_DeferredTaxAssetsCapitalizedLicensingFees-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized licensing fees</link:label>
    <link:label xlink:label="cmpx_DeferredTaxAssetsCapitalizedLicensingFees-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized licensing fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_DeferredTaxAssetsCapitalizedLicensingFees" xlink:to="cmpx_DeferredTaxAssetsCapitalizedLicensingFees-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsOther</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOther-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsGross</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing revenue</link:label>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:label xlink:label="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, weighted average remaining contractual term (Year)</link:label>
    <link:label xlink:label="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term for option awards granted during the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:to="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel3Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_The2020StockOptionAndIncentivePlanMember" xlink:label="cmpx_The2020StockOptionAndIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="cmpx_The2020StockOptionAndIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2020 Stock Option and Incentive Plan [Member]</link:label>
    <link:label xlink:label="cmpx_The2020StockOptionAndIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2020 Stock Option and Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_The2020StockOptionAndIncentivePlanMember" xlink:to="cmpx_The2020StockOptionAndIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfOperatingSegments</link:label>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_MaximumDevelopmentAndRegulatoryMilestonePayments" xlink:label="cmpx_MaximumDevelopmentAndRegulatoryMilestonePayments" xlink:type="locator"/>
    <link:label xlink:label="cmpx_MaximumDevelopmentAndRegulatoryMilestonePayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cmpx_MaximumDevelopmentAndRegulatoryMilestonePayments</link:label>
    <link:label xlink:label="cmpx_MaximumDevelopmentAndRegulatoryMilestonePayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Development and Regulatory Milestone Payments</link:label>
    <link:label xlink:label="cmpx_MaximumDevelopmentAndRegulatoryMilestonePayments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum amount of development and regulatory milestone payments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_MaximumDevelopmentAndRegulatoryMilestonePayments" xlink:to="cmpx_MaximumDevelopmentAndRegulatoryMilestonePayments-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_MaximumCommercialMilestonePaymentsAndRoyalties" xlink:label="cmpx_MaximumCommercialMilestonePaymentsAndRoyalties" xlink:type="locator"/>
    <link:label xlink:label="cmpx_MaximumCommercialMilestonePaymentsAndRoyalties-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cmpx_MaximumCommercialMilestonePaymentsAndRoyalties</link:label>
    <link:label xlink:label="cmpx_MaximumCommercialMilestonePaymentsAndRoyalties-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Commercial Milestone Payments and Royalties</link:label>
    <link:label xlink:label="cmpx_MaximumCommercialMilestonePaymentsAndRoyalties-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum amount of commercial milestone payments and royalties.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_MaximumCommercialMilestonePaymentsAndRoyalties" xlink:to="cmpx_MaximumCommercialMilestonePaymentsAndRoyalties-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_OncologyMember" xlink:label="cmpx_OncologyMember" xlink:type="locator"/>
    <link:label xlink:label="cmpx_OncologyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label xlink:label="cmpx_OncologyMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents oncology.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_OncologyMember" xlink:to="cmpx_OncologyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_ABLBioAgreementMember" xlink:label="cmpx_ABLBioAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="cmpx_ABLBioAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ABL Bio Agreement [Member]</link:label>
    <link:label xlink:label="cmpx_ABLBioAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the ABL Bio Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_ABLBioAgreementMember" xlink:to="cmpx_ABLBioAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MarketableSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_MilestonePaymentsPaid" xlink:label="cmpx_MilestonePaymentsPaid" xlink:type="locator"/>
    <link:label xlink:label="cmpx_MilestonePaymentsPaid-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cmpx_MilestonePaymentsPaid</link:label>
    <link:label xlink:label="cmpx_MilestonePaymentsPaid-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payments Paid</link:label>
    <link:label xlink:label="cmpx_MilestonePaymentsPaid-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash outflow for milestone payments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_MilestonePaymentsPaid" xlink:to="cmpx_MilestonePaymentsPaid-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_UpfrontPayment" xlink:label="cmpx_UpfrontPayment" xlink:type="locator"/>
    <link:label xlink:label="cmpx_UpfrontPayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cmpx_UpfrontPayment</link:label>
    <link:label xlink:label="cmpx_UpfrontPayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront Payment</link:label>
    <link:label xlink:label="cmpx_UpfrontPayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash outflow for upfront payment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_UpfrontPayment" xlink:to="cmpx_UpfrontPayment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_OphthalmologyMember" xlink:label="cmpx_OphthalmologyMember" xlink:type="locator"/>
    <link:label xlink:label="cmpx_OphthalmologyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ophthalmology [Member]</link:label>
    <link:label xlink:label="cmpx_OphthalmologyMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents ophthalmology.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_OphthalmologyMember" xlink:to="cmpx_OphthalmologyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_AdimabAgreementMember" xlink:label="cmpx_AdimabAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="cmpx_AdimabAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adimab Agreement [Member]</link:label>
    <link:label xlink:label="cmpx_AdimabAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Adimab agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_AdimabAgreementMember" xlink:to="cmpx_AdimabAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_FacilityLeaseMember" xlink:label="cmpx_FacilityLeaseMember" xlink:type="locator"/>
    <link:label xlink:label="cmpx_FacilityLeaseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Lease [Member]</link:label>
    <link:label xlink:label="cmpx_FacilityLeaseMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the lease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_FacilityLeaseMember" xlink:to="cmpx_FacilityLeaseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State net operating loss carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueDisclosuresTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of year</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal net operating loss carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentIncomeInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InvestmentIncomeInterest</link:label>
    <link:label xlink:label="us-gaap_InvestmentIncomeInterest-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OverAllotmentOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_TovecimigMember" xlink:label="cmpx_TovecimigMember" xlink:type="locator"/>
    <link:label xlink:label="cmpx_TovecimigMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tovecimig [Member]</link:label>
    <link:label xlink:label="cmpx_TovecimigMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to Tovecimig</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_TovecimigMember" xlink:to="cmpx_TovecimigMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_GeneralMember" xlink:label="cmpx_GeneralMember" xlink:type="locator"/>
    <link:label xlink:label="cmpx_GeneralMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General [Member]</link:label>
    <link:label xlink:label="cmpx_GeneralMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to general.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_GeneralMember" xlink:to="cmpx_GeneralMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_CTX8371Member" xlink:label="cmpx_CTX8371Member" xlink:type="locator"/>
    <link:label xlink:label="cmpx_CTX8371Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CTX-8371 [Member]</link:label>
    <link:label xlink:label="cmpx_CTX8371Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to CTX-8371.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_CTX8371Member" xlink:to="cmpx_CTX8371Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_CTX471Member" xlink:label="cmpx_CTX471Member" xlink:type="locator"/>
    <link:label xlink:label="cmpx_CTX471Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CTX-471 [Member]</link:label>
    <link:label xlink:label="cmpx_CTX471Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to CTX-471</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_CTX471Member" xlink:to="cmpx_CTX471Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_DevelopmentMilestonePayment" xlink:label="cmpx_DevelopmentMilestonePayment" xlink:type="locator"/>
    <link:label xlink:label="cmpx_DevelopmentMilestonePayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cmpx_DevelopmentMilestonePayment</link:label>
    <link:label xlink:label="cmpx_DevelopmentMilestonePayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development Milestone Payment</link:label>
    <link:label xlink:label="cmpx_DevelopmentMilestonePayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents payments for development milestones.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_DevelopmentMilestonePayment" xlink:to="cmpx_DevelopmentMilestonePayment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesOther</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesOther-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PersonnelMember" xlink:label="cmpx_PersonnelMember" xlink:type="locator"/>
    <link:label xlink:label="cmpx_PersonnelMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Personnel [Member]</link:label>
    <link:label xlink:label="cmpx_PersonnelMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to personnel.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_PersonnelMember" xlink:to="cmpx_PersonnelMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income and Expense [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MarketableSecuritiesPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfStockIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Issuance costs from issuance of common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskCreditRisk-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net shares settlement of RSUs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_AtTheMarketMember" xlink:label="cmpx_AtTheMarketMember" xlink:type="locator"/>
    <link:label xlink:label="cmpx_AtTheMarketMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market [Member]</link:label>
    <link:label xlink:label="cmpx_AtTheMarketMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents at the market.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_AtTheMarketMember" xlink:to="cmpx_AtTheMarketMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees</link:label>
    <link:label xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense Related to Distribution or Servicing and Underwriting Fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:to="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock and warrants</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="us-gaap_NoninterestExpenseOfferingCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NoninterestExpenseOfferingCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NoninterestExpenseOfferingCost</link:label>
    <link:label xlink:label="us-gaap_NoninterestExpenseOfferingCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering Cost, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseOfferingCost" xlink:to="us-gaap_NoninterestExpenseOfferingCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockByClassTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_IcfrAuditorAttestationFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_IcfrAuditorAttestationFlag</link:label>
    <link:label xlink:label="dei_IcfrAuditorAttestationFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StateAndLocalJurisdictionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentAnnualReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentAnnualReport</link:label>
    <link:label xlink:label="dei_DocumentAnnualReport-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SoftwareDevelopmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Development [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityIncorporationStateCountryCode</link:label>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentTransitionReport</link:label>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentFinStmtErrorCorrectionFlag</link:label>
    <link:label xlink:label="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityInteractiveDataCurrent</link:label>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_SecurityExchangeName</link:label>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_Security12bTitle</link:label>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_AuditorName</link:label>
    <link:label xlink:label="dei_AuditorName-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" xlink:label="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" xlink:type="locator"/>
    <link:label xlink:label="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount</link:label>
    <link:label xlink:label="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in unrecognized tax benefits</link:label>
    <link:label xlink:label="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in unrecognized tax benefits.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" xlink:to="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorFirmId-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_AuditorFirmId</link:label>
    <link:label xlink:label="dei_AuditorFirmId-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorLocation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_AuditorLocation</link:label>
    <link:label xlink:label="dei_AuditorLocation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" xlink:label="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" xlink:type="locator"/>
    <link:label xlink:label="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent</link:label>
    <link:label xlink:label="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in unrecognized tax benefits</link:label>
    <link:label xlink:label="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in unrecognized tax benefits.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" xlink:to="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplierFinanceProgramTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="us-gaap_SupplierFinanceProgramTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potentially dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_CTX10726Member" xlink:label="cmpx_CTX10726Member" xlink:type="locator"/>
    <link:label xlink:label="cmpx_CTX10726Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CTX-10726 [Member]</link:label>
    <link:label xlink:label="cmpx_CTX10726Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents CTX-10726.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_CTX10726Member" xlink:to="cmpx_CTX10726Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted weighted average shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per share - basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of changes in tax laws or rates enacted in the current period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_RestrictedStockUnitsAndOptionsMember" xlink:label="cmpx_RestrictedStockUnitsAndOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="cmpx_RestrictedStockUnitsAndOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units and Options [Member]</link:label>
    <link:label xlink:label="cmpx_RestrictedStockUnitsAndOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the restricted stock units and options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cmpx_RestrictedStockUnitsAndOptionsMember" xlink:to="cmpx_RestrictedStockUnitsAndOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation &amp; other nondeductible expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and local income tax, net of federal (national) income tax effect</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Effects</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits, percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationOtherAdjustments</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal statutory rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of changes in tax laws or rates enacted in the current period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ROU asset amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationNondeductibleExpense</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation &amp; other nondeductible expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized gains</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and local income tax, net of federal (national) income tax effect</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Effects</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>cmpx-20251231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:02PM UTC 2026-03-04--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-1-formation-and-business-of-the-company" xlink:href="cmpx-20251231.xsd#statement-note-1-formation-and-business-of-the-company" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-1-formation-and-business-of-the-company" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NotesToFinancialStatementsAbstract" xlink:label="cmpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfProductInformationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information" xlink:href="cmpx-20251231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId-2" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName-2" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation-2" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-" xlink:href="cmpx-20251231.xsd#statement-condensed-consolidated-balance-sheets-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCash" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals" xlink:href="cmpx-20251231.xsd#statement-condensed-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="cmpx-20251231.xsd#statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity" xlink:href="cmpx-20251231.xsd#statement-condensed-consolidated-statements-of-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-1" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity-parentheticals" xlink:href="cmpx-20251231.xsd#statement-condensed-consolidated-statements-of-stockholders-equity-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows" xlink:href="cmpx-20251231.xsd#statement-condensed-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount" xlink:label="cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern" xlink:href="cmpx-20251231.xsd#statement-note-2-liquidity-uncertainties-and-going-concern" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NotesToFinancialStatementsAbstract" xlink:label="cmpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies" xlink:href="cmpx-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NotesToFinancialStatementsAbstract" xlink:label="cmpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_EquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements" xlink:href="cmpx-20251231.xsd#statement-note-4-fair-value-measurements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NotesToFinancialStatementsAbstract" xlink:label="cmpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_AssetBackedSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities" xlink:href="cmpx-20251231.xsd#statement-note-5-marketable-securities" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NotesToFinancialStatementsAbstract" xlink:label="cmpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_AssetBackedSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment" xlink:href="cmpx-20251231.xsd#statement-note-6-property-and-equipment" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NotesToFinancialStatementsAbstract" xlink:label="cmpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_EquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_SoftwareDevelopmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses" xlink:href="cmpx-20251231.xsd#statement-note-7-accrued-expenses" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NotesToFinancialStatementsAbstract" xlink:label="cmpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_SupplierFinanceProgramTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity" xlink:href="cmpx-20251231.xsd#statement-note-8-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_AtTheMarketMember" xlink:label="cmpx_AtTheMarketMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NotesToFinancialStatementsAbstract" xlink:label="cmpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:label="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_UnderwritingAgreementMember" xlink:label="cmpx_UnderwritingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="cmpx_UnderwritingAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="cmpx_AtTheMarketMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation" xlink:href="cmpx-20251231.xsd#statement-note-9-stockbased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NotesToFinancialStatementsAbstract" xlink:label="cmpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_The2020StockOptionAndIncentivePlanMember" xlink:label="cmpx_The2020StockOptionAndIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="cmpx_The2020StockOptionAndIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share" xlink:href="cmpx-20251231.xsd#statement-note-10-basic-and-diluted-net-loss-per-share" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NotesToFinancialStatementsAbstract" xlink:label="cmpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:label="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements" xlink:href="cmpx-20251231.xsd#statement-note-11-license-research-and-collaboration-agreements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_ABLBioAgreementMember" xlink:label="cmpx_ABLBioAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_AdimabAgreementMember" xlink:label="cmpx_AdimabAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NotesToFinancialStatementsAbstract" xlink:label="cmpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_OncologyMember" xlink:label="cmpx_OncologyMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_OphthalmologyMember" xlink:label="cmpx_OphthalmologyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="cmpx_ABLBioAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="cmpx_OncologyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="cmpx_OphthalmologyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="cmpx_AdimabAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies" xlink:href="cmpx-20251231.xsd#statement-note-12-commitments-and-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_FacilityLeaseMember" xlink:label="cmpx_FacilityLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NotesToFinancialStatementsAbstract" xlink:label="cmpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialStandbyLetterOfCreditMember" xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_LossContingenciesTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsNatureDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="cmpx_FacilityLeaseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_FinancialStandbyLetterOfCreditMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income" xlink:href="cmpx-20251231.xsd#statement-note-13-other-income" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NotesToFinancialStatementsAbstract" xlink:label="cmpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe" xlink:href="cmpx-20251231.xsd#statement-note-14-income-taxe" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NotesToFinancialStatementsAbstract" xlink:label="cmpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-" xlink:href="cmpx-20251231.xsd#statement-note-15-segment-information-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_CTX10726Member" xlink:label="cmpx_CTX10726Member" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_CTX471Member" xlink:label="cmpx_CTX471Member" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_CTX8371Member" xlink:label="cmpx_CTX8371Member" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_GeneralMember" xlink:label="cmpx_GeneralMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NotesToFinancialStatementsAbstract" xlink:label="cmpx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PersonnelMember" xlink:label="cmpx_PersonnelMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_TovecimigMember" xlink:label="cmpx_TovecimigMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="cmpx_PersonnelMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="cmpx_GeneralMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="cmpx_TovecimigMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="cmpx_CTX471Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="cmpx_CTX8371Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="cmpx_CTX10726Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_TradingArrByIndTable" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="ecd_AwardTmgDiscLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AwardTmgDiscLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AwardTmgDiscLineItems" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AwardTmgDiscLineItems" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies" xlink:href="cmpx-20251231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:label="cmpx_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PatentsCostsPolicyTextBlock" xlink:label="cmpx_PatentsCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PolicyTable" xlink:label="cmpx_PolicyTable" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-significant-accounting-policies-policies" xlink:label="cmpx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-significant-accounting-policies-policies" xlink:to="cmpx_PolicyTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_PolicyTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_PolicyTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cmpx_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cmpx_PatentsCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables" xlink:href="cmpx-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="cmpx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_RestrictedStockUnitsAndOptionsMember" xlink:label="cmpx_RestrictedStockUnitsAndOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:label="cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="cmpx_RestrictedStockUnitsAndOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="cmpx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-tables" xlink:href="cmpx-20251231.xsd#statement-note-4-fair-value-measurements-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-tables" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-4-fair-value-measurements-tables" xlink:label="cmpx_statement-statement-note-4-fair-value-measurements-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-4-fair-value-measurements-tables" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-tables" xlink:href="cmpx-20251231.xsd#statement-note-5-marketable-securities-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-tables" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-5-marketable-securities-tables" xlink:label="cmpx_statement-statement-note-5-marketable-securities-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-5-marketable-securities-tables" xlink:to="us-gaap_MarketableSecuritiesTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-tables" xlink:href="cmpx-20251231.xsd#statement-note-6-property-and-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-6-property-and-equipment-tables" xlink:label="cmpx_statement-statement-note-6-property-and-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-6-property-and-equipment-tables" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-tables" xlink:href="cmpx-20251231.xsd#statement-note-7-accrued-expenses-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-7-accrued-expenses-tables" xlink:label="cmpx_statement-statement-note-7-accrued-expenses-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-7-accrued-expenses-tables" xlink:to="us-gaap_SupplierFinanceProgramTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-tables" xlink:href="cmpx-20251231.xsd#statement-note-9-stockbased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-9-stockbased-compensation-tables" xlink:label="cmpx_statement-statement-note-9-stockbased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-9-stockbased-compensation-tables" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-tables" xlink:href="cmpx-20251231.xsd#statement-note-10-basic-and-diluted-net-loss-per-share-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-tables" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-10-basic-and-diluted-net-loss-per-share-tables" xlink:label="cmpx_statement-statement-note-10-basic-and-diluted-net-loss-per-share-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-10-basic-and-diluted-net-loss-per-share-tables" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-tables" xlink:href="cmpx-20251231.xsd#statement-note-12-commitments-and-contingencies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-tables" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-12-commitments-and-contingencies-tables" xlink:label="cmpx_statement-statement-note-12-commitments-and-contingencies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-12-commitments-and-contingencies-tables" xlink:to="us-gaap_LossContingenciesTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-tables" xlink:href="cmpx-20251231.xsd#statement-note-14-income-taxe-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-tables" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-14-income-taxe-tables" xlink:label="cmpx_statement-statement-note-14-income-taxe-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-14-income-taxe-tables" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-tables" xlink:href="cmpx-20251231.xsd#statement-note-15-segment-information-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-tables" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-15-segment-information-tables" xlink:label="cmpx_statement-statement-note-15-segment-information-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-15-segment-information-tables" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-2-liquidity-uncertainties-and-going-concern-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern-details-textual" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NoteToFinancialStatementDetailsTextual" xlink:label="cmpx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NoteToFinancialStatementDetailsTextual" xlink:label="cmpx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details" xlink:href="cmpx-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details" xlink:label="cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_EquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:href="cmpx-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:label="cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details" xlink:href="cmpx-20251231.xsd#statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details" xlink:label="cmpx_statement-statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_AssetBackedSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details" xlink:href="cmpx-20251231.xsd#statement-note-5-marketable-securities-marketable-securities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-5-marketable-securities-marketable-securities-details" xlink:label="cmpx_statement-statement-note-5-marketable-securities-marketable-securities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-5-marketable-securities-marketable-securities-details" xlink:to="us-gaap_MarketableSecuritiesTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_AssetBackedSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n9" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-maturity-details" xlink:href="cmpx-20251231.xsd#statement-note-5-marketable-securities-maturity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-maturity-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:label="cmpx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-5-marketable-securities-maturity-details" xlink:label="cmpx_statement-statement-note-5-marketable-securities-maturity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-5-marketable-securities-maturity-details" xlink:to="us-gaap_MarketableSecuritiesTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-6-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NoteToFinancialStatementDetailsTextual" xlink:label="cmpx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details" xlink:href="cmpx-20251231.xsd#statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details" xlink:label="cmpx_statement-statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_EquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_SoftwareDevelopmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-7-accrued-expenses-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-details-textual" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_AccruedManufacturingExpenses" xlink:label="cmpx_AccruedManufacturingExpenses-2" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NoteToFinancialStatementDetailsTextual" xlink:label="cmpx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_SupplierFinanceProgramTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_AccruedManufacturingExpenses-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:href="cmpx-20251231.xsd#statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_AccruedProjectExpensesCurrent" xlink:label="cmpx_AccruedProjectExpensesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:label="cmpx_statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:to="us-gaap_SupplierFinanceProgramTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_AccruedProjectExpensesCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-8-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_AtTheMarketMember" xlink:label="cmpx_AtTheMarketMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_ClassOfWarrantOrRightPurchasePrice" xlink:label="cmpx_ClassOfWarrantOrRightPurchasePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NoteToFinancialStatementDetailsTextual" xlink:label="cmpx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:label="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_ProceedsFromIssuanceOfCommonStockNet" xlink:label="cmpx_ProceedsFromIssuanceOfCommonStockNet-2" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_StockIssuableDuringPeriodShares" xlink:label="cmpx_StockIssuableDuringPeriodShares-2" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_UnderwritingAgreementMember" xlink:label="cmpx_UnderwritingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="us-gaap_NoninterestExpenseOfferingCost-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="cmpx_UnderwritingAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="cmpx_AtTheMarketMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_ClassOfWarrantOrRightPurchasePrice-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_StockIssuableDuringPeriodShares-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoninterestExpenseOfferingCost-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_ProceedsFromIssuanceOfCommonStockNet-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-9-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NoteToFinancialStatementDetailsTextual" xlink:label="cmpx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_The2020StockOptionAndIncentivePlanMember" xlink:label="cmpx_The2020StockOptionAndIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="cmpx_The2020StockOptionAndIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:href="cmpx-20251231.xsd#statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:label="cmpx_statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:href="cmpx-20251231.xsd#statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:label="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue" xlink:label="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:label="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:label="cmpx_statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n9" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-weighted-average-assumptions-details" xlink:href="cmpx-20251231.xsd#statement-note-9-stockbased-compensation-weighted-average-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-weighted-average-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-9-stockbased-compensation-weighted-average-assumptions-details" xlink:label="cmpx_statement-statement-note-9-stockbased-compensation-weighted-average-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-9-stockbased-compensation-weighted-average-assumptions-details" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details" xlink:href="cmpx-20251231.xsd#statement-note-9-stockbased-compensation-summary-of-rsu-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:label="cmpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited-n8" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:label="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-9-stockbased-compensation-summary-of-rsu-activity-details" xlink:label="cmpx_statement-statement-note-9-stockbased-compensation-summary-of-rsu-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-9-stockbased-compensation-summary-of-rsu-activity-details" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited-n8" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-10-basic-and-diluted-net-loss-per-share-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NoteToFinancialStatementDetailsTextual" xlink:label="cmpx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:label="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" xlink:href="cmpx-20251231.xsd#statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" xlink:label="cmpx_statement-statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-11-license-research-and-collaboration-agreements-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_ABLBioAgreementMember" xlink:label="cmpx_ABLBioAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_AdimabAgreementMember" xlink:label="cmpx_AdimabAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_DevelopmentMilestonePayment" xlink:label="cmpx_DevelopmentMilestonePayment-2" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_MaximumCommercialMilestonePaymentsAndRoyalties" xlink:label="cmpx_MaximumCommercialMilestonePaymentsAndRoyalties-2" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_MaximumDevelopmentAndRegulatoryMilestonePayments" xlink:label="cmpx_MaximumDevelopmentAndRegulatoryMilestonePayments-2" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_MilestonePaymentObligation" xlink:label="cmpx_MilestonePaymentObligation-2" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_MilestonePaymentsPaid" xlink:label="cmpx_MilestonePaymentsPaid-2" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NoteToFinancialStatementDetailsTextual" xlink:label="cmpx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_OncologyMember" xlink:label="cmpx_OncologyMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_OphthalmologyMember" xlink:label="cmpx_OphthalmologyMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_UpfrontPayment" xlink:label="cmpx_UpfrontPayment-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="cmpx_ABLBioAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="cmpx_OncologyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="cmpx_OphthalmologyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="cmpx_AdimabAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_UpfrontPayment-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_DevelopmentMilestonePayment-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_MaximumDevelopmentAndRegulatoryMilestonePayments-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_MaximumCommercialMilestonePaymentsAndRoyalties-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_MilestonePaymentsPaid-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_MilestonePaymentObligation-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-12-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_FacilityLeaseMember" xlink:label="cmpx_FacilityLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NoteToFinancialStatementDetailsTextual" xlink:label="cmpx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialStandbyLetterOfCreditMember" xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_LossContingenciesTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsNatureDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="cmpx_FacilityLeaseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_FinancialStandbyLetterOfCreditMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCash-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details" xlink:href="cmpx-20251231.xsd#statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details" xlink:label="cmpx_statement-statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details" xlink:to="us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-n9" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-13-other-income-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income-details-textual" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NoteToFinancialStatementDetailsTextual" xlink:label="cmpx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-14-income-taxe-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-details-textual" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NoteToFinancialStatementDetailsTextual" xlink:label="cmpx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details" xlink:href="cmpx-20251231.xsd#statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" xlink:label="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" xlink:label="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent-2" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details" xlink:label="cmpx_statement-statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-n9" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch-n9" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details" xlink:href="cmpx-20251231.xsd#statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_DeferredTaxAssetsCapitalizedLicensingFees" xlink:label="cmpx_DeferredTaxAssetsCapitalizedLicensingFees-2" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_DeferredTaxAssetsLeaseLiabilities" xlink:label="cmpx_DeferredTaxAssetsLeaseLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_DeferredTaxAssetsSection174Capitalization" xlink:label="cmpx_DeferredTaxAssetsSection174Capitalization-2" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details" xlink:label="cmpx_statement-statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_DeferredTaxAssetsSection174Capitalization-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_DeferredTaxAssetsLeaseLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cmpx_DeferredTaxAssetsCapitalizedLicensingFees-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross-3" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n9" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet-3" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-n9" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesOther-n9" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-details-textual" xlink:href="cmpx-20251231.xsd#statement-note-15-segment-information-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-details-textual" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_NoteToFinancialStatementDetailsTextual" xlink:label="cmpx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details" xlink:href="cmpx-20251231.xsd#statement-note-15-segment-information-schedule-of-segment-reporting-information-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_CTX10726Member" xlink:label="cmpx_CTX10726Member" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_CTX471Member" xlink:label="cmpx_CTX471Member" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_CTX8371Member" xlink:label="cmpx_CTX8371Member" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_GeneralMember" xlink:label="cmpx_GeneralMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_PersonnelMember" xlink:label="cmpx_PersonnelMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_TovecimigMember" xlink:label="cmpx_TovecimigMember" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_statement-statement-note-15-segment-information-schedule-of-segment-reporting-information-details" xlink:label="cmpx_statement-statement-note-15-segment-information-schedule-of-segment-reporting-information-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cmpx_statement-statement-note-15-segment-information-schedule-of-segment-reporting-information-details" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="cmpx_PersonnelMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="cmpx_GeneralMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="cmpx_TovecimigMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="cmpx_CTX471Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="cmpx_CTX8371Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="cmpx_CTX10726Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>cmpx-20251231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:02PM UTC 2026-03-04--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-" xlink:href="cmpx-20251231.xsd#statement-condensed-consolidated-balance-sheets-" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCash" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="cmpx-20251231.xsd#statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows" xlink:href="cmpx-20251231.xsd#statement-condensed-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount" xlink:label="cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details" xlink:href="cmpx-20251231.xsd#statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-maturity-details" xlink:href="cmpx-20251231.xsd#statement-note-5-marketable-securities-maturity-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-maturity-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:label="cmpx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="cmpx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details" xlink:href="cmpx-20251231.xsd#statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:href="cmpx-20251231.xsd#statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_AccruedProjectExpensesCurrent" xlink:label="cmpx_AccruedProjectExpensesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="cmpx_AccruedProjectExpensesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details" xlink:href="cmpx-20251231.xsd#statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details" xlink:href="cmpx-20251231.xsd#statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" xlink:label="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" xlink:label="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details" xlink:href="cmpx-20251231.xsd#statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details" xlink:type="extended">
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_DeferredTaxAssetsCapitalizedLicensingFees" xlink:label="cmpx_DeferredTaxAssetsCapitalizedLicensingFees" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_DeferredTaxAssetsLeaseLiabilities" xlink:label="cmpx_DeferredTaxAssetsLeaseLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="cmpx-20251231.xsd#cmpx_DeferredTaxAssetsSection174Capitalization" xlink:label="cmpx_DeferredTaxAssetsSection174Capitalization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="cmpx_DeferredTaxAssetsSection174Capitalization" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="cmpx_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="cmpx_DeferredTaxAssetsCapitalizedLicensingFees" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cell1.jpg
<TEXT>
begin 644 cell1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "5 &H# 2(  A$! Q$!_\0
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MG61EAC5U>0X)V@&0<GC@^E?)?Q$\>ZI\3?%MYK^L2;[B=L1PC[EO&/NQH.P
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%HH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cell2.jpg
<TEXT>
begin 644 cell2.jpg
M_]C_X0@V17AI9@  34T *@    @ # $   ,    ! 9,   $!  ,    ! @8
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   @    M $R  (    4    U(=I  0    !    Z    2  "  (  @ ,EJ@
M   G$  R6J   "<0061O8F4@4&AO=&]S:&]P(#(V+C$Q("A7:6YD;W=S*0 R
M,#(V.C R.C(P(#$U.C0Q.C$X   $D   !P    0P,C,QH $  P    '__P
MH ( !     $   #(H , !     $   $!          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MJJZ'V;'?X/\ J)NF8573?K%GWY.56S>/T3'^PN&0_P!8.EYV^Q]+J/9_.?\
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M<VAO<" S+C  .$))300$       /' %:  ,;)4<< @   @   #A"24T$)0
M    $,W/^GVHQ[X)!7!VKJ\%PTXX0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q =*
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ %*     0 ! 4H
M   !  $X0DE-!"8       X             /X   #A"24T$#0      !
M !XX0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$1       $     (
M  )    "0      X0DE-!$D       0     .$))300>       $     #A"
M24T$&@     #/P    8              0$   #(    !0!C &4 ; !L #(
M   !                          $              ,@   $!
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   $!     %)G
M:'1L;VYG    R     9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   ! 0    !29VAT;&]N9P   ,@    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M   "/_         X0DE-!!$       $! #A"24T$%       !     (X0DE-
M! P     !LP    !    +    #@   "$   <X   !K  &  !_]C_[0 ,061O
M8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/
M# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,#/_  !$( #@ + ,!(@ "$0$#$0'_W0 $
M  /_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
M          $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q
M!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-4
M9$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6
MYO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q
M(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,7
M9$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='
M5V=WAY>GM\?_V@ , P$  A$#$0 _ /2NJ9.7C8-EF%2<C*,,HKB1O>0QK[-6
M?H:]WJ6_I*_9_A%EV]=ZR:P^GI=C&N!/Z06.?(J>_8ZFNKV.^UM92QWJOJM9
M_H]]:V<O)9B8MV58'.90QUCFM$N(:-Q#5PG6?K_U3'S,+*QJ@SIX$96.X-<7
MOD[V>M^9^AV/QW,V?I/4]3U?H)DSPCB)('@V>5A[LABC",IGBE'CD8W4?E'^
M+Z7HL_JGU@JLM&/A[:V&M[7/K?:?3LLJQBS]4LLWWU1EYEGH^KZ>)]E_1^KZ
MBB_JOU@=:^JC&EQ+&LWX]C6-:7T,]=][K&^IZU%MV1Z+*OU/T_2R?TE7Z7>I
MM9?2RZN=EK0]L@@PX;FRUWN:IH\)_>*T9HB@<4;'\O4Y1ZGU$=5IQ3@VC$(+
M+\HM!&\[_0LK]*RW] [T/TG^C^TX_K>@M5>>X'U]ZIE=;RLAK0>CU!S68Q:T
M/D^W&_2_3]>U[-]K7/?771Z_^C76_MZK]@_MKT7[-L^CINW;O1^E]'T_4_PO
M^B_2)HR#A,K-75LTN4R>_##P0]PPXN 2._!+)Z_]9_5?_]#U3G0KCNN]-JZ
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M -:TZ!P<_4>W=[JO3W^Y65\JI*'7B_1V_P '9LZ<'Z>_^'\S_]DX0DE-!"$
M     %<    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M   4 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  ,@ P #( -0
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MQ &B    !P$! 0$!           $!0,"!@$ !P@)"@L!  (" P$! 0$!
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M^A0<S7FV\5=BKL5?_]7[^8J[%78J[%78JT>AQ5_/S_S\"_YR$\S>?/S3U_\
M*G3-4EL?R\\@7*V%QI$#M&FH:I$ UQ<7/$CU!$Y].-6J%XEANV<3VWKYY,IQ
M U&/VE^H/^!5[):?2Z#'K\D8RS9MP3_!&]N'NOF>^_)^>*,4='0E)(V#1NI*
MLK*:@@BA!^6: &GUV<(S%2%OW0_Y][?\Y1ZC^8>E77Y.?F'K4FI^<O+D'UGR
M=K-V_*XU'2XP!)!)(QY236O7D?B:,U-2C,>U[#[2.8>%D/JCR\Q^M^9/^"G[
M$P[-R#7:2/#AR&I@<HS[QW1ER[N+WA^HE1XYT#XZWBKL5=BKL5=BKL5=BKL5
M2[5M5TW0]*U+6M8OH=-TG2;66\U/4)V"106\"&261V/154$DY&4A$$D[!LQ8
MIY9C' $RD: ',D\@_F3_ .<I?^<A]=_YR$_,;4M9DN[B'R-H\[VOD'RX[%8K
M>T4T%R\0-/7N!\<A.XJ$K11GGW:6O.KR$@^D<AY/V'[#>R&+V?T48RB/'F <
MDN>_.@?YHY5RZ\WS-2NQ%?;-8'N)"Q56_?[_ )]S_G=Y@_,_\L=;\G^;=1EU
M;7/RQN[:UL=4N',EQ/I5VCFV65F^)S"T3IR)J5X@[@G.Y["UDL^(QEN8[7Y/
MRI_P6/9O!V7VA#-@CPPS@GA&PC*)'%7D;!]]OT8K^/3-Z^5NQ5V*O__6^_F*
MNQ5V*H/4+^TTJPO=3OYEMK'3K>2ZO;AND<4*EW8_)03BK\?OS0_YR$\^_F7J
MU[):ZY>^6O)QD8:)Y<TZ9[8M;@_!+>2Q$/)(X^(CEQ7H!WQ5CWD7\ZOS*_+O
M4K>_T3S+?:E8Q2!KSRSJEQ)=V5TE?B2DS,T3$='0@@]:C;%7QM_SEGY;2V_-
M;4OS#T=))/)?YP^IYI\L7K]I9F"ZE92]EFM+OFCKV'!NC#."[;TLL.H)/*6X
M^+];_P# M[;P]H]C8\<-IX!P3C[N1^(H_-\P?C3MFF?2;95Y*\X^8/R]\V^7
MO.WE:\;3_,/EB]CO]+N1]D21G='%1R2124=>C*2#UR[#FEAF)Q.X==VKV9A[
M1TL]+GC<)Q(([NH(\P_J/_)+\V="_.[\M?*_YC^7R(H-;@XZGIQ-7LKZ'X+J
MU?\ XQR \2?M+Q;H<]'T>IAJ<8R1Y'["_%/M!V)F[&UV329=S$['^=$_3+Y?
M(V.CUW,ETSL5=BKL5=BKL5=BK1Z'%7Y%_P#/RG_G(B33+"U_YQ_\K79CO=8A
MAU+\Q;J%B&CLR>=II]0?]W%1+(/Y @Z.<YGM_7\$? AS//\ 5\7W+_@0>R(U
M&4]IYQ<8$C&.^76?^;R'G?4/Q>SCWZ.=^'OB!:DT_5;_ )QGU'6O^<</R)U#
MS7;QQ6WYD?GQ<0W'E*UND#FP\OZ>KQIJ<T1._K22N8584;X6W6HSN?9_22Q8
M3DE_'^A^6/\ @N]OX]?VC'38C<=.""?Z<JXA\*'N-AC&I^8_,FM7\FJZSYDU
M;5=4F;G+J%S>SF0M_D\754'@%  [9O7R9]>?\XQ?G]YEMO-FE?EQYTU:?7M"
M\P,;;RWJMZYENK*]"EHX&F:K212A2J\JE6IO0[*OTK&*O__7^_F*NQ5V*L$_
M,_0[[S-^77G?R_IA;](ZOHE[:V07JTLD+!%'^L=L5?AM$&6-$D1HI(QPEB84
M9'3X65@>A4@@CQQ54Q5.5\O6/YF^5=5_)_5YH;277KG])_EQK5P0B:=YH2/T
MXXI)/V8-3C MI>PD]*0[KF#VCHAK,!A_$/I>L]BO::?L]VC'4$_NI;91_0)Y
MCOE'G\QR?F_J.G7^DW][I6J64MAJ6ESRV>H6,RF.:">%S')%*AW5T92K ]#G
MG)B8D@[$%^S<.:&>$<D#Q1E$&)'42W!\T!D6\OW+_P"?6":HOY5_F3).LJZ-
M)YKB&F%J\#<+91?62E=NACK3OG9^S0/@SOE?Z'YE_P"#9+%_*6 1^L8_5\9'
MA_2_4O.C?&78J[%78J[%78J[%6B10]_$8J_F<_YSATK6-+_YRD_-8:O'('U*
M\MM0TV9ZTELIK.$0LA[JJKP^:G//^VHF.JG?6OT/V#_P,L^/+V#IACYQ$@??
M9O\ 6^31OMFIHA[W8[6^CO\ G&K\HK#\T?.EUJOF\O9_E5^7=LNO?F5J@V#6
MD;4@L(VJ/WMZX]-%!!IS(W&;3LG0?FLU?PQW/ZG@_P#@@^UL>P>SI2@?WV6X
MPZ[]9^Z(W]]#J^K_ #GYLOO//F;4O,]_ ED;SA!I>DP@+#I^GVZ^G:6<*J %
M6*, &@W:I[YZ$-@*Y/Q_.4IR)D;-DV>?G9\SNQC%B]4_(WR]J'F?\W_R_P!.
MTZ-G:PU:'6+^5=A#::>?6DD8]JD*@\2P&*OVK'\<5?_0^_F*NQ5V*NQ5^7?_
M #EK^49\H>:%_,/1+;T_+7G&XXZW$@^"TU=A7G[+= 5\/4!_F&*OD/%5.45C
MD'(H>)(<&A4C<,#V(.XQ5])?FM_SA%=?\Y#^4/*/YT>2-8M/+WYF^:-#L;KS
MCIFHATL-7NEA5#>B2-7,$\H4%SP*N=SQ;DS:'M3L;\Q+Q,="74="^M^PW_!.
MGV+A&CU<3/"/IE'ZX>6_U#[1RW% < \E?\^QOSOU;6[>#SMK.@>3_+J2 W^H
MV]PVHW;1@[BW@C5$+$="[J![],U.+V>SREZR!\;?0.U/^#-V;APG\K">29Z$
M<('O.^WN#[^\S_F9Y'_YQ/\ *VA_DE^4WE^/5=7T&T66[^NRGT;=K@F0W%^\
M05IKBX-9"B\0 1]E>(SK]/IX:> A'8#E[_-^=>V.U=1VKJI:K4&YS/P [@.X
M<@\KT/\ YS0_-&QU&*?S!HFA:]I18?6K"UCELKCC7?T93)(O*G3DI&6NN?HG
MY \^^7OS)\K:;YN\M7#3:;J 97AE 6>WGC/&6WG2IXR1ML1](J"#BK-,5=BK
ML5=BKYL_/O\ YR&TW\H8K71=*L8O,'G?5(3<6NERN4MK2WJ5%Q=LOQ49A1$7
M=J'< 5Q5\86W_.8/YV0WZW=Q+Y?OK3E5]&:P:*(KW594E,@^9)Q6KV>G>=_R
MN_+#_G/3R/;ZZLDWD'\U/)R'3WU"-5N7M?4K(EO<)5!<VDA)>-@593RH0>:G
M6]H=FPUD?5M(<B]I['>V^K]G<GH''AF090)K?O!Z2^P]>E>1]._Y]8?FC)J_
MHZS^97EFST"-Q74[*&[N+MTKOQM7CB4-3L9:9HH^S4^+>8KXOK.?_@X:7PO1
MII\==3$"_M)^3Z3_ #J_)SRM_P X^?D5Y,_+OR';3C2=7\QK<^<-<N:&[U6]
M@MG>*2Z=0!3DM40 *H4 "M2>ETFCQZ7'P0_:7Q#VB]H]5V[JI:G4FSRC$?3&
M/</=U/5\<9E.A6NZQHTCFB("6/788J_5K_G%C\H'_+[R?_B;7K/T/.?G*..>
M]B<?'96/VK:T]FH?4D_RC3]D8J^J,5?_T?OYBKL5=BKL58SYR\I:+YZ\L:SY
M3\PV_P!9TG6[9K>Z0;.M=TDC/[+QL RGL1BK\CO/O_./OYI>0-4N;23RS?>:
M=&5S^CO,VCP-=1S1 _"9X8^4D,E/M K2OV21BJ:?EG_SC=^8OYA:O:Q:OH%]
MY/\ *(=3K.MZI$;:9X/VX[2!_P!X[N*@,0%7KN=L5?7/FG_G+3\MOR^EB\H>
M2]#N_.%OY=1-.:>QECM["$6RB(10W$O+U2G'B2JE:_M'%66_E=_SE3Y#_,?5
M[3RU>6EUY.\R:BQ32['4&22WNW'^ZH+J/X3(1T1@I/[-<5?FS^:S7[?FI^9;
M:GR^O_XFU 3\NO$24A^CTN%/;%6!8J^EO^<8?S</Y;^=UT+6;GT_)OG::.WO
MY'-$L]1V2VNC78*^T4A_U6/V<5?K2#]XZXJWBKL58=Y^\[Z-^7?E+6_.&O2<
M-/T:W,GI#[<\K'C%!&-ZO(Y"CY^&*OQ.\T^9M8\Z^9-:\W>8)?6UG7[@W%W0
MU6)1\,-O'7HD* (H]J]3BJ0XJ^M_^<-+V;3_ ,Q?-]Y+<)::':^5WGUZZF8)
M#$L5PC122,Q '$<]SVY8J]T\R_\ .;7DG3M1EM/*WE?4O-]C"S(=:$L=C;RE
M33E )@TCH>S%5KVVQ5-(?S!_*[_G*_RIJWY<7$EWY6\TR1+?Z=IUZJ?6(;BV
M/*.[M'4F.=8SLZ@@\200 :XJ^*O,G_..OYT>6=2ETY_(]WYCA5B+?6="X7-M
M.H- _$LLD=?Y744]\5>Z_D5_SBKYEE\P:9YN_-'3TT?1]'E2[T[RG(Z37-W<
MQGE$UWP+)'$C -PJ2Q K0;%5^D.*NQ5__]+[^8J[%78J[%78J[%7@O\ SDUY
MBU/RS^2GG:_T>9[6_N8(=/2[C-&A2]G2WE<$=#P<@'L<5?CNB+$BQQJ%CC 5
M$'0 ; 8JN^(%621H9(W62&>,\7CD0AD=".C*P!!['%7N_GL+^9_DFU_.*V1?
M\7>6UM]$_.2QA%"_%0EAK00?LRK1)#V/^H<5>$8JM=$D1HY!R1P5=?$'KBK]
M=_\ G%OSUJ?GK\I=,FUN8W6K^6[J?0KR^8U:X6T"^C*Q[LT3J&/<@GOBKZ+Q
M5V*OS8_YS9\W:A=^;/*WD5)&CT?2[#]-7, V$UY.[PQ,WCZ2*W'P+'%7Q-BK
M1) ^%&D8D!(T%69B:*JCN22 !XXJ]S\ZG_E67D>#\HX&5?.'FL6^M?G#<Q$D
MP(5YV&B<A^S&I$DH[D^#4Q5X;^%,53/0]9O_ "YKFB>8M*E:#5-!OX+VPF7J
M'C<57W#J2A'<&F*OWGMY?7@AGX&/UHUD],]5Y &A^5<55L5=BKL5?__3^_F*
MNQ5V*NQ5V*NQ5B'GWR=IOY@>3_,/DW5RR6/F"S>V>=/MQ.:-'*OO&X5A\L5?
MB3YE\N:QY.\PZSY4\P0?5]:T"Y:UOD_9<=8YHZ]4E0AU/@<523%6?_EEYU'D
M3S;:ZE>0#4/+.L1-HWG?19-XKS2;LA)E9=JM%7U%^1'?%4T_-[\JM6_*7S)<
MV$\$UQY0O7,WD_S006M[FU?XDADE XK-$#Q8&G(49>N*O,M/MKO5[VVTO1;2
M;6=5O7$=CI5BAGN)G;8*B)4[^)V'4FF*OV"_YQX\@M^6'Y=:;Y7U6[MW\TWL
MTVK>8[.*57]&ZNJ$PK0U(B0*A/0D$]\5>\8J[VQ5\/?\Y9_E/J7G>'2_/WDF
M#_$&L>6K=[#S#H=DRRW,MB7,B2PQKN[PN6JO4J305%"J_-QYHHY#%(XAF4E6
M@D^"0$=0R-1@?8BN*OI'\L/(6H^4O+NM?G[YRT62#0/)-K]:\C:/?HT3:IK$
MA$5I.T348012.I4D#DVXV7%7SW>W^H:K?7^K:M=-?:MJMQ)>:K?.:M-<3-RD
M<_,G8=A08JAL5>Z?\X]?E7<?FC^8-E#=0-_A/RN\.I^:;FAXR%&YVUF#_-,Z
MU;P16\1BK]C*4Q5V*NQ5V*O_U/OYBKL5=BKL5=BKL5=BKXK_ .<N_P GW\R:
M'%^9?ERQ:X\Q>5H/2U^T@7E)>:4"69PJ[L]L27'<IS'ABK\T597571@Z. 4=
M=P0>A!Q5.- \N:GYPU[1_*>BV[76J^8KJ.TM($!)"L1ZLS4^RD25=F.P Q5^
MZ2Z'ITFCV^AW]I#J>GP6\5L]M=Q)+'(L2A061PRGIW&*OSR_YR8_,2W\C^8I
M/RU_*W3;'R2_U..X\Z:_HMM#9WLOUGXXK*.>%5>-> #N5-34*"-\5?%$4US!
M<K>P7EU!>JW-;Z*XE2<-6O(2JP>OO7%7Z7?\XG_G7KGGJVU?R-YPOFU7S!Y>
MMTO-*UN6GK7E@S>FPN"*!I86('*GQ*03O4E5X!_SDO\ GGYE\S><M=\B>7M6
MGTCR9Y9G.GWRV4C0RZE>QBEP9I4(;THV)14!HQ!9J[ *OEG2M2U30[Z'5-#U
M6]T;4[=N<&HV5Q)#,C#OR4[_ "8$'OBK]3?^<<?/.G?G!Y7N-4\T:#I-QY^\
MJW:66MZP+*$/<AD#V]VIX50R+4, :!E--J8J](_/;R1??F%^5/G#RMI8YZM=
M6JW&D1D\1)<VDBW$<=>@YF/COXXJ_%YEE226&>%[:YMW:*[M)5*2PRH>+QR(
M=U93L0<51-AI^HZQJ-AHVCV4FI:SJTR6VE:;$*R3S2&BJ!X#JQ.RBI.V*OV>
M_)?\K['\I_(NF^6H2EQJTO\ IOF75%&]U?R@>JP)WX)0(@[*![XJ]8Q5V*NQ
M5V*O_]7[^8J[%78J[%78J[%78JT0#UQ5\R^;?^<2OR@\U:I<:Q%87_E>\O)#
M->QZ)<_5[>1V-6;ZNRR1H23OP"XJ]"_+;\DOR[_*H3S>5-&*ZK=IZ=YK][(;
MF^DCK7AZS_96O[*!1[8J]9Q5^-'_ #D<2?SW_,BI)I<V0%>P^HP[8J\6Q5]4
M?\X:G_D-%R/'RQ>U_P"DBWQ5\]><F+><O.3,2S-Y@U4DGK_O9-BK',5???\
MS@O_ 'OYG?/2=O\ 8W.*OT%Q5XOY\_YQ^_*C\QM0;6/,?EA%UN0 3ZS82R6=
MS+04'JM"RB0CL7!.*IE^7_Y)_EI^64TEYY1\M0VFJ3(8Y=:N'>ZO"AZH)IBS
M*I[A: XJ]6Q5V*NQ5V*NQ5__UOOYBKL5=BKL5=BKL5=BKL5=BKL5=BK\9_\
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ML)11X98S1D8>QZ'H1N-L^A\&>&?&,N,B6.0!B1Y_J?CG6:3+I,LL.4&,XFI
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MJ*GN:9LAV1J?R<M88UB!J^\DUZ>_?FZ&7M#I(]HQ[.$B<Y!) &T0!Q>H^8Y
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2NQ5V*NQ5V*NQ5V*NQ5V*O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>graph1.jpg
<TEXT>
begin 644 graph1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $' D4# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** ,3QKXQTKX?>%=3\1:W.UMI6G1&
M:XE2-I&"Y X5023D@8 [UYJO[5GA%@"-$\;D'D$>#]2_^,U9_:R_Y-V\;?\
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M6V;;[:=Q>,2M("48]T#8!KWS]HZ/PSJ'PMUU];MCK#Z4(YX=.M]0FM7:Z?\
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M4HGLB]S<2R+/%L1Y=JRRG[H>/.!NRV!GFNR;XW^%=#LKV"*"_6VTAXK((D(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTU=/TF]\/Z?8+<"[6VA\/*(UF P) /-P& X&*H']G6 RS28\,!I[9;.7'AM
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M@-"LO%W_  F;37CW<.B^?<.(Y;F"5/+("QIM50V2P+@Y^4?*<Y)!];J=H_\
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M_P#$5J44<S"QE_V)+_T%;_\ [Z3_ .(H_L27_H*W_P#WTG_Q%:E%',PL9?\
M8DO_ $%;_P#[Z3_XBC^Q9/\ H*W_ /WTG_Q%:E%',PL>'ZE\,OB_/J-U)9_%
M!+>T>5FAB:RC)1"3M4GR^<# K/MOAW\7[[SOLWQ<MI_)D,,GEV<3;''53A."
M,]*]\N(%NH)(7W;)%*ML<HV",<$$$'W!S5+1=!M- CN4M%=5N)VN'WN6)<@
MG)Y_A'7WKV%FU9*W)#_P7#_(^=ED.'DV_:U?_!M3_P"2/E[]O7XC>-_@+^SC
M9>(/#'BFZM/$0U2SLYKPQ0R*X9'\S"LA R5!Z<5^<7_#PW]H/_HHD_\ X+[3
M_P"-5^@7_!6/_DU6/_L8;+_T&6OQQKZ+)Z-*MAG.I!-W?1%8V<Z4U&$G:W<_
M2+_@GS^U5\6/CG\?)O#?C+QG<ZGHZZ+<W8@6UMXCYJO$%;<L8/ =N*^DOV@_
MC+XQ^&?CU-(T76"MF;..<BX@CD;<2P/.WIP*^%_^"3G_ "=1<?\ 8N7G_HV"
MOK/]L3_DK47_ &#H?_0GKT,!A,/5SGV,Z:<>2]K*USXSB['XO!9%[?#57&?.
ME=.SMJ9'_#4_Q'_Z#,/_ (!Q?X5[U\,O'OB/Q9\#O$'BN_U>4ZO8QWC0F..-
M8P8HMR97;SSU]:^*J^M_@;_R:OXO_P"N.I?^B*[^+,!A,'ECJX>E&,KK5))[
M,^4\-\XS',^(*>'QM>52#6TFVMUT/D+_ (;Z^,7_ $&K'_P71?X5N>!?VX?B
MUXB\;^'M*N]:M/LM]J-O:S;+")6V/*JM@XX.":^6:ZKX4?\ )4O!W_89L_\
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M1Y)_P\7^-G_0;T[_ ,%D7^%?7_["GQR\:_M#Z)XMN_%VL;Y=,N;>*W^PV\<
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M/B_XH_LQ:[X\US5RVOV:Z@86MX(XXAY,6Y,H%YYZ^M?DC7Z>?L6?\F*^*_\
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M1XE]4_(T8E]4_(T 245'B7U3\C2,)MIVE">V0: ):*JYO?2W_-J,WOI;_FU
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M#?\ V$!_Z)>OD6R_X_;?_KJG\Q7UO^V:9#\/O#F\(!_: ^Z2?^6+5.;?\C7
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M0 4444 %%%% !1110 4444 %%%% &?JWA_2]=6/^TM-M-1$62@NH%EVYZXW
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MQ=.$:E=RBY3BN9:ZJ[U1Y]^SW_R77X?_ /8<L_\ T<M?07_!5_\ Y&7X=?\
M7I>_^AQ5F_"#]B_XL^$OBKX1UK4O#\$.GZ?JMM<W$@OX&*1I(K,<!LG@'@5I
M?\%7_P#D9?AU_P!>E[_Z'%6F$H5:&75E5BXW:W5NQQ9_FF S7C'+9X"O&JHT
MZB;C)2L[2WLV?!5?H[_P2A_Y%7XA_P#7[9_^@2U^<5?H[_P2A_Y%7XA_]?MG
M_P"@2UIE/^]Q^?Y,Y_$'_DG:_K#_ -+B?$_BC_D9=6_Z^YO_ $,UF5I^*/\
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MY>&_^O!__1E?.-?W3P[_ ,BJAZ/\V?X'\:?\C_%>J_\ 24?7?[&'_(@^*?\
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M_2B&OR]K]0OBS_RC/M_^P)IO_I1#7Y>U]7F.]+_!$_ ^"_AS#_L(J?H?0G[
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MH @^T-_S[R_^._XT?:&_Y]Y?_'?\:GHH @^T-_S[R_\ CO\ C1]H;_GWE_\
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MM/#+ZM<QZK+'+.=1ECD*E P&W:%Q]XUZ'#X*T.WU"UO8M-ACN+4EH"H(6,[
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M-D+_  ^\. QLG_$P'+8_YXMZ&ODBR_X_;;_KJG_H0KZZ_;1_Y)[X;_[" _\
M1+U.;?\ (UP'K/\ )%\._P#)/YMZ4_S9\?U]$?L5.4\<>("$9_\ B7+PN/\
MGJOK7SO7T7^Q-_R//B#_ +!R_P#HU:[^(O\ D55_3]4>1P;_ ,C_  OJ_P F
M?&O[3QW?M"?$ D%<ZO/P?]ZO,*]0_:@_Y.&^(/\ V&)__0J\OK^$\5_O%3U?
MYG^_&0_\BG"?]>X?^DH_0WXLR$_\$T[=?+<#^Q=-^;C'_'Q#[U^8%?J%\6?^
M49]O_P!@33?_ $HAK\O:^KS'>E_@B?@?!?PYA_V$5/T/H/\ 8&8K^U9X+(4M
M_P ?? _Z])JZC_@I4Q?]I1R5*_\ $GM.&_X'7,?L"?\ )UW@K_M\_P#22:NH
M_P""EO\ R<L__8'M/YO3C_R+7_C_ $,JW_):T_\ L'?_ *6SY3K].?V+I"/V
M%_%2^6Q&S5_F&,?ZCZU^8U?IY^Q9_P F*^*_]W5__1%/*?X\O\+)\0/^172_
MZ^P_4_,(=*ZWX1''Q8\%'&?^)W9<#_KNE<D.E==\(?\ DK/@K_L-V7_H]*\F
MG\:]3]!Q?^[5/\+_ "/K'_@L@Y=_A=E&7!O_ +V.?]37YK5^E?\ P63^_P#"
M[ZW_ /*&OS4K^G,H_P!RA\_S9_G%COX\OE^1^EW_  1N8B+XH#:3F2PY&..)
M:^^Y/^2P6_\ V I/_2A*^!O^"-G^H^*7_72P_E+7WS)_R6"W_P"P%)_Z4)7S
M6._WZM_A_P#;4=3_ -WH_P"./YG94445\T>^>4_M,6UM>_#%K6ZMENTGO[:-
M8GB\Q2V_@E1R<=?E(.0.V:](T.(P:)I\9=I"EO&N]P S84<G  S^ K@OV@$@
MN_ R:?<K8F&]NXXF:_U..P5<98%7<$%OE^Z.>I[5W'A_9;>&]-S*LD<=I'F7
MS/,# (/FW8&[US@9IK9^H/=&G17$6/Q9TN^\>MX26VNDU%5#B0A#$R,CNC@A
MB2&$;]N",'%='?\ B;3-,>-+J[6)I+E+-058YF<95.!W'X4)-[(#4HKF9/B5
MX:BMI[A]5C$,%U]BD?8_RS<G9T]C[<4^Y^(?AVS.I";4XT_LZ1(KK*/^Z=CA
M0>.<D'I5^SG_ "O[A77<Z.BN=N?B#X>LWU!9M3C1M/57N04?]V&QM)XYSD=*
M?_PG>@[[A?[13=;V@OI1L;Y83C#].G(]Z/9S_E871OT5SP^('A]IDB&I)YCV
M?]H*NQ^;?:6W].F 3CK[4ZR\>Z#J$MC';ZBDKWT3SVX",/,1"0Q&1QC:>OI1
M[.:Z,+HWZ*YRU^(?AV]_L[R-3CD_M%F6UPC_ +TJ<'''&/>BU^(?AV]6U:#4
MXY!=71LX2$?YYO[G3W'M1[.?\K"Z[G1T5S'_  LKPU]E%S_:L?D&Z^Q;_+?_
M %V,[/N_KTJ2X^(GAVU%^9=3C06$ZVMSE'_=R,2 IXYR5/3TH]E/^5_<%UW.
MCHK*_P"$HTK?L^V)N\X6^,'_ %A&0O2A/%.E2-$%O$)DE:%.#RZ]1T[5/*^P
MS5HK(A\5Z3<"(QWJ,)5=TX/(3[QZ=J0>+M(,8<7J;3 ;D':W^K!QNZ4<LNPK
MHV**R7\5Z3&)2]]&HBB29R0>$?[IZ=\BGR>)=+B,H>\C4Q.D;]?E9ONC\:.6
M78+FG169_P ))IGF%/MD>X3?9\<_ZS^[]:2/Q-I<K1JM[&S22-$@YY9?O#\*
M.5]@N:E%94?BC2I5B9+V-A*CR(>>57[Q_"C_ (2G2?++_;HM@@^TYY_U><;O
MI1RR[!=&K167)XGTJ%9"][&HC1)')SPK?=/XTLGB33(6E#WD:F)UC<<_*S?=
M'XT<K[!<TZ*S/^$DTS?M^V1[O.^SXY_UG]WZTD?B;2Y6B5+V-C*[1H!GYF7[
MP_"CE?89J45E)XHTJ18V6^C*R1M*AYY1?O'\,4?\)3I.PO\ ;HMH@%R3S_JR
M<!OI1RR["N:M%9<GBC2H1*7O8U$2H[YS\H;[I_&EE\3:7"TJO>QJ8Y%B<'/#
M-T'XT<K[!<TZ*S!XDTPN$%Y'N,WV?'/^L_N_6DB\3:7.8@E[&QE9U3&?F*_>
M'X4<K[!<U**RX_$^E2QQNM_"5DB:926QE%^\WT&*4^)=+568W\ 581.3OZ1G
MHWTHY9=@N:=%9LGB32XA*7OH%$05G);[H;[N?K1)XCTR)I%>^A5HY%B8%NCM
MT7ZFCE?89I45G#Q#IA<(+V$L9C !NZR#JOUI(O$FES>5LOH&\W>$PWWMOWL?
M2CE?85S2HK,7Q-I3JC+?P$/$9E(?J@ZM]!BAO$NE(K,U_ %6(3DE^B'HWTHY
M7V"YS/Q>^%MO\6_#4&CW.H2Z<D5RMR)8HPY)"L,8)_VOTKP74_V5?!VCZI#I
MM[X[GM[^9D6*W>V7?(6)VA1GGH>G3'-?4,GB32XA*7OX%$04N2WW0WW<_6N/
MU/P;X1U+5'N;K4)7DCN4"Q/=%A!,6+8CSDH6).=I'IP*]K"9OF&"IJCAZCC'
M>UE^J/FL?PWE.:5GB,914YVM>\EMZ-&#\(?V<[+X2>)+C5[;6KC47FMFMC%+
M"J  LK9R#_L_K7RG^T%_R6?Q7_U]#_T!:^^U\1:8SJ@OH2S2F!1NZR#JOUK\
M_/CWJ-K=?&/Q/)#<1R(]U\K*<@X1<_E7V7"N+KXS,:M;$RO+DM?;JNQ^9<?9
M;ALMR6AAL%3Y8>TO97?V97WN<+7O?BS_ )-H\4_]B59?^EDU?/XNX" 1*I!7
M<.>WK7O/BF^MY?V;/%,:3(S_ /"$63[0>=OVR7G]17K<;^]E%1+L_P CS_!N
M,H<7X)R5DJE/_P!+1^?=>Q?L@?\ )RG@/_K];_T4]>/[&]*]>_9%=8/VD? ;
MR,$7[<1D^IC<#]37\<X.E4^LTGROXET\T?[6\25J7]B8Y<R_A5.O]R7^3/KS
M]MO_ )'+PW_UX/\ ^C*^<:^A/VTM5LKSQCX<,%U%*!9RQ_(X/S"3E?J/2OG4
M7<#;<3(=V2,-UQUK^Y.'=,JH7[/\V?X+\9PD\^Q32ZK_ -)1]@_L8?\ (@^*
M?^OW_P!I"ODBY_X^9O\ ?;^=?5?[&NL6$'@/Q0LEY C?:3+AI #L$0RWT]Z^
M3KJ]MQ<3'SH\ ER=W8G@_2N/*O\ D:8_UA^3/2X@C)Y#E*2Z5/\ TI%BR_X_
M;;_KJG_H0KZZ_;1_Y)[X;_[" _\ 1+U\?VEW M[!NF0;98\Y;IDC'YU];?ME
MZK9W'@#P^D5U#(\>J")U5P2K^2WRGT/M4YM_R-<!ZR_)%\/1DL@S;3I3_-GR
M37T7^Q-_R//B#_L'+_Z-6OFX7<)( E0DDJ,-U(ZBOH?]BK4[.'QQKI>ZB3?I
MN5W.!NQ(I./I7?Q#KE5?T_5'D\'0DL^PK:^T_P F?('[4'_)PWQ!_P"PQ/\
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M3\S!TKKOA#_R5GP5_P!ANR_]'I7)K&Q PIY&>E=;\(E*_%CP42#C^V[(]/\
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M^F+U\C67_'[;?]=4_P#0A7UU^VC_ ,D]\-_]A ?^B7J<V_Y&N ]9_DB^'O\
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M7.>:\4^F/?**^=6_;!\-Z;H<FKZGH.IQZ?<SXTN6V1)/M<7R;B0'RC)Y@R&
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M+?L#('_:L\%AAD?Z7_Z235U'_!2I%C_:4<*,#^Q[3_V>G'_D6O\ Q_H95O\
MDM:?_8.__2V?*E?IY^Q9_P F*^*_]W5__1%?F'7Z<?L70HW["_BIB,MMU?N?
M^>%/*?X\O\+)\0/^172_Z^P_4_,8=*Z[X0_\E9\%?]ANR_\ 1Z5R(Z5UOPB
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M".UM;*(0VT<<:8B0 #:O&0, #WQ4L>B6L3(R1QHR*%4K"@*@'( ^7@9K0HH
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M<@9.,\^U;KC_ )YQ_P#?9_PHW7'_ #SC_P"^S_A0V!X=XP^)OQ=TV^T9M(\
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M.WC[QJ+PU\>?%][J7B^QU.QLK?4M$T*:_>PCM7_<SIM\O=)YA#"3+-Y> RX
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MX)_Z&73?^_S?_$T?\+P\$_\ 0RZ;_P!_F_\ B:/J.+_Y]2_\!?\ D']JY?\
M]!$/_ H_YG>T5P7_  O#P3_T,NF_]_F_^)H_X7AX)_Z&73?^_P W_P 31]1Q
M?_/J7_@+_P @_M7+_P#H(A_X%'_,[VBN"_X7AX)_Z&73?^_S?_$T?\+P\$_]
M#+IO_?YO_B:/J.+_ .?4O_ 7_D']JY?_ -!$/_ H_P"9WM%<%_PO#P3_ -#+
MIO\ W^;_ .)H_P"%X>"?^AETW_O\W_Q-'U'%_P#/J7_@+_R#^U<O_P"@B'_@
M4?\ ,[VBN"_X7AX)_P"AETW_ +_-_P#$T?\ "\/!/_0RZ;_W^;_XFCZCB_\
MGU+_ ,!?^0?VKE__ $$0_P# H_YG>T5P7_"\/!/_ $,NF_\ ?YO_ (FC_A>'
M@G_H9=-_[_-_\31]1Q?_ #ZE_P" O_(/[5R__H(A_P"!1_S/'?VTOV,[G]K1
MO"AM_%D7AG^Q/M&?,L#<^=YFSTD3;C9[]:^3F_X)*VZ:@EB?C7I0O'F^SK =
M(^=I<;B@'VC.['..N*_1,_'#P201_P )+IO_ '^;_P")KE-'\2?#+1->;5H/
M%$#W!E><1S7C/&)&4J7QMY;!;YB2?F/->G0J9IAX*G3A))?W?^ <E3%Y34DY
M2KPO_C7^9Q?[%O[&UQ^R7'XK6X\5Q^)O[;:W8>78FV\GRPX[R/NSO]NE>U2?
M\E@M_P#L!2?^E"557XX>",C/B730/:4__$U2\/>+]&\8_%@7&BZA#J4,&B.D
MKP$D(QG0@'W(!K+V>+G*I7Q$&KQ=VU;I;M8RJXS!3]E1P]6,GSQT4DWOZGI-
M%%%>&?2!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %136D%P0988Y2.A=0<?G1133:V$TGHR/\ LRS_ .?2#_OV/\*/
M[,L_^?2#_OV/\***?-+N3R0[(/[,L_\ GT@_[]C_  H_LRS_ .?2#_OV/\**
M*.:7<.2'9!_9EG_SZ0?]^Q_A1_9EG_SZ0?\ ?L?X444<TNX<D.R#^S+/_GT@
M_P"_8_PH_LRS_P"?2#_OV/\ "BBCFEW#DAV0?V99_P#/I!_W['^%']F6?_/I
M!_W['^%%%'-+N')#L@_LRS_Y](/^_8_PH_LRS_Y](/\ OV/\***.:7<.2'9!
M_9EG_P ^D'_?L?X4?V99_P#/I!_W['^%%%'-+N')#L@_LRS_ .?2#_OV/\*/
M[,L_^?2#_OV/\***.:7<.2'9!_9EG_SZ0?\ ?L?X4?V99_\ /I!_W['^%%%'
M-+N')#L@_LRS_P"?2#_OV/\ "C^S+/\ Y](/^_8_PHHHYI=PY(=D']F6?_/I
M!_W['^%']F6?_/I!_P!^Q_A111S2[AR0[(/[,L_^?2#_ +]C_"I(;6&W),4,
7<1/78H&?RHHHYF^H*$5JD2T445)9_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>graph2.jpg
<TEXT>
begin 644 graph2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $$ G # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*6A?^"V'_P")H_X5?X-_Z%+0O_!;#_\ $T ;G]KV/_/[;_\ ?U?\:/[7L?\
MG]M_^_J_XUA_\*O\&_\ 0I:%_P""V'_XFC_A5_@W_H4M"_\ !;#_ /$T ;G]
MKV/_ #^V_P#W]7_&C^U['_G]M_\ OZO^-8?_  J_P;_T*6A?^"V'_P")H_X5
M?X-_Z%+0O_!;#_\ $T ;G]KV/_/[;_\ ?U?\:/[7L?\ G]M_^_J_XUA_\*O\
M&_\ 0I:%_P""V'_XFC_A5_@W_H4M"_\ !;#_ /$T ;G]KV/_ #^V_P#W]7_&
MC^U['_G]M_\ OZO^-8?_  J_P;_T*6A?^"V'_P")H_X5?X-_Z%+0O_!;#_\
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M_!O_ $*6A?\ @MA_^)H W/[7L?\ G]M_^_J_XT?VO8_\_MO_ -_5_P :P_\
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MAQ#!H-TTD>H:9YO[B [69)X4)^0[@$9%PI#@XRN:[2@ HHHH **** "BBB@
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M!/X5]K@<@IU*,:V+GR\VR5E^+_(\^IB6I.,%>Q^F/_#Q[X)?]!?6/_!+<_\
MQ%'_  \>^"7_ $%]8_\ !+<__$5^3:R*X!5@P/3!ZT;UR!N&3TYKV/\ 5G!_
MS2^]?Y&'UR?9'ZR?\/'O@E_T%]8_\$MS_P#$4?\ #Q[X)?\ 07UC_P $MS_\
M17Y26%A<ZH\Z6<#W3P0O<2K$,E(T&7<^@ Y)JKYJ8SO7\Z7^K.#_ )I?>O\
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M^K.#_FE]Z_R#ZY4[(_63_AX]\$O^@OK'_@EN?_B*/^'CWP2_Z"^L?^"6Y_\
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M!C&GIJ-L]R9AE!$)5+[AW&W.?:O;=;^*GA*.9-5,5D;NWUW5[6%/#^DV"O\
MV8QA:TS'-"T3)D2;6*EQSSBO!_[(U'_H%ZA_X!R__$T?V1J/_0+U#_P#E_\
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M(IW@AC6>XB12J1NY!#J <8(Y P:BM]5*^&=3\/OJ0GA-W;FT1=WE,=[[Y "
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M)]5"^6& !*LK@@X '?(INO\ PK^)?B*WO(I]$M(C>7GVVY>.^3]XX78@(+$
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M9_Y!US_V$M0_]+9ZT)+.VEBECDMH)(I3NDC>)2LA]6!&">!R:S_#/_(.N?\
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MH/@?P[X"UCQ5J'B7P]JJ>(=2@>2*1O[2-Y'8M*0SA%)/E[MHP><!<*0!BIM
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MVFH ^XQ ::;>C ]FKB?CA_R17X@?]B_J'_I-)7;5Q/QP_P"2*_$#_L7]0_\
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M5;*_O9YO"FEZW;WMI%KK33W%W_HUO(&CG+9,<=QYS!#QO _A7;7LM "4444
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M+%9WJH+VTD;+QS H1D\CS$"N S , :] MX(K2WB@@C6*"%%CCC08"*HPH'L
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M>'_\)CX>_P"A@TC_ ,&$/_Q5'_"8^'O^A@TC_P &$/\ \57N']B:=_SX6O\
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MX&["'L_^%&_"J=X-%30-*#VR+ML(9BK>4D<<(1T5@6CV10J48%3M7(-:-[\
MOA_J$NH23^&;9VOG$LN'D4(XE6;?$ V(6\Q%<M'M)8 GF@#SFP_;$TRX71;B
MZ\-W>GZ7=M<1W6I3W*+;PR0SRPR)$Y $S PEMN58JZ;59CM'7_ W]H+3OC?_
M &@MKI=QIDMM;6U\@>19DDM[@/Y1+J,+(/+;?'R5RO)!S6I:?L^?#NQFLY8?
M"UFIM)6FC0LYC9S*TVZ1"VV0B1F<%PV&8L,$YK=\&?#?PW\/1=CP]I<>G"Z*
M^;M=WRJYV(-Q.U%R=J+A5R< 9H Z:BBB@ HHHH **** "BBB@ HHHH ****
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M]/FQNS_TS]ZW: /,/VE_#VH>*_@CXFTG2]-76+^Z6!8K%XS(DV+B(E74<E,
M[L<[<UY0?V0=0U*?Q3?W<GAW3;K6+&XBM;&PMG>TTV5YH7,<>0I\F18<2[=I
M8S2<8//U-10!\/\ Q8^ OB?29=<E@\(:-KE[XIL;JTM]"TW3)I]*T:5Q BRV
M\@4"*9_+WO(ZQ(< [LH0_9>,?V.=4UG3+5=/OM(BNGFUS[:C((TE%_>F=+C>
M89&,T:;8\@*V,[9$ Y^KJ* /E74?V2]>GU'Q(T,F@M8WSB6.*6:;SKB874<X
MF:<QM)"P*LQ0M/&SL#L51MIMC^RAXHTYK.]N)?"/B2X@M4M3I6J631Z>W^CM
M#OV1I@/&" I" ,K2<1EN/JRB@#YZ^&G[+US\/_$7A[5I+[3]0O\ 3=:>^GU1
MH"MW=6IT=;$1,YR?]:BR;2Q7 ')85]"T44 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q/QP_Y(K\
M0/\ L7]0_P#2:2NVKB?CA_R17X@?]B_J'_I-)0!K?#[_ )$+PU_V#+;_ -%+
M705S_P /O^1"\-?]@RV_]%+704 %<=K7QE\!^'+MK74_&6A6-RIVM#-J$2NI
M]"-V1^-?,7[4GQRU+7O$]_X,T2]EL="TYO(U"6V<I)>SXR\18<B-,A2 ?F;<
M#PN#\]P0K;1XAC6&,=HUV@?E7W^5<)U,=06(KU.12U2M=V[[JQ^29_X@X?*<
M5+!X6E[64=).]DGV6CO;KM9]S]$/^&A?AC_T/WAW_P &47_Q5'_#0OPQ_P"A
M^\._^#*+_P"*K\\_,?\ O-^= =S_ !-^=>W_ *D4?^?[_P# 5_F?+_\ $4J_
M_0(O_ W_ /(GZ&?\-"_#'_H?O#O_ (,HO_BJ/^&A?AC_ -#]X=_\&47_ ,57
MYY^8_P#>/YT>8_\ >;\Z/]2*/_/]_P#@*_S#_B*5?_H$7_@;_P#D3]#/^&A?
MAC_T/WAW_P &47_Q5'_#0OPQ_P"A^\._^#*+_P"*K\\_,?\ O-^='F/_ 'F_
M.C_4BC_S_?\ X"O\P_XBE7_Z!%_X&_\ Y$_0S_AH7X8_]#]X=_\ !E%_\51_
MPT+\,?\ H?O#O_@RB_\ BJ_//S'_ +S?G1YC_P!YOSH_U(H_\_W_ . K_,/^
M(I5_^@1?^!O_ .1/T,_X:%^&/_0_>'?_  91?_%4?\-"_#'_ *'[P[_X,HO_
M (JOSS\Q_P"\WYT>8_\ >;\Z/]2*/_/]_P#@*_S#_B*5?_H$7_@;_P#D3]#/
M^&A?AC_T/WAW_P &47_Q5'_#0OPQ_P"A^\._^#*+_P"*K\\_,?\ O-^='F/_
M 'F_.C_4BC_S_?\ X"O\P_XBE7_Z!%_X&_\ Y$_0S_AH7X8_]#]X=_\ !E%_
M\51_PT+\,?\ H?O#O_@RB_\ BJ_//S'_ +S?G1YC_P!YOSH_U(H_\_W_ . K
M_,/^(I5_^@1?^!O_ .1/T,_X:%^&/_0_>'?_  91?_%4?\-"_#'_ *'[P[_X
M,HO_ (JOSS\Q_P"\WYT>8_\ >;\Z/]2*/_/]_P#@*_S#_B*5?_H$7_@;_P#D
M3]#/^&A?AC_T/WAW_P &47_Q5'_#0OPQ_P"A^\._^#*+_P"*K\\_,?\ O-^=
M'F/_ 'F_.C_4BC_S_?\ X"O\P_XBE7_Z!%_X&_\ Y$_0S_AH7X8_]#]X=_\
M!E%_\51_PT+\,?\ H?O#O_@RB_\ BJ_//S'_ +S?G2YD..7Y^M'^I%'_ )_O
M_P !7^8?\12K_P#0(O\ P-__ ")^B=E\=_AQJ-PL%MXZ\/2RMP$&I0Y/_CU=
MO%*D\221NLD;@,KH<A@>A!K\LI 74K(-RGJKC(_(UZ/\#_C7J/P<UZV1[F27
MP?-($O\ 3G8M';H3@SPC^ KU91PR@\;L&O,Q_!U3#T75PU3G:ULU9_+5_<>[
ME'B10QN)CA\;1]FI.RDI72;VOHK+S^_34_0FBFHZR(KHP9&&0RG((]:=7YP?
MLP445Y+XT_:1\.^$]6FTVWMKK6+F!BDS6VU8T8=5W,>2.^!^-95*L*,>:H[(
M[<)@L3CJGLL-!SEY'K5%>"?\-;:7_P!"Y?\ _?Z/_&C_ (:VTK_H7;__ +_1
M_P"-<OU_"_SH]G_5K-_^@>7X?YGO=%>"?\-;:7_T+E__ -_H_P#&C_AK;2_^
MA<O_ /O]'_C1]?PO\Z#_ %:S?_H'E^'^9[W17@G_  UMI?\ T+E__P!_H_\
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M_JUF_P#T#R_#_,][HKP3_AK;2_\ H7+_ /[_ $?^-'_#6VE_]"Y?_P#?Z/\
MQH^OX7^=!_JUF_\ T#R_#_,][HKP3_AK;2_^A<O_ /O]'_C2C]K;2LC/AV_
M_P"NT?\ C1]?PO\ .@_U:S?_ *!Y?A_F>]45R?P^^)FB_$FPEN-*DD2: @3V
MMPNV6(GID<@@X.""1Q765VQE&:4HNZ9\_6HU,/4=*K%QDMT]&@HHHJC$****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXUX.:J<LW*R5M]NO3?L?.X_,YX2NJ3H\U-1YI2NO=6O1K7;NMSMO^%5>"?\
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MK5U__D7M4'0"RF  Z >6W%7JHZ__ ,B_JO\ UYS_ /HMJER<GJRE%1T2/5_
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M;>5YTEQYT1/F$2;TPC[/W>T_,P-4?"O[07BB2WUS7+C4CJ_AW0[+3-?O@;6
MSFRDEECO(@(5"HZ)LD\O<[H4*LQW8KZ3'B>V Q]FUC_P2WO_ ,9K*\2_V'XP
MTP:=K&FZS>6(F2=K?^R=0179&W*'VQC<N1RARK=P:.678+HX?Q-XP\3Z!X$\
M"3:WKD7AB;6+D_VWK_V..1-+1H99HHMK@QKEA'#O<$9!_B85R.I_%WX@64%Y
M8:<5UW5(M&/BNVNUTAX$NK 6OE^6(&^96-V-VTG?LXS7O9\3VQ))MM8R>O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
=110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>graph3.jpg
<TEXT>
begin 644 graph3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $I E # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#@_C1X^UCX<>#5U;1- F\0737D-L\<:EEMHW;#3NJ_,R(.H'/(Z#)KD/
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M&E4:3M>T=?/65S]/J*_,'_A*O$/_ $-'B3_P?7O_ ,=H_P"$J\0_]#1XD_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX6O%3;@_=WTV]1\\7;7<]<KG/B%XXL?AOX/U#Q%J,4\]G9^6'CM]F]B\BQJ
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M=>U3S&I*GB'7UG425[]OD<TL/A4X<LY67]U?_)GR]\-/^4I7B/\ Z^+_ /\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YI_\
M!5#_ )*IX'_[ TW_ */K](=)_P"059?]<4_]!%?F]_P50_Y*IX'_ .P--_Z/
MK](=)_Y!5E_UQ3_T$5]-F/\ R+L'Z2_-')2_BU/D6Z***^9.L**** "BBB@
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^:?_!5#_DJG@?\
M[ TW_H^OTATG_D%67_7%/_017S)^UU^QQJO[2OB[0-9T_P 3V>A1Z98O:-%<
MV;S&0M)OW JZX]*^H+. VMG!"3N,<:H2.^!BO=QN(I5<%AJ4)7E'FNNUVK'-
M3C)5)M[.Q-17G_VCXG_\^GAC_OY/1]H^)_\ SZ>&/^_D]>$=)Z!17G_VCXG_
M //IX8_[^3T?:/B?_P ^GAC_ +^3T >@45Y_]H^)_P#SZ>&/^_D]'VCXG_\
M/IX8_P"_D] 'H%%>?_:/B?\ \^GAC_OY/1]H^)__ #Z>&/\ OY/0!Z!17G_V
MCXG_ //IX8_[^3T?:/B?_P ^GAC_ +^3T >@45Y_]H^)_P#SZ>&/^_D]'VCX
MG_\ /IX8_P"_D] 'H%%>?_:/B?\ \^GAC_OY/1]H^)__ #Z>&/\ OY/0!Z!1
M7G_VCXG_ //IX8_[^3T?:/B?_P ^GAC_ +^3T >@45Y_]H^)_P#SZ>&/^_D]
M'VCXG_\ /IX8_P"_D] 'H%%>?_:/B?\ \^GAC_OY/1]H^)__ #Z>&/\ OY/0
M!Z!17G_VCXG_ //IX8_[^3T?:/B?_P ^GAC_ +^3T >@45Y_]H^)_P#SZ>&/
M^_D]'VCXG_\ /IX8_P"_D] 'H%%>?_:/B?\ \^GAC_OY/1]H^)__ #Z>&/\
MOY/0!Z!17G_VCXG_ //IX8_[^3T?:/B?_P ^GAC_ +^3T >@45Y_]H^)_P#S
MZ>&/^_D]'VCXG_\ /IX8_P"_D] 'H%%>?_:/B?\ \^GAC_OY/1]H^)__ #Z>
M&/\ OY/0!Z!17G_VCXG_ //IX8_[^3T?:/B?_P ^GAC_ +^3T >@45Y_]H^)
M_P#SZ>&/^_D]'VCXG_\ /IX8_P"_D] 'H%%>?_:/B?\ \^GAC_OY/1]H^)__
M #Z>&/\ OY/0!Z!17G_VCXG_ //IX8_[^3T?:/B?_P ^GAC_ +^3T >@45Y_
M]H^)_P#SZ>&/^_D]'VCXG_\ /IX8_P"_D] 'H%%>?_:/B?\ \^GAC_OY/1]H
M^)__ #Z>&/\ OY/0!Z!17G_VCXG_ //IX8_[^3T?:/B?_P ^GAC_ +^3T >@
M45Y_]H^)_P#SZ>&/^_D]'VCXG_\ /IX8_P"_D] 'H%%>?_:/B?\ \^GAC_OY
M/1]H^)__ #Z>&/\ OY/0!Z!17G_VCXG_ //IX8_[^3T?:/B?_P ^GAC_ +^3
MT >@45Y_]H^)_P#SZ>&/^_D]'VCXG_\ /IX8_P"_D] 'H%%>?_:/B?\ \^GA
MC_OY/1]H^)__ #Z>&/\ OY/0!Z!17G_VCXG_ //IX8_[^3T?:/B?_P ^GAC_
M +^3T >@45Y_]H^)_P#SZ>&/^_D]'VCXG_\ /IX8_P"_D] 'H%%>?_:/B?\
M\^GAC_OY/1]H^)__ #Z>&/\ OY/0!Z!17G_VCXG_ //IX8_[^3T?:/B?_P ^
MGAC_ +^3T >@45Y_]H^)_P#SZ>&/^_D]'VCXG_\ /IX8_P"_D] 'H%%>?_:/
MB?\ \^GAC_OY/1]H^)__ #Z>&/\ OY/0!Z!17G_VCXG_ //IX8_[^3T?:/B?
M_P ^GAC_ +^3T >@45Y_]H^)_P#SZ>&/^_D]'VCXG_\ /IX8_P"_D] 'H%%>
M?_:/B?\ \^GAC_OY/1]H^)__ #Z>&/\ OY/0!Z!1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&4,"" 0>"#WIJPQH05
M15(7:"!C ]/I6/XUU^\\,>%M1U/3]'NO$%];QY@TVRQYD[D@*,G@#)R3V )P
M<8/C'PK^-_Q-\6ZIHL/B+X;W6CQ3Z>)[R$6LT3K)]F$C,DDI6, S9@$3D/QO
M)"F@#XW_ &SI3;_MXZ9, "T7]AR 'H2)2?Z5[3X"_P""C[1_#O4_%/COPQB.
M+6UTBUA\.#<Q_P!',Q:3SI!Z8X/X5X)^UYJ-QJG[;=C/<Z9=:1*1HR_9KQHF
MDP)#\V8G=<'_ 'L\=*\=N_\ DV^^_P"QV'_IO>OTK#8.AC,%05:-]%^+=SR9
MU)4ZDN5G[;V-VM_96]T@*I-&LBANH!&>?SJ>O(M)_:6^%^F//H%]XVTNPU71
M+>)-1@O)#"+9OD3#.X"YW,HP">M>E^'?$>E>+M%M=8T34+;5=*NU+P7EI()(
MI5R1E6'!&01^%?GE2C4I:SBTO-'J*2>S-*BBBL"@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG\\OO7^0?7)]D?JE_P /*?@K_P _FO\ _@DG_P */^'E/P5_Y_-?_P#!)/\
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M1#E' 93Z@T^O%/BYX\U?P3J7A2VMY=7,6IH($&E0Q*D<H QD2Q2,Q8L,*QC
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?@%<?\?EW_P!?$O\
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MIHHT445[)@%?IQ_P2V_Y(3XF_P"QGG_]);6OS'K]./\ @EM_R0GQ-_V,\_\
MZ2VM?*<2_P"Y+_$OR9VX3^)\C[(KY\_;%\'WGBSPSX;-OX7O?%%M9Z@TMW!:
M71B"1^6<&1=RADW!22<A=@R"#BOH.O /VG]1T?2;[0#K?AS6M:M;^.:T673O
M%0TB%7P"(Y$-Q$)-PW$MAMH4YZBOR\]@YO\ :?M]$OM1^'UIJT=A!9:A;O9M
M->21W(DC=X,VZ!V#9; /G)\WRX_BKZ:TS3XM)TVTL8-WD6T20Q[VW-M4 #)/
M4X'6OG3X_P ;3^(O"-I)I^GVNB6MDMRUT+J,W!59H!Y:;OO(,C.W+-G@8SGZ
M4H ***\IG^'WCH_&2\\26_BN./P[)&1;V$KS.D0^S+&(6MP5C91,#/YNX.=V
MSA1F@#X'_;5_Y/ILO^N>B_\ HQJ\0NO^3;[[_L=A_P"F]Z_0#Q5^R.GQH^.O
MB'Q7X@\1P+K6D2:?%"UGI\L<+".(2IE/M)[L<\\^U0R?\$X] D\'R^&3XF?^
MS)-2_M5L6<OF>?Y1B^]]H^[M)XQUYS7W6#SG"T,/3I3O>-KZ=F_,\VIAYRDV
MCXI^-_\ R5#XV_\ 7S;_ /I3;TGP\_Y'2S_[)UJ'_IMN:^Y/$O\ P3YT?Q9K
M?B35;_Q-_I?B!TDO?)LI57*NCC8/M/R\HOKWI-(_X)\:/HFHQWUMXF_?II$N
MB#?92E?LTD+PMQ]I^_LD;#>N#BMUGF$5'V>M[6V_NI=_(3P\^:_];GQ!X5_Y
M%_\ 9X_[&N\_]+[*N,\<*KZ9X\# '_BK&ZCVO:_12Q_X)]Z/IUIX2MX?$W[O
MPO?2:CI^ZRE)\UY8Y6\S_2?F7="G''&?6L[4O^";OAW5H=4BG\32;=2OSJ4^
MRTE!\X^9]W_2.%_>OQ]/2M(9]@XRN[[OI_>;[]B7AJEK?UL5/AA^W7H'ACPO
M>^'-1\+:F(? _ARRDN;VVFBD-R%%K!B.,E<9,X/)Z*:])TG]NOX:7USX4MKQ
MM5TB?Q'IYU.W^UV@,<$ :8%I75B%Q]GD)QGC'K7(I_P3YT=&\2,/$W/B"QCT
M^]_T*7_5(\+KL_TGY3FWCYY[^M)/_P $^-'N9= D?Q,=VB:8VDVF+*7_ %#&
M8G?_ *3\S?Z1)SQVXXKY^I/*:C;M)-_Y>;[G4E778]^\&?''P!\0K%KSP]XO
MTG4[83_9MZ7*KF7"G8 V"3AUZ>HKN P;."#CT-?'FE_\$W_#ND2Z%)!XB+/H
MNH?VE:&6RD;$VZ)OF_TCE<PIQQW]:])^$?[,5[\%-<\3:MX<\4VSW?B&83WH
MU#39IT#!Y'_=C[4-HS*W'/&/2O+KPP:3="<GV32[][]O(VBZGVD>]T5R/]E>
M.O\ H9M!_P#!!-_\F5'<:7X_$$A@\2>'FG"GRUDT&<*6QQDB\R!GTKSC4[*B
MO$T@_:,_LV%FO?A?_:!N")8Q9ZCY(AVC!5O-R7W;N" , <\D5XSKGQ^_:JT2
M#7)F^$>E7$=I=+!9?9K"XG:\0R,I?;'<LRC:H;D?Q8KNIX.I6=H-?^!)?FS-
MU%'?\C[2HKX5M/VN_CX=<U73+_X?Z=836/AV762)-!U#)N$MUE%K_KL9+-MX
M)/'3/%<H/^"A'Q:M->\)Z3JGAOPQI-WK8#207FGWD4L -Q)$"$><$@A-W..M
M=:RC&2^&*?S7KW,W7IK=GZ*T5^9UK_P4S^)]WX875DT+P<S'44L3$MO=$ -$
M7W9^T=>,8KM_$7[=GQ-T+6/BM9+IOA.9?!,B1Q.;&Y!O,WJ6V6'VCY.'W<9Y
M&*N62XZ+LX?BNZ7?NT)8BF];GWU17YQK_P %%_B@VJ6]I_8GA'$NC?VKO^R7
M60WV1I]F/M'3*[<_CBMS0?V\_B=K,WPK1M,\)Q?\)K?RV4I%E<G[($O%MMR_
MZ1\^0V[!QTQ2EDV-BKN'XKLWW[)C6(IOJ?H!17YSW'_!1+XH0^ ?$?B,:+X1
M,FDZY!I"V_V2ZQ*LD=P_F%OM'!'V<#&/XCSQ3=3_ ."BOQ0L-7\4V0T7PBXT
M: 3*YM+H&7]["F"/M''^M)[]/>FLEQS=N3\5Y>?FA?6*?<_1JBO@G2_VY_B;
MJ'B_PAHIT_PFB:]X:.OO,+&Y)A86]S-Y0'VGYAFW W<?>)QQ7'6/_!27XI7=
MCX8N#H/A!3K%Y):LHM;H^4%>%=P_TCG_ %IXXZ4EDV.D[*'XKS\_)C^L4UU/
MH/Q5^T5\1? K>--<N/"XU?P[IFJ7FF6D)MFMR\D<J>1LD4NSJ\8FW.T:J'$0
M4MNQ56#]K/QM9Z^]I=>!3J"2Z@]K&+42PI;Q_:;E(Q*\B_ZUXX8\=%)E4\ C
M/@E[_P %)OBE:Z9XDNQH/A!CI-Y':JAM;K]Z&:8;C_I'&/)''/WO:NSU?]N;
MXFZ9XN\;:,-/\)R)X=\.C7$F-C<@SL8;:3RB/M/RC_2",\_<''-#R;'1=G#\
M5Y>?F@^L4WU/3+S]K#QRL2747@*W@B0W;-;W,TZM.%MY'@196C58W+1-NW K
MC&#WKZ&^''BU_'G@+0/$4ME+ILNIV45T]I.CH\1902I#JK?F!7P3IW_!17XH
M7VL>&+(Z)X11=8M3<,XM+HF([YEP!]HY_P!2#V^][5):_P#!1#XH7'@;PMX@
M.C>$5DUK7)](:W^R76(EC2V;S ?M')/V@C&!]T<\TWDN.3MR?BO/S\F+ZQ3[
MGZ+45^?NN_M[?$[1_P#A:.W3/"<O_"&:E%819LKH?:P]W);[F_TCY" F[ SU
MQ6+)_P %%_BBFJWEG_8GA$K!HPU0/]DNLLWV5)]F/M'3+;<^V<4HY-C9;0_%
M=D^_FA_6*:ZGZ.45\#>'/VZOB;KNN?"G3VT[PG"OC8L)9!8W)-GB\EM_E'VC
MY^(]W..3BN)D_P""EWQ23PPNK?\ "/\ A N=0DLO*^S76,+$K[L_:/\ :QCV
MIQR7'2=E#\5W:[]TQ?6*:UN?I?17YZW/_!0#XGP:;\1;H:3X28^%+BUAC7['
M=?Z3YMR826_TCY< 9XSGI1KW_!0#XGZ+JEI:+I/A*83^%H?$1<V=T,.]KY_E
M8^T= ?EW?CBI638UNW)^*[)]^S0_K%/N?H517YY^!_\ @H'\3_%_B;P#I4FD
M>$K5?$U^UE)*MG=,;<"81[@/M W=<X.*S9/^"C/Q13X8W_BO^Q/")EMM<32!
M:_9+K:RM;R3>9N^T<',>,8[]:K^Q<=?EY/Q7=KOW0?6*?<_1ZBOSW\=?M_?$
M_P '>+/&VC1Z5X2NT\.B$I,UG=*9][PKR/M!VX\XGO\ =]Z3PO\ M_\ Q/\
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M */U*C3?^/SXQ_\ 8F6__HW3:+[_ (^O@Q_V*%S_ .C]2KFZ?U_(7_7XG+>
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M>/F>=O,:*HJGRJ]][_HNYO1P_LI<U[CJ***^8.P***8RN948/A #N7'7TYH
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M**/90[!]?Q7_ #\9R?\ PKFU_P"@UXA_\'$__P 51_PKFU_Z#7B'_P '$_\
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MMPWASX&MYDH-QJ&H*P#G"8OXQ\@_@/<D=3S4_@3_ )&B]_[)I>_^FUJ;I_\
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MD$'('I7/:-\#/ /AZ]MKO3_"NGVTUO UO'A"5V,&5B5)(9BKNI<@L0S G!-
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MPO'W_7Q9_P#I*E=M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'EW[4?\ R;E\2O\ L 7G_HIJ_+/3_P#D6?@%_P!A
M+4?_ $X1U^IG[4?_ ";E\2O^P!>?^BFK\L]/_P"19^ 7_82U'_TX1U]WD/\
MN[_Q/_TB1YN)^)>GZH\\7_DFUS_V'8?_ $GEK]U=)_Y!5E_UQ3_T$5^%2_\
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B-O$^-\<:J<=,@8J>BC&YC7Q_+[:VE]O.W^04Z4:5^4__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>graph4.jpg
<TEXT>
begin 644 graph4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %  G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
ML'QSXNB\">%=1UZXL+W4K6PA:XGBT]$:58U4L[@.R@@ $XSGT!K-TSXK^'+K
M2(;W4M0M_#<DELMXUCK-W!#<0P,VU)'42$*K$C!SW Z\4 =A17!>+/C?X1\(
MZIIFFW&IQ7NHZBAEAM;&6.601;=XE8;AM0KR&/![4[PQ\;_!?BZS^W6&O6@T
MV26&"VOKF9(8KJ20-M2(L06;*L-I .1P#0!W=%<W+\2O",,.HRR>*M%CBTV1
M8;UVU&$+:N25"RG=\A)! #8Y!]*9IGQ)\/ZE8Z[?&_CL;#1;UK"\N[YUAA60
M)&V0['!4B5,-GG- '3T5QFB_&'P?KM[KUK!K]A'-HA)O!/<QIMB$44OGC+<P
M[9D_>?=SGFE\3_%[PEX4T)]5NM<L[F+[&;^&"SN(Y9KF =7A0-F0=>5XX- '
M945@0>/_  O=:E#IT/B32)M0G#M%:1WT32R!"P<J@;)VE'!P.-K9Z&LR3XO^
M$(Y()&\0:=_9DUL]RFK_ &V'[$0LHB*>;OQOW-C'L>_% '945QI^+GA>>UUR
M;3]2CU<Z+<6UM>QV+!S&\ZQ-%@DA2"LR-D'&,]QBJVI_''P+I5SIL<OB?2Y(
M;Z[>Q%W%>Q-;P3+$TNR60-A"50X!Y)P* .[HKSQ?CMX3_MW5]%ENVM]6TZWE
MN?L<[1I)=)&\R-Y +_O#_H\AP.@P3C-:7AGXO^#O%T,;:?XAL&DDO)=.6"6=
M8Y&NHL>;"JD_,R[AG;GK0!V-%<5KOQA\+Z%#X7N/[074K/Q'JZ:+8W>F%;F'
M[0ZR,-[J<*N8RN>S%1WK L?VC/#6M0S-HNGZWKEQ'>W]G]EL+'=*RV;JD\ZA
MF ,09T"G.7+ *#0!ZI17&:1\7/#6O>)-&T73[J2YGU?2AK-G.L+"%X"1M!8X
MVNPW,$(SA'/\)KLZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ-J,?VB+[6UK%.&@F6$.A5A]X/ CJ^>"6R&!Q6U_PSU\/O\ H4M'_P# -/\
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M?X4 >CUE>*] C\5^%M8T269[>+4K.:S>:, M&)$*%AGC(W9KC?\ AGKX??\
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M.HF^ NFS_#SPIX2;49S;>'Y_M$4_DINF;R9HOF&,#_7D\=U%6O\ AGKX??\
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MX??]"EH__@&G^%'_  SU\/O^A2T?_P  T_PH ]'HKSC_ (9Z^'W_ $*6C_\
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MTRW\2Z/<:E:J[3V<5_$TT03[Y= V5"]\CCO0!D_\)WXB_P"B<:__ .!FF_\
MR51_PG?B+_HG&O\ _@9IO_R56]X=\9:!XO6X;0=<TW6UMR%F.G7<=P(R<X#;
M"<$X/7TJ_::E:7[W"6MU#<O;2&&=89 YBD !*-@_*V"#@\\B@#DO^$[\1?\
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MXR_\ K7_ .2:_-GPWX6UGQEJ\6E:!I-[K6IRAF2SL(&FE8 9)VJ.@'>K.M^
M_$OAF&_FUCP_J6EQ:?<I97;WELT0MYV4ND;Y'#%06 [@9J'P[@$^5SE?U7^0
M_K=7>R/T=_X>D_"[_H6_&7_@%:__ "31_P /2?A=_P!"WXR_\ K7_P"2:_,/
MSHPJG>N&Z'/6CS4_OKW[^G6K_P!6<%WE]Z_R%]<J>1^GG_#TGX7?]"WXR_\
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MF_\ @^D_^1J^%>O&#GKC%&<UI_J_E_\ (_O?^9/UJKW/NK_AZUKW_1,=-_\
M!])_\C4A_P""K.O$?\DQTW_P?2?_ "-7PO11_J_E_P#(_O?^8?6JO<^[_#O_
M  5.EL;R.._^%MO;:8TA>8Z7K&^4;CEF5'A16.22<L,GO7W9\./B)H7Q7\%:
M7XJ\-7@OM'U&+S(I"NUU()#(ZGE75@5(/0@U^$E?IQ_P2VGDD^ _B2)G+1P^
M)[@1J3PH-M;,0/JS$_4FOG,[RG#X*C&M0NM;6O?OW]#KP]>523C(^R****^*
M/0"BBB@ HHHH XKP'_R-OQ&_[#</_IMLJ[6N*\!_\C;\1O\ L-P_^FVRKM:
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M_,AJ;37+N>'T5[WXG_8\U_P6-=N-=\5^'],TO2;"*_DOYA<XD$DQA6,1B+S
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M$>U:]@GTO99)Y:6R(Y%I$\5OEASD+(V3_$3DU]#_ /#L#XE_]#=X1_\ )O\
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M]L&Y@^%.G>'=$T!]'\56UKIUH_B5;F-W9;.;S8F \H2'D!0KNRJN0!S7:?\
M#L#XE_\ 0W>$?_)O_P"-T?\ #L#XE_\ 0W>$?_)O_P"-UE]=R6R5UI;I+IM?
M37YE>SQ']6/ O$OQW\7>*M,UG3;N32[;3M7A@M[JTT[2X+6+;%,9TV"-1M)D
M8LS=3GGBO/J^OO\ AV!\2_\ H;O"/_DW_P#&Z/\ AV!\2_\ H;O"/_DW_P#&
MZ[(9SE=-6A-+_MU_Y&;P]9[H^0:*^OO^'8'Q+_Z&[PC_ .3?_P ;H_X=@?$O
M_H;O"/\ Y-__ !NM/[=R[_G[^$O\A?5JO8^0:_5C_@FJI7]EVQ)! ;6-2()[
MC[0U?/'AW_@ESXQGU:!?$'CG0[/2=V9Y-)MYI;DKW""154$^ISCT-??WPF\#
MZ-\-/!5IX6\/VOV/1]*9K:WB)W-@<EF/=F8EB>Y)KY?/<SPV-I1I4'>SNW9K
MI;KZG9AJ,Z<G*1^6'[?2,O[6_C<D$!H=/(SW'V.(9_,'\J^?Z_5G]JC]CC3/
MVB]4FUS3M47PYXQL@MLMY)#YMO=P[%98YE!##:2Q5U.1N(((Z?,G_#L#XE_]
M#=X1_P#)O_XW7J99G.#I86%*M+EE%6V;_)&-;#U)3<HK<^0:NZ)K>H>&M9L=
M6TJ\ET_4[&9;BVNH&VO%(IR&!KZQ_P"'8'Q+_P"AN\(_^3?_ ,;H_P"'8'Q+
M_P"AN\(_^3?_ ,;KTWGF7-6=3\'_ )&/U:KV/%9/VF_'C:A:7,,VBV4-NMTK
M:=9Z);0V5S]I %P9X%3;*7 &=WH*KC]H[QVL-[$M_8QPW;WC211:?%&B_:K=
M+>9450 B^5&BJ /EQGJ:]R_X=@?$O_H;O"/_ )-__&Z/^'8'Q+_Z&[PC_P"3
M?_QNN;^T\G75?^ O_(OV-?\ IGSQ\-_C-XI^%%O/;^'Y['[-+<Q7H@U&PBO$
MANH@1%<1"13LE4$@..:V[7]IGX@6OAL:)_:-C<6_V=K0W=SIT,EXT)G\\QF<
MKO*^;\V,]37MG_#L#XE_]#=X1_\ )O\ ^-T?\.P/B7_T-WA'_P F_P#XW3EF
MF43?-*2;_P +_P A*C76B7XGAFF_M'>/M'UJ\U:SU6W@O[S7O^$FFD%HA#7W
MEO&6QC 0I+(I3I\U:)_:J^(37OGO<:++$+:"U2PET2V>SC6!V>!D@*%%>,NX
M5@,@'%>Q?\.P/B7_ -#=X1_\F_\ XW1_P[ ^)?\ T-WA'_R;_P#C=)YED\G=
MM?\ @+_R'[&O_3/GKQ-\:_%OC'PC;^'-7N[.[LH5BC^T_8(5O)(XRQBC>X"[
MV1"YPN<#CTK#\2^-]7\72Z!+JDL,TFA6$.F6#)"J&.WB8M&IQ]X@L>3R:^H?
M^'8'Q+_Z&[PC_P"3?_QNC_AV!\2_^AN\(_\ DW_\;K2.;Y5#X9I?]NOK\A.A
M6>Z_$\/\:_M(^._'EI>P7U[I^FF_NX[Z^N-#TZ*PN+V>//EO-+$ [E<Y&3P>
M:Y&#Q_KL/AK7]!-\UQI^O7%O=:@;D>;--) 6,3>8V6&-[9YYXSTKZ>_X=@?$
MO_H;O"/_ )-__&Z/^'8'Q+_Z&[PC_P"3?_QNE'-LI@N6,DE_A?\ D#H5V[M?
MB?(-%?7W_#L#XE_]#=X1_P#)O_XW1_P[ ^)?_0W>$?\ R;_^-UO_ &[EW_/W
M\)?Y$_5JO8^0:_3;_@EHI'P+\4,00&\43X/KBUM17B>D?\$N_'<VHP)JOCCP
MY9Z>6'G36-O<33*O?8CJBD_4XK[T^!WPMT+X,>"D\(^'8G33;"0?O9B&EN)6
M16DED(QEV8DG&!V& !7S6>9IAL905&A*[O?9KRZ^IUX:C.G+FD?F+^W_ &LM
MM^UKXQ>6-D6XMM/FB)'WT^RHF1[;D8?A7SW7[&?'W]F/P=^T8DT7B!+FPU:P
MEVV.LZ<P6X@5HT+(<@JZ$@':PZ\C!KY[_P"'5V@_]%+US_P6VU=.79]AL/AH
M4:R:<5;17(JX:<IN4>I^>]7+[6M0U/3;#3[R^N+JPT]'CL[6:0M';J[;G"*>
M%#-R<=37WY_PZNT'_HI>N?\ @MMJ/^'5V@_]%+US_P %MM7H_P"L6 ??[O\
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M3\JLGRD#J.*^W_\ AU=H/_12]<_\%MM1_P .KM!_Z*7KG_@MMJ7]O9:OLO\
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M:DCUS39?N:A:M])E_P :/K<^R#_5[#?SR_#_ "/N+_A>'@3_ *&6S_\ 'O\
M"C_A>'@3_H9;/_Q[_"OBB.:.89CD23_=8&GX([&CZW/L@_U>PW\\OP_R/M3_
M (7AX$_Z&6S_ /'O\*/^%X>!/^AEL_\ Q[_"OBJBCZW/L@_U>PW\\OP_R/M7
M_A>'@3_H9;/_ ,>_PKGO#GQ>\&V?B#Q5<3>(+6.&[OHI8'.[$BBU@0D<?WE8
M?A7R715+&S2:LM1?ZNX;^>7X?Y'V%'\9/!/VR^<^([,+)*K*3OY'EJ/[OJ#4
MW_"YO __ $,MG^3_ /Q-?&]%)XR;Z(?^KV&_GE^'^1]D?\+F\#_]#+9_D_\
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MV9OA9<-E_ VD _[$.W^1%-C_ &8OA7'T\#:2?]Z(G^9K+ZI/NCH_UAH?R/\
M#_,_+OXK_$U+GXF^!UTK4[J/3[>7S;I8=R!\N,Y7C=\H(Y]:]'F^,>GR.19:
M;=W1)X' S^6:[SXB?#SPR/\ @I+\-O"VDZ!IUGH]GIBW-Q8PVZB*1@EQ)N=>
MA/"=?05]_P"G^&M(TD 6.E65D!T^SVZ1X_(4H89ROKL;XK.XT(TVJ=^97WMN
MWZGYH66H_$3Q20N@>!M1E#<!Q92R?J0!75Z/^S/\=?&94W,":#;MU-Y=)#@?
M[L>YJ_1:BNA82*W9XM3B&O+^'!+[W_D?%6@?\$\;R[(D\3^.6=NIBT^W+_\
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M/@'13JNM3O!9B18@8T+L6;H !^)_"MFWN([NWBGB;?%*BR(P[J1D'\C7S?\
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M8 3D9;UYKUNBNQ4;:7_J]SYR>.<WS<NO^:MJ%%%%=!Y@4444 %%%% !1110
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M'F*.X$8#0N,YVNJNR^A"CIBJG@GQ;XJ_9A^-J2:IX;>64Z.PNK*/48@DT<K
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MOT=\)^(XO%&AVMZK0K<-&OVFWBF67[/+M!:-BO=2<5\$_LW:-+\5/#6I>'/
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M[I/M?J_30BA5G7IJM[-QBWI=6OY^A]9UROA/_D:?&W_81A_](K>NJKE?"?\
MR-/C;_L(P_\ I%;UX</AEZ?JCI?0T(_^0AJ7_79?_125/4$?_(0U+_KLO_HI
M*GK-[C"BBBD 4444 <W\0?!5OX]\,W&ERR?9Y\B6VN0.8)E^ZP_D?8UR7A;X
MM_V+.GA[Q^IT76H1L%[,/]&O%Z;P_0$]^WTZ5ZC5+5]%T_7[0VNIV-O?V_\
MSSN(PX'TST_"N6I2ES>TI.TOP?K_ )GL87&TE1^JXN#E3O=6=I1;W:;NK/JG
MH[)Z/4_.;Q7\5+RQU?XC>%-/T72;6TM-:6\TVYCA,S!4D*85F)#!@RGIT)'2
MO1OBKH$_[04OA[Q1X0TJ[U3Q)#HL<6M101"."0J-RA"Q \Q6:08SR" .E>S?
M$;X/_"7X;6NI^+]6\//=?:%%LFG+<.8GD/38N1M)QR<\ 'BJ_A;Q#K7_  K;
MPMX!^']WIA\6/H?VJ\U&XRL5@ JX^4#+2LS@+D<!2S9X!]K&U/[5PU+"2IPI
M+FUDKW=TEJ[:)6OL^MCLP^/P.3XQYA@%.<U%)1E913[V3?,WZQ5]SX1\1W#:
M++=V5_%=Z?JT'/V*2%X[N*0<IA" P8'!!]<'-??'[/\ \:]=\3V=G:>/9;#3
M-3O((!81',<US)L_>97G@D9#'&23C-?(_@SQ/XCT#XWRZ9X<T\_$3QX+F2SU
M&ZNP\MO'\VV4KNP3C!_>/A1CA>]?9OP\_9OT_P *>)#XAUO5)?$>L))YL#R*
M52-O[Q&268=NP]*TQ>1T,CG[.G6]HI)6=K?<KMV[-VOV(S?.\9G4*57%T%2E
MJ[7N];;]O3\3V.BBBO+/G@HHHH *-"^Y>_\ 7U)_2BC0ON7O_7U)_2J6S$01
M_P#(0U+_ *[+_P"BDJ>H(_\ D(:E_P!=E_\ 125/2>XPHHHI %%%% !1110
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M# SP5&=/"Q2;ZWD][;M]ET2/0/V>/BCK7P_\,6O@W_A&I-<T_38I)XY[!\W
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MCE/'_A:*_:+[-?1.;>\MN\4R\,/IW'UK>T36+7Q#HUCJEDYDM+R%)XF(P2K
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MG).WMJ2Z+>+M^2/JI4*=?(8Q:O[.IW?5?YLC_P"%&:/)_P ?&K:U<_[]W_\
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M!$=]\T;_ &?&,EKB%LA<C#9)Z$ ^LZCN;F*SMY9YY4@@B4O)+(P544#)))X
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MS0!9@D,T,<A0QEE#%&ZKD=#4E%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,@CRHP".@&!P3G9_X4=X*^P:[9-HV^UUOR/M\;W,S>:(6W1 $OE0IY 7'4T
M<\_[5'P\-R88M4GD4VINHYVM)8HW(W_NR74;'(3< X4,""I.:C'[5OP_*Z63
M?72&^E$)5[5U:VY \R4'I%U/FC*84X)Q6]<?L_> +J*XCE\/(Z3F,R W,WS%
M$*)_'V4D53C_ &:?AQ&J@^'?.VX53/>7$A" Y$?S2']V.1L^[AF&.3D L6O[
M1'P]O)A%'XA"R>29V66SN(_*&7PLFZ,;'/E281L,P7(!&*T-<^-7@SPWJ>KZ
M?J.L_9KO283<7J?99F$2!8W;YE0ABJS1L0I)"L"0!S6<O[/_ (0MH;>*TLYK
M=1>VE]<O).]Q)>/;.\D(E>4LQP\A).<D?*3MXIFM_L\^#O%.NZ[JNN6UWJMQ
MJMQ'<&.6]E2.V*QPI^Y5&4(6%O&6;[S<@G;Q0!D:1^UC\.]6UFYT\ZA=V21.
M(X[V[LI$MKABSJ-C@'@^6Q!; (Z9P<;UY^T)\/;".UDF\20B*ZE,$,J03.CR
M;/,V;@A&[;SC.:KQ_LW?#F.PO;(>'%-I>*$EA:[G*E1')& ,O\ORS2],<N3U
MP:6[_9U\"33V]U;Z*+.^M'DGM9XYI"(IG"_O"A8HY&Q<!P1QC&"<@'>:)KMA
MXCT];[3+I+RS9WC6>/.UBCE&P>X#*1D<<5?K(\)>&+'P5X7TK0=-5DL--MH[
M6'><L550,L>Y.,D]R36O0 4444 %%%% !1110 4444 %%%% !1110 4444 %
B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>graph5.jpg
<TEXT>
begin 644 graph5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $' D8# 2(  A$! Q$!_\0
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MV0/_ *-JC\0R9/B_IP8EA%X?G9 >BEKF$,1]0H'X5%0!I_\ "X];_P"A!O\
M_P &EE_\=H_X7'K?_0@W_P#X-++_ ..UF44 :?\ PN/6_P#H0;__ ,&EE_\
M':/^%QZW_P!"#?\ _@TLO_CM9E% &G_PN/6_^A!O_P#P:67_ ,=H_P"%QZW_
M -"#?_\ @TLO_CM9E% &G_PN/6_^A!O_ /P:67_QVC_A<>M_]"#?_P#@TLO_
M ([6910!I_\ "X];_P"A!O\ _P &EE_\=H_X7'K?_0@W_P#X-++_ ..UF44
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M_CM9E% &G_PN/6_^A!O_ /P:67_QVC_A<>M_]"#?_P#@TLO_ ([6910!I_\
M"X];_P"A!O\ _P &EE_\=KF8-5TNU\72>*H?@S;Q>)9"6;5DFTX7))7:6\S?
MNR5 4G.2!CI6G10!I_\ "X];_P"A!O\ _P &EE_\=H_X7'K?_0@W_P#X-++_
M ..UF44 :?\ PN/6_P#H0;__ ,&EE_\ ':/^%QZW_P!"#?\ _@TLO_CM9E%
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MHIH)M1L721&&&5E,F"""00>M8O@_Q%9_#VUGMO#'PAC\/P7#!YH]-N=/@$C
M8!;;(,X' ST' J[10!I_\+CUO_H0;_\ \&EE_P#':/\ A<>M_P#0@W__ (-+
M+_X[6910!I_\+CUO_H0;_P#\&EE_\=H_X7'K?_0@W_\ X-++_P".UF44 :?_
M  N/6_\ H0;_ /\ !I9?_':/^%QZW_T(-_\ ^#2R_P#CM9E% &G_ ,+CUO\
MZ$&__P#!I9?_ !VC_A<>M_\ 0@W_ /X-++_X[6910!I_\+CUO_H0;_\ \&EE
M_P#':/\ A<>M_P#0@W__ (-++_X[6910!I_\+CUO_H0;_P#\&EE_\=H_X7'K
M?_0@W_\ X-++_P".UF44 :?_  N/6_\ H0;_ /\ !I9?_':/^%QZW_T(-_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !4MK_Q\P_[X_G452VO_ !\P_P"^/YT ='\!/^2.>$O^O%/YFBCX"?\
M)'/"7_7BG\S10!SGQ _Y+!9_]B]+_P"E4=15+\0/^2P6?_8O2_\ I5'45 !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK=<9!'YBLSQ#\/['5[?24TYT\.R:9J"ZE ^G6<.PRB*2+YHV7:P*RMVSP.:
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MH;:!"L<>XDEN7D8L>27YZ4 ;]%%% !1110 4444 %2VO_'S#_OC^=15+:_\
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MX/M+&RM-*L?L8:*&SU/^TH0KNS;Q=8'G;MV\M@<L?2O$7_;<\0?\);?^'O\
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M#S"SY)<]?;H.KK(\)>%-*\"^&-,\/:%:"PT;3(%MK2V#LXBC'1<L23^)-:U
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MMP"?2O:?AI^PG\/O#7PH?PKXST]?&>L:E=IJFNZM<32))=WH#8PZL'\M?,?
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MY/K1DT >(Z'8:EK&C_!#6[34=6NF^V"758A*WD-)):W!GDN4 Y*SG8 QVJ<
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M"JC!$2D9&"?3J:L,:2RR+&JR2X,CA0&? P,GO@<"G4 %%%% !4MK_P ?,/\
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MQQW!D4$2_* &++M^;J1BK&I:C::/IUWJ%_<Q6=C:1//<7,[A(XHU!9G9CP
M"2: +%%<G+\6O!EOK.@:3+XFT^/4]?ACN-+M6D^>[CD&8F7C #_P[L;CP,FK
M'AGXE>%/&FKZKI6@^(+'5M1TMMM[;6LFYH?F*$^C ,K*2N0"",YH KW'_)5D
M_P"Q=/\ Z5BNBKG;C_DJR?\ 8NG_ -*Q715YE?\ B,]*C\""LGQ%:V%];K;:
MI%!/IDL<RW45T%:%XO+.\."<%<9SP:UJH:E#'=36L$R++!-YL<D3GAU,9!4C
M(R"/8_AUK V/.-/^)'P[N[ZX;^R6LWLKI95GFTAT($B0SF[QMW)%F: F5@!E
ME-5V\2_"F2.&]CT*UN(KQ'TN.6'2&9YU5H8Q#&H3+AC)$HV_W1G&WC?@^!WA
M:$29&IS&7:DS3:C*YFA"11BW<YYAVP1#9_L YR3FS:_!OPQ::L-4\B[FU#[4
MM[]HFNV9C(IC*D_W@/*3KDG')-7=$69D:5XE^'FL:QH-EH]E;->R>1]AGCTQ
MD1!"IG6$2E0$=$D9]A.X>8>,DBO3:\PTOX,6GA;QEIFL:=?R6^E6#DV^E!GV
MF62-87D=C)AFV#@A0>@.<<^GU+MT*5^H57U#/V&?!P=AP<XQ^H_F*L56U$D6
M%Q@X.PX.<?KD?S%);@]C3HHHKVCR HI54N<*"Q] *S_$WB#3?!>@7^MZ]>Q:
M3I%A"UQ=7ET=J11CJ3_( <DD <F@#YE_X*.>$=/O/V?;[Q=)<W]GK'A^:VCL
MY[.^E@1$GNH4EWHA ?Y<XSDCG%>9>%O%OCG]HK08/AO^S_'J?@3X/:=OMK[Q
M_K<LLE[=!F+21V[,=_)9L '=C&YHQQ7C'[6_Q@UO]IKPA?>+;S54\&?"W3[I
M8?"VAWK>7=^)9A/''/<A/XA&CEB>0G"C)+$?IC\)9?#3?#+PU#X.U.WUCPQ:
MV26EC>VSJZ2I&-A.5 4MN4Y( YS0!\5>,/@KH_[//Q0^%UCX&^#OB_Q?:>%-
M0?5==\1P:?'=OK)EMPJA7)QN1R?DPJJ<XR>3]_6\QN+>&8H\1D17,<GWDR =
MK>XS@^XJ0,1W-)0 4449 ZD#ZG% %+6M;T_PYI5QJ>JWL.G:=;+NFNKA]L<8
MSC)/;DBLOPS\1O"OC,7C:#XBTW5ULT$ERUI<*XA4YPSGL.#R?2K/C#6M#\.>
M%M3U7Q*]LF@VD)FNVNHQ)'L'."I!W$GH,')Q7Q'^SCIVK_M#^#Y/#6CQ)X3\
M V5[,VLZA:PK'=ZF7E:2.#<!RH4CCD+WSP*^UR?(:.8Y=B,?7DZ<:4HIS=N1
M*5[Z6O*6EE%/5RC>RU.:I5<)J*UN==^TQ\2]8^/'@CQ=X=\ >9'X0T:W:YUK
MQ'N*176SD6\?]Y2>W\6 >%Z_1?P(\%6OP]^#WA+0K.>6YA@L(Y3+/C<[R#S&
M/';+''L!5+Q?\#=*\0?#BW\#Z-J=]X.T!%:.6+1PFZYC9<,DA<'.3\Q;J373
M?#_PA-X%\+VVBS:[?^(OLY(CO-2V>:(\ +'\H VJ!@5TYGFV#KY-3R[!/DA"
MHY<C3YI>ZDISE;E<GKHG9)I+84*<E4<Y:NQT5>&?'+_DX/\ 9O\ ^PWK/_IL
M>O="I'4$5X7\<O\ DX/]F_\ [#>L_P#IL>O@3J-GQ[^S+X0^(WQ.TOQWJHG&
MM:;]G\A(HXO)81N682J4/FB0%4._.T(NS:>:K:/^RKX*T3XB:]XT@CD?5=:6
M[2ZAF@@>VQ.%5=D1CVJ8P& (&7\Q_,+YKV.B@#P/1?V*OA]H7@'7_!\'VR72
M=;DM9+IYTA><&+'F>7(8]R"8[BP7&PR-Y>S->G_"KX8Z1\'_  5:>%]#,C:=
M:O(Z23JGFL&8D!V4#>57:@9LL0HR2>:ZVB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *EM?^/F'_?'\ZBJ
M6U_X^8?]\?SH Z/X"?\ )'/"7_7BG\S11\!/^2.>$O\ KQ3^9HH YSX@?\E@
ML_\ L7I?_2J.HJE^('_)8+/_ +%Z7_TJCJ*@ HHHH **** "O!OVH?B+\0_A
M[=>$9O"%A?SZ'+<%M6FTG2EU&Z;$L0$/EE@8T:)IV\P!CN15^7=FO>:^1?V[
M$\*Z7XA\ :[XIM?">O00V]_9Q>'O$U[=VAG:0Q$7$<ELCL?+Q@JP S("#G%
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MSJ*I;7_CYA_WQ_.@#H_@)_R1SPE_UXI_,T4? 3_DCGA+_KQ3^9HH YSX@?\
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M 5+:_P#'S#_OC^=15+:_\?,/^^/YT ='\!/^2.>$O^O%/YFBCX"?\D<\)?\
M7BG\S10!SGQ _P"2P6?_ &+TO_I5'452_$#_ )+!9_\ 8O2_^E4=14 %%%%
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M *EM?^/F'_?'\ZBJ6U_X^8?]\?SH Z/X"?\ )'/"7_7BG\S11\!/^2.>$O\
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M6(@DYSD@4 >F4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI/<C6Y\?^DE%% "_\(EX_P#^@+X>_P#!Y/\ _(E'_")>/_\ H"^'O_!Y/_\
M(E%% !_PB7C_ /Z OA[_ ,'D_P#\B4?\(EX__P"@+X>_\'D__P B444 '_")
M>/\ _H"^'O\ P>3_ /R)1_PB7C__ * OA[_P>3__ ")110 ?\(EX_P#^@+X>
M_P#!Y/\ _(E'_")>/_\ H"^'O_!Y/_\ (E%% !_PB7C_ /Z OA[_ ,'D_P#\
MB4?\(EX__P"@+X>_\'D__P B444 '_")>/\ _H"^'O\ P>3_ /R)1_PB7C__
M * OA[_P>3__ ")110 ?\(EX_P#^@+X>_P#!Y/\ _(E'_")>/_\ H"^'O_!Y
M/_\ (E%% !_PB7C_ /Z OA[_ ,'D_P#\B4?\(EX__P"@+X>_\'D__P B444
M'_")>/\ _H"^'O\ P>3_ /R)1_PB7C__ * OA[_P>3__ ")110 ?\(EX_P#^
M@+X>_P#!Y/\ _(E'_")>/_\ H"^'O_!Y/_\ (E%% !_PB7C_ /Z OA[_ ,'D
M_P#\B4?\(EX__P"@+X>_\'D__P B444 '_")>/\ _H"^'O\ P>3_ /R)1_PB
M7C__ * OA[_P>3__ ")110 ?\(EX_P#^@+X>_P#!Y/\ _(E'_")>/_\ H"^'
MO_!Y/_\ (E%% !_PB7C_ /Z OA[_ ,'D_P#\B4?\(EX__P"@+X>_\'D__P B
M444 '_")>/\ _H"^'O\ P>3_ /R)1_PB7C__ * OA[_P>3__ ")110 ?\(EX
M_P#^@+X>_P#!Y/\ _(E'_")>/_\ H"^'O_!Y/_\ (E%% !_PB7C_ /Z OA[_
M ,'D_P#\B4?\(EX__P"@+X>_\'D__P B444 '_")>/\ _H"^'O\ P>3_ /R)
M1_PB7C__ * OA[_P>3__ ")110 ?\(EX_P#^@+X>_P#!Y/\ _(E'_")>/_\
MH"^'O_!Y/_\ (E%% !_PB7C_ /Z OA[_ ,'D_P#\B4?\(EX__P"@+X>_\'D_
M_P B444 '_")>/\ _H"^'O\ P>3_ /R)1_PB7C__ * OA[_P>3__ ")110 ?
M\(EX_P#^@+X>_P#!Y/\ _(E'_")>/_\ H"^'O_!Y/_\ (E%% !_PB7C_ /Z
MOA[_ ,'D_P#\B4?\(EX__P"@+X>_\'D__P B444 '_")>/\ _H"^'O\ P>3_
M /R)1_PB7C__ * OA[_P>3__ ")110 ?\(EX_P#^@+X>_P#!Y/\ _(E'_")>
M/_\ H"^'O_!Y/_\ (E%% !_PB7C_ /Z OA[_ ,'D_P#\B4?\(EX__P"@+X>_
M\'D__P B444 '_")>/\ _H"^'O\ P>3_ /R)1_PB7C__ * OA[_P>3__ ")1
M10 ?\(EX_P#^@+X>_P#!Y/\ _(E'_")>/_\ H"^'O_!Y/_\ (E%% !_PB7C_
M /Z OA[_ ,'D_P#\B4?\(EX__P"@+X>_\'D__P B444 '_")>/\ _H"^'O\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>scan1.jpg
<TEXT>
begin 644 scan1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $" W # 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]&/B7\<O
MGP=DT^/QEXCMM!>_#FV%PCMYH3&[&U3TW#KZUQ7_  VW\#_^BAZ;_P!^IO\
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M7PP_Z&^S_P"_<O\ \31_PTU\,/\ H;[/_OW+_P#$U^<=%'^L>)_DC^/^8?\
M$+<I_P"?U3[X_P#R)^CG_#37PP_Z&^S_ ._<O_Q-'_#37PP_Z&^S_P"_<O\
M\37YQT4?ZQXG^2/X_P"8?\0MRG_G]4^^/_R)^CG_  TU\,/^AOL_^_<O_P 3
M1_PTU\,/^AOL_P#OW+_\37YQT4?ZQXG^2/X_YA_Q"W*?^?U3[X__ ")^CG_#
M37PP_P"AOL_^_<O_ ,31_P --?##_H;[/_OW+_\ $U^<=%'^L>)_DC^/^8?\
M0MRG_G]4^^/_ ,B?HY_PTU\,/^AOL_\ OW+_ /$T?\--?##_ *&^S_[]R_\
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MO_Q-?G'11_K'B?Y(_C_F'_$+<I_Y_5/OC_\ (GZ.?\--?##_ *&^S_[]R_\
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M#]O_ -\O_P#$U\BT4 ?77_"Y?!?_ $'[?_OE_P#XFC_A<O@O_H/V_P#WR_\
M\37R+10!]=?\+E\%_P#0?M_^^7_^)H_X7+X+_P"@_;_]\O\ _$U\BT4 ?77_
M  N7P7_T'[?_ +Y?_P")H_X7+X+_ .@_;_\ ?+__ !-?(M% 'UU_PN7P7_T'
M[?\ [Y?_ .)H_P"%R^"_^@_;_P#?+_\ Q-?(M% 'UU_PN7P7_P!!^W_[Y?\
M^)H_X7+X+_Z#]O\ ]\O_ /$U\BT4 ?77_"Y?!?\ T'[?_OE__B:/^%R^"_\
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M=I>6N\Q^8@(&X=1R*^(Z^G/V<O\ DGA_Z_)OZ4 ?(O\ P59_Y"7PX_ZYWO\
M.*O@BOO?_@JS_P A+X<?]<[W^<5?!%?KN1_\B^E\_P V>'B?XK"BBBO>.8**
M** "BBB@ HHHH **** "O<?@9^SMH?Q2^'/BOQIXD\<IX*T;P]=Q6MQ/)8FY
M4AU4ACM8$<L!@ UX=7VY^Q1'JLO[,WQ;71?"%CX\U(ZM:^5H&I(KV]T=D>0P
M8@' RWU45Y>95IT*'/3=G>*OIU:3WT^\VHQ4I69X;\:/V=;+X<^ M"\=>%_&
MMEX[\':M=/8)?V]NUN\4ZACM*$G(.QAV((Z<BO.=;^&GB_PUHL.KZOX5UK2]
M)FQY=]>6$L4+9Z?,R@#/;-?=GQ3\(:QXP^%7PF'B+2=-^#?C"#QA#8Z1X?LW
MC>P"22?\?)MN5++RW/T/WZZOQGI>J/\ "[]HK2]97QUJP@TIT;5_%;1K8WDJ
M(Y+Z?;HH$<:X4[EX^[T(KR*>:SA"*E:3NT]KVYDE9KW7ONONZF\J";=M/^&/
MSG7X;>+G\,?\)&OA;66\/[=W]J"PE^S;?[V_;C'OTJ/PW\/?%/C*SNKO0/#6
MK:W:VO\ KY]/LI)DCXS@LH(SCMUK]*-*M=8^(FDZ3INJ0>,?AIX@/A%8DUS1
MKF.\\,/;+'G+D[H02.<%5?!QNQ@USW@$QV_P1^!8\%:9X]U6TC0^<W@*]M[>
MU%Z'7S?[0#CE2V_[WRXW9[57]L3Y7[BO>V^FS>^W3O\ +NO8*^Y\3>#?@JWB
MSX)_$+X@'539MX2FMX3IK09-P9& .6R-A&>F#TJI\1?A4OAGQ#9Z9X9NM4\6
MK)I<>I7#KHMQ;209SO'ENNXHO'[S&TYZU]8?$>_M=6^$G[6UW:Z1_89?4]-^
MTV GBG\NX B$IWQ$H<MDG!X).><UZC8WEQI_[5T=U Q6>#X2B5"1G#+*I'!Z
M\BD\SJQ<IM::NVG\L':]N[>H_8Q>G];L_-?Q%X&\2>$+:SN==\/ZGHMO>KOM
MI=0M'A688SE2P&>.:EN_AWXKT_PW%XANO#&L6V@R@%-3EL9%MV!Z'>1C!['I
M7UMX3\8S?$+]D#PSJOQ'U:YUZTB^)UG'=7FJ2F5DMBR%U+-T3YWR.@!(KZ#\
M9ZK>Z5\1?B%/<^%/B!K7AK^QW2X%]JEE%X8DLS$O-LLA4!@,\9W?>SU%:U,U
MJ4I<C@KIM/6R=FMK]=?ZN2J">MS\IJ*0;<?)G9_#GKCM2U]*<@4444 %%%%
M!1110 4444 %%%% 'N/[%7_)Q>@?]>MY_P"B&K]'Z_.#]BK_ ).+T#_KUO/_
M $0U?H_7Q><?[RO\*_-G?0^ W_"_BN7091%)F6R8_,G=/=?\*Q_VLKJ*]^ >
MK3P2"2)Y;<JR]#^]6H*X/X]ZC/#\']9M%?-O+- 60] 1(#D>G2O@\YPZE@ZU
M2.ZB_P C[+A>=L[P2?\ S\A_Z4CY#HHHK\'/[G"BBB@ HHHH **** "BBB@
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M[C18\!--EOY6ME Z 1EMO'TKRG_A<FA_\\+S_OA?\:/^%R:'_P \+S_OA?\
M&AYIE[WJQ#V-7L=W17"?\+DT/_GA>?\ ?"_XT?\ "Y-#_P">%Y_WPO\ C5?V
MM@?^?J%["I_*=W17"?\ "Y-#_P">%Y_WPO\ C1_PN30_^>%Y_P!\+_C1_:V!
M_P"?J#V%3^4[NBN$_P"%R:'_ ,\+S_OA?\:/^%R:'_SPO/\ OA?\:/[6P/\
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M-_X; \%?\^>K_P#?A/\ XNC_ (; \%?\^>K_ /?A/_BZ/[+QO_/IA_K?D/\
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MLE9XF%O\MNA[PM]<I9-9K<S+9NP=K<2$1LPZ$KT)]ZG76]12YM;E=0NQ<6H
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M_P 71_PV!X*_Y\]7_P"_"?\ Q=+^R\;_ ,^F5_K?D/\ T%P^\]RHKPW_ (;
M\%?\^>K_ /?A/_BZ/^&P/!7_ #YZO_WX3_XNC^R\;_SZ8?ZWY#_T%P^\]RHK
MPW_AL#P5_P ^>K_]^$_^+H_X; \%?\^>K_\ ?A/_ (NC^R\;_P ^F'^M^0_]
M!</O/<J*\-_X; \%?\^>K_\ ?A/_ (NC_AL#P5_SYZO_ -^$_P#BZ/[+QO\
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M/[?'Q&M%+2>!M)V?WD$S+^88T ?=M%?G^W_!1[QBI(/A30P1U!,W_P 52?\
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M;;#$\I]$4F@".BMF/P=J\@!-H8@>\KJO\S5E? FH,"?-M !QDS"@#G:*Z1?
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ML?Q)\./"^KQLJJ+6;I]S;S[UZ[I7C/X=:-&LMJ-$A9?E4VH1G'_?-6+SQ;X
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M,3*S8X!)'05N>)?#-UX9UM]-N67Y@'CF0<2QD?*X_#^M95J@R1R-RX)/H>]
M%.XD>*-%+;PO&UN>#VY[5P&I6ALKV6+!"YRN?0]*]'6#>N=W1N"3@FN<\;Z>
MBPV=W&,8_<OSU_B4_D3^5 ')4444 %%%% 'T_P#\$V/^3N_"?_7M??\ I+)7
M[+5^-/\ P38_Y.[\)_\ 7M??^DLE?LM7LX'X'ZG/4W"O /V^?^30?B-_U[VG
M_I;!7O\ 7@'[?/\ R:#\1O\ KWM/_2V"NRM_#EZ&<=T?B31117S1V!111C-
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MMY77<L;E?4*:9TH **** /Z0/A[_ ,D_\+_]@JT_]$I705S_ ,/?^2?^%_\
ML%6G_HE*Z"O*>Y]A'X42V?\ Q]P?[Z_SK^;CQ]_R/7B/_L)7/_HUJ_I'L_\
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M%J;;2+>*50$9E*F4J.<@$@?C79^)-5^'D6F6L?BKXP:QJ%E;SK*D=A:E\X&
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MPKD\&:I)J/A69+E6XDTZ^/RO[(WK]:P?%-MX<\7WTMOXA%QIFKQ+\L:H1)
M,GC!#KW#"MKQK#J.A#RY-=>33))"MK?#[T;*#@,1R"0.*P(];L?$$(M]6U<1
MWEG'NMM44 3Q,3W/\0]?:@#R[QU\+=0\$SQS2$WFCW)S!?Q'(D'8-_=/M7,R
MJT7E9.60<\C _.O1?$?Q!\0W4$_AW4KJWO[%RI^U0*#N7/!KSJ]A4-^[<XR5
M(<8)% $<5WY<8<LK-V7'^?6OH;X-^)="T_PQ-=BXB@U.%2'C8^@Z@=\U\YQH
M(Y",9*+_ !'.:N07[6R)L#*=FTA>ASZT 7_%^L0ZIKU[=0VRK+)*7>5,$O\
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MD,%H@$JXZL&_F37U/XB_92\&> ["SUG[#$\FLLC:3=6MS(S-$(E9WD/][+8
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M:W)-';16D<RAQ% ,(/7 [5Z,5W[XMV5X8#KFN'\?"W&HV(1C@Q9DP.GS'^E
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M<\/S2SSZB%+>:/LL"8.68D9QZ]A7Z5?"#]L^R_95^#>F>$O$.F2W&I.SO9O
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M70V9XV8_%'YFE:J2Y51@$$_+P:<Q5L; 05/W3U->X^!?V?FFBAN=9D;S)1Q
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M/$7[.?AK5M*F73H!8WX!,4H8\GT(- ''_!#29=5\):=I< Q<&6YN\GKM1/\
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MQ_=ZK]:_-6OV#^&VFS>$_P!E/2K5GD%@?A0+EX!\JK+/.[GZDE^M 'QQ^TA
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M#DXY %?,&G64?AGQ(8O$-N[1Q##QQN#D_P )!Z$=_I7Z<? +PGHWQ'^&=E/
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M/[-N],\QO)^8I\OS 8[@C]*ZCPCYA^''B5_">GW&H1?8S(#)/J8FC)-M"O\
M$?<] />N1\<_M)Z+\0KV"%_#C:;Y3A8=228&1>>"R8QCV!K@OB#\3K/5=%AT
M/P[%<VEA(?-U"XN&'FWD@/ ..B+Z=SR>@KS6@#VG5DN],\074=RI0ME2@&T,
M#T?'OUJSX942ZI&C3!0LBK@=R/;\*F\)WUO\5?"T41N4C\4Z+:;'MG'-[;1@
M;70]W4<$>@!]:[#X,7.BZ7K4=OJ-HL\MU,JPRRYS&._'<DT >F^./#LVM>%D
MN(;#[$(8-H(!)<XZ^U?,-R9-SQLAAD0X8.I!/OS_ #K]1;?P+976BQ1!,JZ
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MTW0;3 4M'+<L,?WFV@_^.F@#V+_@FQ_R=WX3_P"O:^_])9*_9:OQI_X)L?\
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M2QU_,_7],'[-7_)NOPN_[%?3/_26.@#\^_\ @M%;RW/BGX1I -THM=3<)W8
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M3+U5XVZ,I'(-9O[)FJZ'XA\4>)OA9K/E/;^(H#?Z!)/]TWB#]Y ?3>HR/=:
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M. K-U;ITX'M7E7CWQ5IWAG3+N28 WDR%$AC;+$GUSVKY9N-2,=R\D<[(2_\
MRS+#GGD4 ?7>J?$?0]"N;D37OD"+LW()]AU_*O.?$W[2*PW>W1[ RQ#),DQQ
MOQ[=OQKP9Y+B^E!,I=\EBTKDD ?7M5FWMPTHCB7[=<-P%_A'X#DT :7BOQ9J
MWCC5&O-1NS(1R$)PD8]%'2H= \.7FNWAM=.@?"@F20G"J/5F["I=1MM-\&0)
M<^*KQHI67='I-N0US)]1TC7W:O/?&'Q;U7Q+:OIMFB:)H9/_ !X6AQYGO(_5
MS]>/:@#L->\5^%_ ]PUM _\ PE>II]]HF*6D;]QNZOCVX]ZX#Q'\2];\1QO;
MF5-/L&/_ !YV">5&?KCEOQ)KE:* "BBB@#Z?_P"";'_)W?A/_KVOO_262OV6
MK\:?^";'_)W?A/\ Z]K[_P!)9*_9:O9P/P/U.>IN%> ?M\_\F@_$;_KWM/\
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M4\0Z*/E-E?G<4'_3-^JG]/:O1;*PT+QW:RWGA"\8784M+HMY@3J/]GLX'J*
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M0Q0 E3++Y:@$$'KCT'KFKUO.\$96TCV2/P'(W28_H* )ELH[2'-QPX&5MXR
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M<]0#&#G\>U<\W[0?BXXVOIL9'0IIT((_\=J&3X_^.W;*:YY'& (;:%<?^.4
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MW7X7?]BOIG_I+'0!^<__  7%_P"0O\)/^N&I?^A6]?EO7ZD?\%Q?^0O\)/\
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M0!O?V1X>TO!OM7DU*0'YH-+BPO\ W]D 'Y*:>/&PTLXT'2[71R.ER1]HN?\
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MMT/X&LNM71?%>L>'2?[-U.YLU/WHXY#L;ZKT/XBM@>/H[X8UCP]I&J$_>E2
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MJ6O.&O[R6X"_=C)PB?[JC 'X"LZB@ HHHH **** "BBB@#^D#X>_\D_\+_\
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M6>&=?;_B>>&%L9V^]>>'Y/(/U,+[D/T7;6;+X4L[XEM&UJUO%S\MO>'[+/\
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MPE>M_P#08O\ C_IZ?_&I!XS\0  #7=2P.@^V2?XUCT4 :G_"5:T,_P#$XO\
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M8D'YTC+@]QDL?SI\Z_/\ Y7_ %YET7OP^U(?O],UW0Y/[UG=17<?_?+JA_\
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MHCX:?]$\\*?^"2V_^(H_X41\-/\ HGGA3_P26W_Q%%% !_PHCX:?]$\\*?\
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MI'BK1TT[6M*LM8T^Y5EGM+^W2>*4 JRAD<$, P!&1U -%%:T]WZ/\B6>,?\
M#.GPG_Z)AX-_\)^T_P#C='_#.GPG_P"B8>#?_"?M/_C=%%9%!_PSI\)_^B8>
M#?\ PG[3_P"-T?\ #.GPG_Z)AX-_\)^T_P#C=%% !_PSI\)_^B8>#?\ PG[3
M_P"-T?\ #.GPG_Z)AX-_\)^T_P#C=%% !_PSI\)_^B8>#?\ PG[3_P"-T?\
M#.GPG_Z)AX-_\)^T_P#C=%% !_PSI\)_^B8>#?\ PG[3_P"-T?\ #.GPG_Z)
MAX-_\)^T_P#C=%% !_PSI\)_^B8>#?\ PG[3_P"-T?\ #.GPG_Z)AX-_\)^T
M_P#C=%% !_PSI\)_^B8>#?\ PG[3_P"-T?\ #.GPG_Z)AX-_\)^T_P#C=%%
M!_PSI\)_^B8>#?\ PG[3_P"-T?\ #.GPG_Z)AX-_\)^T_P#C=%% !_PSI\)_
M^B8>#?\ PG[3_P"-T?\ #.GPG_Z)AX-_\)^T_P#C=%% !_PSI\)_^B8>#?\
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0_P!)HZ**=+IZ(SJ[?,__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>scan2.jpg
<TEXT>
begin 644 scan2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "9 CT# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K\WO%GCWQ+=^*-6FEU_4][7<O"7<B*!O(  !   ["OTA
MK\P/$?\ R,.J?]?4O_H9K]%X,HTZM>M[2*=DMU?J?C/B7B*V'PN&]C-QO)[-
MKIY%C_A-?$/_ $']5_\  Z7_ .*H_P"$U\0_]!_5?_ Z7_XJL:BOU7ZGAO\
MGU'[E_D?@']HXW_G_/\ \"?^8OB+XO:MX9-DESK/B"YFO9&B@@LIIYI'8*6/
MRJW9034FB_%O4=>T^2\M_$NKPQ12M!,EW>30/#(IP4=68%3[&N ^)VD7.HWG
MABXAL]2O+>SNY9+@:3*8[A%:!U4A@0<;B >>E<?%X1UR.SBA;0IY=+DU.YN8
MUO0EU>1(Z* 90S;6+-O^9]Q48KQJJC2KRBJ$7%?W?):WM;=O^M3Z;#RE7PT)
MRQ<HS>]YZ;RTM>][)/Y]=$?0+>.M>5T0^(]25W^XIU&0%OH-W/X57U#XDZQI
M=E>W5QXDU,16<+7$X6_E9D15+$[0V>@KYWL? OB6UM/#K/I%Q/J5O:VL+"Z:
M.6 &.9B=SY#PE5.=R$AN!CBGK\//$@EU!)+:ZEOO+U$S7BB)8[H2HXC7>/GD
MW%E^4XVXK+VL6M,(M?[O_ _JWS-U0FI/FS%V7]YZV_[>>_Z^J/H&Q^)VKW\#
MS)XBU:*)2,//?2QA@5#9&6Y&&'/K5QO'6O(4#>(]24R'"!M1D&\^WS<_A7A>
ME_#Z]N_$E@VJZ69M.COKB9UE.4P;&WC0D9Y&]'&/45SUU\.O$SVMO'-9W=P&
MTU+2U2+RV:TD65SR[G,7!1@ZYZ8]JIS48MO"I[].UO+K>RWV(C3E4DDLP:T3
MUD^M]+\VZM=[:,^E_P#A-?$/_0?U7_P.E_\ BJ/^$U\0_P#0?U7_ ,#I?_BJ
MPH$>.WB21S)(J*&<_P 1 Y-25[BPF&_Y]1^Y'RSS'&I_QY_^!/\ S-G_ (37
MQ#_T']5_\#I?_BJ^EOV,_%.L:Q=>)++4-3NK^VCCBFC2ZE:4HQ+ D%B2,C&1
M["OE"OIO]B+_ )#/B?\ Z]X?_0FKY;B?#4*>5590@DUR[)?S(^]X%QN*JY_0
MA4JR::GHY-KX)>9]:T445^'']3A1110 4444 %%%% !1110 5\__ +8GB[6/
M"WA'P^FD:C/IWVW4&BG:W<HSH(78#(Y R >/2OH"OFC]N/\ Y%7PC_V%)/\
MTGDKW,CA&IF5"$U=.6S/EN*:LZ.2XJI2DXR479K1_>?-7_"R?%?_ $,FJ_\
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MC_T'-=_[^0__ !JOH:BC^W<S_P"?\OO#_53(_P#H$A]Q\\_\,3^$?^@YKO\
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MITOBVW0O+I*^+8/-7"AF'_'O@L%()4'(!R176_\ "GOB'Q_Q;U.>G_%5V_\
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M%?,'C3PMJ/@C5WTKQGH=U8W/)#31@$C^\LB\,/SI6 ^C?^'J7CS_ *$WP_\
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M ";!?_\ 84L__0S0!\A?\/+/C/\ \]/#O_@L;_X[1_P\L^,__/3P[_X+&_\
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M+:N?3GYE_6OC#XC_  C\4_"G6CIOB+2Y+1V)\JX7YH9QZHXX/\ZVL>8>\_\
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M9+.S+1IUD X/OFIK:%KNU5[D+!9@;DB![>]4]9O/+TQ[AFCT_2TX,TAVAO\
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MC>'I&+PRW5ROR@1;L$=^1VH&<SIU]+&OD+-Y:/DA=F[GM7B7[6/QWL?A_P"
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M8R1Q]0*^\Y%Y<E=K \^] #&7!.,D=JYOX@> =(^)?A6\T'6K=9;6="$EV@O
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M,J/:O*9[IF*I@4#/R].G:N=\4J@N(G'+%2"?6MV.2252'7##J*Y?Q#-YNHL
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MKMQONIY;N5CP&)/Y"BX7/ISX[_MCKXML[C0?"D$UMH\@*SS.Q1[D>C$<[?\
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MW)X:;3I'Y9=.N7A0G_=!P/PK$_X=W?!K_H%ZG_X,7KZ9HH ^9_\ AW?\&O\
MH%ZG_P"#%Z3_ (=V_!KMIFJ#Z:B]?3-% 'S6O_!/?X0)]VQU=?IJ<E._X=^?
M"+_GSUC_ ,&<E?25% 'S;_P[\^$>/^//6/\ P:25&_\ P3U^#TGWK#5F_P![
M4Y#7TM10!\S'_@G;\&3UTO4S_P!Q%Z7_ (=W_!K_ *!>I_\ @Q>OIBB@#YF_
MX=V_!G_H%ZG_ .#%Z[?P+^R3\+OASF31?#,"WW\-]='[1-&?52^0#]!7L5%
M'A?C3]C?P%\1+XW?B2Z\0:Q+_"+G5I"B>RKT ^@KFC_P3N^#3==,U/\ \&+U
M],T4 ?,$W_!./X+3XWZ9JIQV_M)ZM^'_ /@GO\'?#.O:;K%CINII>Z?<QW4#
6/J#L!(C!E)'<9 XKZ4HH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>scan3.jpg
<TEXT>
begin 644 scan3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $O E8# 2(  A$! Q$!_\0
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M!22C?7O='YAX@9EB\LRZE5P=1PDYI-KMRR=CJO\ AK'XG?\ 06T[_P %B_\
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ME7_^&:_B;_T*<W_@7;__ !ROT%HIQXQQ\5:,(+Y/_,F7AOE,WS3JU&_.4?\
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M<GWKH?#?_!/_ ,'V$BOKGB+4]7P<^79P);(WL=VX_D: /TR/C7P\.NO:8/\
MM\C_ /BJ#XV\.CKK^EC_ +?(_P#XJOAW1OV5OA/HC!D\$VNHR=/,U2>2Y)_
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M\ #%>9K/;1Z;9DQRK?)-(Q?<-A0@8P.H((/KG-36,UL^F"T:WDDO/.,JW!D
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M2SN9 JW(CNHNBR*N2??_ /51I6@ :[8R6[LJK<1G9)Z9[&@#Z2HHHH ****
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M1BB"(94*.F!V&* /,QNBDP5*$<\Y!_"O)OC)\7O$_P ./$NGPZ4(3;7-MO\
M-N 6W29(*_R_.OK?4M$AU*U>*:)!D<-@94U\[?&+P!!XJ\+ZG8S8^W6B/-:R
M@<K(HSCZ$#!% 'SHO[0WCVVU5;Q=:((;/V=X@8_]TKZ5ZMX._:<M?$%]%;>*
M;=-&OF('VZWSY3'_ &UZK]:^<]/L+C4X)X495\B)[D^8 !\H&>:J/]GA0)YC
M3S.<DIP ?3GK0!^B,%Q=26<<\+QZC:R*"LD39#+_ %JL;6"[),.ZVF_BA8''
MX5\C_!GXY:A\.;Y=-U!YKGP_(WS19W/;$_Q)[>JU]=0ZQ+J>C6VK6?D7^G7
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MP\Q]HY.%YH R992,DHOF,^X=1CZ5Z/\  /X77WQL\?0^'K69K6TC3[3?W<A
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M:AI5PHE>Y+-\JQ!?F&!\N<$=SBN<[CY7\?ZOIWB?75U*SANUD>-1<->.K[F
MPH0 ?*H4*,$DUS5PK!V+JRMDJ8V^G^>U>H_%23P%KFB:#?>"M/G\.ZQ'%]@U
MG1)9O.C$J@8N(Y<X;=R".QQ7#+]I\5ZPIO;IVO98Q&K28_>LHPD>> .F-Q-
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ME#]MN+M?W,)X#+W9L]%'<GZ=36=\7M$?P[HGAJPEN7NFA$V9&Z#.WY5'91T
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M=/(1A5<,61L^^6'_  'WKY-N 98UC:52@4*%W\8&<#\"3^=?K/XV^&]E\8O
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ML;.AG=)9\'!//RJ?H.?QH ]7HHHH **** "BBB@ HHHH *_/'_@L%,EOX?\
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M2=,/<JQ^@"D\^Q->$^-_VZ/ OA\30>&[*Y\3W2\+/,PA@)[\'G@_4&OO&Z^
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M *]T_P * /&7NK=5R;A<>[\UB:KJL.UDA)9FZR2-P/I7T%_PBVC?] FR_P#
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M*%7E3WX'K7A'[=W[9A^)EQ%\*OAY?R6WPJ\.XM5EB;:=8F3@S2$=8\YVCO\
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MHY0/@N:[\"F>[,=AK0B:$" &>/*R87)/'(SN_,5_07^Q*8#^R5\*#;+(MO\
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MCTDA^<C\@:_1/_@AY_R*?Q7_ .OZP_\ 1<U 'Z?4444 %%%% !1110 4444
M?FI_P6]_Y)?\-/\ L,7/_HD5^05?K[_P6]_Y)?\ #3_L,7/_ *)%?D&JEV"J
M"S$X '<T ;O@[3([W4C<7(!L[0>;(&Z.?X4_$_IFNN226:^\ZXN'=W^9O+7
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M?^CX:^*/B8Q;6[,\[?L$&T'TVXK[7_X(M?\ )R'BC_L7)/\ T?#0!^TE%%%
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MSJ?F&#T^AK]QO^"J1Q^QIXIY"YNK09/_ %U%?AWH>GMJ&JVU@VV-9G57ED.
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M5-5O-;U">^U"ZEO;R=B\L\[EG<GN2:[77HM?^,/CO4=1:(M<2!6E;DK&H 4
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M_P!J6GVB&2[>>,%,$$!FC\Q1G'6I_%4FD6?[1?C_ ,*:!!#:^#;+Q#=W5M!
MOW$&?W8] &SC'2@#YSOT>WBNK5\*R2%2.Q*C!Q7ZY?\ !+:,IK_QA8KM:3^P
MY&7T+63$U^3%U*C0SC"DRO(Y?KGK^M?K;_P2_8-X@^+A&2ICT @GO_H3<T ?
M>U%%% '#^(/ ^HZCK=W>VEU;+'<;"4F5LJ54+V^E4/\ A7NM?\_=A^3UZ/10
M!Y%X/T6X\9Q0S/\ Z/IX \^6,G]XW=$/IZM_6O6+6UALK>.""-8H8U"HB#
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M]Z_V&O\ DT'X1_\ 8O6O_H-?@+\6+C;=Z18'):WM!(Y/K(=V/RQ7[]?L-?\
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M[5'Q#L/C'\1M&U#2FDCTFRL3' ^TJ"?+).!]2?RK\\-2MU=[P%OG4,,8ZG-
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M*?>BURX<>^(5K\XK,Q0WSQ,Y5!B1&/3:>1G\"*_1;_@M[_R2_P"&G_88N?\
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M#'@_I7R1=31:9JEQ%SF.5E(_&@#O_A;K4.A^--%O[@#;#<*CGLR$X(-?K?\
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M_P"27_#3_L,7/_HD5^3OA>_$,\UI)((X;I0,GH'!RO\ A^-?K%_P6]_Y)?\
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MW$;RRZ-I<FR2?!87$V?F./[H->FZO\1+*TTU+=)T"R1[5>$X(!Z8STK]*(O
MWAR& PQZ!ID<)ZQK9QA3^&*B?X>>%I2"_AO26([FRC/_ ++0!^4L_BZ:\O3*
MFRW8[59]WS-C@5V?@_P\]W*]_?RQ^2#\BC!WYK])S\//"Q(SX;TDX_Z<H_\
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M?_'C3KSP^R^3J4\%XAB/W7W?.1Z8*DU_15>^#- U*W,%WHFGW,!ZQRVJ,I_
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>table1.jpg
<TEXT>
begin 644 table1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %N G # 2(  A$! Q$!_\0
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M4O2_^P</_0VKY^H _0#_ (:B^&W_ $,*_P#@/)_\31_PU%\-O^AA7_P'D_\
MB:_/^B@#] /^&HOAM_T,*_\ @/)_\31_PU%\-O\ H85_\!Y/_B:_/^B@#] /
M^&HOAM_T,*_^ \G_ ,31_P -1?#;_H85_P# >3_XFOS_ ** /T"/[3OPX$:R
M'Q -C$@'[/)R1U_A]Q3?^&HOAM_T,*_^ \G_ ,37P5+_ ,@NU_ZZR?R6JE '
MZ ?\-1?#;_H85_\  >3_ .)H_P"&HOAM_P!#"O\ X#R?_$U^?]% 'Z ?\-1?
M#;_H85_\!Y/_ (FC_AJ+X;?]#"O_ (#R?_$U^?\ 10!^@'_#47PV_P"AA7_P
M'D_^)H_X:B^&W_0PK_X#R?\ Q-?G_10!^@'_  U%\-O^AA7_ ,!Y/_B:/^&H
MOAM_T,*_^ \G_P 37Y_T4 ?H!_PU%\-O^AA7_P !Y/\ XFG2?M._#B(J'\0!
M2RAA_H\G(/0_=K\_:MZE]^V_Z]HO_0: /O7_ (:B^&W_ $,*_P#@/)_\31_P
MU%\-O^AA7_P'D_\ B:_/^B@#] /^&HOAM_T,*_\ @/)_\31_PU%\-O\ H85_
M\!Y/_B:_/^B@#] /^&HOAM_T,*_^ \G_ ,31_P -1?#;_H85_P# >3_XFOS_
M ** /T _X:B^&W_0PK_X#R?_ !-'_#47PV_Z&%?_  'D_P#B:_/^B@#] /\
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MZ* /T!_X:>^&_E[_ /A(!MSMS]GDZ_\ ?-)_PU%\-O\ H85_\!Y/_B:^"/\
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M#"O_ (#R?_$U^?\ 10!^@'_#47PV_P"AA7_P'D_^)H_X:B^&W_0PK_X#R?\
MQ-?G_10!^@'_  U%\-O^AA7_ ,!Y/_B:/^&HOAM_T,*_^ \G_P 37Y_T4 ?H
M!_PU%\-O^AA7_P !Y/\ XFG1_M._#B9MJ>( S8)Q]GDZ 9/\/H*_/VKFE_\
M'V?^N4G_ * U 'WI_P -1?#;_H85_P# >3_XFC_AJ+X;?]#"O_@/)_\ $U^?
MXZ44 ?H!_P -1?#;_H85_P# >3_XFC_AJ+X;?]#"O_@/)_\ $U^?]% 'Z ?\
M-1?#;_H85_\  >3_ .)H_P"&HOAM_P!#"O\ X#R?_$U^?]% 'Z ?\-1?#;_H
M85_\!Y/_ (FC_AJ+X;?]#"O_ (#R?_$U^?\ 10!^@'_#47PV_P"AA7_P'D_^
M)H_X:B^&W_0PK_X#R?\ Q-?G_10!^@'_  U%\-O^AA7_ ,!Y/_B:ZSP+\3_#
MGQ(2\?P]?_;UM"JS$1LFTMR/O >E?FG7UC^PU_QX>+O^N\'_ *"U ''_ +:?
M_)2]+_[!P_\ 0VJ'P3X&\%-X"\-:EXBMM-MX+^&[>]U"ZU)H+I"A(3R(O^6A
MSCC%3?MI_P#)2]+_ .P</_0VKPN\UF^U'3K&PN;IY[*Q#BU@;&V$,<MCZGFC
MI8#U"'X*:0ZV._Q%<H[:,VO7@6RW>3:@=$PV6<G''3'>K2?L^V<+_:KSQ'+%
MH]U)9PV$\5B7FD:Y4LGF1Y^0 #D_E7F]KX]\1V.J66I6^LW4-]96XM+>=" 8
MX1P(^F"OL<UV/@3X[ZKX6U;5=2U1;O7;V_,3/,;PPDF/[JL ,%?8 >U/K_7]
M; :>H_ ?3].N=+LCKEY/J6HWMS;0V]O8B0".!R'D)W#' R.WJ0*MM^SSIMG<
MW;7_ (DFM;*.&QEC>.V660M<R-&J':VWAE'()&#7GFI?%'Q+J&OQZLNJ36MQ
M!///:K#@+;&4DNJ9'0YP<YS3+WXG^*]14K<Z[<RJ1"I7" 8B<O$,!1PK$D4E
MY@^MC:^)GPMMO 6GVUU::R=5!OKC3K@-;^5LFAQG;R<J<]?:O/:UM7\6:QK]
MOY&HZC->0_:)+O9)C'G/C>_ ZG S6325QNW0MR_\@NU_ZZR?R6O2/AQ;>'M1
M\"^([J^\)6VJ:CHZ0M%,]S,IN#++MPRJ>, \;>N*\WE_Y!=K_P!=9/Y+4NG>
M(-2TBTO+6RO9;6WO-GVB.,@"38VY<]^",C%,1[$_[-T"W^E))K<UI;WDETDQ
MEMUWP&&+S3\H8\8R,-AACD5FV7P0T?4=)CN[?Q'=F:[TR[U>RA>PPKV\&1\[
M[B%8D=.>*XVZ^+?C*]>-Y_$-T[QF1E.U 0778YX7DLI()-='X9^.ESX7^'LO
MAJ#3GDD>VGM5G>[8Q!9<[F\K'W@#Q@X[XH ZG3_V>M$TSQ1H&GZOXB6\EGNX
MK>^TZWV++EXBXV88MM'0E@#W KQ7Q#;6EEKVH6]B\LEG%.Z0M,FQRH) R,G%
M;$OQ1\73Q:9'+XBOI%TQUDL]SC]TRC"MG') X&[-8.J:G=ZUJ-Q?WT[7-Y<.
M9)9G !=CU)Q@4/?^O($5:*** "BBB@ JUJI*^01U%K&?_':JU;U,;FMP>AMH
MO_0: /:+[X:>#;K4K_PS96&H6>M0>'TUA-4:],D1?R!*R/$1P#G .:9J/[.B
MW]]J[:5J<=M#8QPD68C>XE):V64L1NW!26P"%;GM@5PFI?&/Q9JNBRZ7-J$2
M6TMNMI*\%M''-)"H $;2 ;BN .,TL?QF\70WDUVFI(+J7;B;[.A>,K&(P4.,
MJ=@ XH?6P+97-23X+.D&D6O_  D%G_PDFI);2QZ,T,@98YFPK>;]W(')'%7I
M?@&;CG2O$UIJR,UW;1E+62,R7=NN][<!CG)7)#=#C&*Y9OBWXL;0K?2/[7=;
M2 IY;K&HFPC;D4R8W$*>0":?J?Q>\6:OJ^EZE<:K_I>F2F>U,421JDI^\Y50
M 6/<GK0!V=M^S9=21W1N/$MC9O#(ML!-"P4W7E"1XBV["[<A2WJ>G%9LWP,
MM;6&#Q)!<Z_<Z1_;$6D):/N:/&2@DW8W8SCCG%<U8_%CQ3IRZJ(M2##4YWN;
MD30I)^^;(:1-P.QB"1D5>\'_ !4N-#\9Z3XBU>&;5;C2+-;6QCAE$(4*I5 Y
MP=R@,<CJ: ,#QMX7_P"$+\2W6C->QWTUJ$6:2)"JK(5!9!R<[2<9]16%5C4;
M^?5=0NKVY?S+FYE::5SW9B23^9JO27F-A1113$6M,_X_8_Q_D:V?AOH-IXI\
M?^'='O@YLKZ]CMYA&VUMC'G![&L;3/\ C]C_ !_D:?H>LW?AW5[+5+"40WUG
M*LT,A4-M<=#@]::WU ]RUCX&>'-6N+#3]/N!X5U=Y[OS;>>_74@;6%"WG$(<
MIG&-N>]<I-\"F;P@VO6GB2SN5EA>ZLK62!HGNX5?8&!+?*QZA3^=<%HWBO4]
M UJXU:QN!#?W"S))+L!W"4$/Q[@FKL7Q$U^+PE_PC0O5;2 I18GA1G1"<E%<
MC<JD\X!J>@=3L[3X9V'@7P5/XC\=:-J%U(]\EC;:;:W0@V@KO,KN-W7H!ZUI
M^%OAAX7\5:,FHVEM?PQS:E?01QWDY#K#%:><@8*!\P;OW'6O-_"7Q!UWP.ES
M%I%VD=O<E6FMIX4FB=E^ZVQ@1N'8U>7XN>+%DDD;56DDDN)KIWDC4DR2Q^4Y
MZ=TXQVIL#KH/@)&EA97;>([:\G,%C?7.F+;R1NEO<2*@_>9QD$XX^M5_%?P9
MLM!;5+B?Q!:Z2INKR/2["6&65KE('VG,@^Z2>!D'-<HGQ1\2QEBM^ 6M;>S/
M[M?]5 P>)?P(!SWJU'\9O&$5KJ-NFKD1W\LLTI,*%E:7_6>6Q&4#=P*!G=:'
M^SU#;:SX:;5[Z6\TW4YY;:6!8'M)5=;<R@J6.2N<#) /'3%>).,.P'0,1^M=
MS/\ &_QC<3V\\FI1F:"8W*2"W0'S3'Y9<D#DE3@YKA2<DD]2<T=1=!**** +
M/_,._P"VW_LM>E_!SX?Z3XOT#Q+?ZAI<NKW.GO;+!;IJ2V*XD9@Y9VXX S^%
M>:?\P[_MM_[+5FS\17]AHFI:1!,$T_46C:YBV@[S&24Y[8)H ]NN_@/X1UI;
MJ#0_$(M9Y-<&FV5Q,S7,<A, ?R/EP"0^1YGH*XZ#X%7DWA ZXVJQV^R2))(I
M[5XXU#S>5D2G&[!Y.%QCO7(Z%X^USPW:65MIUV((;.]_M&!?+!VS[=N[GKQQ
MBM.3XP^+)=*.GOJ2M;^6L63 F_:K[T&[&<*Q)'UI+09V-W^S5?VOB"*P.MPB
MS^RS7<U^]HP2-(R!E<,1)NW#&&SSR!7#ZSX-L?"GCX:'J^K+/IB,C2:AIR>8
M6C90PVJ3PW.,$\&K/_"Y?%RWMK<IJ21&V65$@CMT6!A)_K-T>-K;L#.1VKF-
M9UR\\0:M-J5]*);N9@S,J!%XZ *   ,=!5+1JXCH/BUX9T_P=\0M6T?2EE73
M[8Q^4)WWOAHU;D_4UR%:/B'Q!?\ BG6+C5-3F^T7T^WS) H7.%"C@>P%9U2A
ML****8@H/0T4'H: +FM'%ZY_V$_] %>WWGPE\(V7@>/4+NVET]Y-!74$U:35
ME^:Z(XB%L?F()[UXCK S?./]A/\ T 5)K?B"^\1M9MJ$PG:SMDM(3M VQ+]U
M?UI] 6]_ZZ?\$]9\7? :PCNPV@ZR L9L([K3Y()9I;<W$8(?<H._)R=JC(%1
MI^S7=OKT.G?V]"JS6 OHM]MMG<>84*B(N.1C)^;..V>*XNW^+WBRTOY[V'5/
M*NIFMVDD6->3 -L7Y#CWITOQA\4S7<%P]W;.88?(CC-I'Y:IOW@!<8&&Y!'-
M+K_7];@=/;_L\7S:-J%[<Z[9V,L,US#:V]S"\9N?(^\26P8\]@1FJ'PA\+>$
MO%%M>KX@M]29XB9)[^.<6]KIUN$)\UV.=[EL )W[5B/\7?%LUCJ-I-JIN8K^
M2268SPH[AG&'*,1E,CKMQ4/A;XGZ_P"#=&N-*TR6T%A/*)I8;FSCG#N!@$[P
M>F./2@#EI0BRN(V+QAB$8C!9<\'\J;3I)#+([MC<[%C@8&2<]*;0 4444 %7
M-+_X^S_URD_] :J=7-+_ ./L_P#7*3_T!J -_P"%/ANR\8?$/0]&U%9'L;R8
MQRK$^QB-I/#=N0*];/P;\%75W:P2K)H5XUG?S7%B-56]\E8E!BG9DS@9SE.^
M*\)\/Z]?>&-8M=4TV;[/?6S;XI-H;:<$=#[$U)HWB34/#][=W=A.(9[J"6WF
M;:#NCD&''XT^@'I>F?L[W&J^)5TNWUY)K>:VMKFVOHM/D9)%FSMW#($>,<Y.
M?0&JB_ '49?"4NLP:I!<S1RO$UI!"SA667RR'<$E#_%RNW'\586G?&?Q=I?E
M"WU- L4<$<:O CA!""(B 1PRY//6JO\ PM7Q.-/NK--06&.YWK))%"BRE7?>
MR;P,[2W.*':X&K\4/A!+\-+:"5M;L]5<SM:SQ0H8W@E SC!)W+U^;CITJ_XN
M\$>'(/A=9Z_HUKJ%KJ4-W':WL=W.'8;HR=[QX'E[F'RXSD=:Y#Q;\0-=\<K;
MC6KM+KR<D%84C+,< LY4 LQP.34OB#XE^)/%.B6VDZGJ37-C;E2$V*K.57:I
M=@,N5' STJ>@SF****8@HHHH *^L?V&O^/#Q=_UW@_\ 06KY.KZQ_8:_X\/%
MW_7>#_T%J -/]HKX%>)OBKXXMK_1#9""VLUA?[3,4.XL3P #QBO+?^&.?'_]
M[2?_  */_P 37VS;_P#(0N_HG\C5N@#X;_X8Y\?_ -[2?_ H_P#Q-'_#'/C_
M /O:3_X%'_XFON2B@#X;_P"&.?'_ />TG_P*/_Q-'_#'/C_^]I/_ (%'_P")
MK[DHH ^&_P#ACGQ__>TG_P "C_\ $T?\,<^/_P"]I/\ X%'_ .)K[DHH ^'V
M_9%\>26Z6H;2_-B9G;_23C#8Q_#_ +)J/_ACGQ__ 'M)_P# H_\ Q-?;,/\
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M !H\^+_GM%_W\'^- 'QW_P ,C>-_^?C2/_ EO_B*/^&1O&__ #\:1_X$M_\
M$5]B>?%_SVB_[^#_ !H\^+_GM%_W\'^- 'QW_P ,C>-_^?C2/_ EO_B*/^&1
MO&__ #\:1_X$M_\ $5]B>?%_SVB_[^#_ !H\^+_GM%_W\'^- 'QW_P ,C>-_
M^?C2/_ EO_B*#^R-XW(_X^-(_P# EO\ XBOL3SXO^>T7_?P?XT>?%_SVB_[^
M#_&@#Y'O?V1?'=Y<&:-]+V,J@9N3V4#^[[5!_P ,=^/O[^E?^!1_^)K[5MKB
M'[/'^^CZ?WQ4GVB'_GM'_P!]B@#XF_X8[\??W]*_\"C_ /$T?\,=^/O[^E?^
M!1_^)K[9^T0_\]H_^^Q1]HA_Y[1_]]B@#XF_X8[\??W]*_\  H__ !-'_#'?
MC[^_I7_@4?\ XFOMG[1#_P ]H_\ OL4?:(?^>T?_ 'V* /B;_ACOQ]_?TK_P
M*/\ \31_PQWX^_OZ5_X%'_XFOMG[1#_SVC_[[%'VB'_GM'_WV* /B;_ACOQ]
M_?TK_P "C_\ $T?\,=^/O[^E?^!1_P#B:^V?M$/_ #VC_P"^Q1]HA_Y[1_\
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M&'8^)O\ AUGH/_0_ZE_X )_\51_PZST'_H?]2_\  !/_ (JOMG^T[?\ O/\
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M?NO^"7F@VX4CQ[J)SZV"?_%57_X=BZ%_T/>H_P#@"G_Q5?;FH:C RI@OU/\
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MX2T767A%NVH64-V80VX(70-MSWQG%8U<-4HQ4I+1C4DW8NP_\A.Y_P"N<?\
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MPO\ ^)W_ $43Q/\ ^#6;_P"*H_U8Q/\ S\C^/^0?68]C]G,-Z&C#>AK\8_\
MA?\ \3_^BB>)_P#P:S?_ !5'_"__ (G?]%$\3_\ @UF_^*H_U8Q/_/R/X_Y!
M]9CV/V<PWH:,-Z&OQC_X7_\ $_\ Z*)XG_\ !K-_\51_PO\ ^)__ $43Q/\
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MCU6VUW3;NX!:%I%A,+PR '<!M+8QTW ]L5O147)\SM_7^0GMH9EUXJ\#>%-
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M?"WPXBO9HHUTF]TV.PSI=Q+?.MS?W^SYXYEWA50-G&=G(7!.35@?L ?&4?\
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M=F][)''9V:S3JTT67R9-JPG&6^]D+SQ;7_@G_P#&9W"C1-+R>!_Q,D_PJ?\
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MT3^1JW0 4444 %%%% !1110!4A_Y"=S_ -<X_P";5;JI#_R$[G_KG'_-JMT
M%%%% !1110 4444 %%%% !7*I/&L]X"Z@BXDX)]ZZJN9BMB\UVWE%LW$G.W/
M>@!/M$7_ #T3\Z/M$7_/1/SJ7[&?^>!_[XH^QG_G@?\ OB@"+[1%_P ]$_.C
M[1%_ST3\ZE^QG_G@?^^*/L9_YX'_ +XH B^T1?\ /1/SH^T1?\]$_.I?L9_Y
MX'_OBC[&?^>!_P"^* (OM$7_ #T3\Z/M$7_/1/SJ7[&?^>!_[XH^QG_G@?\
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MP/\ WQ1]C/\ SP/_ 'Q0!%]HB_YZ)^='VB+_ )Z)^=2_8S_SP/\ WQ1]C/\
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MNX\L!@[<UDI4';]QO_=06EJN;8\S_P"%O>/?^AX\2_\ @WN/_BZ/^%O>/?\
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M:YB,?OKO_KXD_G7=@\;6P,W4HO5JQ$X*:LS\S?\ AW+\5_\ GOX>_P# Y_\
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MZ&C_ %AQ_=?<'L('Y;_\.U_BY_SW\.?^!S__ !NC_AVO\7/^?CPY_P"![_\
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M_C^?_P"-T[_AVO\ %S_GX\.?^![_ /QNOU$M@?L\?':I,'T-'^L./[K[@]A
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MK?\ YY_^/'_&C^SK?_GG_P"/'_&K-% &9%I]N=2N1LX$<?\ $?5JM?V=;_\
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M .*H_P!6LQ_E7WH/]:<L_F?_ ("SZO\ [.M_[A_[Z/\ C1_9UO\ W#_WT?\
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MSZA^Q0_W/U-'V*'^Y^IKY>_X:.\:>NF?^ Q_^*H_X:.\:>NF?^ Q_P#BJ/\
M5K,?Y5]Z#_6G+/YG_P" L^H?L4/]S]31]BA_N?J:^7O^&CO&GKIG_@,?_BJ/
M^&CO&GKIG_@,?_BJ/]6LQ_E7WH/]:<L_F?\ X"SZA^Q0_P!S]31]BA_N?J:^
M7O\ AH[QIZZ9_P" Q_\ BJ/^&CO&GKIG_@,?_BJ/]6LQ_E7WH/\ 6G+/YG_X
M"SZA^Q0_W/U-'V*'^Y^IKY>_X:.\:>NF?^ Q_P#BJ/\ AH[QIZZ9_P" Q_\
MBJ/]6LQ_E7WH/]:<L_F?_@+/K:WT^W,$?R=O[Q_QJ3^SK?\ N'_OH_XU\G1_
MM.>-XT51_9> ,?\ 'J?_ (JG?\-/^./32O\ P%;_ .*H_P!6LQ_E7WH/]:<L
M_F?_ ("SZO\ [.M_[A_[Z/\ C1_9UO\ W#_WT?\ &OE#_AI_QQZ:5_X"M_\
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M ![R?2@#)HHHH **** "BBB@ HHHH **** "M+2.DOU%9M:6D=)?J* )K?\
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M1)\JXP.?I33:V$TGN4O^$/T'_H"Z?_X#)_A1_P (?H/_ $!=/_\  9/\*O\
MV:3_ )^I?R7_  H^S2?\_4OY+_A3YGW%RQ[%#_A#]!_Z NG_ /@,G^%'_"'Z
M#_T!=/\ _ 9/\*O_ &:3_GZE_)?\*/LTG_/U+^2_X4<S[ARQ[%#_ (0_0?\
MH"Z?_P" R?X4?\(?H/\ T!=/_P# 9/\ "K_V:3_GZE_)?\*/LTG_ #]2_DO^
M%',^X<L>Q0_X0_0?^@+I_P#X#)_A1_PA^@_] 73_ /P&3_"K_P!FD_Y^I?R7
M_"C[-)_S]2_DO^%',^X<L>Q0_P"$/T'_ * NG_\ @,G^%'_"'Z#_ - 73_\
MP&3_  J_]FD_Y^I?R7_"C[-)_P _4OY+_A1S/N'+'L5+?P?H/GQ_\233_O#_
M )=D_P *UO\ A#?#_P#T ]._\!4_PJ""VD\^/_2I?O#LO^%:OV27_G\G_P#'
M?\*.:7<.6/8H_P#"&^'_ /H!Z=_X"I_A1_PAOA__ * >G?\ @*G^%7OLDO\
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M ."__P"SH_X:*\=_\_6E_P#@O_\ LZ\WHH_L3+O^?*_'_,/[>S/_ )_O\/\
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M)?/&\;:G,R. &4S'D8 _D /P%+:>)[_3[V6\MM4FM[J88DECFVL_U/>OL?\
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MN>1[_,WYFJUSJ37D@>>Y\YPH0,[9.!P!^%?=?_")^$?^@#H__@!'_P#$T?\
M")^$?^@#H_\ X 1__$U:XK@M5A_Q_P" 2^#ZDM'B/_)?_MCX/^T1?\]%_.C[
M1%_ST7\Z^\/^$3\(_P#0!T?_ , (_P#XFC_A$_"/_0!T?_P C_\ B:K_ %N7
M_/C_ ,F_X!'^IDO^?_\ Y+_]L?!_VB+_ )Z+^='VB+_GHOYU]X?\(GX1_P"@
M#H__ ( 1_P#Q-'_")^$?^@#H_P#X 1__ !-'^MR_Y\?^3?\  #_4R7_/_P#\
ME_\ MCX/^T1?\]%_.C[1%_ST7\Z^\/\ A$_"/_0!T?\ \ (__B:/^$3\(_\
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M*^_[YC_^)H_X:/\ B;_T.5]_WS'_ /$T?ZP87M+[E_F'_$-LX_GI_P#@4O\
MY$_2&BOS>_X:/^)O_0Y7W_?,?_Q-'_#1_P 3?^AROO\ OF/_ .)H_P!8,+VE
M]R_S#_B&V<_ST_\ P*7_ ,B?I#17YO?\-'_$W_H<K[_OF/\ ^)H_X:/^)O\
MT.5]_P!\Q_\ Q-'^L&$[2^Y?YA_Q#;./YZ?_ (%+_P"1/TAHK\WO^&C_ (FG
M_F<K[_OF/_XFC_AH_P")O_0Y7W_?,?\ \31_K!A.TON7^8?\0VSC^>G_ .!2
M_P#D3]%-2^ZGU-4:_/=OVC/B7)C/C*__  $8_P#9:;_PT1\2O^ARU#_R'_\
M$T?ZP83M+[E_F'_$-LY_GI_^!2_^1/T*HK\]?^&B/B5_T.6H?^0__B:/^&A_
MB5_T.6H?E'_\33_U@PG:7W+_ ##_ (AMG/\ /3_\"E_\B?H517YZ_P##0_Q*
M_P"ARU'\H_\ XFC_ (:'^)7_ $.6H_E'_P#$T?ZP83M+[E_F'_$-LY_GI_\
M@4O_ )$_0JBO@CPS^TSX\T?Q%IU[JGB*\U73(9U:ZLY@A66+.&'"@YQR/<5]
MX6-];ZI8V]Y:2B:UN(UFBD4Y#(PR#^1KU,'CZ..3=*^G<^0SSA[&\/SA#%V?
M.KIQ;:TW6J6JT^\GHHHKT3Y@**** -:V_P"/>/Z5+45M_P >\?TJ6@ HHHH
M**** "BBB@ HHHH *BN?^/>3Z5+45S_Q[R?2@#)HHHH **** "BBB@ HHHH
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M%_\ EEY97S"?<UVGB'X@7'A[XCZ!J?B>PO/#^GK9WT'EQNUVDAWQ;'(B! )
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M*W_YXI^51W-E;B!_W*=/2@#-\Q?[R_G1YB_WE_.F?9(/^>*?E1]D@_YXI^5
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MN/I4E-N[Y&D_*^WZ?>>G45XCI&K:U_PGNHVLNLW%S#8WHMTB?5(HO,VQ*<&
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M*UO8;2XU4+<2H\B!8P%8!@JJ"2/F.<X..F.M+ZAD_P#S[7_DP_[2SK_GZ_\
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M\*O_ %N7_/C_ ,F_X!'^IC_Z"/\ R7_[8^%_MD'_ #WC_P"^Q1]L@_Y[Q_\
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M/JL>E6HMF1DG9K<3^8&!PJ!&'7D]ACFJCAZLW918N9+6YZ?_ &='_P ])_\
MO\W^-']G1_\ /2?_ +_-_C7(>'OC/X6URRT"2;4[?3+W6X!/:V%S,OFE22%R
M5)')4@<\X.,XK;\,>//#_C1KI=#U:VU,VI E\AL[<YP?<'!P1P<'FHE2J1OS
M1>@[HM1:?'_:-R/,F_U<?_+5O5O>K7]G1_\ /2?_ +_-_C6/X,\36_C&R_MB
MTCDCM;E 8O,QET#NH;Z'&1[&NCK-IQ=F,J?V='_STG_[_-_C1_9T?_/2?_O\
MW^-6Z*0%3^SH_P#GI/\ ]_F_QH_LZ/\ YZ3_ /?YO\:MT4 5/[.C_P">D_\
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M J_V='_STG_[_-_C1_9T?_/2?_O\W^-6J* *O]G1_P#/2?\ [_-_C1_9T?\
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MYO[4D71H;O[*!Y7G7Z94IDYVJ0<YYZ5Q5O\ M4^)9?#=U<S:+9V[P:*=4;4
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M?^_:T?9KK_G\/_?M: +=>)>(?V<_AEXQ\1:KK.M^"M,U/5;JZ=I[N</OD(.
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M4O\ S_/_ -^UH_L*7_G^?_OVM %.BKG]A2_\_P __?M:/["E_P"?Y_\ OVM
M%.BKG]A2_P#/\_\ W[6C^PI?^?Y_^_:T 4ZTM(Z2_45#_84O_/\ /_W[6K=A
/8M9!]TYFW8ZJ!C\J /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>table2.jpg
<TEXT>
begin 644 table2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $3 DX# 2(  A$! Q$!_\0
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M%Y_X$O\ XT?ZK2_Y_?\ DO\ P0^NK^7\3]]/.C_OK^='G1_WU_.OP+_M6_\
M^@A>?^!+_P"-']JW_P#T$+S_ ,"7_P :/]5I?\_O_)?^"'UU?R_B?OIYT?\
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MT\>_[VF?^E#5R%=?X:_Y)IX]_P![3/\ TH:L:OPKU7YHJ.YR%%%%;$A1110
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MC_A3/Q _Z$;Q%_X+9?\ XFOJ/K-#_GXOO1Q\DNQQ]%=A_P *9^('_0C>(O\
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MN"-!;@-C;T)4C\#64\30O'WUOW79E*$M=#R6BNP_X4S\0/\ H1O$7_@ME_\
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MX^II** %W'U-&X^II** %W'U-7)&/]CP<G_CX?\ ]!6J57)/^0/!_P!?#_\
MH*TF!4W'U-&X^II**8"[CZFC<?4TE% "[CZFE4.YPNYC[<TVO/OBGX,/C;Q!
M\/+6YL)M0T*WUJ6?58DD9(O(^Q3JOF[2"R&1HQMY!.,BDP/11'*Q("N2.#@'
MBN0U?XI^']#\6+X:N9[Z362L+/!::;<W*1"5BL9DDCC9(\E6^\PP!D\5Y%IW
MP(UGQ+X,T*VU"P\/^?I;WUI%'XKL[N\N$MQ>S&W"O%<Q_)Y)CQNR<8Y[4_Q5
MX%UO3/$-Y_PC.@>(K#Q;/)I"6FOZ9J+KHAA@6-)?,A,F(T6,2H8I%D9MRE6R
M>)N^PSTZR^-7A6_\8V?A9+K48M<O))HK:"ZTB[@28Q*6E*R/$$(4#.X-CD<\
MC/<;CZFN$\-Z'J%_\6?&GB?5K66&*!8-%T'SN@LU199Y4YX\R=\$]2(%':NZ
MIKS$+N/J:-Q]32450"[CZFC<?4TE% $=PQV)R?\ 6Q_^C%KZ$KYZN/N)_P!=
M8O\ T8M?0M<E;=%Q./\ B98S:CI5A! \<<AO%(:4$K@(_I7"?\(AJ?\ S]6/
M_?#_ .->D^,O]5IO_7U_[3>L:I@VEH.QQ_\ PB&I_P#/U8_]\/\ XT?\(AJ?
M_/U8_P#?#_XUV%%:<TNX61Q__"(:G_S]6/\ WP_^-'_"(:G_ ,_5C_WP_P#C
M7844<TNX61Q__"(:G_S]6/\ WP_^-'_"(:G_ ,_5C_WP_P#C7844<TNX61Q_
M_"(:G_S]6/\ WP_^-'_"(:G_ ,_5C_WP_P#C7844<TNX61Q__"(:G_S]6/\
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MM]>N-3GN+RU.B0:4[:A#):[#<AX<Y&P21GY22PD7:&S1SON%D=#_ ,(AJ?\
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MB:1YIG)'EVZ!&)8\XP!R:\OU']K#6](UOX0I=:#I\>C>+=#LM9U6\/VC,"S
MFX:W8 H$MD7S9/,.2C#&#S1SON%D>T_\(AJ?_/U8_P#?#_XT?\(AJ?\ S]6/
M_?#_ .-<+K?QRU_1?V;M1^*CZ'9&XLXQJ[Z(TC"6/2S,"!)SE;G[*?-P< ,0
M,8KV2RO;?4K*VO+2036ES$D\,@_C1E#*?Q!%/G?<+(Y7_A$-3_Y^K'_OA_\
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MCAE^S#H.=YS5G6_AII^O^/\ P_XFNO+ECT?3+W2UTN6U22"5+EH22<]-HAP
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MRO15C^R[_P#Z!U]_X"R?_$T?V7?_ /0.OO\ P%D_^)K?FCW)LRO15C^R[_\
MZ!U]_P" LG_Q-']EW_\ T#K[_P !9/\ XFCFCW"S*]%6/[+O_P#H'7W_ ("R
M?_$T?V7?_P#0.OO_  %D_P#B:.:/<+,KT58_LN__ .@=??\ @+)_\31_9=__
M - Z^_\  63_ .)HYH]PLRO15C^R[_\ Z!U]_P" LG_Q-']EW_\ T#K[_P !
M9/\ XFCFCW"S*]%6/[+O_P#H'7W_ ("R?_$T?V7?_P#0.OO_  %D_P#B:.:/
M<+,KT58_LN__ .@=??\ @+)_\31_9=__ - Z^_\  63_ .)HYH]PLRO15C^R
M[_\ Z!U]_P" LG_Q-']EW_\ T#K[_P !9/\ XFCFCW"S*]%6/[+O_P#H'7W_
M ("R?_$T?V7?_P#0.OO_  %D_P#B:.:/<+,KT58_LN__ .@=??\ @+)_\31_
M9=__ - Z^_\  63_ .)HYH]PLS(UOPMI7C2P_LC6K,7^FS2H9+<R/&&*L"/F
M1@W7WKYD^%^JZ=\%/@3X:\?PVZBVN-0N[3Q#=W,\T\KVWVJ[C@*L[D+ME6!<
M@<J<5]9C3=04@C3[X$="+63_ .)K,;P+:OHC:,WA@-H[9W:>VF$VYR^\YCV;
M?O\ S=.O/6I;BW>X]3YNT/\ :%\<7VEI9ZA#HVF:[IT]GHFOW4UNWV2PU*[O
M&2*0C</W:6Z!]I/S--'E@,UZ+X.^+FH1:SK&AZQINH>++G3=;&DKK/AC2FDM
M74PPR[K@!V$)3SMK8)'R$\<BO3IO!,%Q%J<4OAGS8M4;=?H^F%EO#M"YE!3]
MX=JJ,MG@ =JDT?PDOA[3XK#2O#\FF6,6?+MK/3VAC7)R<*J@#)I)KN!\N^"7
ML= \3^&/$-S?1^*$U?Q ]K;^+=%\03I?W$DTLBK;WNFR\>6G$;+&/D$8;"X-
M<_XF^)GB'Q1\ _$MM;:QH_A2RTG0M.E>V*.+B]-S,26AE,NZ-1MV*1O+-N!.
M,"OK2V^&FE67B&77[?P;;V^NRY\S5(M'"W3Y&#F4)N.1UYYJ*^^%.AZHMDMY
MX'L[M;*,Q6HGT4.($)R53*?*,\X'&>:6G<9X:?VAO%A\:W\O]BQRZ%'XAO\
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M_P"@=??^ LG_ ,31_9=__P! Z^_\!9/_ (FGS1[BLRO15C^R[_\ Z!U]_P"
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MX"R?_$T?V7?_ /0.OO\ P%D_^)HYH]PLRO5R3_D#P?\ 7P__ *"M1_V7?_\
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M -_!7Y9_98/^>,7_ 'P*/LL'_/&+_O@4?ZCO_H(_\E_^V#_B*:_Z _\ R?\
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M'L?,.8^@OM]M_P _$7_?8H^WVW_/Q%_WV*^??[-L_P#GSM_^_2_X4?V;9_\
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M $,U\V5]&_!.]@A^'MHCN0PGGR C'^,^@KX;B_\ W*'^-?E(_7/#/_D;5O\
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M/N)_UUB_]&+7T+7SE-J%NXC4.Q)FB _=M_ST7VKZ-KEK;HN)X9^V-_R2*/\
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MWU3_ -#6O1JSF!X9^V-_R2*/_L)0?R>OEWX&6VF7GQ5T&+5DMY;4R.5CN_\
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M$/BZ]:SNG_L^#";,_P"DGN?]RN>JY;?\@R__ .V7_H1I.""[+O\ PF5Y_P!
MZ'_P)/\ \11_PF5Y_P! Z'_P)/\ \16-13Y$%V;/_"97G_0.A_\  D__ !%'
M_"97G_0.A_\  D__ !%8U%'(@NS9_P"$RO/^@=#_ .!)_P#B*/\ A,KS_H'0
M_P#@2?\ XBL:@ D@#DGM1R(+LVO^$SO/^@=#_P"!)_\ B*#XSO3UT^$_]O)_
M^(KP+6/VD+'3-=\?6\.CS7ND^%-&741J$<H47\_VAH)(8LC 1)%"&0G&X/QA
M<GK_  1XWU+6O%&N>%?$&FV6F^)-)M[2\ECTR\-U;R07 D\LAF16#!HI%((Y
MP&!(-+EB.[.^TO5(-$N=2N-.\/6%C/J5R;R]DMY=AN9RJJ97PGS.551GKA16
MA_PFE[S_ ,2^'G_IY/\ \37C&N?&^VT?X?\ B+Q9'IK7UO:WMSI^C6<$G[[5
MYH=RMMXPBF2.7GG"1LY]*I^,_CY%X2\$^"]632#J.K>)182C3HIL+:6\\D*2
M3N^/N(TZJ.,NQ4#O@Y8A=GN8\:WHZ:?$/^WD_P#Q-+_PFM\,_P"@1<C!_P!)
M/(_[YKS_ .)GC-OAUX/U76XM(OM?GM(I'BL-/3+RLJ,WS,>(T 4EG;@#U. >
M-U_XZ?V%JO@^W?3;7[/K>GV6H3O-=E)%6XE6/;;KM_>F+=YDF2N$&:'&*%=G
ML6O:K#XJT];#6O#]CJUBLL4ZVUY+YD8DC</&VTIC*NJL/0@&KY\:7K$DZ?"2
M>23<G_XBO*Q\2II?AKJ7C"#3(YX;19+U+!9_W[V*G<)&&/DD:$&58SZJ,\UV
MEI=P:A:6]W:RB>UN(UFAE7HZ, RL/J"#1R1"[-__ (3*\_Z!T/\ X$G_ .(H
M_P"$RO/^@=#_ .!)_P#B*QJ*?(@NS9_X3*\_Z!T/_@2?_B*/^$RO/^@=#_X$
MG_XBL:BCD079L_\ "97G_0.A_P# D_\ Q%6'\77HT^.3^SX,&5EQ]I/8#_8]
MZYZKDG_('@_Z^'_]!6DX(+LN_P#"97G_ $#H?_ D_P#Q%'_"97G_ $#H?_ D
M_P#Q%8U%/D079L_\)E>?] Z'_P "3_\ $4?\)E>?] Z'_P "3_\ $5C5B^,O
M$I\(>&KW5ETR^UF6!?W5AIL7F33N>%4<@*,]78A5&23@4<B"[.T'C.]'33X1
M_P!O)_\ B*KZAXC;5K"YL;[1K2\LKF-H9[>>;?'*C##*P*8((.,5XJGQDUG6
M;#PBN@^';&XU76O#C^)KB'4-1,$%M;H(]T:.$8NY:0 ' 4 98C(K>G^+.GR_
M"C2_'&G6TEW#K%O:/IMD[!7GFN2BPPEAD#YW )&0 ">U+EB%V>I1^,+J&)(D
MTV%8T4*JBY.  , ?=IW_  FE[S_Q+X>?^GD__$UXUJ?Q5U70?B9HGAG4M$L(
M;;6+YK"S\K4M^H2JL+2/>"W"X%L&1DR6#C@D<XH\$_%?4M?^(-SX2UC1;'3-
M2CTXZH]O8ZD+N:P3S0B17@"A8Y'#!EV%@0&&>,DY8CNSV7_A,[S_ *!T/_@2
M?_B*JW/B#[;>V5Y<:):3W=D7:UGDF+/ 77:Y0[."5R"?0D=Z\F\3?%74O"WQ
M$T/0KO1K%-.UG4X=+L6.HC^T;LNFZ2YBMPI!@B/#EF#<$XQC//\ AK]HIO$3
MW-LND6D6H23P1V4*WVY55Y9UD6[8J/)DACMI)77D!63G)I<L0NSZ"_X3*\_Z
M!T/_ ($G_P"(H_X3*\_Z!T/_ ($G_P"(KA;SQ<EAXZTO0)H5%OJUE-<6%ZKY
M\V6$J9(B.@_=NKJ03D!_09Z&JY$*[-G_ (3*\_Z!T/\ X$G_ .(H_P"$RO/^
M@=#_ .!)_P#B*QJ*.1!=FG>^+;J>W\IK"%%=XU+"X)(RZ\XVU[;7SU<?<3_K
MK%_Z,6OH6N>JDFK%)W/#/VQO^211_P#82@_D]?$5?;O[8W_)(H_^PE!_)Z^(
MJ_9.#?\ D6R_QO\ *)_,7B5_R.H_]>X_G(*]3^'7@/3_ !#X2MKPZ7;ZIJES
MJSV*1W6K?8@5$:, @_C;+'@9/3BO.)-'OH9K.%[29);U$DMD*',RL<*5]02,
M"M"]OM:T72[31[E)+&&*Y;4(%9-DBR_ZLL&Z\&/'L5-?5XJ,J\%"C.SOW?GV
M:?XGP& G3PM257$4W**5K66[MW32T[IGHT_@GPM:::]W86=KJMM)J=Y;PS:I
MK0L&,41CV;5;&[[S9..PX&:YV?2?#7ARVT.VU+2K[4[O5K-;U[BTN=C6ZR,P
MC2%-I$A 4$ECR3CBHE^(WB+Q MXTNEZ7J_E/+J,[3Z7'+Y1?8)9.GR@D(3VR
M?>L_3OB?KFE6\,=NUFKVQ<VEP]G&TUEN))$+D909)( Z$Y&*\ZGA\6E:4KN_
M\[\[:^6FR5SVZV,R]R4H0Y5;3]W%]KZ/>]G:\FUW6YUUAX%\-0&U-T(S=3Z/
M9W<-OJ-\;2WFFD+^;F;:0C *-J$@'YN>*9;>&O#NGZEXOL[_ ,,7F_2;,ZA"
MMSJ)5]I:(*A,8*LO[PD./O#::PK?Q3XMMKM=-ELH[L_8(4;3KVR25'@B0R12
M%&')"LS!^N&//-8<_CC5[F]U:ZDGC:74[86=QB)0OD@IM1% P@'EH!CH!BB.
M&Q,Y.]2Z=MI/NNUM+)_Y]$3QN!I0CRTK--K6$>SWO>[3<>UNW5V- \&W/C,W
M<NE"*-DNX(19,S,R),Y16W8Y56V@D\_,#5[4_#6A6O@&XO[.ZN+[5[;5%LYY
M\!+;85E(\L=6SL#;CCKC%96C:SKO@*X^UV9DT^34+)XU=X_];!)E2RY]P<,.
MA'%4;37KJSTQM.3RFLVNH[MHI(PP:1 0N<]1ACD=#FO0E"O.=XR]U-6_5/\
M3\3QX5<)3I\LZ;YVI)W6S?PM*^GGIZ;FYIFAZ)=_#S6]1\R[DUVSE@^3 6".
M-Y"O7.78_@!CO6IH_P /++Q%X+T:YM=0@M->O;F\CCM;@N?M0B5&54PI"'EA
MEB 20*Y'_A(+M;;5;>/R8;?4G1YXHHE5?E<LH4#[H!/0=N*V_#'C7Q';65MH
M6CQPSN'F:UVVB27$3R*!(8W(W*2JXXK*M3Q*BY4YV?-?5Z6Y;6VV3U].MS?#
M5L%*<85:=UR\NBU<N>]UK>[CI?OI:Q#XC\!77AJPFO+BZMY+<3Q0VSQ[O]*5
MX1+YB9'W0K)G/=P*YBNF\9>+D\0V6@Z=:_:!I^CV?V:'[45,C,6+,QV\8Y"C
M_91:YM(9)(WD5&9(\%V R%R<#)[<UUX=U?9IU]_ZM]^_J['FXU4/;..%^'^F
M_DMD^J5QM?2?P/\ ^2<V?_7>?_T,U\V5]8_L]^&+'4?A9I]Q-]H\QKBXSLG9
M1Q(1T!KX_C!VP-/_ !K\I'Z=X9*^;5O^O;_]*@;]*IVL#@'!Z'O73_\ "%:9
M_P!/7_@4_P#C1_PA6F?]/7_@4_\ C7Y%[1']*\I\\GX*Z]J7B#P_-KGB?3]9
MT[0M4CU.SU&32=NO,(Y"\<$EX),;.=C$("Z#:>I-8.I_LU:QJ>DVFE3>*+"Y
MTRVBU*U2UN;&<Q!+JX:=9RB3J'GCWLGSYC(P=H.<_4O_  A.FYQB[S_U\O\
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M_LT:EJ26T#1:/:/;6L4, ;8JJ[N[,3([%F8]0H "BO;?^$*TS_IZ_P# I_\
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M^8Q&=I6N>E\5:9=_#S4HH)M'M-6U#2(OM<,=O'%YDD=X_P H4+@2>45(Q@G
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MF-SN]A2L!HT5D?\ "7Z)_P!!2V_[ZH_X2_1/^@I;?]]4[ :]%9'_  E^B?\
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M@&('4@'BOD74?!/CN_T3PU'J'AW4+?PW9QZK"NEZ?97%V[3M*AMKEK5KM)(
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M;?:C;P7]K ZB<^9-%(+K8(XI6C09EX4,5 !)!R!SX2VKW[6<-H;ZY-K"V^*
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M^X61GZE\+5UK4+2_U'1/#^H7UF<VUU=1B66'G/R,T1*\\\=ZU#X6UDGI8?\
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MV$892S %1D<\US,?[3W@N+QQ?Z+>ZE!;:6FFZ;J=EK48EF@N8;PN%=V5"L*
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M-[&[^5$/(;S!'LP6X^\.!1[1A9'JO_"+:SZ6'_?]_P#XBC_A%M9]+#_O^_\
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M6EW!J%I;W=K*L]K<1K-#*G1T8!E8>Q!!HYV%D<?_ ,(MK/I8?]_W_P#B*/\
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MO_#7P#\1/"?CFR:]O[FY\.B>_DNDN=2\Z/$MQ<2HR+][<?,A&U@0H4X9?NL
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>table3.jpg
<TEXT>
begin 644 table3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #7 88# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** /+
M?VBOC%J/P.^'_P#PDUCX<;Q%%'>6\%ROVI8%MHY)5C\PY!+<N % []17*_$O
M]JNT\ _&31?!D&D?VGIK&6/6=86<*-/F%I+=QPA,?.YB@=B,C:&C_O5VGQW^
M"EM\>O!@\,:AXAUC0-.:=)YSHTJ1O<;"&17+*WRAPK<8Y45RVO?L=_#GQ3K^
MAZ]J^FRW^O:?.;FYU)Y"LNIR&V:W9KD+A6)5LY '*CMQ0!Y5I7[=/B*^?1])
MF\#6,'BCQ;:Z5J7A2U&I%H)K6^ED1#=/LS&\8C+,J@YR #7MOPC_ &@]'\>?
M#73O$GB&2R\)W\EU=Z?=65S>+L2YMIGAE$;MC>N4W XZ,,UP.G_L)^%=.TJ.
M-?$_B.;6=/%A%H6M2SQFYT6WLG=[:"#Y-I13(X;>"6!&3Q7K'@OX7:1\)?A2
M_AC2FGNK:V@NII+J]823W$TK/++*[8&69W8\#'.!P* .[@GCN88YH766*10Z
M.ARK*1D$'N*DKGOAY_R('AG_ +!EM_Z*6NAH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BO.OCE\:;+X%>$(O$6HZ'J^MV
M37<-K(-*A5_LXDD5!)(S,H5 6 SG))  -<Y\0_VDX_AA\5-#\+Z]X0U:WT'6
M)7M;;Q0LL+6[3K;FX<>4&\W8J*VZ3;@%<>] 'M%4-?\ ^0%J7_7M)_Z":^:=
M+_;PTS4K6&$^!M:M]?UB'3[OPQH\ES;^9K=M>R/';S!PVV$9C8N'.4&#SG%>
MO_#GXJ67QF^$<GB:QLKC33-'=VMQI]V5,UK<0N\4L3%202'0X(.",'O0!TOP
M\_Y$#PS_ -@RV_\ 12UT-<]\//\ D0/#/_8,MO\ T4M=#0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 45')<1PD!Y$0GH&8#-24 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR('AG_L&6W_HI:Z&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP<LM2N$N_%^I7?C2\4[A%J.$LD/^Q:K^[]/O[CD9!KOX84MXECC18XT&U40
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M?$2:UEU_0(;QK9"D01WB503D\(0,^]=7I'AO3-"MK>"QLH;=8(Q%&RH-X4#
M!;J>!W-<\?;<[YK<O3N:/DY5:]SCOVA/B;=?!OX+>+O&UE9PZA=:+9&ZCMKA
MBL<A# 88CG'/:O(-"_;@TIO!!\=ZUIOD>%M;U<Z1X1M[-U:^U0Q(WGS2!V5(
MEW))M#,"%7GE@*]X^*GPWTOXO_#S7?!NM2W4&E:Q;FVN)+*01S*N0<HQ! /
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M3G)R?4****T("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF:6-UDB9R\3YV.@88QSUS7HVF6;:=IUK:O=37KPQ+&;FY(,LI QN<@ %CU.
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(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Feb. 27, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-55939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Compass Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4876496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">80 Guest Street, Suite 601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">500-8099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CMPX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,087,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">CohnReznick LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Melville, NY U.S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001738021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 30,643<span></span>
</td>
<td class="nump">$ 43,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">178,263<span></span>
</td>
<td class="nump">83,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">913<span></span>
</td>
<td class="nump">6,029<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">209,819<span></span>
</td>
<td class="nump">132,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use ("ROU") asset</a></td>
<td class="nump">9,099<span></span>
</td>
<td class="nump">6,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">568<span></span>
</td>
<td class="nump">568<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">219,588<span></span>
</td>
<td class="nump">140,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,585<span></span>
</td>
<td class="nump">2,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">11,383<span></span>
</td>
<td class="nump">6,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligations, current portion</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">13,968<span></span>
</td>
<td class="nump">8,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligations, long-term portion</a></td>
<td class="nump">8,829<span></span>
</td>
<td class="nump">6,296<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">22,797<span></span>
</td>
<td class="nump">15,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value: 300,000 shares authorized; 178,324 shares issued and outstanding at December 31, 2025; 137,820 shares issued and outstanding at December 31, 2024</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">627,665<span></span>
</td>
<td class="nump">489,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">280<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(431,172)<span></span>
</td>
<td class="num">(364,683)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">196,791<span></span>
</td>
<td class="nump">125,233<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 219,588<span></span>
</td>
<td class="nump">$ 140,403<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized (in shares)</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding (in shares)</a></td>
<td class="nump">178,324<span></span>
</td>
<td class="nump">137,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued (in shares)</a></td>
<td class="nump">178,324<span></span>
</td>
<td class="nump">137,820<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Licensing revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">55,969<span></span>
</td>
<td class="nump">42,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">16,870<span></span>
</td>
<td class="nump">15,133<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">72,839<span></span>
</td>
<td class="nump">57,475<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(72,839)<span></span>
</td>
<td class="num">(56,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest income</a></td>
<td class="nump">6,350<span></span>
</td>
<td class="nump">7,250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (66,489)<span></span>
</td>
<td class="num">$ (49,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic and diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">157,695<span></span>
</td>
<td class="nump">137,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (66,489)<span></span>
</td>
<td class="num">$ (49,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (66,419)<span></span>
</td>
<td class="num">$ (49,202)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">127,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 463,796<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="num">$ (315,308)<span></span>
</td>
<td class="nump">$ 148,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued in ATM offering, net of costs of $0.5 million (in shares)</a></td>
<td class="nump">9,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued in ATM offering, net of costs of $0.5 million</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">17,568<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based awards, net of tax remittance (in shares)</a></td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based awards, net of tax remittance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(232)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,560<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(49,375)<span></span>
</td>
<td class="num">$ (49,375)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Net loss (in shares)</a></td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(232)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">8,560<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,560<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">137,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">489,692<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="num">(364,683)<span></span>
</td>
<td class="nump">125,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued in ATM offering, net of costs of $0.5 million (in shares)</a></td>
<td class="nump">39,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued in ATM offering, net of costs of $0.5 million</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">129,357<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">129,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based awards, net of tax remittance (in shares)</a></td>
<td class="nump">669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based awards, net of tax remittance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(1,027)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,027)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,368<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(66,489)<span></span>
</td>
<td class="num">$ (66,489)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of options (in shares)</a></td>
<td class="nump">545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,275<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Net loss (in shares)</a></td>
<td class="nump">669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(1,027)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,027)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">8,368<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,368<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2025</a></td>
<td class="nump">178,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2025</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 627,665<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
<td class="num">$ (431,172)<span></span>
</td>
<td class="nump">$ 196,791<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Parentheticals) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (66,489)<span></span>
</td>
<td class="num">$ (49,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">8,368<span></span>
</td>
<td class="nump">8,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount', window );">Amortization of premium and discount on marketable securities</a></td>
<td class="num">(1,673)<span></span>
</td>
<td class="num">(1,651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">ROU asset amortization</a></td>
<td class="nump">1,196<span></span>
</td>
<td class="nump">1,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,116<span></span>
</td>
<td class="num">(4,857)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(664)<span></span>
</td>
<td class="num">(1,841)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">5,096<span></span>
</td>
<td class="nump">3,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(369)<span></span>
</td>
<td class="num">(1,217)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(49,143)<span></span>
</td>
<td class="num">(44,855)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(194,557)<span></span>
</td>
<td class="num">(88,158)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale or maturities of marketable securities</a></td>
<td class="nump">101,276<span></span>
</td>
<td class="nump">134,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(93,306)<span></span>
</td>
<td class="nump">46,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants</a></td>
<td class="nump">137,999<span></span>
</td>
<td class="nump">18,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs from issuance of common stock</a></td>
<td class="num">(8,638)<span></span>
</td>
<td class="num">(543)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">1,275<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net shares settlement of RSUs</a></td>
<td class="num">(1,027)<span></span>
</td>
<td class="num">(232)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">129,609<span></span>
</td>
<td class="nump">17,338<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(12,840)<span></span>
</td>
<td class="nump">19,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">44,051<span></span>
</td>
<td class="nump">24,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">31,211<span></span>
</td>
<td class="nump">44,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash to the Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">30,643<span></span>
</td>
<td class="nump">43,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">568<span></span>
</td>
<td class="nump">568<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">31,211<span></span>
</td>
<td class="nump">44,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amortization of premium and discount for marketable securities .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable', window );"><strong>Schedule of Segment Reporting Information, by Segment [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgHowMnpiCnsdrdTextBlock', window );">Award Timing, How MNPI Considered [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 11. Executive Compensation.<a href="#" id="itm11"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The information required by this Item 11 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2026 Annual Meeting of Stockholders and is incorporated herein by reference.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiCnsdrdFlag', window );">Award Timing MNPI Considered [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgHowMnpiCnsdrdTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgHowMnpiCnsdrdTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiCnsdrdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiCnsdrdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of information about profit (loss) and total assets by reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 9B. Other Information.<a href="#" id="itm9b"></a> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Rule 10b5-1 Trading Plans</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">During the three months ended December 31, 2025, <span style="-sec-ix-hidden:c1174"><span style="-sec-ix-hidden:c1175"><span style="-sec-ix-hidden:c1176"><span style="-sec-ix-hidden:c1177">none</span></span></span></span> of our directors or officers adopted, materially modified, or terminated any contract, instruction, or written plan for the purchase or sale our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any non-Rule 10b5-1 trading arrangement.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We recognize the importance of safeguarding the security of our computer systems, software, networks, and other technology assets. We have implemented and maintain a security risk management program that is designed to preserve the confidentiality, integrity, and continued availability of information under our ownership or care with the aim to continually improve security features in order to keep pace with the evolving cyber threat landscape.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We face a number of cybersecurity risks in connection with our business and recognize the growing threat within the general marketplace and our industry. Although such risks have not materially affected us, including our business strategy, results of operations or financial condition, to date, we and our vendors have, from time to time, experienced threats to and breaches of our data and systems. For more information about the cybersecurity risks we face, see the section titled &#8220;Risk Factors &#8212; Risks Related to Information Technology and Data Privacy&#8221;.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Risk Management and Strategy</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">We have implemented internal controls including regular risk assessments designed to address financial, operational and information technology (including cybersecurity) risks and controls across our organization. These assessments are overseen by our Head of IT and Chief Accounting Officer. We implement cybersecurity controls and procedures designed to address cyber risks and threats, supported by third-party technologies and security advisors and providers. We also provide cybersecurity awareness training to our employees during the onboarding process and periodically thereafter. In addition, we engage external third-party information security consultants to periodically conduct information security testing and assessments, and to evaluate our overarching information security program and specific incident response procedures. We also maintain a Cyber Incident Response Plan, which is overseen by our Head of IT and is designed to coordinate our response to information security incidents. Finally, we hold and maintain third-party insurance coverage for cybersecurity risks commensurate with industry standards for a company of our size and stage.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">We recognize the importance of safeguarding the security of our computer systems, software, networks, and other technology assets. We have implemented and maintain a security risk management program that is designed to preserve the confidentiality, integrity, and continued availability of information under our ownership or care with the aim to continually improve security features in order to keep pace with the evolving cyber threat landscape.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Cybersecurity Oversight </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The Head of IT is responsible for implementing and maintaining the information security program. The Head of IT role is currently held by an individual who has more than 20 years of professional IT management experience and maintains a Global Information Assurance Certification. The Head of IT reports to our Chief Accounting Officer, who together are responsible for coordinating information security risk assessments and overseeing periodic testing of our cybersecurity controls. Our Chief Accounting Officer meets with the audit committee of our board of directors periodically for the audit committee to provide guidance on the prioritization of the risk remediation and ongoing implementation of cybersecurity improvements across our organization. We also engage an external auditing firm with information security expertise to conduct regular auditing, testing, and review of our information technology risks, processes, and operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Management also generally provides quarterly updates to the audit committee on cybersecurity and other information technology risks. We have implemented a process for the Head of IT and the Chief Accounting Officer to receive incident reports and report quarterly (and, if applicable, in the event of a cybersecurity incident), to our internal disclosure committee and the audit committee, as appropriate. Management presents to the entire board of directors on an annual basis, including any key findings identified in our cybersecurity assessments.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Head of IT is responsible for implementing and maintaining the information security program. The Head of IT role is currently held by an individual who has more than 20 years of professional IT management experience and maintains a Global Information Assurance Certification. The Head of IT reports to our Chief Accounting Officer, who together are responsible for coordinating information security risk assessments and overseeing periodic testing of our cybersecurity controls. Our Chief Accounting Officer meets with the audit committee of our board of directors periodically for the audit committee to provide guidance on the prioritization of the risk remediation and ongoing implementation of cybersecurity improvements across our organization. We also engage an external auditing firm with information security expertise to conduct regular auditing, testing, and review of our information technology risks, processes, and operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Head of IT is responsible for implementing and maintaining the information security program. The Head of IT role is currently held by an individual who has more than 20 years of professional IT management experience and maintains a Global Information Assurance Certification. The Head of IT reports to our Chief Accounting Officer, who together are responsible for coordinating information security risk assessments and overseeing periodic testing of our cybersecurity controls. Our Chief Accounting Officer meets with the audit committee of our board of directors periodically for the audit committee to provide guidance on the prioritization of the risk remediation and ongoing implementation of cybersecurity improvements across our organization. We also engage an external auditing firm with information security expertise to conduct regular auditing, testing, and review of our information technology risks, processes, and operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">The Head of IT is responsible for implementing and maintaining the information security program. The Head of IT role is currently held by an individual who has more than 20 years of professional IT management experience and maintains a Global Information Assurance Certification. The Head of IT reports to our Chief Accounting Officer, who together are responsible for coordinating information security risk assessments and overseeing periodic testing of our cybersecurity controls. Our Chief Accounting Officer meets with the audit committee of our board of directors periodically for the audit committee to provide guidance on the prioritization of the risk remediation and ongoing implementation of cybersecurity improvements across our organization. We also engage an external auditing firm with information security expertise to conduct regular auditing, testing, and review of our information technology risks, processes, and operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">The Head of IT is responsible for implementing and maintaining the information security program. The Head of IT role is currently held by an individual who has more than 20 years of professional IT management experience and maintains a Global Information Assurance Certification. The Head of IT reports to our Chief Accounting Officer, who together are responsible for coordinating information security risk assessments and overseeing periodic testing of our cybersecurity controls. Our Chief Accounting Officer meets with the audit committee of our board of directors periodically for the audit committee to provide guidance on the prioritization of the risk remediation and ongoing implementation of cybersecurity improvements across our organization. We also engage an external auditing firm with information security expertise to conduct regular auditing, testing, and review of our information technology risks, processes, and operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Formation and Business of the Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business Description and Basis of Presentation [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>1.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Formation and Business of the Company</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Compass Therapeutics, Inc. (&#8220;Compass&#8221; or the &#8220;Company&#8221;) is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Our scientific focus is on the relationship between angiogenesis and the immune system. Our pipeline includes novel product candidates that leverage our understanding of the tumor microenvironment, including both angiogenesis-targeted agents and immune-oncology focused agents. These product candidates are designed to optimize critical components required for an effective anti-tumor response to cancer. These include modulation of the microvasculature via angiogenesis-targeted agents; induction of a potent immune response via activators on effector cells in the tumor microenvironment; and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. We plan to advance our product candidates through clinical development as both standalone therapies and in combination with our proprietary drug candidates as long as their continued development is supported by clinical and nonclinical data. References to Compass or the Company herein include Compass Therapeutics, Inc. and its wholly owned subsidiaries.</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company is subject to risks and uncertainties common to companies in the biotechnology and pharmaceutical industries. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants.</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Liquidity, Uncertainties and Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Substantial Doubt about Going Concern [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>2.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Liquidity, Uncertainties and Going Concern </b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Since its inception, the Company has funded its operations primarily with proceeds from the sale of its equity securities. The Company has incurred recurring losses since its inception and had an accumulated deficit of $431 million on December 31, 2025. The Company expects to continue to generate operating losses for the foreseeable future. The Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into 2028. The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company is subject to risks common to early stage companies in the biotechnology industry including, but not limited to: having a limited operating history and no products approved for commercial sale; having a history of significant losses; its need to obtain additional financing; dependence on its ability to advance its current and future product candidates through clinical trials, marketing approval and commercialization; the lengthy and expensive nature and uncertain outcomes of the clinical development process; the lengthy, time consuming and unpredictable nature of the regulatory approval process; the results of preclinical studies and early stage clinical trials that may not be predictive of future results; dependence on its key personnel; risks related to patent protection and the Company&#8217;s pending patent applications; dependence on third party collaborators for the discovery, development and commercialization of current and future product candidates; and significant competition from other biotechnology and pharmaceutical companies. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>3.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Summary of Significant Accounting Policies</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Basis of Presentation</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The accompanying consolidated financial statements are presented in U.S. dollars and have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and as amended by Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Principles of Consolidation</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The accompanying consolidated financial statements include the accounts of Compass Therapeutics, Inc., and its wholly-owned subsidiaries, including Compass Therapeutics LLC, Compass Therapeutics Advisors Inc., Trigr Therapeutics, Inc., Compass Acquisition Company, LLC, and Compass Therapeutics Securities Corporation. All intercompany accounts and transactions have been eliminated in consolidation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Use of Estimates</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the accrual of research and development expenses, useful lives of equipment, interest rate and term operating lease ROU and liability, the percentage of completion of contractual arrangements, future cash expenditures for liquidity estimates, the valuation of common stock and estimates associated with stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates. Changes in estimates are recorded prospectively in the period that they become known.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Segment Information </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has <span style="-sec-ix-hidden:c305">one</span> operating segment. The Company&#8217;s chief operating decision-maker, its chief executive officer, manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources. All the Company&#8217;s long-lived assets are held in the United States.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Cash and Cash Equivalents</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company considers all highly liquid investments that are readily convertible into cash with original maturities of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held in money market funds or commercial paper. Cash equivalents are stated at cost, which approximates market value. Cash and cash equivalents were $30.6 million and $43.5 million on December 31, 2025 and 2024, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>






<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Marketable Securities</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">All of the Company&#8217;s investment securities are debt securities and bank instruments. The Company carries these investments at fair value. Unrealized gains and losses, if any, are reported as a separate component of stockholders&#8217; equity. The cost of investment securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income. Realized gains and losses, if any, are also included in interest income. The cost of securities sold is based on the specific identification method.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Concentrations of Credit Risk</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash equivalents and marketable securities. The Company invests its excess cash primarily in money market funds, U.S. treasury notes, and high quality, marketable debt instruments of corporations in accordance with the Company&#8217;s investment policy. The Company&#8217;s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. The Company has not experienced any realized losses related to its cash equivalents and marketable securities.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Property and Equipment</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are recorded using the straight-line method over the estimated useful lives of the related assets as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%; margin-left: 28pt; margin-right: auto;">

		<tbody><tr class="finHeading" style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 30.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Asset Classification</b></p>
			</td>
			<td style="vertical-align: bottom; width: 39.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b>Estimated Useful Life</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 30.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment</p>
			</td>
			<td style="vertical-align: bottom; width: 39.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">5 years</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 30.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and fixtures</p>
			</td>
			<td style="vertical-align: bottom; width: 39.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">7 years</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 30.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Software</p>
			</td>
			<td style="vertical-align: bottom; width: 39.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">5 years</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 30.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p>
			</td>
			<td style="vertical-align: bottom; width: 39.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">Lesser of estimated useful life or lease term</p>
			</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheet and any resulting gains or losses are included in the consolidated statement of operations and comprehensive loss in the period of disposal. Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Impairment of Long-Lived Assets</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Long-lived assets consist of property, equipment and right-of-use (&#8220;ROU&#8221;) assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in the consolidated statements of operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did <span style="-sec-ix-hidden:c311"><span style="-sec-ix-hidden:c312">not</span></span> record any impairment losses on long-lived assets during the years ended December 31, 2025 and 2024.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Fair Value Measurements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:29pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level 1 &#8211;&#160;Quoted prices in active markets for identical assets or liabilities.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:29pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level 2 &#8211;&#160;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets and liabilities, or other inputs that are observable or can be corroborated by observable market data.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:29pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level 3 &#8211;&#160;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected are reported in earnings.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Research and Development Costs</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Costs associated with internal research and development and external research and development services, including drug development and preclinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation and amortization, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials and other costs. The Company recognizes external research and development costs based on an evaluation of the progress of specific tasks using information provided to the Company by its service providers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Costs associated with licenses of technology acquired as part of collaborative arrangements are expensed as incurred and are generally included in research and development expense in the consolidated statements of operations if it is determined the license has no alternative future use.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Accrued Research and Development Expenses</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company has entered into various research and development and other agreements with commercial firms, researchers, universities and others for provisions of goods and services. These agreements are generally cancelable, and the related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made to determine the accrued balances at the end of any reporting period. Actual results could differ materially from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Patent Costs</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expense in the consolidated statements of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Stock-Based Compensation</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company recognizes the grant&#8209;date fair value of stock&#8209;based awards issued to employees and nonemployee board members as compensation expense on a straight&#8209;line basis over the service period of the award. The Company uses the Black&#8209;Scholes option pricing model to determine the grant&#8209;date fair value of stock options and adjusts expense for forfeitures in the periods they occur.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The fair value of each equity award was determined by the Company on the date of grant and by using the methods and assumptions discussed below. Certain of these inputs are subjective and generally require judgment to determine.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><i>Stock price: </i>The stock price used to value equity awards is based on the closing price of the Company&#8217;s common stock as reported on the date of the grant. For equity awards issued after June 2020 until the Company started trading on a public market in the second quarter of 2021, the valuation of the Company&#8217;s common stock was $5.00 per share, which was the share price paid by outside investors in the Company&#8217;s Private Placement in June 2020.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><i>Expected term</i>: The expected term of the equity award represents the weighted average period the award is expected to be outstanding. The Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average time to vesting and the contractual life of the award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><i>Expected volatility</i> &#8211; The expected volatility is calculated based on the historical volatility of our common stock over the expected term of the option.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><i>Risk-free interest rate</i> &#8211; The risk-free rate assumption is based on U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#8217;s equity award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><i>Expected dividend </i>&#8211; The Company has not paid and does not intend to pay dividends.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Net Loss per Share </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, stock options, restricted stock units, unvested restricted stock awards and common stock warrants that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The following potentially dilutive securities outstanding as of December 31, 2025 and 2024 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: auto; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,028</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,766</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,352</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,062</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,380</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,828</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:29pt;"><b>Income Taxes</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the deferred tax benefits will not be realized.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company files income tax returns in the U.S. Federal jurisdiction and in various states. The Company has tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>New Accounting Pronouncements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">In November 2024, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2024-03<i>, Income Statement </i>&#8211;<i> Reporting Comprehensive Income </i>&#8211;<i> Expense Disaggregation Disclosures</i>, which amends existing income statement disclosure guidance, primarily requiring more detailed disclosure for expenses. The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The amendments can be applied on either a prospective or retroactive basis. We are currently evaluating the ASU to determine its impact on our disclosures.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Recently Adopted Accounting Pronouncements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">In December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09). The amendments in ASU 2023-09 are intended to enhance the transparency and decision usefulness of income tax disclosures through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 for public entities, with early adoption permitted. The Company applied the amendments prospectively for the year ended December 31, 2025, and the impact of the adoption of the amendments in this update was not material to the Company&#8217;s consolidated financial position and results of operations for the year ended December 31, 2025, since the amendments require only enhancement of existing income tax disclosures in the footnotes to the Company&#8217;s consolidated financial statements. See Note 14 for additional disclosures.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>




<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>4.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Fair Value Measurements</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The following tables present information about the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>Fair Value Measurements as of December 31, 2025 (000's):</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Quoted Prices</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>in Active</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Other</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Markets for</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Observable</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unobservable</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Identical Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Inputs</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Inputs</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 1)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 2)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 3)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">86,636</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">86,636</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Certificates of deposit</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,960</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,960</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68,977</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68,977</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. government treasuries</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,664</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,664</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Asset-backed securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,026</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,026</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds (cash equivalents)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,383</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,383</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">79,024</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">107,622</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">186,646</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Measurements as of December 31, 2024 (000's):</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Quoted Prices</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>in Active</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Other</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Markets for</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Observable</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unobservable</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Identical Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Inputs</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Inputs</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 1)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 2)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 3)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,963</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,963</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Certificates of deposit</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,269</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,269</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,084</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,084</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. government treasuries</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,399</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,399</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Asset-backed securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,524</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,524</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds (cash equivalents)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23,880</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23,880</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40,363</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">66,756</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">107,119</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>5.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Marketable Securities</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The objectives of the Company&#8217;s investment policy are to ensure the safety and preservation of invested funds, as well as to maintain liquidity sufficient to meet cash flow requirements. The Company invests its excess cash in securities issued by financial institutions, commercial companies, and government agencies that management believes to be of high credit quality in order to limit the amount of its credit exposure. The Company has not realized any net losses from its investments.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>



<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Unrealized gains and losses on investments that are available for sale are recognized in accumulated comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are included in other income in the consolidated statements of operations and comprehensive loss and are determined using the specific identification method with transactions recorded on a trade date basis. The Company classifies marketable securities that are available for use in current operations as current assets on the consolidated balance sheet.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The following tables summarize marketable securities held at December 31, 2025 and 2024 (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Measurements as of December 31, 2025 Using:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amortized Cost</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized gains</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized Losses</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">86,417</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">223</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">86,636</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Certificates of deposit</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,950</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,960</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68,943</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68,977</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Asset-backed securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,010</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,026</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. government treasuries</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,663</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,664</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">177,983</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">284</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">178,263</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Measurements as of December 31, 2024 Using:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amortized Cost</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized gains</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized Losses</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,794</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">175</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(6</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,963</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Certificates of deposit</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,262</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,269</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,081</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,084</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Asset-backed securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,484</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,524</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. government treasuries</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,408</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,399</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">83,029</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">230</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(20</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">83,239</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Maturing in one year or less</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">126,119</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">56,386</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Maturing after one year through two years</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">52,144</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26,853</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">178,263</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">83,239</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>6.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Property and Equipment</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Property and equipment consist of the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,741</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,716</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and fixtures</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,612</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,612</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Software</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">364</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">364</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total property and equipment&#8211;at cost</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,739</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,714</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Accumulated depreciation and amortization</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,637</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,361</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Property and equipment, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">102</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">353</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Total depreciation and amortization expense for years ended December 31, 2025 and 2024, was $0.3 million and $0.6 million, respectively.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>7.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Accrued Expenses</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Accrued expenses consist of the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Project expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,217</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,873</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Compensation and benefits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,682</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,793</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">484</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">621</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total accrued expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,383</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,287</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Project expenses in 2025 were primarily made up of $7.9 million of accrued manufacturing expenses related to tovecimig and CTX-10726.&#160;Project expenses in 2024 were primarily made up of $2.6 million of accrued manufacturing expenses related to minimum contractual obligations.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>8.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Stockholders</b>&#8217;<b>&#160;Equity</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">On August 12, 2025, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Jefferies LLC, Piper Sandler &amp; Co., and Guggenheim Securities, LLC, as representatives (the &#8220;Representatives&#8221;) of the underwriters named therein (the &#8220;Underwriters&#8221;), pursuant to which the Company agreed to issue and sell an aggregate of (a) 33,290,000 shares (the &#8220;Firm Shares&#8221;) of its common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), at a price to the public of $3.00 per share, and (b) pre-funded warrants to purchase up to 6,710,000 shares of the Company&#8217;s Common Stock (the &#8220;Pre-Funded Warrants&#8221;), at a price to the public of $2.9999 per warrant with an exercise price of $0.0001 per share (the &#8220;Offering&#8221;). Pursuant to the Underwriting Agreement, the Company granted the underwriters a 30-day option, which the underwriters exercised, to purchase up to an additional 6,000,000 shares of its Common Stock (the &#8220;Optional Shares&#8221;, and together with the Firm Shares, the &#8220;Shares&#8221;) at the public offering price, less underwriting discounts and commissions. The Company received aggregate net proceeds of $129.3 million, after deducting underwriting discounts and commissions of $8.3 million and other offering costs of $0.4 million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The 2025 Pre-Funded Warrants were determined to be equity classified. Accordingly, proceeds from the offering were allocated to common stock, the 2025 Pre-Funded Warrants on a relative fair value basis and were recorded in stockholders&#8217; equity. As of December 31, 2025, all of the 2025 Pre-Funded Warrants remain outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">In the first quarter of 2024, the Company sold through its Jefferies ATM Agreement, 9,790,577 shares of common stock at an average price of $1.85 for total proceeds of $18.1 million and net proceeds of $17.6 million.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payment Arrangement [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>9.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Stock-Based Compensation</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Stock-based compensation expense for the years ended December 31, 2025 and 2024 was classified in the consolidated statements of operations as follows:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended<br/>
			December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,346</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,971</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,022</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,589</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,368</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,560</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>2020 Stock Option and Incentive Plan</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">In June 2020, the Company&#8217;s board of directors adopted the 2020 Plan and reserved 2.9 million shares of common stock for issuance under this plan. The 2020 Plan provides that the number of shares reserved and available for issuance under the 2020 Plan will automatically increase each January 1, beginning on January 1, 2021, by the lesser of 4% of the outstanding number of shares of our common stock on the immediately preceding December 31 or such number of shares as determined by the plan administrator no later than the immediately preceding December 31. As of December 31, 2025, 5.3 million shares remain available for future grant. On January 1, 2026, an additional 7.1 million shares became available for issuance based on 4% of the outstanding shares of common stock, for a total of 12.4 million shares available for issuance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The 2020 Plan authorizes the board of directors or a committee of the board to grant incentive stock options, nonqualified stock options, restricted stock awards and restricted stock units ("RSUs") to eligible officers, employees, consultants and directors of the Company. Options generally vest over a period of <span style="-sec-ix-hidden:c685">four</span> years and have a contractual life of <span style="-sec-ix-hidden:c686">ten</span> years from the date of grant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><i>Stock Options:</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The following table summarizes the stock option activity for the 2020 Plan:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options (000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average<br/>
			Exercise Price<br/>
			Price Per Share</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average<br/>
			Remaining Contractual<br/>
			Life (in years)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate Intrinsic Value (000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,876</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.81</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.05</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,193</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.58</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.10</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited/cancelled</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.04</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2024</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,062</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.83</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.23</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">579</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,777</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.63</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.76</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(545</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.34</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,214</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited/cancelled</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,942</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.40</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,341</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,352</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.13</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.69</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36,614</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested at December 31, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,513</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.38</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.24</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,932</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">For the year ended December 31, 2025, the weighted average grant date fair value for options granted was $2.69. The aggregate intrinsic value for options vested and outstanding as of December 31, 2025 and 2024 was $36.6 million and $579 thousand, respectively. As of December 31, 2025, the unrecognized compensation cost related to outstanding options was $13.7 million, expected to be recognized over a weighted average period of approximately 1.4 years.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">&#160;</p>



<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The weighted average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and directors during the years ended December 31, 2025 and 2024 were as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected term (in years)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.26</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.92</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">86</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">81</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><i>RSUs:</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The following table summarizes the RSU activity for the 2020 Plan:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares<br/>
			(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted<br/>
			Average Price<br/>
			Per Share</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted<br/>
			Average Fair Value (000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested, December 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,500</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.83</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,745</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,791</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.89</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,275</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(525</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.87</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,032</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited or canceled</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested, December 31, 2024</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,766</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.41</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,076</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,073</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.59</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,779</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited or canceled</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,665</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.34</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,896</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested, December 31, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,028</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.33</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,395</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants. The weighted average fair value is the weighted average share price times the number of shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">As of December 31, 2025, remaining unrecognized compensation cost related to RSUs to be recognized in future periods totaled $1.6 million, which is expected to be recognized over a weighted average period of 1.2 years. As of December 31, 2025, the total unrecognized compensation cost from all plans to be recognized in future periods totaled approximately $15.3 million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>2025 Inducement Plan</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">In December 2025, the Company&#8217;s board of directors adopted the Compass Therapeutics, Inc. 2025 Inducement Plan (the &#8220;Inducement Plan&#8221;). The purpose of the Inducement Plan is to enable the Company to grant equity awards to induce highly-qualified prospective officers and employees to accept employment and provide them with a proprietary interest in the Company. The Company intends that the Inducement Plan be reserved for persons to whom the Company may issue securities without stockholder approval as an inducement pursuant to Rule 5635(c)(4) of the Marketplace Rules of The NASDAQ Stock Market LLC. The maximum number of shares of Stock reserved and available for issuance under the Inducement Plan is four million shares. As of December 31, 2025, no equity had been granted or outstanding with the Inducement Plan. On January 1, 2026, a total of two million options were granted as part of the Inducement Plan to two new officers as a material inducement for those officers to join the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Basic and Diluted Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>10.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">Basic and Diluted Net Loss Per Share</span></b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Basic net loss per share has been computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock plus potentially dilutive securities outstanding during the period. Potential shares of common stock exercisable for little or no consideration are included in both basic and diluted weighted-average number of shares of common stock outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 29pt; text-indent: -2pt;">&#160;During the year ended December 31, 2025, basic and diluted weighted-average number of shares outstanding were 157.7 million and included pre-funded warrants to purchase 6,710,000 shares of common stock with an exercise price of $0.0001 per share. During the year ended December 31, 2024, basic and diluted weighted-average number of shares outstanding were 137.4 million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 29pt; text-indent: -2pt;">&#160;The computation of diluted net loss per share for the year ended December 31, 2025 excluded 17.4 million shares subject to outstanding stock options and restricted stock units because their inclusion would have had an anti-dilutive effect on diluted net loss per share. The computation of diluted net loss per share for the year ended December 31, 2024 excluded 17.8 million shares, subject to outstanding stock options and restricted stock because their inclusion would have had an anti-dilutive effect on diluted net loss per share. The following potentially dilutive securities (in common stock equivalents) have been excluded from the computation of diluted weighted-average shares outstanding for the years ended December 31, 2025 and 2024, as they would be antidilutive:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,352,430</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,061,604</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,028,125</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,765,625</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - License, Research and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>11.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>License, Research and Collaboration Agreements</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Collaboration Agreements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b><i>ABL Bio Corporation ("ABL Bio") Agreements</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">In November 2018, the Company and ABL Bio, a South Korean biotechnology company, entered into an exclusive global (excluding South Korea) license agreement which granted the Company a license to tovecimig (ABL001), ABL Bio&#8217;s bispecific antibody targeting DLL4 and VEGF-A. Under the terms of the agreement, the two companies would jointly develop tovecimig, with ABL Bio responsible for development of tovecimig throughout the end of Phase 1 clinical trials and the Company responsible for the development of tovecimig from Phase 2 and onward. ABL Bio received a $5 million upfront payment and $6 million development milestone payment. In addition, ABL Bio is eligible to receive up to $96 million of development and regulatory milestone payments, and up to $303 million of commercial milestone payments and tiered single-digit royalties on net sales of tovecimig in oncology. ABL Bio is also eligible to receive up to $75 million in development and regulatory milestones and up to $110 million in commercial milestone payments and tiered, single-digit royalties on net sales of tovecimig in ophthalmology.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">In May 2021, TRIGR and ABL Bio terminated license agreements to several preclinical assets. As a result of the return of these assets to ABL Bio and termination of the license agreements, the Company is eligible to receive royalty payments if ABL Bio develops or licenses two bispecific antibodies that were previously licensed to TRIGR.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b><i>Adimab Agreement</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company entered into a collaboration agreement with Adimab, LLC on October 16, 2014. The agreement includes provisions for payment of royalties at rates ranging in the single digits as a percentage of future net sales within a specified term from the first commercial sale for certain antibodies, including our product candidate, CTX-471. There were <span style="-sec-ix-hidden:c891">no</span> milestone payments made during 2025. As of December 31, 2025, future potential milestone payments in connection with this agreement amounted to $2.0 million.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>12.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Commitments and Contingencies </b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Leases</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company accounts for operating leases on a straight-line basis over the lease term, with recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments. For leases with a term of 12 months or less, we recognize lease expense on a straight-line basis over the lease term.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company has evaluated its leases under ASC 842, <i>Leases</i>, and determined that it has one lease that is classified as an operating lease. The classification of this lease is consistent with the Company&#8217;s determination under the previous accounting standard.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">When available, the Company will use the rate implicit in the lease to discount lease payments to present value; however, the Company&#8217;s current lease does not provide an implicit rate. Therefore, the Company used its incremental borrowing rate of 6.25% to discount the lease payments based on the date of the lease commencement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company has one operating lease for its corporate office and laboratory facility (&#8220;Facility&#8221;) that was signed in December 2020. The Company moved into the Facility in January 2021. The Facility lease has an initial term of four years and five months, beginning on January 1, 2021.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The terms of the Facility lease were modified effective September 27, 2024 through the execution of a new lease. The modified terms extended the non-cancelable lease term through May 2031. The modified terms also included the right to use an additional 10,724 square feet that commenced in May 2025. The classification and incremental borrowing rate for the lease did not change as a result of this lease modification. Right-of-use assets obtained in exchange for new operating lease liabilities due to the lease modification were $9.9 million for a total right-of-use assets as of December 31, 2025 of $9.1 million. The remaining lease term of the Facility lease is 5.4 years as of December 31, 2025. The Company has $568 thousand of restricted cash associated with an irrevocable letter of credit required by the landlord to enter into this lease.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Lease costs related to the Facility were $1.3 million and $1.1 million for the years ending December 31, 2025 and 2024, respectively. Cash paid for this lease was $0.8 million and $1.4 million for the years ended December 31, 2025 and 2024, respectively.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The table below presents the undiscounted cash flows for the lease term. The undiscounted cash flows are reconciled to the operating lease liabilities recorded on the consolidated balance sheets:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(000's)</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 84%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Years ending December 31,</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,525</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,204</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,249</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2029</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,294</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2030</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,356</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">995</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total minimum lease payments</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,623</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: amount of lease payments representing interest</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,794</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Present value of future minimum lease payments</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,829</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: operating lease obligations, current portion</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease obligations, long-term portion</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,829</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Defined Contribution Plan </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company has a 401(k) defined contribution plan (the &#8220;401(k) Plan&#8221;) for substantially all its employees. Eligible employees may make pre-tax or post-tax (Roth) contributions to the 401(k) Plan up to statutory limits. Since January 1, 2020, the Company has been matching employee contributions to the plan up to 4% of salary. On July 1, 2023, the Company increased the employee matching contribution from 4% to 6%. The Company made matching contributions of $0.4 million and $0.3 million for the years ended December 31, 2025 and 2024, respectively.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Other Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock', window );">Other Nonoperating Income and Expense [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>13.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Other income</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Other income consisted of interest income from investments on marketable securities of $6.4 million and $7.3 million for the years ended December 31, 2025 and 2024, respectively.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Income Taxe<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>14.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Income Taxes </b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company had <span style="-sec-ix-hidden:c944"><span style="-sec-ix-hidden:c945">no</span></span> income tax for the years ended December 31, 2025 and 2024.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">&#8208;The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal statutory rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(13,963</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(10,368</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Adjustment resulting from the tax effect of:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">State and local income tax, net of federal (national) income tax effect</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,416</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.6</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,454</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Foreign Tax Effects</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Effect of changes in tax laws or rates enacted in the current period</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Effect of cross-border tax laws</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Tax Credits</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Research and development tax credits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,045</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,864</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Changes in valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19,744</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-29.8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,778</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-32.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Nontaxable or nondeductible items</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock compensation &amp; other nondeductible expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">680</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-0.9</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">532</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-1.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Changes in unrecognized tax benefits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">376</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-0.7</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Effective income tax rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">In 2025, state and local income taxes in Massachusetts comprise the state and local income taxes category. The company had no federal or state income tax payments or refunds for the years ended December 31, 2025 and December 31, 2024. The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. In determining the need for a valuation allowance, management reviews both positive and negative evidence, including current and historical results of operations, future income projections and the overall prospects of our business. Based upon management&#8217;s assessment of all available evidence, the Company believes that it is more-likely-than-not that the deferred tax assets will not be realizable, and therefore, a valuation allowance has been established. The valuation allowance for deferred tax assets was approximately $79.2&#160;million and $59.5 million as of December 31, 2025 and 2024, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">As of December 31, 2025, the Company has U.S. federal and state net operating loss carryforwards (&#8220;NOLs&#8221;) of $200.4&#160;million and $206.7&#160;million, respectively. As of December 31, 2025, the Company has federal and state research and development credit carryforwards (&#8220;R&amp;D credits&#8221;) of $9.3 million and $2.5 million, respectively. For income tax purposes, federal NOLs will not expire since they were generated after 2017 and federal R&amp;D credits will begin expiring in 2039. For income tax purposes, state NOLs and state R&amp;D credits will begin to expire in 2040 and 2031, respectively.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service (the &#8220;IRS&#8221;) and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50% as defined under Sections 382 and 383 in the Internal Revenue Code, which could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the Company&#8217;s value immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) amended IRC Section 174 to require capitalization of all research and developmental (R&amp;D) costs incurred in tax years beginning after December 31, 2021. These costs are required to be amortized with a half-year convention over five years if the R&amp;D activities are performed in the U.S., or over 15 years if the activities were performed outside the U.S. The One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) enacted in 2025 allows for current deductibility of domestic R&amp;D costs and immediate deduction for previously capitalized costs for certain taxpayers retroactive to 2024. The Company elected to take the deduction in 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">As of December 31, 2025 and 2024, the Company had <span style="-sec-ix-hidden:c997"><span style="-sec-ix-hidden:c998">no</span></span> uncertain tax positions, and as such, <span style="-sec-ix-hidden:c999"><span style="-sec-ix-hidden:c1000">no</span></span> related interest or penalties have been recorded in the statements of operations and comprehensive loss. The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense. All tax years of the Company from inception are open to examination by federal tax and state tax authorities. To the extent utilized in future years&#8217; tax returns, net operating loss carryforwards at December 31, 2025 will remain subject to examination until the respective tax year is closed. The Company has not been informed by any tax authorities for any jurisdiction that any of its tax years is under examination as of December 31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred tax assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal net operating loss carryforwards</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">42,075</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,775</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State net operating loss carryforwards</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,063</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,063</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development credits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,297</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,252</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Section 174 Capitalization</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,015</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22,724</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,001</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,922</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,685</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,812</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Capitalized licensing fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,266</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,375</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">406</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">494</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Subtotal</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">81,808</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">61,417</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(79,245</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(59,521</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets, net of valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,563</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,896</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred tax liabilities</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Right-of-use assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,486</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,839</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(77</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(57</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting Disclosure [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>15.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Segment Information </b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Segment reporting is prepared on the same basis that our chief executive officer, who is our CODM, manages the business, makes operating decisions and assesses performance. The Company operates in <span style="-sec-ix-hidden:c1115">one</span> segment. The Company&#8217;s business is research and development of drug candidates. Costs, including supplies, outsourced development, and other research and development costs are tracked by major program. While internal personnel costs are tracked by program for overall program spending, it is not broken out for management review. Facility and equipment costs are not allocated to programs. Research and development expenses are summarized by program in the table below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Licensing revenue</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">850</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Personnel</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,935</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,918</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,616</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,965</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Tovecimig</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23,680</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23,177</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CTX-471</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,183</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,879</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CTX-8371</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,355</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,403</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CTX-10726</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,200</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">55,969</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,342</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Personnel</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,236</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,472</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,634</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,661</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,870</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,133</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Other income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,350</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,250</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(66,489</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(49,375</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Basis of Presentation</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The accompanying consolidated financial statements are presented in U.S. dollars and have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and as amended by Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Principles of Consolidation</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The accompanying consolidated financial statements include the accounts of Compass Therapeutics, Inc., and its wholly-owned subsidiaries, including Compass Therapeutics LLC, Compass Therapeutics Advisors Inc., Trigr Therapeutics, Inc., Compass Acquisition Company, LLC, and Compass Therapeutics Securities Corporation. All intercompany accounts and transactions have been eliminated in consolidation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Use of Estimates</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the accrual of research and development expenses, useful lives of equipment, interest rate and term operating lease ROU and liability, the percentage of completion of contractual arrangements, future cash expenditures for liquidity estimates, the valuation of common stock and estimates associated with stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates. Changes in estimates are recorded prospectively in the period that they become known.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Segment Information </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has <span style="-sec-ix-hidden:c305">one</span> operating segment. The Company&#8217;s chief operating decision-maker, its chief executive officer, manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources. All the Company&#8217;s long-lived assets are held in the United States.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Cash and Cash Equivalents</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company considers all highly liquid investments that are readily convertible into cash with original maturities of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held in money market funds or commercial paper. Cash equivalents are stated at cost, which approximates market value. Cash and cash equivalents were $30.6 million and $43.5 million on December 31, 2025 and 2024, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Marketable Securities</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">All of the Company&#8217;s investment securities are debt securities and bank instruments. The Company carries these investments at fair value. Unrealized gains and losses, if any, are reported as a separate component of stockholders&#8217; equity. The cost of investment securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income. Realized gains and losses, if any, are also included in interest income. The cost of securities sold is based on the specific identification method.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Concentrations of Credit Risk</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash equivalents and marketable securities. The Company invests its excess cash primarily in money market funds, U.S. treasury notes, and high quality, marketable debt instruments of corporations in accordance with the Company&#8217;s investment policy. The Company&#8217;s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. The Company has not experienced any realized losses related to its cash equivalents and marketable securities.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Property and Equipment</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are recorded using the straight-line method over the estimated useful lives of the related assets as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%; margin-left: 28pt; margin-right: auto;">

		<tbody><tr class="finHeading" style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 30.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Asset Classification</b></p>
			</td>
			<td style="vertical-align: bottom; width: 39.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b>Estimated Useful Life</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 30.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment</p>
			</td>
			<td style="vertical-align: bottom; width: 39.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">5 years</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 30.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and fixtures</p>
			</td>
			<td style="vertical-align: bottom; width: 39.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">7 years</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 30.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Software</p>
			</td>
			<td style="vertical-align: bottom; width: 39.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">5 years</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 30.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p>
			</td>
			<td style="vertical-align: bottom; width: 39.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">Lesser of estimated useful life or lease term</p>
			</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheet and any resulting gains or losses are included in the consolidated statement of operations and comprehensive loss in the period of disposal. Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Impairment of Long-Lived Assets</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Long-lived assets consist of property, equipment and right-of-use (&#8220;ROU&#8221;) assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in the consolidated statements of operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did <span style="-sec-ix-hidden:c311"><span style="-sec-ix-hidden:c312">not</span></span> record any impairment losses on long-lived assets during the years ended December 31, 2025 and 2024.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Fair Value Measurements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:29pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level 1 &#8211;&#160;Quoted prices in active markets for identical assets or liabilities.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:29pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level 2 &#8211;&#160;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets and liabilities, or other inputs that are observable or can be corroborated by observable market data.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:29pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level 3 &#8211;&#160;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected are reported in earnings.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Research and Development Costs</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Costs associated with internal research and development and external research and development services, including drug development and preclinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation and amortization, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials and other costs. The Company recognizes external research and development costs based on an evaluation of the progress of specific tasks using information provided to the Company by its service providers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Costs associated with licenses of technology acquired as part of collaborative arrangements are expensed as incurred and are generally included in research and development expense in the consolidated statements of operations if it is determined the license has no alternative future use.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_AccruedResearchAndDevelopmentExpensesPolicyTextBlock', window );">Accrued Research and Development Expenses [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Accrued Research and Development Expenses</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company has entered into various research and development and other agreements with commercial firms, researchers, universities and others for provisions of goods and services. These agreements are generally cancelable, and the related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made to determine the accrued balances at the end of any reporting period. Actual results could differ materially from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_PatentsCostsPolicyTextBlock', window );">Patents Costs [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Patent Costs</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expense in the consolidated statements of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payment Arrangement [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Stock-Based Compensation</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company recognizes the grant&#8209;date fair value of stock&#8209;based awards issued to employees and nonemployee board members as compensation expense on a straight&#8209;line basis over the service period of the award. The Company uses the Black&#8209;Scholes option pricing model to determine the grant&#8209;date fair value of stock options and adjusts expense for forfeitures in the periods they occur.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The fair value of each equity award was determined by the Company on the date of grant and by using the methods and assumptions discussed below. Certain of these inputs are subjective and generally require judgment to determine.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><i>Stock price: </i>The stock price used to value equity awards is based on the closing price of the Company&#8217;s common stock as reported on the date of the grant. For equity awards issued after June 2020 until the Company started trading on a public market in the second quarter of 2021, the valuation of the Company&#8217;s common stock was $5.00 per share, which was the share price paid by outside investors in the Company&#8217;s Private Placement in June 2020.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><i>Expected term</i>: The expected term of the equity award represents the weighted average period the award is expected to be outstanding. The Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average time to vesting and the contractual life of the award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><i>Expected volatility</i> &#8211; The expected volatility is calculated based on the historical volatility of our common stock over the expected term of the option.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><i>Risk-free interest rate</i> &#8211; The risk-free rate assumption is based on U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#8217;s equity award.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><i>Expected dividend </i>&#8211; The Company has not paid and does not intend to pay dividends.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Net Loss per Share </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, stock options, restricted stock units, unvested restricted stock awards and common stock warrants that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The following potentially dilutive securities outstanding as of December 31, 2025 and 2024 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: auto; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,028</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,766</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,352</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,062</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,380</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,828</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:29pt;"><b>Income Taxes</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the deferred tax benefits will not be realized.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">The Company files income tax returns in the U.S. Federal jurisdiction and in various states. The Company has tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>New Accounting Pronouncements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">In November 2024, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2024-03<i>, Income Statement </i>&#8211;<i> Reporting Comprehensive Income </i>&#8211;<i> Expense Disaggregation Disclosures</i>, which amends existing income statement disclosure guidance, primarily requiring more detailed disclosure for expenses. The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The amendments can be applied on either a prospective or retroactive basis. We are currently evaluating the ASU to determine its impact on our disclosures.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"><b>Recently Adopted Accounting Pronouncements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;">In December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09). The amendments in ASU 2023-09 are intended to enhance the transparency and decision usefulness of income tax disclosures through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 for public entities, with early adoption permitted. The Company applied the amendments prospectively for the year ended December 31, 2025, and the impact of the adoption of the amendments in this update was not material to the Company&#8217;s consolidated financial position and results of operations for the year ended December 31, 2025, since the amendments require only enhancement of existing income tax disclosures in the footnotes to the Company&#8217;s consolidated financial statements. See Note 14 for additional disclosures.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_AccruedResearchAndDevelopmentExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_AccruedResearchAndDevelopmentExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_PatentsCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the patents cost policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_PatentsCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Property, Plant and Equipment, Estimated Useful Lives [Table Text Block]</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%; margin-left: 28pt; margin-right: auto;">

		<tbody><tr class="finHeading" style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 30.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Asset Classification</b></p>
			</td>
			<td style="vertical-align: bottom; width: 39.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b>Estimated Useful Life</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 30.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment</p>
			</td>
			<td style="vertical-align: bottom; width: 39.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">5 years</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 30.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and fixtures</p>
			</td>
			<td style="vertical-align: bottom; width: 39.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">7 years</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 30.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Software</p>
			</td>
			<td style="vertical-align: bottom; width: 39.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">5 years</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 30.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p>
			</td>
			<td style="vertical-align: bottom; width: 39.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">Lesser of estimated useful life or lease term</p>
			</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,352,430</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,061,604</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,028,125</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,765,625</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cmpx_RestrictedStockUnitsAndOptionsMember', window );">Restricted Stock Units and Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: auto; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,028</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,766</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,352</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,062</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,380</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,828</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated useful lives of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cmpx_RestrictedStockUnitsAndOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cmpx_RestrictedStockUnitsAndOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>Fair Value Measurements as of December 31, 2025 (000's):</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Quoted Prices</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>in Active</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Other</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Markets for</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Observable</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unobservable</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Identical Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Inputs</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Inputs</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 1)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 2)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 3)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">86,636</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">86,636</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Certificates of deposit</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,960</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,960</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68,977</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68,977</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. government treasuries</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,664</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,664</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Asset-backed securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,026</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,026</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds (cash equivalents)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,383</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,383</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">79,024</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">107,622</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">186,646</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Measurements as of December 31, 2024 (000's):</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Quoted Prices</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>in Active</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Other</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Markets for</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Observable</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unobservable</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Identical Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Inputs</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Inputs</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 1)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 2)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 3)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,963</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,963</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Certificates of deposit</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,269</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,269</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,084</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,084</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. government treasuries</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,399</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,399</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Asset-backed securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,524</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,524</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds (cash equivalents)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23,880</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23,880</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40,363</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">66,756</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">107,119</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Marketable Securities [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Measurements as of December 31, 2025 Using:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amortized Cost</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized gains</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized Losses</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">86,417</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">223</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">86,636</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Certificates of deposit</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,950</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,960</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68,943</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68,977</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Asset-backed securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,010</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,026</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. government treasuries</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,663</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,664</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">177,983</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">284</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">178,263</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Measurements as of December 31, 2024 Using:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amortized Cost</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized gains</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized Losses</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,794</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">175</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(6</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,963</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Certificates of deposit</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,262</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,269</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,081</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,084</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Asset-backed securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,484</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,524</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. government treasuries</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,408</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,399</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">83,029</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">230</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(20</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">83,239</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Investments Classified by Contractual Maturity Date [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Maturing in one year or less</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">126,119</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">56,386</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Maturing after one year through two years</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">52,144</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26,853</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">178,263</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">83,239</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,741</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,716</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and fixtures</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,612</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,612</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Software</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">364</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">364</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total property and equipment&#8211;at cost</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,739</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,714</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Accumulated depreciation and amortization</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,637</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,361</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Property and equipment, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">102</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">353</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Project expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,217</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,873</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Compensation and benefits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,682</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,793</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">484</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">621</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total accrued expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,383</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,287</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended<br/>
			December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,346</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,971</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,022</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,589</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,368</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,560</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options (000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average<br/>
			Exercise Price<br/>
			Price Per Share</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average<br/>
			Remaining Contractual<br/>
			Life (in years)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate Intrinsic Value (000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,876</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.81</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.05</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,193</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.58</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.10</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited/cancelled</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.04</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2024</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,062</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.83</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.23</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">579</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,777</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.63</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.76</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(545</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.34</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,214</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited/cancelled</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,942</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.40</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,341</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,352</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.13</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.69</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36,614</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested at December 31, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,513</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.38</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.24</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,932</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected term (in years)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.26</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.92</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">86</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">81</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares<br/>
			(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted<br/>
			Average Price<br/>
			Per Share</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted<br/>
			Average Fair Value (000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested, December 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,500</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.83</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,745</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,791</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.89</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,275</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(525</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.87</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,032</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited or canceled</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested, December 31, 2024</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,766</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.41</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,076</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,073</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.59</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,779</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited or canceled</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,665</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.34</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,896</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested, December 31, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,028</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.33</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,395</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Basic and Diluted Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,352,430</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,061,604</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,028,125</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,765,625</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(000's)</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 84%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Years ending December 31,</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,525</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,204</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,249</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2029</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,294</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2030</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,356</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">995</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total minimum lease payments</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,623</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: amount of lease payments representing interest</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,794</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Present value of future minimum lease payments</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,829</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: operating lease obligations, current portion</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease obligations, long-term portion</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,829</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Income Taxe (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal statutory rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(13,963</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(10,368</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Adjustment resulting from the tax effect of:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">State and local income tax, net of federal (national) income tax effect</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,416</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.6</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,454</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Foreign Tax Effects</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Effect of changes in tax laws or rates enacted in the current period</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Effect of cross-border tax laws</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Tax Credits</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Research and development tax credits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,045</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,864</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Changes in valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19,744</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-29.8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,778</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-32.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Nontaxable or nondeductible items</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock compensation &amp; other nondeductible expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">680</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-0.9</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">532</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-1.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Changes in unrecognized tax benefits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">376</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-0.7</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Effective income tax rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred tax assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal net operating loss carryforwards</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">42,075</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,775</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State net operating loss carryforwards</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,063</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,063</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development credits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,297</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,252</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Section 174 Capitalization</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,015</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22,724</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,001</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,922</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,685</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,812</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Capitalized licensing fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,266</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,375</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">406</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">494</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Subtotal</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">81,808</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">61,417</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(79,245</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(59,521</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets, net of valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,563</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,896</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred tax liabilities</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Right-of-use assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,486</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,839</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(77</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(57</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(000's)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Licensing revenue</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">850</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Personnel</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,935</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,918</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,616</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,965</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Tovecimig</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23,680</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23,177</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CTX-471</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,183</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,879</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CTX-8371</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,355</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,403</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CTX-10726</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,200</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">55,969</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,342</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Personnel</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,236</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,472</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,634</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,661</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,870</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15,133</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Other income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,350</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,250</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(66,489</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(49,375</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 2 - Liquidity, Uncertainties and Going Concern (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit), Total</a></td>
<td class="num">$ (431,172)<span></span>
</td>
<td class="num">$ (364,683)<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies (Details Textual)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 30,643<span></span>
</td>
<td class="nump">$ 43,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment, Long-Lived Asset, Held-for-Use</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies - Schedule of Estimated Lives (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software and Software Development Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">17,380,000<span></span>
</td>
<td class="nump">17,828,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">1,028,125<span></span>
</td>
<td class="nump">3,765,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">16,352,430<span></span>
</td>
<td class="nump">14,061,604<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">$ 178,263<span></span>
</td>
<td class="nump">$ 83,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">86,636<span></span>
</td>
<td class="nump">44,963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">14,960<span></span>
</td>
<td class="nump">15,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">68,977<span></span>
</td>
<td class="nump">12,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">1,664<span></span>
</td>
<td class="nump">4,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">6,026<span></span>
</td>
<td class="nump">6,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">6,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">186,646<span></span>
</td>
<td class="nump">107,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">86,636<span></span>
</td>
<td class="nump">44,963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">14,960<span></span>
</td>
<td class="nump">15,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">68,977<span></span>
</td>
<td class="nump">12,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">1,664<span></span>
</td>
<td class="nump">4,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Asset-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">8,383<span></span>
</td>
<td class="nump">23,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">79,024<span></span>
</td>
<td class="nump">40,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">68,977<span></span>
</td>
<td class="nump">12,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">1,664<span></span>
</td>
<td class="nump">4,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Asset-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">8,383<span></span>
</td>
<td class="nump">23,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">107,622<span></span>
</td>
<td class="nump">66,756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">86,636<span></span>
</td>
<td class="nump">44,963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">14,960<span></span>
</td>
<td class="nump">15,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Asset-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">6,026<span></span>
</td>
<td class="nump">6,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Asset-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Marketable Securities - Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 177,983<span></span>
</td>
<td class="nump">$ 83,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">177,983<span></span>
</td>
<td class="nump">83,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">178,263<span></span>
</td>
<td class="nump">83,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">86,417<span></span>
</td>
<td class="nump">44,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">86,417<span></span>
</td>
<td class="nump">44,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">86,636<span></span>
</td>
<td class="nump">44,963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">14,950<span></span>
</td>
<td class="nump">15,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">14,950<span></span>
</td>
<td class="nump">15,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">14,960<span></span>
</td>
<td class="nump">15,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">68,943<span></span>
</td>
<td class="nump">12,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">68,943<span></span>
</td>
<td class="nump">12,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">68,977<span></span>
</td>
<td class="nump">12,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">6,010<span></span>
</td>
<td class="nump">6,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">6,010<span></span>
</td>
<td class="nump">6,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">6,026<span></span>
</td>
<td class="nump">6,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,663<span></span>
</td>
<td class="nump">4,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,663<span></span>
</td>
<td class="nump">4,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 1,664<span></span>
</td>
<td class="nump">$ 4,399<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Marketable Securities - Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 126,119<span></span>
</td>
<td class="nump">$ 56,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo', window );">Maturing after one year through two years</a></td>
<td class="nump">52,144<span></span>
</td>
<td class="nump">26,853<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 178,263<span></span>
</td>
<td class="nump">$ 83,239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Property and Equipment (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment&#8211;at cost</a></td>
<td class="nump">$ 6,739<span></span>
</td>
<td class="nump">$ 6,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(6,637)<span></span>
</td>
<td class="num">(6,361)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment&#8211;at cost</a></td>
<td class="nump">4,741<span></span>
</td>
<td class="nump">4,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment&#8211;at cost</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment&#8211;at cost</a></td>
<td class="nump">1,612<span></span>
</td>
<td class="nump">1,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment&#8211;at cost</a></td>
<td class="nump">$ 364<span></span>
</td>
<td class="nump">$ 364<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Accrued Expenses (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_AccruedManufacturingExpenses', window );">Accrued Manufacturing Expenses</a></td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_AccruedManufacturingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued manufacturing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_AccruedManufacturingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_AccruedProjectExpensesCurrent', window );">Project expenses</a></td>
<td class="nump">$ 8,217<span></span>
</td>
<td class="nump">$ 2,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Compensation and benefits</a></td>
<td class="nump">2,682<span></span>
</td>
<td class="nump">2,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">484<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 11,383<span></span>
</td>
<td class="nump">$ 6,287<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_AccruedProjectExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued project expenses classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_AccruedProjectExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stockholders' Equity (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 12, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137,999<span></span>
</td>
<td class="nump">$ 18,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember', window );">Pre-Funded Warrants in Connection with Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">6,710,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,710,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_ClassOfWarrantOrRightPurchasePrice', window );">Class of Warrant Or Right, Purchase Price (in dollars per share)</a></td>
<td class="nump">$ 2.9999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmpx_UnderwritingAgreementMember', window );">Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">33,290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="nump">$ 129,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees', window );">Expense Related to Distribution or Servicing and Underwriting Fees</a></td>
<td class="nump">8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseOfferingCost', window );">Offering Cost, Expense</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_StockIssuableDuringPeriodShares', window );">Stock Issuable During Period, Shares (in shares)</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cmpx_AtTheMarketMember', window );">At The Market [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,790,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_ProceedsFromIssuanceOfCommonStockNet', window );">Proceeds from Issuance of Common Stock, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_ClassOfWarrantOrRightPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The purchase price of the warrant or right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_ClassOfWarrantOrRightPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_ProceedsFromIssuanceOfCommonStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of common stock, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_ProceedsFromIssuanceOfCommonStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_StockIssuableDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issuable during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_StockIssuableDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense related to distribution, servicing and underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for cost associated with issuance of security by investment company. Includes, but is not limited to, legal fee pertaining to share offered for sale, registration fee, underwriting, printing prospectus, and initial fee for listing on exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cmpx_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cmpx_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cmpx_AtTheMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cmpx_AtTheMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stock-based Compensation (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,614<span></span>
</td>
<td class="nump">$ 579<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmpx_The2020StockOptionAndIncentivePlanMember', window );">The 2020 Stock Option and Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmpx_The2020StockOptionAndIncentivePlanMember', window );">The 2020 Stock Option and Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cmpx_The2020StockOptionAndIncentivePlanMember', window );">The 2020 Stock Option and Incentive Plan [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</a></td>
<td class="nump">12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</a></td>
<td class="nump">7.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cmpx_The2020StockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cmpx_The2020StockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 8,368<span></span>
</td>
<td class="nump">$ 8,560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">3,346<span></span>
</td>
<td class="nump">2,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,022<span></span>
</td>
<td class="nump">$ 5,589<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stock-based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, options (in shares)</a></td>
<td class="nump">14,062<span></span>
</td>
<td class="nump">7,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.83<span></span>
</td>
<td class="nump">$ 3.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual term (Year)</a></td>
<td class="text">6 years 8 months 8 days<span></span>
</td>
<td class="text">6 years 2 months 23 days<span></span>
</td>
<td class="text">8 years 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 36,614<span></span>
</td>
<td class="nump">$ 579<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, options (in shares)</a></td>
<td class="nump">4,777<span></span>
</td>
<td class="nump">6,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.63<span></span>
</td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm', window );">Granted, weighted average remaining contractual term (Year)</a></td>
<td class="text">8 years 9 months 3 days<span></span>
</td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted', window );">Granted, aggregate intrinsic value</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, options (in shares)</a></td>
<td class="num">(545)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.34<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited/cancelled (in shares)</a></td>
<td class="num">(1,942)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/cancelled (in dollars per share)</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 3.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue', window );">Forfeited/cancelled</a></td>
<td class="nump">$ 2,341<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">$ 1,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at December 31, 2024 (in shares)</a></td>
<td class="nump">16,352<span></span>
</td>
<td class="nump">14,062<span></span>
</td>
<td class="nump">7,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at December 31, 2024 (in dollars per share)</a></td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="nump">$ 2.83<span></span>
</td>
<td class="nump">$ 3.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested at December 31, 2025 (in shares)</a></td>
<td class="nump">9,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested at December 31, 2025 (in dollars per share)</a></td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested at December 31, 2025 (Year)</a></td>
<td class="text">5 years 2 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested at December 31, 2025</a></td>
<td class="nump">$ 18,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of granted award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate intrinsic value of options forfeited or cancelled under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards granted during the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stock-based Compensation - Weighted Average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years) (Year)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">4.26%<span></span>
</td>
<td class="nump">3.92%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stock-based Compensation - Summary of RSU Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted', window );">Granted, aggregate intrinsic value</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, balance (in shares)</a></td>
<td class="nump">3,766<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, weighted average price per share (in dollars per share)</a></td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="nump">$ 3.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Unvested, weighted average fair value</a></td>
<td class="nump">$ 2,395<span></span>
</td>
<td class="nump">$ 9,076<span></span>
</td>
<td class="nump">$ 5,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average price per share (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted', window );">Granted, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(1,073)<span></span>
</td>
<td class="num">(525)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, weighted average price per share (in dollars per share)</a></td>
<td class="nump">$ 2.59<span></span>
</td>
<td class="nump">$ 3.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Vested, weighted average fair value</a></td>
<td class="num">$ (2,779)<span></span>
</td>
<td class="num">$ (2,032)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited or canceled (in shares)</a></td>
<td class="num">(1,665)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited or canceled, weighted average price per share (in dollars per share)</a></td>
<td class="nump">$ 2.34<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited', window );">Forfeited, weighted average fair value</a></td>
<td class="num">$ (3,896)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, December 31, 2024 (in shares)</a></td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">3,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, December 31, 2024 (in dollars per share)</a></td>
<td class="nump">$ 2.33<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of forfeited award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of granted award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Basic and Diluted Net Loss Per Share (Details Textual) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 12, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic and diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">157,695,000<span></span>
</td>
<td class="nump">137,384,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</a></td>
<td class="nump">17,380,000<span></span>
</td>
<td class="nump">17,828,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember', window );">Pre-Funded Warrants in Connection with Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">6,710,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,710,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Basic and Diluted Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">17,380,000<span></span>
</td>
<td class="nump">17,828,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">16,352,430<span></span>
</td>
<td class="nump">14,061,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">1,028,125<span></span>
</td>
<td class="nump">3,765,625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - License, Research and Collaboration Agreements (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cmpx_ABLBioAgreementMember', window );">ABL Bio Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_UpfrontPayment', window );">Upfront Payment</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_DevelopmentMilestonePayment', window );">Development Milestone Payment</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_MaximumDevelopmentAndRegulatoryMilestonePayments', window );">Maximum Development and Regulatory Milestone Payments</a></td>
<td class="nump">96,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cmpx_ABLBioAgreementMember', window );">ABL Bio Agreement [Member] | Oncology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_MaximumCommercialMilestonePaymentsAndRoyalties', window );">Maximum Commercial Milestone Payments and Royalties</a></td>
<td class="nump">303,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cmpx_ABLBioAgreementMember', window );">ABL Bio Agreement [Member] | Ophthalmology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_MaximumDevelopmentAndRegulatoryMilestonePayments', window );">Maximum Development and Regulatory Milestone Payments</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_MaximumCommercialMilestonePaymentsAndRoyalties', window );">Maximum Commercial Milestone Payments and Royalties</a></td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cmpx_AdimabAgreementMember', window );">Adimab Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_MilestonePaymentsPaid', window );">Milestone Payments Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_MilestonePaymentObligation', window );">Milestone Payment Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_DevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents payments for development milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_DevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_MaximumCommercialMilestonePaymentsAndRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of commercial milestone payments and royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_MaximumCommercialMilestonePaymentsAndRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_MaximumDevelopmentAndRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of development and regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_MaximumDevelopmentAndRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_MilestonePaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation for milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_MilestonePaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_MilestonePaymentsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_MilestonePaymentsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cmpx_ABLBioAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cmpx_ABLBioAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cmpx_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cmpx_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cmpx_OphthalmologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cmpx_OphthalmologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cmpx_AdimabAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cmpx_AdimabAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Commitments and Contingencies (Details Textual)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">30 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 27, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,099<span></span>
</td>
<td class="nump">$ 6,731<span></span>
</td>
<td class="nump">$ 9,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">568<span></span>
</td>
<td class="nump">568<span></span>
</td>
<td class="nump">$ 568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined Contribution Plan, Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=cmpx_FacilityLeaseMember', window );">Facility Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lessee, Operating Lease, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property | ft&#178;</a></td>
<td class="nump">10,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</a></td>
<td class="nump">$ 9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, Operating Lease, Remaining Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating Lease, Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=cmpx_FacilityLeaseMember', window );">Facility Lease [Member] | Financial Standby Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">$ 568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=cmpx_FacilityLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=cmpx_FacilityLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_FinancialStandbyLetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_FinancialStandbyLetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 12 - Commitments and Contingencies - Undiscounted Cash Flows Reconciled to Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount of lease payments representing interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,794)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: operating lease obligations, current portion</a></td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">$ (338)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligations, long-term portion</a></td>
<td class="nump">$ 8,829<span></span>
</td>
<td class="nump">$ 8,829<span></span>
</td>
<td class="nump">$ 6,296<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Other Income (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Investment Income, Interest</a></td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Income Taxe (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="nump">79,245<span></span>
</td>
<td class="nump">59,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 200,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Income Taxes - Schedule of Effective Tax Rate of Provision for Income Taxes differs from Federal Statutory Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="num">$ (13,963)<span></span>
</td>
<td class="num">$ (10,368)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local income tax, net of federal (national) income tax effect</a></td>
<td class="num">$ (4,416)<span></span>
</td>
<td class="num">$ (3,454)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local income tax, net of federal (national) income tax effect</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign Tax Effects</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign Tax Effects</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Effect of changes in tax laws or rates enacted in the current period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Effect of changes in tax laws or rates enacted in the current period</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount', window );">Effect of cross-border tax laws</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent', window );">Effect of cross-border tax laws</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits, amount</a></td>
<td class="num">$ (2,045)<span></span>
</td>
<td class="num">$ (2,864)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits, percent</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="nump">$ 19,744<span></span>
</td>
<td class="nump">$ 15,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="num">(29.80%)<span></span>
</td>
<td class="num">(32.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Stock compensation &amp; other nondeductible expenses</a></td>
<td class="nump">$ 680<span></span>
</td>
<td class="nump">$ 532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Stock compensation &amp; other nondeductible expenses</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount', window );">Changes in unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent', window );">Changes in unrecognized tax benefits</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Effective income tax rate</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 14 - Income Taxes - Significant Components of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 42,075<span></span>
</td>
<td class="nump">$ 16,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">13,063<span></span>
</td>
<td class="nump">5,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">11,297<span></span>
</td>
<td class="nump">9,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_DeferredTaxAssetsSection174Capitalization', window );">Section 174 Capitalization</a></td>
<td class="nump">6,015<span></span>
</td>
<td class="nump">22,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">5,001<span></span>
</td>
<td class="nump">3,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">2,685<span></span>
</td>
<td class="nump">1,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cmpx_DeferredTaxAssetsCapitalizedLicensingFees', window );">Capitalized licensing fees</a></td>
<td class="nump">1,266<span></span>
</td>
<td class="nump">1,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">406<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Subtotal</a></td>
<td class="nump">81,808<span></span>
</td>
<td class="nump">61,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(79,245)<span></span>
</td>
<td class="num">(59,521)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">2,563<span></span>
</td>
<td class="nump">1,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="num">(2,486)<span></span>
</td>
<td class="num">(1,839)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_DeferredTaxAssetsCapitalizedLicensingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized licensing fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_DeferredTaxAssetsCapitalizedLicensingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cmpx_DeferredTaxAssetsSection174Capitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from section 174 capitalization..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cmpx_DeferredTaxAssetsSection174Capitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cmpx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Segment Information (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Segment Information - Schedule of Segment Reporting Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Licensing revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">55,969<span></span>
</td>
<td class="nump">42,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">16,870<span></span>
</td>
<td class="nump">15,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">6,350<span></span>
</td>
<td class="nump">7,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(66,489)<span></span>
</td>
<td class="num">(49,375)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=cmpx_PersonnelMember', window );">Personnel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">11,935<span></span>
</td>
<td class="nump">9,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">10,236<span></span>
</td>
<td class="nump">10,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=cmpx_GeneralMember', window );">General [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">4,616<span></span>
</td>
<td class="nump">3,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">6,634<span></span>
</td>
<td class="nump">4,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=cmpx_TovecimigMember', window );">Tovecimig [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">23,680<span></span>
</td>
<td class="nump">23,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=cmpx_CTX471Member', window );">CTX-471 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">4,183<span></span>
</td>
<td class="nump">2,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=cmpx_CTX8371Member', window );">CTX-8371 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">3,355<span></span>
</td>
<td class="nump">2,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=cmpx_CTX10726Member', window );">CTX-10726 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 8,200<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=cmpx_PersonnelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=cmpx_PersonnelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=cmpx_GeneralMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=cmpx_GeneralMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=cmpx_TovecimigMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=cmpx_TovecimigMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=cmpx_CTX471Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=cmpx_CTX471Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=cmpx_CTX8371Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=cmpx_CTX8371Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=cmpx_CTX10726Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=cmpx_CTX10726Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>163</ContextCount>
  <ElementCount>307</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>48</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity-parentheticals</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Note 1 - Formation and Business of the Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-1-formation-and-business-of-the-company</Role>
      <ShortName>Note 1 - Formation and Business of the Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995551 - Disclosure - Note 2 - Liquidity, Uncertainties and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern</Role>
      <ShortName>Note 2 - Liquidity, Uncertainties and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995552 - Disclosure - Note 3 - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995553 - Disclosure - Note 4 - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements</Role>
      <ShortName>Note 4 - Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995554 - Disclosure - Note 5 - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities</Role>
      <ShortName>Note 5 - Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Note 6 - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment</Role>
      <ShortName>Note 6 - Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995556 - Disclosure - Note 7 - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses</Role>
      <ShortName>Note 7 - Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995557 - Disclosure - Note 8 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity</Role>
      <ShortName>Note 8 - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995558 - Disclosure - Note 9 - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation</Role>
      <ShortName>Note 9 - Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995559 - Disclosure - Note 10 - Basic and Diluted Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share</Role>
      <ShortName>Note 10 - Basic and Diluted Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995560 - Disclosure - Note 11 - License, Research and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements</Role>
      <ShortName>Note 11 - License, Research and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995561 - Disclosure - Note 12 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies</Role>
      <ShortName>Note 12 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995562 - Disclosure - Note 13 - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income</Role>
      <ShortName>Note 13 - Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995563 - Disclosure - Note 14 - Income Taxe</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe</Role>
      <ShortName>Note 14 - Income Taxe</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995564 - Disclosure - Note 15 - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-</Role>
      <ShortName>Note 15 - Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995566 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995567 - Disclosure - Note 4 - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-tables</Role>
      <ShortName>Note 4 - Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995568 - Disclosure - Note 5 - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-tables</Role>
      <ShortName>Note 5 - Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995569 - Disclosure - Note 6 - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-tables</Role>
      <ShortName>Note 6 - Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995570 - Disclosure - Note 7 - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-tables</Role>
      <ShortName>Note 7 - Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995571 - Disclosure - Note 9 - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-tables</Role>
      <ShortName>Note 9 - Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995572 - Disclosure - Note 10 - Basic and Diluted Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-tables</Role>
      <ShortName>Note 10 - Basic and Diluted Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995573 - Disclosure - Note 12 - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-tables</Role>
      <ShortName>Note 12 - Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995574 - Disclosure - Note 14 - Income Taxe (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-tables</Role>
      <ShortName>Note 14 - Income Taxe (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Note 15 - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-tables</Role>
      <ShortName>Note 15 - Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995576 - Disclosure - Note 2 - Liquidity, Uncertainties and Going Concern (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern-details-textual</Role>
      <ShortName>Note 2 - Liquidity, Uncertainties and Going Concern (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995577 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995578 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Schedule of Estimated Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies - Schedule of Estimated Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995579 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995580 - Disclosure - Note 4 - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details</Role>
      <ShortName>Note 4 - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995581 - Disclosure - Note 5 - Marketable Securities - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details</Role>
      <ShortName>Note 5 - Marketable Securities - Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995582 - Disclosure - Note 5 - Marketable Securities - Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-maturity-details</Role>
      <ShortName>Note 5 - Marketable Securities - Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995583 - Disclosure - Note 6 - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-details-textual</Role>
      <ShortName>Note 6 - Property and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-tables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995584 - Disclosure - Note 6 - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details</Role>
      <ShortName>Note 6 - Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Note 7 - Accrued Expenses (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-details-textual</Role>
      <ShortName>Note 7 - Accrued Expenses (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-tables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995586 - Disclosure - Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details</Role>
      <ShortName>Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995587 - Disclosure - Note 8 - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual</Role>
      <ShortName>Note 8 - Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995588 - Disclosure - Note 9 - Stock-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual</Role>
      <ShortName>Note 9 - Stock-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-tables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995589 - Disclosure - Note 9 - Stock-based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details</Role>
      <ShortName>Note 9 - Stock-based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995590 - Disclosure - Note 9 - Stock-based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details</Role>
      <ShortName>Note 9 - Stock-based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995591 - Disclosure - Note 9 - Stock-based Compensation - Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-weighted-average-assumptions-details</Role>
      <ShortName>Note 9 - Stock-based Compensation - Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995592 - Disclosure - Note 9 - Stock-based Compensation - Summary of RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details</Role>
      <ShortName>Note 9 - Stock-based Compensation - Summary of RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995593 - Disclosure - Note 10 - Basic and Diluted Net Loss Per Share (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual</Role>
      <ShortName>Note 10 - Basic and Diluted Net Loss Per Share (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-tables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995594 - Disclosure - Note 10 - Basic and Diluted Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details</Role>
      <ShortName>Note 10 - Basic and Diluted Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Note 11 - License, Research and Collaboration Agreements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual</Role>
      <ShortName>Note 11 - License, Research and Collaboration Agreements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995596 - Disclosure - Note 12 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual</Role>
      <ShortName>Note 12 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-tables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995597 - Disclosure - Note 12 - Commitments and Contingencies - Undiscounted Cash Flows Reconciled to Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details</Role>
      <ShortName>Note 12 - Commitments and Contingencies - Undiscounted Cash Flows Reconciled to Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995598 - Disclosure - Note 13 - Other Income (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income-details-textual</Role>
      <ShortName>Note 13 - Other Income (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995599 - Disclosure - Note 14 - Income Taxe (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-details-textual</Role>
      <ShortName>Note 14 - Income Taxe (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-tables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995600 - Disclosure - Note 14 - Income Taxes - Schedule of Effective Tax Rate of Provision for Income Taxes differs from Federal Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details</Role>
      <ShortName>Note 14 - Income Taxes - Schedule of Effective Tax Rate of Provision for Income Taxes differs from Federal Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>995601 - Disclosure - Note 14 - Income Taxes - Significant Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details</Role>
      <ShortName>Note 14 - Income Taxes - Significant Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>995602 - Disclosure - Note 15 - Segment Information (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-details-textual</Role>
      <ShortName>Note 15 - Segment Information (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-tables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="cmpx20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>995603 - Disclosure - Note 15 - Segment Information - Schedule of Segment Reporting Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details</Role>
      <ShortName>Note 15 - Segment Information - Schedule of Segment Reporting Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cmpx-20251231.xsd</File>
    <File>cmpx-20251231_cal.xml</File>
    <File>cmpx-20251231_def.xml</File>
    <File>cmpx-20251231_lab.xml</File>
    <File>cmpx-20251231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="cmpx20251231_10k.htm">cmpx20251231_10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cell1.jpg</File>
    <File>cell2.jpg</File>
    <File>graph1.jpg</File>
    <File>graph2.jpg</File>
    <File>graph3.jpg</File>
    <File>graph4.jpg</File>
    <File>graph5.jpg</File>
    <File>scan1.jpg</File>
    <File>scan2.jpg</File>
    <File>scan3.jpg</File>
    <File>table1.jpg</File>
    <File>table2.jpg</File>
    <File>table3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="622">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="13">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>100
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cmpx20251231_10k.htm": {
   "nsprefix": "cmpx",
   "nsuri": "http://www.compasstherapeutics.com/20251231",
   "dts": {
    "schema": {
     "local": [
      "cmpx-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/exch/2025/exch-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cmpx-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cmpx-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cmpx-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cmpx-20251231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "cmpx20251231_10k.htm"
     ]
    }
   },
   "keyStandard": 282,
   "keyCustom": 25,
   "axisStandard": 19,
   "axisCustom": 0,
   "memberStandard": 30,
   "memberCustom": 16,
   "hidden": {
    "total": 23,
    "http://www.compasstherapeutics.com/20251231": 1,
    "http://fasb.org/us-gaap/2025": 12,
    "http://xbrl.sec.gov/ecd/2025": 4,
    "http://xbrl.sec.gov/dei/2025": 6
   },
   "contextCount": 163,
   "entityCount": 1,
   "segmentCount": 48,
   "elementCount": 474,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 622,
    "http://xbrl.sec.gov/dei/2025": 37,
    "http://xbrl.sec.gov/cyd/2025": 13,
    "http://xbrl.sec.gov/ecd/2025": 8
   },
   "report": {
    "R1": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
     "longName": "001 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals",
     "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-8",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
     "longName": "003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity",
     "longName": "004 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity-parentheticals",
     "longName": "005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parentheticals)",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "d_2025-07-01_2025-09-30",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-07-01_2025-09-30",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows",
     "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "ecd:AwardTmgHowMnpiCnsdrdTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "ecd:AwardTmgHowMnpiCnsdrdTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-1-formation-and-business-of-the-company",
     "longName": "995550 - Disclosure - Note 1 - Formation and Business of the Company",
     "shortName": "Note 1 - Formation and Business of the Company",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern",
     "longName": "995551 - Disclosure - Note 2 - Liquidity, Uncertainties and Going Concern",
     "shortName": "Note 2 - Liquidity, Uncertainties and Going Concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
     "longName": "995552 - Disclosure - Note 3 - Summary of Significant Accounting Policies",
     "shortName": "Note 3 - Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
     "longName": "995553 - Disclosure - Note 4 - Fair Value Measurements",
     "shortName": "Note 4 - Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities",
     "longName": "995554 - Disclosure - Note 5 - Marketable Securities",
     "shortName": "Note 5 - Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment",
     "longName": "995555 - Disclosure - Note 6 - Property and Equipment",
     "shortName": "Note 6 - Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses",
     "longName": "995556 - Disclosure - Note 7 - Accrued Expenses",
     "shortName": "Note 7 - Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity",
     "longName": "995557 - Disclosure - Note 8 - Stockholders' Equity",
     "shortName": "Note 8 - Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation",
     "longName": "995558 - Disclosure - Note 9 - Stock-based Compensation",
     "shortName": "Note 9 - Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share",
     "longName": "995559 - Disclosure - Note 10 - Basic and Diluted Net Loss Per Share",
     "shortName": "Note 10 - Basic and Diluted Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements",
     "longName": "995560 - Disclosure - Note 11 - License, Research and Collaboration Agreements",
     "shortName": "Note 11 - License, Research and Collaboration Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies",
     "longName": "995561 - Disclosure - Note 12 - Commitments and Contingencies",
     "shortName": "Note 12 - Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income",
     "longName": "995562 - Disclosure - Note 13 - Other Income",
     "shortName": "Note 13 - Other Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe",
     "longName": "995563 - Disclosure - Note 14 - Income Taxe",
     "shortName": "Note 14 - Income Taxe",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-",
     "longName": "995564 - Disclosure - Note 15 - Segment Information",
     "shortName": "Note 15 - Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies",
     "longName": "995565 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables",
     "longName": "995566 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Note 3 - Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "cmpx:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "cmpx:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-tables",
     "longName": "995567 - Disclosure - Note 4 - Fair Value Measurements (Tables)",
     "shortName": "Note 4 - Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-tables",
     "longName": "995568 - Disclosure - Note 5 - Marketable Securities (Tables)",
     "shortName": "Note 5 - Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-tables",
     "longName": "995569 - Disclosure - Note 6 - Property and Equipment (Tables)",
     "shortName": "Note 6 - Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-tables",
     "longName": "995570 - Disclosure - Note 7 - Accrued Expenses (Tables)",
     "shortName": "Note 7 - Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-tables",
     "longName": "995571 - Disclosure - Note 9 - Stock-based Compensation (Tables)",
     "shortName": "Note 9 - Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-tables",
     "longName": "995572 - Disclosure - Note 10 - Basic and Diluted Net Loss Per Share (Tables)",
     "shortName": "Note 10 - Basic and Diluted Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-tables",
     "longName": "995573 - Disclosure - Note 12 - Commitments and Contingencies (Tables)",
     "shortName": "Note 12 - Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-tables",
     "longName": "995574 - Disclosure - Note 14 - Income Taxe (Tables)",
     "shortName": "Note 14 - Income Taxe (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-tables",
     "longName": "995575 - Disclosure - Note 15 - Segment Information (Tables)",
     "shortName": "Note 15 - Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern-details-textual",
     "longName": "995576 - Disclosure - Note 2 - Liquidity, Uncertainties and Going Concern (Details Textual)",
     "shortName": "Note 2 - Liquidity, Uncertainties and Going Concern (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
     "longName": "995577 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)",
     "shortName": "Note 3 - Summary of Significant Accounting Policies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2021-06-30_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesIssuedPricePerShare",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details",
     "longName": "995578 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Schedule of Estimated Lives (Details)",
     "shortName": "Note 3 - Summary of Significant Accounting Policies - Schedule of Estimated Lives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "cmpx:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "cmpx:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details",
     "longName": "995579 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details)",
     "shortName": "Note 3 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details",
     "longName": "995580 - Disclosure - Note 4 - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Note 4 - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details",
     "longName": "995581 - Disclosure - Note 5 - Marketable Securities - Marketable Securities (Details)",
     "shortName": "Note 5 - Marketable Securities - Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-maturity-details",
     "longName": "995582 - Disclosure - Note 5 - Marketable Securities - Maturity (Details)",
     "shortName": "Note 5 - Marketable Securities - Maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-details-textual",
     "longName": "995583 - Disclosure - Note 6 - Property and Equipment (Details Textual)",
     "shortName": "Note 6 - Property and Equipment (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details",
     "longName": "995584 - Disclosure - Note 6 - Property and Equipment - Schedule of Property and Equipment (Details)",
     "shortName": "Note 6 - Property and Equipment - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-details-textual",
     "longName": "995585 - Disclosure - Note 7 - Accrued Expenses (Details Textual)",
     "shortName": "Note 7 - Accrued Expenses (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "cmpx:AccruedManufacturingExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "cmpx:AccruedManufacturingExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details",
     "longName": "995586 - Disclosure - Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "shortName": "Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "cmpx:AccruedProjectExpensesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "cmpx:AccruedProjectExpensesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual",
     "longName": "995587 - Disclosure - Note 8 - Stockholders' Equity (Details Textual)",
     "shortName": "Note 8 - Stockholders' Equity (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "i_2025-08-12",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-08-12",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual",
     "longName": "995588 - Disclosure - Note 9 - Stock-based Compensation (Details Textual)",
     "shortName": "Note 9 - Stock-based Compensation (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details",
     "longName": "995589 - Disclosure - Note 9 - Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "shortName": "Note 9 - Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details",
     "longName": "995590 - Disclosure - Note 9 - Stock-based Compensation - Summary of Stock Option Activity (Details)",
     "shortName": "Note 9 - Stock-based Compensation - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-weighted-average-assumptions-details",
     "longName": "995591 - Disclosure - Note 9 - Stock-based Compensation - Weighted Average Assumptions (Details)",
     "shortName": "Note 9 - Stock-based Compensation - Weighted Average Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details",
     "longName": "995592 - Disclosure - Note 9 - Stock-based Compensation - Summary of RSU Activity (Details)",
     "shortName": "Note 9 - Stock-based Compensation - Summary of RSU Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual",
     "longName": "995593 - Disclosure - Note 10 - Basic and Diluted Net Loss Per Share (Details Textual)",
     "shortName": "Note 10 - Basic and Diluted Net Loss Per Share (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31",
      "name": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details",
     "longName": "995594 - Disclosure - Note 10 - Basic and Diluted Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "shortName": "Note 10 - Basic and Diluted Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R57": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual",
     "longName": "995595 - Disclosure - Note 11 - License, Research and Collaboration Agreements (Details Textual)",
     "shortName": "Note 11 - License, Research and Collaboration Agreements (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "d_2018-11-01_2018-11-30_TypeOfArrangementAxis-ABLBioAgreementMember",
      "name": "cmpx:UpfrontPayment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2018-11-01_2018-11-30_TypeOfArrangementAxis-ABLBioAgreementMember",
      "name": "cmpx:UpfrontPayment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual",
     "longName": "995596 - Disclosure - Note 12 - Commitments and Contingencies (Details Textual)",
     "shortName": "Note 12 - Commitments and Contingencies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details",
     "longName": "995597 - Disclosure - Note 12 - Commitments and Contingencies - Undiscounted Cash Flows Reconciled to Operating Lease Liabilities (Details)",
     "shortName": "Note 12 - Commitments and Contingencies - Undiscounted Cash Flows Reconciled to Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "i_2025-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income-details-textual",
     "longName": "995598 - Disclosure - Note 13 - Other Income (Details Textual)",
     "shortName": "Note 13 - Other Income (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-details-textual",
     "longName": "995599 - Disclosure - Note 14 - Income Taxe (Details Textual)",
     "shortName": "Note 14 - Income Taxe (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details",
     "longName": "995600 - Disclosure - Note 14 - Income Taxes - Schedule of Effective Tax Rate of Provision for Income Taxes differs from Federal Statutory Rate (Details)",
     "shortName": "Note 14 - Income Taxes - Schedule of Effective Tax Rate of Provision for Income Taxes differs from Federal Statutory Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details",
     "longName": "995601 - Disclosure - Note 14 - Income Taxes - Significant Components of Deferred Tax Assets (Details)",
     "shortName": "Note 14 - Income Taxes - Significant Components of Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-details-textual",
     "longName": "995602 - Disclosure - Note 15 - Segment Information (Details Textual)",
     "shortName": "Note 15 - Segment Information (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R65": {
     "role": "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details",
     "longName": "995603 - Disclosure - Note 15 - Segment Information - Schedule of Segment Reporting Information (Details)",
     "shortName": "Note 15 - Segment Information - Schedule of Segment Reporting Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cmpx20251231_10k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "cmpx_ABLBioAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "ABLBioAgreementMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ABL Bio Agreement [Member]",
        "documentation": "Represents the ABL Bio Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r43",
      "r46",
      "r993"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r802"
     ]
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and benefits",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "cmpx_AccruedManufacturingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "AccruedManufacturingExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cmpx_AccruedManufacturingExpenses",
        "terseLabel": "Accrued Manufacturing Expenses",
        "documentation": "The amount of accrued manufacturing expenses."
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_AccruedProjectExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "AccruedProjectExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Project expenses",
        "documentation": "Amount of accrued project expenses classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_AccruedResearchAndDevelopmentExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "AccruedResearchAndDevelopmentExpensesPolicyTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Research and Development Expenses [Policy Text Block]",
        "documentation": "Accrued research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
        "negatedLabel": "Less: Accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r115",
      "r620"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r56",
      "r120",
      "r616",
      "r647",
      "r651",
      "r1003"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8",
      "r15",
      "r482",
      "r485",
      "r565",
      "r642",
      "r643",
      "r876",
      "r877",
      "r878",
      "r932",
      "r933",
      "r934",
      "r935"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in-capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r932",
      "r933",
      "r934",
      "r935",
      "r1004",
      "r1066"
     ]
    },
    "cmpx_AdimabAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "AdimabAgreementMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adimab Agreement [Member]",
        "documentation": "Represents Adimab agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
        "terseLabel": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r74"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AllocatedShareBasedCompensationExpense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r394",
      "r403"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potentially dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AreaOfRealEstateProperty",
        "terseLabel": "Area of Real Estate Property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetBackedSecuritiesMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset-Backed Securities [Member]",
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r772",
      "r803",
      "r944",
      "r945",
      "r946"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r89",
      "r116",
      "r147",
      "r148",
      "r149",
      "r186",
      "r197",
      "r213",
      "r216",
      "r260",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r469",
      "r471",
      "r536",
      "r604",
      "r605",
      "r612",
      "r688",
      "r755",
      "r756",
      "r766",
      "r802",
      "r808",
      "r809",
      "r822",
      "r959",
      "r960",
      "r1018"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r121",
      "r147",
      "r148",
      "r149",
      "r260",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r469",
      "r471",
      "r536",
      "r802",
      "r959",
      "r960",
      "r1018"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AssetsFairValueDisclosure",
        "totalLabel": "Total assets",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r788"
     ]
    },
    "cmpx_AtTheMarketMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "AtTheMarketMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At The Market [Member]",
        "documentation": "Represents at the market."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_AuditorFirmId",
        "terseLabel": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r826",
      "r827",
      "r840"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_AuditorLocation",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r826",
      "r827",
      "r840"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_AuditorName",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r826",
      "r827",
      "r840"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized gains",
        "terseLabel": "Unrealized gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
        "negatedTerseLabel": "Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortized Cost",
        "terseLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r270",
      "r611"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-maturity-details": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-maturity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturing in one year or less",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r607"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-maturity-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-maturity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Marketable Securities",
        "label": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
        "terseLabel": "Fair Value",
        "totalLabel": "Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r270",
      "r506",
      "r529",
      "r530",
      "r531",
      "r532",
      "r601",
      "r733",
      "r788",
      "r792",
      "r799",
      "r942",
      "r1008",
      "r1009",
      "r1010"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_AwardTmgMnpiCnsdrdFlag",
        "terseLabel": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-1-formation-and-business-of-the-company"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r872",
      "r924"
     ]
    },
    "cmpx_CTX10726Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "CTX10726Member",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CTX-10726 [Member]",
        "documentation": "Represents CTX-10726."
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_CTX471Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "CTX471Member",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CTX-471 [Member]",
        "documentation": "Relating to CTX-471"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_CTX8371Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "CTX8371Member",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CTX-8371 [Member]",
        "documentation": "Relating to CTX-8371."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r113",
      "r735"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Money market funds (cash equivalents)",
        "label": "us-gaap_CashAndCashEquivalentsFairValueDisclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r531",
      "r532",
      "r1006",
      "r1007"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r62",
      "r144"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of cash, cash equivalents and restricted cash to the Consolidated Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r62",
      "r144"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r62"
     ]
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r816",
      "r817",
      "r818",
      "r819"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_CityAreaCode",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r151",
      "r334"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "cmpx_ClassOfWarrantOrRightPurchasePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "ClassOfWarrantOrRightPurchasePrice",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cmpx_ClassOfWarrantOrRightPurchasePrice",
        "terseLabel": "Class of Warrant Or Right, Purchase Price (in dollars per share)",
        "documentation": "The purchase price of the warrant or right."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r466",
      "r467"
     ]
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r963",
      "r964"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r81",
      "r613",
      "r675"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r283",
      "r284",
      "r729",
      "r952",
      "r954"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r812",
      "r813",
      "r814",
      "r816",
      "r817",
      "r818",
      "r819",
      "r932",
      "r933",
      "r935",
      "r1004",
      "r1063",
      "r1066"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share (in dollars per share)",
        "terseLabel": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r676"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r50",
      "r676",
      "r694",
      "r1066",
      "r1067"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.0001 par value: 300,000 shares authorized; 178,324 shares issued and outstanding at December 31, 2025; 137,820 shares issued and outstanding at December 31, 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r311",
      "r316",
      "r615",
      "r802"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ComprehensiveIncomeNetOfTax",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r125",
      "r127",
      "r132",
      "r602",
      "r625",
      "r626"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r534"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r743"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r772",
      "r774",
      "r788",
      "r803",
      "r810",
      "r1060"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r854"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r854"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r856"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r856"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r858"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r856"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r849"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r831",
      "r850"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r831",
      "r850"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r848"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r848"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r848"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r832",
      "r851"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r853"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r853"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r854"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r857"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r855"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r852"
     ]
    },
    "cmpx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-maturity-details": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-maturity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturing after one year through two years",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_DeferredTaxAssetsCapitalizedLicensingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "DeferredTaxAssetsCapitalizedLicensingFees",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cmpx_DeferredTaxAssetsCapitalizedLicensingFees",
        "terseLabel": "Capitalized licensing fees",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized licensing fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsGross",
        "totalLabel": "Subtotal",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "cmpx_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cmpx_DeferredTaxAssetsLeaseLiabilities",
        "terseLabel": "Lease liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsNet",
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
        "terseLabel": "Federal net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
        "terseLabel": "State net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsOther",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "cmpx_DeferredTaxAssetsSection174Capitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "DeferredTaxAssetsSection174Capitalization",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cmpx_DeferredTaxAssetsSection174Capitalization",
        "terseLabel": "Section 174 Capitalization",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from section 174 capitalization.."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch",
        "terseLabel": "Research and development credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsValuationAllowance",
        "terseLabel": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Less valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxLiabilitiesLeasingArrangements",
        "negatedTerseLabel": "Right-of-use assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxLiabilitiesOther",
        "negatedTerseLabel": "Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DefinedContributionPlanCostRecognized",
        "terseLabel": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent",
        "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Depreciation",
        "terseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r27",
      "r137",
      "r736",
      "r737",
      "r739",
      "r741"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r27"
     ]
    },
    "cmpx_DevelopmentMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "DevelopmentMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cmpx_DevelopmentMilestonePayment",
        "terseLabel": "Development Milestone Payment",
        "documentation": "Represents payments for development milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r355",
      "r386",
      "r387",
      "r389",
      "r776"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureTextBlockAbstract",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-1-formation-and-business-of-the-company",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentAnnualReport",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r827",
      "r840"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentFinStmtErrorCorrectionFlag",
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r827",
      "r840",
      "r842"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentPeriodEndDate",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentTransitionReport",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentType",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share - basic and diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r133",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r173",
      "r175",
      "r178",
      "r179",
      "r180",
      "r185",
      "r309",
      "r392",
      "r456",
      "r465",
      "r503",
      "r504",
      "r603",
      "r627",
      "r746"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r182"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r181",
      "r183",
      "r184"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
        "totalLabel": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r780"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
        "terseLabel": "Federal statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r150",
      "r413",
      "r443",
      "r780"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
        "terseLabel": "Changes in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r780",
      "r925",
      "r930",
      "r995"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
        "terseLabel": "Effect of changes in tax laws or rates enacted in the current period",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r780",
      "r925",
      "r930",
      "r995"
     ]
    },
    "cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount",
        "terseLabel": "Changes in unrecognized tax benefits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cmpx_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent",
        "terseLabel": "Changes in unrecognized tax benefits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount",
        "terseLabel": "Effect of cross-border tax laws",
        "documentation": "Amount of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r422"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent",
        "terseLabel": "Effect of cross-border tax laws",
        "documentation": "Percentage of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r422"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
        "terseLabel": "Foreign Tax Effects",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r417",
      "r780",
      "r925",
      "r930",
      "r995"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
        "terseLabel": "Stock compensation &amp; other nondeductible expenses",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422",
      "r925",
      "r930",
      "r995"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments",
        "terseLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r925",
      "r930",
      "r995",
      "r996"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
        "terseLabel": "State and local income tax, net of federal (national) income tax effect",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r780",
      "r925",
      "r930",
      "r995"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414",
      "r780"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
        "negatedTerseLabel": "Research and development tax credits, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r925",
      "r930",
      "r995",
      "r997"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityAddressAddressLine1",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityAddressCityOrTown",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityAddressPostalZipCode",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityAddressStateOrProvince",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityCommonStockSharesOutstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityCurrentReportingStatus",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals",
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows",
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-1-formation-and-business-of-the-company",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-maturity-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-weighted-average-assumptions-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityEmergingGrowthCompany",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityFileNumber",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityFilerCategory",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityIncorporationStateCountryCode",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityInteractiveDataCurrent",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityPublicFloat",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityRegistrantName",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityShellCompany",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntitySmallBusiness",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityTaxIdentificationNumber",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityVoluntaryFilers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityWellKnownSeasonedIssuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r101",
      "r108",
      "r109",
      "r129",
      "r130",
      "r131",
      "r153",
      "r154",
      "r155",
      "r158",
      "r166",
      "r168",
      "r170",
      "r187",
      "r261",
      "r264",
      "r275",
      "r308",
      "r335",
      "r392",
      "r438",
      "r439",
      "r452",
      "r453",
      "r454",
      "r457",
      "r464",
      "r465",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r502",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r547",
      "r549",
      "r565",
      "r623",
      "r642",
      "r643",
      "r644",
      "r663",
      "r713"
     ]
    },
    "us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ExpenseRelatedToDistributionOrServicingAndUnderwritingFees",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees",
        "terseLabel": "Expense Related to Distribution or Servicing and Underwriting Fees",
        "documentation": "Expense related to distribution, servicing and underwriting fees."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "cmpx_FacilityLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "FacilityLeaseMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Facility Lease [Member]",
        "documentation": "Information pertaining to the lease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r517",
      "r788"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r516",
      "r517",
      "r519",
      "r530",
      "r570",
      "r571",
      "r572",
      "r733",
      "r764",
      "r765",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r788",
      "r792",
      "r799"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r508",
      "r510",
      "r788",
      "r1009",
      "r1012"
     ]
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r512",
      "r514",
      "r515",
      "r516",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r600",
      "r788",
      "r793"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r340",
      "r345",
      "r346",
      "r507",
      "r517",
      "r530",
      "r570",
      "r733",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r788",
      "r799"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r340",
      "r345",
      "r346",
      "r348",
      "r507",
      "r508",
      "r517",
      "r530",
      "r571",
      "r733",
      "r764",
      "r765",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r788",
      "r799"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r507",
      "r508",
      "r509",
      "r510",
      "r517",
      "r530",
      "r572",
      "r733",
      "r764",
      "r765",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r788",
      "r792",
      "r799"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r508",
      "r510",
      "r788",
      "r1009",
      "r1012"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r516",
      "r517",
      "r519",
      "r530",
      "r570",
      "r571",
      "r572",
      "r733",
      "r764",
      "r765",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r788",
      "r792",
      "r799"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1012"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r305",
      "r331",
      "r477",
      "r492",
      "r524",
      "r535",
      "r538",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r610",
      "r624",
      "r762",
      "r788",
      "r790",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r803",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r947",
      "r948",
      "r949",
      "r950",
      "r1005",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014"
     ]
    },
    "us-gaap_FinancialStandbyLetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialStandbyLetterOfCreditMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Standby Letter of Credit [Member]",
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation if defined events occur or fail to occur."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "terseLabel": "General and administrative expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r697"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "cmpx_GeneralMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "GeneralMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Member]",
        "documentation": "Relating to general."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GuaranteeObligationsByNatureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GuaranteeObligationsByNatureAxis",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantor Obligations, Nature [Axis]",
        "documentation": "Information by nature of guarantee."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294"
     ]
    },
    "us-gaap_GuaranteeObligationsNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GuaranteeObligationsNatureDomain",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantor Obligations, Nature [Domain]",
        "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_IcfrAuditorAttestationFlag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r826",
      "r827",
      "r840"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse",
        "terseLabel": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r26",
      "r68",
      "r136",
      "r737",
      "r789"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r69"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r282",
      "r473",
      "r474",
      "r475",
      "r476",
      "r511",
      "r513",
      "r518",
      "r537",
      "r538",
      "r539",
      "r637",
      "r639",
      "r698",
      "r732",
      "r733",
      "r781",
      "r782",
      "r786",
      "r787",
      "r791",
      "r799",
      "r1001",
      "r1002",
      "r1033"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r282",
      "r473",
      "r474",
      "r475",
      "r476",
      "r511",
      "r513",
      "r518",
      "r537",
      "r538",
      "r539",
      "r637",
      "r639",
      "r698",
      "r732",
      "r733",
      "r781",
      "r782",
      "r786",
      "r787",
      "r791",
      "r799",
      "r1001",
      "r1002",
      "r1033"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r413",
      "r414",
      "r427",
      "r435",
      "r780",
      "r999"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r413",
      "r414",
      "r427",
      "r435",
      "r780",
      "r999"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r150",
      "r407",
      "r413",
      "r423",
      "r424",
      "r425",
      "r429",
      "r434",
      "r444",
      "r446",
      "r447",
      "r448",
      "r609",
      "r653",
      "r662",
      "r780"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxExpenseBenefit",
        "terseLabel": "Income Tax Expense (Benefit)",
        "totalLabel": "Effective income tax rate",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r96",
      "r147",
      "r169",
      "r170",
      "r186",
      "r201",
      "r216",
      "r412",
      "r413",
      "r445",
      "r628",
      "r738",
      "r740",
      "r742",
      "r780"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r410",
      "r411",
      "r429",
      "r430",
      "r433",
      "r437",
      "r656"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
        "terseLabel": "Changes in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r780",
      "r995"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate",
        "terseLabel": "Effect of changes in tax laws or rates enacted in the current period",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r413",
      "r418",
      "r780"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
        "terseLabel": "Foreign Tax Effects",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r417",
      "r780",
      "r995"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
        "terseLabel": "Federal statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r780"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxReconciliationNondeductibleExpense",
        "terseLabel": "Stock compensation &amp; other nondeductible expenses",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422",
      "r995"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxReconciliationOtherAdjustments",
        "terseLabel": "Other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r995",
      "r996"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes",
        "terseLabel": "State and local income tax, net of federal (national) income tax effect",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r780",
      "r995"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxReconciliationTaxCreditsResearch",
        "negatedTerseLabel": "Research and development tax credits, amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r995",
      "r997"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccountsPayable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInOperatingLeaseLiability",
        "terseLabel": "Operating lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r864",
      "r921"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r844"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r847"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r847"
     ]
    },
    "us-gaap_InterimPeriodCostsNotAllocableDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterimPeriodCostsNotAllocableDomain",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interim Period, Costs Not Allocable [Domain]",
        "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_InvestmentIncomeInterest",
        "terseLabel": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r200",
      "r216",
      "r755",
      "r879"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r98",
      "r227",
      "r228",
      "r525",
      "r526",
      "r1027"
     ]
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r863"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r863"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r558"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals",
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows",
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-1-formation-and-business-of-the-company",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-maturity-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-weighted-average-assumptions-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r559"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseDiscountRate",
        "terseLabel": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
        "totalLabel": "Total minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r926",
      "r931",
      "r1029"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r926",
      "r931",
      "r1029"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r926",
      "r931",
      "r1029"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
        "terseLabel": "2030",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r926",
      "r931",
      "r1029"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r926",
      "r931",
      "r1029"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r926",
      "r931",
      "r1029"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r926",
      "r931",
      "r1029"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
        "negatedLabel": "Less: amount of lease payments representing interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm",
        "terseLabel": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r1016"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r147",
      "r148",
      "r149",
      "r260",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r470",
      "r471",
      "r472",
      "r536",
      "r674",
      "r748",
      "r766",
      "r822",
      "r959",
      "r1018",
      "r1019"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r82",
      "r618",
      "r802",
      "r808",
      "r809",
      "r925",
      "r929",
      "r951",
      "r1015"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r112",
      "r147",
      "r148",
      "r149",
      "r260",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r470",
      "r471",
      "r472",
      "r536",
      "r802",
      "r959",
      "r1018",
      "r1019"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_LocalPhoneNumber",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r285",
      "r286",
      "r287",
      "r290",
      "r404",
      "r763",
      "r955",
      "r956"
     ]
    },
    "cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "MarketableSecuritiesAmortizationOfPremiumAndDiscount",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cmpx_MarketableSecuritiesAmortizationOfPremiumAndDiscount",
        "terseLabel": "Amortization of premium and discount on marketable securities",
        "documentation": "Represents amortization of premium and discount for marketable securities ."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_MarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesTable",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-maturity-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table]",
        "documentation": "Disclosure of information about investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_MarketableSecuritiesUnrealizedGainLoss",
        "terseLabel": "Unrealized gain (loss) on marketable securities",
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "cmpx_MaximumCommercialMilestonePaymentsAndRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "MaximumCommercialMilestonePaymentsAndRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cmpx_MaximumCommercialMilestonePaymentsAndRoyalties",
        "terseLabel": "Maximum Commercial Milestone Payments and Royalties",
        "documentation": "The maximum amount of commercial milestone payments and royalties."
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_MaximumDevelopmentAndRegulatoryMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "MaximumDevelopmentAndRegulatoryMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cmpx_MaximumDevelopmentAndRegulatoryMilestonePayments",
        "terseLabel": "Maximum Development and Regulatory Milestone Payments",
        "documentation": "The maximum amount of development and regulatory milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r192",
      "r286",
      "r287",
      "r288",
      "r289",
      "r350",
      "r381",
      "r382",
      "r383",
      "r404",
      "r510",
      "r598",
      "r636",
      "r638",
      "r652",
      "r666",
      "r667",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r725",
      "r726",
      "r727",
      "r728",
      "r730",
      "r731",
      "r761",
      "r767",
      "r775",
      "r781",
      "r783",
      "r784",
      "r792",
      "r793",
      "r797",
      "r798",
      "r805",
      "r961",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "cmpx_MilestonePaymentObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "MilestonePaymentObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cmpx_MilestonePaymentObligation",
        "terseLabel": "Milestone Payment Obligation",
        "documentation": "Amount of obligation for milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_MilestonePaymentsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "MilestonePaymentsPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cmpx_MilestonePaymentsPaid",
        "terseLabel": "Milestone Payments Paid",
        "documentation": "Amount of cash outflow for milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r192",
      "r286",
      "r287",
      "r288",
      "r289",
      "r350",
      "r381",
      "r382",
      "r383",
      "r404",
      "r510",
      "r598",
      "r636",
      "r638",
      "r652",
      "r666",
      "r667",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r725",
      "r726",
      "r727",
      "r728",
      "r730",
      "r731",
      "r761",
      "r767",
      "r775",
      "r781",
      "r783",
      "r784",
      "r792",
      "r793",
      "r797",
      "r805",
      "r961",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r963",
      "r964"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "us-gaap_NatureOfExpenseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfExpenseAxis",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Expense [Axis]",
        "documentation": "Information by type of cost or expense."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash (used in) provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows",
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r64",
      "r84",
      "r109",
      "r110",
      "r124",
      "r126",
      "r131",
      "r147",
      "r148",
      "r149",
      "r152",
      "r157",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r169",
      "r170",
      "r177",
      "r260",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r309",
      "r312",
      "r314",
      "r317",
      "r392",
      "r456",
      "r465",
      "r504",
      "r536",
      "r622",
      "r695",
      "r711",
      "r712",
      "r738",
      "r740",
      "r742",
      "r820",
      "r959"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r138",
      "r139",
      "r140",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r164",
      "r171",
      "r185",
      "r224",
      "r225",
      "r261",
      "r262",
      "r263",
      "r264",
      "r274",
      "r275",
      "r281",
      "r306",
      "r307",
      "r308",
      "r309",
      "r390",
      "r391",
      "r392",
      "r393",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r527",
      "r528",
      "r547",
      "r548",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r654"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrAdoptedFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrTrmntdFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "us-gaap_NoninterestExpenseOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoninterestExpenseOfferingCost",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NoninterestExpenseOfferingCost",
        "terseLabel": "Offering Cost, Expense",
        "documentation": "Amount of expense for cost associated with issuance of security by investment company. Includes, but is not limited to, legal fee pertaining to share offered for sale, registration fee, underwriting, printing prospectus, and initial fee for listing on exchange."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r1065"
     ]
    },
    "cmpx_NoteToFinancialStatementDetailsTextual": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "NoteToFinancialStatementDetailsTextual",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_NotesToFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "NotesToFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NumberOfOperatingSegments",
        "terseLabel": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r937"
     ]
    },
    "cmpx_OncologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "OncologyMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Oncology [Member]",
        "documentation": "Represents oncology."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingExpenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r738",
      "r742",
      "r749",
      "r936",
      "r938",
      "r939",
      "r940",
      "r941"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLeaseCost",
        "terseLabel": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r801"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLeaseLiability",
        "terseLabel": "Present value of future minimum lease payments",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease obligations, current portion",
        "negatedTerseLabel": "Less: operating lease obligations, current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease obligations, long-term portion",
        "terseLabel": "Operating lease obligations, long-term portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLeasePayments",
        "terseLabel": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r555"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease, right-of-use (\"ROU\") asset",
        "terseLabel": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ROU asset amortization",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLossCarryforwards",
        "terseLabel": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "cmpx_OphthalmologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "OphthalmologyMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ophthalmology [Member]",
        "documentation": "Represents ophthalmology."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "us-gaap_OtherAccruedLiabilitiesCurrent",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized gain on marketable securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r259"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeAndExpenseTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income and Expense [Text Block]",
        "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "terseLabel": "Other income",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r785"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_PatentsCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "PatentsCostsPolicyTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents Costs [Policy Text Block]",
        "documentation": "Represents the patents cost policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsOfStockIssuanceCosts",
        "negatedLabel": "Issuance costs from issuance of common stock",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
        "negatedLabel": "Taxes paid related to net shares settlement of RSUs",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsToAcquireMarketableSecurities",
        "negatedLabel": "Purchases of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "cmpx_PersonnelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "PersonnelMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Personnel [Member]",
        "documentation": "Relating to personnel."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990"
     ]
    },
    "cmpx_PolicyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "PolicyTable",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cmpx_PolicyTable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyTextBlockAbstract",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_PreFundedWarrantsInConnectionWithUnderwritingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "PreFundedWarrantsInConnectionWithUnderwritingAgreementMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrants in Connection with Underwriting Agreement [Member]",
        "documentation": "Represents pre-funded warrants in connection with underwriting agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock and warrants",
        "terseLabel": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "cmpx_ProceedsFromIssuanceOfCommonStockNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "ProceedsFromIssuanceOfCommonStockNet",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cmpx_ProceedsFromIssuanceOfCommonStockNet",
        "terseLabel": "Proceeds from Issuance of Common Stock, Net",
        "documentation": "Amount of cash inflow from the issuance of common stock, net of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity",
        "terseLabel": "Proceeds from Issuance or Sale of Equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r657"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale or maturities of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r12"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r599",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r734",
      "r737",
      "r740",
      "r742",
      "r768",
      "r769",
      "r804",
      "r805",
      "r806",
      "r807",
      "r811",
      "r862",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r957",
      "r958",
      "r1032",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1061",
      "r1062"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r599",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r734",
      "r737",
      "r740",
      "r742",
      "r768",
      "r769",
      "r804",
      "r805",
      "r806",
      "r807",
      "r811",
      "r862",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r957",
      "r958",
      "r1032",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1061",
      "r1062"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r558"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r93",
      "r94",
      "r95"
     ]
    },
    "cmpx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Estimated Useful Lives [Table Text Block]",
        "documentation": "Tabular disclosure of estimated useful lives of property, plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total property and equipment\u2013at cost",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r114",
      "r621"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r558",
      "r608",
      "r621",
      "r802"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r93",
      "r94",
      "r619"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r558"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife",
        "terseLabel": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r192",
      "r286",
      "r287",
      "r288",
      "r289",
      "r339",
      "r350",
      "r381",
      "r382",
      "r383",
      "r389",
      "r404",
      "r510",
      "r573",
      "r582",
      "r598",
      "r636",
      "r638",
      "r652",
      "r666",
      "r667",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r725",
      "r726",
      "r727",
      "r728",
      "r730",
      "r731",
      "r761",
      "r767",
      "r775",
      "r781",
      "r783",
      "r784",
      "r792",
      "r793",
      "r797",
      "r798",
      "r805",
      "r814",
      "r953",
      "r961",
      "r1009",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r192",
      "r286",
      "r287",
      "r288",
      "r289",
      "r339",
      "r350",
      "r381",
      "r382",
      "r383",
      "r389",
      "r404",
      "r510",
      "r573",
      "r582",
      "r598",
      "r636",
      "r638",
      "r652",
      "r666",
      "r667",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r725",
      "r726",
      "r727",
      "r728",
      "r730",
      "r731",
      "r761",
      "r767",
      "r775",
      "r781",
      "r783",
      "r784",
      "r792",
      "r793",
      "r797",
      "r798",
      "r805",
      "r814",
      "r953",
      "r961",
      "r1009",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ResearchAndDevelopmentExpense",
        "terseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r732",
      "r738",
      "r739",
      "r755",
      "r1026"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash",
        "terseLabel": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r873",
      "r923",
      "r1028",
      "r1031"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted cash",
        "label": "us-gaap_RestrictedCashAndCashEquivalents",
        "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r79",
      "r113",
      "r144",
      "r614"
     ]
    },
    "cmpx_RestrictedStockUnitsAndOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "RestrictedStockUnitsAndOptionsMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units and Options [Member]",
        "documentation": "Represents the restricted stock units and options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "terseLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r74",
      "r617",
      "r646",
      "r651",
      "r661",
      "r677",
      "r802"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r108",
      "r109",
      "r153",
      "r154",
      "r155",
      "r158",
      "r166",
      "r168",
      "r170",
      "r261",
      "r264",
      "r275",
      "r308",
      "r392",
      "r438",
      "r439",
      "r452",
      "r453",
      "r454",
      "r457",
      "r464",
      "r465",
      "r480",
      "r483",
      "r484",
      "r487",
      "r502",
      "r547",
      "r549",
      "r642",
      "r644",
      "r663",
      "r1066"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing revenue",
        "terseLabel": "Licensing revenue",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r186",
      "r198",
      "r199",
      "r212",
      "r216",
      "r220",
      "r222",
      "r223",
      "r336",
      "r337",
      "r338",
      "r599"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
        "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r801"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrAdoptedFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrTrmntdFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
        "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r178",
      "r180"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r780",
      "r995"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1006",
      "r1007"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfProductInformationTable",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-1-formation-and-business-of-the-company"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operation, Product Information, Concentration of Risk [Table]",
        "documentation": "Disclosure of information about concentration risk of product within nature of operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r558"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-tables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-weighted-average-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r354",
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r389"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r75"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r72",
      "r73",
      "r74",
      "r117",
      "r118",
      "r119",
      "r188",
      "r319",
      "r320",
      "r321",
      "r323",
      "r326",
      "r331",
      "r333",
      "r477",
      "r657",
      "r658",
      "r659",
      "r660",
      "r767",
      "r861",
      "r925",
      "r927"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_Security12bTitle",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_SecurityExchangeName",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r186",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r202",
      "r203",
      "r204",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r223",
      "r750",
      "r753",
      "r754",
      "r755",
      "r757",
      "r759",
      "r760"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r219",
      "r222",
      "r751",
      "r752",
      "r758"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensation",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "cmpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cmpx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited",
        "negatedLabel": "Forfeited, weighted average fair value",
        "documentation": "Intrinsic value of forfeited award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
        "negatedLabel": "Forfeited or canceled (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited or canceled, weighted average price per share (in dollars per share)",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, weighted average price per share (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
        "periodStartLabel": "Unvested, balance (in shares)",
        "periodEndLabel": "Unvested, December 31, 2024 (in shares)",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
        "periodStartLabel": "Unvested, weighted average price per share (in dollars per share)",
        "periodEndLabel": "Unvested, December 31, 2024 (in dollars per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
        "negatedLabel": "Vested (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
        "negatedLabel": "Vested, weighted average fair value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested, weighted average price per share (in dollars per share)",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-weighted-average-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-weighted-average-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
        "negatedTerseLabel": "Forfeited/cancelled (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, options (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding, aggregate intrinsic value",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "periodStartLabel": "Outstanding, options (in shares)",
        "periodEndLabel": "Outstanding at December 31, 2024 (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)",
        "periodEndLabel": "Outstanding at December 31, 2024 (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested at December 31, 2025",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested at December 31, 2025 (in shares)",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested at December 31, 2025 (in dollars per share)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited/cancelled (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r359",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ]
    },
    "cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, aggregate intrinsic value",
        "documentation": "Intrinsic value of granted award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested, weighted average fair value",
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-weighted-average-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term (in years) (Year)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited/cancelled",
        "documentation": "The aggregate intrinsic value of options forfeited or cancelled under share-based compensation arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, weighted average remaining contractual term (Year)",
        "documentation": "Weighted average remaining contractual term for option awards granted during the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding, weighted average remaining contractual term (Year)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested at December 31, 2025 (Year)",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesOutstanding",
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146"
     ]
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software Development [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r50",
      "r53",
      "r54",
      "r101",
      "r108",
      "r109",
      "r129",
      "r130",
      "r131",
      "r153",
      "r154",
      "r155",
      "r158",
      "r166",
      "r168",
      "r170",
      "r187",
      "r261",
      "r264",
      "r275",
      "r308",
      "r335",
      "r392",
      "r438",
      "r439",
      "r452",
      "r453",
      "r454",
      "r457",
      "r464",
      "r465",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r502",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r547",
      "r549",
      "r565",
      "r623",
      "r642",
      "r643",
      "r644",
      "r663",
      "r713"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals",
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows",
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity",
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity-parentheticals",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-1-formation-and-business-of-the-company",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-13-other-income-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-maturity-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-stockbased-compensation-expense-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-rsu-activity-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-weighted-average-assumptions-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r187",
      "r310",
      "r311",
      "r313",
      "r315",
      "r549",
      "r599",
      "r655",
      "r664",
      "r665",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r676",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r696",
      "r697",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r713",
      "r740",
      "r742",
      "r815",
      "r1064"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals",
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows",
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity",
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r187",
      "r226",
      "r310",
      "r311",
      "r313",
      "r315",
      "r549",
      "r599",
      "r655",
      "r664",
      "r665",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r676",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r696",
      "r697",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r713",
      "r740",
      "r742",
      "r815",
      "r1064"
     ]
    },
    "cmpx_StockIssuableDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "StockIssuableDuringPeriodShares",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cmpx_StockIssuableDuringPeriodShares",
        "terseLabel": "Stock Issuable During Period, Shares (in shares)",
        "documentation": "The number of shares issuable during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued in ATM offering, net of costs of $0.5 million (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r49",
      "r50",
      "r74",
      "r657",
      "r713",
      "r723"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based awards, net of tax remittance (in shares)",
        "terseLabel": "Net loss (in shares)",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r49",
      "r50",
      "r74"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon exercise of options (in shares)",
        "negatedLabel": "Exercised, options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r49",
      "r50",
      "r74",
      "r365"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued in ATM offering, net of costs of $0.5 million",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r49",
      "r50",
      "r74",
      "r663",
      "r713",
      "r723",
      "r821"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based awards, net of tax remittance",
        "terseLabel": "Net loss",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r49",
      "r50",
      "r74"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon exercise of options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r50",
      "r53",
      "r54",
      "r74"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockholdersEquity",
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r53",
      "r54",
      "r65",
      "r678",
      "r694",
      "r714",
      "r715",
      "r802",
      "r822",
      "r925",
      "r928",
      "r929",
      "r951",
      "r1015",
      "r1066"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r318",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r335",
      "r477",
      "r493",
      "r716",
      "r717",
      "r724"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r566"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r566"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r566"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-2-liquidity-uncertainties-and-going-concern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierFinanceProgramTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplierFinanceProgramTable",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-details-textual",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier Finance Program [Table]",
        "documentation": "Disclosure of information about supplier finance program."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r280"
     ]
    },
    "us-gaap_TableTextBlock": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TableTextBlock",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-12-commitments-and-contingencies-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-6-property-and-equipment-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-7-accrued-expenses-tables",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_The2020StockOptionAndIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "The2020StockOptionAndIncentivePlanMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-9-stockbased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2020 Stock Option and Incentive Plan [Member]",
        "documentation": "Represents the 2020 Stock Option and Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_TovecimigMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "TovecimigMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-15-segment-information-schedule-of-segment-reporting-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tovecimig [Member]",
        "documentation": "Relating to Tovecimig"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_TradingSymbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r305",
      "r331",
      "r477",
      "r492",
      "r524",
      "r535",
      "r538",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r610",
      "r624",
      "r788",
      "r790",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r803",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r947",
      "r948",
      "r949",
      "r950",
      "r1005",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-5-marketable-securities-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r770",
      "r772",
      "r774",
      "r788",
      "r1030"
     ]
    },
    "cmpx_UnderwritingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "UnderwritingAgreementMember",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-8-stockholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting Agreement [Member]",
        "documentation": "Represents the underwriting agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_UnrecognizedTaxBenefits",
        "terseLabel": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r428",
      "r779"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-14-income-taxe-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
        "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r779"
     ]
    },
    "cmpx_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "UpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-11-license-research-and-collaboration-agreements-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cmpx_UpfrontPayment",
        "terseLabel": "Upfront Payment",
        "documentation": "Amount of cash outflow for upfront payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r189",
      "r190",
      "r191",
      "r192",
      "r604",
      "r606",
      "r747"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r180"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.compasstherapeutics.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.compasstherapeutics.com/20251231/role/statement-note-10-basic-and-diluted-net-loss-per-share-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
        "terseLabel": "Basic and diluted weighted average shares outstanding (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r180"
     ]
    },
    "cmpx_statement-statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-10-basic-and-diluted-net-loss-per-share-schedule-of-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Basic and Diluted Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-10-basic-and-diluted-net-loss-per-share-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-10-basic-and-diluted-net-loss-per-share-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-12-commitments-and-contingencies-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-12-commitments-and-contingencies-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Commitments and Contingencies"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-12-commitments-and-contingencies-undiscounted-cash-flows-reconciled-to-operating-lease-liabilities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Commitments and Contingencies - Undiscounted Cash Flows Reconciled to Operating Lease Liabilities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-14-income-taxe-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-14-income-taxe-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 14 - Income Taxe"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-14-income-taxes-schedule-of-effective-tax-rate-of-provision-for-income-taxes-differs-from-federal-statutory-rate-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 14 - Income Taxes - Schedule of Effective Tax Rate of Provision for Income Taxes differs from Federal Statutory Rate (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-14-income-taxes-significant-components-of-deferred-tax-assets-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 14 - Income Taxes - Significant Components of Deferred Tax Assets (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-15-segment-information-schedule-of-segment-reporting-information-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-15-segment-information-schedule-of-segment-reporting-information-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 15 - Segment Information - Schedule of Segment Reporting Information (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-15-segment-information-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-15-segment-information-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 15 - Segment Information"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-3-summary-of-significant-accounting-policies-schedule-of-estimated-lives-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Summary of Significant Accounting Policies - Schedule of Estimated Lives (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-3-summary-of-significant-accounting-policies-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-3-summary-of-significant-accounting-policies-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-4-fair-value-measurements-financial-assets-measured-at-fair-value-on-a-recurring-basis-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-4-fair-value-measurements-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-4-fair-value-measurements-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Fair Value Measurements"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-5-marketable-securities-marketable-securities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-5-marketable-securities-marketable-securities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Marketable Securities - Marketable Securities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-5-marketable-securities-maturity-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-5-marketable-securities-maturity-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Marketable Securities - Maturity (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-5-marketable-securities-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-5-marketable-securities-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-6-property-and-equipment-schedule-of-property-and-equipment-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Property and Equipment - Schedule of Property and Equipment (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-6-property-and-equipment-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-6-property-and-equipment-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-7-accrued-expenses-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-7-accrued-expenses-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-9-stockbased-compensation-stockbased-compensation-expense-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Stock-based Compensation - Stock-based Compensation Expense (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-9-stockbased-compensation-summary-of-rsu-activity-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-9-stockbased-compensation-summary-of-rsu-activity-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Stock-based Compensation - Summary of RSU Activity (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-9-stockbased-compensation-summary-of-stock-option-activity-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Stock-based Compensation - Summary of Stock Option Activity (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-9-stockbased-compensation-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-9-stockbased-compensation-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Stock-based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-note-9-stockbased-compensation-weighted-average-assumptions-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-note-9-stockbased-compensation-weighted-average-assumptions-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Stock-based Compensation - Weighted Average Assumptions (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "cmpx_statement-statement-significant-accounting-policies-policies": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.compasstherapeutics.com/20251231",
     "localname": "statement-statement-significant-accounting-policies-policies",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-8"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>101
<FILENAME>0001171843-26-001337-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-26-001337-xbrl.zip
M4$L#!!0    ( -<[95R]Y K]AA@  "@9   )    8V5L;#$N:G!GG9=Y/-31
MV_>_]BV)D)TL*4)A[$R4/2:R"T5D21)C[%.RAR%9DLB6W62)+)%];[(.QC9#
M"#%C'8R96[_7L_SS_/'<]^=<UU_G.N=UWN><U[G.19FB+ (7C/0,]0 J*BK@
MX5D#*!C@-D!#3?W/SD1[9G2,='2TM'3,# STC.>8SYUC869A83W/<8'U//MY
M%I8+W!?8+W)R<7&=8[O$P\W)P\')Q?EO$BJ:LS&T=$QT=$R<K"RLG/]M47X
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M"X>Y5A;JP-T9Q&OX FO"7>Z(XQT@&7/K:,HU8*:H;ZV@=+]'?7S Z%K_'JC
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ML-$5,%X1N)9\?O$8BJ1':TD3B[L.V?LKUN$S(X6MGAB'CD1&K5>^/_ZV5U(
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M@^BNJ.;']XW;7<U_":9,_Q=02P,$%     @ USME7+I2H/(&4@  6FP   D
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ME'I$RX70I2=]'F-HUML-F\G:9TEN"Y""WAO>4;1_E"7^3B:./40JU"*\BK&
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M\M=S\ :9J%N8_%KL^P #?S#8Q1@$"?35=_1PPH.I  8 ?P 8_^>"]U&, 2
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M&_AX+_%^'X>_"(%;@+_@=,=5@N_G%?&9X];1"R4\;E,=B[G[A\ $C@;AKYL
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MI*;Q8S%\2Y'C!U?!P<%"P>)"8']785%965EA$3%A,3%!/(9@0*@/Q"%$T">
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M)LNA[UFA@N]S[]0^A'Z>MNT?<33<:@&SA''Q$O+N5AC'/Y$I686A6W0F:G"
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M^(O7!=F5M2G?AU5+*G6JI0<YO2"BARX+Q19I%TQ]"=Z]NQ(6<?:KM6+MM+:
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M(N?X])1P$<O[VX_J"SD,=8SB6^8>2;;:GPKKOWDJRW@("&HAI+E%OKKM6#$
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M]IKHPM!U?P3S'#7Y>&6K\+<"O]'[]>DPA/BV_.I>6<3LHG9C$TC^JUSK QS
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M#ZQ<&%]":-D6+LOY\D':/\)&7S[5-P>@=X#QX[?M&VXSV=4]J-<X%)- G\H
MIC#@88$T7EC0[XXH^&,E/'S&+[Z<9^YVH^/@A*D?*&MY1\R5/.@Y.'OZ*A90
M4RQ@?&-AV^5GG4O9:$1SWH!/C>-?0/,#9A$/"L^[NW7TC<.?D@,J2)HD93 0
M&$.?,&/+W6,S7C#C'R5PA&T\9H-5GK5B/A3W-\L<$ZG_;**E]KB/0W9C]FJO
MMZ>=5! F!JAM"CX)1$Q\Q@?0.*A1&5U<9 FSO;A,E*VD[*=C%NRZ>EL*)<_]
MO+0;$GZ?U5/! &T27GO4(>ALG(ES1JVW';1FFG+BLK30DFM,T9.Q$X,#Y)%Y
M1F:VQ-&@-4A10H<6G5I&M?RX.0(JQ^.EB&87)8^G1\3>OC'-;#[8UMO4 .IB
M][3X).Z&4,U9D=RXS:AR=?22)7U=F7>Y0ZT0Z6D(91S@,@%)U1OD$:(O$# 3
MD='N/'1JD4-$0.SEGES(7_?XL7;2A!?8IHPEA1<M0OZ>2D@WM*M O(5PB?Z;
MSM+DCPUUNO5FZ,_@=YT=QO?[ZXJU>W0U/!#6ZA=P^O&QSV."QVVWMD!VJ(!M
MZ</PA_@@9<F@E#:-TJ7&E:A$QDF0'GV?.8'Q4=V\P]N4J(=BI'SM=<>2*SG$
MS6O=3YK"QXR:]3SW!"YM&\2(GPL>C">&\#"M+7<J5BKFDIY );^J>&P,'4>6
M3\OPAH5Z/"%&J%X3I"]<_%XEOWD0F/N6Z^D@NR?@1$+W/V^PPI[X::3HV[-V
M[]+W=P5IM3ZN>$-KKT8C[8O%&$?ZX?S30E7Z""JJ&#<6$&#Z<6GGXPI:U\%'
M.4;L]-'L9X>?S5S+.Q)>\/M4QXK68S,^8^ONS8*!G 7>Y5^,H_LI=.M]2GLW
M?S> TKT;. E=X.[2TU&][@MVXI!,,:<O?<H+(+!375P7)P9G%E2E5M)=8E.I
M\.7@V%7P#S@.TJ4LI]^K-(N0HJ_#"&N0@<<$=[+VT]FX&V;EIV MLSWS4H%,
MY51^UIQU-YR_)\ XV>^$?1W5[!,J&>'UFG)/XKN9DF+D_>3P]1Y7B%=M9(]K
MQ$+PNIFLQ8F'=HRXN;!P'L0O#)0S,FKA5[5&5;_4G0)T3?%ZB!CBQG3OWMJ_
M?!+KZ[/0(FX>!W+)R7?@#ESF9>KXE/:Q?IVFN.OO2R6^-R'O+R4/^$*1O;XA
M1]V2T&UMB_F?$#%2E?X-.[(Q8\)*6L>KU@27U\8C**C8X<.D S,H-IKGCT%S
M9[D3!3ZPS]3; V_*U:[<3ZTT.3NK*I^IB#LPF+W0_*$'.)&6WYD\7D@$,8A-
M>OP3&\,U$Z11_4JS.)&/ O."\]<6J+K1M?]-H+/#M*8U'[GM^VV-FHE2J"50
M2)2?%#F#W1"NT\R0<4O -9<!]P8A%[C0M$Y]\D>1&Q*"IP]X4LV^(>XD51N!
M#Q.J0TZ>!C]X^HM0')J>!.BSF94A+%L%C*Q$6]77KJ4<]<< (4([2IR7W SK
MWI/<]@G9MFX['';N)]:SGFU%*&Y3RZR<:*SIDTF\0$Q+J+$ZVRXT'[Q\TK]J
MKO?1J('&F3R3-712:XC1GRW?]P1:J8+:_9TC^AW4HP<?&*^?9&,&O?DT%YO.
M/8$WLM[\*3Z:O5I(-UAY-!#FY\Y^A58[4]5D^M=F^M/-1W;'C\544J+UO+W#
MFK/*!]K.*X4"I>7NPZ87ZIWK->R'=TK*5_"]0^Y?KI,QUY1F:5<]VH<H(A9,
MID9R$YT![DW:/T-S/O),0]QS^EAB^/?-,ZD7G:&6GQ3$[(.^QK>T,C0>P=YE
M68\8-DDJ.VI&RV.V$64,)L)FV&D"$N@-=0A>?]S^P/3K9-EB8)H8OYU5SR!G
M@L%)#$)*4S*0Z85ZU^YU7+;!1,H@UKFK^O2GOHI378.J-]YYPEQ)U9O1"=J&
MV9-G8G\116O3:)-+B-"J;3>3E0LK(%D".?;MD:N7:9\>\"N(Z=0YB %U3\#
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M[6BD*%N8:EW60[NOP[9-MOFTL[[IX]"?"?\6U?Y/O_#_M==DY'\ 4$L#!!0
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M((_#@SBT>=1PL8%,#@_ET&92Y?H!N1H>O]%QS2%7EK!M'1H#1;>W PC?_V*
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M.70"A=DT QS01&?FF.7Q0'B:)YO163^#"4</287.*!ITTA@Z( X4&K9"A9T
M2.BTBBX7>P+H<G#LF7^;U712EM/@8Y#$8@I&LG18(7P:+HM02YH#DD;!(Q.:
M3E:;$0]V9FQ[.9VN(UNNI]./S [%U'PE&A-4C:,2C;0KA98J.+T7,^5$C/][
M"W83T,,N$C6<TZA(RGA/(FAETC9>T0GGTODH/6&QG5V+M='P^%[\E0GJI4&M
M1-T.]B*/B%8BC1]D^?8\)LD9*Q[RR0,K\L]2X9U6^FXW#9OXT![ &=[8E'D#
M7J.639JWAZ<>3F=X3'87CG!AL@?>4= Y+!"]Q/IK;H>.RJ<@*Q8+PM=EX>/X
M,8UG<2A8"$@%:))V^I(E<;@7809Z*EV&=N&J=*?3^RK>5U%5S12OC^*DD$KP
M.6IQ_B1#YC2223^9SBKR#?AX>T/5#=TDO-;U RCN\[7P1@02O"8+JKSD'-KM
M&'AQ>G=[X^6'AP4#U9<D^M@!D(-SL2^R-=V_CD(I]];V=JG?(KW4-->WLDYI
MXUUZ-?2VW+LW%JJ=ZI*+0FQ&N5AJPH6XB)_D7YERHK1WL%S/Z-MD9S#><)8R
M&?>N $[\M$06[(X)E"WB-(R%F:L*X1D9TW9%C'ITY\GZ7M"AL%TT>N+@2%*E
M7&,:/8^'(Z<ZY#D)7.YX7X5^R&[OOBK5"*B/W0CRLP^ZM[8W'FAK]%BKLUV^
MV"S_1DI]O?WSC*YHPLHI5,(^E5]*N[^;/(7JPMZFE$7[#>G'D6WQV0B?C0!>
M@&TCEL&ZQ@PP"@SCC>%#\*EC*+(>UAC2%)T9GP BF";#&UV:1N?3,F"D 54J
M<OBI/TSV$LN7AH8*T$%J._+;T5*V^[G=:3P-LQN=KE-OVON@:77,':5^,V/"
M]-)EAM:VN\EM+0>(;FF 3?C:(Q>MT1^4*P:9ES02,Z++3 'FTH"\&CJD:U_-
M> R?-D>H,'P&4TKH-@!=N%Z'4+E#J-X/P8S$/%C)$Y)"#$3RN=@_X0;$Y;6.
MXP*$!R3*(^X\XDZ%L9*E!T](^+LPYW;;NC*G!.AA%U$EO/U2)^4TF\[.Z))E
ML1HO ^AA'1,FRY>0Y$8L?W[-\JI( (UD48_Z@\VMX+%^ UKFGR\E\IV>T8<<
M. M!?3Q63@]/)/:3LII 58]4S)&]\I1?JATFFJ:W4MI<5LLH3R[P[3]/2!8K
MC]<9']^-=$[6NS__%HL=FX?S]96,%2K2UGJ=7?'UY=F*N.#TCX*F8=W>U:&G
M&XZ>%U@K" 34QPT7E^FRR+-RDGQ0P_O:>SCGX*,V!Q^1<?!)FX-/&#BH6Z%*
MY)I&S^/AR"V>MX:^[/5VH<UCZQC'S26^;[JS<&"J!-#5+D]5N3227*;"6BTD
M72HK0=W:*N5?6$K756&<BR*-U"Z&NO$Q80R-TUN>6IY1+FW\.\I7L2RN-YW5
M3(5,IN6S^D=*%3#$*[R,FE_A5(M^O;OGI1)< \,#[1T\YM9C;@U *]MV-V9#
M8Z$4C%[$@QDQ89$+HC5*TB(%I?N%%'QK/NA7)R1H! I= E;G,[>M$:5O@ ID
M,/S:P "K0;=&P*'G42R3]CVA3@IML5'LZV3(S714,-!A%PTD:(%NE0QB8;X
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M?>6OOD*?B>G(+]A'0I=!Z7G75XM9A#3ZWT5[^V3 N),!W;P2=%NO9FZ@>US
M8;S_YX"$H9!?%-"GI9CEVN=ZF@=P$>-OH\9']WUT7W6:I[HE*+LA:ZF?Q"*>
M5--I[[@B/%#8<S2?U\ 4KS%/;[%<)C'E%1:$BMWCD9.%,MC7WL-'G'S$R9#=
M#IALWE0?OZD.U2ECM\Z-;,8.#?5?@DS>2RH#'Y1G)7HE7VO:ZLHQ7)CK ()@
M%OMKUN4O_YKD]W-:X;-J,T_J1CKF0 ,!-YS* BXT^HUP3DK4V"E+4QI*<4I
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MMK,3<UU!B;?6O;5^U-:Z^+ T$^ODE!5ISNO+*(':>A_#&'<[HB9%/F>\?@G
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MA6$I0#$%0<:<B2&=E_90N5FM[=U3W_*)0'V\6^/=&N_6('-KVG6/=U-&[Z8
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M,_BKG%XC9CWLN=OQ3>,ZC!'D<1]O#/<!N[ZK/JYJY(P25)^^)3@,()QM>98
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M+ H:<)I10<F\C%>&+!$6->-5D)%L\_A9WY, AE[G))YKE/9>9P,F)U<G,0.
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MUB0+LLV]H0&;!72K3.6S0,S2\M<E9ZNXW)/$1'W9.8I%#YX%4IC!C(J/1I)
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M:;3U]N_FA-,38?%$^PU.66/U_2%?Y<OJFN)H;U^3]JS0*Q/.9=Q'!2#5[H^
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M-HGE<2?_/:-U2&JWN(=N76K;S6,MH248WI(H6\*+2L/LGU<F]; _T++\B71
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MX7*SJX@,0W#-D2$\3:N714&C4Y;L>Q=#7R/,8+<9U^*]3T]'ELVQ8KQK3I
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M9RW3XY?'1!1Q0:.2GE'Y\R*O[R;F]W75J<4=U#2.ATRD?@/H9!&JA)SOJSS
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MQ5-'30:^0FEM3/NN6-H=*,/Y9!''A=A)9?]-X^:L;& [4_T%S)PRVK"':E-
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M&>6,RVE]8>KR+DOO^])9*#Z-L1S#K7JQ%\/DM17(9D\0MJ$EWUY_FTE?3$T
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M#6NX%7\GY[7&XK__+5O[ +NM!]L2V(5A97? M&>(C0).IT=-PT2'JLK1V-[
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MKLC;T*[(V_FY(OO<GG!%>ED85,#>:0O8.V<"]BZT@+V;GX#M<WM"P'I9Z%_
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MQ<F'DY0M[@LJ-IR'!7/T08Q\]C;H6DPY4<*IDI8L7EXMX;=RI>B@6P%D>%Q
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M,_PD]K#GL$5?NY4]I%$I#&WT +'_"(0(2%D3Y349M^SJC&I$*)@&GT)O\;<
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M3EY.LZ@L;R$:>\@H3;^!-4G#+3M/<P@$CX@@V$EW*&@'LDH*;&8(WOESB #
MY?(7N=5Q68C;7<WFU561POJZ_K*LORW?#CE-)FUA'2L,35_+7Q0X5 4T/UQ
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M047D9:;EX7C$=F2DLKQS]Y0<#T7;H',W4QN$1 89YVZG]BP$L><,%U0^(KC
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M\P8WQPUN<JD8MQ!!74%'?I[B]C*),R !CE.L?$>Y8\$%L)":"<(9:-08!ZC
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MIIBH>4L=)6^ZXI_$#A;O__"1^6U625VRH;JN(ER]AX&R]@\"*XYJ2.%M0^1
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MNG!<04B;4Q,LD+@2G*'(>\H"@BM!&XHXM1#27>&H$85R6,YS/I3#G.VUG?G
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M;GW<K?D0.!<#!'T(G#P$;@B)<X*!<P.XKR886-=1>IQ@M%V?MLT)AN3U9(H
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MT2B0'N_"V9IYAH(G@,P'CC=X7Z9B:(8SOYO/.-STV$C9DR-J?_8^_#;78%-
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MW?ZXPGTOCI4=VF(8@H'S$['L!] F]%X)QA0V6B'+ \BRPHBPOA#R+81(OE?
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M&$4B?%HQSWR9ZG4U?C"]ZM3KQ1T<+XH[^:F>!+QO>-+N#_&D5<;6'DMR_R[
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MJQ1ZQ&E$=W1\(&Z+.[S0%6E).4FF"<(-(/6IZ)":405%@0<CCV)Y@P0\$#S
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MTD/-@1,=*() C%>UF\;*JQ"[0NQ%\&)E6:"CP&C98&=BCVOE"M#H!QCJ14$
M"JQQ3U!)&*4:4C*B<2M,).'PE%J2.2^CT4SO.FZ$"K<KW'YJW'9=4A-99;H
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M^?+MM1IP3'!L].>(IP/DO;ESAL+K8=X:G<ZHKE8$*C(8FHDP1JQN]LB&L)3
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M,HC'H$Z [I"G\MKDQ:M4IM[@*^\FGT"7NZ>4"I7)NN8K+;#>T#OZ]=-[>.D
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M>@V^J$-]S6PJ*T]4Q64K:+\2+OORQ[_^T*YH^S5!>WEH>XDTJ-?@B3H>=J-
M)L-*?:I8; 7MU\%B7_[XUQ_:%6V_)F@O#VUK]>G/\*^Z+_H]784]\QKNOTVL
MXV^/O(@[GW]!5WTS\S]]S?>G[L$G>=#Q4GDCTS$[XBEG5^IF\D_OY8&]HN<Y
MUK+@K<^ZGKTGXR2%V?!J>GT9N[K37H1Q% 3"+US)CC?*M]OJP2@1^0]TY[T7
MA8GTX2^?B1L>9(@L]][;OO0(4W9J9S(4[.(RP>W"Z0UAM]TQNSP^/+VZ9JU&
M2YV%O=@R4/>/LC2"TV/GEY=X>IN[C>TWM<)QBL)!J_-+X?T!OQ'P'^0$= ^]
M+Q.LWF11S+HB347,;F4Z8!P;LP:X-!FR-!OBSUD,ZRXL@!WIMP]AVP!?=@ES
ML+='AY?O<!5[[3<-VEIQ"S B#P)@(%FLATZR;CT=C^!@U7_?2AB.#W0DVM.>
MU,CCL2=#./8:@W.\_X$^3-$-N _XPSP>>B)6Y\.'HRP(@"*9??C=^B%5IX>0
MY RP"5Z"HPZ"Z)9E(X0*'XWBZ$X.L0WOF+7:; C##X"Q(]+H%^")?BP2O.F
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M=$QZ@.CUI,>]L3&8W2WC5_8X\&%G^WCZ6>)^PP-88X-U6((+XT7/AUH(+@G
M<2-]-/!1H.X_*_Y,V2V/X*/M23[:?E5\="$JEL(-M%U[60!VN/6/ 7%ULGX&
MLK#=;&\IRFKM?,AIS:%BTE?;^RU&AC9BNB8:!WE'01%7WX8_M5JM=TB*DQB,
MOVWOOE.$!!2'CDM8F#^*))!K :EQX:AT(VD060E@2[[[/&K37I#Y M7P&NC:
M2OD&N[]A)+LB=G(..9MR=N$N$&E0>R6()^"T,K8FAQ=E@<^\. (Z1Z\!#D/+
MG7D0/!XR3GX2U]L1A05.1WL> U9(4(:!D=&8"E9#Y&%>#)('3L3JP&0RP D"
MT_%_1RBJ']"ZB05/]4NP2EPD'@M &(;N"L='ER7D8!O0L7R#Y0GTG.%W8/)D
M7IK%R+&Y##(XN12V;]TBEQ=7)]?6,P+K'43 @#EZX& 2^!>V!X8/@ ?644^C
M.BT*+.I$)LB_?&#5$K$0F!9L;61YH04\L&E<; _-;QSM]O:V@8Y"3(*@)Y)&
M/[IA;T\1X65/PO&>'5ZSYO9V<V=O:_-9?6V5>V:O<L^\5O?,*<@1X.$!BI%M
MT@QY& )4T-]"_IF<II&OR30I9?G(Y'5$P-K[Z';!WUJ[C=:;1ZF.-2T4D)>A
MP(%'1X%(A1V[1E_Q6,F![<;F&UI!KT1:U<RZ1G7DG+2B9J.YV;J7Q2R+8D5:
MLJM8.5\XBM5# Q9P?/E<1,9_7W 5E42EYO81+0OX2 W>G-2+-U^57GQ?ML!W
MI?PQ%SXFD/T/T(SN1F!6*L40G:^@6OD2V0OPKC0:U2E.Z6.TO1='0Z5M*=>M
M=)C@CLM\')6O7@QPH:(Y&79:1;?E##=+F9,%3NGP\GZGREKZ5$!$_C</,Q1Y
M"C]NA5*V0]PX(13(R<[5X3G[^53CECDT.JC=CXGQI& (P7HD+/*5QSL*+A$\
M>=+"'38XD+%?)TS$('DZ4!B>B#0%W$T:#N@*@1!W"5QGH1@I&4[S8B/&M]^P
MMVT6923OMYIVT>^08$#7XS=P^G@P=;-.\T2- OGP%MAQ0\HJ@*=N9)0E\ +%
M?LP;M(@N,'Q/_B<;\BY[^W^W07? 5Z:?2V\C-$^'46P</Z1.)CB3,\8[]R#
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M5^7O"L<YA^E4=85G3MS&#CI=_ZH!!Y.!"!]*A;:H6"..WI+O#I25;H0*-]T
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M>'L?,EO_X2*(9]!&DK5^=GKZU8,O[R[^KS$,ODM?_U/6]-K3@0NNA@ZWS#Y
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M.Q3-;(5XY=Z]KZ>#KRT9>/=X\2.5>Y@]L'!LY+;$3'<'E^&[<ALZ#<+I471
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M7C8K MDV%?;BNYX;%%_E=;,I%Z^.3XX75 )M@"@4LP_!XC<E($!,>:6YO*W
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ME"_MR-Y,4^P>U;%J'2"HB 9K4ZRIF86F(N2]]&BC9)1R<[%1%>UGOGRFS2M
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M%?$"+RH%P'E7:O7MB[-/[MZ>P-L3^)MG=JX[&]+R.*Q+G5%?C.-6BFL[$7#
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MZ%Z.%@T7O(%A])@7Q$@4B[C\]CR[[DQ]EMIRDIH7F^GT#GIO+06N\AU,('5
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M%&(]+%ITG%TI.LV/YTUO2C<R=@UF@'G?N\YQA04[R!=)C;[W"@"M5(BXTUE
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M,Q#\-2BF'^MP,#^E]#SIMY^:MEHOOHU3F%Y&,BY.\"QO7I+G>4K4Z7''<\@
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MDN-+K*WX(A5 KWWBBX%*V).)E*\O1H0_T@6$]9GQ4#W(1$+3[2.U+2R"<D2
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M'3+R2U_<I+B UBU:*?=*VJU(*UN0J&("J&LLW58E-9:&.\AH]=:&PW&W*Q0
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M>K'0Q4+?>D.:-<V(SVOCBM5V,)RDA()@^A&#=?;5U@E*S(;6Y<XAJA]!ZIZ
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M'P*OR =H=POX"!.2B>2"]#6>#"Q608!<NC/*FNPV3?H$LF7Q .2B,T9TAH6
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M<S.Q6':H4I)!2?Z*4=FA"(1BH]1^G@DI9)=<9=/)RG-"H4)90Y1H8H@C<I?
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M.>#/WHFP9-MS^2X-J5(EXC+P"2(*_< /ZHQC?QK;83FSK R1<T$O[X)J58=
M;C F=N9>)7^%MF7%AL]H +DLNF2F\1G6V!802 WWVJ6A2]9R.F+?F+;S&_6<
M#1PH=2R[B(6QZ7 30]F$T.G#PS!GKYXF$&#H=RY7WW"047K?;BHJ"BD#4B0-
M"/G8J'UXVS8>LZ),&*TEC> A'EA%;?0FD2VE'M2TV_U"_OD9QZV5*4GU$6M
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M@V^RG'EK%^&MA>,+MGO V$0.$1TE)XX2)'?'D_4&@=(WD?\?8<H6K1=\*CP
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MDGU[4^I@TLP0NU+ICPH=>EH$SOYIQ(_GS36?O%8%UW@.FGY$V4;[=DNDY:3
M5R2ZVR/:&9[W)"7PBC48:>9R,"_%+![174,255CQ+#O[$08([%B6S%7Y4&F(
MV^*J*P]>^!368?:(A^CL+#S\M3WB[)[5:1'I8[HMG!Q:79?U0,LR>C(^KGG\
M,4Q8ZR86MPD668ID/*SX=9"G(K](' 5&9OC^0B%XF<IW]%([F@R0>I?*8Q;(
MWM>R9B8-^,,WUE5[Q#&M<D,60K6<[0"^2%[1[3I*>0GMW#A89E0FNWWSA]*L
M.7I1R]3M+&N9O*!B3*+%_H%EI7"$ET0]*E:-LU^TY<89'@;Z&X3;F+RS@Y+_
MP&ASCTBKV,)F"O%@=N3XXZ!81FZ:XUX,12@<!,_#$K@L0E*([F?5P)/Y?;1.
M@K9Y&:?;YXNBPNV?.IZZVN $+!=N1'6^/94XFUQV'=+O'K3*LZ'G#0IYJ#V?
MCLA&Z "&WBR?S)//6"U<I12JP:NM,'FBV7P32_&XWTBXC!]RT>%\EWC#+S]=
M\(;O'][P =.A[S,5+XFQ8@<!$T+R[1!=_ SAF]\*'[+6#.3XQ?1<G,"6*Z51
MP/TQDV](:J?9O$8GF3G)_#)>0L ND\#A5/^QH4SB5<^:IEJH[U77E'(V<>$J
M*#IZ-W'V^,CI@+:0+-^&#GFEU60AOIB;H,7Q?659X;(V<PS%-_W(WO!86K1C
M+!JCY:H&_X''/\4&<L0_;V<7!5-8IC\7',4O9?E&J@PC-'\=@F=AJN"RMC52
M$?J,=5PNU<L!00&PY 0#& F"*K@8,FY#!1^YH-X6@W]8@\<6K>NT^@2&MZLK
M]LPS#"V+$2Y&^+:-4$,S]T;4;7;U@-1!=/!_E=9$B]5F\'U[P#-^7TGED*:C
MP501AK88ZV*L#SI;,M1@B1CKD^MD;3JK9X^T5]7&I11=6O)> ,"+53X\ #C/
M$$%F:F5+,3O#W-? 20(6CR/>DE&=96<$/:?,$\HKA&"$7FK//JK>,[<8=LEX
M, IKKOU' //E\A%LG":IQFW=1DK-_T7ZF1V"$+]:?9)C&PPAV!-#T8;EJ!=2
MS7X:JME_^P/^TB.H'6G5[0>"T$SY/*,>F*1@1&$G9'AEIQA6BBBL5!-:>^V:
MJWZ/C36XQ0NT^^$0V%JE0H% TT;4[?%B'%ZP<C#)6M?,;DF?&[$0SO&/Y@$S
M:7LIR,E/V ,?;U'PA[UP!MJ^E([>Z (*4.N.KQG\3/+Z8'U[Q)P+J* O7Q/L
MN#FM4/?7"ZN9=B2IPP)'>L 69(BIE71L.(+O:X:#ZZBW,Z$>8PC L/9]*1W>
MRF\ZEX+B<JIB(T;T:/EMC9@^^ WY'JMV,XH)8?5<M#@@)V!R\V!MY:IQN&T0
M<8=0M62%J3#+H?>6D0>\%D@]2VW8J?%&OK@L>Z!TQZ_QYYC+;E3,_2GHLO?R
MPNGTR6\??%L9(>E_N8I*NS=XF11C;6@2T2*.V(/NQ:TJ&3Y\?%UA%UCB-A'1
MS)26A2R/:1AYBF7Z,T%(.4O@C8NHO^:EQ4BG8ZU:1;_[Y.M_/OGD]T5 S:+%
M@RD0XO/8>E\)"+"GYM&]^N+D6HA'_9RC,K^KP.K11INQUZ7]^"[;CY\M[<>/
MHOV8.2^_'XW8S.]X+C0KC$1\TZR#I?-0"#?')U@X()=FRI*3WC<GO>]1(I@Z
M7UYU+M+D!AZN+B/:D!NS?L^2R\6:/WQKSO&T;QV$M@Q:UO*(Q^D!S 5,E'_O
M3<#3NAEJF7U)DCNBX\0H-__Z8NT:MZMZ1@#68<B7AE\\85/>5^G@96<L.^/>
M.X.B$C )ZI<'\.6,/$OL'M'P,%8F,2'?EMW61R$;G&3SGM2C0@%U<C55&?$*
MER;AL"-\JS #S\L66[;8@Y3W(\@\!T;$0@I)IY RWZW3;*'@9JIK]]J)5)>1
M'&(Q^<7DW_FI,A,C30N3D6Q,XB0D.>EOL-RQPO] -PX'">$4%TM>+/D]S8,Q
MSYV.UE-IGRJWXT.!)H(FRF&+@2\&_A &3G:(_1"6;<M;Y*R6K]%U,VI&-+K%
ML'QII:ER&;534,U,<@O97F8OQ0^+]E_8>'.9Q=DFKB(G;!=KP?(LV^F].B]V
M%76G>?MLXN1F%_H PAU,VS =-3>HBBXFU]+NO/VCE<(QHCJI2;R5%ERF9UR0
MAV06+QNHF0E0W/MU:"^^/WOL74$CD$..\2H3\(LEY\$79! /D8XW98[3]#%E
MW$)#0..@9L]9#Y@VSJ?%D<B$E4Y)&0Z$G!1Z,3,\+6-7-,TNI$$* (G$P6=@
M(,PGD0=?2'ETNJBJB,TCZ[@F-WN>TX#_SX/ F951W,Y5!S\5])=R:S06J%Q]
M*]+"-S@M7!-OS=QAFJ>^.7.FEMP8A%.08--T?-&%;SUL<\@;>:9VL@JRYJ='
M/L_FXINZ<9W+X)2*L%;$62>>UC 8S!#F[-R-ZX+\LK*C&*X9%N=._SQ%818\
M)W_#I1WG>YYM)*.,;Y1+F%<$&)$F@>N0S9A5C7=$O(=BEM-D0DE$?'\1Q78M
MVKX(?'WZ[#DWH<158._*TN-8I%KHR[B A7_G <&R.GB[00BU&K!,K4B<!^K*
M/A7HG([,,VE)CA#@D9OP+XXK!!HF>J4!A(;.9:BO\*TF/ 97D8BM<]>H$>O>
M8 TR#A4%W!IRA8@BPL80-^&/JI!\H*<8JQ2GV ?/6-J4Q(687BM29R61]\O5
M*WKS^ BG4<+ #ZG B>J G;/TN<SP'T'_!F]G^N(T<(9%7(6+BS@+W =M=*'.
M5V5QO"L/VVY*3QF(R-&I&,%K?EW_&R4@</V8(U>0=9>K)^R'&-"AO$!^XQHP
MIU:?>H0\C8C(0#;"Y_$93.L'OH<, ]JD^B@O,Z>8G7'M;(X"\!OEG=:6.+:!
M34N4-VKLPGW#8\PAT*"7--D861<W%Q0TE@55N ]3'J) 9-CC/<-/$<>*!2JK
M\'DV<OLMP,H+*/#+SQ=0X,<*"OQA#.>.J=J,%\C39^#!,7A"D5Q7$H>ALZ.0
M+<62<_-E"VZ,!R'2QHR3E@KUQO'L"LWQS<FB"QTF'R7^VZR6DD9T&2C+F)&1
M>-VQ)AA+?Y=A3L:&!17R;=4M)D5,&$&33G"+0V,XTS:4G#+>GSPR)\J4@R$Y
MX&:#AS-GPRR ,.(KRW*""!<;G,>&M)6BL::*+V9=P6)M]D)11JN7)2@SB2[-
M(B;9-EAPCSO49]0?))\I=T+%Q4EB<.CP!5=V$&YG6PBK=LI[BH<8$O;K3T8"
M+**/PS9S7M3>7A_K5_BO8+U@?C=[A#)-=! P^:*S%7GV:/"7VW=P4VI/<%+#
M[KT6NZ"+Y98@&B(>J54[>!KIZ8@7TH5SDI:JY]B1R@1D'_&N>\>Q+1&0(+'?
MY)Y#A@.V%B F3(.6E7E8VPRF"-K,9P  :\W,E0S0Y/BZ1ZY=G#H)KSFLJB7G
M^<!CN#SY4)@V,2^;/ 6-A;#G2(H<)L V4QIIP\$SF2-8;DV&FW8:;IF: !\@
M/\H_J!<S'^?K:D8O]S*IQV7\)CER3:AA/<3+6;M-YI/)J]-NXAH0_A3+'(7'
MAAN IT**O3,0J<H;5)0!19$C=R66H#!;3QPY1\!W7 IZ,"*NU*>S+L_><DHU
MB>(-%7,ZCCE6MTIL[NUQ\S@W @]5*OVJN*[1DA2A^E*8XE;8#A :E;53DD=P
M(.M!DX[I.)5( PAA$UI1L,58"QA/^,T6&:N9V"4I"P\-'8S""H$)E*TZ\-2^
M]"?ILT*Y0_^3YM)T+#HW-':/@$K8QV@J31Q!N#D9*.M124EG,]@S(XEEU;O,
M5%8^E;1+HY6M=-3N4=KPO>M8&+,)J:YP+F'ZW$S+2C-5VID)F64F9NGMWE=E
ML&I,3>]^0.GRCA9_7J>!7#*<TARR$@\Q.B ]_"3:6.8&EKWPKG .=[;K@.Y4
M;!REU0$?QZUNI>M4^,(YU-S=\MO%_!?S?[='@:989U',LQ%+P#=3=2H42*1&
M@&KG%2IJ+9#GQ;;?/]=NNF.,I8E-V,5;+Q;] 5ITTS87-L^4+OPA0'=BP06+
MBJ+LHSB).2^_F/EBYN_*S,^:M_;%[@@P9M&U"!L^CS$>?_H<R)A@.0%DW+GZ
M]!5<?MDFRS9YR]O$2%N;,=B C3/0,G7AOZR(TX[@TX+$HU8WW'=#97)LAI):
M4=)UQ@RW:@S U][IQPFI-VAKZND.A'13,>)5MJ.KU?E?SY(6<.&S!_JO@&C^
M0IBO":TGG>@@MV%EPQ@Q$,QH]8MJ\=2^NQ](NIQ#1_.&:LJN0]7B'#NMPJ+A
MU\$VZ)6'"F=LKO^B52>]V3L]0V R"L!FG0506'/E?RVJ.0 &?UM4Y@+&^_*/
M"QCO8P7C?;^3;8Z2ZQ'B-=68# WR5.</M6/1,;/^.=?J2#_0;'][:!G?-6F;
MPTD.GDK"]!R!,J&!.Y>X$P6+,^H-1\0(]JS):5*QY#\5<ZWI%+<<8'0*8+XO
M;ODFBU&WR.0/O->MX/-O*M\-1YF#ZS/0B"O4R&J8:?=*1CT#SFZU&PA&M_)P
M5J'E4#AZ5;=K>!5[5]:(YF1Y7L7][RL"J_. AWF_D&BY0L4HZ4PZUNUI]=J=
M2#@74JY]=33W!=;J6XA*ZR+8XPW.?^@;;V!A:-!I"R&MV\8]('JY>->R%^AL
MYJ-U6\C);&R40V"9[9!(N&4\9AUDVOCA&G=%Z+<4[VY,YA%S:YMQ4+4B8@.]
MKN!W:/=+]()O)KP-Q$J@EKDHU*)-E4CE7#F^5(;JVECD>MA>.:4G94LD.B)T
MXWW9#^@;"N,GE#N+9G)D"B=$PJ'&,+)*B<W),-$<@^7Q4Q$_GL@5G)3+&_8'
M3MLI-(A-EL&=<>PH&BT__KD;D9AZ!:<N1-O("MTHO?436 Y6HZ&E[NGEREZF
M+2L#.JITPQ:-R0;<*Q.3EU$6>$0(;A9;5Q@]YZQKH(?#3P;HE^":#6$W0@ "
M@;K!:]$:MEA\V<2C0S=8%77]8'?!LU1; 5(; O;+U:W^+-PI)068'?BZO6%:
M<V2'CX'QCO6:)RBSX%6T:AIK4=OL%YC!C5^/H[O^0\B/V>3CCV;6-)UQ'JLZ
MIQX&]>57[DV))W9!\H82(GC$:*.AU/S*[8;"!_WBCY#&GU W [8YC2/#&?D]
M[#T,*CXK5I]_^OF7O%-^O'QU:6\3>2+]?L#ARILF_(A8(0(>!>=N3^OP9!,9
M3;+4/0NE[X:N9M'D3FP"7Z4[X,'@Y.J^;X_Q[]&T+E=/F;L8Q<]W;DLW%=Y]
M'MC7.9TM@L>7F2HEXA/(>EL/FN@1N-\[01H>T5' 'UZ!,W 4B?WQ4UJU/UVN
M?H*$#+8MO_$CN-601<646#<7/O;H;D<3469PO8OZ'3:6F=ELFMO1"Q2,8= -
MY^.*]!\^Y+-I.E-GU1[\X%%. 4^$HRL)EV=4[S/*N]6.<9-&O29*\(+GA_R)
MJAR4<L\,W14)#IXGBJ\$(]^1>CUN1"__W:N@8Y3,(?(%98]\O#'$TS'1(**O
MQ[+'XS4?GYA*6'[5M@9QKCI92;_7KW[WR>8?3U^@# )5RTIPW*BN,9;>-!G'
M;2C[\3., ,DD-XMYM4$A%R/-X.A9K<-"5_?LY==T^+A^3[^!42IBAN-ISY D
MQ/1ZHP\ZT17IS**.COL)V^/D)="R9VF5#/=IYDV95=S\X_F+Z5K)?I4]FK!%
MCM<HO_P%1%WT*C&&;'"YPFKYN%BZ5VFZF(YN'F39##@$,"(RP:4LR'&B*;-Q
M++#<I9_SJV10+6F2!"*JPBNYTYGQ,=/_U"]-OW&/TXG.G 3)N/3Z%Z-_-T:?
MVJR):X--TE&VV.-BCV_;'@<<WG,>AX9U]!9E*65"(0!%P$=V&()1'Q,RM(%%
M$"BE%POEZ&XQTL5(WXG39*L3C9I$9L]"NG4Z?;'*Q2H? K:7&0*/$ 4'>10F
MNS3\&@<(L!:IZ3EF<^41*:(7S-QBHP]CH_\>2N65]?VH.96WWUU)A!C8#C"J
M1T'!Y7T#LBW@ER^_6, O'P7XQ93U<<"RV7+ 0VV.,SP)6-@C.I[VL,8B/[9=
M>'Y3>('D% H:PO:2\WJ7=[BB]NS<&Z22\L3?V&:H*ZD<@QG%XZWKO\MW=C>]
MTNS5&Q=X<3?:.8P]6A(R,K^N)%3F.C[2_A 9E>'^Z77$W=0]]/[S5%5*HFZ#
M>G]J(!LEA25MZYT*.;B$<GVS)WRG'XZPCXDWLX<[=-(I).8/;K,/++:-3%PU
MHP1Z0[QK5\>8M%#N9N\M8K\S'%GPF:K/<8-1[Y1)+X? :"18,^1$S5$#,S-F
MPI@4Q66%171T]X^=,!IIOJLMF5[8#>?EM]N.@2GXS9;UO&+_AD(F5Q,=F(9,
MWL7-P(M*X$+>")W#:DHDKKZ-M3W06BOB/?,VL8\S1@O2*T;3G?</@?[7NF(G
MV D5U5--O11Z@GXX#D/?G_6%?@(V??O:K<83>&*'JX%Y!3-WGW.(7(8J^\!Q
M&%D,TQ$F?&&H8'!:5=X/X6; H'QLE%IRY,215?'F+5<_PCD"AH4!<QUL^6ME
MB>=)*J8JZN0#-2(4LN#Q^G2Y>IKS*P$52F!46J!=:(2[LE=(E;C@+3Q2Z158
M%5YM^CH#IQ<5ZW@,0VWO]@& \Q:V[88KEJ,8D4*J!R\;N=?'YW4$5D&P*0?F
M/03@A!R\,G8R=_;>>O3*^3,Z;7D3A./UY.2(#1Z)69/4A_Q"F4$BY")21&$S
M5#+FH$6Q);=XNWO+/668F!B:V:A"2>KI!F G5@>F/)T]\QZ?A3W[A6*MLFB*
M,65W)QP6>0R?>&H!(D=_S=#SW?U];O2VA3*K3GX7]6CV+88VO=E!<_9RB_+)
M/&]X0C3610.>&]KYP.U(TT,S='<NLMCE:"PY3 B4J!&STS!_O;&[=@VYK]&.
MT;!BFS;9$>Y9F-FV>+I:&DF3$S)#L+M</:-'T#B;8F(.J-]@7$_]*'CE\*.;
MZD@ 0'@:,("#G\02WIJ)>:IRBZ(S%+PK(_'/ QQEV%QPV!O;.)X0B<@#.)]=
MC[T&N,FR9L -^ETD'#": DK8'IQ<O!..#(L(.MPBIQ)D095?=R5A?HB" U:)
M*.&WJLRSK]955'H+JVTI(1]O_OPD%6!0>8<PU*>6KB.?YBB>/8:G!D'3CAK(
M6,VB. $)_VOP$B*Q5=M2JER2[Y3?I");JC"9'"D^R;DWDJ 8. I>/$P\T_ 1
M#8\:*9AD9-8/W;6#34NFAT=UVU2]SC!R(BK$<\+6/%/_C=.E(;Z1VT)D;$TW
M%V&[JY??/G_%H/GP?/;Q=$(RYV3,M(BRRDX6H%P=7!@ZO1JJ+9+<[D\>]R<=
M%8>AT3\?X=G]*J6N<;5<C-)KXH$F#CYX?1%RK<H?HXT$/PVGZA;ILF6^%9Q:
M)03@AC$5DR7T(0<=J.K;%LFYD\2T^H7#Z&)Z/N^HSU X6'J38[EY75[1_[0/
M6& Y8O-:+0C_@^EG+06W#BU4RN\K1,4X5]+BM(5\OA?%*^0U;^69#RQLA6;W
M)OQ/V*5MMUV]=NZHD/M\(R)S!$4>6UK_Z8$TT?CP(Z,*_,5&J;+=V1V255RR
M%,?\$/@\I+5S)8<'/K$1B(O.V1P)3.K_C^<O^+3\Q],71?16XX*0>#5#$<YW
M%>? GP1#1VR_.;4MU'L]5#6?'_ =S3W@6"&4$=J?0\&SKL5*G)C RI]\CX<H
M?#UL>KYY<:3P0>9P+[N^01*06?DU0W-N"AB7JW\2$SOJPV$_E/Q10@C_NI&L
MVQSG99,6(G4;Q*,Y98]GK(H-#V@H0WIA.QI()W4$].,:+XC(SBS?B4YVWDF>
ML; *!C&".8^23T*D7%7T70)ME][:EU\NO;7WK[>V@!,^?' "3SB(MC17&U !
M+D21&IA)+%Z80JO4'4:%B"2F+<C-;KOR)E:?]7@:E6T+GI#GOT&  @?J@F-<
M#/ZM&_Q/94<3I?]T?8]1$UC=CQ"=]#6$)O)O9(K[MMY2]KEP;"XV^< VV;G=
MX%/984,IB!-H(S4>'PJ^,;<.47GR.2S=531^W:VLK^>2\Z9,JP5F9MROX")8
M 5PL?K'XM\\C* >]=]7_2I,?U<<;SN%SU5W=(TP_@4(FQ'#/]0TN1]/_&L4?
M&%34)1>0T9L_XR\\J>%YO\*4?#'NQ;C?MG$[Y!LDQ<7F9Z5&T>:,QW_?NDWG
MG#=5$S7F&'EOJNN*D">;KD)6@#KNAO<-_/MN>@__J+"CA@O5E(P,R@MOC32]
M>IH])^U+JA,3"633EP?I<#+K5_)/4U7H+-&)9<2A'\\"_.!R?K-WVT&TP^C:
M<EN,5 IT7EE=8?X2DEQAR7/@RC\1G1[**W>Y>M4>HL!A>1/N.A4' ]-J*%((
M=4D!UF1K: 2#07;5@*_1A5YY^-+&J:+XZ ?Q6Q6V-[!PQLNR43V\:9LG77,*
M23#M0WU O6;@\BK23Q?R6:L:3A=I+*(P6@=)M?+CP T@BGX3QY@2M%D*QFFS
MN)S-B/Q&Z;6HF(J,/PK]4P'Q2;/>G%&ZW37-T$=/VS/6%IL9XIV$:H4L;<PS
M1[QAR-P2.J/*Y%*@""FL2L4DJMHSF;?(8]!$#T9]ZRXY.%&2$ZR"Z5U_X$W_
MC+MZ#GL;Z^J1W);-E&A8J>SLO-H!MVN(C+:L#H:5BYJ86T3_(&</HKUHN3-N
MCYI=D3P"$6F3MK=51^5?C3!&^5'E>;&$4(&W"KW'KG8;@Q^6*T>6,/U>PNS?
M[G87] _T2[&_F6'"(C QFI!T_H4RZL9+TR>22VLO7H_/L(YDK3._B 11!)'9
M4B^3:8'Y483=3>B4>N[DX(E=(?D2L54R00_^X,W>\7W#OND.X?&#LTC:HH1I
MA.OX/C1Q9$TO@CL._+@[Q5F&&):I>A&GH[>HW6I&*+])I*8#.S<:7UTR32'I
M'%LQ*'2R++]\"OQ1.ZQU$]$<@MO J5&#JCY%6TE754Z=JK-G[]C)6W@)A31%
M#&C8DR7@CQCCH#V3&U48O?F@%B+#&VTVR(6"9@DW83 C</1VR%%WXI$_>'SX
MAXHHV60W)8W3L'WPO(#7LNDO^O8"W]UP</$HB)86?#%?XO%YL>E.S6/>M"47
MF."IW\BL[;Q( 1!@Z-KL=A;3@?=/_H6,DH\58=%,!"R14O46.!5!*,'N1/L8
M:?G8F52O8:?MVQ:B,(TD.^YK4_Z8O;_HDAE91T&1=&)K;$#7D95[!&?:L+VZ
MBI9O3C&U7'=MN56X%7$UX>P?.N< J"NWY9$C)V:+)+UR15%/B%00-;-MC^H1
MD>ER_!E]6PHSO(DBL!%O6C5CZ'YLIP=$5XWNJ<RB@Y(V.KD6!@8*I.K&S.O*
MR C7JE20?E?IQ.3CVUZ8>AA[JYIKQ!-=Q;)<#<8%"W4-!W[45(#C,(#D&1?$
M RN$V=LF+I=H)/GDE,B=^3;]$5-1$[O!^4LXMT@(=QS6:!VP[)0AS;30;T&
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MR]/QPL*+='1;6"MBJ+ODZ07\)(MZGL;S%P&L;.'4^A/BOWGJ>)=_Y/"65%0
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M+_(24X,-/"3_YY,-W1/_[@U<Z%AZ3W)SY(]-:ZF.BXR_<(/J)'%Y*R_6S_=
MV=JD/:EQ>6P-CP:1:MWB/O;F1@>>HLZF+:Y?U^!Z.A68,8_7.>)_,KYT:6_]
M%NVMSY;VUL?:WGH.QPGNX+G:U#W $$O)*H&X\'GL^3@VBSL^;EU#;'I2+D=U
M8#\CYDT9*OQ9DU[\'W"$P"O8=L.527S!U6,(!LX</['C(LHT1O H XEZW@X]
M!Y\+3]OF"O,B%7;$@E,$'K;'UDL^[R0FWKDM783.'+Q/Z\Y76X?G$)55"E&)
M"@;47"&^E@YR2ESZKFP\%F$02X(%-?-0A1J-/?(%/W;D7X)/^Q'<HU!1J3!Z
MAJ:TKX[P_/V-<[%#QQ@X5<QR4<D\8+<X,J+SRB2J\N>1U1U<OV^WX-6N5!J$
M[NX#SX9RO3R.^/6]7SM*)OGU4^F%@IA@^Y@V@!-.=H%$8"%)XL96R(^L!07N
MPCSN+-I*!.2Q9I51ID]?U(8KMA61$H7")YH-,@RJZ%)4 0IU/J:;3CE'R2SQ
M(C53.HDT1;3I ZP"KHIH"5>IQ)9]4/@X.!;J5A^.X(I%FY8&@U)X)OW*>JA?
M:ZD6[N22J<P(W=5LJ2W%ZR#K1X^D3HS;W'-]".5DFJZ(.F LMO-J:(+7I=-+
MA;A7+G2'PEZ1R^O4S9"+&S-R@E6P5S('QQ@;C4JTX*R1CFD/5ZEZHL8:&R%W
M"M?55FPDM!"IC,]\$XXA9W,0QY+D4#B81[4FQ,UIFTWF$K064G533V6.TFS-
MG,0WDK(K[C/L^V+F;)F 9CK(FK>?0TQT1!IMRV#V8K*;'I_3,H5C(E"- H'L
MQVAEY52;)BNZB6,3>]L>)X6O0FO&BM*)</4<BF?ZP_&,$72!&?08F4PTR 2<
M._Y-W>CTT'2GDY/;_F@"N;WM!Z?Z//AX"*7DF('HWXPP-/SZ/_[Y_=??%JM_
M_/CDY3><L?[CVW]]^_+['U]I24EK1"%]99 JMSLHP?SS5SY@]M,MHWIQJH=V
M*W66]- B";LVU48->6^(\O@SZ0\F<I.C1L2CW$I2&)1R(,?B6'>J]FT+AUQ#
M@0"!) +BVL1/\:0?#8;Q82<E QLLD/)X(AQ:<J$B%S(S$%QJ7S:SD4&!>"=%
M,B,ES/@C5'Z:D$0/KF?E+JF,Z5Z4N"4H(9$WYX0G_09<\ \(CSL<>7(E.;%I
M84936>^22?#=V!.5?_[T%?_R??\OE<1O.QB+=!HPTPXY^\0?WZJ.9J6\XXZR
ME8)=PVY'*;V*>G-=6/U)RKTL[;FE'8^A<?%$9 I36*GAPE_6=.($0BVH+]^8
M4)B#N(B@ ;<=Z126!30+.)F<*BF3^L#C%^WF?D^L;;$8)(6US>![2,<[7^02
MX7#:AZ9W*FNM>KW8U;EX76U>8WT;<MRN'+92!<7"9C;M0R)NVWGC]-AF#D03
MK8S<D$@BVA0Q%(VV_S:0]4+$Z>"?6<&  @<L9N'T4GF ((82<>6JP]0&$MMB
M'$NMAPXL2646Z$][=N"[2F)^B<E<V6$_[A$S>?]WAJ2Z2 3$1JB/VPKAKO;N
MAFJPG%R1Z"B>I0>2T6CKH&;?.4K5L7@3JR*FA'!'/,XLY0&#\C;3YMQ4RR1'
MU9W;(87=0*/=DI@O=0.X(*^;YE?O$NH<:"V/5C!RYW2FT)0\7IB""7Z@WQ/!
M@D7->+#SS3Y!:9P3<TEXU>_Z+MYNR_5[6CACO/_4A7L:Q==?&FGRI>?Z6_1<
M/U]ZKA]KS_49H6/!)?J*X<40G\XR?BAZ1ZENRA%0*W3[3.,2MOE)@YKQ/ TA
M"'N.!F*7I27R%\:LL7JWN*@Y%QT: [=X:()GCR&]I" V\-@UU<M7UU6K]9T
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M*$^>.<0R^J0+@[>L(!Z\:4#IW4VR#>K1YRF01O)%]%KT']IUMP3,B<\S84X
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M J9TT7NNZ ='V:N?2RAR584U7#GXWO0YK7--^[?)>=M!5&&0.OTR=W]&*OU
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MWY,)7AQR.&>X%&E@2Y61NQA3<!WY=G*W:G(O[M)LYU)$W5P#PB,(5UL,%P9
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M1;4_'(EMI/F-SCXS*X>?A7';SR5ESY#(H)I\Q7,:04N;D8D(1-$\/,1EN\D
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MX,+#)N0(&9X2/"/45>#QK#/\IGUU(D$O>MP'TW6.CDB54#UP7P>E0AH&/?:
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MO3I];CSV:%HMNVSNH%O\BJSV>5V>U^5O8S4%R2#ZE4CPF?@#$ @*X<E[>:.
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MW%]6G2U+D:T,C[/1_F<D!:/F0$)*O4Q?_(,"E;.5L+0[YIXTH0]4PAT[*;C
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MVO&X"E'PW-M5DWPF3U4OU3IH%$J]QZU:7Q$R/7(.M)/UT:).LN.I VR%EC>
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M<31$U2S*J]XW8Y>EK2+!;^$LX!@G\=FH- -*^_$@F0"G;R*^G\]$&+=4RER
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MOHX!KM$/"CG7<F\@).4)Z)5OCU21QK5QE.F=&=X(:QE#O$PY1L8^OVK&N"P
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M#W6=>:$F U1JZF-8K7L=Q]0YL>I-1JV7H3"+0[/!"0XJ**)<X8)E7/IUY=V
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MQW?'SD#X: ,PI035!$'&Q>@=2R((F%@)\\,\=R1X,+&,48CH[]#/WD2C^YL
M<P0+J3("'H1BZV/R7=955XH>[U:"\=Z)Y$&5NN,7J).?L>8<>6G?4DX7RO:Q
MHU:?\&V_,I7Q(8-&*!N'J8<2FBE+8@4H6@#ROS*!#Z9+(Y#RHE#"2'XA%*>
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M0=(C*4:5J8)Z(74.&XW&7]-7ZY*0A==B/B"=%=::"NN_*$8M_"-/%@)IL21
ML&\73BN45BA7HD$3,9))Z44B#>6OEX^>TJ>O<#*W0VM*J,G_@^[6FGRKBKLH
M[&*KT0$/OGT&_W=R\FIU'MA&O:YW<\5%'[8+AN.)@C%[2G[4?=R/RW1^YRNQ
M#377^;&\ETGYKU*='?S:/'7;9XTG.M5:XAQ4=>"7-!_/V9,(81L&D3B2=[[-
M5@./$X=-4#?PU*\U6KD53](/-9.:]G&S;66F/C)34^5RXK:Z)QO<-K5U DY.
MR/[OJ1,0<2KCGCH"2SAC;6Q+?T/?"8RJ7E/ZO(JPDF8ES4J:E;3*OG?<1N.I
MDU(MY:Q&3L_.1S[T_\[YCC?.O'"_?)DVB*D?YQA%W+Z-/[_SSP9)-C&G>V=C
MOF,!ZQ4_6;S?S\19K-C59UZV7,6=KS-4LS11LX2?LTO57!V/W?>EP<DH;&T8
M[*Y41GWSN.' &T."*]*)<:6D.+H/Q<4^3//>?V3.W0-#%;V:2<9#6N0D( 1S
M?CR/D,N'\B,Q\=$ 6L T2YVU^AI<XX:#&.DI):-FCB>3*GV"3O "Q7+F(#0K
M)1+\T#X^;R.P%'?===J-;WY%\[A[4KR"\@XZIV??_A:S(Y+UC/\<I#+[FV9<
MDSH]RCP)ISI/HFZ,@7:[?^-V;]5KNY>SIID!X#M2I+%RHH\E/Y0H03I EE1]
M"!AC[C8'>3GIMD\.^Z\..Z^H#$B5$T4Q)ZZEDF\ -POGHU=G_!X[UY'S#R^B
M J6FJD_R0(=@\18BP3W&6HO)7")N2:D= ^B"*=/*PT%E](AT98\Z3;UN&W#%
MN=E-76@W.\^1"4AS>MR<-A@]T<=BJCE9-(SEK)>JV3KN3+^@_*1"L5DT#>>I
MZQ1FH!CD"=4;@,'K)\'8Q ^<^UKFG_@4@\H_5\8*RQ(P$$5UJP7#!M'^C63Z
MNJGE0:PO&#"+\<NPP@?Z,P)7\.B?6Y[87]3_=H^=__>6R7W\_\\HR.UNN"#7
MXA"<-RT.P>[B$%1NQE,3WF^Z A\AA')"P24_]P+T^20-N/Y7:[-+332)W[DM
M"(:N#511O<E/=Z_JOE2R=,JS&_SZ>X2LRURX]HAN.FE]*@>5I@&?,_Z.2(A8
M>I$B2], G!&BKY:6!"OU9849HI,ST8'^L(D?NE-?>A1/_SW.DZ>_D*?EOQ.V
M7  3YB$17#)*N9_8Q2?<08U5S&BW&=5AA^'D"&NO?0*K"_P )A<'S@57CZ)X
MLY=6OEP2!^^,V"@0]E__'>?@Y4BN:\^7M;RJ^,TO;TC/V)!8FU;%_BK9<RM8
MO\HKP[5MS_DK"C,TD6 <<%(59H5F\9!9F#?CY11.C7.'2'32N3*?P0WB!9'Q
MT-S!)\BVC:X@#$.$J7BDD\-,6R;^J-G2=$2".-394R3R$":^<A088\&[JV$&
MX$]8P7D4QO$7+E+0$\;4A@RT9S#SY+"Y$QP?@SZFTM7L86V.!I48<HG;U+:\
M8]YX=C5O-07O>]F'#[(/=[H/4[OXB1DZ=DKB1WC2V!$#/O:YWIDT:U,-SS0G
M77UC79&P43)89HB*R9S$.(7,C-SW\E2#0RBI1I:Z8(#ZPJ#%DP=%H;]53#"1
M-C)=L="DV$\LX90D+K ?CYWM5T_D(B#G 4G!CEEI#0=!(3SP"(.(HBO$%.3"
ML:M/<-9'@QB6%X4DB,=P]!QY?3(_I&"9:TARD4L&JS&8L0P/P]"' $_]1STO
MY9")-EUDTHD3<@2"&8SA%#O,83PH3(@C*P'UTWX@N>(<Z@4Q.46%\D45C@2F
M/9$](KF3%]T',8*3$](R<\&.\DA(;D5)5)6/0/21FC(;<C/C8"PP!QBW7@2G
M8L+?)+CY/E9<,9SY%$44C! L1]']/A;(X*3 -"&5&/XX]K(AG@N@LW!B3B1*
M V+A$P@GD<+#\(ZX1XIE2A&K2<WJC* K80F_?Q3TX?#NP;8+B8/5>0B\TMB/
MN'<8P[EGABZJJ5?O\"0ON9H=S6]%[\&.>0J^FGN*C H8JE2;GSM,W1#10Y#$
MD80@Q?T?AJ T=7^IB1BYUY"=#8<\$LB%'J3@.[%<3?A]J:00\XM5R^%X'(0A
M1C0(6F0LXTZ>_\ 8"KAXLTN5#1-B#54BK014$SD2GU:"%D0Q(X#UZ8'U=IA.
M*X3CFY17Q0E'Y*>C'G%**'MI"KN6(2GU^!S+/89LF'H.1Z_[A"^%8V+11R_S
MMCR\4>7-$197<5!2RG1G4;?N B68^,-8L_01*@[(89Q)AQ_-NV2O#4/EO,)V
MTPPHS*>A^&#@^X.!(K659Q^W8+?%G1$1#4;B!2D1.S),%]'="B3BH]>4=@+N
M="KKPQ<%H>;,1= =V,7L88P9>1TD''H&5C^(#6 3?$)1^3(<R@C$F=Q%%'8I
M]XX$/\$RZPJLH 'Z4]-00GBC S,-:Z3W6I^0O[53DWHA:6P9C32*%/%RZ:1[
MIB.F2A_,QLAW3OPTT6A$($\@-V"QB'$'^1)X=F'-P)%%=,"4A%4+J@'?%&=R
M79G*?(*>L(AR(1\IR3<+%N,U(6D+GR#4XZ6G9Q9/:F]M62(051G,9NPI9!P)
MV4PK1G/SY4K[Z^[E>!41"(E*WQ\2S#PR&2%,/#]/4/"^&".P%#CP#RACTJM(
M\SX27@SR69M!E!,Y>SU3QD-NWK+!P&'+J/RLB>(!1>! R)6@BY<?NETML_B*
M'SKG^G>%'\3L3()VS"S*"SX%/W1<=9:#71A*?O@Y]T12._ET9='OYZ.<3[4^
MX</1[<\/G;:^OR 9*599D<XS;D^?&"<+@</O1:E$/T+6=_#M,KG.7S/8L@^D
M.7A,7LH7;&S:G[+AKOK%O&.I\ .8RU5\D:Q!1%W %Q]\K8)+5.D^T%D+F5 R
M4=F!:7RE ?8\[A$X&E]SD]I63;'75]46$[CJV9R=P5EATW.:%(S=ZL6@0G(\
M,1*YK%MTQ:7]QA/BHWH.>KG>\(C?0ZP^W+I^?P7=.\<GCL*@#U\A:P$#ZX/^
M92(:FM.G5F3W].T%4I[Q\9K6DG0+$DF8-MZ<%#1VDA%864<9=<)]1'-:V$ R
MM)C\P1J7SRPZ&G/L_ X/A:BTALQQP%L(YKM0D*8PE;2P6AV2#))AW(U3 LFA
M+#%MF]7F5-!=Y%CT,A7Y(N! S: @'1$GA9?TBP GBITZXA#T$K&+\"TTQ>+X
M8?)TR*BK]\GA(S5;XD6IUY?NQ,4S^NV'5J-0IRC<7CIT&4X0QP$;54?W>./0
MY6KA5AP[;Y0_+TF!J]TJ>1-JS&-!<D*MP9,\%2PM)4@T% ]SMD$>](:DDXN<
M3/H0A(IHL.7Q4MVFPFM@X&=Z<_<P8D5M8*J1AW'V*8&DV:7[,GZ<)(IG6Q.Z
MS.*#/0[AR,VD*3@I ^\!5I":P< X28 RWU>D(0<>2*ON@QI*1=-&HQZ/VVA+
M,WB0IX*/%"(>8C B]"9H_PA$#E\>!B/F<J8PWK-'0;3F$3U)M(C2N%?8B3CA
MQOCON$W97/+AFN._4E?RMPU5N595:"]USUOV4G<O+G4K3/0;P1%S&3R+D"LM
M!FT[_R(BC?L!N5;JY$D[O^2 /G+8M-"K8U X09^=VPP5#CM'(Z3!HSA8U$\$
MV0^MS^.$U1H&X@?:>4".*OE.=7Q!5:2P=TM'F6/G'5AT^32%<>63,^<C:>6E
MYL23FN0_4N\+Q;26GOD"&P!ST&F>SG:*6.],AT82WV4XUL<*DZ3/$%->AL>V
M% .N(<X]+U:/[BGZ0J(6*RV/-H>U_#0D\77I4M"XT] 0P^R$H(?N^?^!(1FW
M5B-BO&8'KSB]QGG6UU=V06H(T&2[75Q=D=9L&^$[E9[X% [\S@;T+(S^*D7K
M)L'+!DPNQ>1X\LI G]SD/?";G'>@%T"?'"K94C>L_.35S;O2'YKR#Z^0<E3@
M"7B/9++-!P[TCNB.EB@9C9#H6#*"& 2-AP<H;0<&G+BB#7$NU)<.9*V"5&\8
M($([EU$;N&)X;4/0SP=7ZG=XQBQ8T.DLU#)I[12]$[I4P81FE=ZC7T")T@ZN
M;W&@I.C4/;SAGE3\P(&#'7A2^+^G-B,5(NBQ:S#%']K'K6:Y]$!4O)&VLD0+
MC8TI[_"4\V/WQ("MP],PF-P(4M,HT&C^<-8X;NOCYV%/(#@]^!1T+8<7IZ$G
MDZOIR@YI.$NHW\]$96(I\J^V6TE4"?M5]8AI9M6P2?J)8>"'SO%)$?AGR2+=
M^@A"KI#4!U/TCA0>+2B+^W&*=Z;X+0S1ZK5%R3D].=87"[LWUY^G)]9YA /X
M".]DS3W-\8][>=%#NTUZ53I;^^ZH[1R^#T),!S]VVNWV4:M[UCUIO8)YA4_]
M8B'OWEWB4T6MA5)H'%B1#!+%E;E,5I&/J<Q[2<'2*1$L:\CX/&5F%A((4 HX
MJNINZ/?Q)N_LRQJ+KV(TEBYN:6G9,;F3VZ]SZ+TZ;+U2ARF3BZ)/ 96?D,Z*
MRE@:7299NE?9"V]Q.49Y>.]E1<X13CLM#;7#*K5<21?-;G?J<1J'9$VD5U!E
MFJ1?X')RV4#E+YE]VN[UK7:J+K(CF,8CZ5E6NT\7GS_NJ_<$!H4#P]E,=95'
M^<;3Q9PJW(UJ[QKLL/+9[_ 24_M*WPXR>/>1,099"?U#T,1#^Q\^7#J'<K6*
M3V'%BL84IP;=1,V6J4TY@G=T^Z,?UFF<^,IB3V$G/@C\Y8MSXR49T4)A7U 1
M7\+TPE/O@^R_]WAIYSM_\4;CU\YEK/-AP;V";\SI,&U9?4C?=I;M:JFBO,@@
M23-',K23HTI&"=8$]95;DJ4Y4^4ZY^[I><,].3V=5UZ,?FVDJV +O[9Y?';"
M9TXJ'2MY+LTSHPJ-LH^F?9OFZ7%W-WR;:KWXN_(#,]C#.Z_FX)!XD=_G((W-
MECM/-42%<TP>4W$Z-/A\?C>_,J."*K27Z]P$>+JZ S$+X5^E*H[9J?LMOX<S
M#NC"D>% N/R@A]=9DMF&DHC24E=NRW_3?9#^2,G31[8Z3CL5050](*%]!/!+
M9T^MNLH70X/Z^,JG5DXNH(-L^60*'A+XNV[KO'26-)M_'Z"#3)^; P@HS[K8
MY2Z6W\J"^!\:Q_ RX\Q:>J%D"27FJV(\?/@EW2 /0F..J_ )&/IFH #@< Y[
MKS".?203LC2O (:WU1D:;!S\VG5/F].';V.R9/V4IB]E2BZSQS?0S'MNYE^R
MF04[WCH^A_]0UV4'60"]J((UX>EI4RJ@,*8W4T@+U9+OE@1#E4O/GC2==N/(
MQ_M!E0:HA:KT/=5MWZV8Z7(A<;<BZ(%B,W>>F08-GBR)FTR$+M6^X$.&8/(8
MY5NF9)6OLXM%D0X$S;KK4,E72:M@A0">K5-]XQI0O4#*[KZ:R 3<F("(U?1V
MFC51K?,BC +#&&14HJRB*(LU2V\Z,\(Q19Q%#X9B %*$.ILPBO;2]KQM+VWW
M]=+V,\/<G#@5AH)/;+[@TP3;Y%Z!2H#S282!Q\X%P6W =L8<R-D,XN+H0W<V
M81CW549=V0YG3_6&KCNY'.5!0MVPS:9[3\EGF@A)]RLDGV[!$RF-I>S_$WE,
M,D_\R<XP/XO)%K2+COQ5-)#QFUNAZEHP_L3'K=;.NO2?Z9KDR;'KP,'5[47A
MH6. +_((8"HNC@5=DJP66V'X?E',2=G];"NQ%C'E:&KS1_!5R,'*O*^.@B)!
M?UWSS5-T->YC(BG;YFDY;LEJFHP2$_".PVF>_ C[+1G'G"X>PF,1;R8L)ACE
M(]4<W\Y7E^5BW^,17N7$A#G%FQ8'!1VC>W[*<=;ED3@NKY\5_,'/5/UN]S;B
MG8..%IC#B!V;2I2"[2]RK-88M_.R-7=65\P=L;Y*1)D/TLRHM*$P4\J0/%P^
M,N>ZT7R?NG=5>?)56>Y9_"#ZP2BX=YW+S_]SU#EM\@]G[=,FAQ?AEV;CE*"3
MT,#CN1I/$2K)'8ZEI<HY\NT?1$))]7 "&^EAZ0(%+&B<FZ3+P_2*D:JJ2^.B
ME73A^@EM:X87UUH=7MPRIN^\>WK^ND:H<::0P0OQ'BK"J^F)S#G+1=6>JLXP
MGAF7Q3.T\OF=\JF(TX^49E4*S[PX3[U0@M&H;_5$) :!#*7P2466]9=0X.3+
M.'>BX&@7T;UWS]9DKD8>Y!%7<EBIMU*_;*F_A"\DZ.YKK^B:RZNEUZL.39>W
MUT68D\XR'M5O*@=)";)1O45 5E5  W,+1ZR 6P%?F8"_-23PHUD..D_BWWY<
M6.2YYA^\_R2_5_6-?;X)HX^4J*OT KTM,CQQIT] $4@G/BUY_YS&$]Q++(%
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MT\_*;QI]\NX306]\M6-,#<'<4JUI&J?-COHI)?V2H\\4:*C<OL_/1<%)TYO
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MF=!>V<7?W.)WW+.337*.6C;O#6KF0ZF:7V&4^R'PN3XNB!Y4Z<">Z.E:<@_
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MX$FH&2R3+,WLO?+4%KMM2G7,8UT?BHCT$6Z>ZKP)'PP.T9+!T 2^1J!T1>2
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MH1 XL7)W[,AF@'D#Z3_9(NG72Q[&:;JJ1;\KQ42NBP"&I"$<)V*(+)T/POD
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M_@;%2JNXQL(J[NK3>T/'-8[KE(YK_0&[>?3F>4D>V[HW3[N[U9NG1N[!/D0
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MK5.7U[&4?R3[ZG8]/.;*X:UZ/F_MRH#JM2N=7G&M:S=V_PCGZSOX^> 84UP
M%MN>P@N&^73Z[EVVE_+7F6G_^BF>(LTPY8D4CDCAATQ/8U+H&#-#K#)"@E4&
M(+.9FQ[S?L0T?8"(?[H]!?&MV8X/0^@NO P$#%]X='5+F^@N;[PQ8AY#:B8?
M.>I6VM"T=7M@PH>\\)[P3G:[B"(V+C4FT)XVL'0/V.WFR]D?1[.\5*W^DB58
MQ"LDP>BEH].99UW=WT8/2PH],2,M,<#,=T?#8]=YGG]QP"Q+N_GR_<>?"Q^<
M[:L/9<'L=H*$J78$"Z9_O/L\BL(D-_TOE\=GMY?]/X[[5_>7MQ\UW7K6IUXH
M'S $8+/4HCYI(\9WISYY^:2)X,??JO1/5EQ$O'7TV^Q._GZ1O9-X'&OOX_WU
M^3?3_AE30\8.1!N!/U*?RZ%5;4Z2K'AG":J:75TQ_/'Y 1MD3V"[-) QKCYA
M@6\.8 U@>IV ;#&TN^#!,PT3GLJ\SSJ_+'5O-+2<Y^<C;>3BI?@W>-!O^FD4
MY=GM]!-2+M*!/12#YS!/[0HFZA4RL_=?;9#$3N#!-GH?EDUAPQ=3@@WLP+*0
M,SC@!6?B?QRAR0[,,=$-C*)$?WL3?1#]S;\/5\<]?C5B3*$G "];^L0#\@Y_
MFQ$*BZ73*S05VFO3-IA- OB%8IT4W.7JA>\FYOH[TT5<:#=AWRT&=/,M@:V.
M <<)9  66WOYY5-LN'^G$>^L/9B+@O^+Z:YV":1JI*+@RP+@!6?1)+,E%"=M
M@9/JBI->RTFKY(U(E'RFZ$A>.FI*3D<2):OMJ/8U5!0[H"<6G;A&9@+:,YXV
M=)VQYDS $/+1RX+^MR>JQ?ZX*PK:C8B!58?#/&2Z%]50ZI!V.)1$ O 0LG4/
MI/@_(TZQ*&15JTO3IZJQ&N;; 5<$'%! MCQ4FX7!UHRIMKESJFWV*HU.<7ES
M)>^<%EF=S:.]NOX2L.6:[V@N Z(=F!;3;'$OXJOX.P8ZM ";K2%N=+99L"\F
M@1ICW3$DXN2]5UZC_WHTC0LV >XU=;J$,%JICQW8^?_JJBEB(:J!)L*)XB5^
M2-G*0G,3^'K)\^_;1C]Q^FOF8-4[;9G4!>E(:M\I.)=<LSK8O5:WW3RYMN2R
MR:2]&/<>TG'F8E2-@N67**L!YRW)/=Y@OW'9^R9)0#P'2ZM9 '6OO?TV1ZM-
MI-566Z$9*YMP_NI+:E68!0HJU]@,QF0>&J8W@ WR51,PF61.CCNY^986A8/Q
MY.7CG]$1)U#5$^1Q/;SAQ '*^(4@C;>ZG&N5=J<ADV#:TSA)R6@Y"S1OU0NT
M2%IN%5>.5O+HR;[>K[?7/S3=\YBOG*U%"YL<6;,).,'K,-KUC8'&?HMKN1[^
M\%@?3SXI=RY?4)5?MU5OK5+K*8>K1,/)0\59*3"O-3EW1\7MXJ#DE#$JT64)
M0Y^/=/L1GIW.&4"*\\@(M4S]P;14_H :0XU1XER+0]/[P;R<Z*:A,7Y5<EGF
M(&:7!O:HRVQ?"#EE"LBC1*W6XW.Q$O75'KBH/ETP_O.K+4CA@@T9'+PAE*>^
MS2'<2+EZ<^IFJU*K*<M HN'D<::ULE*'7FL:[)*J3YN5;JLC$S'+Z$C;>]M@
M-E U(">MITWT*?IUU;TID8C)2O=Z^\49'OD-/_&W%^5(Y750D289*#<KK>CM
ME^.&*;=6Z3959$E9F+,7HANPV,)4%Z(TAF1KM0ZE:T@5//%OL4=TW3SH2E7%
MD60:3A[*S<HBVLA]N!G*;50Z<N4+2>MP/33[, I>:A;27!0WFN[X7HR*NA*H
M1CNOBM]8=\@"BN+>V!ZRM5K#U==*L'1L/!1D;X;X;[0EJDB2KJFJXJ6">2DK
M-^KMVL"6>*E6J=<D<AN7N@OKX1C3M>XD!'E:"F"QWR;V04NZ#4%((3KBC>L\
MF08SSJ8_@)82XJX?$=(&D'IJ38GL(.DT!\4ZNV.=#>%8[8IU,+HL$<A5J=6$
MO7<R?,K$O#7M)^8IS%LUE#JD \2\W7O;"--7 W<PTC%OU1FJVF])-+5<%:R]
M"72P&WU*((_W3G_P5V"Z+*N&=NU>C<U*2]*</@DHZ7 )=Q,X8=LDW&ZW4FM)
MA?*CS("";D37&3!F" O  UK2'!<^XPL"4Q>E3/(F1]QL D0L)(0KH(,[((.^
M;?S)J6!Z/=SDG5FM512^IE3#R4/(FT 8VQDA-YJ57D>JW&MILW8.SK:<N!AH
M\Z=4'\E ?9N@+J=R=@XJA-!^"W99KAEP(TCKQ@)B!.%V&5+7NF#7I8X:*!;:
M;Q9Z"V3:SEBH*9$6H )O,NL)N?DY[T6"S@=4'2A8K#U,,6$G*RBWW[;W0<N[
M3<"VY60=? TI:7-9![U&I5&5R):73G]0K+/YL\OAG$U Q6V;<TZ;[4JG4R^,
M85;;8N5:D$EER,[5&9JV;@]4KHX:2AW2X>7J[+V=-!>9-#TO (''T+DZ<,9C
MN/<];&^TWZ:0E(I:K@:V"9RY9/3FJSCSZ^$YG3CULUH[6M.I]'H2525*2$F'
M2KB=34#);8UPNY5:3:*:&&4*%'HKAJ0%!.OYZFZ43\3D./8ZF\"2"P,9UT.2
M*"$MG",IK-WNK]V0,Q%0 O(Y7&K=!'[<%JBU)5-UJ JAR6$:LA?F#DR/KC^Z
M]S1G@I2QYV$R225*CD#9!'1<*K,/#_J:G_.E( !C[<XM]8Y$23 2TM'!DNTF
M<./6)MNA^<*,X_\RUYFEV/_WMVZ]5O\D+\U*="$>@E5XK[\PA!#'2!ZS=)\9
MFN]H-O,U#_LM>_!PW[<8JF-X2][>_=CUY:@2Z8I-+.EL C\NU.AO.8W=.T!W
M_S3]T<BQ\&RO''>CK>AKE6I=HN)*Z9)+%$\5S%.;P)';,4_5&\5EGZA<U5+I
M%;FYJLD,U:P\E/VVNP]"XN4(O"W"R5V%A/3F'+M:O5=I5XL+]6XJR4ZQS;ZP
MS1:AY#;(-IU*H\!0D$I-+9^&P#/E2"^@=L=8KX(:0H7K"5CW^@24:(N>QR[S
M?-<<H'<"WU^6K5I^F2>E,,LW9S:1OX4R"O^[C,_^-CIV?*-O&^D7$I^\@34X
MQCRR]L *T!:Z?.%D=@N&TN5PR 9KU>LUD]C:]4JW697'(%+A;QF\_MU-Y(/)
MSP@$8%:IRX0:*_%EOO?F/@Q]OO+=S8])][4'!M^WT?YWAMJ4Z:Z**QR2:=.=
M26LS=R,?(TEX87H3Q].M+\"P$_@&_(W3,>V &0)EV['7+M9K5JHMB1I4;I#.
M% ?N#0?6,SBPL2<<6&]6ZG6)TE/7I#.)U)A#\$F0&L-/X%6Z#(/WBM%B=BTN
MEQ)V PC;< *$_)RA[+]++3SSYYTC/1L9TG/[CH[=2,\&M@XK3G]9\6@.+A"B
MF"]DOJ8R'J1G/HETET-PP=PR(,&!:9E$?%31M[)3!G,^_1'CYW<.I(N:*26#
MGND6%0C>C1CS%^9G[$*HJC'4&&4:0R(1N/?FVTS[<X(]0E$W*_\.S4"33??+
MU>G:;S&H0 F;4=;Z_KGNNE/0UOY/MP*VKB54K;3E*AT]+ NG--3;>8M%LBWJ
M;38JS:[$U"O1_;CW)L+,_7@[FU*E@J\'%/KIKGO7SCE+9N36NO ,[?+':A3+
M[#7+]-:]X!7+J/"F!/<_%GL[OFZ]*L_ZL$SE0PVG]*J%Q#)5<%)QTSYR4S&9
MC2K:*(LJL?>N!%Z]=1=,)AP9!I0*P_0&EN,%+@LCC]1S0#-M3HM 4[OJ,3!G
M*#66&$J[)N8= M*K*2F*.?0I270S'(*1^<-V&6SK?\&&?-1-6P.]Z #;P"MU
M.%*'-P'@F=5].R:T+T!GWQQO+16X>73:*:Z.5QF3BGL6<\\F<$2WQSV$_E%<
M@'G3UN,[^/G@&%-< &[7*;Q@F$^G[]YE7Z:_SDS[UT_Q%&F&J0M3W)?BNDQ/
M8U+H&#-#K#)"@HL&8 (R-SWF_8AI^F#@C">ZC5D,H"SX,(0.]J&.K6E]]NB"
MV3C17<(5]4?,P\X4B<Q3@0\&'_)\>(&@[DYVNXC4Q@$=: -+]X#L;[Z<_7$T
M2]?5ZB]9_"]>(4%#+X%REG[6U?UM]+"D;!(STA(#S'QW-#QVG>?Y%P?,LK2;
M+]]__+GPP=GJ7<B7L]L)G%[M"G9(_WCW>11IUC?]+Y?'9[>7_3^.^U?WE[<?
M-=UZUJ=>R*NH-=HLM:A/VHCQW:F#V:4)??EO5?HG2Y46;QW]-KN3OU]D[R0>
MQ]K[>']]_LVT?\;4D+$#BZ6$-L?"*]XC@H1FE_)&CJZOQPS82A+9V?,T8&Y7
MG[  ;"A8PU=[<$+1H[O@P3,-$YX*VKU.%QAQ_9$V<O%F^AL\Y#?]-/(#[8R/
M$6J(Q(_O:*GL]JM(QMQ%,F;9]$HH\Y$X4]3[3B@;WX,Q$.!@-?T\K5.<!9YI
M,\^[8-[ -0F7O&\;9[IG>M?#&Q?$N>V3V^\>'GQF41LKH=*TCC3X$A 0<*D;
M,.0[;AQR$?&/(PQ' >L)KTSTMS?1!^'?6<*7J,"T#6:3I'TA.Y@,?WZGY]O_
MOC.9M\;%L^N=91;U,O:>Y>ZEAP?T6CM9$>1*#WQG]].["IVZQ/@A+8B;7#OG
MUW[6"G(5K7)I/_$(45I=7>2=Y\O(]PB^7\<"&_H(_57[I#DN;5KR37LJWOR@
MF: TP95DVD2OH H]LHKFV'@5/DZ/A\X@\!!/U70F(QVF-J 1,<K/GP/*^A.S
MG FJ8!/7F8!L]G5W"L?FFW@ QP\(#XP3B&9+Q4!@'/C:.+!\<P*,.0I@7]#'
MCV!"WHEV'0 K#4Q@-',(XH-F@3,%>L"E$)(\5L"-S(GVP/QGQI!0'DWGD0&=
MF#S9 #]ICL>!S31OZH'TY<^=F!,&RT5(.*RV@Y.Q'5@"SMX(!@@D:QLDOF&B
M(YBD!0MT85<T![X,6@)S89-L0P#+X"!^,(8]'IL#UV'VD^DZ-@KZBA@ /P@&
MQ"@UP6/8I$>&5P0\.<R.X),]#C=?"S>??^0$CQR4V(QYHM8+"P%1P^'UL<O,
M&.A+&Z M%IX6Z$4XDHM)&2XJP#!IV'5&,$WF$Z,S.^:+ ?D*GX?1X&D#+-!R
MP^'%KFECF(45E8+A-M &/.G> %_'0,V3J2]<]"=X&"Y%/$/7)G")VGYX:-$<
MZ#DX1=UW7"("/F>8)XEM!/?+/X=/M+>Z!><8EZ[1$(X73"8PBH>+'S-$KC*]
ML:=QBI_RYQ&YLB?=B(DI<)^8:5'=VHGV3S@1^!4_I1M/O-D=4ED6-8&6^3B*
MF"UD'>I]H'N<2(BV= O.2O",R01QV'B(#Z!0T!J>3?BP&"AB.L,-'E-TX6GP
MI$?\"0\S72TJ(DV-#?R".^&X/E]W-$$<%V[Q>,*ZKY]H<(LSE\%"A;[#Y9&0
M,D*\@,KM,M..J&6)9F<"73Z/',N::LXS$K&74/6RC;)<NV*!O3_K2MZQZ+Y/
M[ _M^<-_@(IQ$UW3^\F/.4!>\W4P8/'@1<]$9$+Z'KXFB!TDL@\D:W-1@5^=
M$=#(6QC*9UQR #\"98"TA!,%@@ B)EHE$9<X..K?TOF$8@*$L3O@-4Y):GD&
MTL?'>,$ 2, ;!GAJ.#T+6;O"GPCL\E< -(CDZ3/.XL,TB40C)981/MMYP"V(
MGP8;)AC*"^<"1$*?YA_5;(:3029X!&GN$N?#&AY1%CEX'TT0&QRVA28AGLE?
MA"=%#P\G@!N//7!T7!S(#5 A:!>C\W.H"IL?!PK16-Z@>$&^-1+0HS,GA=3M
MH[05DIGY)M\AUQG/'B-^/GW6$2F<  -IJ,/BERLI]C-QGR:,=%4MF(A[$_2Q
M)Q/Y%B4@K);!H3E3)B0,>D?@0M9S_2"[8;F-:F2AYU 8(MLR5N[B [UP@@>_
M_^ $_A<'KGXP!X&A,XR4KC)2EEH!=;F-E&\F:%+ ?=.*]B,EMI&;Z/0U<?S:
M09HJ27DY AT$M"@K(+_(\XBA=D,J#B/U%9B.RS&^>R#C00Q52":9P [,".\]
M_?$1Q#H\1=P-KHX-%I,2%3WT(-^1!4G*Z0^F!8?$;U&N_Z!&I,--@4<T$$>$
M&A6%DQGA+&GZT.<S1+4G<5$N=2+3>K#S,3,6^I-+=YYW)FH,N*7XRV3^UL%#
M'J*)Q#4Z)T(J@0O6A.?"C+CB.DFUR:2K2;=8="T!6\%YQ:'\]-6+H\ $ A>I
MPL4/N7B.EN.![:AY\Y,DBAKI!E[4^F 0C />B,Q@8%R:=&'_/3,ZUJAFI5JN
M6,?$-9A+W44,4J\?CWO!AXW"8>W5PV'M!$)TLS&?50G&CV61B6-K%Z 1C1^
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M$WGQC8 ".?'G2+FAAH,G*:T_?_F@=EAL$*L]7LY\A,#DOF14R=+^Y$HH2=T
M4T:&^=DPX>0KF#4V#"QXR!._I/#X)F$B((@CF+1&D17:"^:.DR$6S'O4;J]_
MI#9XRJ<!GT)_"J4@#L-,F]"%!R>$P1^<INZZF&\RYI%3X=#C89<X),*]A588
MN8ZWDH_%([31P\EA[_F@#G"?:KSOGN? GE(LUZ2T-?B,R/74GU%G.HE9F^N\
M=(YH UNH63Z9[)F?DH6>&1J.TF4X0YCN(!AC1'> ,QOJ T%#N!*XFRCSKL^7
M'?J"0<A;2,!#5#Q%7-'Q$KQRHIW'([#4Y%PV0$\ )0)Y$YX.:4U#W91//8H
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MKZ?E^QJ=8,(07.TD871*HR83 UB:K(H'!X.U0@?ESIW8MX\YB&)QA'L6#\[
M4/:I_,/B_6S%&&$%UQR<6#Q":$$@PL> DB5@#\WC\$G[I1+=IRJ>DRU\XIV+
M[;0D;^E$'OE )HFL.B'<4W!P2$21(R6DG3D:">DP'K<BCF<:E]^GCD?J+A7_
M[L-4PYG&]N^EV)\KV)[S>&>NA[-7V=DT^P'D%KJ-Q *YAK KLM>W#1Z(R0%#
MO1N,F!%8['KXQIG--=!H9J3NK]9 (VY60:TYXE85I)8=4XK5Q ,](_PMLPG&
M3*^,SF2FE<9BE?(5\)NDVI@VEH&BLO/RJO8;>8BCZTYF=E5SX*^;>W!^+>56
MQX!#1RPF:E:[S&+8!)CJO)TDZ) ?%7QL\J)1@)=0?*L5#?_]4"2Z:[@'<ZTT
MDL)Z6=^1C<UWU>U*GW42-EFQSQ;8IZ[8Y[7L@_>XY&RCZ*@<=-24G(Z4^-U3
M[45&?GA?K59_]3[LBB46T?J."#O#59S1 F)KY!\:0NWV+\6V:+C-='4M(H+0
M-;[1/@SYPJ"@X9J_9/9KV*98R,Y2:;:/I/1KW-[]F$M]R4QZ>>/$>"9PE"#3
M6#E!YKAQ=%JK5.O=N029'9%9UAE+1^<'RU:=#+9JQFS55&R5SU:-2J?=EI>M
M)%(GTAW>MJA-%]EU+1D\V['FH DW=M*ZVK7<VX"CH##QN/+<<Z1HMWCEY%(4
M.1 9\E"+_!*TUJXT6G5Y1.@&:5AQ]]YP=Z]X':F<W-VL5-OEYVZ)]*@=N66*
MTZ.B_T(@4%^W]ML+,TN4#2!*PPDP/Z%\DC5_\MFBM55=27&25L@U0<AU*HWN
M?/619-1S:$Z8P^:JVDH*B[1<U2"NZA;HLMP85\G5C7CSD M?[8$S9O?Z2W9N
M>[?;KM:ZM7JKTVGM!%3A4S()+M%%E::IP3SW$)A*+,['Q?$>SH.H+2-!GALL
MV:(IV0MB*@H93[2+,!4<'I/7UV@&]3+L_"1PV?"+6.I%F-0<BLAWS8> YUIB
MGC0;3QQ7=V.L'_Q4V J*-RP*L;+C/LHS/2 IUY=RJGGJ;_9$>6FEB?T[$8*5
MLH=Q?EC&AMTO.-P)/"#LZVSSA0]@!TPQ)BR/LME7WQN!^VT(7 !F<Z G_)9+
M-:+)^E:$CYG2MN@O HV>CE&D@?,>C?!'"-E-V.*9.QABSR0J9P6H#$<:A?GZ
M5@C&Q0L*J'_E"JM"""G1<Y4F%JW$]&;:B":A_5)-K3E&?*JF ?<ET=<K<WN)
MU(Q@@.BE6/_&L)VGCB#"#U.84US]KF/*.%4.4.8]<)/^*+J&A0@)GH :)-Q^
MR_S)<..QC0OFW]/\/-QY;)EF66$Q8FI[0F1FCJTJ&O.&F.O[EX<?5AX.38N@
M0D+Y@DW< S<^8BH&O6(& 1#]!Q0$SS '$1 U?"B$Q2-VG@%>QK)&?"962J09
M,LU_R=8>A(_!.PWK49<&ZG67*.+@K// IHZHL,87DJR$*?LLPL$+Y23.91*X
MV(^>8-FHZ;U&V&E. J]CZ72Q%P!01X!UR(D>NUQ*5GA3@-6?1@3'ZU%RUE]*
M,,Q0?X!Y]/EM!>N_<1W;090L*BA>U..RT6LT>K5NH]OI-7K5HN":\$GQ[+7T
M]/=0S="^PZ5"7(9&!"^FNNK?G870)XF]N,,B&2+@'Q-"3PF[LO?OXJ[LWYT3
MC5LFC<_F:443BDR$.9*LB(8/:+<1DB'*$)>!O/?P9A??F_FT "+5+DQ/?WQT
MJ0$Y,/(%[[:(($CXA1 ;!*@26Y!'FH40>K$>8D3?TQX#T\ ;!P'MP69QS0BB
MAR,XN=1'1@?A:22_1M 4$; XBD+8#(*]H#LY[..EVS9'9TS#-J)$@Y.A+C$<
M8R9*HJ^UJ.*I71%B%S$5Q]'71+N7H8F&6"0<%S^J4^&E^O!A6)MNA"!5>)_Z
M?JA+T)Z%#6FH41AAXG&@ &9RM%."S@MU,.JH[KN.:%M&@%HGVC]Y<TR"N+-]
M&' &W1.W*86(A3>Q*(I#T1RXB6W>,XA\:@$RX-O2QW-(\]G^RYR(-($L&Y6T
MO &ZP%>/J[U(>)")I[V_=R9P(76:U0\?M:]C!'P18(= 1_$GD\) >Y]XW(<Y
M @<.2KRO\4)=G_=0Q_O8'I$.2A@8V.AVHJ-V/A4@M@-"Z47<FF%@V0)N-J%7
M)<@7F[TZP>,("3PU[9R/)T40!T<1):F$XH%*NHV]0_2$6I8P%PE3(M&0XB2U
MRCS9M*I$:G*48@YM1:V2J!9Y!=$2X?0*@>*G3R,A4Q"H5ABBI.?EM+6/\8U#
MP2%0=L()A'^GCAPDIZ<%_ 9[%C <(6;M3,N.!.Y6 F8SMFA!KS2C,PBA=].8
MZ*NMPS-#0DO,-42(<VP4GYP8Z=I*6LLY%!0JJ([CP_J8]\J%Q4BBH#4S!K<Z
M;%:-'SW&K7%MV.*E& FMX$C2<"1-!4>R,AR)%#[:=[2D]-0W8'AACWELJ,X2
M5^"<E=6JYY5.K]M559#+"J7*.9'V1,/1N1  U58OC%TO X^9Y:>E!P?J6?-D
M6;V(F!Y5@^]\>GC0&IVT]F?<B-'+FO/^]Q5-84S0XJCGD\=A'..V7#$\]^PE
M&-][.2[3R%L5>8/3/1T)[=/%<!I9BQQ3F.ME!L*)\ZL]:K;IYW7IC/Q+*<N(
M8%[BSWM2@U#D8T!$TJE/F]RWC6_Q%@LR-J[MVW ;$=G'(Y"&.72EJXOZ>?^J
M>MSIG/>/FZU^_?CL_.SL^*IYUN]>U>J]7K<Y(^1HZJ8-%D;?_\=1__+BLMGJ
M=H_/SWJUX^95[?*X"_\_/F_5.HW>&3R[U5I++KX97:(UJZTH;(F]J\ZL-66O
M:LZ_8G*!>429Y4=^!ZF2XT,CZJ(J]64L.?Y?&  N<8+!SE3*% GL.PDD.D#M
M/0%L? S8OW"8[,MDF_2UPO"E'$H=W-97JI0,=</L[(;!X!4%2_;^?E''GW'\
MUQB)5T=_B$>O=$NEHB@512XZ58(J0U#]28W/* =B[P65(H L)>4!^VEB)$2=
M_R&>_P_;.1P*4*J*4E6DHR$EJ5:35%\Q"D[M!GEVPMY+*T4%651 ?9O5V:NS
MW]NS5UJ*TE(DHZ'5H? *%UPE[@OQ_ANEG]9VAH0O49.1MTQ%T=R;::ZN:$[1
MW(YIKJ%H3M'<KF@N3I:6G.@.#_8T+)UH=@ON1@-DLH^NI:+MK](/I0ZI!$.I
M0RK!4.J0MN;9*EA7.(16,^>.BSB0/M:;VL:>MZG+"@G\?='854F::S6Q>#-9
M!FTF>\%$)<YGT^C7W\/J;K)+J?%#]!Z/.= ;-=[Z(?F(1-WEE<L16*?I[R<K
M,Z.ZZ?!!85'[5]OSW0 _0U^.Z.R"/?@Q!/1<YXD?=Q=SX-%/NFEA+L>5X][I
M5@) .OVL/'SHH?G"C./_,M>9A8:F4OSZ)WG:2NPYDGIYV:^U'?:K'P#[+8%G
M[[8K[8;$K>\4"TK"@NWML&#C %A0W8"*_=[*?IW5V&_O>*?DUY=$YO3>=QQ#
M<QKW=DC@6X188S "Z]QOLWJ5X>019-VR6]()$KL>7G "4UK$ 6D1Y>*W7ME-
MYZ+X;5FWP&:EURZN6Z#B.7EYKEXMNZVL[CC%;R7BMUJAQK&ZH,IN&A]&I'D\
M9BYO8*%/$$5(V<2RR*]ZV6WBB+9ND+2^._Y7WB;2^*?IC\YU;]2W#?QQ^5=@
M/H$L@V<7+2%!IVAW*[U.1UX)*0&/'"Q+-LIN-DO*DDK#5^RX!CMN*?]JA]%G
MQ8Z*'?>&'5?,QSHL7BJYMBF1/7X(H6KJN/[HP!;;U-[1=XD53+;G2>#E$G1;
MRGK;F67^X^Z>T]54JK2=6J7=;LHK"B5@@8/EN!43W:0UO(OB.*7)*W9;@]VV
ME(ZU,\-:L9MBMQ*QVXK96/O%*^56!B6RBP\A3DUP*<>X 0P6%M&6,HJE$6*-
M+:6W[<PH)A([(PI32H-2&J3GMQ73VZ0UB0OCMV4>^4JU+G'MF 0\<+ LMZ6,
MK)V9Q>J*4_Q6)GY;,=WJ3<RB[II2&+F'$/S]T['9%%_[R7QM"#O@:>\'NC?2
M6)RR\&'')N_J@/Q;G,/;494+DVTKSSU'!)8=8HQHFC=_O$**7D7H9B?K1-.X
M,+V!Y>!,UH6'J#2Z#7FD[@;)6TZFDW-6I1,%98<[*T04E,CRV'N.DW-6I9,#
M9<=<4W) R0$)9U4Z.5 H^)O2Z[?%QQ(Y7?8^LR#ZKT?3N'=\W=)TT9JE6#]+
MHP _RU(2ADEIAA,\6&R6AN4"S%Q]WCFRM21X=$N<UT3(FY.OG5ZE6I<H)VOU
M4RY4)Y%E6HJ[0^XN"?K=;KF[5NU4VO6Z8F_%WN5F[V9)@/8VS-XE]G#(PD*2
M3DMQ=LC9NX#TV_&MBUCU38ER0-9E N&V> <_'QQCB@O O)G3=^'2O@=CF,/@
M]-V[;$O_UYD%_/HIGBS--67-"V->V/+IY)7)KL: A2$YFG:@1U3:O[RX;+:Z
MW>/SLU[MN'E5NSSNPO^/SUNU3J-W=MZ_:K6.8%=H=\1F_^,(KRQF6<()$/WM
M3?1!]+>E>T T0].^QZ]&G9G%>0T<R](G'AQL^%MTN,37'[76+S/'7>_@>0NJ
MZK5^R2"/=>F,Q(II&\PFLGHA'P\YM3AQ^&YB/;\S'5=]M"MWUQ8=6;OH.[FH
M83>VI!,#JH[=K^[8K26O!4VG9A$7;$#7@M:H532X;IK:^VJU^JOWX6.)^GLK
M7ML"K]4+8C49>>A_80!F:#=PP;,]ZVJN2& U$KB#MPGQVO;WG@ V/L;2!L_;
MI*_B^TNK@Y-_-Y<V!E=*AKIAMGK#F+;6'_CF$]O[^T4=?\;Q7_LC;%"@CO[P
MCE[IEDI%42J*7'2J!%6&H.(9L1Y&@/9>4"D"R%)2'N"A3QB@4>=_B.?_PW8.
MAP*4JJ)4%>EH2$FJU2355PS.(QUI?5'PL.?22E%!%A50?J,Z>W7V>WOV2DM1
M6HID-+0ZJE+A@JO$B5WO*6U?JWV0/%-+MJDHFGLSS=45S2F:VS'--13-*9K;
M?=*TY$0G$9S&CC!,PXJ.9O>7 J$U.)GLHVNI:/NK]$.I0RK!4.J02C"4.J2M
M>;8*UA7V'GH+ACYWW(GCZCZ6P=K&GC?SR@H)R%6=GUMUGP4\W)0/#"L7JS"B
MLW3/!M7XY( :GY28_;+P?C? ?CO#_2Z0_9: ;S2;E5Y;(L10Q8*2LF 6U.X&
M6'!GD-OJ!E3L5V+VRT)CS6"_O>.=DE]?$IG3A] ^[!SW%HOD?$;(-0:;.)[I
M[[=9+26R?ZX@RP*>+94EG2"QZ^$%)S"E11R0%E$J?FME(<&6RG0NBM^6H5:V
M*O5V3_&</,/)PW-9&*VELI75':?XK43\EM64?G?&L;J@RFX:'T:D>3QF+M*O
M-M$GB"*D;&)9Y%>C[#9Q1%LW2%K?'?^K/; "@QG_-/U1=L\[&21DO5+M2M3,
M24(>.5B6S&HZ7RJS65*65!J^8L<UV'%+^5<[C#XK=E3LN#?LN&(^UF'Q4LFU
M38GL\4,(5?\XN3O1'AW88ALI6_-=8@63[7D2>+D$W9:RWG9FF?^XN^=T-94K
M;:?2Z$GLFI2 !0Z6XU9,=)/6\"Z*XY0FK]AM#7;;4CK6S@QKQ6Z*W<K#;NT5
ML['VBU?*K0Q*9!<?0IR:X%*.<0,8+"RB+644RR/$MI3>MC.CF$CLC"A,*0U*
M:9">WU9,;Y/6)"Z,WY8H'NU*JRZQ0UX"'CA8EMM21M;.S&)UQ2E^*Q._K9AN
MM6?,4N[[22+#^! "QG\Z-IOB:S^9KPUA!SSM_4#W1AJ+TQP^[-A,7AW$?XMS
M>#L2<V'R<.6YYXC-LL.2$4WSAI%72-&K"-WL!)]H&A>F-[ <G,DZ4K=Y=%IO
M5+K=JCQB=X/T+2?7R3FKTLF"LF.D%2(+2F2N[#W'R3FKTLF!L@.U*3F@Y("$
MLRJ='"@4,4XI]EMC9(G<+GN?CQ#]UZ-IW#N^;FFZ:.A2K*>E48"G92D)PZ0T
MPPD>+#9+PW+!;*X^[QSA6A(4NR7N:R+D#0E83.2J5AHR@7&N?LJ%*B6R3$MQ
MM^#N3DDP\W;+W>UVI=-J*^Y6W%UR[BX).M^&N;O$'@Y96$C2:2G.#CE[%SB
MN[UT:]5.I5:3J#IB72807HMW\//!,::X $R<.7U'2\-3,^U I[6]>Y=MZO\Z
MLX1?/\73I=FFS'EAS0MC/IF_$DYL(@:'??T>C&$#!CBT83Y%4\??X:749U(4
M9B"%M8ZK-?B7_TK$-DL57^TGYOE$35]M3 WJVP9WCN$>H+/+3Y3DH ^,N;YN
MVO>NCC8_)ZJ8ENYA^#/+&?P\"@D?B(H!?4U@3-\-V!&LC!XM3NL?1ZC1,LL2
M3H3H;V^B#\*_9[D_8G_3-IA-Q_]"KACR/?%#S'=!^<YDWB$DGEWO+'/JS!WU
M#*'.TNG2D__\<-HZ6=:#5TQ/#WQG]].+Z4&[2U2]S,\XEY.VS#8TCYPQ9H9X
MW0B1DZTNO&PCICD/_V$@Z9YX&P<?7CEWQA/=GI*RTOGD:6;$4]K$L<S!5--=
M!F2G,1MYA+[CZ4/FPQNVH4U<!F?S1!(&'\F_S@R>2571=$][!H; G_",,3 ?
M,J!FF<"<!K"GY@7#H3DP":H#/L"8KU'VU=!RGC6\14QQ7YQH]_%TQ3@P7?B/
MO0R8Y_&OP;/CXB;-]+P YO(PU8:A0QT^X?FF'^"$87Z#&+YS0(\VD=QP90D,
M$?T1KC)\GC_2?5B$#2_0&P_,,AEN)DS]@>'Z1W"9:P.7P=JTOP)@6A_GJI&X
MP$]9YAC>P4W4QTX C\ ]@S6(K["7"8FB]&)'L'NVX\-VP /_"PO"%VW8*9!;
M'HP^=)TQ/24^/.]D$5UMF'9!D,,9(%30*<IY;6#I'ERT-U_._LB6?_/7GWB%
M="%Z"65MZEE7][?1P[+ZR"<&F/GN:'CL.L_S+Z*DUFZ^?/_QY\('9[NW0YDU
MRZ*@6]1:XHI+_WCW>12)]9O^E\OCL]O+_A_'_:O[RUN0CM:S/O5"/0"]YC9+
M+>J3-F)\=^IP86@B7O"W*OV3%4H0;QW]-KN3OU]D[R0>Q]K[>']]_LVT?QZE
M+_FL'Z0<A/221Z%+[X(\G4K0T^RZ=BYM?]@1MSZ"Q/-(I@A^1<TZYE0N55#*
MZF'>,ZJR(&7A%WS990/GT:9'@2C1!X-@'%@Z"ED462X;@6@&D4Y/KX :;:$T
MU&WX+9H"O@72$)4LSP3Z@I>$R )1Y.(,;-BR,7:C<J<5'.9Y9 Y&*%.YR,]Z
MU@@6SQ_D3,"4)XF:%ESPLND8J+]84UC&D\F>O5E!16O-F@:J[)9IHQBWM2&H
M_MH3ZOXH=.%J&#@>R%_=,_G./L,F@"1V-?@?/A2>"?.S'_FW!Z8+F^;Y< 70
M"P;!BO.-Q]4-=->=@L*6$,HP$PI( 5E-2?@^\(. ,?"$=BE>=Z,:A&<6WVGP
M(F[5DVG 139+ ? !E]'MCS?W_)E-7#"W7)/.W0LL'W>7WU,H5>'P-6K/+ [I
M1+O-Y19D 5,@T=%=2K0"KSAC?(,?() >AGB)*^"<?:XSX$'&M$D/G6<9>AD'
M,1C,; RS-[3 P_F2KC,!PQ$T%# )X(D<D!YUG3'S1P[0G>F/--_5;8];D!X1
MB8M3A0_I^)8!3Z9.U$BL:?X@&0K/A%6.8STUH<#DB(; HY6C 8W;GURB%[W*
MXZDXC;D=>M M9 7-&X&^M7^D/'0L$!%T@KAE'BB98R3&_[*<;1XQ"TC UR[8
M@)P16J-6T=#N)-I ;X?VGBC-"3QXQ?OPL>@]V[P&]S93/#:S8BMKUIYN],^K
M%YU>[[AQ=M$\;G;/+H][E_7F<?6LT[UL7%[V^OWS&8-;$QX,9O1]M,AKY]WS
MBSY\N=_K'S<[%ZWC?K??.NY<]"ZNNM7.V7FMMY:1+I09L!+N\:N1>B2\,J!1
M6?K$ U4C_&U68VW-:K5DC(?*5*_URS(]\A7>I!6\!_%Z?F?DZSC*<RAL.J=E
MB]DJ^>[?K8X!1PZD8O_CJ-9<;B<4F]&TTWR>K#U(EU9]?CA%EZU&/ELMZ?S%
M>PKNYGEY^P,OWH_+/$H%YS$F4\44IVV!T^J*T5[+:/VQ ^2&"O0Y6$:2,Y"B
MJ!)0U*P'0]&4HJD-TM0WLNX542FBVIR.*3DU251BL"-DA]  ;G9_*1;E 34D
M45^P&Q+9C22!987#/&0FKZBAU"&5?BAU2"482AW21H>22%?8^W+$3]C&U\4(
M)H;I'-O8<UCD+ PRN5*6<U*16XTL ,E6F(J<V]A,G&T:/6X=)+KT$R*?&[K<
MSC"\NV8Z<K==:=8Z\F0C2XBIJ,@?R3\+S[$X\H\SD;ZXCN?%SITONFF?,6
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M#NTF/V3.6M0R77'6[CE+(M5A[RWTS&XFD\P4;6J^7/ND8ZZVM^>1:"GE7*X
MRP*K7JFZ=2LBJ%WIR%1P)R'E'"RA+FA67PRAUB0"=9'X&CP$"_H;\[R/6J+;
M!5#+Q 6"T8F"\2K4>7\F>F&_[[^#, >R&ZFTZPMRN9:4LL?$<Y&@'?C=8O@+
M"*Y^@H1RA=K:\JS=Z,@CSZ1K&ZIX:'<\M"!+3'(>:K0ERH)\/0])I#4<FO&<
M7=E<T6RVY]:R@L&)Y-[:R-2Y@NP[6U>6U:K%Q0=5OT+%*8LY96W@ZRUP2J-
M4,D=M53;/4+4]J%$N+=ZH9FNL9<)LST$%'$Y%+7&; .,^V2-OX9"FKZ*-%C1
MGG5/^WM.MM1,$DDN,,@B"DXJMA'%ME>GV-;1:?5DGF(UV&$KW(2\^=<RYM^,
MY[\2!VYD_O,5&.'\*YK+O F#%Y^8-3TA<BJ(AK>! 046#JC*OG>C3Y$_T: 9
M#-R &=],_<&T./1=+AQ4N]Y3<%!+\98Z<L-!B0/7+KEP\@X2""K<!"&AO?V
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M>B=\B0GQY='-;Y@@<WW']32#RL CU=?+TWT3RA-S<06P\9;E/'L?%VWEALV
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MP1=5/&@O2:^$<=5Q6E<\0FH46/A.:#A/@#^D/7X%_0)Y"3TPH3O>AY/13K?
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M+OJVBS77QG(2]YN;%9)-Y?*?K,R%E?*?96^ ]%*S.AD(KE2APU2%$-L^RO)
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M)EXO8%77,,"Z4,B\IP[2@B)S'E]>4?3\1OERK51O%*B,F.++A>#+]863 (O
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MG.J-8W9"K^D-2WX*XT.\?C-)-@#'AU/I,\/EHW-Y= .1VBX>-3S2'Q@N[L
MK@CKLQ@JQ;"MP,.'7VP+5$YF<,^ESO @WD,?SHV)-^RDT3P\]5=H^^+-#HL
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M7RXN[A>!BE3,^<A!"'LBTI/=]#:!S1HVF:$A<GJ0\60?&+9/FDS7 :Y C"0
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MPGC&OHQPG\>>[V??$&$RZ'+^"S!/A!%QQ#G-&\BX3/$1,\T8L!]!)6C<PD^
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MJ,/ IYX1C,=/\P$S:7>.,TQO@6MP>.E=K!6?9#,-[1X.GZ!,IP5H(1W,6L\
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M42'LT']>Q"_;\S[BT]"3PB?!8(.Y[_IL]]<4<V^X!=( JWS,/A5ZI$0R$(T
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MY.+R?#D:>IA7X?=<$$75O!K'E-CW\_\ 4$L#!!0    ( -<[95QI+88F-3D
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MJR6/4](TK+X[U&(.,!T UM,--X#1.RH:SY?T><*PKY#$<NNNN>7L)0?Y:Y?
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MN0^OR7+7S2# :H9'8]I:.RUA"\A+'%)*NFUNL[6M:<3A"#Z$(9;MV-],J_F
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M-&:A!$HI"UD#TV%FKGFA61$=2+W+NZ1]7%[XS8;-)I'#>E&FA4%.M0 M/*I
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M15$\E')S=+=2GH>P8DIQBS_E8%&$@OGLI&KIQ!?ST)XB4+O-'0@DJK_><6@
MY##FJI/@3G1^+ODIV9FL)/>64LJBF&HD;7K1HLC2>#D --*9[C68U[KNTZ;)
M^/:U=7%4A?:+N\FL&[OC_NR.!]PC?/1A?'P(_UV<!Z/CP\ Q0];7F!C0(=$!
M^+H00Y^ ;(EM4Q%,-"= 6RH.$<AA9?,$=6IW)V(R])08W889<Z>F-K4"[&;0
M.?&:8V&@@\,*>$T\P] (G6Q,].CP.?ARVF3Z9O;#:!^2 #%+AC.FXJ2FQT>4
MP&FJ,# 2<;NCTH6QZ!^I[LI0&YP"FR@-*C%Y0E=6) 5/L18)QO]T*]X.S?/8
MJ^6B->IR!0H;><GR/76;.@O3+ZA@%IXTL1(_3;L!M3L_7=%0Z!*'OEZY^"Y9
M*X5/X01I4/$N9[+#4D?#[M(=8N&5W?_,V!.W>EV*#<=Y^VG/G1KV:C>@RI,9
MIP^SQ[1=D"J-#])Y6G=7S6P<L*%946(@$_4>RF="=RMOE_5J#?9F=G=T(W/N
M3^8\X,ZWYQ>CBX_GZ+TZ?3_Z_N3,WWIP7+$,3_L63)Q(@#4K\4:HW#"MQ);P
ML9^\TH@D83M%TNN80T]RD[@CFS[=VW416*W( 0ZQF=Q-$4QPD\HI39)Q:SA3
MTS5[FMOV_%.?L184&RQYR.@P_ER$A;C:G-1ZS?R.>A'4>PKM.(V!6=R_6!#$
M.#'=F(ZKTFQ^J9O*"5LU5ZKN37QP$_Z<M$.S%Y08:O:JG7\ID4:3N]I7J*8^
M8_F.I#!R^N2JP:8L@NF>VA:R@=Q0EP5%4]"/ H_;\.C[X]$/N /,N_'Q^&ST
M/C@]._GMZ!PC$.O+IW^'[B]%<.C4>M\FZX_*DJ2ZC@''J5J8&(:?P&2AUFQ;
M.$E#II+5;IFJ4\)J<97D75C9:UY76S0XT^,ON$H5)9![U>LUUX)_OV$$V.6C
M"G<EMLET?85H;K?6L">Y'%=6Y]D9AY"N$6X'@$2.2 $787?I2,8U)@>XFTZX
M8_R^5AO;ED1VQ/L\2A$OJ]N+3W(3$#6,(,3H2[PZQ  [RND.D)]I_=*!>HBJ
M.OB48_&CW(LI\U-X<X=RL46PU^Y6  J_=EG.[[8L7$'?:H\,VI+*0&"719[&
MM!:<QH&R&JW'J6XGO2V>OS]Z\4+=C!.&DFI2E3;7*'+91V%^$<0!W1!YRV+]
M<8JH<J<K&2VV=$)GLLCMVUW@ Q@1VZ/2\54FS/[0<AGV++Y$W4PQ"V9Z8$HG
M.5Y$I<*K!ZHY"+?((6*YC+2=5J:HRV$];P!!5+=S0 2G3E197%(NA^RJEZBM
MV]RN4%36Y$JV!3.#*P6$T^VP[3\'";W2R5=TMTV5H227*X9=V782GKT]E^6B
M+!O2HK%CDTU6(\@H"T2 X"4AIE@U!HED&EP6\ #J=QAEQBT@F3:<AV4>P)O9
M;DI$6Z4]%EZKQT['#1"(6<K-GC!(QWYN6 N@6JYV'4SP-4ZXONPU(BW0_DQ?
M2<XX<ULQ^MW(^@P5WHO^]6_GKDV]DBWQSBE00H-_-&5:)?PB5,SB1E;3Z.^R
M"2;!#A="*GN7L#1S?PGU@JQ8MWX%9)%%,<88+@DLEKQ3>GEC#]W,]$XW5SEG
MC;01Q,U DO+7T)*5;(\TY3JR6*/ZEU[4C%:KZ"$KSN:ADX_5;8-&UI9@D"+L
M& TF!G)&0 (LXD>UB<@T% 9I88B&R* 7HF4E:0SE-YKZM\ZI"[E<W)ZBOCWL
MZV_#V\'KP0J@68N>E]?IG!(.R[XCT-MEQD/ZM+S2XXX.G@0\)$^*ZQWN^,8N
MQXA7+#)0JCHS3U0-QU%;],2W-G5R=\RM>'I?N15/-[D5WW5NQ:UP>YS^71[6
M^D?2JXQLZ^C[/7GWIF753P3MHSV6R+NN"A9D&H'#8J1[(3/;--UO$48(;^1W
MZU9,KRJ?Z_5::C:9M]1D7_N<&F.%0T+^0"4*TVI+UAZ;?M>ZV^HKT6-.:,'>
M. 43P<CQCQX@QM[89G.X-*CC:-+H4XLHWT;7R>JU"1IS%A!!*:%PI??[^>AN
M^8;GK76%)WMUG2:PGEM79*>DFXCO'6.V5NDJ2N\3IN!CMU*N18BI_ZOH%3Q8
M+7#;.&7<X !^$N]T4I!]!JN">C275J""+_DRC/*J3YZ.D2=NVE3'3R7$;= %
MENM.LNH&0$^B@%/.#3ISM#(F3&$)FENX5HSL40N_J,\DZHM>I!PB(L.!@"AP
M!&+I<7EDTI0HBR*.0G/0NU/1L^Z[-UVU>V] FT<U1+9/NE)^U;;$^I&<+?:0
MEG\3R?$C.0^XC]WX[5L<Y6_CX'!T,?YNH^X7'2<[5;Y;A#.W-IREFX9(%7V+
MQ/SFD-W;(=M_P)W;WIW\-CX[/CI^%[P?_>T[/ENMVFGZ*(XES"63."++0R,&
MV=%,"2FA=@:"[M/TVGOL#GPG62=O"D2P9HWZ/:9#3L7C*)V$#E6&#9V4='J>
M1W6-[E^G_+:*BX72X4W!]Z1K37:*N:MOP#>.EUWSZ%=!$T"CA(NXGQ?YM8HR
MN J^^Q!5513/&O2VH:Z%2KRR299< "W*]104 E+.,0=T48+YD"XRM1HP]'??
M]C_&:=;CVWKV%;XM;SQ?Y>AZ]NVZMOK\5-\L0WKTBA2;T2GFJHP/@]=_#UZ?
MC,X.4=4Y/#H#Z7%R=OX"6$%,.,_!WD\AR)+]Y__.$?W[Y[QYP^8-FS=LWK!Y
MP[_Y#8Z,?3\ZO]BQ(KXWOO>U<;OG]Q6W>[XR; 5_3(ID"7;-K)YGK_X_4$L#
M!!0    ( -<[95S'-JD_.CP  (Y9 0 -    97A?.3(S-30Q+FAT;>U]Z7/;
M2)+OY^F_ L^[,R-%4&I)/MJV;$?(LNS6K&UY)7GZS:<7(% DT08!-@J0K/GK
M7UYUX: HN\<'K8W=;8LD"G5DY?G+S">S>IX_>S)3<?KLI[\\J;,Z5\_4Q__W
M:._N_7N[V_#MDY_Y0_CV_VQM1:]4H:JX5FDTOHK.9TV1JNI%.5?1N[*JXSS:
MBO9^WH/_W=E[$-U[?'_O\>XOT;LWT=;6LR=S5<=1,HLKK>JG=YIZLO7PCGQ:
MQ'/U],ZDK.9QO96J6B5U5A9WHJ0L:E7 KVN5J\6L+-33HKSS[*<G/_.,GXS+
M]"K2]55.CQ?UEL[^K1Y'NSN+>C^B#R;Q/,NO'D=_^Z,IZ_WS;*YT]%9=1J?E
M/"[XP_UH$:=I5DP?1SM9$>UL[V;%?I0TE2ZKQU'<U.4^OG-A7C2/JVE6P(\7
M'R-Z4:T^UEMQGDWAPRJ;SLR[/VDRL"?XVV!5YKF_MQ[Y^RBB3T:15E4VZ;P6
MQAH_._HXR\99#1]L[_[RY.?QLR<_X\_@/XMG/ZVZK%Q-OJ%5_:T8Z\7^P#K\
ML5LC[[N1=O=@_O3G15QE<5$_+I#\\GUOU0G0GJKV96-PP;2AAR=OWAV<G47G
MOQZ='KP[>G]^?'@VBH[?'F[S[@Y/I[-2?T([ Q,*7F]6_H67?/3FW>N3?[TY
M>GL>';PZ/3K"?WWCBUWA#;3N#%@8?'OW ;WR?);IZ&B^R,NK.7P<'4PKI>A?
M&W_[KX=[>SO[]A/Z>W=_<Q2EQ!!C'963Z!]QT<355;0[BI )CB(8;QZG*AJK
M^E*I(CHLYXM8:V">P$@7JJFS!"C]N$BV1U$<O5!Y?!E7"EA?M2B!TP(?C#:R
M(LD;Y%!1G.?1Y:S,\ZNHO"S@K;H9ZRS-8(V*WK]L^'JF(ED%_:RX<FN(BS0Z
MJ'YOBNA=%>LXC3:\7Q]]5 F,=*',[[>CHX^)6M3195;/HDKI!;#LJ"[I%:=*
MUU66X.]A.A>J@-W7WD[BJ_!W1W\T67T5O2B3!C_7T8:*DQGN8ZHF&2YNK/+R
M<A,GGOD#Z&:A0(JDL&+@U[@E,@--?RRJK*RBV/Q<VZVGEYJEV&G(5L 8T[BB
M3<9/85]_QS6!1((+$<%NJJR T[0G@2LOFSK*LWE6\SGA*.5D C_/%3XUBI2C
M)#N?"":GU04<3Y$H]_'VVMVEWX _'AV<C8)=AD/+X+205GAS!D[%?>(],5;R
M$.L?_K@E'R_L^ES3(* [I!D>BR8U(B:"XF-<OZU^>_+;B.31T<N3TZ/1D^Q9
M].3G[!G<#E@[\ <EG 08!.[2O*D;4-82>SEQP[P+P]OD[1M^7\*3530M2_[S
M(LZ;>)RK\ U\V)5*5+;@FZZ;R21+,E4D>#F >65PQS-^!YQAG'PHRLM<I5.5
M\L.+N*J1F=%\D!M,@-V5E_KQ]WMJJ$_Y_]=WA+O;/(/N_W_2/',2Z<G/S;/O
MF'Z7[L0O>_3^C7ASR5:<PPVG34 19Z^_GB'G7Y&C\(^7,),%Z/X-3)XE6B![
MFJ+.<B!J(&*/N<-/D/-D!6D"*)02$. I<7@2D43857F1:>)(2/QP&7P9B^MR
MXO7<GS!^O/O+OO;?:$<U<[[,>$TR7%S3)R,9,IJKN&#9!M_4UXT^CZ]P+&]-
M;79;M7>Y)O%7 V70CD]0!)-4C34P'B-.145@-DW<R-_==2?L\3+"?E?J3-2(
M-'K1( ]T=-XF7K",+H@YTJ',,D6:WUQ520:,_019+C!K8?=R:",X#- I:R*#
MTGO2#6X>-,KNX=%)J"+RVV<Q3@3OP**\!%6,ODH;9MN:J&=2E7.F!GP5_G>,
M-T#II,K&'CT=G2 ML6Q)&U!KP=Z>E15L>1HI,Z_^/4C515FK 6*>-*@IE]4'
M6JVA2C4!NJRU6?ZXT2#>M,B_R23.*MW:M.WH;5GC9=,U_,AHAS"*FI;PUZAU
M#7#I?#8H;6E5XQ+42AHV!3TFJ<L*%')[?>,%L@4X,WGM<_PU_O'"_+@UH8!I
MT*_="<%.JF(:3Q6RH$J!19>5#;P-O2Z@I**TMIN= +DT!2K@,:KJF3F\O$0S
M0_/QXE* (&2#O-^!A9)F.LE+4,/-;O+4B13*J"B!*Z(M">JPQP.[!P6J/#E^
MD%7*2CL_ @LT0G-32,P0KSFA<_X;+APIVHM%GB6XV/;A6+Z?(KNA>1,E U6"
M[0L?$-'B;TJY![@8.C_@G_,Q?+"02ZI[&&D$=AD<=(<S"R=<84Q8?P;4*=8,
M3=DW[X1*LSP#EJRC9N$IO<BF/0UO*7</>7/_Y>*[I^AWJ;70B*SP(:(E/#=S
MW\>XC7\T8/KQQH)6.,G@:R1),(D24#AE-"(LWG*:LEY7KB^*W=XRQ0YI1!4Z
MMHS_5.4D;]^0W:E_>'7O>:Q5=!;G<775(PTM=6? R5#RC?'GFG[NKOLBSM)(
M;BLZK_&2_/>]7^Z/=G9VD/]$5RJNAD;N'=%39^#YK$RS!$CZ(H,M&E\9;N6Q
M\\HR!'O8**XS.&,5<GZ?N_?_/E02_>G![>2[9K2Q*2RD8.F7(5L!7EP)WV,+
M#RZOD21NG[>-SHCC>Y_[&WI%# !'@-M?%*IB?IAI-@=UW:>CVCUM-)J?,$I5
MDK\&)0M*&61,5N@;AOE%^4.:741)'FO]],Z[5\__YXYYY666UC-T/^_\%71I
M>GP+?>*/V54NGY#SGS["@$$PULOS4SN8[U@7AVODO:#U[&RR5967W0\3!7OW
M[M7;]V_<&N 7&!WQ__/3DUEE7OSNX-71UO/3HX/_V3IX>7YT^AB$W65\I?=!
M(%5@PC\&L5VH8#+[0"J\JKW%QWTXW1R#(O^U0_\#SX']/JW*IDBWPJ\Z&_#K
MB_X-X,C")R[__.3P=59\6+H!=A]ZZ>?&T0=SV(_[@R3? #]=:F4<%TAQ[)IU
MW&78T$ K&?5(O.[ -\BS U\FL9ZA,U3&2@(QA@Y<UDF<HK\*(^S8#$,\N8;=
M4,CB"N0C ].P\[]W_Z_#:I'/]^AM*XW].9SVG%_PO"P:';#:."&O7#R'ZU0/
MSWCIS$91-HG(UO.477L6&>N+NLQ9?:^4KS.N<D0;=:!K9S5HT&R$BMT&]@3\
M! P 78)!,F3VXY8Y/7UHEQ=Y7+!<$0W3;7L/J4A$ J9#CI:4UWO&L60=W2?U
MZD$G8N%<\6-5J GHWR-R3L=5,;C'+9NOT?4*KNDT%MUWB*8T*2KKKNTER[C3
M&?#1K9,BLEQJK11@,@CZ]B1;J@$CHUC.H O":*0^@XXC-+"V@*[&^#RIO/=W
M2.,USAVSV?0"YT1@#WVH/!O&H3"J@HJ;J+WBFS=ND1XW3%;!Y4A%Z5[FO[2S
M @9<1R_@"3,ENKB9]ID)SLWC'W7\4<QC'!;-<)B1)L< W6-\3[#:T377M^?J
MDK^(MC(SL2BZKM&Q[T!CNU8+?PJ= *&3&'7=)&Y ^A"(QC"JZ"[<D*YGE!8&
MIZ"SC]'&@\UH#B0WLZXAMV?^PBB 0G-UGKM*+60MP7[@CXP[9>TOV]+;=E:7
MR8?H9$%"@V_=62C$VAZ[ 4D)AX6^'"=F1^15*UE!LEZ4*V/^B$?%OT[^L09N
M_FDEP0F/&="\2YYW8$7R6NQEFHB 7S15,D/EA\0Q$,L4 ^!\3W>13Q"O *JI
M&%B _D+4JO@]H4L2E2 ,NX,017.:'HK4'ZBFR*:AIQ"7!9:JDE_*&.&X?-_>
M'IR]./C?Z$U<?0!-R5Y"GAPMGGDA+\WQ*OH*[I8?OR'FT1^0:9NE>SM[]T'T
MI$W"=^X=ZA^&+]&7^(G=2>-*O<S0!*^K!O2WBH$@,>H.=AQ$=*2^_SST(. G
MI!F-(A!XY)[7R4RE32Y,C1VV7OA(*W+BU3.VP#5<:O9K\'XX3(&_2T0YY.^,
MZ75T *"T;NSN;)('!-ZOK [EK<Q_&4D!C]3<NWA]K95U%H0OG91-%6W<DULH
M;Z9#V7.:NA">>5YH@,4):,! \I5&GX3\G&]$RC[&5(+0\SBCF%=K+"),N'B$
M-B%&&I47JA+'OKN 655?;1'#O6LY+NTH3]S?UK$:&4J?QQ^S>3,W&O(".;[6
M9#\QH_?D5AY?CHPSNH=DY &Y#:\SGOXI;N/]!W?O@Z" 7=R^GJ-^1UQ[2&M,
ME_'LHX_(@)>%RP:4)+A2<W@I&&CS,; ,Y;SC)"JMHUO)"U!U;\BP&[>CS&E3
M&;:-D5R\*Q+9( HT<12T!NE41X-1XC)'N 3??)A@ O>&X"\S%=B=&,W2&-/)
M]*QK<^ B4/P,>]/(F\+X6I5R< A.-,ZUNH/W*-Y".KVJRZ=W:O-!4Y=;BVG1
MS)_>T2B:Y',0<6"I7='G>_(9GC>C>EN$X7V/U/'T#B$Z^4,802@KED\68$EG
M'Y_>D3_IK<%["%WB?H"D0\Z8IW?8L=;R#'W%"W+KJ'S_QIWS6%7N$-NG;,]T
MR30^!XJ\=^LHO764@E!1RX3*"2E=S\4GM+*#E-!K2;9 302X-;!A(VR,>TFD
M>I\"*B:H_2UYP/0RM]>PBXWA&?C\NEAT0\<X68JJ0?<%3@"Q+2LK"'7\03P?
MM-D@.U>U(3SM+GR>Y/I5&.+2(R]\OLRYN>8G.%VJW1%,W!V=8M@X:<BH4.6D
M_*#2AI\X.(H]8A^U7<]*-&D6*LDFF04$>][R*9H"7MRB%U <FK]]9R^3=*Y>
MO(D;>M-:)]YO6=>WAA3^BF=A%,KP3O>O/]1&-T#&Y PAR:\"X'\;=&^LV7WK
M-1]%L_(2G>)LT14M^!,L&#U1%D*&.F0ET>>Z!]4_LIZM!QOQ)GI?>KQ;O/VD
M<9IQ8 8<!8D#?$M+SS4H_$/RI $1=+8"+]PK!"V?,A(1KUE&O)W?((XU1L/%
M!6.G#G%1)6@M[.7<,'@HH09$/P4I"NMZ007"<G<9A.7<G<XRA(;G^[5&4 _.
MU!PH'NZX(A.]2RY.@CI[/<FJ!.T'9,]KBQ5?"3+S0L7U[,9'P5?0G@2CRU(<
M:EV)>Z5X^8M,Q^,L#R2083Y(O6[#KH7=9:V(+@8$4AP^EPR+AKT-#"HB<!TI
M"QBI9+$V5CV_(6:I-<J9.(\F39$$0JHG>HZ>!/51W$D&?8CO<DA$<\,Z,0C\
MF;FCGH<$5:/YO$R929,+Q82(T)_\< =C*#K:X.!2H10)%EP0XH5DAIND9,'&
M[NYML5^.AZ 8"WY.^$+G\84CUPR"+J/+F1(,<252RKQ_>,]U*0]_N7U==0M[
M<,4LC@V,C;&6;4<\[0O9!//,F@362P_&,Q@G$U [#(C!>WVJZCC+47["R<VN
M-!@Q,6RTRIGZ6G*7=EQ"7&Z6[:P NS73!E/K8#Q$"Q2E_]Z2S!?!C7@'V3DV
M."U[<O B4%(8JTR".;77%'_JWQG43[*B4>)_QQ^'V\"TY(5%X+143W*"$"MH
MDIK]:?3[3.MF )^>E.6"DN7YU!WBEM;=.D&WY9QX5<BFT*/=6=.5H(_[[\1
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M86I!&YFY+OMVLR8"W1)5OH.TDVE E<#*RA@NG<S+:(/#-[T3,65RO8+OE:*
M4X'8#TXGP!(7M=J,0'&BJ01.G)@2->L9V,E37L<+J1'D>8[W(\HY; I*QY5*
M'F')#QUMN"SJT4#%()?'N-=;H6N3>%=$0H^F>B$P4)/VW4GH8((3OS0\T)O]
MW89S7K-:4[ZM_?)6+>0B_=D=VV!]I%;>:7]R^G"JZ4&2$)S_9)Q+\,UFFW['
MMVN5?,E[R_(EW[+N05T>N@>X3O4.AX(^2[,7WUKH32>Q],AY;?V &2;GVH1N
M#U:"(;<1AWMN6""_V^S$%J[O"5CVU!*0Y@J):9UB0!6]BS,<4LI\Q>BV0>].
M75X?:+*QE]Z1^_(4C.[KEWG$S)W$!'9E+Y-@J1;"8Y-XG#\#&TW ,C%A=-TI
M=WFJZ,!M-D?4\WWW@!Z3J&O#%GO320-9/;[BJ#1S8%,KCSX2"7CS,4L6"U*-
MV(MUMT/;XTTO];Z3MM,37O=G60@I]M\-F!'55MX7R?I).S,(=.A,+>V=6GS-
MY RLA9^J;>4\RY5:<Q#7<.^@N-"+SUCG,  !U"@/=]FJBS"BLGRUHH* ]S;;
MQL7-]H-UJ(W_V#(Z<_^$([O6<+JN\4]0IZ(GB(^OT8/S:'OV??) W1"D!S8"
MJ3BNF"0J9SS4@-[GDEOM;UU.J =AH7J12T WDZ7RYK83P\TBEO>_4L3R_FW$
M\H>*6 Z8(?>7F2%GMN[]NYCS^DRML^@]EOY8%2NX4M&=DZ;6Y""8#5?985W)
M_-(PY&4E>4+@]^-H%9?'#72#_DX"I"1T^Q_V.^O:^S XI&*]H^"RH*DXLUA(
M&$=)CSUMBAK8$G"H/+9L$B!(SK65,L%!U5YZ'C&[Z%<AX<!-O>!3Z>O#J5MQ
M0F#DMM0*C0B$SZG^3-LXF@)U510[SDVL&JYPAN64IC$"EX.3H%(75(25VV%Q
M%BD7XJ)";0R(0M?4!/N,6=N.N[<-T,$A.YQQ.[Q-[-(2[/@F[CAMKU^XV3JZ
MJ-E1&_')$5\JW>K!Z_M>.8K$>V;3X/"W[DH>< \0V=CY7*68S@2:0$)[Y\<M
MSMRIABVV3WFCP_Z-9 GPNY8_!AL!1BR!RJM*79324(_ZCP]YH/OTD@T"21&1
ME!7^4"(UL>X6EKYN3IN]!$>4C1K=QB^;KJ,CENSG>;/]2F]=E_#RS1TK_:[;
MD'S1.\!T9TNW ^< :GOD]QOP/; 2P)&3#H@RI.1NE;FV^MPJ]N(78Z24<G-5
MPM:\UR8(C?HOEM3D3$W!H23.P0J(N1.<;:5+$$ G)61S.G,-.F1@WB"'>8,A
M;SCM8#.O^^V9JLO)Q&[QFM/XL NF50FU#[<L9(1T##KY/&OF<JK:%%;RZS+R
MEEOXIHS#+00[%78\F!3&LB,JG"1"?&D)V$*7>9:2E#N9%QEPL.AYDV*+J%-L
MMY)0*BOQ1%.8YN%]JAL*I%;@3=KP(M@GST\/6K'K_IO/>X0*^P+T^CBON5BL
MN9^5/(CCV<]ZNCXS8\CM!0V[/I@O90LK+A8)2^2-,3:S5;\H9YBB(O,XE00D
M%K@R1= 3FLH UUH7L2V-9W$J/0"PE?! ;R9NYTV,**[R3 HR85V0EF= Q):$
M%QUZK\-:A"%PS8\!=93J!;,K#35$/H6Y5"&B8VA1"BD4Y+LQ6^E*:W4>MO5"
M\.T(P+K&\1UP<2ZN)*^EX^^M#)J%42D/H\2J40W\KT"_P\)TO3+W[%K*LQW(
M0MK;P')/]G)N6BUS4=;*X*\EZ1&UW:#) CR\O!",#>W]LOO ;-2[!O2U)/J5
MIWC&D$R\A**J]]PLV$G8':FK944658665I?F,VX%G5]UZ=@4(J,4%:$ZYTB,
MQR56U#H+7M#75*2./VX9Y3EU4/9VCR3N,H "K P6Y&4A8"9B95> C$I_:9C&
M.OB"'GPE7]"#6U_0#^T+NK[RFO#R/NLMTT:Q93@C"'<RXDSO)E_''50U6D:&
M!6Y@EAWCQZ]4;0 :TMV2.ZUM#+<2W71(]46542\U;RY]W>6-\;@ DS,K^]@W
MH5DX)YN(UVGT7(S=>V!!2$^2R#15I85Q@_ ;FL!W'!QU2&\CQDT+Z# Z<]^V
M09+V1R"&V'$0 E!0_F(WNR![BE5'= 7!GRS9T$O08VJN6(N_W6!Z1'%Y!2HU
MJG#&BV'<:]<[,WHU(=\5]&!G*W6]$<<*MHXN$+#/ECW(?JQ4FP9>U%>QYSJU
MU<OV_F9T)W,&-;L>LUBPQ'R.\E_:T?K]1DWHV:M_CO%G04&; [VW\^C W/9C
M4\+@%(WV!O>;';5@D3P(+1+/>L4?.6O$D,$T,P4#>OI+AELEMSZ/J9'DE<4C
M!9OM'\VDJ?!BCIR!8;K#&R.E[3]*XCJ9;8$^:GY )0BP)Y@A]TK552D&H9P
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ME>0QA=SS7$W9\=P4RJPDEX8"["T@2QN!_OBP;T5[]XWO?VHJ-X;XV?Y"'HR
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MLU?#N+'FL(K8@G^,R_0*>,VLGN?/_C]02P,$%     @ USME7'.*,#^:.P
MG5D!  T   !E>%\Y,C,U-#(N:'1M[7WK=]1(DN_GZ;]"E]V=L<\INVV#:<#
M.<88VK. 6=N]?>?3/2HIJTJ#2JI12C:>O_[&*U]ZE,O0S:/PGMUMK)+R&1D9
MCU]$/)W5\_SYTYF*T^<__>5IG=6Y>JX^_K_'>_?W'^QMPZ]/?^:'\.O_V=J*
M7JM"57&MTFA\'5W,FB)5U<MRKJ+W957'>;05[?V\!_^[L_<P>O!D_]&3_?WH
M_=MH:^OYT[FJXRB9Q956];-[33W9>G1/GA;Q7#V[-RFK>5QOI:I629V5Q;TH
M*8M:%?!VK7*UF)6%>E:4]Y[_]/1G'O'3<9E>1[J^SNGSHM[2V;_5DVAW9U$?
M1/1@$L^S_/I)]-=_-65]<)'-E8[>J:OHK)S'!3\\B!9QFF;%]$FTDQ71SO9N
M5AQ$25/ILGH2Q4U='F"?"]/1/*ZF60$O+SY&U%&M/M9;<9Y-X6&536>F[T\:
M#*P)OAO,RGSWM]8G?QM%]&04:55EDTZWT-;X^?''63;.:GBPO?OHZ<_CYT]_
MQM?@/XOG/ZTZK5Q-OJ%9_;48Z\7!P#S\MELM'[B6=O=@_/3G95QE<5$_*9#\
M\@-OU@G0GJH.9&%PPK2@1Z=OWQ^>GT<7OQZ?';X__NWBY.A\%)V\.]KFU1T>
M3F>F_H!V!@84=&]F_H6G?/SV_9O3?[P]?G<1';X^.S[&?WWCDUVA!YIW!BP,
M?KW_D+J\F&4Z.IXO\O)Z#H^CPVFE%/UKXZ__\6AO;^? /J&_=P\V1U%*##'6
M43F)_AX735Q=1[NC")G@*(+VYG&JHK&JKY0JHJ-ROHBU!N8)C'2AFCI+@-)/
MBF1[%,712Y7'5W&E@/55BQ(X+?#!:",KDKQ!#A7%>1Y=S<H\OX[*JP)ZU<U8
M9VD&<U34_[+FZYF*9!;T6G'MYA 7:71T7=2S+([.LRJNTFC#>__XHTJ@K4ME
MOMB.CC\F:E%'5UD]BRJE%\"TH[JD3LZ4KJLLP?=A0)>J@/77WEIB9_C>\;^:
MK+Z.7I9)@\]UM*'B9(8KF:I)AM,;J[R\VL2A9WX#NEDHN$=2F#-P;%P4&8&F
M/Q955E91;%[7=O&I4S,5.PQ9#&AC"O/&9<:GL++_Q#G!G01'(H+U5%D!^VGW
M F=>-G649_.LYIW"5LK)!%[/%7XUBI2C)3N>" :GU25L4)$H]WA[[4[3[\ A
MCP_/1\$JPZ9EL%M(*[PX [OBGGA?C)5\Q!*(WV[)VPNK/M?4"$@/:8;;HDF0
MB(F@>!O7;ZG?G?X^HAOI^-7IV?'H:?8\>OIS]AQ.!\P=.(027@(L E=IWM0-
MB&N)/9RX8-Z!X67RU@U_+^'+*IJ6)?]Y&>=-/,Y5V -O=J42E2WXI.MF,LF2
M3!4)'@Y@7QF<\8S[@#V,DP]%>96K=*I2_G@15S6R,QH/<H,),+SR2C_Y?G<-
M)2K___JV<'>;1]#]_T^;Y^Y.>OIS\_P[IM^E*_'+'O6_$6\N68H+..&T"'C)
MV>.O9\CY5^0H_/(29K( Z;^!P?.-%MP]35%G.1 U$+''W.$5Y#Q90;( 7DH)
M7.$I<7BZ(HFPJ_(RT\21D/CA,/AW+,[+7:\7_H#Q\>XO!]KOT;9JQGR5\9RD
MN;BF)R-I,IJKN."[#7ZI;VI]'E]C6]Z<VNRV:J]R3==?#91!*S[!*YANU5@#
MXS'7J8@(S*:)&_FKN^Z$/5Y&V.]+G8D8D48O&^2!CL[;Q NZT24Q1]J46:8F
MT5N59@EP]5/DM\"IA=?+CHU@)T"DK(D&2N\SU[+YT,BZ1\>GH83(7<]B' 4>
M@$5Y!7(8_90VS+,UD<ZD*N=,"M@5_G>,Y*]T4F5CCYB.3Y&0^&))&Y!J0=V>
ME16L=QHI,Z[^!4C595FK 4J>-"@HE]4'FJTA234!HJRUF?ZXT7"W:;G\)I,X
MJW1KT;:C=V6-)TW7\)(1#:$5-2WAKU'K#.#4>6/PJJ59C4N0*:G9%(28I"XK
MD,?MV8T7R!-@SZ3;%_@V_O'2O-P:4, QZ&VW0["2JIC&4X7\IU*@T&5E [VA
MT04D5+RJ[6(GY7S>%"A]QRBG9V;S\A*U#,W;BU,!@I %\MX#!27-=)*7((.;
MU>2A$RF445$"2T15$F1ACP%V-PKD>++[()^4F79> @4T0FU32,P0K]FA"_X;
M3AM)V8M%#J< )MO>',OT4^0U-&ZB9*!*4'WA 1$MOE/*.<#)T/X!\YR/X<%"
M3JCNX:(1J&6PT1VV+&QPA39A_AE0IZ@R-&1?NQ,JS?(,^+&.FH4G\2*/]L2[
MI:P]9,S]AXO/GJ+W4JN>$5GA1T1+N&_FO(]Q&?_5@-['"PLBX22#GY$D01]*
M0-J4UHBP>,EIR'I=6;Y(=7O+I#JD$57HV'+],]#_<0G?DM*I?WA9[T6L570>
MYW%UW7,56NK.@)-EP$7'^+JFU]UQ7\19&LEI1=LU'I+_W-_;'^WL["#_B:Y5
M7 VUW-NB)\O ]UD)URZ0]&4&2S2^-MS*8^>590AVL^&/>09[K$+.[W/W_O=#
M"=$?'IQ./FM&%)O"1 J^_3)D*\"+*^%[K-[!X34WB5OG;2,P8OO><W]!KXD!
M8 MP^HM"5<P/,\VZH*[[!%2[IHU&W1-:J4HRUN#-@K<,,B9[Z1N&^47Y0YI=
M1DD>:_WLWOO7+_[[GNGR*DOK&5J?=_X+!&GZ? M-XD_84BY/R/9/C]!?$+3U
MZN+,-N;;U<7>&GD=M+Z=3;:J\JK[,%&P=N]?O_OMK9L#O('.$?\_/SV=5:;C
M]X>OC[=>G!T?_O?6X:N+X[,G<-E=Q=?Z "ZD"O3W)W!M%RH8S &0"L]J;_'Q
M '8W1Y_(?^S0_\!WH+Q/J[(ITJWPI\X"_/JR?P'8L?")T[\X/7J3%1^6+H!=
MAU[ZN;7SP6SVDWX?R3? 3Y>J&"<%4AS;91UW&=8R4$5&.1*/._ -,NO CTFL
M9V@)E;:2X!I#ZRW+)$[07X41=G2&(9Y<PVHH9'$%\I&!8=CQ/]C_KV&QR.=[
MU-M*;7\.I[W@#EZ41:,#5ALG9)*+YW"<ZN$1+QW9*,HF$>EZGK!K]R)C>5&7
M.8OOE?)EQE6V:*,.9.VL!@F:-5#1VT"?@%=  = E*"1#.C\NF9/3AU9YD<<%
MWRLB8;IE[R$5<4? <,C*DO)\S]F5K*-]$J\>=MP5S@X_5H6:@/P](LMT7!6#
M:]S2^1I=KV"73F.1?8=H2I.@LN[27K*,.YT#']TZA5VKR^1#=+J@K6/F=!Z2
M4EMO'J!7H #4J!RQCTBW+9E-65WFV@@AHM>@M=GH^N? $>KH)<B-H]#2-JW$
M/NCQ3!IWR>,.9#F>BY'=2-(A@V!3@7*N%1^**)Y.T0?%(NHNRJ<DH\)9KMB[
MAUH[\C;N)S0,("M"SQ>0,@JU]%$$.ADLDBP:ZNLX+9 7E;PI;83M,L&^.SQ_
M>?@_H(E4'X!?62KFP='DF6/RU!S#H9_@&/@F5#Q[ S;1MG"XM[.W'YT4:9.P
MN?4]<@%CD*(?\8E=26/0N,I0$*ZK!KAHQ=[8&$^P;0?=JJEOQ0KE>'Q"_&D4
M78(62\N4S%3:Y*)YL]G$L^!J1:IT/6,Y6*M%S-H%KX=SZ_FK1)1#5H>8NJ,-
M@*MC8W=GD_00Z%]93N;-S.^,F+A':JXOGE]K9IT)8:>3LJFBC0=R&J5GVI0]
M=U\*X9GOA09 L==T0P+)5QHU WF=3T3*FGXJ?J!YG)'9N=46$28</'+X NU!
MQ^6EJL2\Y@Y@5M77P'X^1AOW'V[RBYI6E ?N+^M8C0RES^./V;R9FWMJ@3>@
MUB3%$&3)OWWR^&ID3$(])",?R&EXD_'PSW 9]Q_>WP>&!JNX?3-?70/>G2[C
MW<<?D0$OLUCC'5D0FBSU94DX4G/H%,2D^1A8AG(V*G+K6W.3D@[P FU(O!JW
M'3UI4QFVC<X4/"MB7R0*--9,E,EH5T>#CIHR1X\EGWP88 +GACS0,Q5(?VA3
MUFA9S?2L>_/C)/#Z^;HZ[=>@%+6,4DZ)D[X0<6MEW8.\PDFV0/8"6P!K:RC(
M2&YR5/MN%1'.[+LD7.IE$N6P],J>#_Q^W;=QLM1;A68U' "ZC58^]77\02QR
MM-AP(%85##R6'7Y/A_4ZM![ID6>97J8W?.T=7 Y,[0=<FAXCZ;+')"$;&9F=
MG"YEW03#<ENH&)9%UQ]RRYPX&W)D?.(\/G:K?504J($HKX!^E4TR"[CQ%-(I
MWO.>:: 7L!/*MGTT((-TVA2>R V]:44/[UV^R*V4A&_Q*,QM$9[M_OF'5\U&
M D(*>VGRZP!:UP:U&5'UP"JFHVA67J'>R>):T?(PPH1![G%>6@3A5&+@[4/-
MC8R6&SW<B#<WLFRSZU>7Y<<UL>W "-C0$ <NI-8E9E!N1W&CR7_860H\>*\1
M%'3&GGX\;AGQ>.X!6Y NCV9QP>[)(YQ4F4?OR7X>;1B7HU #.A@#"."V;Z%E
M6+A*V:D)!RK.M;J'DF>\15.LRV?W:O.@J<NMQ;1HYL_N:53FY#DHA4 RU_1\
M3Y[A\6(P>NM >K_C<7QVCX#(_!!:D(,=RY-%!6/_^.R>_$F]!OT0),J]@$>6
MC(C/[K%!N&71_"K<_XN+M-^G\=W2P%A5;H/;%&#W>\DP/@==OW=G_/^AC?_B
M;+Z_S-E\X9C\,E^JAQ2PBE(/',S<"WA'C"M2X[NWCA/(G4Z?9%6"'!.EO;6%
M=*[DW'ZIXGIVZZW@F]SN!.- 4FSJJPNS7].S]3+3\3C+ T'6R#!(O6[!;@3(
M9"W?"]KF4VP^%R!TPQ8)=O\3#(9T#_0IL'0\5CWOD,RE-8JK<1Y-FB()9-T>
M/Q=:&]1',3D9G!#VY3!#YH0%QXYT*'C-G%'/BH*:UGQ>IBSKD9E%, QD<WZT
M@XX*'6TP2KM0BN13G!!Z]F6$FZ2SP<+N[FVQ[8Z;V(Y.V+E#2"!G%88MUXQ5
M+*.KF1*T7R7"KNE_>,UU*1]_N75==0E[$( LU1O ":.BVL9Z6A<R,<PS:V&P
MEGP0":H:U*?$NAN][E-5QUF.8CCLW.Q:9PF<)[BP<J:^EOA.*U[.6Z-L@W?M
MTDP;C("!]M"O5Y1^OR590\3#ZVUD9]M@M^S.04>@ZS"JD.3[U!Y3?-4_,RC5
M9T6CQ$:/+X?+P+3DN4Y@MU0/AEB(%112S38W>C_3NAE DB9EN:"H5MYUAXVC
M>;=VT"TYQT<4LBCT:7?4="3H<?^9&("F3W"+T3W)!-)M-XBIL=MGG+T6#,@>
M1YRZ4\#'&>N992L>BK"NI'B2M@9+:O3*^\!ZW??(".JJX5V[BG'0_<1$(KEV
M/FGF5?;@Y?&5LQN,>L*I>(ZOZ&ZAE3( YS<*/2B'"6W*[N/']T?1WN/HM^WS
M[:-M4,-W'_YRL/=P9S=ZFCU7L'CJ7Q@*LVT7^W .#">)S2FW-P<:?*'14?1@
M+VQL=V_7;VT;FUOSNW:IG_8B-!?X]FXR$WSV#>RD'=OF=O0*&?3@J1\9^PO"
M*LT@#+Z":1<C( 2+&\JDZRJ%[NX\XMW,!G<3;6X-'*2.58=.>58W=%01Y@?;
MA_=KS*=NGFGS:0\?)$:Y K);H@9&-_&!C<--\O%-&F:-3:78 3!I-/NWC3!@
MQXD8#\0BVI--2!)RO8XQ%-3!E5TLPD&T\6(3KRA,-: 9RR(_=8 C3-72&<>(
M'N"8-HXV<7$(H+" 'PTG!KD$PP#(A0R#K:_;(H'%B9//*(SKK7S@=RG7;LS\
MNTR2&#W2,<@32:-K(*"*V24PK!0DDJR E=3(LZ*&H08VRLD,!4\91M1B*_:,
MK:L[TYV*X6-A0!'H-78V44^ FN!!@&V"_=63:V-'!B&,D?(8VG4HK1-K5" "
MT1X#A<EC))-4(5-"/V%Q6>:7V,Z\K)"D81/@]*4*?=.)RH"_>70)'TRJN$E_
M@"T:WB,Z@8X-M?=H)/'<.4;X4-PIRZNP=AR=(L9U]#FO$C<Q8@YR539YZD.'
MQBH08X%%-#DU;[E#5ORSJ:Z982T:YFDQPD!0>2D_C0ET=-0K#+3QQ.AVM+3!
MC<1S9=6<]2>?RV47'ZT3ZK?%EG]9]1WV9;>7)ZUL>+QY;$,?![]G70)1;%6$
M)(:TDN<8DD8W8KR(DXQ/NU.;-B6 &A4T-P=DX, X%'=]7[1X9W2[JA 05R#E
M"^R+-(/VU-D_*I?AG>G_5J;_^U_)]'__SO3_0YO^+;,;YG6QL=#WRC%.(?+0
MC2[S@T-11X]ZC"UBCKDIY<M&)ZG+VE\^ETM$%R<<7&9E'CC>AS:G;>LQ+-U3
MFPUL#161]5_=Y=)[3TRX*(XD)(46/V"$11Q-LE1QU')!4AMA5:>Q,0Z3R<]_
M1C?\M('M*UF\0XN6*N V-0!2"8H@%3>>8!JAL6(#&T.5>^VU=G C<[B,ZILJ
M_DP&Y$T(0^LI[MP%Z]I0;T-J.L)$*X4(AA7H*I<"SY:XA-9\R6KJT+! AM0>
M&7^-?=(M)'Z XRCQ@^7#&#*<!B-8=V?64C#MQ8IXG#_0T.:G[PCZV(X.B^ME
M"*%58L[[W50DR*:ETJ2168N3:B&2K U0FG%FZ613$@Y($Z)\63&6W**A_-P9
M;J?1F*(* I.W@8<'PPI7:<W)=2FBMX=<[?+V(4-#(KV1',.$!3[8< S+C_M.
MMD+2OT<^%.TV-F/OLP'+<5_*!U+"8/R*,@!B6I9:+:SKT4?%O4<4N=;1!@,B
M^380B6BS%7-4)H1P%\MIG\6:H77:TF#_ 227+0I?*/QA>L'>Z2(6CW&7WL0W
MU\4F3LB8/HI>23I+@;"*QGAA!]Q<+4OSR N&1-9#1H)UD7:'E_,/6T\_YX#$
M0A$'2*I2ZRWX9HOSITC:@TJEC7C\-;0.S]!;2'AODS$3\RTV8X0<(40 ?Z8$
M2@5FB82UB*=\'YD@@3;\^ ?8NY4V+['H78KV4N6TBA=PAT=Y*2[ZV%SJ(9L4
MX+-V(3BAV7,DV%]AL!7!"$C<3I#G,Q<$+@__KB4F+-JXOX..EIQW*ZTR,I[#
M/4_ ,BO5VJ%9F:#'#%=!1]F"G48P3LK*Z>#@/.TUTJF&Z6"9"<&2P2#:+Y0+
MOV.)B'NX<)C^UH4I=[DO)TC>$]V]J4DB^(%OTY 5>(X3FYF -$)**PIJ92U\
M((YZ1102N40^^J+NKW4P43_X2B;J!W<FZA_*1/TI0F+()M!/-6'4AC,T )=
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MRA)6G',6IL@+8W1F*WY1##QY1:BV/0?^T(4K0P0YH:D,$+-U$-NW\2Q.I4X
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M#%O#@Y1;2-V!)SJCC,#,(SSG?HL\'>E1Q5\?]-;?F2JF\32P%IHHH?;Z69E
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M>1<=OOM']/[L].CX^.7)N]?1QN^_'E_\>GP6O3@\/WX9G;Z+CD[?79P='EV
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M^LM?GM85_ /_FYH.+M&$D\2YV>EYEJ:Y.RC[]+&92IW:S^%,P'"+9_?V[D5
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MR;)7]KZU3+V*0 ?_&)?I-=S+LWJ>/___4$L#!!0    ( -<[95R^&+/6J&T
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M=3VL0TIE;4=NBTJ7'F?;/6GC6EL3]'M>M Y^!$\#=/"1'PV"\M(":\0YM)(
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MZK>J;.(-_^V6"95!8[U/4Y82(\_MDY -E#?2@V^*-R:\*[)6"WXB\)J![C1
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M'&9M7$4.[FUP7Q%^P]55DB&9UU0>NG1Y76B@.$;8^PN#K:U(9-8;.KE__/G
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MEV0,=K%AMRE!9E '2$$A)3?@$^54+==(<'UM%(*^RD _Q"098EVBGXCHGS2
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M%9+6Z%JW"J&LP]\O/(BRJJ]+U)D3EN!-%#G5Z\^^B/O88K4BQ/Q#VN1;7;Q
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M+;A_[N,+GX&0F18@!%=!5DF["*)^+<-ROO"2*XR6[AI_S$:?2Z52^:M+U I
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MZ(SZ?K#D/[OT ,*KS'W5?6FEJ/ _/AO=6#V' +@11P0 GP2*\;'9S<]7W F
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MT6A>@"D#+%SRY]Y72BCZQE1W.)&NYW2&PF\H#O5"EM>F)G/(VR[;@P'ME@0
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M D"^B  (:C\ (HS;\2^O$0#!$.PP*FJI?=G;^Q8^S$2"2/,E"  Z"%8(2$H
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M^#@X^/>)"8GO_V\/5 = CH>!C>F*A?$0P"3'P"+'0/4 ( # P,'XQP#^^\#
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MC3>AQ/X/W%A5^,,^J+!9I'E-?F>#N-<'B8+K#L [ERM(9 5\_)]T1MOQ=ZO
M714PESL"0QHDH3FZ%]ABV5VHR;RP]&NQUJ7ELM+"0^P12YHP*%='CW8>\)0]
M8+!H:'C,:/L4,Q8#KFN#X$(!]U# K[SOX-5Z$/)1 EP'28P"OJNBVTJGHRQ"
M#7 &._Q& 6/_+6>+FQUL,T1^S/_9T:BJTWK9Z:@EC/TUF<I5@BUC! 6$F:VN
MW-ROY4=0=Z. GO&_._,;\=B_<;;PO]VW5/;O<D%_=P*P^&^]K739EH! +J"
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MW'=_9RJ[;A?T7T@DY9N6P7STO<P[XXB?8LGP-_S'KD:9?HSRRB%>@YH[H]N
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M]Q^@*9FA\Q3\;\ZH\LHW;G&U1]TN)<X2;K:G9E9]&_Y6[+TA'7B!?$JK+2@
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MJ=&^_TOA?Y2>;!MVV9J(2[V)L2SY6%$'!!]UC\+>\?"6D_*OW.,*>/_G%SA
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M\1@MT&,?!RBAA6Q=X@!=QN<YHCC [2>=5]=$,10XP"'OMAU&4A0*O "VR>,
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MX;VU7,_@.S&)X"1U?_&]<U0KZ\FU1K7.4.<3&K:=N?XXZAWS]>:7!YR6<C7
M# +_]OSE-Y3I]5]KD&-Y#@70,IYDNHV*TD<PSYG<E7 )R>]WC"4(6J]3+KYU
M&IM"#(7)I6P86,V<'"G!&WAOCI;JA%8%@(LT*N/-K2IG?ODIT4-83.>7V'2T
MJ65@;^PM0469GT<X^442U]8]9PED.=XLOS/@[96*@IV_GLIFJIST7C=L?07F
M_6QRD,3Z*DO598ZU--/5XD4@(S*V+H6_1,W!SH&[O@Y6&]UCUYR8&"U4UD:D
M&K9%*KO2O)IYX1RR7[D<L7>JSY(1&NX)^GK]FYB$A$:#$>'6S>D,HD2MN6FS
M(]'=#71P[W+1[U()3^-=D$CT8GTJ^./DS'T*8Q.P/O1QH]@YJ,B<Y=GR5N ;
MKZ&U^/88/_WO9:H>KXK@WQU'&XPFH2Q<K6[?.>];=R_3]\NO%5=I3^TKB%XE
MGM[,T([725GEWX^R=$KYU5>V/%;0/[[(>OL36^UB[<$Q#D!B]B2A#VPC V=?
ML?%L56X2=*S,E1Y4(7X1E+3P9!WF%+K_?;1^Z@)SZ[.MY(OVG)J4U*3&/.?*
MBW8Y<$<$&4\)N!@.5WU'4S2[QPR?[YU;$OT\EH^:VN)DG^[\@GD0#4T7J]9F
M)*NF>7BF)9/*2<CA,H=H?]S%*L:&2N]4O/J*T9SAJ4N!ZOI%:Q)GN-*&#,;9
MJLTB:A[>8PG7D:YF$\!&OBK<$8ZGVX'Y=I30N@KTGPDL/KV^Y"WA\X&M"_Y@
M'J'JKIAY1XIW2-C#^%?1R6RFFB-U?I8C>$#3[/=90-+D4+NY@U7AS&956P#;
M>*2PU./CWL@[C4EP^]$O"KL<'FYCI5^D6=\_/"7:S(\8@*5XGE8C[ MYOFGF
M?;/VWM\XKPY]Q\%Y%A$3 V:KCOI5)X5,3JFWK4;\Z@.OU26+.(DPIEEJ[]X=
M2D%TP74 <)]?>MMR,F%5'GRYK1'JC0WA@E(Y'E,'MHD$69_2DETJD@>YXI0,
MC'*?[TMYX@"5V59!H67+J^G)-P_[1*KL H2_7^WZ2C?(SF$YM#RN"D-TACJ;
MLM?87W$K##XR87WW7B+=ZT/'7:WRA05-GHQ3V_1A/_%PU63J,>Z%0;9[,5X5
MVLI&-5-M'F 7D9_FB&V>VUS&!"S>]0*TRO?]EP- 1G +FC[('(-,H_3'V6Y[
MJH&RQ331VZ-+';?ZUN8!W0:9UYUH,W]\VDPWP->.=9H4]M!<O94E <T%F8*#
M@@ZKF1>,@0+#3O4/+_2_$^<IU&JS(WM);K^D&(2&4!\:;MWOVGU^HAO):6;^
M2T2R 72^;U<3Y=$B;QVNOG#$,R]!F.W-N-_GD?Z\*D+2Y_?7F@P=;255<MO+
M2Y7H5%?O@BF6<-J[P8P$76-KZ05%<#1(A_J%!G=L&\3F35UKU$% 7_^E*='B
M6YNX2<;WQ R9!)G33=,U.B #QI_=O/RJE((#8,L64>5VQ[T,D"J)&FK'K#*+
M7*PRRST!8?J]>$10DS&<WW_T_(';3056F@$GS4JOOO1>L[,/5<["7P^%1LX]
MO^$ XWR&X%C(]6NM0W64%,GMTK 6P\9GYT5/@SR([2MS":2'7!!8]?5EZC0%
MZZ!TK#AR,R3?=->+"JX!5HR!ZIH_3UXP,[W-I4G FQ6]1=GM)L@_5;KBH&D*
MZ3X\.<+<:E/BO4G^,%G.33\E2ZY^<_'4(J5,6PM2*XI)?HR'/SV0S>23!?_$
M2[&N0\PSD5+3NU.;(AIJ(QQ,&-"N[X5_T=6T;^VACA0$626*'#C$P];VD.6>
M_]:#6/ZU4!(AN_MSW#1(+K7^NH<VMVMRCX0C(0#$^R_^*W[#\W1K4^%D,W;_
M:NU\RKZ$;?;@7F<;1([PVW9OH"2<WT2DCRLQV)MNR%\;]?T >D!IZLCLE,5>
M5FRYTR"GW5XWHPY7%M_TB#3-O[$ND#+4DYT,,^9'270=^:L@]PMS0*59](?C
MAC73%0>!HR(/1\#BPT%Y0KF?DKO779^JJR>C$N#:%;^RA2:+?IQ\%_?F3!IY
M*KX3Z?FQ_U!5B(<OY-M=655B%</^N36B7V;^-DB/Q4_P&':.L/+;^PGC]3TA
MKDQ)G,-;Y%&]V='59]8. [PE&,*V&;.U9S\Q5HK89I\ NN\GO>ENPLFC]QZB
M5-^"GW<=3HTZ$&\Y+[(-N"S;>.LN$V6SH8PCP"E^B;GH=U!P@49Q2ICYLQ9K
M :A, L$-&&K<C>!575HX\76 9PH*3;E&RM,!]X'I9'^@UVHU_\PX$"0):7'I
M< ,F3PD,ZW*F3Z%!*&K=2&;IW)(L@4M5D(7^)G2O)>C:VME3@)?>&5,0B9/F
MB^6C]%&T)C)7B7;.T0CE6!&86D7SX6X#?<,W'X?:>UWEPWCJ[C.\HME/YVK&
MK!OJ04DVPC=9M9K$IM$KP]SQ5227Z9#'2)C<6T',E9WEA[2&),$X",C*.8D5
M@WO?KIO-3S+=KU"M1YHW'.4FO9(T0@3ZN=^N:<L(HLCD[_.0.^B%4*)!+QHF
M/02'*O!HX#7EJ6PZD8])N1;7<+BD")24*5Q'4>W=&1[#3.FCVOL;6D9+BN;Q
M)7IC+%UHS8'Y-UPJ3CA5=C$Q(;)%[)9+%Q53F!WF 9H(CS6Y9RH55!6HN& ,
MM\VT;&NOLO;S;Q'=&B72N@.\3]:4K7KK$T%1D3\$25_Q>B:E93VIQX@D$E+[
M^U&CEL3G56G4YS/=YNG4LU?-!MG)TD$H6T0OD-Q9P0&4OV2)Z)-:%YLU4;=M
M:CYTX@KR+"$+WB!DF[UQ<SY0'T2)I;VFXL_[[M6J?+2V0<\%N"(NRQ,6>3<B
MV,A5*#&%($2PA9;(Q8WQMH77^S92+"G2P)YF9W*79D1JHQ<>FB DS)4JH2F8
M%>4B9L-!,$L*6*[7A?.9=0:MAD,U:U-[?87D?D:83Z?#Y)\GKSWZ( ?E\!+:
M'WEKE5IUMSTW',:93>E[1*&U7#]]%ERW=%-U=7?$BK(P^E98,3P@BE\)<<U:
M)#03RLDG8.+$R F@HO!U(5 AE2YF)/SQC$!-Y/ZXXY/_M=ODC1/04Z>.>#H8
M51]9+Z@UDL7L%R&NRTI:15.]TZV[P-MQ2[%LIKA<8*+(3*&>;F(A=."U"YUB
M);V3^*$""9:)4Q>/IE..< ""CW_?.]*8PH_F31L.T/4&!V ^VQ%,O50FPP&4
M)O8AY><#5T3*4$P\<=/5)[#3'#.$SFIT,)HY->CFC3S2O.SW[G0,&'&E'!Q
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M@#P+: '49\[\?5,.&LJ;]APM+0T-[7DZNK/G&,\S,C*<9V!@8F:[P,3,RLS
M<('K BL[!R<G)R,+]T4NCHML')P<?P>AHJ9<0T-+3TM+S\'$P,3Q'S[(G0#K
M.2J),_>IJ2X#9UBIJ%FIR+T " "H:*G^<0#_]: Z0UGC6;IS].<9* (-%X S
M5-349VBH_ZZ:TAM!Z0=H6&G9+LEIGF4WMJ.[[,,A'Y56<$[X=DT7I\D81N2Z
MO>]S^O-<W!=Y>$7%Q*](7%50O*&DK**J=4=;1U=/W\#T@9FYA>5#*X<GCD[.
M+JYN?OX!@4'!(:'1+V)BXU[&)Z1GO,K,RG[])J>PJ+BDM*S\P\?:NOJ&QJ;/
MS2W=/;U]_0-?!H?&)R9_3$W_G$$MKZRNK6]L_MKZC=W;/SC$'>&/3_[J1050
M4_V?Q_]0+U:*7F=H:*AIZ/[J174FZ*\ *PWM);FS;)K&='8^[)?EH\YQW$XK
MJ.FB%[YN@N&T]QT[SR6BL"R*_:O:/S3[YQ1[_K^EV?^EV/^M%PI@I*:B&(^:
M%0 #1-/"A"O _T<;=31^;!7ML#P0;6$^ID#?IND_G3JK[O/!L3%YEDGM(^'K
M2]6H4>'W@]5:G3!^@N%*/N=O<Z6%LY-/#T[=Q9J-&L<'O/6L[=^P?2S8#S\.
M+/<8QCDSC5*C?KUG20N S,JL+HN_4#=;D>7X=5+=Q(,=P<4YV*N_%*]]KA:\
M=B?2VV??+SW2;B1"<PG)KKL*H7.Q%8JE:X@S__3\6"CU^5AE346,B+?>?(KD
MO@.NBPRDVZT@3R55RTBI)1';F*8^7G T&7#>!7Y;_:EP+'(=?.]:/AUTQ,!H
M,.)U\?[#ESSB4;8CCZ2XSB:[R$8:(5H]F .4T*+<M3?E$PH*W%'.\0<5$::Z
MD](!-C>6N&+WAARS)  1MNKBZ"_"< .DK9J1VO7W5PH3;G$8:P/_><U,,>*6
MJZH1&JLEU!BU<859R</$Y^0^;8OD_M73E>RD-N=K4P%@3G?[C4/MKMAAT[RI
M<]1,W<JK\3]NEPLQ/K\GKR_RPPMOT*9%!K1TX\&8B# R,."^NX5Q4O4V";B,
MF(#N@2]5K#A9W"LNX#7CO3=='[ _90&&E".^@O[]92YDX$5%+_A (3B##-!-
M(PF!]63 I :YCP/!CWE@O9!A\&8?A)!-L<0_.P#\4)*/#(#M\&0@]?^7 RA@
M@^(O>V/QB-Z:EK<5U:W!>AIM0[H;DG] ,V$K9ZNP[,O:#7^:P;.*AI+-!\>(
M\S'N<.E/M=< H,]@$SBCJ<S3%QR"8%GQ3?"I,#?0;W6-./J==O@(W(>7N5RE
MKB'(EE2(V+4V\V]1^E$T]:NPV29H)2B.H+(RK]1CD<VM^W#RC,(UZY^CJA];
M7YFGC9W789!D;*9>U\C<IYM[9\9A?(O?HE_:NE]5J0=M#J-RP;K;2LC)/^SQ
MN2SE(V<:;WE=!E/,DGI-2H^'/V>9Q!^<O<I5M&*-Q.NK@]T]RBB^=9PV.Z?@
MK5.WT[ W\(Y/K^]-SG[PS]LA/L]"!G&H*]1[L[B:]-_0%Y&B83_M&]N\$D[>
M9%T4E2]4^FD:X_O1,BP39' $1KVE)@,TNYAJ'=AW!= Z4W 9FN*V(CU],)QY
M (1XR0"'1.62C)>7H2>8[[!7BKA@R-)CY/8J850#Q@FY/=V#]C+&C!+8^=UR
MM _[LS]8N7"GS\ZC]!RRN+GEES/CA$X3MF"/D2]/1E^"G8C6O9'24X<"D2O#
M#]J=6SK>5(M=&.#WJ.=2Z=RD7OB\R$@&AJ2J83LV[61@_(T;Y*<2Z>Y /_CP
M^",9V%)]8"_1;_E4RQWJ[G[(SV<*QT,"\ RGIL&2N.3//Y8QZ;_=3A[='_8A
M%KFN,=5R,31MJ)S&@6/":"/]85WBL#59+ .IK7Z7>#[T:/<Y&6AH_("%X)*P
ML![K?*:9+5PH3P?K;U:;ZX.R:=XUC 7WSR[-;/=+?OLJ/ZW+;I4G$%8_[KE;
MI#>5Z>FB/1H8<5V;P^)9 "W%AO\IS0$_0-(6\".U.9.!,0]K3O@JZ)@C8/0$
MFT\&M!NHK?.SK<0)40J+)P=Q9."65>N#>LCQ&5?DX18+Z5E#(+)\&5.$OX$8
MD#7G,(8TD0$H%ZQ#E>B6--Y:(ZA;)1UAA&7O6^#%6B0//!?/17=X?O X'<:_
MCQT:9 U2U9*ZH[?@=)O0ZS=G?J\ L]W]_3="+'?YE ]M8J0Q9/:]^I!%3,@J
MA&W]2*K,_>I'QZ#&^=[]A..<$-1:8I5^WZ!8XPSJVV[V9@0G(LSR-&=.6M95
M>;FBWR?1QW-$K6+>2GUZRUVM%35M))O[P7U+6D+!4EVE.+?W4[#TCO]:^LP?
MZE[-'VO,%Y^K=U[8%/]$5P)9D8T+I5W(797<3@9!2.-IAPR).O7Y@@_2OJB_
M$AY9^X)4-KM[H7?-FYHT5\:S]XW)W3//]MT@&3"KN)?S[NJ'#EOWAQ5>VS\>
M1F9I.!5V9+;A Y9>8)E>&+LVB@F7S1M*<1WUKP:6%UQWHDJ3+R]YHW.XX+?/
M;\&"-9G6F2 P<%;#Z>N?@UGG/1JS+->R+N%<Y$O27G,R?69YO5J@<K:I('>B
M]T&,LN;I/+J4F(NF^-):G_?Z4P'>S(^3B<;HH* R_]:38VO3+^6%"4?PC/.G
M6CA12G32@I$!N]G%C09L1$3!*1L9&+R$) .?T+O[5@0RD R>DZ!\PK;DP5#,
M $FG ;D]2_&(P@@JZ'6"VZ>44UPZ/BP0]:1*BMW:NJ=<X^W7U$^OOW0BT[OO
M#^E!%W37Y>L(<U$'?>';V)Y.[A;X !((_H0W'S8=VXD<]="H\PN\/_/%<[)@
M9@,A]%;"<J[FU8>KS:.KN@<UXHEM@2@E-)_=<FONC\:ZU@L&,FO3.5S)LVH.
M%XZC (_/K*]?=]#/?YD]4 P?6(WW;S?%54[42YN9AQF^BNHKEFO5DJI@SW1_
M^P&BJ&^3=/$:(UUDY-OWS,*K8IDKR5Z=W#A;9I>)7K9Z>WJQ29':.\>Q&_(Z
ME9O4XH]G6_D,KXA,LV/(0">2\P#$OFCK1KH:9UKG?C:!"G;]+D+"VHXUF)75
MN&CO3Y.JTB[C;^\;6'3]?;IU!-JV*1$3UQM]/UBD \39 %9!&Z=?7K2#M%Q,
MIYO,.8+\F_BUDM_(0LA@X20#,P]_@ ]B)%%DP,WK6#<N!K;=HTFZ/SVS#(ZB
MA <$?%_]F&!V\VRP,\G8T8\,V*-W2:^&32*[D'M.&G(4@1$+,J _7D0)?H5#
MFZ2^V46B1%8Q,1JV]C7<@>)R.0A21@DG<KX&=(@7Q@X0Q//(P+\-0QDX2F[+
M.,5_.)R"';2HPDGT:F3@$NPE]'"]#/;+=#*_%D3(7^R#5->1@9*QZ4@EXJ8
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M9(#"/R^W^%@:7/B0;/S\T<<;>RW6K/2#'X/"YK8) ECDBF?[Z=/?9."\3%M
MH+JDN_2XSMC6U.5MUMEX;OF0BZ<#^=DE3\*#B.])$@0EXL<#2%RH;HJG=<]T
MQE;:T+2J1^*<_<JM6KM>P']K0/ P$3-!,LE< 9_@*<1Z7+0Z"-= !EX]#X:2
M.NIEB8*2H<'J:GVWF<\O]!EN+DYFFSQ*7D0+QI]Z$L+Q1:<W@Q=[K" QX7[^
MN):4=Z*3 \833YT\5FR*7"_(G)5$+YZ?F7_H\HEAQ'S;,D^;+3>Q-_[1$Y97
MY]*XJ;?R0J<W+0B<6B2#LB@RL,.D1((CQ@7$29KFT,,^\ &KK:!JLFHPO[1>
M_[='TQ$[8Q/WC"9SO-RYMD']X+TKV_F'JV!2HMO/4D,V([Z!RW&ZM \MGUP(
MC;:EFH0/V;"3;N5X$4.UR,![:1M$64/^3RO+!OJXN#8[II14R]RPF[I&[O'2
M$^HZ(@\S?!&::6^ITD-_@/!VB NP[_LEL*5T*$D?,??!Q\E\6="U'MTD260E
M5$![=H[-LD65!VUF]G6A[:7AB]H1E&C,J+C"<B+HCR"P&5+*$P58#U-P-"GN
MG20%5^ED8(_B4 WKX'TL&5B2)P/"('S<G"89T+ @T8'V-;P*.U+)0"POEH[(
MHFI!HJ>4/&LYX.78-HJ(UK=,,O!<'W8L!C]$2)"!?#@9H,H^IB-H_1&BG%'&
MIX8?YRN-0?7^NRE!F!Y;BDS!I@$9Z!)!$C)T3Z9?D8'1 3+P;)@03;IT= $V
M2AD]:H PFOL+4?S?S_AOMZ*(Z#X$VUPE YV.)(K<A=.7X,TARMDJR7GDP&+\
MOY^.<&WZ)?A7R#@2HR]+!D3&_MLMH$B^C.@%[:_#EGS(P/6-DW]?ZG4.G#)N
MEW1F#(2Z%:C7AXKD/L.-?+M^B"@F70Q7F=#@P,L,].18#RMPG:ZE;RQ%2_=6
M]Q6G88!A.7'@,2-5)P*^\G2?[HU=@2[CK)M%J.)8=4?9+P)+]TR6?G)%_("V
MMO)><8Y'X\16Y( %5!V_V,4-O:"AOA7:L/E"_:X]9J/(G;:TSJX<I>L@8B#\
M60;S=<&N-_W""-O:R^[H28OODQ:;XNBSG -1ZFI!U:5U&O$.,A]?L 9B),)3
MDM\&","-K>N-;_%[]2)B RE9OEYR1#["V6(L_;?H<WW_X7?)ZW&,75IGS:23
M2R;ISNLQJDXK+LO.5'1K,$_)("H[?M:,>DA_JDLQ9KP6K_WIU<!Z3, \3OF:
MDEU@ZONSBK\$I;&!\"4(TV\K$K)<J]3EY"F37T" G)I#LHY^YZ!&YQG]3B##
MLH,'W[XL>W&[UN5$IU)F=YS:I^Y+&F>JU-U3FU>2\O'+<^_3.^S7&+_345&J
MN>^N%PAFM0T6UL'J0>7%]OJ\.M1#3;^_&H(^B+5WM]$ML<0H1(29XIO\(APX
M)WL&0A/H^50Z$Q:IHVTI8>+\9@_TX%ST(1G@'6D^,-REP"N@7SDP6V$=AD&0
M] 5$.4?(0'<S9IIX1H@(ZX?C+31X*2YY!X3 CX7@H##"F>9KR%%9 BULSUE?
MVP^&J0ZG5/.W7H*AV"(2YV@L\A<KW39)P38B>Y$, "K_DOV7[+]D_V>R>CJA
MTRK_QB_!RX_P[J2H"Y'(5>W-F0@R@*'.8"#L48*W!1D0\URPG'6[,>H1Y,4Y
MTHKY_C5JK.,]QIV[-_+\IRD":Q7>:49X_.FAH62BF+N>V1W;IT]CNI/.Z.R<
M3OPWP^H2)/.98-\OLTP3W(I4:UQ+**57)[<8)[$9MD3)2!GJ2)P-,=.?#,S$
MSO;>_QF<L _E';:NR_W,)BLYQ'SVQN&W_>GQ#BCQ&7@-K2$#F^8C T3EA-/.
M<!7,3_#>_Z'%WFYL?DW3LTCNX&EKK&+T[YR8A<I:J494<K<ZJU?VB-J9PK3H
MSD'UR "TZ5<W@[Q+TU,!;!9(K[01*0U.9=]OYM!Y*.'-WE$/Y-C @D(7MU?^
MDBR]K.9%U'=8?Y>Z-!F 6G&3X)PEF&WMB6KP4FG>I?$G3<D[7&%+TO%J.E*3
M\*E/,+<(P>%[Q+;PZV76UL7F$+_"LU%^];&OSQ*V?TNH(A_%M2"?MR!)=U:]
MNT^5=H=72&84.I +PIBQ'%_-HR,#GQ063S20>OYY"JW@DY7\DW.($1!>HC_9
M<9D,Q'<PQ-UK,M1;&Q<-M-P?W#_9AQ;G<8^C%2+.?UL8HFV*&[;X^:9?CT=Q
M:75N ?IBPV J&ZJXEOS*Y6H&SM=CJ\V$$)*_YC:FS;E?$O-//#+"WY1,X@XV
M7-&NL,;G]N!4N^5#PC9?AD2%=+(Q7N,1P82^/:P<90EGP(!B2K.,U'K,T^@]
M(ONQ!K8N298OY8\]OQ8%I3&O)C6]RHWO+,8CL/D]B^?\O\@H!F6%Y;Y9;GP^
M])-:N"W)C'Z0RD)H/1ZP_]0F?'H7K]6OBEZ/J1NE;6^H;Q*_GUGD<O&.=%+1
ME9U;H*?1C#K3PQXBC*F,R)G [FD#2,)4H/GW&936ZHCVY::H,[J\Q^:$JRG
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M&C^C&>%#YW][/0>L9RCR/(4:;"#_WDLE ]U(B0K#G@6>*77K<C+@_,O*"-<
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M!.E%I/<2"+TGU  AF9QWOIGYCN^WSCDS_UK_K'E(%NN^G]S[V?O:UVZP@I_
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M,TZG<Q]R-I+B<7FYVB*CHW7=O,_W;!X9[[^A!>X0J7"MJOO\=5!E#%JZ_<Y
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M%M]MM4C[W_>:NCIB,_*<U8X/N6)D':M-"NXJ'OX=#&X()AX/J(B10^<W5O%
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M-X[83Y8QT)ACTC\9P8UJ4" C]*TB:3A%'!.J'\N7I.%VGD>X"1W'.FH=]LF
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M5GJY&EIFWY$B>V.XC4TCDU3U**46#S0-E8H%D/N]'@P469CVU];T];GFAWM
ML_YTUG:@@T(D=93I<'/FD(;1[TGUJ()<+CB!WE%  6']<>[G#]OZR)N3%MF"
ML\8EBZFD-\I$&M069LU:IZ13&ZDSR]<&^R@%<K8HW"/;QSW$?]J(;Q!U'<!N
M-I9C\KZMGNDMC&54OJYX519S4KS1D8CT_Y4Z[2E&N<'\@)IZV?;'J41H>X]1
M0\SZ<$;P\G*6:'5=@"$6/L^M/^GG/+2]A96E,#7/?$7EO&K&1Q>O2B^1$-%K
MD\#G]J'#C&^<WV,Q16:Q0XEM]"?#9ZF"F\^])S56$FXM:_TWTMXSJLDO6O>-
MHM)!I$@/TA$0I=>@(%U NA @2I$2 >F=B(@H5;J"$*5*#2UT$J5*%T*17H+2
M(:$&2,+EO_?=]=RSSQCW?'B_I(WQKC7GLW[/7/-=6=W9$3_A%>_@(W1\^>G-
M/W=_/H%=D9C@VH&7ZO!E/*$ZB1A]V'%JZN]TS'U7UJU^N8%D;(F#)$BJBA1#
M??4<Y'ALSOICY=(_W7K2L?LA0YN.^NG'GF*YD4T8.W_BZ"%1C27CYG'SQ[$"
MM^V\9 ='FK(MR1;*@2MO =R<>-%6KR^&Q_ZA$ (S]F2\$'_GPSD@T+Q6_6@*
MUIU2(E@>EWLC06^_UX[,H^SQZR![@<655W#TX,2_<VS&"K.5.V@Z5ISN$R@C
MF+BR8Y:I\HI2<3MKB8S4\Q^4(^_DN\*VF\\!":KN$R*%VPTD,@1?XGF6C2GD
MM#+YC=2R4&Y[M1G^0GV[YN(S#\E\H_EGTSD79%F_2983[CH5YX5PN#XF;=MC
M<*GJ?26&>(&.#_YCX^> S2P9F#Z@%BO%Z0:Z-&)45F&$LW[/QN>HL67=#*!<
MAM%,-30F[LR++7O@]>/X[^X4. %_3@Z> ^IB$NMV67\3 G6J4JR9=L.FXH3G
M 33W<M%!DR5@XF,9P8!3JQ@$XK+H0QKJ13H&%D[' /W5+R.VW7#&+B 3]DQD
M:2>O;XYC6ZCG[XR67P;P<H0:M)1JI$(VS?-81I,#^/;)>*EOJ$!B4*N:>F(>
M1!:4Z78@U^1\QAUF,U;E#V1WRPK)+>,>6H$MB%)N@BTO7%H 6O':!1?:?MKA
MJ[\8=X4*5IJDKST2,U=Y-J2ZR+K+ 7#-$Y.ZW.XV#O5%^-$JKU>GH75;P'32
MQ@$XXCM;IK2=(.0Z,FC@SG7F%\5*%EZ[9^/A-@A'J>URQGTR(S%):5K'4<\N
M875+;%E1I,E0?%F%F>+-Y0WJFTJ/YRR&E$^MQ"O(_1"N5ND$H>A#^#M'^X"9
MV1(?];DTQE6SVZP"S0K%68NEKJ52N?"<=Z((A8DP.ZSQI87PI"X0,&4H#.L\
MUW(?O!8";*\[2(I35CLQ;['V6V<,OG;!JJB80]8HR]D#K)"0WX&*C=@'6ZU
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M(+U+#47>U>GQI(PPF0B)/H3)\/HX\#0J;D*>64410TD?,[$*G1!*0J%_YZC
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M!3 ->&X*?W.%N/H,ZI3<F1WC.JOM;.ZR932 GO(&!Y%+TNPX -NR;&DA!DW
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M Q2.:X*VVL[QO"+ JOZ=!,+A(9=#D[3"4P'A29R+.8#48 FXF0;MJ3J5-7H
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MT5)DH252**'V>\+%U*X]B1+=%E6T]GN[K9;(=_@9:VJXP\)W #A#U9&Y!H&
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M,NU37=$]+?A3%6]UXE"\Z#D+ODR',=B:,5COA8UAQH%$L$,>9NCGA 4JISO
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MSX "^_A>;DMX1S$JXS=CFJP$ZBC]W5>]_M)?X9J:",7/ *QX@V= 'NHSX!F
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M#-3G+I>H.(;<'-Q\7=RC"7D0$2)_9*(A?VTH=Q1F2ZQY/U3%(NN2 .+;(.[
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M1JNT_[G)U D,-R&N)+[H%\>=>I#R2^V?$AG^&YGQKD9EQE3VO5[$Y=O&-=2
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M/^:=\J'SEJLO=;OBX?QTY/:W4<U1_9@,%#@FQJ<T V:3N-966757T;Y.X']
M@@6?]35#M.^*P^7"ZTX4NQUU9-M2'QD%M*L5JYO2^2L3G@&B3B1L_ T,KV0T
MJA\SW7'8+W^4U<<ZK2G4*<FT3_G!%]>T?>VPJQ3<OJ\T&46*ZTEV F0!1)7K
M'<%W.B%\"A4==5=B3@N.#-/'O"=Z6ZEK*G5))OSR= @(5M98(Z%C,UIC* !#
M@WN#9T!4T.**P0H*%(9MFF*)]90JO)ZIHV&8TAY??$!#Q']PYY^=70,"I1&G
M'J"[<O1C+*(&DA\YC%0^R/IH!B 3J1]_]3?%4%5J1Q#-2;C<>[!?T6P1;*^B
MB!CN(#LZIW%YB-^8;1J-=G^Q:YVV@31BEZ=F\8XSS&JM,[>=OC#6^_T[K]MP
M*KG;8Q^M* !+VQ-*S"TM3CAC<R"7-DM[WLL6D-!P 1,>.K>H'^4N"&<W?<G=
MO]>EG%!+_G.*!)(XD;G_ *J]]@5/UK.S=A(_L4QP6L>-^<OZ&['UM4$JM-]%
M)2A@HWI=4NTC+?BI^><=&%-"*A\4K]7@ 5.HC>W):EH.[I'>C#V(Z%O%%2)S
M>R3'R3":S;FH .*.$'%T$*O\-+9P[-IU<2^5GJH,::IUDN",Y\/([T/)-W_'
M,='X6C;/(L7Y'ULUYP^>7L^P/Q&#5/M<-I5YI)L5./B6H%O\J1>4K'^V$WQ0
M4,8947R+C]$VSEX]2,!U/-9?/H5G1%][6'CQ[2U5SKY/V]3+S&=6U\O@7<1P
MFN\#@ )/\.Z9;6EPQ%\[K#+!0TM!E5MH?<J>BP;L FKRUAE8(N4M7W43=E1=
MD;CH)V7\7>[9''PX:J$TW8FVPMH%^?,'X))BL=1B^^OS7Y/YZ?(Z#,<<(U+[
MWOU<45??$PN$M%G\X][9V B9Z]XE2^+D1[T#_ =!&FGG]',)V1!,98+N5I<!
MKWG<DQ<-=F>$:-EJ M%6!M?7\8T#H=/7/4 *1>@JG%-+ 1O6G62[[Y0ON6RM
M+;@4/Q S-YF4/XJ<\#=?WA+%6(!,&^TW+53F0_'!;(:BL*Z^P?RO< [P))M9
M?/L$C[&'HF")MD:H@UP#R\-X;;>U-Q%ELZZ?K.&>T>*,6%G:DV)*!T\.O'@3
M:QS=3Q F7EM<$_THWJ^P;AT_@C  3(.W9QV-7\63@<Z LW5'@A80"B4(GX,2
MA6]+.?<JUBV6P8K"E\C7[V/R;U5?'2/L# BBM@7?=2]IUF2,G:^*E"I ?E5]
MRDN$7-->$1D80$_3-PU Y5>.XCBRI(6O^],P&AF"7E'YHV/WT%?S[>>0@K0C
M[Z4=])VCZZ*=7T<;.&*^\WCGD>;K0C1:WBL0BU-M3IK+J*75G52X8U1<;^?'
M L_: D9Z%<A!F&J@J[^B2Y9'V8C-U;4IUFK[$%G!/.0)4PT,25P-0I7:@0@@
M:Z4WUD\TT]03'VE?\?TA/._--VH< +Y'>P: D&9S?L-I>IK;:@U6]WW\(>RB
M#3*,#>K84YE#C^(725XTFR^!;]L=+YI@&90L/^F!SLX0=BV8WP!#J8L#Z__:
M?>MYSS0T]$4MK#]! CEHB%M[KZ]Y+.\/?%&WODV@)R,P](P6S/Q[*3S*ZGT?
MS[!H: C=^^_YG_LQ7U^X5W1SHNV_MT\X5+,%X]N_HAL@ZC;XTVI?6BV][A)Z
M*RN,BT9H'X [X5&N2"6G.OF9TWECD;ZIL4''I>[46'[/;MLF;]L\2' &XB?#
M%.WG5BP0G5]5,\5[;U#J$#V,+MI(;ID5/?(%X^/Y]RM*I\$B/RYXH<OF"?61
MWJRT'I(;590=L7:M,GOI-^1AYH56MJYOB3O2$4.N"I^]?,+#>;/T.)/NE>M;
ME:YB.69!(=&ATHILZ?=="H)HD)D?ETOR]4JQ"NSYRM*[O&$.A9(,*:^2HD8A
MH<OSXY\R .?19Q&K+&"8242=T%C6Y^%-*@KYJNPI>LX%TU99ZU1E.![38-![
M0I[?M]4CV@&",&#$SVZP-GFOYV+]4ZU_\3)15>2ZKPC9BA-'D)"ID;;@S =3
MT?1]+N-"WXUR>C5E*8[+8:44B&BU)V.HP0F%Q,S9U=+\]0FP!OJ45B26O&@W
M"ZZT0#+0K^-B(:4S+TSDNM%,47_)_%31$AQR7OL9%=GK:#=;7J\RU/L>B;VY
M$C%@C%H=5LT^,PM^:].[:BCA5RUBN8C!\)T*TT\>D@\W\OIC+50/][#(W05]
MM*.:;"7N;-1FZ<(*5J0J;PAJZCPL$Z> :RC5--;60G=_.MI\"65LB%M&7U%R
MIJT$MEWX>Q]I<[:2Y*^!U)UQ'H-9C<CE'ZH=;?/?D(RV<EN<5GVAI#G#GD"C
M]X:1:$+G>IV)#^ZF](=S[7R(*HK-4]^->O HN+ QC3"8\O!:8!;8AR0!!7NA
ME?U+%U"Y/FK^F8V:63Z<UQH==;[*[".JC5%G@[%$RX$>:1QR@F.H+L9-U#G.
MQ/F+$:&X^5#VEE5'1)U8!=/"<-.1 2KN@=G2X8U1%G_N,Y5DY7I_\5.YC,V9
M?%2A7UZKQ\,3J8$_DB$7DM0*FR:+PD?=7/:.O^%J>F5G?#A\VFL:ZF\;Z_!Y
MSO_R%[#U8'NCJ,B^MZ>RN YMGWABG@?I7\C)6WE;37/0*S0LR7GM+MZJM\U.
M[O3M+&]AYZ9C%JOC^,A%/Y'"'0;(J?,*[3,,<9S]I@9Y$V5+WWCSWY91H.U^
MB2H+C, F;Q1%V4BTO@[I632M!V6CAA^7U!=XZ7C04P;_C?&? 9I)O@(I]>H(
M5U1OCK) 68'Y]M(+UC*+#&'R%MEL<2.E;Z>/ZJBOIK0#8G,7;4V<'4Q/V!^7
M5I='69V\K3YC)^\3:4D>_T&Q_9?ZKOKB,V!@1.(L?D_M7RO)$VART-=/\GO?
M.H[Z)-+SXX-RSN5$&9\!QLP/HX0(8WZ2SX"D+IMG@/EEQYT6E8SZPW_XXM]J
MAWYM]]*@Y.-GP"NV>M];40OHGXN>R64]/?@Y'FY/A>V<MMNMM1K+QD.VA4GZ
MC.+Z=J*)ZEPX:&E](*C5!J8B0D,%BNX59VB?S<]X!JA RZ^+>84_J7[8*8M*
MZ*NF08$DTG.)1/8CY.)>K(N';%3B/K!"LU,VJ/3\Y#8:'3OK(+-:+B"RA>Q/
MOS$%1"0 @+;W7":4]JM8,)W>V5886D0[.]QDP$<0#!&5LLB'ETJW9U 8L HM
M,F>QJW^,.3;526%;V**=6Q4GG7!?PSA8#$C..YAMMDZW)A8QH!#L_=+;-#:C
MUDGVY'$[4#Z_! H8_#71Z@%#?-&TJ0Y&G.9H502R[E=O)C DXZ,HY%C_&2A8
MI<TTPD@!P 0\OH(Z0@16<:!7HTVAY;O3CE812])F$072H9ZRWC)=I!I#,;@S
ME;K9J.":6BAGF./E4H%O44^AOIR#NXY=!CXB^C8]> >PM=KP#N%=X:]<7)6M
M)\6:P/GFP,LR'1G#DX&'%,L7SNK^##C0K8AJ'7H&]-H4RJU+:7%$WCO&\<2>
M908VOA"M9L/5^4P;W(<[O_"E!];,^887@T#Q7>FB6\JYFMRC_AEFWZ?39@3K
MZW?AM3DW.PX<+]3-1<QM7V8K9DZZQWWO,@K4.IOSCSE$59"6&$>[_4<%RTY-
MANB?R)5WQPE>X!8[R09_2SF(QJ!JHMZ?>M5(4:\>"]\S68I0Y0RS9)WG5:/3
MO'@=P@$M,2VN0N6HR=+6=71@7%\[,0B1E(\3QZZY[9?^>"159X- Q0GE^_YG
MP+(V>U._J]0 5G*@)/P1%GA=!+W^"2WH?F*H@=27>RZR?^A]8I^N>P;42.7.
M*Y$[U0P]WKKJ\E1@$:.WD<87L06:5@:KPI4D)SA;::C+J>.1/J8E+RL1WN .
M<"LQQW[GX7H( IAB J[B0P/QZH O;^X26""?[B65:?=[*R#++)"/7!WMQ^XG
MO/>UVVEB_LVX%36BC!O*K)WMI-.B8GGZ6#@4G[XZEK.'U$844)&P*4A$\I5+
MHGSP]4PEUA%09XNGQ.<MJ^;8,\U-(O02_2("@91FQG@4E67G>G?TY,2WD\$+
M*XT.R-FSFXA6<IWK^/.*Q%I=N(,4>5X'P<W.KRKE*C'A,EO^KZ7:X&=E:X=5
M T5VU'39UT^6SCQ_0]DA+2F&20#M?3QIX9EG0/@S "S1M185P#']P+GA3#;P
MYVANIZ\^MZHIXJ\6V=(NJ#N&I7K[NM)-I$>UV\*(4I32_+O1SY:;_,*VM(!^
MS:7O3N/6^5&LW7S_6N9]$4%@9#L/3""4G8/F [3G<**P)*7R81*,.GA$H]T)
M@!V]T+FT+;RX!PW"[D#<G%>=M?E\EXR.O;394J0]IFX#]!WZ-YTNRA]UY^Q9
M\J^Z8S"A1Z9<?"YJE=B:!42!'HS.PQ?*U[:W([)ZT>6Q<6])!_LQGS;5&G:<
M'S 4KFVWV]\?"C0+='<0K]DE#Z/F.1<K7E\8@!>(.M=+COWO=3+A;7Y&&UE
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M\47,5<7%N-9P+:Y5PV&]G!O'_I&JC-UJM#<R?KE_7O;['ES'<RON"XYYK/%
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M$,?O@Y4'C%YFQHD0V</V,U-3K&F\W[=C L3>]>0&0([B=4Y83E5.SQF.W[M
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M(PF0A1JB[;K-8&TN7YKSMF>I]);%])'Z;CA:^$Z/S6V<"5W>NTJ)^/@OO%]
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MW9SB#MT?)F1_0ILA^,F\$H[SL9*+!0?8YB)D[:>]&!JO<)Q=CA.X$@VC\03
MIM%D!P9\%;M66NUGX*%U@<0?[GMGLF\T9?BXSXJJ[2Z<>@F W_Q;*UA%)5RB
M^M_/^<RGISW1E./3BQ<8D]!1?]&$28Q?^+F@Z<?97^,05T!_WW&EFJ@B92=7
M-%72"ZD@1TE,N;/<<;KWA-5"8U_344BCDWO,*LF[YU>- C #/W<8?DD1'("G
M228 N S^/DSYU,7V#IL]7DDTKL;I8^M6']&,Y"PF@G]/*I>70EEI&\]*@D2-
MQK],E-1&+X,P*Y?E#G>"/K%O3S(<)06?W"6:@#@R"&F,>.H\_C_HX/MW=_']
M+;+-LMYHEHP_82&%]Q  U%8X/1"'D)]8>31$10>TQV"JZ<5T6: M"9'_7BA\
MYO7AA=C]N(.=(5#8'> M+%[NW._"#,SC4:6'D@L5,KL="*_O&4]W.=M[6![$
M HBL_W8G<K147]#T04$<F3>"Y[ T)O]0,6T5I+F69W0H9-1-5_!LG?(I(^-0
M*O4M.G7B[%1J<I*KW80(9S4&]OF*2"\Q=VVT!65N=Z'UH0\[R^;[^5(G+63X
M@@7W6"(\?_SDB*S*HPTT/CF@Q<J]L$B/5B#[$](?]3%-.G7&]/';O(_)4OY!
M6W%K8<PXGFD<<_7/15?$_8;IWTLT.ED:8WM[NPFT_1Y" UR2W1!;[DB[1"+]
M0@I-1GE <.A?_H?@.6=!;6)?;%QG8[V$&XK43)(FR'*==NFX##)>:P"H-]J6
MPY.LF1L_;>LA:^[DW2G4*1[]TE\"F<I/NJO]V:R0!CKX(D-JD>'7D/XC7<$Q
ML*U3U38;_;0P6++<8G/^]YB$OWGB%)GS7I%\4!01<ZUXY$["H;51"?C>875B
MX5;J%IX;<YJ'LKC7GK 2[F2YV!M$-Z_&FX$>RAH*R3GDBEF")[9ZC1'__)WS
M<M)JPJU![D;&1M\I23/\<[ F<YF#>Z@RG6L]F O9ZD&&-5(=$UI:@TU4?JF/
M7;L8JLO7[V<=$<?.- #HNK&M*.I$6Y2@Q_4=)K7JT\R1)84&#N=PZ.!()3T]
MQ%/F%0-M?M3W11/)19//V"L9I%N#[F!VSGS7,I-%'U6RI!Q$H9BI6VJ_&1[<
M"%?^]BR;U$Q*D+4U8A5#5'HE>5#[48?7\#I*SV'3;HWS-Q?X_03%28*C<@D
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M([G>8[/A2XL*ZO070X^9,AG=K6K .M;:KIN05;VR<J7V9)?5O%[JA@:'3W>
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ML&[P(=\ZY&0,B7T)^NM"HC,217_8OUJNA0=H0>B8"\KZ:Q=_+N"9Y/]0:_7
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MDX\[3451Q5.3E6=7";WB^.!LMW^/:^B/J<[HSXO%ZLT&+HW+K^A[%G84I_!
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MBW_^D37='/W<T']\2H[>#._7\08JJV(_(41LMOY8I?<SAI,K-?\VE;8?G/P
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ML*0'>KB?3;@U9]_1 9 FVB.:B*8H9N79B\4.I@--J_?\I(41>W)XC1(TOQX
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MI7Z>(]F-7@^07%H60XOLA'P>"3>8GTJH@+'=S*T@0>;7GQJ;I_Y!TY*A+S\
MM"M#W3 HR]R067UNU,3AK&$!CDA_*T]80C64.^!GD+3Y?_Q!<\]'V+4&)J64
MF+R>F\OOI@8O"@]S/=I)*S.V]6W(N2!"+!FII+*]?/4&A\RLT/ DJPC\%65F
MM^N3LG\;7ZM.:X1K1CL(<_73V[E?/KH^B^:S]MG"KXE(CG[^$5"X!\!&0"SO
MLV4Y0+WO9E?EQW<2;E?T<_4O#F&/9-!?P^ZGCK/I (LU]RE\8/GKR7W),T)5
M@TRB93EOH83\SQLM_&28/[)2X[E>35.I^HU1SG9'EGC8T^7=E)>E/<RA ?QS
M5?S2.I6'7U&<O1E"P%O+])VWGJ_O-FA:^/"\&/RF,+PH(1B06%HA_PU?A]-&
M'NYA+7Z5I^I'@<I=K VW(&V%IVUV5\)86] G&"S0YL9UN+!=_M2+("/YV5,W
MMYQ?%7W/=R$TS.'^W BX(=+[J-BZ-:#.2F0V^N7.!R09?.56[V\ /J(_,EQ:
MZ$NA'?*7J.N[(%R 3?!0-=M5RO@O$9?03FZC(K7?!LJOA@-#;<?\R[ '1587
MI]9.JLI@^0Y-\\KC/*,RA:HN3'X"@&#8MEFN6<-</!BX:1:W$(:A3IG=?%L?
MPJWJ%_NNYSV%#<LUK3B\ ;1\\0"P:\_5RI9*I[T8?2M'+M.7\I;APQ:,R>OE
M<6X#(X4F]O&:7_EFA$"K,@UKHK8Z;L T^LOD<P3_/PA,V56K&.>11P*R)NO"
M@:1VR%TM[")$;B@1H;V!BQB!$&5JT5GL8VUR5RR=LZU;&\IK2'3 *WMF\G:!
MM66JDVUGOH )3XAIZU9VV%F^MM\#X%D :Q 'RN%7":3(U+1\>6?U0Q'NP#8>
M@<:ZZ2:"?GTG&2G4[^W5R9;@<J0F.0JQCF:H_/"&@)HM&[R,]Z+=K#> NAY1
M'>-XO)6N\!TOZ5E>]B70>*>C;?TTS@I%O9X5>SE%K8VD:HWB.8)\/XJ9H??.
M8V%8SZ+7BSN&JP#@]P6=.$;@YW/"RZH*N3I%#E1_8AU<YS.G\_&( J/<@WPO
M*3>:4A\ UH/7^@0?WC6[#6&7<&OT!Y*W:R'Q8+=E2+Y2MI41TF2+5SBJ5*YE
MH2@E,(FIPW=D8Y&'"Y[]W/E@IWV/)A6V5"(#\316'V92SW:%9%*+F,HHI\L7
MW8)I.#</XI 8U$%SF[C$M5NX;WS_I>T5^&K>ZR?3CY/ -\:_XZ#T7B^^CDYY
M F1G9R!\7T)PO7ST7]VE^)*,M03&9 R)Q>3VX*VZE"@VJG0A_D#!&![##C;Y
M'#"PV#Z7LX7^RQ3KHF.1&\<(DBZQ=$6VI_V%G:F/J0%->T+_C^BMU.EQO O_
M_SIPV<7\+^82ICI+=_AHKO3_.5VA0&-9:RP\&^ (W+]@>*3^M NR[/#?#;=1
MO(C0/E>0S28\UMF9WO*KS);!F, /&.I_VDG,9/C&MQ<I1@K>5))7G,/=49^N
MIIRM&C,7EKA'1?OCGDVQ$W=4IB*<+@S'!:5YA6AW++]Y ;8L;\]-W.T55ZEF
M3XCJ7M+W@@](3!4\F=Y<P2* 7QX C^=!SBM/#0\UV^<LXX0SQL=TQ;<&7,NG
M;&4['';,&$ &Z.<;:A9RK<G@$8DX]A(Y%H_/,MW,.5Z=Y/=E 2P@P\G)235M
M7GO\0L+8O]@278"GO3C(E0K,N.%H:2RD'LAHP!+!ZT529_)F;K@UDF#/_^J8
M;5H3+_LM3]S)8]%=PG3: 0F(;./$G,&LQ^#1U0C/OK1=XH9TBA"*[G#GG+\@
MEX9&<8OT-$'1-WCQ 3"GCI(H[EW+BV$B-!JBVYAV(&VQ@PUK:UM8/0!@>]A;
M\ 5@;ZH12&6%MHJ..T?V<N,&@] 9W)S*O,DK#A@([-: VL1S]CX "-:0>9%'
M"\(1)U+^ZB+FO4_S^'3V0\_RKL,#I%=8$DZLC(^)W#(!$?^GD3/>"$Y2U)\H
MS?=MT\G3OHG#G57WR5 [*2"A/F<06H/==5_G?0#,AW\I_OLY_>TC#;S2*G"N
ML@AOD:K,M("0HYYK<4WV(]]QO 4@8Z"-"_[HAI/D T E@5[\T@[G:Y&@8\(+
MSM-J<8F+:CT8L":GJC'$&2U3#L<]TM<-U7XU]%*:2# Q0_:&6>6*)!1:<YV(
MD5@T^->E90+9<XGJXM])7AX(DXTN'6D32C"*;]3+2H,9435WXOOIF:F':K]0
M;HM#=X9\VPFFN4:57-S'N?582,K$2+ !PF^#.%GF*M7-SM_EZZ^@ZJT?[A%8
M$6]PE9GC_?@*UG(,"9&_[&X]^[R0QK1!L$%J"7HU/_C1[GJ++"\,&-6NHK:Y
MWQ*"\R/ .-?]R&$O#=&1K0NU-@)Y66"Y=:&E_&VQQ=:!?=Q 6I!D_Z9XZ_LT
MCA"=X21NX 8\])=TX/I(!^M].GO:5\CKFX^WB88W=5<),Y<D_TBE40[QNF/!
M#SISZNUS]8 3(3/I><S</]S-.C-Y<OHQ4:N1',^!.^K;P$A>6_+@9D(]%O1.
M8;\5[U],F4%F=Z)7<UH-DRQAG3&"0%!5<VIP$&3 !TZYD2N%=((EMNM5H&*0
M%A&GFLV"]638#6_V\'X#"#J0>AM$4 II]S)4C!&7QVG#ZT4GP(V%)@!;!M,P
MI(FE0,E;_*NI2<NH)WPG+80U82N; /#??+_-0=(HO77BY V6O'T,#]+74('%
M[ =OU=0NRRVU"]JKV2RF4\ G@ -L._?$R^YR)(H7 XZP^AI3..YFIHH9Q$@@
MFGKSYC-ZKT:W?K33%BP?ZKU+(C1N:P0P%<?$H/KVQ59X$0IM(;A7D(HAGDD;
M%BJ.'P\ 8EOLB0"*#TVR9$T)*U8O.X+(O@X^ /J DK?45Q:(&6@,AG_![K;_
MEV]X>%I]QL!+ *B7[]$C228CH.'-Z?IN6#%"-E(VB^$ Z9-KK];$_/(P=:$S
M Z6S 45IK5 T(_7^ZIZ:SF4,3?XJ<0IV^KA]PGY:WPA@1,HQ)A[[(81Z,W63
M2T&];QHB%6?"-][R9A.4,W:Y?NV6?&Q:E%!8!8[VHVEHB;!-*VF-OZI\_UC0
M-V^RE9\.;(ULZ@NDMB<'Q6I]TA^TY:44H%.:LB>.39V^%!E>6O&YR;6Z*7C*
M7;U"X856YWIT<)"T;'=N7.A,5OE88NWXP <2U:[GZKPS7>)ZMRW8N='A>WT!
M*6C(BZ9J=0F^I%!Z(GWW,T9@:,13VFO 8>=>86G!.$'Y[_SP/T9Q_@KS'6@-
MN1$S"U^]XM[/NU5E#!2Z_"\G/@#TW;]X3AB-N&_DA=D!EKD:II<XO0!=ZD"B
M3/3NU/SV_6+UVBX;-L/<G@N:"JZ5IXP4ZQY9U#L[84G43*9?$H'NFSWI_V*W
M^93],)-EL0X#O-@"RE3F;6"W6U[(M-(!!D.WD@J%*E+$AY:/35L0A$:1"DC>
M"S'!5PIN6)_L?"T9@DT_L?,-<\1)=-V$9)\?ZGZ$2[/T&$O&D8M+7.:3Y(,]
M-RG;IW_5'\L>FSJT?&)/9D!'O6?L;#C)_, ZC$5D[_8HJOM24T;F</T!0'2@
M.&)8V]F:].OW^U_#FZ<E7S7.(0T>HXJS!PL2QX.Y$FDF!+GYP7)TVJ8K>[<Y
MZ74EIJH6908J&:1JS"N*.,\N<5R5BCV Y,+<^F 3DBB>ST9.0F9UL=I-X8$S
MW=PA3620?')NM[^OJZU1[Q!-V7*),@G$4G,.:V;4=IFS,6#F#3/!*66##[>*
MK8H/@!J57J):?AU"4J$E)B5?P!D\RLNE#&1^RX)C^5Q +0'K]M[-U&2#\=5A
M/S.)H[0BFU2,2$/7P,??XIY7#X##N2:T&@)3L.[9.0DI>/)*J5V:\^N'CD^;
MSG%%7Y]:8X8RJR,WF"E 6>O6==LRT*A\L5N<U/LI4.AU$K/:@:#,;!!05-JJ
MD)'>*%=$CTQB*2N#@:X7T@QT#)PW-2.P35_A04RD:B(ZMB*$7NJT:;2:LC?^
M\"W 2^,,>0I^R_.?$U>"VFQ2!8#H?_LO?.R5 :(-=+WI$NG1\C-&U8[FS4N0
M-XOBC3+;',Z9 \SAD@2#?XDP]_/'@ZT^\ZSDRGC3$N\1:\<WM9U,D=&2K'S4
M'/]5ZH0Q'A 0B4KH?8] 9ZI'XY I697.LY-VD=+,OA8MP]X#&N[(2J/85%&5
M=R*HNO=&7/5_4P:4V018NC)9+.-",;>07;U.$; I MH3,36YJ1YI. =A58P8
M,K+@:-[TRP4-LKBARS$$J+1UEUAFHDON%E[U^"\ERVSV5!_NQN,B ,DSQI[_
M2/U.XM^FJ[!)L,):&S.> _6(Q0;C:Q^5)B) IFP+8]T0Y1QF=K5^-:+S,5AX
M-M-?>V&SC]H+[F)1PAXTRE:;1%,F02 T)').?7R/J 9BFQ[(<B 2TIC#Z^>/
M,!,.'+7?R-1?\[&Q^\\_%GSM%HFCMY-06+[B0.WB&>@M<SQROU_-+BCEKRR1
MCU_MS'2R8;#M-#F\O=RA+"'R#T%CJ528A)1Q1'=A=W#XE1Y!$>IW&QKQOV+D
M4BH:]_J@!]W8''^O/F&[R8:N!,F,K.'U (_X(\3T,LJ>-S9$'=!E5]UOM'Q\
M  05P&?"K="",^8SZ$\5AQF?>QDVAZ($ #@\CQ* \Y07D<?*]SD(BS7=Q#4U
M:=A_I-=8=H.=U3"/VK=_XB1W["1@/S<;0-<])$&8EW/5'DVQ*NT.8M\&0P>M
ME$,@*WRN%86IS=F:>#4H:N4.5*2/C471HJI;H'3XH_N)X*&O&@H R]1Q@D/P
M)X@^2&6BG3K?_O$9+-I337TZIVD..SXK$EW[(8FZ981I>DCZ30F(OO?:E!'1
M=^A=;J*T;9_+$GE2F]LX.[_/3&.#X7'K=_6Z0BZ.G1);$.!;PH;UK_L!;S88
MR<?6V=L_S"_W82EO  5@B&Q/O,GF)[*L^P*Q^WPYYBTU!CC()AJV!)E13XPT
MLBHCM!TH<GE7QHVI9H@?Z\W7.C6CM,_L'ZLK,U7?4V[]_F>WAGTWKQB@ML%H
MZN2GU=*<Y$Q>)UG)1*'+\[G,'%]=?/'V4_DF([NG:<")H+T3OU++S+8^C]/*
M>MT#@&<N^$#Y6.[II/ /SZQ#/_U"]N%YCH1'P=<_.@"4W>BW<S^1)#'5)8VP
MOP6$3DX)N89/\S'2>0-M+O2@QI$>0PY89+W=Y*EN&[T(HSS54C(GB,WY!O,"
MC>=[9@BX#?S?7H8)"E@%GMD"R:"'*U,/ -7/D,#_U=/2) T:R?]6_"019A8I
M^RJTM[4^_39A9P(R_=:+PK(4R!,C\_'\1%!JSFV#A B>;QJ6-K/N2?[6C>;F
M1=S9KR+/Q^W.'4KKD$1>?IX"1&FTS=DO0K+2 [6AFJ0' *%OGX;9R:YLP[G2
M%UFF)U3Z,\'PT39VZP[JM:OV5HWX(XM<[?0,KB].H]?>'KN'Q@&5^:8@FT^Y
M TAP.75(3( !==W+$Q+C:5%4B +H;X%.SLV6KWF0; ]2M/)%HI4;<(1!=T\@
MF_M9MA,<6N4A^2JRZ3S#MME#L^]R3 B^:_;<%/UNIEWNM\$!=<1'105 HUAP
M0DEG^WA(1Y$@"\L0@25Q.W]3 \ S]PF209(SNHI'1(<-Y&*4+'QL*NT_[=+R
M^L)VU0YO2@0O <WAACB$T5U%^_TP7;$B_1,;S/,A'\9RQ8+Y/,MX69^!H)E]
ML]T,2(&^E@V=.C0MIRK]@O13F*PWVD^9@]%Y/)KMN=HZCM2)#M@BW@W_[EZ?
M2U]J"#C/>W3HQ42/*ERO>JLCJYOF[N7(MZ#5PPYMXST.^00E6 MT(9F?N5@E
M,$$EJH9U5.<%W'I5DC(C3]VN4[3V4O@#LB([@)LX>G1J'9@<?\>KHI<)'Y,H
M;8N8H,LB%TW=)+3[@8R=3-WN&UPI5XS:?:#_@[?WC&KJ\;9%-T40$2--.E'I
MT@3I+2A*$1$0!>DBO4L/-13I)0)2E:)4I4GOO83>>R>A(Y!0 X1P^?W_;[QS
M[SGWT[GWO0_YD)&=D9&]UYYKSC76GE.G2[NV1_<=;*3$-Y*;^0J ,@(XQ43.
M$$4EXL<2K32S)\VSQLMR6==<F*0ZNZ<.:N=@1"DP[_ *%R6;\DD)9<3S[Q N
M[^J_6NA..3[\,"O+L$"1]H9:;;SY(MKO?0_#_9CH+2-JXZ(K *T"#E!0QTH7
M0W<,1E%/2VP(9:5.3"I70@ Y-Z[O,MDE+.X:I#/X)^BDT+QQ_B/+LNI[7O9E
M^G.S@GN3W!>/8L>B7&(JUR%5CNV-8-W+I)(L=%?*G0RQ,#J]/\E<\W'SJR47
MKWH'I::R<.K8I.624,9S\-V9/N^BA>B#N??-R:;PG^6$BL(D\D7ZO$.W?,RP
M;J8<GZ/!(3XS#YLJDAY=N#^V^D8JN>HZ:$6T!O8'5W(%-]BO>#/)6FI&JD\5
M9;ZKB;%HB2<*,3@I(;VLNP+L87>6H*P7+:RD$]3O&L=U>L8%^6LC;EX!X40P
M:M;OKNL->?A;E.B^:^)-*O-.[MN*JOZ<X4-<.Q_5O*2C%)W:&?$Q4X"QT4U1
MC.__$XYME(967VG'ENBJ*>Y-Y(T5+9'=@TSUS< 66%0R05I8WN4;HSX"D;[4
M?-73M6EU-[N$(Q9;S$NW7WBP$F,(KP ;&_%?5(53P@A+<TJP%\<'",A@8O^N
M]:&UT!S68NZTKBM;V 2^[AL: ^ QRW=J2ORPGA<T.W*$(YD8+GBEH7C;I",C
M)46?9Y)R5EQI%V0MKPJZ+\_43(KCL#VIQ2DA2196!CC5*Q?/\LA$E@YZ9V1U
MD^](WXY_SWH?8U2*W*<UVM'[J7A@5-U?FG',_BD?,DT$@'*,,."H*V#E_KUS
MMP;C&3QX[&M.0J2<,NF^Z@.PG^*V/IH>T"9FSQ VL'0:RD3]P.43)6(3\E0%
MX"YN#HN& Q6"?,ZG',KLEF,19V-=8!H!G&;FT[R:N^4J&VI!IW#'ML9J5#/<
M7D9\I><(]:@O?TDPB?FE\SO0XD?I6V?:@"5?2UI6+8L5H?@;LUL(* M4QJ.@
M3BY2KO;WW*S>LP.#_CD-+UB&GIEV3O9! J.UN0R?*7O&RTT?G2(%M'[;OB,#
M!<I0#_S5H6?L@TD?6,GDBZS4N08I-::^HZK/S7:%Y=&+^-<C/1?/NYT%!(;N
MS.S170/F9$-5"$<X^VJZL]5_.W;,?9X:H]IQX13KZ>IY!11W-?]4_7]3QW;5
M@C!*'<O?B3Q=(0<\Q75,3[KZ_;AQ0UEX FR#OK5>2)++?5W:SZ7ES&@H!&44
MD&U[K]KH?OJ4.GSHXM&^I677EL'E_"G]@$^1R:_YK</PHJ'$9=;O&[/7] TZ
M]2!2:P)5&^LNQ9?73]]B5'O^3RSHBTYJSV_5U <F (LLM$0;*^28C5T0%23<
MT>JT2TV<.2I(N@(2Q7_?(<61O1::BCAP=8NW+=Z-#E21! ?D=MZOK@M'.997
M.*[S;2,>H;X'0J2 <0PLN*2!K,1@T^-+@(>U9(S?IYJ_2J7T]R^FR% #ND<7
M-^JK/E2[#ZQW*9AE1R@(;O]L^EK5''D2-CQ)7L(YAQ3+N*OON2:MI1>LM'#R
MY4YZ<]\J+-)=+^:;AVONS/#S6VI$J\*09S=E030$I^(=QO>L,NY> 99J'AUU
MB7.-Y @I8IO)K>NN[! G(SY<$'1V"R>-#5BI1B\VBS:I=I[&O?(]AKA> >KY
M)<,@_V::AY-RI-",%8<2EU(S]^91"]/#%^+26:V;A;+2E[9K0RS09RC=L;V*
M;VO@.?>GV65?BV]CX(T,IRRP6\#9081KJ8BPL$0[SS68_LMBE7>S9-IX^2EV
M!3/W=&S?E/<G@L?[5RK_-NW;1&;,L,=Q23K;38_]A>\^]8K.OI<%QT%X,O/E
M2%^Y?AD/Y"+*8$S@8]S-,ZN(758'*>HXV$O@PE9K4J!!)M4AX4>7B"SAJ.##
MT4E:RNCP@XV8>1T%5 8! F.[/%F_,F#9V_A-JRR6MNUV=C(GV[$V,!4+=6PQ
MXBK%M&WI1<QO<Y_RA:!!L;L3M4Z#=&=3== ]%1^F97M]C>%E"F][N[9%DB^?
M+3\"?+[A X"?+;ZGKK(AG77259U/Z9=UM3U%;TVK._,]UL:;)2X)JH\M!D>G
M#3*,\T:;*)HQD+!F2U@X8]VVV(&NK5AU6>1T]E"\A,?\:V]32=+AR8THV'*6
MMF"V$CA41MR]KBR+;<#[T1D37$E>SK%EF(0+1V/:6:7#.!0J0L]BUAC!69OA
M<&>"ZQ9HBAA/BPFVP[9WGI?$X)2\BVUUU#SR%YK.V!V'":8)6FBC_]V<O#9:
M((0JA<9&T$!H2I$=G7G=LM^)^R:)+ZGHFI?;Y[JTHWM_>*S-/T4 0WJ73RZ_
M7Y?*_M^,4+)?AJVKUN?V4:>*GDFK[F_Y^;X?W2(A.+Y&@ AC:. _^>44;H9R
MS]#1>LK+5K%!#LJ#R[4[T0AV+V2U*XMY)KHI-G>6VS..C&78V4,<V)A*79.!
M9-HLL30XY5DU@:N>5':V5)<'WZ&)BGM_<BKYE_>OFO3)LRL@6,CC)(-I)_'+
MUN#O%3ZF@?HZM@Q.FOOV1/751(O^#.BAUE0?/%5&YZ*H^#T\PYCI<ZLB-%BC
MIKNS0?<*0(1M\I)V+$+J,*%1E4R-SQ:E)=G?7G#47 $ZM+^C?U'!Z@!B/]%?
MJ"5:=63?!?WDS;\5OK*W&?U2J/';DW+3^,/T0D2<;7)#E6XZP_<][U<!,4]B
M@R* M0:H<3N&19?0KOILC]@G[KN3D0MJ*?PD$4_/8[,]1=>R0HKFV?-5\\B@
M.U;U%6\Y7>X-.V@S><&USH<X=RN)W;>P?KDVW95ELR?KEZU!Y"B8W2#/;OF(
MA :\H2L5V%U%IS]]6[&=J)FD.%C77.A7SYY0"VLE:\Y=1I_MVNE2"$4KA&?=
M7R:].1<T4X!7FUKQN(PXM\3'(8S[+V&OP.4ZN&\E;?L7M$=#EQPQ_A#)*V"Y
MIOF #JMR!1B("E[>6FP6;I!$JBFU>55(Q20Y3U9K7@%W5Q_O%4K=]0XRSFW^
MK_D6!'NS<J4K5T!8KU&7E0\$>>_BW+!]MZK&89U.E@R_A7ORSLV>%?6T[L"Q
M*+OB6^V'3TL*2^@2ZN*I=F,ZGQ<KTXD3>]3:8_ZM9>/Q@Z^\>"#">!)_J5^[
M6;7F4%/*LNB<:C?6B2T(1=-C&U9R?5\YK*I+=DBOL)C1D]WM)[,ULM(=37<P
M7VWN6Z#3RV!KP>V.E2G-,_&_+^G]1&P8C7YDO39IJA3ZPZ##>R!U\J@]D)MH
MV_$VSG)81DU@9OV"I77E>8<]V_3%.>-?.HW@(@7V)IL\1?I5;YT.GML6LCT"
M743!?FF^WA.;E=':@VRW7?ICCS7BJ&/A+X%+$C2HLXCI&6\V-.MU-<8XQ/FY
M^QCD_$6ZUYG@]X"A^:VC8B+DU-_V(JC#Z"'2PW]_Z@TZ)ZH@W_H\YQL>/S)1
M#1(BZ!7^3H)B8-@W9H[6.]@3CRYF9V J(U,D+94Y--;&#V30^+'A1-$Q>23Q
M'I8EFXR=Y0I.>39$7CQLK!]ZEI>_/-W!W@+.DTY\L!,K\%FE:^GA,7E/R[;Z
M)%T]$L?RB;#X1P4@6-2Z$]N#> 0C,DX'5Y;\_2ES Z6_U2 KD\3X:L^LZN(9
M\OD;V$0/?A2.W#=<_X5>TJFJ*I\\8C ;:7AGPI-*MLLAU&S@7RC4?50\<4V<
M*"P[%UF^O<#6+I?L'A-H5NI#9;YE*C'%2'#-FXH0G$T48%TTAY-]RR:0SSZ5
MF7(CIB=]G!J**6G3X"\TXVQWANYN0D XK=]7@,5FWKM[4Z ##A0/ VO:X:L_
MV!<K^Z!?GIFN;C[9WY22/3>%)OVI3_0N@T3W(ZK:.YMX_M2JD^NOC:F6?^%?
M.V/>Y<*_[_*BDSDADH&/7@&AX'L5ST=\I-';%+?5\\YB]8M#5^;<[^IV%-Y4
M,ND:B4I@BF1.=%#S=/R;@DE20^/AQ59& F]'9,39'R7&L0M3;75#YZR[/]YY
MUSC V8A1?XW66MHR!B7@I'\8BI'D>0@X"O3@P4]^<\EPKYZ*$.QF5 []'2C!
MO<7W8" !@KM+7;-O;4UE&_\&2I38JSK,=GPJS$XD'6,;K91A0[_97U9J37O?
M(Y+.,VGNY%WP7D_QN8[FF3GCM"![IK9I_2^9J0$(F<P[;]).%B;UNG%1AOM3
MYF+4 X[.VR/EA)0U,KL?0:+UF&L,-<3:8YR]0;L#+_:H1A<U^>@$&+YGSB\H
MDE@1%6!THG L&.,5P_T T6ARC;C><^*8!^XI#94?ZDT7O9I&@JE*V&\_WC>&
M-],WD>W ;N)L\ZT\T*O/.E=\KH!">#X;NF2T YM7D!?^M[)(MVE&!E1GJ&?Q
M;!-H56NDITSW.C1Z@-EH$\^@DS%Q07J'IQ7)FUC:?28BUNUU&5[V&B;=6+N5
M$P:8I0.T1PNG?X<*H74'DGPB:PDY#Q_S9\XDGB)<C#K1UPUZ"MFHHQLA?2ET
M%-NHGL%?_W)%W0 &VI$'<_AP8OE+?%0Q'"$9IGD&!GUNG-T_PIT/'J\&;)(Z
M0UEVCEV686V06WX#5\!MQP8=)%>,K-3HX^I3I^@E^W@V\^!<ST\&)LF^!Y Z
MWNLR;KT"B/QZ4OG'SR?Z&6T,E?[H=>V(E?RN<M9T.KU[]."3K!HTKQ,4GCK5
MN40YNV0SHI2W>6ZAI8P^3KGL3-YJ;&X6D*IZ+'4+.!Q@0_2AU&?%',.N )H*
M!C?H4^^:"EZGVOOA;R.AY.($=S_$SF],-I)V9%337@%=MK^.)/;40RN4^C6M
MW7L?1F5*W!J8J'-=]M9)@)YVZGF$N/;5<@*+KX*IZ.?X5(Z';,XL4&^$YAMB
M![M5KX ^X?9T3QJ"X\5?&+#"<+'#\ZDF^<AR9[(3%MBCPPQJOU%>BL4%UI:^
MNSW"KYR:61>:&=&6<<ASC5<Y2QR1+U>_D$Y5ZE974W#'<%RXM7^BPRHM2XH0
MY"";[]DL2DPP'FK6"U-V/_L4"W_!\HB%J#TI=7>E<BS3AYM3A:PM_]CB[R-#
MQ3DUM!F9"[*@*T+;<&1+;%6T/T-S5/34YG")WD=_PD?5YMP^E3/\QS519[T7
MRFK9 )\8FH+; ']%]VFQQBVG%/9$5T";SJ^\):ODG&S'>8=M[ EJL09$B5.=
MQ"DQS:5HJ?\QO?ZN.]F:HE_-6C.5;<+/?_O!9OQ?L7J!.&:<B8##EH[WK:^
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M;_3:&U-%@(\OGSIQ-'/82!WZ7==-',_OG&2 C,N?U.L\2 NK#HJ!C2_I+:H
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M *=,'Q'5BI[D_=5<:?XLWJZOYMXV(XJHMS440!@2$78(L GMH;Q7$TF_QT8
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M\!^+?#R6IK[77,+,>J!87\K,M$OZ4F1[RQNN!?40%9/6ELWB"-_,HN7IP#V
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M_\#^;[ !M8UE/ )$D_^?,+").X\5V3NBT-96FQM9RM/?>OILCFX\MY:EI2
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MDHFQ "\8QNB#%A4OVW@X6@-"9&35M\T-J=S,V6U0Y93=X+PVX0XC-284]^F
M1XEL<W_AOMNK,#TZD'ANDO:N58\K?17<]1S:2^3M-"-IAT]<I7X,:J=>Y<KL
M\@R5QVZ_>9Q^$[-:E!M35C*ZZ[A*I)K*&S%&D8@7A5EY-TIKX8-2)609*J**
M(>F7::W=?Y/TN3%/:T+$U&M#>^GC_P502P,$%     @ USME7-4(@-/W6@
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M4TZ32/+#]/I7)Z,D\W6%6CO?@-QEN ,NL.:$^%++Q:/K-\AS_6SR5H085V]
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MO"186/<;K9PB:=!L@8ZI3J4>A:ZXHXRZTZ>1N![=OO$LMM: +]QVT-?!/5@
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M2-NU9(*% <>U47)CX[L,RS_BN-T\C](TG\CJ@A9.-N0FHB/7DG)%V!(B-K&
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MV+A,1+I"]DV;L(")2 40QT0)OS]AY9ZTYA]8R8+QO!)WWTA/['HT+?^I\"Z
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M%-O<OCQL?M_7MB+!56/X_A(S]3#%"P"R_+(3G<LY4U&%\EL+TFQ^S_E[FK]
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MK/.UO,QC>MRB4X,#-)]V8@'S.KN!(]^RZ;/\/(L_L8P_L121P$_I<7A[,/(
M_$J>,%CY![((OJ*"(/_\4]4E@ Y!4[R3$*&?<1M!-.*&4H2?RS^$^U:_%6&D
M<S;6<[K8(EIOA,Y-=N($$:DL13'28L;8/KJ;+/\=XMJ-TXT;ZO9&G2O(L&SQ
M?OUIUNV75U[GWT01S>LCK<Q?EA2]G#]=T 9IDS.\ Y;B<B YHJI \X<DSG=
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M&&>F,1-FKMMUBI:0H^#N,H8-J!=(6S_XT(U?76WCU-O4=D?&2]YW;RB"B;_
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M%.4G51*+XJ]-'DN2TK"GJ:[8'9N?0]#J64TVX2D#F>_IOIO7V7PW8&P(&Z3
MV=B2NDK7;8DH>:*(S)L;NNH1PE,Z?5SC:@\,42-B9[M&?,(%+*#)UW.Y6^DU
M,3C%&&U^4I0_K1@54.CNNR)H5DF;_:8E]#@&9.*0+UY^V13NMMO?5-*2/[15
MZA[6*%?1&_NV$Q,M>7-6TC35[D=\X&K"[C?R786CUL0=#1?,<J.UO=NQL3?K
MMQTIO\K;9YSF#D676@JP:ML[2US&W3;RQ9\%)[UVB\[+,$6T/$Z\7!E],*BS
M#I1M;6\@*:(VCC\^)60K*USSDG_1MU0_LPZ;:$3&+'!>16@<97EVE8-;Y9J;
MTEY4%5@X4F/X1XPW)R^7TD<>I4Y<EG,_].R7K_OQ@.+BNR2NIER,KXC_?,95
M3D[@;_"7+PUN$YF>MB&J@<73$Q-@]Y!35N7RA5:.;3V+;#?(YI.R MREKRV=
M._/F6FY^\1<K3>885--AOX+&/?(F2M=:9+BJ08[]!RX0;#WG"NZEWNVS+3=Q
M&A<6736]/A_1H.5T"',X'Z-4\K.53N3JQLW-]2MA%Q+*J&5O26D$:"?DC')Q
M"X$?)U)LUUXTG7 <Q%[)H;U^K,SG1'4C594@A/%:0PWP3<Q^F5[Q% / =^ 8
MF;2+,G5?]B;)F!^2"W9B">K[&[\RU=3!]\%U%D[YDM!5]V&Z!O4! <;45D$Q
MT_WV:IHVW_XW#]V.F6Z,L)854;9IF"3#6IV!K!GN@CL!#!O93K-#]J<OW#/8
M2N S,3S9:L7,%^_RT%6LA,/_? . F6%^(?$F][54(%.U^_/&[W?X:XPA\T9C
M>_F76);0DTDXOC .4B0DNL:HRT8N]F2GZ%N?2GM%<JUVUM 8D?]X_/=[^Y1P
M2[-H]N^HOF/\CTDC7FMWU: [U*XSFK7_J(OFTQ<QTP55PSOFOOZLF3%A4G=L
M!\SC,%V5/)*5HJSU9PLH>P>EPL3:R KY1B&YOS=^-HAM58U)4^!&LK1]WAJ3
M%H-;_)V:$YF-"$O5:)$RIQ4%^4E-3U)<8 YJSO7'$RLC[O62FI,:.5L&M8FN
M1<EWN[\W:2IJQJUHOBS90'-K*BK&U.0(H79*.GDN]GD@);7T8#6$?QP,65H[
M^Z84Y]S6)7Y$Z-0Y6 >\7RED^= #Q&X8 H>!8F'=XHJU$\\S.RP<K4?G^A/E
M9Z3?.'^4BR16-&%!VY?+C,O: W!?=W;D'9'*&X'EJ_UR5?582P*J]G-KZGBO
MV+OHF]^/Q?P$"VQ<)Q0\"Z.*IWR;K_]*N03[.#SZ_CP<JCMV&'I%A$N6]4=U
ME89CG/1TBT;(HUI]\M+^DOR\70JW6)9?[K[2EMWLO%1^Z%%M?9W4VHD'-Y),
MW3QM3>M#/+5,5WX."#C<GQS6C ,LMZJ1;"AV^&X&8 JT(W@T^GGT)2+\"O=/
MI9F;W0@D =.N&M0H16(F_0CC)I&&%(6+9H.OOP'?)[88#(_5<H6N85LL?E[F
M^/NX_UCXW1J<Z+:,L,7[W\%X[Q*1G%N*V+P'B^D-C]YJE3,KX.(4-?9-\-@G
MTW0;B 5*P5:CQZ)QHK_$TV.[QK)JHR)?0#9#"AA+WKV@>7SW>L*HI^RLG>WH
MYH[R]'VM/S74\N;&N@;#0+D]*8T@1=9H.-4=@W8&1@87=*'>9-36"1RTN^$"
MNK:+^.-).?N+XLN8,4+8T/%P^<#5JG75-+;5 ^@HS[,GFT5X8"OX#UV4=&ZA
M0^"X=OI)JM"RU$[06.Z C\%QP=BDQ6%+X@F*MTN)"O[+?/^QY^?:#?#<GF,F
M#_';-,C\A;VZ]Y*?;Y.]([^@8KS3C(5ES12ZD.1HC/]<K>Z5P-%98J-_,8KO
M,4!]J4[>B3[\T/I>PJ5%WK><QU]PMB$/&Y[G)O)S<Z-C2VT2R_GTBNK?>=,W
MB>03#A*'N)IRDPO/T]L.?$Z64+2V,@FL9/NA[UW(P,A;1-DR-YOX34%M=ZY7
MG%<BA\#Y!.]X96_ ^@^W^8LM JIN9PS;YI27D9PNMYXBKSR&EKNK.@B-[!'+
M'SRO&ZLF92^]M%ID=5@P]0$05?Z&8Q5YC7&*TP:=Y.6V6!40G^UL<@A;@RG[
M2MPA) D-TK0G?$$Z]3Z=9H_"^HUL_%Q0WE;7_!6<LO';,ILJ@^_YY$D(:CM0
M9L79^_5EW&X"H:%WV<)63?3X)3FH,;3ZFIPRZ'1!]]'W64V3'S/7HVZN_;2A
MP5&]P!E\.JV4:O-H\77-OZ\798JCDV23[,=W<L!!$D<>UVCNO[7YZ;_5]SH&
M_30HK$E.2.2I.SUI*)]U;0LR3IOHW!$F0])=RCLW.M;5R%;WP5VI1ZI^_- ]
M/?NR%7( *M/6$_+*W6+MR!DF,&/\$C_0'1R4R,-V-':&HE 42:]'+S  K]+N
M&6!@7!"W/0#"F,=VUJZ RVVO/6*=OI$SU0*>.L_.\VU$??"L7Y5.>S)=$GU1
M1?ZLZ>^*9Y$/?]3_R)>[0IC5-TD)7]==M@S 'QR])@QW7C:CB-@7; ],3&#?
MIO!L1.KUA)5,NV4&+G/->SA6^=LKBU^R-[V=<VW&$G3C6=)GA.XBC'1)("=D
MI1,' HJ\#%;9S8:3TU$O\<A>5(R#,@<9&E_^,0N]DH#=GP5!@P%'[V.]OM9M
M/72X[U[Y;4\<,JT%SKW0.*<O(/^TQ_Q)ST"7,,W??%YH?"]U:?+<ME?:WS2=
M"V2[B6"%#YGZ6&>>U &./\9E QI-,1D&><:U=Q,C&F88 "&XY1T&(&F/9SWC
MYM;JPB=0'Z\=;:W7.UKURC D\7"BUP3@/+Q\.3JFS'I30(VC\B0 U'FQV^7O
MI:R+)W;!79IJA"UL[UM%\;%[!/,?LRQ1QJ3!>N2Q=;W*G-[26?L<,_NQ.*#Q
M^C"QB-U6?K!47;[30V?JG+[O8;&[MDPM1<?V(89',LIB71V9\'*UA@#L:)04
M5H'R;OA$T0\I25@'8QQTQ@R+B>;'C14U$61^X@6F5/4*OGX ?I290"FD1_"(
M/D;\:@9H]6_8 >/"KL(UVE?-OI&80L[M]2*J>4)\2M29@(K1OAJ&"9,CI<BE
M>'N+IQ1+T.:^>5F%&JY#,2I+V=%ER(I9[\9\VP8KO%#:7PX%0>U<TA[%$17O
ML:L,XM!5J4VZ"-8<ZA9?#E82W6$ GCT6_XO*\D;<1H9%J-8KZ=SD;M.L9ED'
M?\?#VJ#"I/W9N4E7)RZ5EVD/6WV]W;EW;2P[DM;LC?"0CJ28'R>60+SS\ 73
MMZO&0"ZY=#?@\?U?><A%,.FW5+<M3\_HK;\&TIA-9RKO@]MJVV.\^256S0S
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M!<ZM::_OCL6;KB$EL[T!+-H?MD^]:7^7,OOL''CC[G]:%;$PIOX'4$L#!!0
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ML:FSJ[NGMZ]_8'!R:GIF=FY^ 09?W]C<^K/]=V<7<7)Z=GYQB;RZ_L<O/(
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M<F;:VK;7'K]G?77A%?/U:]5D9&SYD?4,^L),] ",= 1'A.!0X[U]<Q@7U*9
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M(98'4B(S%]= <4+6)^4U*A4/>CT5BV&B <^,SH605D>?H6=<AEA@]>J?0/H
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M4)]TOS62Z?MM51$6\SYBIFWVI-/T:[_?A"Y)UI(#SR\#:M!2#U2?5^\_''
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M5U$.2@4R^E$DG7%GY5:4BW0YRLS9WE21\UXG]C@JPQEU%>+3>&Y&'<'6QIB
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M-;4,IKWI[PBY$_S!.YO2+J?-H0;=*@>*"VM:C1 C\]<8O52-7/>I^5AGFVH
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MIS=YZT+UA+);0(:Z+<1T M35Q!-:]J#1K^"S^G>6[-'5)&5K-N LFU)VZN.
M4,3[@^@/QG,[VJOVG23/7A@V;'N*&C5]X"M\1@/$SV9>X&LSJG3*!R"V(X'?
MD^6I>Z\C'S?'^E)=ZX^MUK:5/_*.4AZWZC=683[\."IRZ(W&JRQ\PJ*YWTZE
MP(\%GK#TFBURM"FB2X^4BA'->G9?&;5AMZ=%+?$L][(J[ CZ"^HS&7\D"]^$
M2L8J]KH?_750'3FL9!2&\0TP0TZ,C0.'91&S^5,RX*)=9>N,FH0G42&D\H+$
M7.\R':%=<BP-H3LRRVHW3)M$^+DT,IF#)5"=GK?W'R6\#F[VY91*NJ]$7:P%
M$]9W^65<S="!86E$F$64?RPZ8-?_^N==[AU6M4^<@1]$:)D7YB#W'84B(8KL
MGWPOKMGBTL3R9\M"Z1LB/HA7@B 7[-,FR-@[MT=L"U(2/ ?;\J6/XN/JZQR+
MD*X(LJY4I:QB$/6./FQFP_C;@77H6K0DC[WUSA?A$=]?76M%8%NCO/1D5/&3
MK%(<$/()CF2!R4UM(R/+0W,9?Q^,<>?-^?&V&9\UNS1I/H>U6[;3.3!K!HHY
M23Q\4 EC[*X.?K-IM9&I7.MG$U]F:J?Y:+7:5)GO.YF$K+\L7\>YGXEEQRJ%
MT5Z7MK(/>[X3)HZ#5Z^VT?S*?51VKU^.U-M]/6^5^NPFZD?YX@[BI;%VPXSU
M%X4M*+U7.NB]/C?/G7U):R;W9\9RZ+._<[K7AIFQ9"SG;78:%'3W\W+.:R_L
MSZ-PE)D[U<PWB][>B<G*\H_EY]X[/K.%37\PJJQ.U'(^I=?:\P["977ZKY<*
M5$[O)P[K<0;CL7YP3$8.E8ZM58;!\M$E-7-Y^2U<<4VCGI^0'A6<4W+J=<TF
M#%H(S87LJT.+S,E%5BQ0EDB(=S;BRE G:K TX.)!%;HN5[2L<'E9D86A,J.*
M"N=,5&\)-:P@*DY^P2LS-5BQT<%S[_S($%89YHR2+!FR+'X$<Z"25(5;,.4X
MA[DR,663VZV=K.N3EZC*$(SX,]QP0%ZW'F.!".[CF 4)(_:"N$?& _VQUF\3
MVM*^LJ*)O/D,G^T2E?UZ.T@\G,-*Q-Y8,;3FUYK2"[HMP9\%TRK+AHZ)?, "
MH9-V!/OJSV8$CA[(B]^73I$-><XAS7AZ:F7N.D<W[CV^F.'+$:@23'CZC)7\
M-&N*=D1D\'9_DNJ#1EUPI_3K6^2SU0K#\;]L?YB;TMR\<8BRMSX>G/A2;>J]
M\9*TX[B96T_R^D_;CVGF)]5)^7A?A8#8<X3R07QE"40#>2?'&;V9R5O7RK?/
M$T%\FDTY]_(_MYGES%M((9:^FLL,B2"4?^E ^UK.>R>(Y%H:A$BYK>'#IYO@
M)_BM8]U2\II4)B9=?=<OTOI0M^=&P'5],#%-<J2C5E(4.O-O3V;7PR LD#U.
MW*>!3T_LV],<"QVUR^2^]8!#Y!O+2]9;EQ=B4'75PTI(P[:C=^RK2:E;;\S6
M+7!Z:*=-:*JFP=FH2ZVVX81SH; ME[0E].WF\$;A*[COQVQ2"8%U69VNB_43
M<<Q(M 7)8>Z;U[D3X82Q;;7-QY7K5JNWG#VBT-RC7?HS0DXC)?Z_J!$]5#?#
MDL1<:Y9M?)$SYVCE[LN'KB4.-"O+U/*J%%3$3KDYEVND.W*,WA90&D<&&D6'
MN4I[JB2!:2MA(-,_D!!#-Q/2U:*NJRIMYK4@8'PEH$'N*?B45::TUL]HP'G1
M,]*T/,_96P@^,'>&G-U9FQ*R\>1F/)A6><VVXC!H\)XUZ?<&?BO9&KBK""54
M9HJ,-V^:^]CL::<XDXZOX.P^P,4>D-/BJ#Q9"V;>BRV0+KTI_7HO#]3U5S.'
MXOP\;O^'8P72#7;"!SJ+8<7G,DAW\AJE8)AM-N4D(AX@99TXW)S.RHP=FAQ=
ML4UA9;?5]7OYK4(5RF_)0+1UQ,.S-\)RH1P&\47GHPQSD">7*L?^IW8PQ:;*
ME(]5E%)'G ].ND+&&-G3YRHQ0V9T$$V$6L?UYS;>;RNJEMX"Z],R94\B7U<1
ML[G&S38=Q4")6AYZK9>3Z2.(0V$;KYK2!AKK/>P@C2R'O^*C;1MV3)-R_OHJ
M)>8N_,UDKC>CG.]8,.#_0<S9L"V3I3/BOO[W68K 2\'CU*:V7=@3U-QZV77&
M]P#!<JB]\MV$4G68WL*RB:J9L=C$_I01;!/&_NV4\XGR(V_M+E"^>Q:51P/J
M#GQ94Z<Y>G1VXCN5,@($-^M>;W:26[E13585%/AN8?/ =92X5;0[E?O[>AI=
M,)*S8_*^4Q?GIW1]O+VL-'$YOMDUQ'M8_E=MY?*5_X.P[XYJXNW6#2*B($1!
MNA 5D"9%>@^@@(@(@O2F(C4"TD,-17H' 04I2I46.D@+'2G2.U)"[R340-K-
M[YSOW'7.=]9=]X_Y8V;-9/;L=^_]/,]DWG>+?ZK ]H]YM"E<E-(X]>I53/+4
M3^4TUDVH#W-YV2VZ#,O(K&W6^G-BE:!$0'OZA$]*3R:R8,SOK:-KHFH9$?"S
MBW?>KTL-^?N,_=A"8_4P8@RGC=J/F<->+/)6*[XP2=2!>T!P]R<^7M_'C%#2
M_#02S'N;=#;ED?B$/Y>N7VPDYOUKR;H$LSM1&GE1:E?A_2P:>PKJNZ^$!-<&
M>JI[8A15M(?$1K#ZN[-TD()OCU\4R5G%4$1S!E(6?ABAS"4,5.[<QD%1M3W?
MF%N^)6GS#5^YSR9@.Y-*CH:W.$MX3LE;YO4K<9BJ! +/2WJ(@+=$0/C4G&&G
MY6WH_*O:/U,E&R9SS_&ZUROR0@@3L1>"OI1A)_9PCR:Y7&Q1P$B,V$2@NK(2
M2..?/V(-O_E!HVQ1UI^"C$\P$BV2_AJOW[-)-,;\:?#2R7TD5_2@A2-]JXK/
M0*=?[3KGO1'*81A=*^-.8^QTCT"9G%+<\LZEX#=9E\A;"EU%5<[Z"O&<<+-I
MTU7J,LB*5#N0;L8^BV-2O.6=KY@U14$NY^SOP?X[%=",C^0\"=X] E-V.<"8
MD^%/68]0P)"A4 \DRZEIB^O!T>*N>76J^<M5K?&ZWEO/II -2?JQ*HE'168)
MSP!8>(>6PA[A'@8UJZS0&IBXG3JBSB=OIN[TM!._7'"K]Q<[%&Y84,QOZQ#:
MU]>VXV]'-GGDM9_E@HX^\QC&4WH(X^_Y7/:TRN.;<(9Y&($5V-YA"20IPU\(
M?-M257PUS\+Z:ZPY8O9F6_8;._)\_AM<W]SZ7OUQWO9IM:JJUOY<WS]&WTL$
ME%<ZO?7U?BYS$_#;Z7NX#64#Y_>"KL77E94Z;2)OR,Y)RC,[?]XT@3/M=Y+*
MNIN8W[K11[UOUMKR4]:XEP,2-4N[KU,X"Q]$E']OB?9A<'<B$6"39XL$B1AR
M+O3-<EKC\89SS@O;L4!%3OPO/S+O,P0MM%^:;8^N;<[]Z':HX4UC-L4+TIB3
MG<.3G<A2)6+S=8-40I=ZKGT$7]'>M"PE2&*<K='1;3[PH,/UV;,OYOLV/!%&
M[.C?E*YP$I>UC@W0QQ1V-,:'X)[ OD,82?$S^>BAG4W,SWN);??.]6)"EL3)
MXKCT&^,,$GZ_XU?A1UU9O:0Z55#O3<L&>@AD0M3#%LH],*R@.C.>+Y%..ZWO
M^$\&[I8X#0\D/$X_:LI^*+V<R++V.56T9R!4!PBX/<T)?V&H]0,:-49]/W>W
MSMFC,%)30&WYRXUVMNO[P_+3/S]ERHQE,9;^\BX=]^43.%P;=\"S-YJAW*@\
M?AKFQW_G\*+@[1?P8C&N!XFO9#:6E.WYLV-E"6/IL7_K+&XWCB4;MC1D\8J/
M.M-UO;&H$H\=']"AO2/DS2)Q>0-Y4H<ZB!<?U.F[(>CFBK/V25( G)S! \$V
MX.O*J&$#&*N9G4E\Q+VF3T)9J Y.HQRN@]V_"0#%E).I)IYHPOT%Q8P2X_AK
M&/N./V[OJL.;FF*^A0I)ZTMO%+.8_1Q(K\F][N$W"G/5JB,""D;IA]\:R'\Q
M>IG_,O'CYP]$0/-:4M2AU]97II 3!$9#$*>ZRF@0-V\T-;O?QWPL&'YPOKHC
M9E%+4=M2RG?G,;]:+OF5TKTQ\<.;IMNI$753L8[K3QPZ(]069<Z6";7'X%[G
M.4L##*M[$_-)Q*EI!L:&3V$PE&XA]XUDPC4SW.R.=+F9M4<DG+_20-MZEML:
MP^7#XLEH].@1K];B\_W6_;HUPMF>!;Y$4>P/2OW%^-KH'/?DJ1I_!>+^[8"3
MC(!\]4+%2?12]W"\U](=>?*"60N,)[6YO9#17VCZ;-0?]]S03X'7F"@3-#B"
M?SG?]5-!8.I7@/O#=#M,3+)YXY]2GXVP^4*<KLVLKB9X<33CO<MU">@/!P=E
M>X<<OJ]3IOB>W['GO!IJHP+]VR ]S%(N-LJI[VW ^U;_MW(] )#C 39;FUR'
MPI"\U5ERC./[NL\R]H8?!ZA)L7?1YMFR5T<-U5!_+'CX)H[6$.*7%Y=-*#Z+
M#[:L)@*B")(0E;YWO@H/)(^%:C-^GY62EU!834: W&TGT$KL4GNVJ*I=7?1I
M84PM&TQ*<\1&X-97M[/(BM=D>U$:EXF6'Q?L_A3_K1T<=%SE.?\H+$=?T7?6
M_1X*ZO"Q#:T18!?6##3=]M2H8B8-IMM MJZVS(&6EZ<GXD/]4K.*3+L'URUP
M1%;GO9BL$[+A6;O$F?XQ=0&QVT%-F:VUA3;/LAB<5!IQL^>EF8;Z61WTO+&>
MMH%NOT\(M2H@NHR?]S^IZ6<]O9H%BW"_0W:XFB_XX.1.#5D0$D1I@GDYF2H%
M*?DEG;JC'/9&EI?]LT^  N0/$6#GDC:"A_D2 573U=,QA)'<S5'P/@G6E3@\
M<LUSY[FX ]\/4XXU'E*9S%A\U>I2V] Q' C-FV%Q"^LMN1DL]Q'R1U1Y56:[
MVZ.._M&92%46@'Q+%:!=_N3LQJ'CO$SH[#6?90[@NB5'P(3LHT;G+F9A$]'*
MQ=D2/LX2OGM$P&-+NSX(ON6M%Z><!(Z?)00V8-1[-=ZEQ[_D']-@X<)HT'+C
M3IW(1?IP^,1 +0EH(5W1AT?(\)$1RHY1,ZT/I=N<E&[A'Y\]4E!,*4-Z"L**
M_IXV:,I0T;G%R1*N5/RV <0D> \[YYN/.&>K3>H:KSZ09TAAB^F!2FRM3[Y5
M9WKIYJEQ.#^\_FO55IS_G>OEQ$^!OC(F7XASUI+H4FA.)6$J;-5(6^QYK/F"
M,KDWE6<Y;+&'Q*R<K?+ZZT->!1L?OK>.&YM[R&$JLV4Z\WZEH0S6>2YIS3J3
M$<UX$_V\.;@PR_\ZW!R?V KZBQGNK9M^06U_)NJLV[ON[=*[)@I);:'ZXA"7
MHF^#*"G?/K'U9&)09U.3V'J.ADUFV]39[WP]62<".J,=!9;+2[C7^VJ/2@<C
MG<\C/RKK)8\3 7!=H^TT>*[=J-F=YA"=VMBZ0:F''Z7X*!O^<,A.]L;6>J#4
M,KSN%H_;OFXR'-3I*4L*:F3D<F=8A$9K^<L]CX(JW9[]#)V.<SE:#@#UM]Q]
M:GZ3059"/#DYI3%O3/.P%D_GK\UV0WJE6G8F70@58T5]XOI2:QXA.';JZ&[-
M*\]M?_4QA:)>5\;MMSH1(2.\<#%,(7Q;EGIFVV0/9A=VA'P7>^7@[]\4GAG6
M;9PZ>KC#@BY$MO5'79JO5/3CX^=+JG<)$NCXGJ6H^B5ZW(O+SR(#]@6S,L]>
M@QI\Q416>6JAFV.L2W<\B #F>:C;\^H)G)YCJ=UY4_E*?74BEPB'2KA3<6?M
M1T6>IO%3<S'U+ '/:/VC%TQ) FB!D*,ZA6<[D/3(C^M!RW4;KW9W_!TN8H76
M73U[KN!"N#8+R4]SJ*J,_L[)1*DF\3U.,[AJ-2YQ4KA7B2K6C.5YC5X_>6M5
M]W"H#6R8D,#E<C*TA-UI!G<$W)J2=UL1T&+M4&N Q.:OO3%2R9RMWI(SW!*L
MRRS$.'>:J(?5?.GR\4R[HOIM[?>R:^_$6N7P3W&RE_U]@BL7G\7#2T0VDB!-
MO@;7]XJTI<NKG_J#M,=S,W1#]M/H?C]7NN;9(Y?U4=3W>.Q7K$T_=5$Y.Z=1
M$'<BI1SEVW1 SY0SLK'>:,75NZ_W.6X)7X"S:^4F(3EY_I-[4'$%[><U]^X&
M"9CE(@B?:L][(VKGM6]@8+I3'C<,V 05%S6_9C92J'(1 ?RX3RBIJ(-F#^Q+
MJ&V7% )]_!-3-;3=$W"P6W-?O8(9% J /9_XU]Q8:':$(%>XP2\ZX=]'39QQ
M,5(<*6N(NZTLEKBGF,?PC.LWSUG=_//O^.]]_^N"L6GI7$<T(\8V$G@AX;Y>
M;AT:#;C"$:GC;@/4<=\/B)2L><>7UJEE1Y>CTMS*L[>))(:[%ND900%Z9'0O
M9Y4KSNU0_UOUP(8()<B=(]"PGC"537&@>,OO99.(FF'G7"7DC^0;:<"W&O4%
MC1Z%Z_#;YK+>T104:Z^/39WO"?_,N4XG$C/[MF_?G CX=#I; Z:%@&:%=F%G
MUJFJ\DZ15>6Y\TYNIQ)M?^IX@^@"4%(+\UD*_B6FJK]^C9S^?D]!'H'2-1AT
MY13R?.]#!,B>B$A\5VOT4&3\9IF4],^[DK]'8F82+UXR],151\?\R/K3\5S#
M;Q]RTC) N(N63SW7&WAW9/)'E(OO*LA'[=VU;O#"GX!,W!64![P31+'M^8=*
MHTA>Q?Y+4*<4%U[CT)("=Q-5&$8: ZN5R+EU/[ U;^(^+BSY=\-.<9<G._0$
M_DM".X[C9GW2U9%YG>F-HQ3&Q;$AU7>==69DILV%++"%]G[P8&U\V9FEG.G/
M/HY[ ]XP?WV];"--C<+Y-*^C1G\A>\)(>C:.BX-MI$;[PG?"P]<]]-;[?5W-
M^F5:-T.<8*%0)OO$2_WR=Y^[!A4HM8?+=##FR)(E9DPZC!GZN:SUNR-+],NQ
MSP=Q/0]D;)P.?+,F<U?[N%"$[^S[GP/;^1/YK/NK>3<+Z_A=DD)EW5$5:5+<
M\Q!(DSG/)%<2PM#7SL*4-:7$H/=U=-3/_A]9\:E\L[6C=?-UVR:7"ZP'Q3NO
M U_'W((L#\]%KQ1\+\0]]>=\-F$=MZ3]9O$U,)!K=[C%?>DVS.EG>>D!B;C8
MBQH/:CZ]C)V2$KIQ-<_O>)H%'.HWX5Z(9OQ9++=CX8$*A2-@O]:_+8M=4>K9
M8SV*]YO!-*$UNV#T0RG "(.QI^-6W7FI%=>/RH(U;WDKUG:5Z@XMP^@KV(8!
M=]UQQ0^;'H@TU0L@H\Z&,1-3 TG/\:C'M:V?R;@GL7]G3.8E\JM*G^YG\9[U
MMYW94"9NI\^AX)_@S6XK"E+J8VE27D'O7"G[HQ2/LY5R;'(KQIQP&D7;9XT>
MWZ;U!B(>U$=2B]5!=2@MM-<M/^!H,5>6;M2<9^L9K:$5<P*'ZRD<W^UP4N[V
M*0R/!2K(=?KXL?($BPM?G^%)R]_6*55W1J]6GG.E*FXT@:FWL^=8/S\O6^=B
M,Y]G:?L-(#LT2CW;M;^E\Y'RH^P4_M/1]K2D9V7U]\PQ8]1';3!_=LXF.@=H
M^.^+!L*'09A'=_J<D:0D$7V>O\JZ,+5.>36^.N;8\OOD!0E/*!*)@$1MI!0^
MS(D(.%'* 2IBZ+&ZLQ@QE3H4B1AY,'N8,RXP?"@D:>>-62"*DE^*GPCP: V<
M)E%MS/?E0[8B0@=:,&4B1KJNP?FAF<]R$N4*Y,A2M>5OP!_.-Z!&(T(*_&Z\
M\T/,U^\?75DE^6&R +Q?W,I*5QC;,G!DDW]U)@Z(-&U4CS*A9\Y,E[FSSJ,\
M<IF.Z\388PV@6&0-NBL]=S?]39LOS8N+*/5J#E5_7U3U63%*N.N0?\JW$FGN
M&"YIN!]A1@14\I#JR_CY,XEN^NVRZ FYP5<D'+%/GO I@]9W6P8OLF/2KJ@7
M&T>4C]RFP"/ZQ /:*\- >[5>DG,I0Y_])MA6$JR-0"GAQ15E<O[OQG#XS-49
MTYR \'EQ,K1D&98>FCYD/*TU^<'9D9N9P^YQJUAB4]$P>TD5Q@W+SAV[Y]4J
MW&*N\W#:47'24V6PY6:,MW,.O(PBQF%6MXTVNNF>/K2T,&K%P&VC8_,@"X#C
M)5N\736^=U/7;*YY\0EOU(+5#3K>+?5R:8!G^1RVNY'B[^.!HGF6 ZN/[R)Z
M4W]O_U[EZ(U:+=#XV/H<UW:<VLN^_?)[X:RJGQ"G1GF>OA&+T>.(XR0E'.^5
M74SJKFFZV@2=@*\_=ODH<"X&R!9OMOIS>YZYG'ZUMUU!:M4P9"C-U:3GC/%X
M[V!4JN5;H%7*W3YZ6EH94(H[^F^W"\"HT, J*))65K]YB$N#X4H_PE/MW>.3
M0R70UU9%? 8.AJHV29HV&!&^:EW)L!YC S$-W>L?&-]J>U<T#V7KOJS+=,Z;
M@WKN0!Q)_N^KIN9)5P,>7J=D)MQ=G4.\$A9VKJ4V"#[S_/7R.X]YO\+C])X0
M];KZE"]SIB^,JR-?5W#,_ ;H4 Z"J[/WM!01'],WXWBB.M7JEK<'@L=H&Q(;
M:?T%=F$/^\<F9K83J;6$N([T!IAU0S"O/=K;!CBTQXK#XB!-=K5LQQSIOP1L
M/T1%F%9070/3IX^F?RPUN:KIOE];+X+3UNZ\ YBH,T+97!,G7X_PWSA9Q:BW
MO#AW^IU3IQ^PYWUAN"5+U?MKRM%1^=H3SLV$YNRNJ6OYY0-^9:SPV9%3\A(J
M0.U*F;XSUS.K-U8Q:Q4'D\GOUW88FV.\^PYQ*C_")!M6> >L2FA#=GRHEOTL
MT=@V(@#HX:_8LZL?KS>YV13&4%GUIMTXC_I89%C%%UC.2[X_.J([KK-^YS+*
MXY_%E/:/T>B ZS@MC#'C=Z=S'\9ZAM/:09<&@SBE=T=K9NCV=R*PEGW+#X;K
MZCBFZRD-F!?*[=1%M]2GJ "G1  5S@25':,236,C[03$-?[S83/6$YSI)7EN
MR.KK_*36<CK%^3N\?S@T2XQ4%JJ58II#/=A$.+,ID_'3(,M-BW/4\6IO9 !H
ML/*"")B;,WVC807M_AQ_IJVO>$)VWAJY(AEUP/<ZHISSPT\%MGGT2?D/9)YV
M[4ZZ+E]5(GC\D7+?IU6*P /9XZV/D/96D)\NZKRK1&E.:SHQX)KUN-"71[]A
MLWNK?PUSC!SBK1KY&,ZR@#:OE$#B.',,I4)YF5<)Q@DDVX&,23*"OY;IFY&+
M.=L1Z'9RWT9.7&\*UD_+1#__1/OEKL<)KN3D_H\P#%-]@A.[.B8JJ$;3F%F^
M[F,?SSFNEI2T]9WQ5S!-E@U12R_KD]C%OVDHK$&#F%K)L+W);?"29FH4[9 T
M4MF_J#V?\II[C3.?658.V:[IP!V1_E$*HT!RR/[JMN&GC:F%U_V+.C(]T#\^
MXM5WS9EY57(U'->W_5O58RT?#J EV$UJ])(7]F&F)D2 7&;Y3U3:\Y&R1]:H
MS<1"^_Q@LY[> ^'S<[?4RPE%WFEQS2_[CGMKJ49/;9AL[EIA+#E:"RI.^FZ:
MV/Q\-/[XJ>HSG<I[CQ538H/NO(])W='6]8>$N:5HR/Q9:"T]M1\/9>9W7\EE
MJ#+AWHH'XO,4*7<NQ^<AE^R5$S;Z1_E&U[F3*X=K_1;/ZM.M?]>VU"?Q6*:N
MS.D8%F(56T\OV9%X-2U&6ZC1 /712-]8#IHG6)$#I_S9'*+(%NM<&2_-R6DU
M(OZ>3O%'S@@.W3C^EI[<\7&"R,)QP5@ARSS&_8\7*8!;KT/#>^W21.;PR=I$
M0/9\RCP;K"E+&VEIOI5]O?4N5&4;[KY >\-9,D4/G*%(MAMT?P[,WU)N_M?"
M^V-'P>)LW+ @I?3)\-L]7O(DC/TRC52;K->L^.%BO_<OQ-OC_L7>"O90'X7,
M(&A753)%SJX L&6OM7#[15U==.<9.B>68S]!TC+E$\<WCK*EK)3L(D@?PK]K
MWX5W2ZQAA ([$.3BQH7UJ^GM_XHMEKY2(1'[UH+SIGPJ=GA[_[6S1R2<[!6V
M"-$HF[XI_W:E1:S-@GY27J-T4/"D3)8QW=YH5?HN_V6E-,!WA'( A'IE&4/>
ML00LQ=%8*THH^'^:-@7RV85_)P+\VT"JBK6HM+:E"T$8D C8>TO"T),"6>V8
M[#L>H)CLVQ[Q# [&ALUIYR*V#ZZKWV"^O!D@DX]A(P*XX20,QL?(P@B?>Y5
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M:9)?&I;!.L%^(D,PI#G&"&2YYPLC/"B?Q[&@:/+4I.49D!@KA5?BOY7 87,
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M:.\=(O??=>J/$]CF39=FAMDGFSMUFA[*W X1>#.HW XX5@(]&_W7A.B+%T1
M[=3W95@D07A<0EK745'0Z>Q1FZMD=#BY^_MEE&PPC2\B6%$**KQRE7]*MD;2
MB\LZ)U6Y&JS73[CGK^5OZ(620T[B)\ZE%,E1"]U=1^)5 T(IY.)QO8\&GZ\E
M:7!EFS@BVA#AC,F/*J#4G3K]A?SH;1$!\CV5$<KPB+RGQF\=?WL;OY/[3'@
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M<A_.ST2J\;JXJ[B?*@Z;2*-<MMQ_)]7$+HV)4>GA=0.N_+A.^CNQ3\?WI9^
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M[_=;:>::@LQ?=<6>%8JQ_.\3("_(_ MVF812WZ-29'T,H^P;%EXV3>^"X\#
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M+4&J52K2X8#1 B*#$!EP7P9Q$F"5AHL4&8CW K'<ZB1^#'SZ#5,+TZ_<6LD
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M@YOX-CB6#X/WWU;5B#N1MCU=C!Z'C=]VP6.F<A$;6# (<''X;21\-*34D@S
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M2&[*."BN;WUUAN4[6CJ='5K#1Y$!1F:<.LD?[@]BD3]8_XN9F^-XJ%QW?:2
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M(]IX<E9HNA<<08.'[P+E <DK,VD0QD!L!<B)F69\^]WGJ#^'<W]V1<6F9B6
MH^XD<;!EYU3]IVC0"_9_V^#$=A+=$BZCXVRK;2ELRU\ ?PLS.H0^ I^FA]9
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M>6U*0_]+E$G<Z(-H'3&Y'(8<EE!3E ;SI=,JM@=/6DV>**<:F7C@4&-_@TU
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MB^@$D(,"[)"LXR21Y?%\.)4QEXH:U@H&W.5E!&'3) 7 [:0&#!XC,)!I'E
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MHS(G<G#? AIF7I!$Y4_/1 J@%4S"48!JS, >Z)T\!&X0?@%<SP7PQC>M)S)
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MTW49#$LX*3/LG'X]8M3]2H)_51;Y,>#:5"LK!-I6>BF-OM05%4WBU8]IT:$
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M:O9/B*IK?9!MMM'CZ3J-3NU?  ?"P>ZS:FHG*[N++0K@I4 +T4RKJK\PE>3
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M#)OK/2TCWU;6_BRD7MCS *,2P^1)R%+-UTZ=-2BI@SQ2FW0Y8G")4(]Z2VI
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M3W;G@T>"A&4"\GTLW,TXC(GI!<;_PA8; 3:7?S3+U;O=?G'MVMU>W\2M2&Z
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M]P?JU"$3LQM1&("*J)"W\V7R7=6.E&_.K7%.Z5[0F$*S8S=O;]L<E-14U[V
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MU%D<N^8#;H'SN:@240'$S8895+2O#BD&J#B1TTN%[_CW+"$;+=MGWJS2[&
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M&UANXW_DV?+1RK_2B&3%A@BMZ\L%1[(IF-C^Z?["''GC>[<BQHL+OSV/ 8I
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M:N8)'E_0D+9]%+M/U7&E7LH!K\F)-H^Z@>' ;(3)[53NM8$#:7]U C5J8;)
M>&(>9S)[ ,G1P#H$_3A8!^)\8T[K6VLK*YL9Y>SL6/"..$6U9-ZW=CZYM%]&
M8R&&?'I.&?IR!'D37HF^/N K+V4ZK2I:QC,UNUZVMYQ'4=8N)T__C)_$!<V)
M> -EH_;%W;M>45F:A=#J4NTO7S<9SXJ(&'(1NIJ9T%4CQN3.S=0E/G]/D'=3
MS2$X12<YU&)L&\GDX%#2E2'R($*9R/6$_D8"YV+L6+H-[VZ0%.N'2C6O>1_I
MBK+(-ANN 850\K>)=_.^B?02,*PDI;5[6J,RZ_1];<$"<#[G-4U$, 90,!;H
M>G%#I4I5Q2VA;Z6\VVQFV4MR?)$@,A5$+*-3XED(Q9[)W:Z;MGK?*ZBI"L@9
MH=(8-!>Z_B8..E,I=1+5:'_G CW^M\]M/@6(BSTRMTY/$3IT)F[CD^\&O]98
MM M:3-2^ZS!)I(V%S:G#T)FR\.0%0M>NS:A9MY[T^&4U3BB1O<7->RIXJ_G4
M.[6A>YMS$2:<'_?L(9>'R]6*.3O:!3T?RX!H2L]\2^_$LHFJ-LJ9G00U;TU^
MC8J3BF"51)RY+4A+7_<[9#%2[^<WKQM*ZC,>,AS</I)G['Q"37LCVHSU\@8"
MHMPO1V;=P+;'60HEK),5ZZW*-^WRGPQJ3ZV!XG)8,RDSITKPF FU@\/J;3,;
M82T; \HT\!"Q+:<[R10Y;8$J^3PL7^=I)"TND7L'#D:<!!PTY.R-M;,R[U6^
MR9M6RS-ML8"LL[*,9%4--=^TM\<#6;&Z=#.K%(OKL$<K7LQR<7;J]KV!&"KR
M5)X_#O68,Z!Z[ZF[:O0Q5<NN[WKGB "TY9.X,4$B8Q"+E&6LJ88Q4FQP]RAI
M9,>7Y7Q[T90(F#^VQOG^BY!N[EJ>FY=6(XD?Z&5<=)55XE4I09)9NM&\CK6+
MLZ.6:F9.<GR>]XT^3H5%E3,1V>[IE]?12#N#0&V/J0>X2OJJD07/#JK,1[T5
MOFS=VN/(04FY/'KY@E9@/A?[FK.@2H'RPE'86-9HW\M%J6'-T'@M]#<,H/H
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M)@Q/H,>#P+KI6.N/'C4V6G+TUQ[UT<8W15&Y,3Z2?-.#^=558(* :L>7X2:
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M,4=>41E*KO[,\,]GMX!#=]N+WY[.R6&K^[8,"1X;A*W$_+'R3+;J[WG[Y;<
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MZF@(1]NR'I;,NP1\8:!SF!C)D9'J%)IA'J6@/6+C,O!67'@GVMZDX'%],<G
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M;>WJ:2%'RD1IA_Q<=9!X00U+]]0'U[XT##5VX^5+A9HTB5O"H0&I86(FZ%V
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MD_DDT$[\!IB?!6+:UOZWC=L-FC0\EZ1"@6$!P$<5H :Q=SM<:0>)OA &^SP
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M>-GOWL,6*&RT%:/('6 A,C;4"< I40M,L1;#(XYPHKXO'=8E$<5EK#AE]2V
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MDQ]7FSNS3&!]U%""LT(CM]DT*#'4[]LV W97[_<> *<R#P#\88$'0,[\_57
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MH94B-F<\T&^80LMTY-]MJ=57>?LY\%P^^FS(%[9,^EI=GW&/BQQCF0N]@S'
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MBRPQ$V@]!%/.QRI57&\Q[FCRZ%"&E:@9\T8'DO)XW":6:/HI "@ %>P7+V^
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MMCL>T6%N@/,TM%*WO_::.JY['/X<Q&DV+VA81K(1*U^H=>EM[F+WN4CFO0W
M=@PG=>"FA3I?O<!J3&,58"7FCCAV](ZECE'#+'S?1L><P'YRHB>17*[IQP?
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M8R.LK7M<_5;A?G%V4Q%N5W'Z:'*V??#DU+;50]8T2Y-7<TTM3O)Y<<0#!JI
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MH#&M[;\RJO\Y\H<+_P902P$"% ,4    " #7.V5<O>0*_888   H&0  "0
M            @ $     8V5L;#$N:G!G4$L! A0#%     @ USME7+I2H/(&
M4@  6FP   D              ( !K1@  &-E;&PR+FIP9U!+ 0(4 Q0    (
M -<[95S=+JE'FQ(  +_K   1              "  =IJ  !C;7!X+3(P,C4Q
M,C,Q+GAS9%!+ 0(4 Q0    ( -<[95SO:*0= 0X  .S.   5
M  "  :1]  !C;7!X+3(P,C4Q,C,Q7V-A;"YX;6Q02P$"% ,4    " #7.V5<
MI&^<4QQ+   U<P8 %0              @ '8BP  8VUP>"TR,#(U,3(S,5]D
M968N>&UL4$L! A0#%     @ USME7$A,N[T]90  C] % !4
M ( !)]<  &-M<'@M,C R-3$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( -<[95P$
MK:,[ 5$  /8G!P 5              "  9<\ 0!C;7!X+3(P,C4Q,C,Q7W!R
M92YX;6Q02P$"% ,4    " #7.V5<MWO^M"<1 P!C;AT %
M@ '+C0$ 8VUP>#(P,C4Q,C,Q7S$P:RYH=&U02P$"% ,4    " #7.V5< %,U
MKX(#  "0#P  #0              @ $DGP0 97A?.3(S-#<S+FAT;5!+ 0(4
M Q0    ( -<[95Q[^_0Y1P@  #,U   -              "  =&B! !E>%\Y
M,C,T-S0N:'1M4$L! A0#%     @ USME7%@+P=-#"   D#4   T
M     ( !0ZL$ &5X7SDR,S0W-2YH=&U02P$"% ,4    " #7.V5<5_5Z5*L$
M  "N%P  #0              @ &QLP0 97A?.3(S-#<V+FAT;5!+ 0(4 Q0
M   ( -<[95PDU1[+I 0  *87   -              "  8>X! !E>%\Y,C,T
M-S<N:'1M4$L! A0#%     @ USME7&DMAB8U.0  [6<!  T
M ( !5KT$ &5X7SDR,S4T,"YH=&U02P$"% ,4    " #7.V5<QS:I/SH\  ".
M60$ #0              @ &V]@0 97A?.3(S-30Q+FAT;5!+ 0(4 Q0    (
M -<[95QSBC _FCL  )U9 0 -              "  1LS!0!E>%\Y,C,U-#(N
M:'1M4$L! A0#%     @ USME7+X8L]:H;0  N'P   H              ( !
MX&X% &=R87!H,2YJ<&=02P$"% ,4    " #7.V5<>^[G0[%R  #&@P  "@
M            @ &PW 4 9W)A<&@R+FIP9U!+ 0(4 Q0    ( -<[95Q^.\X%
M;E,  "1G   *              "  8E/!@!G<F%P:#,N:G!G4$L! A0#%
M  @ USME7/]%*5^4M@  L\@   H              ( !'Z,& &=R87!H-"YJ
M<&=02P$"% ,4    " #7.V5<4RF<  ]A   5<@  "@              @ ';
M60< 9W)A<&@U+FIP9U!+ 0(4 Q0    ( -<[95P_5H"@K-<  //N   )
M          "  1*[!P!S8V%N,2YJ<&=02P$"% ,4    " #7.V5<U0B T_=:
M   A7@  "0              @ 'ED@@ <V-A;C(N:G!G4$L! A0#%     @
MUSME7'\'5GQ1MP  ?KT   D              ( ! ^X( '-C86XS+FIP9U!+
M 0(4 Q0    ( -<[95SP#KU)1GH  (.I   *              "  7NE"0!T
M86)L93$N:G!G4$L! A0#%     @ USME7.7?/H11NP  ;M@   H
M     ( !Z1\* '1A8FQE,BYJ<&=02P$"% ,4    " #7.V5<("1Q,=U'  !$
M2P  "@              @ %BVPH =&%B;&4S+FIP9U!+!08     &P ; #@&
(  !G(PL    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>cmpx20251231_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cmpx="http://www.compasstherapeutics.com/20251231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cmpx-20251231.xsd" xlink:type="simple"/>
    <context id="d_2025-01-01_2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-GeneralMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:GeneralMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-GeneralMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:GeneralMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-PersonnelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:PersonnelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-PersonnelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:PersonnelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-CTX10726Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:CTX10726Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-CTX10726Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:CTX10726Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-CTX8371Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:CTX8371Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-CTX8371Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:CTX8371Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-CTX471Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:CTX471Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-CTX471Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:CTX471Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-TovecimigMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:TovecimigMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-TovecimigMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">cmpx:TovecimigMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2023-07-01_2025-12-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-07-01_2025-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-09-30_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="i_2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_LeaseContractualTermAxis-FacilityLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cmpx:FacilityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_LeaseContractualTermAxis-FacilityLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cmpx:FacilityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-09-27_GuaranteeObligationsByNatureAxis-FinancialStandbyLetterOfCreditMember_LeaseContractualTermAxis-FacilityLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialStandbyLetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cmpx:FacilityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-27</instant>
        </period>
    </context>
    <context id="i_2025-12-31_LeaseContractualTermAxis-FacilityLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cmpx:FacilityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2024-07-27_2024-09-27_LeaseContractualTermAxis-FacilityLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cmpx:FacilityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-27</startDate>
            <endDate>2024-09-27</endDate>
        </period>
    </context>
    <context id="i_2024-09-27_LeaseContractualTermAxis-FacilityLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cmpx:FacilityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-27</instant>
        </period>
    </context>
    <context id="i_2025-12-31_TypeOfArrangementAxis-AdimabAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cmpx:AdimabAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-AdimabAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cmpx:AdimabAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2018-11-30_ProductOrServiceAxis-OphthalmologyMember_TypeOfArrangementAxis-ABLBioAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmpx:OphthalmologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cmpx:ABLBioAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="i_2018-11-30_ProductOrServiceAxis-OncologyMember_TypeOfArrangementAxis-ABLBioAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cmpx:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cmpx:ABLBioAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="i_2018-11-30_TypeOfArrangementAxis-ABLBioAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cmpx:ABLBioAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="d_2018-11-01_2018-11-30_TypeOfArrangementAxis-ABLBioAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cmpx:ABLBioAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2025-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantsInConnectionWithUnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmpx:PreFundedWarrantsInConnectionWithUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020StockOptionAndIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmpx:The2020StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2026-01-01_PlanNameAxis-The2020StockOptionAndIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmpx:The2020StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-01</instant>
        </period>
    </context>
    <context id="d_2026-01-01_2026-01-01_PlanNameAxis-The2020StockOptionAndIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmpx:The2020StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-01</endDate>
        </period>
    </context>
    <context id="i_2025-12-31_PlanNameAxis-The2020StockOptionAndIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmpx:The2020StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2020-06-30_PlanNameAxis-The2020StockOptionAndIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cmpx:The2020StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31_SubsidiarySaleOfStockAxis-AtTheMarketMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmpx:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i_2024-03-31_SubsidiarySaleOfStockAxis-AtTheMarketMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmpx:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="d_2025-08-12_2025-08-12_SubsidiarySaleOfStockAxis-UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmpx:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-12</startDate>
            <endDate>2025-08-12</endDate>
        </period>
    </context>
    <context id="d_2025-08-12_2025-08-12_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-12</startDate>
            <endDate>2025-08-12</endDate>
        </period>
    </context>
    <context id="i_2025-08-12_ClassOfWarrantOrRightAxis-PreFundedWarrantsInConnectionWithUnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cmpx:PreFundedWarrantsInConnectionWithUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-12</instant>
        </period>
    </context>
    <context id="i_2025-08-12_SubsidiarySaleOfStockAxis-UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cmpx:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-12</instant>
        </period>
    </context>
    <context id="i_2025-08-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
        </entity>
        <period>
            <instant>2025-08-12</instant>
        </period>
    </context>
    <context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2021-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-07-01_2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2026-02-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
        </entity>
        <period>
            <instant>2026-02-27</instant>
        </period>
    </context>
    <context id="i_2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsAndOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001738021</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cmpx:RestrictedStockUnitsAndOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="SquareFoot">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2025-01-01_2025-12-31" id="ixv-13059">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2025-01-01_2025-12-31" id="ixv-13060">2025</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="d_2025-01-01_2025-12-31" id="ixv-13061">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="d_2025-01-01_2025-12-31" id="ixv-13062">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d_2025-01-01_2025-12-31" id="ixv-13063">0001738021</dei:EntityCentralIndexKey>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="d_2025-01-01_2025-12-31" id="c1177">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="d_2025-01-01_2025-12-31" id="c1176">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="d_2025-01-01_2025-12-31" id="c1175">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="d_2025-01-01_2025-12-31" id="c1174">false</ecd:NonRule10b51ArrAdoptedFlag>
    <us-gaap:NumberOfOperatingSegments
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c1115"
      unitRef="Pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c1000"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c999"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c998"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c997"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c945"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c944"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <cmpx:MilestonePaymentsPaid
      contextRef="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-AdimabAgreementMember"
      decimals="-3"
      id="c891"
      unitRef="USD">0</cmpx:MilestonePaymentsPaid>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020StockOptionAndIncentivePlanMember"
      id="c686">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2020StockOptionAndIncentivePlanMember"
      id="c685">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c312"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c311"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:NumberOfOperatingSegments
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c305"
      unitRef="Pure">1</us-gaap:NumberOfOperatingSegments>
    <dei:SecurityExchangeName contextRef="d_2025-01-01_2025-12-31" id="c19">NASDAQ</dei:SecurityExchangeName>
    <dei:DocumentType contextRef="d_2025-01-01_2025-12-31" id="c3">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="d_2025-01-01_2025-12-31" id="c4">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="d_2025-01-01_2025-12-31" id="c5">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2025-01-01_2025-12-31" id="c6">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2025-01-01_2025-12-31" id="c7">000-55939</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="d_2025-01-01_2025-12-31" id="c8">Compass Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2025-01-01_2025-12-31" id="c9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2025-01-01_2025-12-31" id="c10">82-4876496</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2025-01-01_2025-12-31" id="c11">80 Guest Street, Suite 601</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2025-01-01_2025-12-31" id="c12">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2025-01-01_2025-12-31" id="c13">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2025-01-01_2025-12-31" id="c14">02135</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2025-01-01_2025-12-31" id="c15">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2025-01-01_2025-12-31" id="c16">500-8099</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2025-01-01_2025-12-31" id="c17">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2025-01-01_2025-12-31" id="c18">CMPX</dei:TradingSymbol>
    <dei:EntityWellKnownSeasonedIssuer contextRef="d_2025-01-01_2025-12-31" id="c20">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="d_2025-01-01_2025-12-31" id="c21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="d_2025-01-01_2025-12-31" id="c22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2025-01-01_2025-12-31" id="c23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2025-01-01_2025-12-31" id="c24">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2025-01-01_2025-12-31" id="c25">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2025-01-01_2025-12-31" id="c26">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="d_2025-01-01_2025-12-31" id="c27">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="d_2025-01-01_2025-12-31" id="c28">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="d_2025-01-01_2025-12-31" id="c29">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i_2025-06-30"
      decimals="-6"
      id="c30"
      unitRef="USD">277000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i_2026-02-27"
      decimals="INF"
      id="c31"
      unitRef="Share">180087915</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="d_2025-01-01_2025-12-31" id="c32">596</dei:AuditorFirmId>
    <dei:AuditorName contextRef="d_2025-01-01_2025-12-31" id="c33">CohnReznick LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="d_2025-01-01_2025-12-31" id="c34">Melville, NY U.S.A.</dei:AuditorLocation>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="d_2025-01-01_2025-12-31" id="c38">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"&gt;We recognize the importance of safeguarding the security of our computer systems, software, networks, and other technology assets. We have implemented and maintain a security risk management program that is designed to preserve the confidentiality, integrity, and continued availability of information under our ownership or care with the aim to continually improve security features in order to keep pace with the evolving cyber threat landscape.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"&gt;We face a number of cybersecurity risks in connection with our business and recognize the growing threat within the general marketplace and our industry. Although such risks have not materially affected us, including our business strategy, results of operations or financial condition, to date, we and our vendors have, from time to time, experienced threats to and breaches of our data and systems. For more information about the cybersecurity risks we face, see the section titled &#x201c;Risk Factors &#x2014; Risks Related to Information Technology and Data Privacy&#x201d;.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Risk Management and Strategy&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"&gt;We have implemented internal controls including regular risk assessments designed to address financial, operational and information technology (including cybersecurity) risks and controls across our organization. These assessments are overseen by our Head of IT and Chief Accounting Officer. We implement cybersecurity controls and procedures designed to address cyber risks and threats, supported by third-party technologies and security advisors and providers. We also provide cybersecurity awareness training to our employees during the onboarding process and periodically thereafter. In addition, we engage external third-party information security consultants to periodically conduct information security testing and assessments, and to evaluate our overarching information security program and specific incident response procedures. We also maintain a Cyber Incident Response Plan, which is overseen by our Head of IT and is designed to coordinate our response to information security incidents. Finally, we hold and maintain third-party insurance coverage for cybersecurity risks commensurate with industry standards for a company of our size and stage.&lt;/p&gt;
</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="d_2025-01-01_2025-12-31" id="c41">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="d_2025-01-01_2025-12-31" id="c42">We recognize the importance of safeguarding the security of our computer systems, software, networks, and other technology assets. We have implemented and maintain a security risk management program that is designed to preserve the confidentiality, integrity, and continued availability of information under our ownership or care with the aim to continually improve security features in order to keep pace with the evolving cyber threat landscape.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="d_2025-01-01_2025-12-31" id="c43">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="d_2025-01-01_2025-12-31" id="c44">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="d_2025-01-01_2025-12-31" id="c45">true</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="d_2025-01-01_2025-12-31" id="c46">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Cybersecurity Oversight &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"&gt;The Head of IT is responsible for implementing and maintaining the information security program. The Head of IT role is currently held by an individual who has more than 20 years of professional IT management experience and maintains a Global Information Assurance Certification. The Head of IT reports to our Chief Accounting Officer, who together are responsible for coordinating information security risk assessments and overseeing periodic testing of our cybersecurity controls. Our Chief Accounting Officer meets with the audit committee of our board of directors periodically for the audit committee to provide guidance on the prioritization of the risk remediation and ongoing implementation of cybersecurity improvements across our organization. We also engage an external auditing firm with information security expertise to conduct regular auditing, testing, and review of our information technology risks, processes, and operations.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"&gt;Management also generally provides quarterly updates to the audit committee on cybersecurity and other information technology risks. We have implemented a process for the Head of IT and the Chief Accounting Officer to receive incident reports and report quarterly (and, if applicable, in the event of a cybersecurity incident), to our internal disclosure committee and the audit committee, as appropriate. Management presents to the entire board of directors on an annual basis, including any key findings identified in our cybersecurity assessments.&lt;/p&gt;
</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="d_2025-01-01_2025-12-31" id="c49">The Head of IT is responsible for implementing and maintaining the information security program. The Head of IT role is currently held by an individual who has more than 20 years of professional IT management experience and maintains a Global Information Assurance Certification. The Head of IT reports to our Chief Accounting Officer, who together are responsible for coordinating information security risk assessments and overseeing periodic testing of our cybersecurity controls. Our Chief Accounting Officer meets with the audit committee of our board of directors periodically for the audit committee to provide guidance on the prioritization of the risk remediation and ongoing implementation of cybersecurity improvements across our organization. We also engage an external auditing firm with information security expertise to conduct regular auditing, testing, and review of our information technology risks, processes, and operations.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="d_2025-01-01_2025-12-31" id="c50">The Head of IT is responsible for implementing and maintaining the information security program. The Head of IT role is currently held by an individual who has more than 20 years of professional IT management experience and maintains a Global Information Assurance Certification. The Head of IT reports to our Chief Accounting Officer, who together are responsible for coordinating information security risk assessments and overseeing periodic testing of our cybersecurity controls. Our Chief Accounting Officer meets with the audit committee of our board of directors periodically for the audit committee to provide guidance on the prioritization of the risk remediation and ongoing implementation of cybersecurity improvements across our organization. We also engage an external auditing firm with information security expertise to conduct regular auditing, testing, and review of our information technology risks, processes, and operations.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="d_2025-01-01_2025-12-31" id="c51">The Head of IT is responsible for implementing and maintaining the information security program. The Head of IT role is currently held by an individual who has more than 20 years of professional IT management experience and maintains a Global Information Assurance Certification. The Head of IT reports to our Chief Accounting Officer, who together are responsible for coordinating information security risk assessments and overseeing periodic testing of our cybersecurity controls. Our Chief Accounting Officer meets with the audit committee of our board of directors periodically for the audit committee to provide guidance on the prioritization of the risk remediation and ongoing implementation of cybersecurity improvements across our organization. We also engage an external auditing firm with information security expertise to conduct regular auditing, testing, and review of our information technology risks, processes, and operations.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="d_2025-01-01_2025-12-31" id="c52">The Head of IT is responsible for implementing and maintaining the information security program. The Head of IT role is currently held by an individual who has more than 20 years of professional IT management experience and maintains a Global Information Assurance Certification. The Head of IT reports to our Chief Accounting Officer, who together are responsible for coordinating information security risk assessments and overseeing periodic testing of our cybersecurity controls. Our Chief Accounting Officer meets with the audit committee of our board of directors periodically for the audit committee to provide guidance on the prioritization of the risk remediation and ongoing implementation of cybersecurity improvements across our organization. We also engage an external auditing firm with information security expertise to conduct regular auditing, testing, and review of our information technology risks, processes, and operations.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="d_2025-01-01_2025-12-31" id="c53">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="d_2025-01-01_2025-12-31" id="c54">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c63"
      unitRef="USD">30643000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c64"
      unitRef="USD">43483000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c65"
      unitRef="USD">178263000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c66"
      unitRef="USD">83239000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c67"
      unitRef="USD">913000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c68"
      unitRef="USD">6029000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c69"
      unitRef="USD">209819000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c70"
      unitRef="USD">132751000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c71"
      unitRef="USD">102000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c72"
      unitRef="USD">353000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c73"
      unitRef="USD">9099000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c74"
      unitRef="USD">6731000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCash
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c75"
      unitRef="USD">568000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c76"
      unitRef="USD">568000</us-gaap:RestrictedCash>
    <us-gaap:Assets
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c77"
      unitRef="USD">219588000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c78"
      unitRef="USD">140403000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c80"
      unitRef="USD">1585000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c81"
      unitRef="USD">2249000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c82"
      unitRef="USD">11383000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c83"
      unitRef="USD">6287000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2025-12-31"
      decimals="-6"
      id="c84"
      unitRef="USD">1000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c85"
      unitRef="USD">338000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c86"
      unitRef="USD">13968000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c87"
      unitRef="USD">8874000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c88"
      unitRef="USD">8829000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c89"
      unitRef="USD">6296000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c90"
      unitRef="USD">22797000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c91"
      unitRef="USD">15170000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2025-12-31"
      id="c92"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2025-12-31"
      id="c93"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2025-12-31"
      decimals="INF"
      id="c95"
      unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c96"
      unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2025-12-31"
      decimals="-8"
      id="c97"
      unitRef="Share">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2024-12-31"
      decimals="-8"
      id="c98"
      unitRef="Share">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c99"
      unitRef="Share">178324000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c100"
      unitRef="Share">178324000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c101"
      unitRef="Share">137820000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c102"
      unitRef="Share">137820000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c103"
      unitRef="USD">18000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c104"
      unitRef="USD">14000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c105"
      unitRef="USD">627665000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c106"
      unitRef="USD">489692000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2025-12-31"
      decimals="-4"
      id="c107"
      unitRef="USD">280000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c108"
      unitRef="USD">210000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c109"
      unitRef="USD">-431172000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c110"
      unitRef="USD">-364683000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c111"
      unitRef="USD">196791000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c112"
      unitRef="USD">125233000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c113"
      unitRef="USD">219588000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c114"
      unitRef="USD">140403000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c118"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-4"
      id="c119"
      unitRef="USD">850000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c121"
      unitRef="USD">55969000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c122"
      unitRef="USD">42342000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-4"
      id="c123"
      unitRef="USD">16870000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c124"
      unitRef="USD">15133000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c125"
      unitRef="USD">72839000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c126"
      unitRef="USD">57475000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c127"
      unitRef="USD">-72839000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c128"
      unitRef="USD">-56625000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-4"
      id="c129"
      unitRef="USD">6350000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-4"
      id="c130"
      unitRef="USD">7250000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c131"
      unitRef="USD">-66489000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c132"
      unitRef="USD">-49375000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c133"
      unitRef="USDPerShare">-0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c134"
      unitRef="USDPerShare">-0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c135"
      unitRef="Share">157695000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c136"
      unitRef="Share">137384000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c138"
      unitRef="USD">-66489000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c139"
      unitRef="USD">-49375000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-4"
      id="c140"
      unitRef="USD">70000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c141"
      unitRef="USD">173000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c142"
      unitRef="USD">-66419000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c143"
      unitRef="USD">-49202000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c147"
      unitRef="Share">127668000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c148"
      unitRef="USD">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c149"
      unitRef="USD">463796000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c150"
      unitRef="USD">37000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c151"
      unitRef="USD">-315308000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c152"
      unitRef="USD">148538000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2024-01-01_2024-03-31"
      decimals="-5"
      id="c153"
      unitRef="USD">500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-4"
      id="c154"
      unitRef="Share">9790000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c155"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c156"
      unitRef="USD">17568000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c157"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c158"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c159"
      unitRef="USD">17569000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c160"
      unitRef="Share">362000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c161"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c162"
      unitRef="USD">-232000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c163"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c164"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c165"
      unitRef="USD">-232000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c167"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c168"
      unitRef="USD">8560000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c169"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c170"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-4"
      id="c171"
      unitRef="USD">8560000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c173"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c174"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c175"
      unitRef="USD">173000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c176"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c177"
      unitRef="USD">173000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c179"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c180"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c181"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c182"
      unitRef="USD">-49375000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c183"
      unitRef="USD">-49375000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-4"
      id="c184"
      unitRef="Share">137820000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c185"
      unitRef="USD">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c186"
      unitRef="USD">489692000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-4"
      id="c187"
      unitRef="USD">210000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c188"
      unitRef="USD">-364683000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c189"
      unitRef="USD">125233000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2025-07-01_2025-09-30"
      decimals="-5"
      id="c190"
      unitRef="USD">8600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-4"
      id="c191"
      unitRef="Share">39290000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c192"
      unitRef="USD">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c193"
      unitRef="USD">129357000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c194"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c195"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c196"
      unitRef="USD">129361000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c197"
      unitRef="Share">545000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c198"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c199"
      unitRef="USD">1275000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c200"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c201"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c202"
      unitRef="USD">1275000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c203"
      unitRef="Share">669000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c204"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c205"
      unitRef="USD">-1027000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c206"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c207"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c208"
      unitRef="USD">-1027000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c210"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c211"
      unitRef="USD">8368000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c212"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c213"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c214"
      unitRef="USD">8368000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c216"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c217"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-4"
      id="c218"
      unitRef="USD">70000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c219"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-4"
      id="c220"
      unitRef="USD">70000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c222"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c223"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c224"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c225"
      unitRef="USD">-66489000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c226"
      unitRef="USD">-66489000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c227"
      unitRef="Share">178324000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c228"
      unitRef="USD">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c229"
      unitRef="USD">627665000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-4"
      id="c230"
      unitRef="USD">280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c231"
      unitRef="USD">-431172000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c232"
      unitRef="USD">196791000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c237"
      unitRef="USD">-66489000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c238"
      unitRef="USD">-49375000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c240"
      unitRef="USD">276000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c241"
      unitRef="USD">589000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c242"
      unitRef="USD">8368000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-4"
      id="c243"
      unitRef="USD">8560000</us-gaap:ShareBasedCompensation>
    <cmpx:MarketableSecuritiesAmortizationOfPremiumAndDiscount
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c244"
      unitRef="USD">-1673000</cmpx:MarketableSecuritiesAmortizationOfPremiumAndDiscount>
    <cmpx:MarketableSecuritiesAmortizationOfPremiumAndDiscount
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c245"
      unitRef="USD">-1651000</cmpx:MarketableSecuritiesAmortizationOfPremiumAndDiscount>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c246"
      unitRef="USD">1196000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c247"
      unitRef="USD">1164000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c249"
      unitRef="USD">-5116000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c250"
      unitRef="USD">4857000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c251"
      unitRef="USD">-664000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c252"
      unitRef="USD">-1841000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c253"
      unitRef="USD">5096000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c254"
      unitRef="USD">3773000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c255"
      unitRef="USD">-369000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c256"
      unitRef="USD">-1217000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c257"
      unitRef="USD">-49143000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c258"
      unitRef="USD">-44855000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c260"
      unitRef="USD">194557000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c261"
      unitRef="USD">88158000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c262"
      unitRef="USD">101276000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c263"
      unitRef="USD">134974000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c264"
      unitRef="USD">25000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c265"
      unitRef="USD">44000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c266"
      unitRef="USD">-93306000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c267"
      unitRef="USD">46772000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c269"
      unitRef="USD">137999000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c270"
      unitRef="USD">18113000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c271"
      unitRef="USD">8638000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c272"
      unitRef="USD">543000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c273"
      unitRef="USD">1275000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c274"
      unitRef="USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c275"
      unitRef="USD">1027000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c276"
      unitRef="USD">232000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c277"
      unitRef="USD">129609000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c278"
      unitRef="USD">17338000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-4"
      id="c279"
      unitRef="USD">-12840000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c280"
      unitRef="USD">19255000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c281"
      unitRef="USD">44051000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c282"
      unitRef="USD">24228000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c283"
      unitRef="USD">31211000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c284"
      unitRef="USD">44051000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c286"
      unitRef="USD">30643000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c287"
      unitRef="USD">43483000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c288"
      unitRef="USD">568000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c289"
      unitRef="USD">568000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c290"
      unitRef="USD">31211000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c291"
      unitRef="USD">44051000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-4"
      id="c293"
      unitRef="USD">70000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c294"
      unitRef="USD">173000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="d_2025-01-01_2025-12-31" id="c295">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Formation and Business of the Company&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Compass Therapeutics, Inc. (&#x201c;Compass&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Our scientific focus is on the relationship between angiogenesis and the immune system. Our pipeline includes novel product candidates that leverage our understanding of the tumor microenvironment, including both angiogenesis-targeted agents and immune-oncology focused agents. These product candidates are designed to optimize critical components required for an effective anti-tumor response to cancer. These include modulation of the microvasculature via angiogenesis-targeted agents; induction of a potent immune response via activators on effector cells in the tumor microenvironment; and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. We plan to advance our product candidates through clinical development as both standalone therapies and in combination with our proprietary drug candidates as long as their continued development is supported by clinical and nonclinical data. References to Compass or the Company herein include Compass Therapeutics, Inc. and its wholly owned subsidiaries.&lt;/p&gt;

&lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; margin: 0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The Company is subject to risks and uncertainties common to companies in the biotechnology and pharmaceutical industries. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants.&lt;/p&gt;

&lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; margin: 0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="d_2025-01-01_2025-12-31" id="c298">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Liquidity, Uncertainties and Going Concern &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Since its inception, the Company has funded its operations primarily with proceeds from the sale of its equity securities. The Company has incurred recurring losses since its inception and had an accumulated deficit of $431 million on December 31, 2025. The Company expects to continue to generate operating losses for the foreseeable future. The Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into 2028. The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The Company is subject to risks common to early stage companies in the biotechnology industry including, but not limited to: having a limited operating history and no products approved for commercial sale; having a history of significant losses; its need to obtain additional financing; dependence on its ability to advance its current and future product candidates through clinical trials, marketing approval and commercialization; the lengthy and expensive nature and uncertain outcomes of the clinical development process; the lengthy, time consuming and unpredictable nature of the regulatory approval process; the results of preclinical studies and early stage clinical trials that may not be predictive of future results; dependence on its key personnel; risks related to patent protection and the Company&#x2019;s pending patent applications; dependence on third party collaborators for the discovery, development and commercialization of current and future product candidates; and significant competition from other biotechnology and pharmaceutical companies. Even if the Company&#x2019;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;




</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2025-12-31"
      decimals="-6"
      id="c301"
      unitRef="USD">-431000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2025-01-01_2025-12-31" id="c302">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The accompanying consolidated financial statements are presented in U.S. dollars and have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and as amended by Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Principles of Consolidation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The accompanying consolidated financial statements include the accounts of Compass Therapeutics, Inc., and its wholly-owned subsidiaries, including Compass Therapeutics LLC, Compass Therapeutics Advisors Inc., Trigr Therapeutics, Inc., Compass Acquisition Company, LLC, and Compass Therapeutics Securities Corporation. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the accrual of research and development expenses, useful lives of equipment, interest rate and term operating lease ROU and liability, the percentage of completion of contractual arrangements, future cash expenditures for liquidity estimates, the valuation of common stock and estimates associated with stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates. Changes in estimates are recorded prospectively in the period that they become known.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Segment Information &lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has &lt;span style="-sec-ix-hidden:c305"&gt;one&lt;/span&gt; operating segment. The Company&#x2019;s chief operating decision-maker, its chief executive officer, manages the Company&#x2019;s operations on a consolidated basis for the purpose of allocating resources. All the Company&#x2019;s long-lived assets are held in the United States.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The Company considers all highly liquid investments that are readily convertible into cash with original maturities of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held in money market funds or commercial paper. Cash equivalents are stated at cost, which approximates market value. Cash and cash equivalents were $30.6 million and $43.5 million on December 31, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;






&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Marketable Securities&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;All of the Company&#x2019;s investment securities are debt securities and bank instruments. The Company carries these investments at fair value. Unrealized gains and losses, if any, are reported as a separate component of stockholders&#x2019; equity. The cost of investment securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income. Realized gains and losses, if any, are also included in interest income. The cost of securities sold is based on the specific identification method.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Concentrations of Credit Risk&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash equivalents and marketable securities. The Company invests its excess cash primarily in money market funds, U.S. treasury notes, and high quality, marketable debt instruments of corporations in accordance with the Company&#x2019;s investment policy. The Company&#x2019;s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. The Company has not experienced any realized losses related to its cash equivalents and marketable securities.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are recorded using the straight-line method over the estimated useful lives of the related assets as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 95%; margin-left: 28pt; margin-right: auto;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="vertical-align: bottom; width: 30.6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Asset Classification&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 39.1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;b&gt;Estimated Useful Life&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="vertical-align: top; width: 30.6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equipment&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 39.1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;5 years&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="vertical-align: top; width: 30.6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Furniture and fixtures&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 39.1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;7 years&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="vertical-align: top; width: 30.6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Software&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 39.1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;5 years&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="vertical-align: top; width: 30.6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasehold improvements&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 39.1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;Lesser of estimated useful life or lease term&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheet and any resulting gains or losses are included in the consolidated statement of operations and comprehensive loss in the period of disposal. Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Impairment of Long-Lived Assets&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Long-lived assets consist of property, equipment and right-of-use (&#x201c;ROU&#x201d;) assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in the consolidated statements of operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did &lt;span style="-sec-ix-hidden:c311"&gt;&lt;span style="-sec-ix-hidden:c312"&gt;not&lt;/span&gt;&lt;/span&gt; record any impairment losses on long-lived assets during the years ended December 31, 2025 and 2024.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"&gt;

		&lt;tbody&gt;&lt;tr&gt;
			&lt;td style="width:29pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align:top;width:18pt;"&gt;
			&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align:top;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Level 1 &#x2013;&#160;Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"&gt;

		&lt;tbody&gt;&lt;tr&gt;
			&lt;td style="width:29pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align:top;width:18pt;"&gt;
			&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align:top;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Level 2 &#x2013;&#160;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets and liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"&gt;

		&lt;tbody&gt;&lt;tr&gt;
			&lt;td style="width:29pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align:top;width:18pt;"&gt;
			&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align:top;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Level 3 &#x2013;&#160;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected are reported in earnings.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Research and Development Costs&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Costs associated with internal research and development and external research and development services, including drug development and preclinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation and amortization, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials and other costs. The Company recognizes external research and development costs based on an evaluation of the progress of specific tasks using information provided to the Company by its service providers.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Costs associated with licenses of technology acquired as part of collaborative arrangements are expensed as incurred and are generally included in research and development expense in the consolidated statements of operations if it is determined the license has no alternative future use.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Accrued Research and Development Expenses&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The Company has entered into various research and development and other agreements with commercial firms, researchers, universities and others for provisions of goods and services. These agreements are generally cancelable, and the related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made to determine the accrued balances at the end of any reporting period. Actual results could differ materially from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from the actual costs.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Patent Costs&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expense in the consolidated statements of operations.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The Company recognizes the grant&#x2011;date fair value of stock&#x2011;based awards issued to employees and nonemployee board members as compensation expense on a straight&#x2011;line basis over the service period of the award. The Company uses the Black&#x2011;Scholes option pricing model to determine the grant&#x2011;date fair value of stock options and adjusts expense for forfeitures in the periods they occur.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The fair value of each equity award was determined by the Company on the date of grant and by using the methods and assumptions discussed below. Certain of these inputs are subjective and generally require judgment to determine.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;i&gt;Stock price: &lt;/i&gt;The stock price used to value equity awards is based on the closing price of the Company&#x2019;s common stock as reported on the date of the grant. For equity awards issued after June 2020 until the Company started trading on a public market in the second quarter of 2021, the valuation of the Company&#x2019;s common stock was $5.00 per share, which was the share price paid by outside investors in the Company&#x2019;s Private Placement in June 2020.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;i&gt;Expected term&lt;/i&gt;: The expected term of the equity award represents the weighted average period the award is expected to be outstanding. The Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average time to vesting and the contractual life of the award.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;i&gt;Expected volatility&lt;/i&gt; &#x2013; The expected volatility is calculated based on the historical volatility of our common stock over the expected term of the option.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;i&gt;Risk-free interest rate&lt;/i&gt; &#x2013; The risk-free rate assumption is based on U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#x2019;s equity award.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;i&gt;Expected dividend &lt;/i&gt;&#x2013; The Company has not paid and does not intend to pay dividends.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Net Loss per Share &lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, stock options, restricted stock units, unvested restricted stock awards and common stock warrants that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The following potentially dilutive securities outstanding as of December 31, 2025 and 2024 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: auto; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(000's)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 66%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Restricted stock units&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,028&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,766&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;16,352&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;14,062&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;17,380&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;17,828&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:29pt;"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the deferred tax benefits will not be realized.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The Company files income tax returns in the U.S. Federal jurisdiction and in various states. The Company has tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;New Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;In November 2024, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2024-03&lt;i&gt;, Income Statement &lt;/i&gt;&#x2013;&lt;i&gt; Reporting Comprehensive Income &lt;/i&gt;&#x2013;&lt;i&gt; Expense Disaggregation Disclosures&lt;/i&gt;, which amends existing income statement disclosure guidance, primarily requiring more detailed disclosure for expenses. The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The amendments can be applied on either a prospective or retroactive basis. We are currently evaluating the ASU to determine its impact on our disclosures.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Recently Adopted Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;In December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09). The amendments in ASU 2023-09 are intended to enhance the transparency and decision usefulness of income tax disclosures through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 for public entities, with early adoption permitted. The Company applied the amendments prospectively for the year ended December 31, 2025, and the impact of the adoption of the amendments in this update was not material to the Company&#x2019;s consolidated financial position and results of operations for the year ended December 31, 2025, since the amendments require only enhancement of existing income tax disclosures in the footnotes to the Company&#x2019;s consolidated financial statements. See Note 14 for additional disclosures.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;




&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c772607327200208">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The accompanying consolidated financial statements are presented in U.S. dollars and have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and as amended by Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;
</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1157138965408101">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Principles of Consolidation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The accompanying consolidated financial statements include the accounts of Compass Therapeutics, Inc., and its wholly-owned subsidiaries, including Compass Therapeutics LLC, Compass Therapeutics Advisors Inc., Trigr Therapeutics, Inc., Compass Acquisition Company, LLC, and Compass Therapeutics Securities Corporation. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2025-01-01_2025-12-31" id="c751342916814027">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the accrual of research and development expenses, useful lives of equipment, interest rate and term operating lease ROU and liability, the percentage of completion of contractual arrangements, future cash expenditures for liquidity estimates, the valuation of common stock and estimates associated with stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates. Changes in estimates are recorded prospectively in the period that they become known.&lt;/p&gt;
</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c829312459439601">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Segment Information &lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has &lt;span style="-sec-ix-hidden:c305"&gt;one&lt;/span&gt; operating segment. The Company&#x2019;s chief operating decision-maker, its chief executive officer, manages the Company&#x2019;s operations on a consolidated basis for the purpose of allocating resources. All the Company&#x2019;s long-lived assets are held in the United States.&lt;/p&gt;
</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1437120533271784">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The Company considers all highly liquid investments that are readily convertible into cash with original maturities of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held in money market funds or commercial paper. Cash equivalents are stated at cost, which approximates market value. Cash and cash equivalents were $30.6 million and $43.5 million on December 31, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2025-12-31"
      decimals="-5"
      id="c306"
      unitRef="USD">30600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2024-12-31"
      decimals="-5"
      id="c307"
      unitRef="USD">43500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesPolicy contextRef="d_2025-01-01_2025-12-31" id="c1538126537632555">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Marketable Securities&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;All of the Company&#x2019;s investment securities are debt securities and bank instruments. The Company carries these investments at fair value. Unrealized gains and losses, if any, are reported as a separate component of stockholders&#x2019; equity. The cost of investment securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income. Realized gains and losses, if any, are also included in interest income. The cost of securities sold is based on the specific identification method.&lt;/p&gt;
</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="d_2025-01-01_2025-12-31" id="c1054360942950580">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Concentrations of Credit Risk&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash equivalents and marketable securities. The Company invests its excess cash primarily in money market funds, U.S. treasury notes, and high quality, marketable debt instruments of corporations in accordance with the Company&#x2019;s investment policy. The Company&#x2019;s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. The Company has not experienced any realized losses related to its cash equivalents and marketable securities.&lt;/p&gt;
</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c404024024206495">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are recorded using the straight-line method over the estimated useful lives of the related assets as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 95%; margin-left: 28pt; margin-right: auto;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="vertical-align: bottom; width: 30.6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Asset Classification&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 39.1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;b&gt;Estimated Useful Life&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="vertical-align: top; width: 30.6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equipment&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 39.1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;5 years&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="vertical-align: top; width: 30.6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Furniture and fixtures&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 39.1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;7 years&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="vertical-align: top; width: 30.6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Software&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 39.1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;5 years&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="vertical-align: top; width: 30.6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasehold improvements&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 39.1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;Lesser of estimated useful life or lease term&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheet and any resulting gains or losses are included in the consolidated statement of operations and comprehensive loss in the period of disposal. Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service.&lt;/p&gt;
</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <cmpx:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c337">
&lt;table cellpadding="0" cellspacing="0" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 95%; margin-left: 28pt; margin-right: auto;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="vertical-align: bottom; width: 30.6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Asset Classification&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 39.1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;b&gt;Estimated Useful Life&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="vertical-align: top; width: 30.6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equipment&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 39.1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;5 years&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="vertical-align: top; width: 30.6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Furniture and fixtures&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 39.1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;7 years&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="vertical-align: top; width: 30.6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Software&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 39.1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;5 years&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="vertical-align: top; width: 30.6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasehold improvements&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; width: 39.1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;Lesser of estimated useful life or lease term&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</cmpx:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentMember"
      id="c340">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      id="c341">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareAndSoftwareDevelopmentCostsMember"
      id="c342">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c636160645746866">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Impairment of Long-Lived Assets&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Long-lived assets consist of property, equipment and right-of-use (&#x201c;ROU&#x201d;) assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in the consolidated statements of operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did &lt;span style="-sec-ix-hidden:c311"&gt;&lt;span style="-sec-ix-hidden:c312"&gt;not&lt;/span&gt;&lt;/span&gt; record any impairment losses on long-lived assets during the years ended December 31, 2025 and 2024.&lt;/p&gt;
</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c450096947591934">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"&gt;

		&lt;tbody&gt;&lt;tr&gt;
			&lt;td style="width:29pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align:top;width:18pt;"&gt;
			&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align:top;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Level 1 &#x2013;&#160;Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"&gt;

		&lt;tbody&gt;&lt;tr&gt;
			&lt;td style="width:29pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align:top;width:18pt;"&gt;
			&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align:top;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Level 2 &#x2013;&#160;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets and liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"&gt;

		&lt;tbody&gt;&lt;tr&gt;
			&lt;td style="width:29pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align:top;width:18pt;"&gt;
			&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align:top;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Level 3 &#x2013;&#160;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected are reported in earnings.&lt;/p&gt;
</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2025-01-01_2025-12-31" id="c806276026833883">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Research and Development Costs&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Costs associated with internal research and development and external research and development services, including drug development and preclinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation and amortization, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials and other costs. The Company recognizes external research and development costs based on an evaluation of the progress of specific tasks using information provided to the Company by its service providers.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Costs associated with licenses of technology acquired as part of collaborative arrangements are expensed as incurred and are generally included in research and development expense in the consolidated statements of operations if it is determined the license has no alternative future use.&lt;/p&gt;
</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <cmpx:AccruedResearchAndDevelopmentExpensesPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c202012018494545">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Accrued Research and Development Expenses&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The Company has entered into various research and development and other agreements with commercial firms, researchers, universities and others for provisions of goods and services. These agreements are generally cancelable, and the related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made to determine the accrued balances at the end of any reporting period. Actual results could differ materially from the Company&#x2019;s estimates. The Company&#x2019;s historical accrual estimates have not been materially different from the actual costs.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
</cmpx:AccruedResearchAndDevelopmentExpensesPolicyTextBlock>
    <cmpx:PatentsCostsPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1476105353443896">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Patent Costs&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expense in the consolidated statements of operations.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
</cmpx:PatentsCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2025-01-01_2025-12-31" id="c1405223953845236">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The Company recognizes the grant&#x2011;date fair value of stock&#x2011;based awards issued to employees and nonemployee board members as compensation expense on a straight&#x2011;line basis over the service period of the award. The Company uses the Black&#x2011;Scholes option pricing model to determine the grant&#x2011;date fair value of stock options and adjusts expense for forfeitures in the periods they occur.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The fair value of each equity award was determined by the Company on the date of grant and by using the methods and assumptions discussed below. Certain of these inputs are subjective and generally require judgment to determine.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;i&gt;Stock price: &lt;/i&gt;The stock price used to value equity awards is based on the closing price of the Company&#x2019;s common stock as reported on the date of the grant. For equity awards issued after June 2020 until the Company started trading on a public market in the second quarter of 2021, the valuation of the Company&#x2019;s common stock was $5.00 per share, which was the share price paid by outside investors in the Company&#x2019;s Private Placement in June 2020.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;i&gt;Expected term&lt;/i&gt;: The expected term of the equity award represents the weighted average period the award is expected to be outstanding. The Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average time to vesting and the contractual life of the award.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;i&gt;Expected volatility&lt;/i&gt; &#x2013; The expected volatility is calculated based on the historical volatility of our common stock over the expected term of the option.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;i&gt;Risk-free interest rate&lt;/i&gt; &#x2013; The risk-free rate assumption is based on U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company&#x2019;s equity award.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;i&gt;Expected dividend &lt;/i&gt;&#x2013; The Company has not paid and does not intend to pay dividends.&lt;/p&gt;
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2021-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c313"
      unitRef="USDPerShare">5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c232136627471447">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Net Loss per Share &lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock, stock options, restricted stock units, unvested restricted stock awards and common stock warrants that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The following potentially dilutive securities outstanding as of December 31, 2025 and 2024 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: auto; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(000's)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 66%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Restricted stock units&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,028&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,766&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;16,352&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;14,062&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;17,380&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;17,828&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsAndOptionsMember"
      id="c343">
&lt;table cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: auto; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(000's)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 66%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Restricted stock units&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,028&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,766&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;16,352&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;14,062&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;17,380&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;17,828&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c346"
      unitRef="Share">1028000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c347"
      unitRef="Share">3766000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c348"
      unitRef="Share">16352000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c349"
      unitRef="Share">14062000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-4"
      id="c350"
      unitRef="Share">17380000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c351"
      unitRef="Share">17828000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c8860181257756">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:29pt;"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the deferred tax benefits will not be realized.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The Company files income tax returns in the U.S. Federal jurisdiction and in various states. The Company has tax net operating loss carryforwards that are subject to examination for a number of years beyond the year in which they were generated for tax purposes. Since a portion of these net operating loss carryforwards may be utilized in the future, many of these net operating loss carryforwards will remain subject to examination.&lt;/p&gt;
</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c393391838793906">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;New Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;In November 2024, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2024-03&lt;i&gt;, Income Statement &lt;/i&gt;&#x2013;&lt;i&gt; Reporting Comprehensive Income &lt;/i&gt;&#x2013;&lt;i&gt; Expense Disaggregation Disclosures&lt;/i&gt;, which amends existing income statement disclosure guidance, primarily requiring more detailed disclosure for expenses. The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The amendments can be applied on either a prospective or retroactive basis. We are currently evaluating the ASU to determine its impact on our disclosures.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Recently Adopted Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;In December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09). The amendments in ASU 2023-09 are intended to enhance the transparency and decision usefulness of income tax disclosures through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 for public entities, with early adoption permitted. The Company applied the amendments prospectively for the year ended December 31, 2025, and the impact of the adoption of the amendments in this update was not material to the Company&#x2019;s consolidated financial position and results of operations for the year ended December 31, 2025, since the amendments require only enhancement of existing income tax disclosures in the footnotes to the Company&#x2019;s consolidated financial statements. See Note 14 for additional disclosures.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="d_2025-01-01_2025-12-31" id="c352">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities that are measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;Fair Value Measurements as of December 31, 2025 (000's):&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Quoted Prices&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;in Active&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Markets for&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Observable&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Unobservable&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Identical Assets&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Inputs&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Inputs&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 48%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Corporate bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;86,636&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;86,636&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Certificates of deposit&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,960&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,960&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;68,977&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;68,977&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;U.S. government treasuries&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,664&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,664&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Asset-backed securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,026&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,026&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Money market funds (cash equivalents)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8,383&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8,383&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;79,024&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;107,622&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;186,646&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value Measurements as of December 31, 2024 (000's):&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Quoted Prices&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;in Active&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Markets for&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Observable&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Unobservable&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Identical Assets&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Inputs&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Inputs&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 48%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Corporate bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;44,963&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;44,963&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Certificates of deposit&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15,269&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15,269&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;12,084&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;12,084&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;U.S. government treasuries&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,399&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,399&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Asset-backed securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,524&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,524&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Money market funds (cash equivalents)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;23,880&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;23,880&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;40,363&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;66,756&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;107,119&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="d_2025-01-01_2025-12-31"
      id="c2FD2CAF0-77CA-45A2-BCBB-F4BA8F129984">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;Fair Value Measurements as of December 31, 2025 (000's):&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Quoted Prices&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;in Active&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Markets for&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Observable&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Unobservable&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Identical Assets&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Inputs&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Inputs&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 48%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Corporate bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;86,636&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;86,636&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Certificates of deposit&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,960&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,960&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;68,977&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;68,977&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;U.S. government treasuries&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,664&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,664&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Asset-backed securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,026&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,026&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Money market funds (cash equivalents)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8,383&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8,383&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;79,024&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;107,622&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;186,646&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value Measurements as of December 31, 2024 (000's):&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Quoted Prices&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;in Active&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Markets for&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Observable&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Unobservable&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Identical Assets&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Inputs&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Inputs&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 48%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Corporate bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;44,963&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;44,963&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Certificates of deposit&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15,269&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15,269&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;12,084&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;12,084&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;U.S. government treasuries&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,399&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,399&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Asset-backed securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,524&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,524&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Money market funds (cash equivalents)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;23,880&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;23,880&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;40,363&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;66,756&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;107,119&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c414"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c415"
      unitRef="USD">86636000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c416"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c417"
      unitRef="USD">86636000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c418"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-4"
      id="c419"
      unitRef="USD">14960000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c420"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-4"
      id="c421"
      unitRef="USD">14960000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c422"
      unitRef="USD">68977000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c423"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c424"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c425"
      unitRef="USD">68977000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c426"
      unitRef="USD">1664000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c427"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c428"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c429"
      unitRef="USD">1664000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-3"
      id="c430"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-3"
      id="c431"
      unitRef="USD">6026000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-3"
      id="c432"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c433"
      unitRef="USD">6026000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember"
      decimals="-3"
      id="c434"
      unitRef="USD">8383000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember"
      decimals="-3"
      id="c435"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember"
      decimals="-3"
      id="c436"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember"
      decimals="-3"
      id="c437"
      unitRef="USD">8383000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c438"
      unitRef="USD">79024000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c439"
      unitRef="USD">107622000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c440"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c441"
      unitRef="USD">186646000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c445"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c446"
      unitRef="USD">44963000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c447"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c448"
      unitRef="USD">44963000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c449"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c450"
      unitRef="USD">15269000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c451"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c452"
      unitRef="USD">15269000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c453"
      unitRef="USD">12084000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c454"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c455"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c456"
      unitRef="USD">12084000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c457"
      unitRef="USD">4399000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c458"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c459"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c460"
      unitRef="USD">4399000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-3"
      id="c461"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-3"
      id="c462"
      unitRef="USD">6524000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-3"
      id="c463"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-3"
      id="c464"
      unitRef="USD">6524000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember"
      decimals="-4"
      id="c465"
      unitRef="USD">23880000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember"
      decimals="-3"
      id="c466"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember"
      decimals="-3"
      id="c467"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-MoneyMarketFundsMember"
      decimals="-4"
      id="c468"
      unitRef="USD">23880000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c469"
      unitRef="USD">40363000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c470"
      unitRef="USD">66756000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c471"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c472"
      unitRef="USD">107119000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c473">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Marketable Securities&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The objectives of the Company&#x2019;s investment policy are to ensure the safety and preservation of invested funds, as well as to maintain liquidity sufficient to meet cash flow requirements. The Company invests its excess cash in securities issued by financial institutions, commercial companies, and government agencies that management believes to be of high credit quality in order to limit the amount of its credit exposure. The Company has not realized any net losses from its investments.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;



&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Unrealized gains and losses on investments that are available for sale are recognized in accumulated comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are included in other income in the consolidated statements of operations and comprehensive loss and are determined using the specific identification method with transactions recorded on a trade date basis. The Company classifies marketable securities that are available for use in current operations as current assets on the consolidated balance sheet.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The following tables summarize marketable securities held at December 31, 2025 and 2024 (in thousands):&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value Measurements as of December 31, 2025 Using:&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Amortized Cost&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Unrealized gains&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Unrealized Losses&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 48%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Corporate bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;86,417&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;223&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(4&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;86,636&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Certificates of deposit&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,950&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,960&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;68,943&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;34&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;68,977&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Asset-backed securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,010&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,026&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;U.S. government treasuries&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,663&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,664&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;177,983&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;284&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(4&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;178,263&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value Measurements as of December 31, 2024 Using:&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Amortized Cost&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Unrealized gains&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Unrealized Losses&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 48%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Corporate bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;44,794&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;175&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(6&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;44,963&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Certificates of deposit&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15,262&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15,269&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;12,081&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;12,084&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Asset-backed securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,484&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;40&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,524&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;U.S. government treasuries&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,408&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(11&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,399&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;83,029&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;230&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(20&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;83,239&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; margin: 0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Maturing in one year or less&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;126,119&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;56,386&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Maturing after one year through two years&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;52,144&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;26,853&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;178,263&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;83,239&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;




</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="d_2025-01-01_2025-12-31"
      id="c3AC0D799-3BD4-48BE-9E24-0B78E3EE9AAC">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value Measurements as of December 31, 2025 Using:&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Amortized Cost&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Unrealized gains&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Unrealized Losses&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 48%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Corporate bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;86,417&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;223&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(4&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;86,636&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Certificates of deposit&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,950&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,960&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;68,943&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;34&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;68,977&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Asset-backed securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,010&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,026&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;U.S. government treasuries&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,663&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,664&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;177,983&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;284&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(4&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;178,263&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value Measurements as of December 31, 2024 Using:&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Amortized Cost&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Unrealized gains&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Unrealized Losses&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 48%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Corporate bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;44,794&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;175&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(6&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;44,963&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Certificates of deposit&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15,262&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15,269&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;12,081&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;12,084&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Asset-backed securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,484&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;40&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,524&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;U.S. government treasuries&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,408&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(11&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,399&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;83,029&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;230&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(20&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;83,239&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2025-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c533"
      unitRef="USD">86417000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2025-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c534"
      unitRef="USD">223000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2025-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c535"
      unitRef="USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c536"
      unitRef="USD">86636000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2025-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-4"
      id="c537"
      unitRef="USD">14950000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2025-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-4"
      id="c538"
      unitRef="USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2025-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c539"
      unitRef="USD">-0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-4"
      id="c540"
      unitRef="USD">14960000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2025-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c541"
      unitRef="USD">68943000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2025-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c542"
      unitRef="USD">34000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2025-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c543"
      unitRef="USD">-0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c544"
      unitRef="USD">68977000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2025-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-4"
      id="c545"
      unitRef="USD">6010000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2025-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-3"
      id="c546"
      unitRef="USD">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2025-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-3"
      id="c547"
      unitRef="USD">-0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-3"
      id="c548"
      unitRef="USD">6026000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c549"
      unitRef="USD">1663000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c550"
      unitRef="USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c551"
      unitRef="USD">-0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c552"
      unitRef="USD">1664000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c553"
      unitRef="USD">177983000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c554"
      unitRef="USD">284000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c555"
      unitRef="USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c556"
      unitRef="USD">178263000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2024-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c560"
      unitRef="USD">44794000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2024-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c561"
      unitRef="USD">175000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2024-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c562"
      unitRef="USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c563"
      unitRef="USD">44963000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2024-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c564"
      unitRef="USD">15262000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2024-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c565"
      unitRef="USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2024-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c566"
      unitRef="USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c567"
      unitRef="USD">15269000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2024-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c568"
      unitRef="USD">12081000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2024-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c569"
      unitRef="USD">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2024-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c570"
      unitRef="USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c571"
      unitRef="USD">12084000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2024-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-3"
      id="c572"
      unitRef="USD">6484000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2024-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-4"
      id="c573"
      unitRef="USD">40000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2024-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-3"
      id="c574"
      unitRef="USD">-0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FinancialInstrumentAxis-AssetBackedSecuritiesMember"
      decimals="-3"
      id="c575"
      unitRef="USD">6524000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c576"
      unitRef="USD">4408000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c577"
      unitRef="USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c578"
      unitRef="USD">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c579"
      unitRef="USD">4399000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c580"
      unitRef="USD">83029000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c581"
      unitRef="USD">230000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c582"
      unitRef="USD">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c583"
      unitRef="USD">83239000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c584">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Maturing in one year or less&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;126,119&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;56,386&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Maturing after one year through two years&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;52,144&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;26,853&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;178,263&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;83,239&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c587"
      unitRef="USD">126119000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c588"
      unitRef="USD">56386000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <cmpx:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c589"
      unitRef="USD">52144000</cmpx:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo>
    <cmpx:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c590"
      unitRef="USD">26853000</cmpx:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c591"
      unitRef="USD">178263000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c592"
      unitRef="USD">83239000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c593">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Property and equipment consist of the following:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(000's)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equipment&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,741&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,716&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Furniture and fixtures&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;22&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;22&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasehold improvements&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,612&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,612&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Software&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;364&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;364&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total property and equipment&#x2013;at cost&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,739&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,714&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: Accumulated depreciation and amortization&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6,637&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6,361&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Property and equipment, net&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;102&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;353&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Total depreciation and amortization expense for years ended December 31, 2025 and 2024, was $0.3 million and $0.6 million, respectively.&lt;/p&gt;
</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2025-01-01_2025-12-31" id="c612">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(000's)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equipment&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,741&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,716&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Furniture and fixtures&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;22&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;22&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasehold improvements&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,612&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,612&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Software&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;364&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;364&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total property and equipment&#x2013;at cost&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,739&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,714&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: Accumulated depreciation and amortization&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6,637&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(6,361&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Property and equipment, net&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;102&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;353&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentMember"
      decimals="-3"
      id="c615"
      unitRef="USD">4741000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentMember"
      decimals="-3"
      id="c616"
      unitRef="USD">4716000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="-3"
      id="c617"
      unitRef="USD">22000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="-3"
      id="c618"
      unitRef="USD">22000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c619"
      unitRef="USD">1612000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c620"
      unitRef="USD">1612000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember"
      decimals="-3"
      id="c621"
      unitRef="USD">364000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember"
      decimals="-3"
      id="c622"
      unitRef="USD">364000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c623"
      unitRef="USD">6739000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c624"
      unitRef="USD">6714000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c625"
      unitRef="USD">6637000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c626"
      unitRef="USD">6361000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c627"
      unitRef="USD">102000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c628"
      unitRef="USD">353000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-5"
      id="c610"
      unitRef="USD">300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-5"
      id="c611"
      unitRef="USD">600000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c629">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Accrued Expenses&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Accrued expenses consist of the following:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(000's)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Project expenses&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8,217&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,873&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Compensation and benefits&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,682&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,793&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;484&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;621&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total accrued expenses&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;11,383&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,287&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Project expenses in 2025 were primarily made up of $7.9 million of accrued manufacturing expenses related to tovecimig and CTX-10726.&#160;Project expenses in 2024 were primarily made up of $2.6 million of accrued manufacturing expenses related to minimum contractual obligations.&lt;/p&gt;
</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c642">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(000's)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Project expenses&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8,217&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,873&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Compensation and benefits&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,682&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,793&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;484&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;621&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total accrued expenses&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;11,383&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,287&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <cmpx:AccruedProjectExpensesCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c645"
      unitRef="USD">8217000</cmpx:AccruedProjectExpensesCurrent>
    <cmpx:AccruedProjectExpensesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c646"
      unitRef="USD">2873000</cmpx:AccruedProjectExpensesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c647"
      unitRef="USD">2682000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c648"
      unitRef="USD">2793000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c649"
      unitRef="USD">484000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c650"
      unitRef="USD">621000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c651"
      unitRef="USD">11383000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c652"
      unitRef="USD">6287000</us-gaap:AccruedLiabilitiesCurrent>
    <cmpx:AccruedManufacturingExpenses
      contextRef="i_2025-12-31"
      decimals="-5"
      id="c640"
      unitRef="USD">7900000</cmpx:AccruedManufacturingExpenses>
    <cmpx:AccruedManufacturingExpenses
      contextRef="i_2024-12-31"
      decimals="-5"
      id="c641"
      unitRef="USD">2600000</cmpx:AccruedManufacturingExpenses>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c653">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Stockholders&lt;/b&gt;&#x2019;&lt;b&gt;&#160;Equity&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;On August 12, 2025, the Company entered into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with Jefferies LLC, Piper Sandler &amp;amp; Co., and Guggenheim Securities, LLC, as representatives (the &#x201c;Representatives&#x201d;) of the underwriters named therein (the &#x201c;Underwriters&#x201d;), pursuant to which the Company agreed to issue and sell an aggregate of (a) 33,290,000 shares (the &#x201c;Firm Shares&#x201d;) of its common stock, par value $0.0001 per share (the &#x201c;Common Stock&#x201d;), at a price to the public of $3.00 per share, and (b) pre-funded warrants to purchase up to 6,710,000 shares of the Company&#x2019;s Common Stock (the &#x201c;Pre-Funded Warrants&#x201d;), at a price to the public of $2.9999 per warrant with an exercise price of $0.0001 per share (the &#x201c;Offering&#x201d;). Pursuant to the Underwriting Agreement, the Company granted the underwriters a 30-day option, which the underwriters exercised, to purchase up to an additional 6,000,000 shares of its Common Stock (the &#x201c;Optional Shares&#x201d;, and together with the Firm Shares, the &#x201c;Shares&#x201d;) at the public offering price, less underwriting discounts and commissions. The Company received aggregate net proceeds of $129.3 million, after deducting underwriting discounts and commissions of $8.3 million and other offering costs of $0.4 million.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The 2025 Pre-Funded Warrants were determined to be equity classified. Accordingly, proceeds from the offering were allocated to common stock, the 2025 Pre-Funded Warrants on a relative fair value basis and were recorded in stockholders&#x2019; equity. As of December 31, 2025, all of the 2025 Pre-Funded Warrants remain outstanding.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;In the first quarter of 2024, the Company sold through its Jefferies ATM Agreement, 9,790,577 shares of common stock at an average price of $1.85 for total proceeds of $18.1 million and net proceeds of $17.6 million.&lt;/p&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-08-12_2025-08-12_SubsidiarySaleOfStockAxis-UnderwritingAgreementMember"
      decimals="INF"
      id="c656"
      unitRef="Share">33290000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2025-08-12"
      decimals="INF"
      id="c657"
      unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2025-08-12_SubsidiarySaleOfStockAxis-UnderwritingAgreementMember"
      decimals="INF"
      id="c658"
      unitRef="USDPerShare">3</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2025-08-12_ClassOfWarrantOrRightAxis-PreFundedWarrantsInConnectionWithUnderwritingAgreementMember"
      decimals="INF"
      id="c659"
      unitRef="Share">6710000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <cmpx:ClassOfWarrantOrRightPurchasePrice
      contextRef="i_2025-08-12_ClassOfWarrantOrRightAxis-PreFundedWarrantsInConnectionWithUnderwritingAgreementMember"
      decimals="INF"
      id="c660"
      unitRef="USDPerShare">2.9999</cmpx:ClassOfWarrantOrRightPurchasePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-08-12_ClassOfWarrantOrRightAxis-PreFundedWarrantsInConnectionWithUnderwritingAgreementMember"
      decimals="INF"
      id="c661"
      unitRef="USDPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cmpx:StockIssuableDuringPeriodShares
      contextRef="d_2025-08-12_2025-08-12_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"
      decimals="INF"
      id="c662"
      unitRef="Share">6000000</cmpx:StockIssuableDuringPeriodShares>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2025-08-12_2025-08-12_SubsidiarySaleOfStockAxis-UnderwritingAgreementMember"
      decimals="-5"
      id="c663"
      unitRef="USD">129300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="d_2025-08-12_2025-08-12_SubsidiarySaleOfStockAxis-UnderwritingAgreementMember"
      decimals="-5"
      id="c664"
      unitRef="USD">8300000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <us-gaap:NoninterestExpenseOfferingCost
      contextRef="d_2025-08-12_2025-08-12_SubsidiarySaleOfStockAxis-UnderwritingAgreementMember"
      decimals="-5"
      id="c665"
      unitRef="USD">400000</us-gaap:NoninterestExpenseOfferingCost>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-01-01_2024-03-31_SubsidiarySaleOfStockAxis-AtTheMarketMember"
      decimals="INF"
      id="c666"
      unitRef="Share">9790577</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2024-03-31_SubsidiarySaleOfStockAxis-AtTheMarketMember"
      decimals="INF"
      id="c667"
      unitRef="USDPerShare">1.85</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2024-01-01_2024-03-31_SubsidiarySaleOfStockAxis-AtTheMarketMember"
      decimals="-5"
      id="c668"
      unitRef="USD">18100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cmpx:ProceedsFromIssuanceOfCommonStockNet
      contextRef="d_2024-01-01_2024-03-31_SubsidiarySaleOfStockAxis-AtTheMarketMember"
      decimals="-5"
      id="c669"
      unitRef="USD">17600000</cmpx:ProceedsFromIssuanceOfCommonStockNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2025-01-01_2025-12-31" id="c670">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Stock-based compensation expense for the years ended December 31, 2025 and 2024 was classified in the consolidated statements of operations as follows:&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
			December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(000's)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,346&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,971&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,022&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,589&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,368&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,560&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;2020 Stock Option and Incentive Plan&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;In June 2020, the Company&#x2019;s board of directors adopted the 2020 Plan and reserved 2.9 million shares of common stock for issuance under this plan. The 2020 Plan provides that the number of shares reserved and available for issuance under the 2020 Plan will automatically increase each January 1, beginning on January 1, 2021, by the lesser of 4% of the outstanding number of shares of our common stock on the immediately preceding December 31 or such number of shares as determined by the plan administrator no later than the immediately preceding December 31. As of December 31, 2025, 5.3 million shares remain available for future grant. On January 1, 2026, an additional 7.1 million shares became available for issuance based on 4% of the outstanding shares of common stock, for a total of 12.4 million shares available for issuance.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The 2020 Plan authorizes the board of directors or a committee of the board to grant incentive stock options, nonqualified stock options, restricted stock awards and restricted stock units ("RSUs") to eligible officers, employees, consultants and directors of the Company. Options generally vest over a period of &lt;span style="-sec-ix-hidden:c685"&gt;four&lt;/span&gt; years and have a contractual life of &lt;span style="-sec-ix-hidden:c686"&gt;ten&lt;/span&gt; years from the date of grant.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;i&gt;Stock Options:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The following table summarizes the stock option activity for the 2020 Plan:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options (000's)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted Average&lt;br/&gt;
			Exercise Price&lt;br/&gt;
			Price Per Share&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted Average&lt;br/&gt;
			Remaining Contractual&lt;br/&gt;
			Life (in years)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Aggregate Intrinsic Value (000's)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 48%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at December 31, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,876&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.81&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8.05&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,193&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.58&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7.10&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercised&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Forfeited/cancelled&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(7&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.04&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at December 31, 2024&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;14,062&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.83&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.23&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;579&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,777&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.63&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8.76&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercised&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(545&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.34&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,214&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Forfeited/cancelled&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,942&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.40&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,341&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at December 31, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;16,352&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.13&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.69&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;36,614&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Vested at December 31, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;9,513&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.38&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.24&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18,932&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;For the year ended December 31, 2025, the weighted average grant date fair value for options granted was $2.69. The aggregate intrinsic value for options vested and outstanding as of December 31, 2025 and 2024 was $36.6 million and $579 thousand, respectively. As of December 31, 2025, the unrecognized compensation cost related to outstanding options was $13.7 million, expected to be recognized over a weighted average period of approximately 1.4 years.&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&#160;&lt;/p&gt;



&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The weighted average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and directors during the years ended December 31, 2025 and 2024 were as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected term (in years)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.26&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.92&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected volatility&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;86&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;81&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;i&gt;RSUs:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The following table summarizes the RSU activity for the 2020 Plan:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Shares&lt;br/&gt;
			(000's)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;br/&gt;
			Average Price&lt;br/&gt;
			Per Share&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;br/&gt;
			Average Fair Value (000's)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Unvested, December 31, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,500&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.83&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,745&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,791&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.89&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,275&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Vested&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(525&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.87&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,032&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Forfeited or canceled&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Unvested, December 31, 2024&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,766&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2.41&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9,076&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Vested&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1,073&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.59&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,779&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Forfeited or canceled&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,665&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2.34&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,896&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Unvested, December 31, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,028&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2.33&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,395&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants. The weighted average fair value is the weighted average share price times the number of shares.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;As of December 31, 2025, remaining unrecognized compensation cost related to RSUs to be recognized in future periods totaled $1.6 million, which is expected to be recognized over a weighted average period of 1.2 years. As of December 31, 2025, the total unrecognized compensation cost from all plans to be recognized in future periods totaled approximately $15.3 million.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;2025 Inducement Plan&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;In December 2025, the Company&#x2019;s board of directors adopted the Compass Therapeutics, Inc. 2025 Inducement Plan (the &#x201c;Inducement Plan&#x201d;). The purpose of the Inducement Plan is to enable the Company to grant equity awards to induce highly-qualified prospective officers and employees to accept employment and provide them with a proprietary interest in the Company. The Company intends that the Inducement Plan be reserved for persons to whom the Company may issue securities without stockholder approval as an inducement pursuant to Rule 5635(c)(4) of the Marketplace Rules of The NASDAQ Stock Market LLC. The maximum number of shares of Stock reserved and available for issuance under the Inducement Plan is four million shares. As of December 31, 2025, no equity had been granted or outstanding with the Inducement Plan. On January 1, 2026, a total of two million options were granted as part of the Inducement Plan to two new officers as a material inducement for those officers to join the Company.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;




</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2025-01-01_2025-12-31" id="c768">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
			December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(000's)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,346&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,971&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,022&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,589&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,368&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,560&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c771"
      unitRef="USD">3346000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c772"
      unitRef="USD">2971000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c773"
      unitRef="USD">5022000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c774"
      unitRef="USD">5589000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c775"
      unitRef="USD">8368000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-4"
      id="c776"
      unitRef="USD">8560000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2020-06-30_PlanNameAxis-The2020StockOptionAndIncentivePlanMember"
      decimals="-5"
      id="c679"
      unitRef="Share">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2025-12-31_PlanNameAxis-The2020StockOptionAndIncentivePlanMember"
      decimals="-5"
      id="c681"
      unitRef="Share">5300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2026-01-01_2026-01-01_PlanNameAxis-The2020StockOptionAndIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-5"
      id="c682"
      unitRef="Share">7100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2026-01-01_PlanNameAxis-The2020StockOptionAndIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-5"
      id="c684"
      unitRef="Share">12400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c777">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options (000's)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted Average&lt;br/&gt;
			Exercise Price&lt;br/&gt;
			Price Per Share&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted Average&lt;br/&gt;
			Remaining Contractual&lt;br/&gt;
			Life (in years)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Aggregate Intrinsic Value (000's)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 48%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at December 31, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,876&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.81&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8.05&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,193&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.58&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7.10&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercised&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Forfeited/cancelled&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(7&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.04&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at December 31, 2024&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;14,062&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.83&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.23&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;579&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,777&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.63&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8.76&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercised&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(545&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.34&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,214&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Forfeited/cancelled&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,942&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.40&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,341&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at December 31, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;16,352&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.13&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.69&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;36,614&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Vested at December 31, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;9,513&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.38&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.24&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18,932&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c780"
      unitRef="Share">7876000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c781"
      unitRef="USDPerShare">3.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2023-01-01_2023-12-31" id="c782">P8Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c783"
      unitRef="USD">11000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c784"
      unitRef="Share">6193000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c785"
      unitRef="USDPerShare">1.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm contextRef="d_2024-01-01_2024-12-31" id="c786">P7Y1M6D</cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
    <cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c787"
      unitRef="USD">0</cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c788"
      unitRef="Share">-0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c789"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c792"
      unitRef="Share">7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c793"
      unitRef="USDPerShare">3.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c795"
      unitRef="USD">0</cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c796"
      unitRef="Share">14062000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c797"
      unitRef="USDPerShare">2.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2024-01-01_2024-12-31" id="c798">P6Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c799"
      unitRef="USD">579000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c800"
      unitRef="Share">4777000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c801"
      unitRef="USDPerShare">3.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm contextRef="d_2025-01-01_2025-12-31" id="c802">P8Y9M3D</cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm>
    <cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c803"
      unitRef="USD">2000</cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c804"
      unitRef="Share">545000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c805"
      unitRef="USDPerShare">2.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c807"
      unitRef="USD">1214000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c808"
      unitRef="Share">1942000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c809"
      unitRef="USDPerShare">2.4</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c811"
      unitRef="USD">2341000</cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedOrCancelledInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c812"
      unitRef="Share">16352000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2025-12-31"
      decimals="INF"
      id="c813"
      unitRef="USDPerShare">3.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2025-01-01_2025-12-31" id="c814">P6Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c815"
      unitRef="USD">36614000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c816"
      unitRef="Share">9513000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i_2025-12-31"
      decimals="INF"
      id="c817"
      unitRef="USDPerShare">3.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="d_2025-01-01_2025-12-31" id="c818">P5Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c819"
      unitRef="USD">18932000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c727"
      unitRef="USDPerShare">2.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2025-12-31"
      decimals="-5"
      id="c728"
      unitRef="USD">36600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c729"
      unitRef="USD">579000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i_2025-12-31"
      decimals="-5"
      id="c730"
      unitRef="USD">13700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c731">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c820">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected term (in years)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.26&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.92&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected volatility&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;86&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;81&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2025-01-01_2025-12-31" id="c823">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2024-01-01_2024-12-31" id="c824">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2025-01-01_2025-12-31"
      decimals="4"
      id="c825"
      unitRef="Pure">0.0426</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2024-01-01_2024-12-31"
      decimals="4"
      id="c826"
      unitRef="Pure">0.0392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2025-01-01_2025-12-31"
      decimals="2"
      id="c827"
      unitRef="Pure">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2024-01-01_2024-12-31"
      decimals="2"
      id="c828"
      unitRef="Pure">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c829">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Shares&lt;br/&gt;
			(000's)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;br/&gt;
			Average Price&lt;br/&gt;
			Per Share&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;br/&gt;
			Average Fair Value (000's)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Unvested, December 31, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,500&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.83&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,745&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,791&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.89&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,275&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Vested&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(525&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.87&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,032&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Forfeited or canceled&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Unvested, December 31, 2024&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,766&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2.41&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9,076&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Vested&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1,073&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.59&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,779&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Forfeited or canceled&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,665&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2.34&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,896&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Unvested, December 31, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,028&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2.33&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,395&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="c832"
      unitRef="Share">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c833"
      unitRef="USDPerShare">3.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i_2023-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c834"
      unitRef="USD">5745000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c835"
      unitRef="Share">2791000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c836"
      unitRef="USDPerShare">1.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c837"
      unitRef="USD">5275000</cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c838"
      unitRef="Share">525000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c839"
      unitRef="USDPerShare">3.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c840"
      unitRef="USD">2032000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c841"
      unitRef="Share">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c842"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <cmpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c843"
      unitRef="USD">-0</cmpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c844"
      unitRef="Share">3766000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c845"
      unitRef="USDPerShare">2.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c846"
      unitRef="USD">9076000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c847"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c848"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c849"
      unitRef="USD">0</cmpx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c850"
      unitRef="Share">1073000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c851"
      unitRef="USDPerShare">2.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c852"
      unitRef="USD">2779000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c853"
      unitRef="Share">1665000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c854"
      unitRef="USDPerShare">2.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <cmpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c855"
      unitRef="USD">3896000</cmpx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c856"
      unitRef="Share">1028000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c857"
      unitRef="USDPerShare">2.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c858"
      unitRef="USD">2395000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="c765"
      unitRef="USD">1600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      id="c766">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2025-12-31"
      decimals="-5"
      id="c767"
      unitRef="USD">15300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EarningsPerShareTextBlock contextRef="d_2025-01-01_2025-12-31" id="c859">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;Basic and Diluted Net Loss Per Share&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Basic net loss per share has been computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock plus potentially dilutive securities outstanding during the period. Potential shares of common stock exercisable for little or no consideration are included in both basic and diluted weighted-average number of shares of common stock outstanding.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 29pt; text-indent: -2pt;"&gt;&#160;During the year ended December 31, 2025, basic and diluted weighted-average number of shares outstanding were 157.7 million and included pre-funded warrants to purchase 6,710,000 shares of common stock with an exercise price of $0.0001 per share. During the year ended December 31, 2024, basic and diluted weighted-average number of shares outstanding were 137.4 million.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 29pt; text-indent: -2pt;"&gt;&#160;The computation of diluted net loss per share for the year ended December 31, 2025 excluded 17.4 million shares subject to outstanding stock options and restricted stock units because their inclusion would have had an anti-dilutive effect on diluted net loss per share. The computation of diluted net loss per share for the year ended December 31, 2024 excluded 17.8 million shares, subject to outstanding stock options and restricted stock because their inclusion would have had an anti-dilutive effect on diluted net loss per share. The following potentially dilutive securities (in common stock equivalents) have been excluded from the computation of diluted weighted-average shares outstanding for the years ended December 31, 2025 and 2024, as they would be antidilutive:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,352,430&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,061,604&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Restricted stock units&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,028,125&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,765,625&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-5"
      id="c862"
      unitRef="Share">157700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantsInConnectionWithUnderwritingAgreementMember"
      decimals="INF"
      id="c863"
      unitRef="Share">6710000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantsInConnectionWithUnderwritingAgreementMember"
      decimals="INF"
      id="c864"
      unitRef="USDPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-5"
      id="c865"
      unitRef="Share">137400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-5"
      id="c866"
      unitRef="Share">137400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-5"
      id="c867"
      unitRef="Share">17400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-5"
      id="c869"
      unitRef="Share">17800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="d_2025-01-01_2025-12-31" id="c875">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,352,430&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,061,604&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Restricted stock units&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,028,125&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,765,625&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c878"
      unitRef="Share">16352430</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c879"
      unitRef="Share">14061604</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c880"
      unitRef="Share">1028125</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c881"
      unitRef="Share">3765625</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c882">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;License, Research and Collaboration Agreements&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Collaboration Agreements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;&lt;i&gt;ABL Bio Corporation ("ABL Bio") Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;In November 2018, the Company and ABL Bio, a South Korean biotechnology company, entered into an exclusive global (excluding South Korea) license agreement which granted the Company a license to tovecimig (ABL001), ABL Bio&#x2019;s bispecific antibody targeting DLL4 and VEGF-A. Under the terms of the agreement, the two companies would jointly develop tovecimig, with ABL Bio responsible for development of tovecimig throughout the end of Phase 1 clinical trials and the Company responsible for the development of tovecimig from Phase 2 and onward. ABL Bio received a $5 million upfront payment and $6 million development milestone payment. In addition, ABL Bio is eligible to receive up to $96 million of development and regulatory milestone payments, and up to $303 million of commercial milestone payments and tiered single-digit royalties on net sales of tovecimig in oncology. ABL Bio is also eligible to receive up to $75 million in development and regulatory milestones and up to $110 million in commercial milestone payments and tiered, single-digit royalties on net sales of tovecimig in ophthalmology.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;In May 2021, TRIGR and ABL Bio terminated license agreements to several preclinical assets. As a result of the return of these assets to ABL Bio and termination of the license agreements, the Company is eligible to receive royalty payments if ABL Bio develops or licenses two bispecific antibodies that were previously licensed to TRIGR.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;&lt;i&gt;Adimab Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The Company entered into a collaboration agreement with Adimab, LLC on October 16, 2014. The agreement includes provisions for payment of royalties at rates ranging in the single digits as a percentage of future net sales within a specified term from the first commercial sale for certain antibodies, including our product candidate, CTX-471. There were &lt;span style="-sec-ix-hidden:c891"&gt;no&lt;/span&gt; milestone payments made during 2025. As of December 31, 2025, future potential milestone payments in connection with this agreement amounted to $2.0 million.&lt;/p&gt;
</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <cmpx:UpfrontPayment
      contextRef="d_2018-11-01_2018-11-30_TypeOfArrangementAxis-ABLBioAgreementMember"
      decimals="-6"
      id="c885"
      unitRef="USD">5000000</cmpx:UpfrontPayment>
    <cmpx:DevelopmentMilestonePayment
      contextRef="d_2018-11-01_2018-11-30_TypeOfArrangementAxis-ABLBioAgreementMember"
      decimals="-6"
      id="c886"
      unitRef="USD">6000000</cmpx:DevelopmentMilestonePayment>
    <cmpx:MaximumDevelopmentAndRegulatoryMilestonePayments
      contextRef="i_2018-11-30_TypeOfArrangementAxis-ABLBioAgreementMember"
      decimals="-6"
      id="c887"
      unitRef="USD">96000000</cmpx:MaximumDevelopmentAndRegulatoryMilestonePayments>
    <cmpx:MaximumCommercialMilestonePaymentsAndRoyalties
      contextRef="i_2018-11-30_ProductOrServiceAxis-OncologyMember_TypeOfArrangementAxis-ABLBioAgreementMember"
      decimals="-6"
      id="c888"
      unitRef="USD">303000000</cmpx:MaximumCommercialMilestonePaymentsAndRoyalties>
    <cmpx:MaximumDevelopmentAndRegulatoryMilestonePayments
      contextRef="i_2018-11-30_ProductOrServiceAxis-OphthalmologyMember_TypeOfArrangementAxis-ABLBioAgreementMember"
      decimals="-6"
      id="c889"
      unitRef="USD">75000000</cmpx:MaximumDevelopmentAndRegulatoryMilestonePayments>
    <cmpx:MaximumCommercialMilestonePaymentsAndRoyalties
      contextRef="i_2018-11-30_ProductOrServiceAxis-OphthalmologyMember_TypeOfArrangementAxis-ABLBioAgreementMember"
      decimals="-7"
      id="c890"
      unitRef="USD">110000000</cmpx:MaximumCommercialMilestonePaymentsAndRoyalties>
    <cmpx:MilestonePaymentObligation
      contextRef="i_2025-12-31_TypeOfArrangementAxis-AdimabAgreementMember"
      decimals="-6"
      id="c892"
      unitRef="USD">2000000</cmpx:MilestonePaymentObligation>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c893">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;12.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Commitments and Contingencies &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The Company accounts for operating leases on a straight-line basis over the lease term, with recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments. For leases with a term of 12 months or less, we recognize lease expense on a straight-line basis over the lease term.&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The Company has evaluated its leases under ASC 842, &lt;i&gt;Leases&lt;/i&gt;, and determined that it has one lease that is classified as an operating lease. The classification of this lease is consistent with the Company&#x2019;s determination under the previous accounting standard.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;When available, the Company will use the rate implicit in the lease to discount lease payments to present value; however, the Company&#x2019;s current lease does not provide an implicit rate. Therefore, the Company used its incremental borrowing rate of 6.25% to discount the lease payments based on the date of the lease commencement.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The Company has one operating lease for its corporate office and laboratory facility (&#x201c;Facility&#x201d;) that was signed in December 2020. The Company moved into the Facility in January 2021. The Facility lease has an initial term of four years and five months, beginning on January 1, 2021.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The terms of the Facility lease were modified effective September 27, 2024 through the execution of a new lease. The modified terms extended the non-cancelable lease term through May 2031. The modified terms also included the right to use an additional 10,724 square feet that commenced in May 2025. The classification and incremental borrowing rate for the lease did not change as a result of this lease modification. Right-of-use assets obtained in exchange for new operating lease liabilities due to the lease modification were $9.9 million for a total right-of-use assets as of December 31, 2025 of $9.1 million. The remaining lease term of the Facility lease is 5.4 years as of December 31, 2025. The Company has $568 thousand of restricted cash associated with an irrevocable letter of credit required by the landlord to enter into this lease.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Lease costs related to the Facility were $1.3 million and $1.1 million for the years ending December 31, 2025 and 2024, respectively. Cash paid for this lease was $0.8 million and $1.4 million for the years ended December 31, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The table below presents the undiscounted cash flows for the lease term. The undiscounted cash flows are reconciled to the operating lease liabilities recorded on the consolidated balance sheets:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;(000's)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 84%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Years ending December 31,&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2026&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,525&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2027&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,204&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2028&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,249&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2029&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,294&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2030&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,356&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Thereafter&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;995&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total minimum lease payments&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,623&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: amount of lease payments representing interest&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,794&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Present value of future minimum lease payments&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,829&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: operating lease obligations, current portion&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Operating lease obligations, long-term portion&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,829&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&lt;b&gt;Defined Contribution Plan &lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The Company has a 401(k) defined contribution plan (the &#x201c;401(k) Plan&#x201d;) for substantially all its employees. Eligible employees may make pre-tax or post-tax (Roth) contributions to the 401(k) Plan up to statutory limits. Since January 1, 2020, the Company has been matching employee contributions to the plan up to 4% of salary. On July 1, 2023, the Company increased the employee matching contribution from 4% to 6%. The Company made matching contributions of $0.4 million and $0.3 million for the years ended December 31, 2025 and 2024, respectively.&lt;/p&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="i_2025-12-31_LeaseContractualTermAxis-FacilityLeaseMember"
      decimals="4"
      id="c896"
      unitRef="Pure">0.0625</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i_2024-09-27_LeaseContractualTermAxis-FacilityLeaseMember"
      decimals="INF"
      id="c897"
      unitRef="SquareFoot">10724</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="d_2024-07-27_2024-09-27_LeaseContractualTermAxis-FacilityLeaseMember"
      decimals="-5"
      id="c898"
      unitRef="USD">9900000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2025-12-31_LeaseContractualTermAxis-FacilityLeaseMember"
      decimals="-5"
      id="c899"
      unitRef="USD">9100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i_2025-12-31_LeaseContractualTermAxis-FacilityLeaseMember"
      id="c900">P5Y4M24D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:RestrictedCash
      contextRef="i_2024-09-27_GuaranteeObligationsByNatureAxis-FinancialStandbyLetterOfCreditMember_LeaseContractualTermAxis-FacilityLeaseMember"
      decimals="-3"
      id="c901"
      unitRef="USD">568000</us-gaap:RestrictedCash>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2025-01-01_2025-12-31_LeaseContractualTermAxis-FacilityLeaseMember"
      decimals="-5"
      id="c902"
      unitRef="USD">1300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2024-01-01_2024-12-31_LeaseContractualTermAxis-FacilityLeaseMember"
      decimals="-5"
      id="c903"
      unitRef="USD">1100000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2025-01-01_2025-12-31_LeaseContractualTermAxis-FacilityLeaseMember"
      decimals="-5"
      id="c904"
      unitRef="USD">800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2024-01-01_2024-12-31_LeaseContractualTermAxis-FacilityLeaseMember"
      decimals="-5"
      id="c905"
      unitRef="USD">1400000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c922">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;(000's)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 84%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Years ending December 31,&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2026&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,525&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2027&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,204&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2028&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,249&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2029&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,294&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2030&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,356&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Thereafter&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;995&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total minimum lease payments&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,623&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: amount of lease payments representing interest&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,794&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Present value of future minimum lease payments&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,829&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: operating lease obligations, current portion&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Operating lease obligations, long-term portion&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,829&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i_2025-09-30"
      decimals="-3"
      id="c925"
      unitRef="USD">1525000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i_2025-09-30"
      decimals="-3"
      id="c926"
      unitRef="USD">2204000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i_2025-09-30"
      decimals="-3"
      id="c927"
      unitRef="USD">2249000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i_2025-09-30"
      decimals="-3"
      id="c928"
      unitRef="USD">2294000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i_2025-09-30"
      decimals="-3"
      id="c929"
      unitRef="USD">2356000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i_2025-09-30"
      decimals="-3"
      id="c930"
      unitRef="USD">995000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i_2025-09-30"
      decimals="-3"
      id="c931"
      unitRef="USD">11623000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i_2025-09-30"
      decimals="-3"
      id="c932"
      unitRef="USD">1794000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2025-09-30"
      decimals="-3"
      id="c933"
      unitRef="USD">9829000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2025-09-30"
      decimals="-6"
      id="c934"
      unitRef="USD">1000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2025-09-30"
      decimals="-3"
      id="c935"
      unitRef="USD">8829000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="d_2025-01-01_2025-09-30_RangeAxis-MaximumMember"
      decimals="2"
      id="c917"
      unitRef="Pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="d_2023-07-01_2025-12-31_RangeAxis-MinimumMember"
      decimals="2"
      id="c918"
      unitRef="Pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="d_2023-07-01_2025-12-31_RangeAxis-MaximumMember"
      decimals="2"
      id="c919"
      unitRef="Pure">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-5"
      id="c920"
      unitRef="USD">400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-5"
      id="c921"
      unitRef="USD">300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock contextRef="d_2025-01-01_2025-12-31" id="c936">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;13.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Other income&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Other income consisted of interest income from investments on marketable securities of $6.4 million and $7.3 million for the years ended December 31, 2025 and 2024, respectively.&lt;/p&gt;
</us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-5"
      id="c939"
      unitRef="USD">6400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-5"
      id="c940"
      unitRef="USD">7300000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c941">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;14.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Income Taxes &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The Company had &lt;span style="-sec-ix-hidden:c944"&gt;&lt;span style="-sec-ix-hidden:c945"&gt;no&lt;/span&gt;&lt;/span&gt; income tax for the years ended December 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&#x2010;The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 48%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Federal statutory rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(13,963&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(10,368&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Adjustment resulting from the tax effect of:&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;State and local income tax, net of federal (national) income tax effect&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(4,416&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.6&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(3,454&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Foreign Tax Effects&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Effect of changes in tax laws or rates enacted in the current period&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Effect of cross-border tax laws&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Tax Credits&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Research and development tax credits&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,045&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,864&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.8&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Changes in valuation allowance&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;19,744&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-29.8&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15,778&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-32.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Nontaxable or nondeductible items&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Stock compensation &amp;amp; other nondeductible expenses&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;680&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-0.9&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;532&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-1.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Changes in unrecognized tax benefits&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;376&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-0.7&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Effective income tax rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;%&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;In 2025, state and local income taxes in Massachusetts comprise the state and local income taxes category. The company had no federal or state income tax payments or refunds for the years ended December 31, 2025 and December 31, 2024. The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. In determining the need for a valuation allowance, management reviews both positive and negative evidence, including current and historical results of operations, future income projections and the overall prospects of our business. Based upon management&#x2019;s assessment of all available evidence, the Company believes that it is more-likely-than-not that the deferred tax assets will not be realizable, and therefore, a valuation allowance has been established. The valuation allowance for deferred tax assets was approximately $79.2&#160;million and $59.5 million as of December 31, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;As of December 31, 2025, the Company has U.S. federal and state net operating loss carryforwards (&#x201c;NOLs&#x201d;) of $200.4&#160;million and $206.7&#160;million, respectively. As of December 31, 2025, the Company has federal and state research and development credit carryforwards (&#x201c;R&amp;amp;D credits&#x201d;) of $9.3 million and $2.5 million, respectively. For income tax purposes, federal NOLs will not expire since they were generated after 2017 and federal R&amp;amp;D credits will begin expiring in 2039. For income tax purposes, state NOLs and state R&amp;amp;D credits will begin to expire in 2040 and 2031, respectively.&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service (the &#x201c;IRS&#x201d;) and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50% as defined under Sections 382 and 383 in the Internal Revenue Code, which could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the Company&#x2019;s value immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;The Tax Cuts and Jobs Act of 2017 (&#x201c;TCJA&#x201d;) amended IRC Section 174 to require capitalization of all research and developmental (R&amp;amp;D) costs incurred in tax years beginning after December 31, 2021. These costs are required to be amortized with a half-year convention over five years if the R&amp;amp;D activities are performed in the U.S., or over 15 years if the activities were performed outside the U.S. The One Big Beautiful Bill Act (&#x201c;OBBBA&#x201d;) enacted in 2025 allows for current deductibility of domestic R&amp;amp;D costs and immediate deduction for previously capitalized costs for certain taxpayers retroactive to 2024. The Company elected to take the deduction in 2024.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;As of December 31, 2025 and 2024, the Company had &lt;span style="-sec-ix-hidden:c997"&gt;&lt;span style="-sec-ix-hidden:c998"&gt;no&lt;/span&gt;&lt;/span&gt; uncertain tax positions, and as such, &lt;span style="-sec-ix-hidden:c999"&gt;&lt;span style="-sec-ix-hidden:c1000"&gt;no&lt;/span&gt;&lt;/span&gt; related interest or penalties have been recorded in the statements of operations and comprehensive loss. The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense. All tax years of the Company from inception are open to examination by federal tax and state tax authorities. To the extent utilized in future years&#x2019; tax returns, net operating loss carryforwards at December 31, 2025 will remain subject to examination until the respective tax year is closed. The Company has not been informed by any tax authorities for any jurisdiction that any of its tax years is under examination as of December 31, 2025.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities are as follows:&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Deferred tax assets&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(000's)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Federal net operating loss carryforwards&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;42,075&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,775&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;State net operating loss carryforwards&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;13,063&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,063&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development credits&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,297&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,252&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Section 174 Capitalization&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,015&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;22,724&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,001&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,922&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Lease liabilities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,685&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,812&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Capitalized licensing fees&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,266&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,375&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;406&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;494&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Subtotal&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;81,808&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;61,417&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less valuation allowance&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(79,245&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(59,521&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred tax assets, net of valuation allowance&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,563&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,896&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Deferred tax liabilities&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Right-of-use assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,486&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1,839&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(77&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(57&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred tax assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1030">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 48%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Federal statutory rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(13,963&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(10,368&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Adjustment resulting from the tax effect of:&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;State and local income tax, net of federal (national) income tax effect&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(4,416&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.6&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(3,454&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Foreign Tax Effects&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Effect of changes in tax laws or rates enacted in the current period&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Effect of cross-border tax laws&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Tax Credits&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Research and development tax credits&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,045&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,864&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.8&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Changes in valuation allowance&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;19,744&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-29.8&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15,778&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-32.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Nontaxable or nondeductible items&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Stock compensation &amp;amp; other nondeductible expenses&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;680&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-0.9&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;532&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-1.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Changes in unrecognized tax benefits&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;376&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-0.7&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Effective income tax rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;%&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1033"
      unitRef="USD">-13963000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2025-01-01_2025-12-31"
      decimals="2"
      id="c1034"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1035"
      unitRef="USD">-10368000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2024-01-01_2024-12-31"
      decimals="2"
      id="c1036"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1038"
      unitRef="USD">-4416000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2025-01-01_2025-12-31"
      decimals="3"
      id="c1039"
      unitRef="Pure">0.066</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1040"
      unitRef="USD">-3454000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2024-01-01_2024-12-31"
      decimals="2"
      id="c1041"
      unitRef="Pure">0.07</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1042"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1043"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1044"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1045"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1046"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1047"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1048"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1049"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1050"
      unitRef="USD">0</us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1051"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1052"
      unitRef="USD">0</us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1053"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1055"
      unitRef="USD">2045000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="d_2025-01-01_2025-12-31"
      decimals="3"
      id="c1056"
      unitRef="Pure">-0.031</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1057"
      unitRef="USD">2864000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c1058"
      unitRef="Pure">-0.058</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1059"
      unitRef="USD">19744000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2025-01-01_2025-12-31"
      decimals="3"
      id="c1060"
      unitRef="Pure">-0.298</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1061"
      unitRef="USD">15778000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2024-01-01_2024-12-31"
      decimals="2"
      id="c1062"
      unitRef="Pure">-0.32</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-4"
      id="c1064"
      unitRef="USD">680000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="3"
      id="c1065"
      unitRef="Pure">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1066"
      unitRef="USD">532000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c1067"
      unitRef="Pure">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <cmpx:EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1068"
      unitRef="USD">0</cmpx:EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount>
    <cmpx:EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1069"
      unitRef="Pure">0</cmpx:EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent>
    <cmpx:EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1070"
      unitRef="USD">0</cmpx:EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount>
    <cmpx:EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1071"
      unitRef="Pure">0</cmpx:EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1072"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1073"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1074"
      unitRef="USD">376000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c1075"
      unitRef="Pure">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1076"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1077"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1078"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1079"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2025-12-31"
      decimals="-5"
      id="c993"
      unitRef="USD">79200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2024-12-31"
      decimals="-5"
      id="c994"
      unitRef="USD">59500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2025-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"
      decimals="-5"
      id="c995"
      unitRef="USD">200400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"
      decimals="-5"
      id="c996"
      unitRef="USD">206700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1080">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Deferred tax assets&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(000's)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Federal net operating loss carryforwards&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;42,075&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,775&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;State net operating loss carryforwards&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;13,063&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,063&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development credits&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,297&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,252&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Section 174 Capitalization&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,015&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;22,724&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,001&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,922&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Lease liabilities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,685&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,812&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Capitalized licensing fees&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,266&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,375&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;406&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;494&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Subtotal&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;81,808&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;61,417&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less valuation allowance&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(79,245&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(59,521&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred tax assets, net of valuation allowance&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,563&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,896&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Deferred tax liabilities&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Right-of-use assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,486&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1,839&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(77&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(57&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred tax assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1083"
      unitRef="USD">42075000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1084"
      unitRef="USD">16775000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1085"
      unitRef="USD">13063000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1086"
      unitRef="USD">5063000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1087"
      unitRef="USD">11297000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1088"
      unitRef="USD">9252000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <cmpx:DeferredTaxAssetsSection174Capitalization
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1089"
      unitRef="USD">6015000</cmpx:DeferredTaxAssetsSection174Capitalization>
    <cmpx:DeferredTaxAssetsSection174Capitalization
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1090"
      unitRef="USD">22724000</cmpx:DeferredTaxAssetsSection174Capitalization>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1091"
      unitRef="USD">5001000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1092"
      unitRef="USD">3922000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <cmpx:DeferredTaxAssetsLeaseLiabilities
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1093"
      unitRef="USD">2685000</cmpx:DeferredTaxAssetsLeaseLiabilities>
    <cmpx:DeferredTaxAssetsLeaseLiabilities
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1094"
      unitRef="USD">1812000</cmpx:DeferredTaxAssetsLeaseLiabilities>
    <cmpx:DeferredTaxAssetsCapitalizedLicensingFees
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1095"
      unitRef="USD">1266000</cmpx:DeferredTaxAssetsCapitalizedLicensingFees>
    <cmpx:DeferredTaxAssetsCapitalizedLicensingFees
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1096"
      unitRef="USD">1375000</cmpx:DeferredTaxAssetsCapitalizedLicensingFees>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1097"
      unitRef="USD">406000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1098"
      unitRef="USD">494000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1099"
      unitRef="USD">81808000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1100"
      unitRef="USD">61417000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1101"
      unitRef="USD">79245000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1102"
      unitRef="USD">59521000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1103"
      unitRef="USD">2563000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1104"
      unitRef="USD">1896000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1106"
      unitRef="USD">2486000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1107"
      unitRef="USD">1839000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1108"
      unitRef="USD">77000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1109"
      unitRef="USD">57000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1110"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1111"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1112">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;15.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Segment Information &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 29pt;"&gt;Segment reporting is prepared on the same basis that our chief executive officer, who is our CODM, manages the business, makes operating decisions and assesses performance. The Company operates in &lt;span style="-sec-ix-hidden:c1115"&gt;one&lt;/span&gt; segment. The Company&#x2019;s business is research and development of drug candidates. Costs, including supplies, outsourced development, and other research and development costs are tracked by major program. While internal personnel costs are tracked by program for overall program spending, it is not broken out for management review. Facility and equipment costs are not allocated to programs. Research and development expenses are summarized by program in the table below:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(000's)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Licensing revenue&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;850&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Personnel&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,935&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,918&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,616&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,965&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Tovecimig&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;23,680&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;23,177&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;CTX-471&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,183&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,879&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;CTX-8371&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,355&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,403&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;CTX-10726&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8,200&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Research and development&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;55,969&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;42,342&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Personnel&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,236&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,472&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,634&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,661&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;General and administrative&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;16,870&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,133&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Other income&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,350&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7,250&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"&gt;Net loss&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(66,489&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(49,375&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;




</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1142">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(000's)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Licensing revenue&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;850&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Personnel&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,935&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,918&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,616&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,965&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Tovecimig&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;23,680&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;23,177&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;CTX-471&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,183&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,879&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;CTX-8371&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,355&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,403&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;CTX-10726&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8,200&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Research and development&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;55,969&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;42,342&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Personnel&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,236&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,472&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,634&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,661&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;General and administrative&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;16,870&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,133&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Other income&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,350&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7,250&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"&gt;Net loss&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(66,489&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(49,375&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1145"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-4"
      id="c1146"
      unitRef="USD">850000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-PersonnelMember"
      decimals="-3"
      id="c1147"
      unitRef="USD">11935000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-PersonnelMember"
      decimals="-3"
      id="c1148"
      unitRef="USD">9918000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-GeneralMember"
      decimals="-3"
      id="c1149"
      unitRef="USD">4616000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-GeneralMember"
      decimals="-3"
      id="c1150"
      unitRef="USD">3965000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-TovecimigMember"
      decimals="-4"
      id="c1151"
      unitRef="USD">23680000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-TovecimigMember"
      decimals="-3"
      id="c1152"
      unitRef="USD">23177000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-CTX471Member"
      decimals="-3"
      id="c1153"
      unitRef="USD">4183000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-CTX471Member"
      decimals="-3"
      id="c1154"
      unitRef="USD">2879000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-CTX8371Member"
      decimals="-3"
      id="c1155"
      unitRef="USD">3355000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-CTX8371Member"
      decimals="-3"
      id="c1156"
      unitRef="USD">2403000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-CTX10726Member"
      decimals="-5"
      id="c1157"
      unitRef="USD">8200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-CTX10726Member"
      decimals="-3"
      id="c1158"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1159"
      unitRef="USD">55969000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1160"
      unitRef="USD">42342000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-PersonnelMember"
      decimals="-3"
      id="c1161"
      unitRef="USD">10236000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-PersonnelMember"
      decimals="-3"
      id="c1162"
      unitRef="USD">10472000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2025-01-01_2025-12-31_NatureOfExpenseAxis-GeneralMember"
      decimals="-3"
      id="c1163"
      unitRef="USD">6634000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2024-01-01_2024-12-31_NatureOfExpenseAxis-GeneralMember"
      decimals="-3"
      id="c1164"
      unitRef="USD">4661000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-4"
      id="c1165"
      unitRef="USD">16870000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1166"
      unitRef="USD">15133000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-4"
      id="c1167"
      unitRef="USD">6350000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-4"
      id="c1168"
      unitRef="USD">7250000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1169"
      unitRef="USD">-66489000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1170"
      unitRef="USD">-49375000</us-gaap:NetIncomeLoss>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1171">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Item 9B. Other Information.&lt;a href="#" id="itm9b"&gt;&lt;/a&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Rule 10b5-1 Trading Plans&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"&gt;During the three months ended December 31, 2025, &lt;span style="-sec-ix-hidden:c1174"&gt;&lt;span style="-sec-ix-hidden:c1175"&gt;&lt;span style="-sec-ix-hidden:c1176"&gt;&lt;span style="-sec-ix-hidden:c1177"&gt;none&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; of our directors or officers adopted, materially modified, or terminated any contract, instruction, or written plan for the purchase or sale our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any non-Rule 10b5-1 trading arrangement.&lt;/p&gt;
</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="d_2025-01-01_2025-12-31" id="c1181">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:AwardTmgHowMnpiCnsdrdTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1182">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Item 11. Executive Compensation.&lt;a href="#" id="itm11"&gt;&lt;/a&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"&gt;The information required by this Item 11 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2026 Annual Meeting of Stockholders and is incorporated herein by reference.&lt;/p&gt;
</ecd:AwardTmgHowMnpiCnsdrdTextBlock>
    <ecd:AwardTmgMnpiCnsdrdFlag contextRef="d_2025-01-01_2025-12-31" id="c1185">true</ecd:AwardTmgMnpiCnsdrdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
